<SEC-DOCUMENT>0000950170-25-029968.txt : 20250228
<SEC-HEADER>0000950170-25-029968.hdr.sgml : 20250228
<ACCEPTANCE-DATETIME>20250228160031
ACCESSION NUMBER:		0000950170-25-029968
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250228
DATE AS OF CHANGE:		20250228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Longeveron Inc.
		CENTRAL INDEX KEY:			0001721484
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472174146
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40060
		FILM NUMBER:		25689820

	BUSINESS ADDRESS:	
		STREET 1:		1951 NW 7TH AVENUE
		STREET 2:		SUITE 520
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33136
		BUSINESS PHONE:		305-302-7158

	MAIL ADDRESS:	
		STREET 1:		1951 NW 7TH AVENUE
		STREET 2:		SUITE 520
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33136

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LONGEVERON LLC
		DATE OF NAME CHANGE:	20171101
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lgvn-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-28T13:18:09.6314+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:lgvn="http://LongeveronInc.com/20241231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_001b3cb7-6a6b-4caa-a178-5fa7e199c284" name="dei:AmendmentFlag" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_b052d2d8-c02c-4026-ad5f-9ad664505600" name="dei:DocumentFiscalPeriodFocus" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f">FY</ix:nonNumeric><ix:nonNumeric id="F_8308b784-deb7-43c5-aa8f-a3d7c8be59c7" name="dei:EntityCentralIndexKey" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f">0001721484</ix:nonNumeric><ix:nonFraction id="F_67f6638a-5395-4219-9e87-130051a737fc" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b32d22a7-f5c5-47a3-8a4b-a4ef13404364" name="us-gaap:CommitmentsAndContingencies" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e2b63699-fc70-43ef-83b0-3ec8d8d5c95b" name="us-gaap:PreferredStockValue" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9969c8c5-df41-4078-a8e1-6b3423b5476c" name="us-gaap:PreferredStockValue" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_4a0b75b5-4668-44fe-9ab3-6ac34d6f5dc3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_68de77cc-d120-4576-8f01-a84116620f4c" unitRef="U_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction><ix:nonFraction id="F_2e46777d-d9ea-4884-a9bb-dd1d15ee5f6a" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0fa78e15-5237-44e1-ac71-f1d25f041ced" unitRef="U_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction><ix:nonNumeric id="F_382d7ea9-fe54-4942-9ed3-f6ed091b8df0" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member</ix:nonNumeric><ix:nonFraction id="F_27ce6dd3-639b-41e2-9150-1333292d9101" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_07d8a382-8bbb-46f9-8af5-da2391d2ed5e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ab57fa60-fbf9-444e-8dc1-8543b8bc25bd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_54696521-4d07-49be-ac31-5b7b09eede1d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_491c5dcc-2520-4145-b055-747c1b012785" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_4cacba37-0be4-4152-b40f-08dfc2bfbbaf" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5860e748-b626-4760-9959-04c8458de42e" name="us-gaap:MarketableSecurities" contextRef="C_5bfdd076-ba62-43f9-b999-3245bcb69f9e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b5db85cc-838d-40fc-a08f-983e2963015b" name="us-gaap:MarketableSecurities" contextRef="C_5d419854-2648-4779-8e89-00e96e30a8d8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_edf3cd8e-fee7-4f2b-bae4-3cb7da56e51c" name="us-gaap:MarketableSecurities" contextRef="C_eeb0c913-518a-4d04-9452-efbaf66ce005" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_26429428-9ef1-47d7-90cc-f345882c97e5" name="us-gaap:MarketableSecurities" contextRef="C_d3638195-ab5a-4291-9ae5-867e2b6cf88c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_261c32f6-80e4-43ac-b52b-25b87d6e73cb" name="us-gaap:MarketableSecurities" contextRef="C_c6ce0b7e-d437-4704-9765-d88f29ce0adb" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8adfe637-2df8-4137-b76b-d02b023f34c0" name="us-gaap:MarketableSecurities" contextRef="C_29c20658-0d07-4fb3-b57a-a2b98683e7ca" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_7a05c076-4b13-4782-980f-f1db531e3014" name="us-gaap:MarketableSecurities" contextRef="C_4106fb7d-8b1c-41f8-b586-7658602c66b4" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1ae67987-286c-4292-ad79-4c71735dd6d9" name="us-gaap:MarketableSecurities" contextRef="C_1400ed16-357f-49fb-8ddc-3ef9e892f328" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b98a551e-dc71-4388-aafc-fbc75338dd46" name="us-gaap:MarketableSecurities" contextRef="C_a54ada20-1a44-4de3-803f-884629580212" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_382c332e-e576-4e25-b8f8-144ea2ba7f4f" name="us-gaap:MarketableSecurities" contextRef="C_c0238eb0-efac-4481-a961-ca7376905c7b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_40e58eda-d3eb-4484-86f2-e1fe5a77793e" name="us-gaap:MarketableSecurities" contextRef="C_e434dc91-ef31-47bc-8cef-615fb2777b8b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_588625ea-79fb-4a9a-8abb-1ccf786357c5" name="us-gaap:MarketableSecurities" contextRef="C_cbb6d537-8377-408a-a06e-a422b97464ac" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1809098a-d0f5-4df3-8175-e912d38dfd37" name="us-gaap:MarketableSecurities" contextRef="C_762471a3-e00f-4635-974d-de11609e581f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_93e3078f-8d95-4815-8772-dedb12df7e8d" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_cdfee0ba-2fda-4acb-bf1e-85d83d8ae89f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_76c75a36-7343-4618-abb0-0a79d6e55a20" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_3d0dcccf-31cc-483e-b3d8-b27e06e3534a" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_cfc4d707-5861-482b-84d7-64104ba53727" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_b35ec15a-1d7a-48da-bb29-ded77d1dd6e0" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b8f1c0ca-aab8-4e72-a961-0a1daf3f73fb" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_c92a5e48-5a59-41b6-85ff-8ee27a7ded47" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_80fc046b-9fe3-4c96-90ec-96afcbbbd494" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4">P4Y6M</ix:nonNumeric><ix:nonNumeric id="F_428f7fa2-6f69-4ce1-97cd-53b8e1f3b7a5" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_800ca5b3-19a9-469b-ad8c-765f4cf802f8">P5Y6M</ix:nonNumeric><ix:nonNumeric id="F_d317f701-e4a6-46de-af03-196205d6c7fb" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_8fb325dd-2a4c-427e-b457-7d9e26d11251">P18M</ix:nonNumeric><ix:nonNumeric id="F_a211f642-62a5-42ee-bc71-d3f13e686a7e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_8828b9f4-08cf-4cd9-86ab-83a206aaab8c">P3Y</ix:nonNumeric><ix:nonFraction id="F_d44a448c-95da-42af-9268-94b3f97749eb" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64" unitRef="U_shares" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e72c3d8a-06d5-4f57-820b-ef886d45e808" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64" unitRef="U_UnitedStatesOfAmericaDollarsShare" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_59df80b9-4b23-4957-add5-f538f80c9bb3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_4dd0ce9c-9e6c-48e8-8f65-86135e742a26" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_08bd69a2-41d1-491f-a362-6162aa80c7fc" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_dc96f2f3-806d-4814-8f8e-b6e47d188ef7" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5f5fbe24-614b-499f-aced-c5af13aee5ae" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_fd5c8872-fbff-42c3-a6e0-bd84c28f075d" name="us-gaap:DeferredTaxLiabilities" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_903b8dcc-7d05-4cc8-8ed2-00092d584312" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" unitRef="U_pure" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9b1b95a1-5cfc-4117-a2c2-f442d0b99222" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" unitRef="U_pure" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_eb2962d5-c458-43df-b1ef-4f45299e5db3" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonFraction id="F_13fc1c78-4d1d-440f-aa75-9a7f20b97683" name="us-gaap:NumberOfOperatingSegments" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_577d3f24-3615-4da2-a77f-a18b9428fc43" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f">http://fasb.org/us-gaap/2024#OperatingExpenses</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lgvn-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_800ca5b3-19a9-469b-ad8c-765f4cf802f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8043ee3e-2733-4b91-a33a-2a0763fad881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lgvn:SeriesCUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-23</xbrli:startDate><xbrli:endDate>2016-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_830ceff8-2513-4d56-879f-3cc26a4081b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_831b093d-c619-43f4-90d9-56df47a2666a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8517f575-39c7-4d46-8576-6a86abfaa79e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_852485d6-ba04-474c-a47e-395518e87aea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8561f2ca-4d1a-475a-bc19-fcface1b15dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8828b9f4-08cf-4cd9-86ab-83a206aaab8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_885350a8-cf29-4eb2-a100-dd267e1f76ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88f70043-2bab-4fbd-a7ff-7ca163bafeae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ContractManufacturingLeaseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89410ccd-0c4e-45f8-bf14-c2ca134fe7ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a695d29-400b-42bb-81da-34af6591dda8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b8d20b6-58a6-4f02-b93e-8d56eedb8243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bd66a75-3699-4e56-8cd2-f92fabc91f0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueConsensusPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e3349a5-e8ad-4d9f-932c-91af4f1b95ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ClinicalTrialRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fb325dd-2a4c-427e-b457-7d9e26d11251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_906ca24e-44d3-40ab-b91a-b4250b408e3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_924ecf1f-101e-4065-841a-2f62764b7c61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-17</xbrli:startDate><xbrli:endDate>2024-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9474be27-a471-40f6-84ce-28e85ee32e08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_966061df-c7de-4d04-b147-85979bffe716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_972466ee-785c-4232-9930-fe53db2cddaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97d5f78e-ff73-4686-9599-d8a719ba798c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a653252-42fd-451f-b16d-80dfc3b20336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9aa77719-3220-42ff-b34d-4e36497e3a08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ad503fc-d399-4534-b7b8-40dad723f514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dcd6c86-0172-4023-b693-3ddef2e87823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fa8323f-6ecb-4760-888b-b865f49ee572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ContractManufacturingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a153ce10-2e61-4bc3-acd9-4005eae448d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a24d65d6-9396-4617-9b12-342686401195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3cf52d5-51ea-46c9-a0ff-4a136cfdc855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a40fe316-3a4c-45cf-a412-d4ebc66d9819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5052b3f-7b15-4f4e-a480-ac371b45c8fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lgvn:ChiefScienceOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a54ada20-1a44-4de3-803f-884629580212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5b385af-6f58-47c5-83db-6be10bedcad9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a75f8163-8123-4c7b-8abf-018d61948b64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7d1800f-a37a-45fd-8dea-2364d19b5d11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JuneInducementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa3f1212-2350-4425-9290-9e78374aa7c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aab874c5-5eb9-44be-987c-9dfe72f5a008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgvn:BiologicsLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-20</xbrli:startDate><xbrli:endDate>2014-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac111904-200e-4f5d-bf20-50cfa1be5544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac1c02ac-9c7a-4aa5-b23c-caf1a6d79afb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac41fb9d-662d-4175-a25e-3ade70bb7db8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad3fe0e4-e995-40c1-bc38-77db69fa7a3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:AprilTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af1e0bf2-f9b3-4719-89f9-f37749bdfb82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b14e7beb-bb0f-4f7a-971e-b4f66076e0c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b186b4ae-25c4-45b0-8e3c-637d9c03a871"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2d83ae4-7a58-420c-b89e-bc88b246fd41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b35ec15a-1d7a-48da-bb29-ded77d1dd6e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5a79c7f-92c4-4fca-aa5a-8390eb7d7186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5cc0db4-91de-465c-bb48-5b53ca7e01b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9192f71-3161-4b98-9cf0-b50270b7d523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b94a44e3-eb07-42c8-b01e-5d44090f5b4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b988428e-be70-43a6-a20f-4a0d1af53866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdad186e-621a-48f4-845c-d93f9eac4f04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdba25ca-ce76-451a-a79b-72c6a6a68dbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be58ec30-718f-49dc-9b0b-5da7ce7d3da6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0238eb0-efac-4481-a961-ca7376905c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0f2353d-d121-47bf-acc8-b4e623af90e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c17b9bfa-207b-4863-b527-d6ad7945f5f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2617445-260c-4016-83d7-e383b81dadab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2653ae9-c06d-4781-a567-ba19aae19693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-17</xbrli:startDate><xbrli:endDate>2024-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c28d2aec-e976-4127-9697-03bb7896c0e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:ClassACommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3264d47-ea98-488c-addc-6cdd4c066842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3874ec0-4371-433c-8e08-3d6bcf9a60d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-24</xbrli:startDate><xbrli:endDate>2024-07-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4442eac-31f6-4b65-9025-3e8e2289cc06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">lgvn:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6ce0b7e-d437-4704-9765-d88f29ce0adb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6d1288e-2e0f-44c3-bc7e-30f39c656ecc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7147bf9-99b9-448b-938b-630f1b775c57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7555a19-6815-4308-a228-e63b0c8a4703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8996def-ed25-41c0-9cde-57e67fd24599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c920b7f7-14c0-4ed4-8bef-d33b2189d204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c92a5e48-5a59-41b6-85ff-8ee27a7ded47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c984fb4f-1fdc-4b32-b577-b0d95a9c9e4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caeb366f-d29c-4739-90bc-fff7fe6667f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbb6d537-8377-408a-a06e-a422b97464ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccb7843f-3d8b-411f-883c-8583123a3129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdc2df3b-5c8c-44c7-a3c8-e65d385a5523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdf836e1-0f62-4f0e-af87-d9a88e484056"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdfee0ba-2fda-4acb-bf1e-85d83d8ae89f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce0f0327-6771-414c-b1ab-e8b2040413f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lgvn:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgvn:SecretomeTherapeuticsIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-21</xbrli:startDate><xbrli:endDate>2024-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cec0b67c-0b8b-4bc4-9170-1fbad94ea8f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ClinicalTrialRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cee66114-9a5c-4865-9e37-ed6c8eea4537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d018a83c-69ba-4776-9f87-503309a9913d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:JulyRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-18</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d059abac-e58b-43e2-a95a-5a8879af8f3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d061083c-5970-4784-a095-643917174816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1bc4f98-b538-4530-9021-04474129f4f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1dbc3f6-3e73-4cc4-a7c7-bc22662d8467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3638195-ab5a-4291-9ae5-867e2b6cf88c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d496e54d-c6ce-4319-8f1d-e8da390d52f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5f7e310-6aa6-4ef9-ba0b-23c17f14bd5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrants1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d68599d9-47e2-4ece-8323-0052aa98f47b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d75ceeb2-ec46-49ab-a15a-5b9237a9730c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JuneInducementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8c195d2-126b-4a62-8221-e81b21de8e4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:AprilTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d928293f-8f03-4263-a9cb-8b1b15166f54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dacd79be-b988-4527-b1bf-f17043f4b8a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lgvn:UMAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dde951fe-7b4d-4fe4-8fe2-29b317fefcff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfe8bcec-cbcf-444b-8845-a535ef3f03eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e11b48f3-b181-48a1-9aba-5a7956f22930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1adbcb7-b9b2-43f3-afc8-b17cbfef377a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JuneInducementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e32174f8-44a9-4669-8a00-c469ea7d76ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e434dc91-ef31-47bc-8cef-615fb2777b8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4cfce79-c2b0-4ca4-8408-3fc1d9f375ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e577d4b1-7eb8-446b-9a4f-8502fde888f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lgvn:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgvn:SecretomeTherapeuticsIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e584071b-f7ae-411b-be56-e2130dbedae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5e6b360-d445-4c3e-bc79-675f33b37486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6f0b313-1ad4-4509-b95a-760e3a3d6430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6f33f88-f256-4289-b5e6-07ec6c716dee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7b06b06-de62-4546-8211-520778c26862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebecf041-4bf7-4e13-a8bb-d1dc47e42040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeb0c913-518a-4d04-9452-efbaf66ce005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f23ba838-5cb1-45db-a43c-3c3ea606ba58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgvn:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3787016-d57b-41d8-93d0-083f687dccac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f492dbe2-0361-48ff-be3f-265ad6408614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5447379-d637-4372-97dd-6cab7114b6af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5c01cc3-f4ac-4cac-b32c-b2eec7d32119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f620f41f-099b-4180-8d31-3b93f07907a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f62d3e71-2071-4235-baa6-e8487a08b092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6a93e10-9d65-4c37-b7bd-599ff82c8e50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-28</xbrli:startDate><xbrli:endDate>2023-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8a92122-f474-4b31-b2b6-a0fe54800397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb198e78-e33b-404a-872e-c2d863686fc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc09c49d-eaa5-4b33-8d36-7cb35209c791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fcc6b1eb-c243-4fbc-8e56-d5caa3a5c35e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff6c86a5-5367-4252-82ff-f27f2520421d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_003e9629-0270-4293-930d-9e35e517c34f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lgvn:ChiefScienceOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01ea16bf-996c-4f70-aec4-bfd677595c42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_060bd5b3-20e9-452b-9a05-b0270d3c7018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07d8a382-8bbb-46f9-8af5-da2391d2ed5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ContractManufacturingLeaseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0922a283-969e-4183-84f1-754212457538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09e3c48c-8324-4e5f-b8ba-e37b4bea78af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a31e712-6c10-4d5f-a17e-78ce49207e63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bffd59a-5e1d-4d4e-8b68-f305bbb2e10c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-16</xbrli:startDate><xbrli:endDate>2022-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c05e440-f556-4213-b61b-eda6feaf9090"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d1788e0-51e1-4f67-b903-b27ef0e08ec1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">lgvn:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d186ce3-11b3-4bf0-afd5-6b860eabc151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e8a73c4-ea0e-438b-b7f5-e4427532c51a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f2e3a3d-a8c9-4849-8d99-8d26291368fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f3486fa-b30f-4c7f-a57a-ecbf7bf415e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:InvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fa78e15-5237-44e1-ac71-f1d25f041ced"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10494440-1436-4801-9d95-e37fad25c83b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10a053c8-c2a2-4e48-84b4-b5ed263c95d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_110002f2-7209-44ec-b8bb-e70434de6600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1265d1c0-07a0-47c5-a6e0-1db933689ef8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12e07091-6e3f-4a59-802d-ada554263431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_130be5b2-21d0-478a-b3b4-fa7cffb2136b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_134d5e58-28b4-43ed-938b-934bfff4116f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1400ed16-357f-49fb-8ddc-3ef9e892f328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1603a247-a9e5-422a-846b-6d3ba3b022c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17a45533-4b30-4885-b609-d19b1db34a37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_192155e6-0c54-4184-b414-7318e5281259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a1782e7-88b3-418e-978c-52f25f9bd58c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a4b8c2d-4195-4bab-8513-5d2b8c496ede"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lgvn:UMAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1dcfeb4c-c36e-4113-9bd0-cb07f984983e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyOfferingPlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ef16fb7-28d8-4b6f-b55c-d02b22740228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_202c13b7-a778-4220-862c-5376ad67002b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20a3ae2b-fe8d-415d-9a71-83546b838508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2165fc3d-60ff-463a-ac2e-ab3e6e0ab4ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2196011d-eb59-453d-922a-463609b50727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2209f280-17a3-4fd1-94a9-c9d5d6bd6b30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_231d6559-39de-40e2-92ca-0ce4ccbeea1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_236ea03d-46b1-4bac-973b-e724dd4cb6ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25de8810-47ca-4f3b-b23d-79bd1ccf287e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_268ad250-3034-4601-a1f3-6fe024bad788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:ClassACommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27694a1f-8536-4e3a-90cb-ee31e0d92d39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28896f23-6bbf-4287-b699-1d223de107ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgvn:firstPhase3ClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-20</xbrli:startDate><xbrli:endDate>2014-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29c20658-0d07-4fb3-b57a-a2b98683e7ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a71fae8-4d00-48eb-bf4d-2a741ccb4f26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-23</xbrli:startDate><xbrli:endDate>2016-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2af1430d-300c-4a83-ab6c-f2efb9b2b469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c7472b4-63fb-4213-8963-db0f9caec040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d460a19-5b01-4993-8a57-12e7d78c57f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e7abbe2-22f9-4dec-88c2-e983a64471e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lgvn:NondisclosureAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgvn:SecretomeTherapeuticsIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-24</xbrli:startDate><xbrli:endDate>2023-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e7d7aea-3be2-4828-ad68-c7631d50cb13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e89703c-f1d8-47e0-91e2-c47b8050d0e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">lgvn:AccountsReceivableFromCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e8cf413-7785-4109-aeb3-90e76b3f91b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_309403c4-9ddf-4b25-a74d-ada45e629444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-20</xbrli:startDate><xbrli:endDate>2014-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30abdd0a-27e1-4d75-a863-e2cce39841ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgvn:StockOptionAwardFourYearVestingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_313e3c1d-a177-40fe-a408-6990d730e5ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31c839fd-7132-4e3c-bef4-2e938e7520cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31d229d0-f489-478a-b8c4-7a980e71248a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31e78a64-3bdd-47be-ac65-3b87c7c4e859"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_329d5c2e-7887-4b19-bf7f-646f3efde941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsAndSeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32a5c33d-d25b-44e7-987a-deec4533967d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33ea8560-6aa0-4787-a29e-7ac5e23721b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3643e2ad-d20e-482f-b92d-71aace47a7e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_375c44e5-dc70-4557-aa86-d4d7438ddb81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesAAndSeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_377db0af-954f-408b-bd6c-7c6b6d74118a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39a27885-81f0-4ba6-9f1c-ee208299badf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cb893e8-ebe9-452e-b2d1-71116392d51a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cf0423a-d017-4bc5-a03a-6a1be7ecd8b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d0dcccf-31cc-483e-b3d8-b27e06e3534a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f3103ec-1fd2-48ed-9be1-19cba6a04ef5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40dda296-3d9d-40bb-bc61-02fd395bf0f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4106fb7d-8b1c-41f8-b586-7658602c66b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4207ea7a-dee3-4ce6-b471-3464cadf1696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:GrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_427d1b69-1c7f-4694-805f-39f18674b82e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43a9f4de-dc23-43f2-a1af-93cc67efc849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43ed4fe3-0d84-459e-a147-85ba5807b813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lgvn:ChiefScienceOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44c40476-bff5-429e-a017-f12f5df662e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44e4401f-ab33-46f4-a549-74a0489db4c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_496249ae-e79a-4060-8ff9-4a44d6dcc042"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ba85633-032f-48ff-b8fd-3307bf64c707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c3eb97b-7e9e-414b-9078-9b9612c6aa90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cacba37-0be4-4152-b40f-08dfc2bfbbaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d1774b7-d786-4c83-9da6-6f4a21fa76cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4dc5b1b6-411b-4ddf-9cb1-ffe97d305ce8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4dd328b2-e009-40a7-afa9-eeb63f4c4773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_528b6a30-52ca-427d-8cd4-51e869799289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5353b9ba-0648-487a-aefb-c0c16431821a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54696521-4d07-49be-ac31-5b7b09eede1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ContractManufacturingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54e1f014-5bac-4239-87f8-50bf65a2d3d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_554ff09e-61fb-4eb8-892c-14e2e6d7f3cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_573f4892-a8c0-49cb-b8bb-f89fab69086c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57c941b5-3999-414f-ab10-1d89c4034885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57e34a04-c6a3-42fb-8d4f-86889f99fd47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58d502e3-e75a-4d67-9f49-bf40b468f239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:AprilTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58e4471a-d2f1-4ec9-b6a9-d4b9eae6b4e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5969aff3-9175-480f-9b07-995e126acd22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lgvn:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgvn:SecretomeTherapeuticsIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_597c2a74-45ac-4076-9561-0e22ff41b523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ad083cc-071f-4968-8655-4ec150277da0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JuneInducementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b020284-3c22-456d-94b9-311e885fa6b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b5ba2d7-308e-4e38-ba50-2a15b6d0f5ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5be6c0a6-1868-4af2-89ef-106e0e069070"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyOfferingPlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bfdd076-ba62-43f9-b999-3245bcb69f9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c5570fa-1707-4ec0-bdd8-26e9735b80d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cc56a11-ee4f-45a8-8b30-e4604e7cc25f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueConsensusPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-16</xbrli:startDate><xbrli:endDate>2023-08-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cfe12ec-4f6d-46c2-b279-5fb305736864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-10</xbrli:startDate><xbrli:endDate>2024-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d419854-2648-4779-8e89-00e96e30a8d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e7f8a23-cf6b-4aa9-b4bd-dc4e77beffe6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-16</xbrli:startDate><xbrli:endDate>2024-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5fc20789-feae-4261-9107-524520b01c0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:JulyRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fe7e291-90ef-457d-8a32-938bb17e4966"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60e8ad0c-7547-4527-8724-24923bdc82a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_610cf94d-af47-4533-bd1a-06eb6eed02ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lgvn:LongeveronMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_611dbbc0-e2ce-41b4-85bf-90180810a5c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">lgvn:AccountsReceivableFromCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61e522cf-6101-40bb-b529-2e57609235e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6366083b-23db-422d-a18f-92b5b0481e03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63c4202f-ab95-43b7-9ac7-8fc5f186cdb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_651c763b-11ca-4b66-a7a6-bbdd17189552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_655c9a5e-6bc6-4cd8-9dec-b75e3ef72592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyOfferingPlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65a27186-d86b-45fd-9ea9-84445417ac27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66ab6a93-936f-44ff-be1a-6cfc54371b2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrants1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_681d8182-c08b-4f2c-b850-c94acff077c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:AprilTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_682a89cb-47a9-46e1-bdd9-3cd1abe13dd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68de77cc-d120-4576-8f01-a84116620f4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-26</xbrli:startDate><xbrli:endDate>2024-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68efe625-4084-44ea-8dd6-7181da4c1023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:InvestorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69d91da2-7bca-4bff-9cb8-c9cfd3c244e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f844770-8d63-4c0a-b0d4-165e7185f787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_701daa93-ad26-4a44-8b06-338415e1f2ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70201005-5bfe-4448-ba31-f3aebe56ae09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_711f128e-33db-462a-b513-6bbea4533ff0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-10</xbrli:startDate><xbrli:endDate>2024-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_713a5589-63ed-440c-848f-a0dc06ed8d24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_724dcd9a-d231-46d1-a3ea-7d375a83a614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72fb5ee4-e997-41b0-a33d-75e6db840ad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_747cbc79-ca1c-46c7-be44-ba004328f6dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgvn:OwnershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7483a01b-1311-4461-aef8-66d710fd0bf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75235aac-f968-4f7c-9c6b-79a7b4522881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7534eddc-bba5-4cf0-ba3e-08178e69ed62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_762471a3-e00f-4635-974d-de11609e581f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7697e068-658d-48a3-9b3b-a722fcb2fa76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-19</xbrli:startDate><xbrli:endDate>2024-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7707aae5-ac5b-4ae5-9938-ac6e3ea965d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77836947-2834-438d-856e-a46d1692ea17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyOrdinaryCoursePlacementAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77ca1123-0343-4fd4-a5b4-64151b7b9e0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b2a701b-185b-46d8-a802-15cd82f62888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bec887e-3248-45a0-9092-39870e2cd880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7dc4f84c-8059-4df0-9eab-ce1957519154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ebcdbcd-409e-4f2d-81dd-ac2a0d38a037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001721484</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-16</xbrli:startDate><xbrli:endDate>2016-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>lgvn:Segment</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_f8479f6d-5b6c-4d05-a3d1-b92c863314eb" fromRefs="F_3e89db0d-7516-4cec-996c-1c90638f3e28 F_65783fe8-1f0d-4364-afe5-73df559ef586 F_e7605902-0fdc-48bc-ac79-49562b553579 F_5e12fe2a-e38a-40fb-b7a3-505eb340170c"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_affce6d7-8e57-4056-a01d-c9ca371ee566" fromRefs="F_e0775914-fe76-4600-af8b-6b08dc8dac74 F_4fe7344d-dc91-49e0-aee7-d442e2d389dd"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_f578064d-d204-42b8-aee5-f8e88fc6a93c" fromRefs="F_1506c981-952d-431b-9ae9-0eee92cf20a8 F_68c40c4e-72da-4111-a80c-2a6b9a5d361f"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_a97c71f4-761d-4b7e-8797-b7ae4e3b378b" fromRefs="F_7b0064f9-c27c-44e2-9b5c-e6fbce2f3e7f F_79c07512-b711-4832-aae8-da319894fc9a"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_cc02af35-7765-4878-8a7d-93447031342c" fromRefs="F_b1e54a54-2fef-4b3f-9eb7-bbe5f27d191f F_28d74d80-ba84-4ec2-b668-ae0a233df880"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_e02994b6-ff61-46f2-aac1-3e0c30130e6b" fromRefs="F_d5e1e494-ef20-49f0-8135-b7dfd7673fce F_be21a908-5147-465a-b102-ef2722d341f4"/></ix:resources></ix:header></div>
  <div style="padding-top:0.4in;z-index:-3;min-height:0.4in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6726c95e-3d29-4ee2-a6cd-abbe6c2db935" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_31355f70-39eb-4f93-8627-9708c10f5f49" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa698a0b-1a62-4315-9811-2eb7a9974344" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c0526a9-aa45-406e-85a3-b231fa4fbf0b" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63658d3e-df75-487f-aa51-9e164a90882e" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:95%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_e8cd5bd3-74ee-404e-b5d1-8d798a917f35" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from                       to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                        </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07911fd8-c977-4381-9ce0-6a70a2b13e02" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-40060</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_320e716a-0c71-4309-a2db-7d84942b4e9a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LONGEVERON INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:49%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_cf51ad73-fefe-48a5-9495-7c6b330695e7" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_cdd3de36-857f-4380-b93d-7181974c50e5" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47-2174146</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(I.R.S. Employer <br/>Identification Number)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:49%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2cbc8cf6-ef3f-4bbf-9913-653fea465fcd" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1951 NW 7</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">th </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Avenue</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_ac92825c-fc92-41f9-83d5-c56847410c8a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 520</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5c86d870-2242-479e-a817-4c141a53ec2b" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Miami</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_eedbd206-3972-486c-85ff-7853cfde6c82" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Florida</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;33136</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_8ae6076c-f924-4018-b64b-51f977885c5a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">33136</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d1b1d2c-dc55-4486-8502-cb6d4daae2c4" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(305)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a562a78-10dc-4a65-989c-ac6f35ef9909" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">909-0840</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:32%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:32%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:32%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5e676ed1-810f-4d99-9a05-3f44f5b08b02" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class A common stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_c8b82cc2-62c7-4aa8-8959-5046dc3ff12c" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LGVN</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">The </span><span style="font-size:9pt;"><ix:nonNumeric id="F_3606efd9-6935-4162-8611-2132e38b569f" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;Capital Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0aee12c-1117-4bd4-92af-1a5e849d3ccf" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c68e67a2-0efe-48f0-99ea-59c3fc68ef9c" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd97f40b-9457-4929-9155-147744696255" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_508c812e-3634-4c19-86a5-0bbe658fb963" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40%;box-sizing:content-box;"/>
    <td style="width:30%;box-sizing:content-box;"/>
    <td style="width:30%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.625in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer </span><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.625in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_85cc83cc-9402-4701-850d-586e20279f63" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company </span><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_86445a9d-c671-4de9-8adf-21046fc54f56" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_c41d5b93-dd14-44ca-ace1-7deaf502b33c" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_88ff95bd-3ada-4eac-810d-2a9c8c9acc0b" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_3db81d20-3260-4045-b844-c6f96dcf8f67" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_728179c3-49f0-458b-8d30-cf7b9b7cbeba" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_95d25ec1-babc-4d28-9599-9913463f349b" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates was approximately $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f5678a1-d296-4195-b39c-85ce3665064a" contextRef="C_bdad186e-621a-48f4-845c-d93f9eac4f04" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">12,438,864</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as of June 30, 2024 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter).</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 17, 2025, the registrant had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1dec795-959a-4112-a14a-e915fa3e1d53" contextRef="C_43a9f4de-dc23-43f2-a1af-93cc67efc849" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,473,898</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, $0.001 par value per share, and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_967515b9-bc41-4c34-997c-c61602e82ac0" contextRef="C_8517f575-39c7-4d46-8576-6a86abfaa79e" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,454,005</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class B common stock, $0.001 par value per share, outstanding.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78cc14b1-e2b0-4279-895e-7410b7f23a7d" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></ix:nonNumeric></span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.4in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:90%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1. Business</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1B. Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1c. Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 2. Properties</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 3. Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 4. Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 6. [Reserved]</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_mda"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9A. Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9B. Other Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 11. Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related Transactions and Director Independence</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accountant_fees"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 14. Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:7.9pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:7.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_and_financial"><span style="font-variant:small-caps;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 15. Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In this document, the terms &#8220;Longeveron,&#8221; &#8220;Company,&#8221; &#8220;Registrant,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Longeveron Inc. We have no subsidiaries.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K (this &#8220;10-K&#8221;) contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current expectations about our future results, performance, prospects and opportunities. This 10-K contains forward-looking statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this 10-K, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements contained in this report include, but are not limited to, statements about:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance, and ability to continue as a going concern ;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to scale production and commercialize the product candidate for certain indications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competing therapies that are or may become available;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the need to hire additional personnel and our ability to attract and retain such personnel; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this 10-K and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statements. We operate in a highly competitive and rapidly changing environment; therefore, new risk factors can arise, and it is not possible for management to predict all such risk factors, nor to assess the impact of all such risk factors on our business or the extent to which any individual risk factor, or combination of risk factors, may cause results to differ materially from those contained in any forward-looking statement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. We do not undertake any obligation to update these statements to reflect events or circumstances occurring after the date this 10-K is filed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 1. Business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company&#8217;s lead investigational product is Lomecel-B&#153;, an allogeneic Mesenchymal Stem Cell (&#8220;MSC&#8221;) formulation sourced from the bone marrow of young, healthy adult donors. Lomecel-B&#153; has multiple potential mechanisms of action that promote tissue repair and healing with broad potential applications across a spectrum of disease areas. The underlying mechanism(s) of action that may lead to tissue repair programs include the stimulation of new blood vessel formation, modulation of the immune system, anti-inflammatory properties, reduction in tissue fibrosis, and the stimulation of endogenous cells to divide and increase the numbers of certain specialized cells in the body.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently pursuing three pipeline indications: Hypoplastic Left Heart Syndrome (&#8220;HLHS&#8221;), Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Aging-related Frailty. Our mission is to advance Lomecel-B&#153; and other cell-based product candidates into pivotal or Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longeveron received notice from the World Health Organization (&#8220;WHO&#8221;) that the name &#8220;laromestrocel&#8221; for our Lomecel-B&#153; product has been adopted by the WHO and published in the </span><span style="color:#1a1a1a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">International Nonproprietary Names (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INN) list 132 on February 13, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HLHS</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our HLHS program is focused on the potential clinical benefits of Lomecel-B&#153; as an adjunct therapeutic to standard-of-care HLHS surgery. HLHS is a rare and devastating congenital heart defect in which the left ventricle is severely underdeveloped. As such, babies born with this condition die shortly after birth without undergoing a complex series of reconstructive heart surgeries. Despite the availability of life-saving surgical interventions, clinical studies show that only 50 to 60 percent of affected individuals survive to adolescence. Early clinical study data shows the potential survival benefit of Lomecel-B&#153; for HLHS patients and supports Longeveron&#8217;s belief that these data show the potential to alter the treatment landscape for patients with HLHS. We have completed a Phase 1 open-label study (&#8220;ELPIS I&#8221;)</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that supported the safety and tolerability of Lomecel-B&#153; for HLHS, when directly injected into the functional right ventricle ("RV") during the second-stage standard-of-care surgery (adding minimal additional time to the surgical procedure). Preliminary data revealed that several indices of right ventricular function show suggestions of either improvement or prevention of deterioration over one year following surgery. Heart transplant-free survival for patients who received Lomecel-B&#153; intracardiac injection is favorable as compared to historical controls for survival. The ELPIS I trial showed 100 percent transplant-free survival in children up to 5 years after receiving Lomecel-B</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, compared to a 20 percent mortality rate observed from historical control data. The improvement in HLHS survival following the Phase 1 ELPIS I clinical trial resulted in scientific presentations at American Heart Association (&#8220;AHA&#8221;) in November 2023 and Congenital Heart Surgeons' Society's 51st Annual Meeting in October 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on these findings, the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) granted Lomecel-B&#153; Rare Pediatric Disease (&#8220;RPD&#8221;) Designation, Orphan Drug Designation (&#8220;ODD&#8221;), and Fast Track Designation for treatment of infants with HLHS. On September 3, 2024 Longeveron announced a positive Type C meeting with the FDA supporting the advancement of Lomecel-B&#153;. Longeveron is currently conducting a controlled Phase 2b trial (&#8220;ELPIS II&#8221;) to compare the effects of Lomecel-B&#153; as an adjunct therapeutic versus standard-of-care (HLHS surgery alone). We hope that a positive outcome could add to the clinical data suggesting the clinical benefit of Lomecel-B&#153; as part of standard-of-care treatment in HLHS patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the Type C meeting, we reached foundational alignment with the FDA on the registrational path to pursue traditional approval for Lomecel-B&#153; for treatment of HLHS, based on the proposed clinical development program, which includes the ongoing Phase 2b ELIPIS II study as the pivotal study to provide primary evidence of effectiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Sunjay Kaushal, M.D., Ph.D, Joshua M Hare, M.D., Jessica R Hoffman, Ph.D, Riley M Boyd, BA, Kevin N Ramdas, M.D., MPH, Nicholas Pietris, M.D., Shelby Kutty, M.D., Ph.D, MS, James S Tweddell, M.D., S Adil Husain, M.D., Shaji C Menon, MBBS, M.D., MS, Linda M Lambert, MSN-cFNP, David A Danford, M.D., Seth J Kligerman, M.D., Narutoshi Hibino, M.D., Ph.D, Laxminarayana Korutla, Ph.D, Prashanth Vallabhajosyula, M.D., MS, Michael J Campbell, M.D., Aisha Khan, Ph.D, Eric Naioti, MSPH, Keyvan Yousefi, PharmD, Ph.D, Danial Mehranfard, PharmD, MBA, Lisa McClain-Moss, Anthony A Oliva,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ph.D, Michael E Davis, Ph.D, Intramyocardial cell-based therapy with Lomecel-B&#153; during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: The ELPIS phase I trial, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Heart Journal Open</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alzheimer&#8217;s Disease</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we completed our Phase 2a AD clinical trial, known as the CLEAR MIND trial. This trial enrolled patients with mild AD and was designed as a randomized, double-blind, placebo-controlled study across ten U.S. centers. Our primary objective was to assess safety, and we tested three distinct Lomecel-B</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dosing regimens against placebo.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The study demonstrated positive results. The established safety profile of Lomecel-B&#153; for single and multiple dosing regimens was demonstrated in study data that showed no incidence of hypersensitivity or infusion-related reactions, there were no cases of amyloid-related imaging abnormalities (ARIA), and all Lomecel-B&#153; treatment groups met the safety primary endpoint and showed slowing/prevention of disease worsening relative to placebo. There were statistically significant improvements in the secondary efficacy endpoint, composite AD score (&#8220;CADS&#8221;) for both the low-dose Lomecel-B</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> group and the pooled treatment groups compared to placebo. Other doses also indicated promising results in slowing/prevention of disease worsening. Additionally, a statistically significant improvement versus placebo was observed in the Montreal cognitive assessment (&#8220;MoCA&#8221;) and in the activity of daily living observed by a caregiver and measured by Alzheimer&#8217;s disease Cooperative Study Activities of Daily Living (&#8220;ADCS-ADL&#8221;). The study indicated potential preservation of brain volumes in some but not all AD related areas of brain 39 weeks after treatment commenced. Brain magnetic resonance imaging (&#8220;MRI&#8221;) results demonstrated a 48% reduction in whole brain volume loss, 62% reduction in hippocampal volume loss, and potential improvement in neuroinflammation in some but not all brain regions via diffusion tensor imaging (DTI).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of the CLEAR MIND trial were presented in the Featured Research Session at the 2024 Alzheimer&#8217;s Association International Conference (&#8220;AAIC&#8221;) in July 2024. The brain volume results measured by MRI results from this trial also were presented at the poster presentation at AAIC. These findings support both the safety and potential therapeutic benefit of Lomecel-B</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in managing mild AD, and we believe lays the groundwork for subsequent trials in this indication. Based on these results, the FDA granted Regenerative Medicine Advanced Therapeutics (RMAT) Designation on July 9, 2024, and Fast Track designation on July 17, 2024, to Lomecel-B&#153; for the treatment of mild AD.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional data</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the CLEAR MIND trial was presented as a late breaking poster presentation at the Clinical Trials on Alzheimer's Disease Conference (&#8220;CTAD24&#8221;) in October 2024 in Madrid, Spain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the totality of the evidence, the FDA granted our request for a Type B meeting and we anticipate meeting with them in  late Q1 2025, during which we intend to discuss possible development paths for Lomecel-B&#153; in mild AD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aging-related Frailty</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvement of the quality of life for the aging population is one of the strategic directions of the Company. Life expectancy has substantially increased over the past century due to medical and public health advancements. However, this longevity increase has not been paralleled by health span &#8211; the period of time one can expect to live in relatively good health and independence. For many developed and developing countries, health span lags life-expectancy by over a decade. This has placed tremendous strain on healthcare systems in the management of aging-related ailments and presents additional socioeconomic consequences due to patient decreased independence and quality-of-life. Since these strains continue to increase with demographic shifts towards an increasingly older population, improving health span has become a priority for health agencies, such as the National Institute on Aging (&#8220;NIA&#8221;) of the National Institutes of Health (&#8220;NIH&#8221;), the Japanese Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;), and the European Medicines Agency (&#8220;EMA&#8221;). As we age, we experience a decline in our own stem cells, a decrease in immune system function (known as &#8220;immunosenescence&#8221;), diminished blood vessel functioning, chronic inflammation (known as &#8220;inflammaging&#8221;), and other aging-related alterations that affect biological functioning.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Clinical Development Strategy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our core strategy is to become a world-leading regenerative medicine company through the development, approval, and commercialization of novel cell therapy products for unmet medical needs, with a focus on HLHS. Key elements of our current business strategy are as follows.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Execution of ELPIS II, a Phase 2b randomized controlled trial set forth in greater detail below, to measure the efficacy of Lomecel-B&#153; in HLHS. This trial is ongoing and is being conducted in collaboration with the National Heart, Lung, and Blood Institute (&#8220;NHLBI&#8221;) through grants from the NIH.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continue to pursue the therapeutic potential of Lomecel-B&#153; in mild AD. We completed a Phase 2a trial, the (&#8220;CLEAR MIND Trial&#8221;), which demonstrated the potential benefits of Lomecel-B&#153; over placebo to maintain cognitive function and slow deterioration of brain structure atrophy, with no safety issues observed. Specifically, the safety primary endpoint was met across all study groups and the trial demonstrated a statistical significance in the second CADS endpoint. Overall, in Lomecel-B&#153; groups, brain MRI demonstrated that whole brain volume loss was slowed, accompanied by significant preservation of multiple brain regions, including left hippocampus relative to placebo. We plan to continue to analyze the data in order to further develop our clinical development strategy. Our objective is to forge strategic collaborations for the advancement of Lomecel-B&#153; in addressing AD. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limited focus on our international program. In line with the Company&#8217;s strategic direction for 2025 and moving forward to focus on HLHS and AD as set forth previously, in April 2024, the Company discontinued its clinical trial in Japan to evaluate Lomecel-B&#153; for Aging-related Frailty. The Company will continue to enroll patients on the Frailty and Cognitive Impairment registry trials in The Bahamas and plans to also launch an Osteoarthritis registry trial.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expand our manufacturing capabilities to commercial-scale production. We operate a current good manufacturing practice (&#8220;cGMP&#8221;)-compliant manufacturing facility and produce our own product candidates for testing. We continue to improve and expand our capabilities with the goal of achieving cost-effective manufacturing that may potentially satisfy future commercial demand for potential Lomecel-B&#153; commercialization.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative arrangements and out-licensing opportunities. We will be opportunistic and consider entering into co-development, out-licensing, or other collaboration agreements for the purpose of eventually commercializing Lomecel-B&#153; and other products domestically and internationally if appropriate approvals are obtained.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product candidate development pipeline through internal research and development, and in-licensing. Through our research and development program, and through strategic in-licensing agreements, or other business development arrangements, we intend to actively explore promising potential additions to our pipeline.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continue to expand our intellectual property portfolio. Our intellectual property is vitally important to our business strategy, and we have taken and continue to take significant steps to develop this property and protect its value. Results from our ongoing research and development efforts are intended to add to our existing intellectual property portfolio.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Pipeline in 2025</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently in clinical development of a single product, Lomecel-B&#153; for three potential indications:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img237815897_0.jpg" alt="img237815897_0.jpg" style="width:661px;height:145px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 1: Lomecel-B&#153; clinical development pipeline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Not currently active for 2025</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hypoplastic Left Heart Syndrome (HLHS)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The FDA granted Lomecel-B&#153; for the treatment of HLHS a Rare Pediatric Disease (&#8220;RPD&#8221;) Designation (on November 8, 2021), Orphan Drug Designation (&#8220;ODD&#8221;) (on December 2, 2021), and Fast Track Designation (on August 24, 2022). HLHS is a rare congenital heart condition affecting approximately 1,000 newborns in the US annually. HLHS is a birth defect that affects normal blood flow through the heart. As the baby develops during pregnancy, the left side of the heart does not form correctly so that babies are born with an underdeveloped or absent left ventricle. It is one type of congenital heart defect present at birth. Because a baby with this defect needs surgery or other procedures soon after birth, HLHS is considered a critical congenital heart defect. To prevent certain death shortly after birth, these babies undergo a series of three heart surgeries (staged surgical palliation) that reconfigures the single right ventricle to support systemic circulation. Despite</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">these life-saving surgeries, HLHS patients nevertheless still have high early mortality and morbidity rates due primarily to heart failure.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently conducting an ongoing Phase 2b clinical trial (ELPIS II) under FDA IND 017677. ELPIS II is a multi-center, randomized, double-blind, controlled clinical trial designed to evaluate Lomecel-B&#153; as an adjunct therapy to the standard-of-care second-stage HLHS heart reconstructive surgery which is typically performed at 4-6 months after birth. The primary objective is to evaluate change in right ventricular ejection fraction after Lomecel-B&#153; treatment versus standard-of-care surgery alone (38 subjects total: 19 per arm). This trial is presently over 90% enrolled and is funded in part by the NHLBI/NIH. While enrollment completion was initially targeted for the end of 2024, given the relatively small patient population, clinical trial enrollment timing for rare diseases like HLHS is difficult to predict and we anticipate full enrollment will be completed prior to the end of the second quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ELPIS II is a next-step trial to our completed 10-patient open-label Phase 1 trial (ELPIS I) under the same IND. This Phase 1 trial was designed to evaluate the safety and tolerability of Lomecel-B&#153; as an adjunct to the second-stage HLHS surgery, and to obtain preliminary evidence of Lomecel-B&#153; effect to support a next-phase trial. The primary safety endpoint was met: no major adverse cardiac events (&#8220;MACE&#8221;) or treatment-related infections during the first month post-treatment, and no triggering of stopping rules. Furthermore, fluid-based and imaging biomarker data supported multiple potentially relevant mechanisms-of-action of Lomecel-B&#153;, and the potential to improve post-surgical heart function.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All ELPIS I patients had completed long-term follow-up, and 100% 5-years post-Glenn survival data were presented by Principal Investigator Dr. Sunjay Kaushal, Cardiovascular and Thoracic Surgery, University of Nevada, Las Vegas at American Heart Association (&#8220;AHA&#8221;) in November 2023 and Congenital Heart Surgeons' Society's 51st Annual Meeting in October 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have filed patent applications relating to the administration of Lomecel-B&#153; for treating HLHS in Australia, the Bahamas, Canada, China, the European Patent Office, Japan, Hong Kong, South Korea, Taiwan, and the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alzheimer&#8217;s disease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. AD, a devastating neurologic disease leading to cognitive decline, currently has very limited therapeutic options. An estimated 6.7 million Americans aged 65 and older have AD, and this number is projected to more than double by 2060. Lomecel-B&#153; treated patients showed an overall slowing/prevention of disease worsening compared to placebo in the completed Phase 2a study (CLEAR MIND) as previously detailed in this report, and met its primary endpoint of safety. These results are consistent with those of our earlier Phase I study</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Based on these results, in July 2024, the FDA granted RMAT designation and Fast Track designation to Lomecel-B&#153; for the treatment of mild AD. We believe Lomecel-B&#153; is the only product candidate to be granted RMAT designation for mild AD to date.We intend to forge strategic collaborations, consider potential partnerships, or pursue other available pathways or opportunities for the advancement of Lomecel-B&#153; in addressing AD.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have filed patent applications relating to the treatment of AD using Lomecel-B&#153; in Australia, the Bahamas, Canada, China, the European Patent Office, Hong Kong, Israel, Japan, New Zealand, South Korea, Singapore, South Africa, and the United States. We have also filed another family of patent applications relating to improving Brain Architecture in Alzheimer&#8217;s disease using Lomecel-B&#153; in the Bahamas, Taiwan, in addition to a PCT application.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aging-related Frailty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Aging-related Frailty is a life-threatening geriatric condition that disproportionately increases risks for poor clinical outcomes from disease and injury. While the definition of Aging-related Frailty lacks consensus, would be a new indication from a regulatory standpoint, and has no approved pharmaceutical or biologic treatments, there are a number of companies now working to develop potential therapeutics for this unmet medical need.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have previously completed two U.S. clinical trials under FDA IND 016644. One is a multi-center, randomized, placebo-controlled Phase 2b trial which showed that a single infusion of Lomecel-B&#153; significantly improved 6-Minute Walk Test (&#8220;6MWT&#8221;) distance 9 months after infusion (although results were inconclusive at six months after infusion), and also showed a dose-dependent increase in 6MWT distance 6 months after infusion. The second is a multi-center, randomized, placebo-controlled Phase 1/2 trial (&#8220;HERA Trial&#8221;) intended primarily to evaluate safety, and explore the effect Lomecel-B&#153; may have on specific biomarkers of immune system function in older, frail individuals receiving the high dose influenza vaccine, as well as to evaluate the potential effects of Lomecel-B&#153; on signs and symptoms of Aging Frailty. Results from this study showed that Lomecel-B&#153; was generally safe and well tolerated in patients with Aging-related Frailty. Additionally, hemagglutinin inhibition (&#8220;HAI&#8221;) assay results in the Lomecel-B&#153; and placebo groups to influenza were not statistically different, indicating Lomecel-B&#153; does not suppress the immune system.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have filed patent applications relating to the administration of Lomecel-B&#153; for Aging-related Frailty in Australia, Canada, China, the European Patent Office, Hong Kong, Israel, Japan, Singapore, South Korea, New Zealand, South Africa, Taiwan, the Bahamas and the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture and delivery of cell therapy products to patients involves complex, integrated processes. Commercial success in this area requires manufacturing processes that are reliable, scalable, and economical. We currently operate a manufacturing facility in Miami, Florida, which supplies Lomecel-B&#153; for our clinical trials and also serves as our corporate headquarters. We have devoted and plan to continue devoting significant resources to optimization of process development and manufacturing to reduce per-unit manufacturing costs and to enable quick scale-up of production upon approval of any of our candidates in a particular country.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current good manufacturing process (&#8220;cGMP&#8221;) facility went online in early 2017 and consists of 4,150 ft</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (385.5 m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) with approximately 3,000 ft</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(279 m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of cGMP space comprised of eight International Organization for Standardization (&#8220;ISO&#8221;) 7 cleanrooms, and ISO 8 ancillary areas and 1,150 ft</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (107 m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) of warehouse, research and development and Quality Control space, including two research and development laboratories. The cGMP cleanrooms are used exclusively for the manufacture of human cellular therapy products for use in clinical trials. The facility is in compliance with FDA regulations in the Code of Federal Regulations 21, Parts 210 and 211.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lomecel-B&#153;, consists of human allogeneic bone-marrow derived mesenchymal stem cells as the active ingredient. These cells undergo culture-expansion using proprietary processes, and are then formulated, packaged and stored frozen (cryopreserved) until shortly before use</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fresh bone marrow is procured from established, licensed U.S.-based third-party tissue suppliers, which harvest the tissue from young, healthy consenting adult donors. Lomecel-B&#153; is produced using processes that FDA has reviewed and authorized as part of our INDs. We currently have multiple suppliers for GMP-grade bone marrow. These suppliers provide adequate bone marrow for our current and anticipated needs; however, if one or more suppliers were to no longer provide bone marrow, alternate suppliers would be needed or our ability to produce Lomecel-B&#153; in the future could be impacted.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Technology Capabilities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From the commencement of operations in 2014, we recognized the potential for a cellular therapy to be a novel product candidate in our chosen indications. We have assembled a team of experts and proprietary technologies that we believe enables us to take a systematic approach to rapidly develop improved cell therapies. We believe having established manufacturing capabilities and operations within the U.S. early in the development of our product candidates is a competitive advantage. Over time, as needed and appropriate, we expect to expand regional manufacturing capacity and potentially add external supply nodes to meet projected product requirements for commercialization. We believe that anticipated future clinical and commercial demand for Lomecel-B&#153; and new pipeline programs can be met, as our process has been designed to meet these demands as milestones are achieved. We believe our scalable robust manufacturing process, along with our proprietary technologies and our industry experienced team, would be challenging and costly for potential competitors to replicate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract Development and Manufacturing Services</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We produce all of our product candidates in the ISO 7 cleanrooms of our cGMP facility to satisfy our ongoing clinical studies and The Bahamas Registry Trial. As a revenue-generating opportunity, occasionally we utilize excess capacity, when available, to provide contract manufacturing and development services to third parties; however, our business development activity is limited in this area.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing Services Agreement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 21, 2024, the Company entered into a five-year Supply Agreement with a third-party biotechnology company developing multiple, novel secretomes to address a spectrum of diseases driven by pathological processes, to manufacture, test, release, and supply the third-party with cardiac stem cells (the &#8220;Product&#8221;) to be used in Phase 1 and Phase 2 clinical trials.  The Company received an initial start-up payment upon signing and will thereafter bill on a variable fee basis for quality control, in process, release, and stability testing service items. The Company will receive a fee for product management and manufacturing services.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Mark Brody, Marc Agronin, Brad J. Herskowitz, Susan Y. Bookheimer, Gary W. Small, Benjamin Hitchinson, Kevin Ramdas, Tyler Wishard, Katalina Fern&#225;ndez McInerney, Bruno Vellas, Felipe Sierra, Zhijie Jiang, Lisa McClain-Moss, Carmen Perez, Ana Fuquay, Savannah Rodriguez, Joshua M. Hare, Anthony A. Oliva Jr., Bernard Baumel. &#8220;Results and insights from a phase I clinical trial of Lomecel-B&#153; for Alzheimer&#8217;s disease&#8221; (2023) Alzheimer&#8217;s &amp; Dementia: The Journal of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Alzheimer&#8217;s Association 19:261-273.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no established sales, marketing or product distribution infrastructure. In order to commercialize any of our product candidates if approved for commercial sale, we will need a sales and marketing organization with technical expertise and supporting distribution capabilities or collaborate with third parties that have sales and marketing experience. As we move our product candidates through development toward regulatory approval, we plan to evaluate several options for each product candidate&#8217;s commercialization strategy. These options include further building an internal sales force, entering into a joint marketing collaboration with another pharmaceutical or biotechnology company, or out-licensing any future approved product to another pharmaceutical or biotechnology company. All such commercialization will be undertaken in accordance with applicable law.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The field of regenerative medicine, which includes gene therapies, cell therapies (such as Lomecel-B&#153;), and tissue-engineered products, is broadly defined as &#8220;products intended to repair, replace or regenerate organs, tissues, cells, genes, and metabolic processes in the body,&#8221; per the Alliance for Regenerative Medicine (&#8220;ARM&#8221;), an international advocacy organization. Regenerative medicine companies number over 2,936 worldwide as of December 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the following table is a general, non-comprehensive list of cellular therapy companies that we believe could be considered our primary competition, either because they also develop mesenchymal stem cells as their primary mode of action, albeit for different indications in most cases, or on the basis that these companies are addressing the same indications as Longeveron.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARDS = Acute Respiratory Distress Syndrome; GvHD = Graft versus host disease; ALS = Amyotrophic lateral sclerosis; MS = Multiple sclerosis; BPD = Bronchopulmonary dysplasia; CLI = Critical limb ischemia; CMD = Coronary microvascular disease; ARS = Acute radiation syndrome.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.84%;box-sizing:content-box;"/>
    <td style="width:11.7%;box-sizing:content-box;"/>
    <td style="width:56.46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Company</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Corporate Headquarters</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Clinical stage pipeline indications</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Athersys</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ischemic Stroke, Trauma, Acute Respiratory Distress Syndrome</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BioCardia</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ischemic heart failure; Chronic Myocardial Ischemia</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BlueRock Therapeutics</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Parkinson's disease</span></p></td>
   </tr>
   <tr style="height:30pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BrainStorm Cell Therapeutics</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Israel</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alzheimer's disease; Multiple Sclerosis; Lateral Scelerosis; Parkinson's disease</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CellProthera</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">France / USA</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acute Myocardial Infarction</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CorestemChemon</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">South Korea</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ALS (commercial in South Korea); Lupus</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cynata Therapeutics</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Australia</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Graft-versus-host-disease; Acute Respiratory Distress Syndrome</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Healios KK</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Japan</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ischemic Stroke; Acute Respiratory Distress Syndrome</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Kadimastem</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Israel</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alzheimer's disease; Multiple Sclerosis; Diabetes</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Medipost</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">South Korea</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Osteoarthritis; Bronchopulmonary Dysplasia</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mesoblast</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Australia</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Heart failure; HLHS; GvHD; ARDS; Crohn's Disease</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ReNeuron</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">UK</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ischemic stroke</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SanBio Co Ltd</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ischemic stroke; Brain Injury</span></p></td>
   </tr>
   <tr style="height:15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stemedica Cell Technologies</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">USA</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.08in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ischemic Stroke; Alzheimer's disease; Heart failure; AMI</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hypoplastic Left Heart Syndrome Competitive Intelligence Research</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Per C</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">linicalTrials.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as of February 6, 2025, there were 39 interventional clinical trials and 25 observational studies   listed studying HLHS in a pediatric patient population across all stages of development. Among those there were 2 surgical intervention trials which are actively enrolling patients and no medical intervention studies. There were 22 clinical studies which were completed in HLHS patient populations and all of them were conducted as an investigator-sponsored trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alzheimer&#8217;s Disease Competitive Intelligence Research</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> also</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> many pharmaceutical and biotechnology companies that are conducting clinical trials of various therapeutics for the treatment of AD. Per ClinicalTrials.gov, as of February 6, 2025, there were 3,608 studies listed on the site studying Alzheimer&#8217;s disease, including all stages (ongoing, completed, terminated, withdrawn) and all interventions.  Five of them were listed as active clinical studies with cell therapies (4 interventional and 1 observational).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mesoblast</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 18, 2024, the FDA approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Ryoncil is the first FDA-approved MSC therapy. It contains mesenchymal stem cells, which are a type of cell that can have various roles in the body and can differentiate into multiple other types of cells. These mesenchymal stem cells are isolated from the bone marrow of healthy adult human donors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe the recent approval of the Mesoblast product Ryoncil by the FDA represents a positive development for Longeveron, as it belongs to the same class of cell therapy as Lomecel-B&#153;.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to protect our proprietary technology, inventions, and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, whether developed internally, acquired from third parties, or licensed from third parties. We also intend to seek and rely on any statutory or regulatory protections, including FDA&#8217;s expedited review program, data exclusivity, market exclusivity and patent term extensions where available.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longeveron received notice from the World Health Organization (&#8220;WHO&#8221;) that the name &#8220;laromestrocel&#8221; for our Lomecel-B&#153; product has been adopted by the WHO and published in the </span><span style="color:#1a1a1a;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">International Nonproprietary Names (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INN) list 132 on February 13, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a combination of Company-owned and in-licensed patents and patent applications related to cell-based therapy and its various uses. This portfolio includes patent applications directed to use of allogeneic mesenchymal stem cells to treat sexual dysfunction. We also have in-licensed a patent family directed to methods of use of CD271+ MSC precursor cells. Our patent applications contain claims that, if allowed, specifically protect the use of our product in individuals with Aging-related Frailty, immunosenescence, and other age-related diseases. We also rely on trade secrets that may be important to the development of our business. Trade secrets are difficult to protect and enforce and therefore provide us with only limited protection.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to file additional patent applications in support of current and new product candidates, as well as for process and manufacturing-related improvements or inventions, should these arise. These expected additional patent applications may be related to existing patent applications or may create new patent families. Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for our current and future product candidates and the methods used to develop, manufacture, administer, and use them. Our commercial success will also depend on successfully defending our patents against third-party challenges and operating without infringing on the proprietary rights of others. We are aware of several U.S. patents held by third parties covering potentially similar or related products, and their manufacture and use. Generally, conducting clinical trials and other acts relating to FDA approval are not considered acts of infringement in the U.S. If and when Lomecel-B&#153; mesenchymal stem cells are approved by the FDA, third parties may seek to enforce their patents by filing a patent infringement lawsuit against us. Our ability to deter and, if necessary, to stop third parties from making, using, selling, offering to sell or importing our products or products that are similar to our products depends on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We can neither be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our product candidates, discovery programs and processes. Unpublished third-party patent applications may exist that would have an effect on our freedom to operate. For this and more comprehensive risks related to our intellectual property, please see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most jurisdictions where we file, including the U.S., the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the U.S., a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office ("USPTO&#8221;), in examining and granting a patent. Patent term in the U.S. may be shortened if a patent is subject to a terminal disclaimer over another patent. Delays on the part of a patentee may decrease patent term adjustment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the term of a patent that covers an FDA-approved &#8220;active ingredient&#8221; or methods of its use may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, the Hatch-Waxman Amendments, or the Biologics Price Competition and Innovation Act of 2009 permit a patent term extension of up to five years beyond the expiration of the statutory term of a patent, including any patent term adjustment to which the patent is entitled. The length of the patent term extension is related to the length of time the active ingredient or method is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions for any issued patents we may obtain in any jurisdiction where such patent term extensions are available. We are not assured that the applicable authorities, including the FDA in the U.S., will agree with our assessment of whether such extensions should be granted, and if granted, the length of those extensions. For more information regarding the risks related to our intellectual property, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may file patent applications directly with the USPTO as provisional applications. We may file U.S. non-provisional applications, direct foreign applications under the Paris Convention and the Agreement on Trade Related Aspects of Intellectual Property Rights, and Patent Cooperation Treaty ("PCT") applications. Those applications may claim the benefit of the priority date of one or more earlier filed applications, when applicable. The PCT system allows a single application to be filed within 12 months of the original priority date of the patent application and to designate all of the PCT member states in which national or regional patent applications can later be pursued based on the PCT application.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all patent applications, we determine claim strategy on a case-by-case basis. Advice of counsel and our business model and needs are considered. We seek to file patents containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications and/or uses we discover for existing technologies and products, assuming these are strategically valuable. We routinely reassess the number and type of patent applications, as well as the pending and issued patent claims to pursue maximum coverage and value for our processes and compositions. Further, we may modify claims during patent prosecution to meet our intellectual property and business needs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors. These include the volume and scope of the prior art, the novelty, non-obviousness, and utility of the invention, and the ability to satisfy the written description and enablement requirements of the patent laws. In addition, the coverage claimed in a patent application can be significantly narrowed before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our future product candidates or for our technology platform. We cannot predict whether the patent applications we are currently pursuing will be issued as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from copying by competitors. Any patents that we hold may be challenged, circumvented, or invalidated by third parties. We cannot predict whether, in certain jurisdictions, a third-party will use a method confidentially that we later independently discover and patent, which may result in a limited grant to the third party of the ability to continue to practice that method despite our patent.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patent protection, we rely on trademark registration, trade secrets, know-how, other proprietary information and continuing technological innovation to develop and maintain our competitive position. We seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contracts with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets indefinitely.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except under specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the employee&#8217;s use of our confidential information are our exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors, or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets, know-how and inventions. For more information regarding the risks related to our intellectual property, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific, and factual questions. Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. Third-party patents could require us to alter our development or commercial strategies or our future products or processes, to obtain licenses or to cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the U.S. that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention. If third parties file requests for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">review of our patents, then we may have to defend those patents in the USPTO. For more information, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors&#8212;Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When available to expand market exclusivity, our strategy is to obtain, or license additional intellectual property related to current or contemplated development platforms, core elements of technology and/or clinical candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company-Owned Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mesenchymal Stem Cells as Vaccine Adjuvants and Methods for Using the Same. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The claims within this patent application family are currently directed to methods of enhancing the immune response to vaccination, which was one of the research objectives of our Phase 1/2 HERA Trial. This research is relevant to Aging-related Frailty subjects, who are particularly vulnerable to the effects of viral contagion, such as influenza or COVID-19, and who may be lacking in immunoprotection. Certain claims address the ability to enhance a subject&#8217;s immune response to a vaccine through the administration of a therapeutically effective amount of allogeneic mesenchymal stem cells in a subject that exhibits &#8220;inflammaging.&#8221; In this family we have one issued patent in Australia and one issued patent in the United States. We have two pending applications in Japan, one pending application in the United States, one pending application in Australia, and one pending application in the European Patent Office. One European Patent Office application was granted and then validated in Switzerland, Germany, Spain, France, Great Britain, Italy, and Sweden. All of the patent applications are national or regional phase applications based on a Patent Cooperation Treaty (&#8220;PCT&#8221;) application filed in February 2017 and claiming priority to a U.S. provisional application filed in February 2016. If issued and assuming all maintenance and annuity fees are paid, patents arising from these applications are projected to expire in 2037. Longeveron has elected to take no further action and to allow to become abandoned, properties in this family in Canada, Hong Kong, Israel, Singapore, South Africa, South Korea, and New Zealand.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Methods of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral Immunity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Certain claims in this family of patent applications relate to the ability for MSC therapy to improve the immune system function in patients with chronic systemic inflammation, a hallmark of frailty. It is believed that raising or lowering specific biomarkers after therapeutic intervention by a minimum amount may provide broad protection from an intellectual property standpoint and reflects clinical goals of treatment and treatment response.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this family we own pending applications in the Bahamas, Taiwan, Australia, Canada, China, Hong Kong (where there are three applications), the European Patent Office, South Korea, New Zealand (where there are three applications), Singapore, and the United States. Patents have issued in China, Taiwan, and Israel, two patents have issued in Japan, and a patent registration has been made in South Africa. With two exceptions (The Bahamas and Taiwan), all of the applications are national or regional phase applications based on a PCT application filed in November 2017 and claiming priority to a U.S. provisional application filed in November 2016. The applications in The Bahamas and Taiwan claim priority to that same provisional application but were not filed using the PCT. If issued and assuming all maintenance and annuity fees are paid, patents arising from these applications are projected to expire in 2037.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Treatment of Sexual Dysfunction and Improvement in Sexual Quality of Life</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This application family is directed towards increasing libido and improving sexual function and satisfaction in a female patient through the use of allogeneic or autologous MSC therapy, whether derived from bone marrow, adipose tissue or induced pluripotent stem cells (iPSCs). In this family we own and we are continuing to prosecute or maintain applications in the United States and European Patent Office, and we own a patent in Japan. We also own and are continuing to maintain a patent registration in the Bahamas. The U.S., Japanese, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European properties are a national or regional phase applications based on a PCT application filed on June 15, 2018 and claiming priority to a U.S. provisional application filed in June 2017. The registration in the Bahamas claims priority to that same provisional application but was not filed using the PCT. If issued and assuming all maintenance and annuity fees are paid, patents arising from these applications are projected to expire in June 2038. Longeveron has elected to take no further action and to allow to become abandoned, properties in the family in Australia, Canada, China, Hong Kong, Israel, Korea, Singapore, South Africa, South Korea, Taiwan, and New Zealand.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Potency Assay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This application family is directed towards assessing potency of mesenchymal stem cells to produce anti-inflammatory cytokines in response to a pro-inflammatory stimulus. In this family we own pending applications in Australia, the Bahamas, Canada, China, the European Patent Office, Hong Kong, Israel, Japan, New Zealand, the Republic of Korea, Singapore, South Africa, and the United States. These applications have a filing date in April 2021 and claim priority to a U.S. provisional application filed in April 2020. If issued and assuming that all maintenance and annuity fees are paid, patents arising from these applications are projected to expire in April 2041.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Mesenchymal Stem Cells in Treatment of Juvenile Hypoplastic Left Heart Syndrome</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This patent family is directed to treatment of HLHS with allogeneic mesenchymal stem cells. These applications share a common priority date of July 2021. National and regional phase applications based on pending PCT application have been filed in Australia, Canada, China, the European Patent Office, Japan, Hong Kong, South Korea, and the United States. Applications are also pending in Taiwan and the Bahamas. If issued and assuming all maintenance and annuity fees are paid, patents arising from these applications are projected to expire in July 2042.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Administration of Mesenchymal Stem Cells for Aging-related Frailty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This patent family relates to administration of mesenchymal stem cells for Aging-related Frailty. In this family we own pending applications in Taiwan, the Bahamas, and the PCT. These applications share a common priority date of September 2021. National and regional phase applications, based on the pending PCT application have been filed in Australia, Canada, China, the European Patent Office, Hong Kong, Israel, Japan, New Zealand, South Korea, Singapore, and South Africa. If issued, and assuming that all maintenance and annuity fees are paid, patents arising from these applications are projected to expire in September 2042.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Treatment of Alzheimer&#8217;s Disease with Allogeneic Mesenchymal Stem Cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> This patent family relates to administration of mesenchymal stem cells to treat AD. We own pending patent applications in Australia, the Bahamas, South Korea, Singapore, South Africa, Israel, Canada, Hong Kong, New Zealand, China, Japan, the European Patent Office, and the United States. Those applications claim priority to three separate U.S. provisional applications, the earliest of which was filed in September 2020. If issued, and assuming that all maintenance and annuity fees are paid, patents arising from these applications are expected to expire in September 2041.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improved Brain Architecture in Alzheimer&#8217;s Disease with Mesenchymal Stem Cells</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This patent family relates to administration of mesenchymal stem cells to treat AD.  We own pending patent applications in this family in Taiwan, the Bahamas, and the PCT.  Those applications all claim priority to a United States provisional patent application filed on December 19, 2023.  If the patent applications are allowed, any patents that issue are expected to expire on December 19, 2044.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Potency Assay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This patent family relates to a potency assay.  The family currently consists of three unpublished United States provisional patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further applications in this family are anticipated to be filed by the conclusion of the first quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements and Strategic Collaborations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The University of Miami (&#8220;UM&#8221;)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 20, 2014, we entered into an Exclusive License Agreement with UM (the &#8220;UM License&#8221;) for the use of certain Aging-related Frailty-related MSC technology rights developed by our Chief Science Officer, Dr. Joshua Hare, at UM. The UM License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how specifically related to the development of the culture-expanded mesenchymal stem cells for Aging-related Frailty, all standard operating procedures used to create the Human-induced pluripotent stem cell-derived mesenchymal stem cells (IMSCs&#8221;), and all data supporting isolation, culture, expansion, processing, cryopreservation, and management of the IMSCs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required to pay UM (i) a license issue fee of $5,000, (ii) a running royalty in an amount equal to three percent of annual net sales on products or services developed from the technology, payable on a country-by-country basis beginning on the date of first commercial sale through termination of the UM License Agreement, and which may be reduced to the extent we are required to pay royalties to a third party for the same product or process, (iii) escalating annual cash payments of up to $50,000, subject to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offset. The agreement extends for up to 20 years from the last date a product or process is commercialized from the technology and was amended in 2017 to modify certain milestone completion dates as detailed below. In 2021 the license fee was increased by an additional $100,000, to defray patent costs. In addition, the Company issued 11,039 unregistered shares of Class A common stock to UM.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The milestone payment amendments shifted the triggering payments to three payments of $500,000, to be paid within six months of: (a) the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (b) the receipt by the Company of approval for the first new drug application (&#8220;NDA&#8221;), biologics application (&#8220;BLA&#8221;), or other marketing or licensing application for the product; and (c) the first sale following product approval. &#8220;Approval&#8221; refers to product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successor agency. The amendments also provided for the Company&#8217;s license of additional technology, to the extent not previously included in the UM License and granted the Company an exclusive option to obtain an exclusive license for (a) the HLHS IND with ckit+ cells; and (b) UMP-438 titled &#8220;Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy.&#8221; The additional technology included a family of patent applications based on PCT Application No. PCT/US2015/060624, for &#8220;Substances and Methods for Treating Endothelial Dysfunction and Methods for Monitoring the Effectiveness of a Therapy in a Subject,&#8221; with patents granted in South Korea, Brazil, and Europe (with validation in France, Germany, Italy, Spain, Sweden, Switzerland, and the United Kingdom) and applications pending in Australia, Canada, China, Israel, and Japan.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have the right to terminate the UM License upon 60 days&#8217; prior written notice, and either party has the right to terminate upon a breach of the UM License. To date, the Company has made payments totaling $365,000 to UM, and as of December 31, 2024, we had accrued $50,000 in milestone fees payable to UM and $15,000 for patent related reimbursements based on the estimated progress to date.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also entered into an additional Exclusive License Agreement with UM, signed and effective as of July 18, 2024, for technology rights developed by our CSO at UM. This License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how, SOPs, data and other all other rights related to UMP-144, entitled &#8220;A method to derive GHRHR+ cardiomyogenic cells from pluripotent stem cells (PSCs) for therapeutic and pharmacologic applications&#8221; and having inventors Joshua Hare and Konstantinos Chatzistergos. UM retained a non-exclusive, royalty-free, perpetual, irrevocable, worldwide right to practice, make, and use the Patent Rights or Technology for any non-profit purposes, including educational, and research purposes. Pursuant to the terms of the license agreement, Longeveron must pay to UM: (a) $5,000 within 30 days of the Effective Date; and (b) reimbursement of $21,307 within 90 days of the Effective Date for previously incurred patent expenses; and (c) an annual $10,000 fee which is both creditable against other royalty payments for the applicable license year and is waived so long as Company is current on annual fee payments in accordance with the Exclusive License Agreement entered into November 20, 2014 between Company and UM. In addition to certain those certain other royalty payments that would be due should the Company&#8217;s sublicense of the technology result in revenue, Longeveron also agreed to the following additional milestones and payments: (c) $150,000 upon completion of the first Phase 3 Clinical Trial; and (d) $250,000 upon issuance of a biologics license application or new drug application based on the licensed technology. The Company has the right to terminate the new UM License for convenience upon 90 days&#8217; prior written notice, and both parties have additional termination rights for material breach of the agreement. To date, the Company has made payments totaling $5,000 to UM, and as of December 31, 2024, the Company (i) had accrued but not yet paid $21,307 in reimbursement of previously incurred patent expenses payable to UM and (ii) had not yet accrued any milestone fees payable to UM.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CD271</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 22, 2016, we entered into a worldwide exclusive license agreement with JMH MD Holdings, LLC (&#8220;JMHMD&#8221;), an affiliate entity of our Chief Science Officer, Dr. Joshua Hare, for the use of CD271 cellular therapy technology. We are required to pay JMHMD a running royalty in an amount equal to one percent of the annual net sales of the licensed product(s) used, leased, or sold by or for us by any sub-licensees, which amounts are payable on a country-by-country basis beginning on the date of first commercial sale and ending on the latter of expiration of the last to expire patent rights in such country or ten years from the first commercial sale in such country (provided that if all claims within the patent rights have expired or been finally deemed invalid then the royalty will be reduced by 50%), and which may also be reduced to the extent we are required to pay royalties to a third party for the same product or process. We are also required to pay an initial fee and, by the first day of each anniversary of the Agreement, starting with the second anniversary, a minimum royalty of ten thousand dollars. JMHMD also received an equity grant equal to one-half of one percent of the then outstanding units of the Company on a fully-diluted basis. If we sublicense the technology, we are also required to pay an amount equal to 10% of the net sales of the sub-licensees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, the Company is required to use commercially reasonable efforts to achieve the following milestones: (i) submit an investigational new drug application to FDA (or international equivalent) within one year of effective date of agreement, (ii) initiate a clinical trial utilizing bone marrow derived CD271+ Precursor Cells within three years of the effective</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">date; provided, that any of the milestones may be extended for up to six months for a total of three times by notice and payment of a five thousand dollar extension fee. Failure to achieve these milestones within five years of the effective date triggers a right of termination by JMHMD. Otherwise, the agreement is to remain in effect until either the date all issued patents and filed patent applications have expired or been abandoned, or 20 years after the date of FDA approval of the last commercialized product or process arising from the patent rights whichever comes later. Further, each party has the right to terminate upon sixty days&#8217; prior written notice, or in the event of breach. If the Company sublicenses the technology, it is also required to pay an amount equal to 10% of the net sales of the sub-licensees. The Company to date has not incurred any royalty or sublicense related expense, but has paid $45,000 in license fees ($10,000 per year for 2021, 2020 and 2019) and for a $15,000 extension fee. In addition, the Company paid legal fees of approximately $19,000 for each of the years ended December 31, 2024 and 2023, in connection with the patent prosecution, issuance, and maintenance fees related to CD271+ technology.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In-licensed Patents and Applications</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bone Marrow Derived CD271+ Precursor Cells for Cardiac Repair.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We have in-licensed the exclusive right to use CD271+ MSC precursors from bone marrow to treat certain aging-related conditions and diseases, such as frailty, Metabolic Syndrome, loss of muscle due to aging or frailty and neurocognitive disorders. That patent has issued in Australia, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, New Zealand, Germany, Spain, France, the United Kingdom, Italy, Sweden, and Singapore. The patent application remains pending in the U.S. While method of use claims may relate to the use of CD271+ cells for cardiac repair, our license terms exclude our use of CD271+ cells for preventing and treating cardiovascular diseases or disorders, including congenital cardiovascular defects. Assuming that all maintenance and annuity fees are paid, patents in this family are expected to expire in August 2031.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Methods for Obtaining Cardiomyogenic Precursor Cells</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  We have in-licensed from the University of Miami the exclusive right (with limited non-exclusivity for educational, research, and non-profit uses reserved to the University) to certain methods for obtaining cardiomyogenic precursor cells.  One licensed U.S. patent has issued, and one U.S. patent application is pending in the licensed family.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Methods for Monitoring Efficacy of Allogeneic Mesenchymal Stem Cell Therapy in a Subject (a/k/a Substances and Methods for Treating Endothelial Dysfunction and Methods for Monitoring the Effectiveness of a Therapy in a Subject).  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have in-licensed from the University of Miami the exclusive right (with limited rights retained by the University) to certain methods for monitoring efficacy of allogeneic mesenchymal stem cell therapy.  Patents have been granted in Brazil, South Korea, and Europe (with validation in France, Germany, Italy, Spain, Sweden, Switzerland, and the United Kingdom).</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trademarks</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have registered trademarks or applied for registered trademarks for &#8220;Longeveron&#8221; in the following jurisdictions. We have phased out the registrations and applications for &#8220;LMSC&#8221; in favor of registrations for &#8220;LOMECEL-B&#8221;. In some jurisdictions multiple registrations and/or applications exist so that multiple goods and/or services may be listed:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:65.9%;box-sizing:content-box;"/>
    <td style="width:1.14%;box-sizing:content-box;"/>
    <td style="width:18.18%;box-sizing:content-box;"/>
    <td style="width:1.14%;box-sizing:content-box;"/>
    <td style="width:13.64%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Territory</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8220;LOMECEL-B&#153;&#8221;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8220;Longeveron&#8221;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Bahamas</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brazil</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Canada</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">China</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">European Union</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hong Kong</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">India</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Japan</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">South Korea</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Morocco</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Panama</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Switzerland</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Taiwan</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allowed</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allowed/Published</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:9pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vietnam</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Registered</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation and Biologic Drug Approval</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. We believe that the FDA will regulate Lomecel-B&#153; as a biologic drug (i.e., a biologic) through the biologics license application (&#8220;BLA&#8221;) process under the jurisdiction of the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;). We intend to work with the FDA to confirm that a BLA is the most appropriate pathway and that CBER will be the FDA center responsible for review and licensure (i.e., approval). However, the FDA may disagree with us, in which case we will follow the FDA&#8217;s recommendation. For future product candidates we will also confirm the appropriate approval pathway (i.e., BLA or new drug application (&#8220;NDA&#8221;)) and the appropriate FDA center with regulatory oversight (i.e., CBER or the Center for Drug Evaluation and Research (&#8220;CDER&#8221;)).</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Biologic Drug Development Process</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., biologic drugs&#8212;or simply &#8220;biologics&#8221;&#8212;are regulated under two statutes: The Public Health Service Act (&#8220;PHS Act&#8221;) and the federal Food, Drug, and Cosmetic Act (&#8220;FFDCA&#8221;) and their implementing regulations. However, approval of only one application&#8212;typically either a BLA or an NDA&#8212;is required prior to marketing. Numerous FDA &#8220;Guidance Documents&#8221; and other materials address specific aspects of development for specific types of product candidates (e.g., cells, tissues, gene therapies, or vaccines). The process of obtaining approval and complying with applicable statutes and regulations requires substantial time and financial resources. Failure to comply with the applicable U.S. requirements before, during, or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold on ongoing clinical trials, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a biologic may be marketed in the U.S. generally involves the following steps:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with applicable regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission of an IND, which must become effective before human clinical trials may begin;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board (&#8220;IRB&#8221;) at each clinical site (or by one &#8220;commercial IRB&#8221;) before each trial may be initiated;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with current good clinical practice (&#8220;cGCP&#8221;) requirements to establish the safety, purity, and potency (i.e., efficacy) of the proposed biologic for its intended use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission of a BLA after completion of all clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory outcome of an FDA advisory committee review, if applicable;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA inspection of clinical investigation sites and the manufacturing facility or facilities at which the biologic is produced; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the U.S.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The specific preclinical studies and clinical testing that is required for a BLA varies widely depending upon the specific type of product candidate under development. Prior to beginning a human clinical trial with either a biologic or drug product candidate in the U.S., we must submit an IND that must become effective. The focus of an IND is the general investigational plan and protocol for the proposed clinical study. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls (&#8220;CMC&#8221;) information; and any available human data or literature to support the use of the investigational product. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical hold is lifted and the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. A clinical trial can also be placed on clinical hold once the study has begun.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCPs, including that all research subjects provide their informed consent to participate. Clinical trials are conducted under protocols detailing, among other things, the study objectives, safety monitoring, and effectiveness criteria. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development. Other submissions to an IND include protocol amendments, information amendments, IND safety reports and annual reports. Furthermore, an independent IRB for each clinical trial site (or a single &#8220;commercial IRB&#8221;) must review and approve the protocol and informed consent form before the clinical trial may begin. The IRB also monitors the clinical trial until completed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some clinical trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data monitoring committee (&#8220;DMC&#8221;). A DMC authorizes whether or not a study may move forward at designated check points based on data and results from the trial. The DMC may halt the clinical trial based on an unacceptable safety risk or on other grounds, such as a failure to demonstrate efficacy. Related reporting requirements for the sponsor, clinical investigator, and/or IRB also include IND safety reports and updating clinical trial results in public registries (e.g., ClinicalTrials.gov).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined. The size of these clinical trials will vary depending on the product candidate and the size of the patient population:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1: The product candidate is initially introduced into healthy human subjects to test the safety, dosage tolerance, absorption, metabolism, distribution, excretion, side effects, and, if possible, early evidence of effectiveness. In the case of some products for severe or life-threatening diseases when the product may be too inherently toxic to ethically administer it to healthy volunteers, Phase 1 studies may instead be conducted in individuals who have the targeted disease or condition instead of healthy subjects.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2: The product candidate is administered to a limited population of individuals who have the specified disease or condition to evaluate safety, preliminary efficacy, optimal dosages and dosing schedule, possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 (i.e., pivotal) clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3: Phase 3 clinical trials are generally the largest studies conducted at multiple clinical trial sites. The product candidate is administered to an expanded population that has the specified disease or condition to further evaluate dosage, provide statistically significant evidence of clinical efficacy and gain additional safety data. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, sponsors usually complete additional animal studies, develop information about the chemical and physical characteristics of the biologic and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must consistently produce quality batches of the product candidate. Furthermore, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final biologic. In addition, the sponsor must develop and test appropriate packaging and conduct stability studies to demonstrate that it does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the development of a new biologic, sponsors are given opportunities to meet with the FDA. These meetings typically occur prior to submission of an IND (i.e., pre-IND meeting), at the end of Phase 2 (i.e., EOP2 meeting), and before a BLA is submitted (i.e., pre-BLA meeting). Meetings at other times may be requested and granted if, for example, a product candidate has received a Fast Track or Breakthrough Therapy designation. These meetings provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use EOP2 meetings to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new biologic.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Review and Approval Process for Biologic Drugs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of all required testing, the sponsor submits a BLA containing the results of product development, preclinical and other non-clinical studies and clinical trials, descriptions of the manufacturing process, analytical testing, proposed labeling and other relevant information. The submission of a BLA is subject to the payment of a substantial application fee under the Prescription Drug User Fee Amendments (&#8220;PDUFA&#8221;). PDUFA fees apply to both drugs and biologics. Sponsors may seek a waiver of these fees in certain limited circumstances, including a waiver of the application fee for the first BLA or NDA submitted by a small business. Product candidates with an ODD are not subject to the BLA application fee unless the product application also includes a non-orphan indication.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews a BLA to determine, among other things, whether a biologic is safe, pure, and potent (i.e., effective) for its intended use and whether its manufacturing is cGMP-compliant to assure the product&#8217;s identity, strength, quality and purity. Under PDUFA, the FDA has a goal date of ten months from the date a standard BLA is accepted for &#8220;filing&#8221; to review and act on the submission, and six months from the date of acceptance of a BLA that has received a Priority Review Designation . However, the time between submission and filing can add an additional two months as FDA conducts a preliminary review to ensure that the BLA is sufficiently complete to permit substantive review. Formal FDA review of the BLA does not begin until FDA has accepted it for filing. These are goal dates for FDA to take action on an application, and they are not guaranteed. The FDA may refer an application in some cases to an advisory committee for its independent review. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation to FDA as to whether the application should be approved and under what conditions. The FDA is not bound by advisory committee recommendations, but it considers them carefully when making decisions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving a BLA, the FDA will typically inspect the locations where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMPs and are adequate to assure consistent production of the product within required specifications. An important part of a BLA is a lot release protocol that the sponsor will use to test each lot of product made after BLA approval, as well as the FDA&#8217;s own test plan that will be used for confirmatory testing of each post-approval product lot that is made before it is released to the public. If the FDA determines that the data and information in the application are not acceptable, then the FDA will outline the deficiencies and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA may decide that the application does not satisfy the regulatory criteria for approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA evaluates a BLA, it will either issue an approval letter or a Complete Response Letter (&#8220;CRL&#8221;). The approval letter authorizes commercial marketing of the biologic with approved prescribing information for specific approved indications. On the other hand, a CRL indicates that the review cycle of the application is complete, but the BLA cannot be approved in its present form. A CRL usually describes the specific deficiencies and the actions the sponsor must take to correct those deficiencies. A sponsor that receives a CRL must resubmit the BLA after addressing the deficiencies, withdraw the application, or request a hearing. Even if such additional data and information are submitted, the FDA may decide the resubmitted BLA still does not satisfy the approval criteria.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following marketing approval, a sponsor may need to fulfill certain post-marketing requirements (&#8220;PMRs&#8221;) or post-marketing commitments (&#8220;PMCs&#8221;). These may include Phase 4 studies that are used to gain additional experience from the treatment of patients for the intended therapeutic indication. The trials may be agreed upon prior to approval, or the FDA may require them if new safety issues emerge. A deferred pediatric study, if required (and not waived) under the Pediatric Research Equity Act (&#8220;PREA&#8221;), may also be conducted post-approval if the product includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BLA approval may also include a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) that requires sponsor post-marketing regulatory efforts. A REMS is a safety strategy to manage a known or potential serious risk associated with a drug or biologic and to enable patients to have continued access to such medicines by managing their safe use. A REMS may include medication guides, physician communication plans, or elements to assure safe use (&#8220;ETASU&#8221;) such as restricted distribution methods, patient registries, and other risk minimization tools.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA may withdraw the product approval if the sponsor does not comply with PMRs, PMCs, a REMS program, or other post-marketing requirements. The FDA may also request that a product be recalled for an identified safety issue. Finally, new legislative or regulatory requirements may be enacted or established, FDA policies may change, or FDA may not achieve its PDUFA goal dates, all of which could impact the timeline for development programs and regulatory approval.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Expedited Review Programs for Serious Conditions</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under various statutory and regulatory authorities, the FDA has authority to review and approve certain products on an expedited basis if the products are intended to treat a serious condition and meet other requirements. These expedited programs are discussed below.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RMAT Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In 2017, the FDA established the regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation as part of its implementation of the 21st Century Cures Act. Regenerative medicine therapies to treat, modify, reverse, or cure serious conditions and that meet the appropriate criteria may be eligible for RMAT designation as well as FDA&#8217;s other expedited programs (i.e., fast track, breakthrough therapy, priority review designations or accelerated approval). Regenerative medicine therapies receiving RMAT designation must meet the same standards for approval as any other biological product, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrating the product&#8217;s safety and effectiveness. As described in Section 3033 of the 21st Century Cures Act, an investigational product is eligible for RMAT designation if:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is a regenerative medicine therapy, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products (except for those regulated solely under Section 361 of the PHS Act and 21 C.F.R. Part 1271);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A request for an RMAT designation can be included in a new IND, or submitted as an amendment to an existing IND. As with other expedited programs, the FDA can withdraw an RMAT designation that has been granted if the designation criteria are no longer met. Benefits of the designation include, among others, early FDA interactions, and potential accelerated approval based on surrogate or intermediate endpoints. Additionally, the RMAT designation does not require evidence to indicate that the drug may offer a substantial improvement over available therapies. Receiving an RMAT designation is not the same as receiving FDA product approval. The FDA granted a RMAT designation to Lomecel-B&#153; for the treatment of mild AD on July 5, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The fast-track designation is intended to expedite or facilitate the process for reviewing new drug and biologic drug products that meet certain criteria. Specifically, products are eligible for this designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The sponsor may have the opportunity for more frequent interactions with FDA about the product development program. The FDA may review sections of the marketing applications on a rolling basis before the complete application is submitted if the sponsor provides a schedule for the submission of the application sections, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section. A fast-track designation may be rescinded if the product no longer meets the qualifying criteria for the designation. Receiving a fast-track designation is not the same as receiving FDA product approval. The FDA granted fast-track designations to Lomecel-B&#153; for the treatment of HLHS on August 4, 2022 and for the treatment of mild AD on July 16, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Priority Review Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A product is eligible for priority review designation if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. The FDA will attempt to direct additional resources to the evaluation of an application for a priority review-designated product in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to the standard ten months for review, but this shortened review period is not guaranteed. Receiving a priority review designation is not the same as receiving FDA product approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Breakthrough Therapy Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A sponsor may seek FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the features of a fast-track designation, as well as more intensive FDA interaction and guidance. If a product receives this designation, then the FDA will work to expedite the development and review of that product. A breakthrough therapy designation may be rescinded if the product no longer meets the qualifying criteria for the designation. Receiving a breakthrough therapy designation is not the same as receiving FDA product approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accelerated Approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A drug product intended to treat a serious condition may be eligible for accelerated approval upon a determination that the product provides a meaningful advantage over available therapies and has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA may require that a sponsor perform one or more post-approval studies to verify and describe the product&#8217;s predicted effect on irreversible morbidity or mortality or other clinical benefit, and that the sponsor submit copies of all promotional materials in advance of their use. FDA has the legal authority to require that the sponsor begin the post-marketing clinical trials before accelerated approval is granted, or that the studies be underway within a particular timeframe after accelerated approval. If the confirmatory post-marketing clinical trials fail, then FDA can seek expedited withdrawal of the drug product from the market. All of these factors could adversely impact the timing of commercial launch and continued marketing of the product. Accelerated approval is an approval pathway, not a designation like the other examples listed above.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product candidate qualifies for one or more of these programs, the standard for approval (i.e., safety and effectiveness) does not change. We may explore one or more of these opportunities for Longeveron product candidates as appropriate, as the programs are not mutually exclusive.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Exclusivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the case of biologic drugs, several types of marketing exclusivity may apply:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reference product exclusivity;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug exclusivity; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reference Product Exclusivity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that the FDA will regulate Lomecel-B&#153; as a new biologic and will require submission and approval of a BLA under the PHS Act. The PHS Act includes a framework for determining when a biologic is a &#8220;reference product&#8221; and therefore eligible for marketing exclusivity. The reference product is the single biological product against which a biosimilar (a product that is highly similar to and has no clinically meaningful differences from the reference product) or an interchangeable biosimilar (a product that is both biosimilar to, and will produce the same clinical result as, the reference product) is evaluated.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA must determine the date of &#8220;first licensure&#8221; (i.e., approval) of a biologic which will, in turn, determine whether that biologic qualifies as a reference product that will be eligible for statutory exclusivity (and when such exclusivity will expire). Typically (but not always) the date of approval is the date of first licensure. The FDA will not approve a biosimilar or interchangeable biosimilar until the date that is 12 years after the date on which the reference product was first approved. However, the FDA may receive an application for a biosimilar or interchangeable biosimilar four years after the date on which the reference product was first approved. These 12- and four-year terms are each extended by six months if the product has been awarded pediatric exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal uncertainties remain about the FDA&#8217;s application of the date of first licensure and statutory exclusivity provisions to cell therapy products. At the appropriate time, we intend to provide information to the FDA so that the FDA can determine the date of first licensure of Lomecel-B&#153; (or any other product candidate that will be regulated as a biologic) and the date from which statutory exclusivity will begin to run. However, the FDA may not make an immediate decision about the date of first licensure at the time it approves a new biologic. Furthermore, there is currently no precedent showing how the FDA will apply this statutory framework to a cell therapy product. The law in this area will likely continue to evolve.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation and Exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Congress enacted the Orphan Drug Act in 1983 to spur development of drugs and biologics to treat diseases or conditions affecting few U.S. patients. The FDA may grant an ODD for a drug or biologic drug being developed to treat a &#8220;rare disease or condition,&#8221; defined as affecting fewer than 200,000 persons in the U.S. or affecting more than 200,000 persons in the U.S. but for which there is no reasonable expectation that development costs will be recovered from U.S. sales of the product. A request for ODD must be submitted to the FDA before a marketing application is submitted (i.e., BLA or NDA), but there is no assurance that FDA will award an ODD if requested. In the fourth quarter of 2021, the FDA granted ODD to Longeveron&#8217;s Lomecel-B&#153; for the treatment of HLHS.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An ODD does not change the regulatory review standards of safety and effectiveness and does not shorten the length of the FDA review or approval process. If an investigational product with an ODD subsequently receives the first FDA approval for the disease or condition for which it has such designation, then the approved product may be eligible to receive orphan drug exclusivity (&#8220;ODE&#8221;) that prevents the FDA from approving any other applications to market the same drug or biologic for the same rare disease or indication for seven years, except in several specific circumstances including, among others, demonstrating clinical superiority of a new product vs. the product with ODE because of greater safety, greater effectiveness, or making a major contribution to patient care. Even if an investigational product has an ODD, there is no guarantee that the FDA will award ODE upon approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may receive approval of either a different product for the same use or indication, or the same product for a different use or indication. Approved drugs and biologics can also be used by physicians off-label, which is within the scope of their practice of medicine. Accordingly, ODE is not an absolute protection against potentially competing products. Moreover, an ODE awarded to another sponsor could block FDA approval of one of Longeveron&#8217;s product candidates for seven years.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The law involving ODDs and ODEs, including the FDA&#8217;s interpretation of &#8220;same drug,&#8221; is continuing to evolve. Most notably, the U.S. Court of Appeals for the Eleventh Circuit issued a decision in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Catalyst Pharmaceuticals, Inc. v. Becerra</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in September 2021 that significantly modified the FDA&#8217;s longstanding interpretation and application of the scope of ODE. In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Becerra</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the court held that ODE applied to all uses or indications within an orphan-designated disease, not only to the approved use or indication within the designated disease as stated in FDA regulations and as applied by FDA in practice. Although FDA announced in January 2023 that it would only apply the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Becerra </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">court&#8217;s decision to the specific parties involved in that case, it is possible that FDA could face additional administrative or legal challenges to its interpretation of the scope and applicability of ODD and ODE, as well as changes to the FFDCA itself.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the potential award of a seven-year ODE period upon product approval, the benefits of an ODD also include eligibility for certain research tax credits and a waiver of the marketing application fee otherwise required under PDUFA. An application for a prescription product with an ODD is not subject to an application fee unless the application also includes an indication for a non-rare disease or condition as well. Products with an ODD, and whose sponsors meet the financial criteria (i.e. having less than $50 million in gross worldwide revenue during the preceding year), are also exempt from program fees otherwise required under the PDUFA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity (e.g., ODE) if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval Requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. There also are continuing, annual program fees under PDUFA for any marketed products. Establishment registration of drug and biologic drug manufacturers and their subcontractors with FDA and certain state agencies subjects those entities to periodic unannounced inspections by the FDA for compliance with cGMPs, imposing certain procedural and documentation requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort for production and quality control to maintain compliance with cGMPs and other regulatory requirements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters, or untitled letters;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical holds on clinical studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of approved products. A company can make only those claims that were approved by the FDA in the application for marketing approval and in accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for certain patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of approved treatments, as the practice of medicine is outside the scope of FDA&#8217;s authority. However, the FDA restricts manufacturer&#8217;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal penalties against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory authorities have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labeling.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Federal and State Fraud and Abuse Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our products are not currently reimbursed by government healthcare programs such as Medicare or Medicaid, any future reimbursement from federal and/or state healthcare programs could expose our business to broadly applicable fraud and abuse laws and other healthcare laws and regulations that would regulate the business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal Stark Law</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If in the future some of our revenues are derived from federal healthcare programs, we may be subject to the federal self-referral prohibitions, commonly known as the Stark Law. Where applicable, this law prohibits a physician from referring Medicare patients to an entity providing &#8220;designated health services&#8221; such as laboratory and other diagnostic services and prescription drugs that are furnished at an entity if the physician or a member of such physician&#8217;s immediate family has a &#8220;financial relationship&#8221; with the entity, unless an exception applies. Sanctions for violating the Stark Law include denial of payment, civil monetary penalties of up to $26,125 per claim submitted and twice the value of each such service and exclusion from the federal healthcare programs. Failure to refund amounts received as a result of a prohibited referral on a timely basis may constitute a false or fraudulent claim and may result in civil penalties and additional penalties under the federal False Claims Act (&#8220;FCA&#8221;). The statute also provides for a penalty of up to $174,172 for a circumvention scheme. The Stark Law is a strict liability statute, which means proof of specific intent to violate the law is not required. In addition, the government and some courts have taken the position that claims presented in violation of the various statutes, including the Stark Law, can be considered a violation of the FCA (described below) based on the contention that a provider impliedly certifies compliance with all applicable laws, regulations and other rules when submitting claims for reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal Anti-Kickback Statute</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will also be subject to the federal Anti-Kickback Statute if any of our services become reimbursable by government healthcare programs. The Anti-Kickback Statute is broadly worded and prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (i) the referral of a person covered by Medicare, Medicaid or other governmental programs, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other governmental programs or (iii) the purchasing, leasing or ordering or arranging or recommending purchasing, leasing or ordering of any item or service reimbursable under Medicare, Medicaid or other governmental programs. Certain federal courts have held that the Anti-Kickback Statute can be violated if &#8220;one purpose&#8221; of a payment is to induce referrals. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation, making it easier for the government to prove that a defendant had the requisite state of mind or &#8220;scienter&#8221; required for a violation. Moreover, the government may assert that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA, as discussed below. Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $105,563 for each violation, plus up to three times the remuneration involved. Civil penalties for such conduct can further be assessed under the FCA. Violations of the federal Anti-Kickback Statute can also result in criminal penalties, including criminal fines of more than $100,000 and imprisonment of up to 10 years. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid. In addition to a few statutory exceptions, the Office of Inspector General (&#8220;OIG&#8221;) has published safe-harbor regulations that outline categories of activities that are deemed protected from prosecution under the Anti-Kickback Statute provided all applicable criteria are met. The failure of a financial relationship to meet all of the applicable safe harbor criteria does not necessarily mean that the particular arrangement violates the Anti-Kickback Statute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, conduct and business arrangements that do not fully satisfy each applicable safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> False Claims Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both federal and state government agencies have continued civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and their executives and managers. Although there are a number of civil and criminal statutes that can be applied to healthcare providers, a significant number of these investigations involve the FCA. These investigations can be initiated not only by the government but also by a private party asserting direct knowledge of fraud. These &#8220;qui tam&#8221; whistleblower lawsuits may be initiated against any person or entity alleging such person or entity has knowingly or recklessly presented, or caused to be presented, a false or fraudulent request for payment from the federal government or has made a false statement or used a false record to get a claim approved. In addition, the improper retention of an overpayment for 60 days or more is also a basis for an FCA action, even if the claim was originally submitted appropriately. Penalties for FCA violations include fines ranging from $13,508 to $27,018 for each false claim, plus up to three times the amount of damages sustained by the federal government. An FCA violation may provide the basis for exclusion from the federally funded healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">State Fraud and Abuse Laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Several states have also adopted or may adopt similar self-referral, anti-kickback, fraud, whistleblower and false claims laws as described above. The scope of these laws and the interpretations of them vary by jurisdiction and are enforced by local courts and regulatory authorities, each with broad discretion. Some state fraud and abuse laws apply to items or services reimbursed by Medicaid programs and any third-party payer, including commercial insurers or to any payer, including to funds paid out of pocket by a patient. A determination of liability under such state fraud and abuse laws could result in fines and penalties and restrictions on our ability to operate in these jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FCA established several separate criminal penalties for making false or fraudulent claims to insurance companies and other non-governmental payers of healthcare services. Under the FCA, these two additional federal crimes are: &#8220;Healthcare Fraud&#8221; and &#8220;False Statements Relating to Healthcare Matters.&#8221; The Healthcare Fraud statute prohibits knowingly and recklessly executing a scheme or artifice to defraud any healthcare benefit program, including private payers. A violation of this statute is a felony and may result in fines, imprisonment, or exclusion from government sponsored programs. The False Statements Relating to Healthcare Matters statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact by any trick, scheme or device or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. A violation of this statute is a felony and may result in fines or imprisonment. This statute could be used by the government to assert criminal liability if a healthcare provider knowingly fails to refund an overpayment. These provisions are intended to punish some of the same conduct in the submission of claims to private payers as the federal FCA covers in connection with governmental health programs. In addition, the Civil Monetary Penalties Law imposes civil administrative sanctions for, among other violations, inappropriate billing of services to federally funded healthcare programs and employing or contracting with individuals or entities who are excluded from participation in federally funded healthcare programs. Moreover, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of copayments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $10,000 for each wrongful act. Furthermore, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and civil FCA, which can impose additional penalties associated with the wrongful act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The OIG emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payers may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts, and statutory or common law fraud.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical and medical device manufacturers are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, the U.S. federal Anti-Kickback Statute, FCA, Consumer Fraud Act, fee splitting, patient brokering and other federal laws and regulations, as well as similar foreign laws in jurisdictions outside the U.S., where applicable, involving fraud and abuse, price reporting, data privacy and security, and transparency. Similar state and local laws and regulations may also</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrict business practices in the pharmaceutical industry, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; requirements to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; requirements relating to pricing and marketing information; requirements to track and report gifts and other remuneration and items of value provided to physicians, marketing personnel and entities other healthcare providers and entities or that require the registration of pharmaceutical sales representatives; requirements regarding the registration of pharmaceutical sales representatives; and other applicable laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), thus complicating compliance efforts. Violation of any of such applicable laws or regulations may result in penalties, including, either separate or in combination and without limitation, significant administrative, civil and criminal penalties, damages, fines, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and imprisonment.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of any pharmaceutical product depend, in part, on the extent to which the product will be covered and reimbursed by government payors (e.g., federal and state healthcare programs), third-party payors (e.g., commercial insurance and managed healthcare organizations), and other payors (e.g., foreign government healthcare programs). Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. For example, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by payors, that an adequate level of reimbursement will be established even if coverage is available or that the payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Decisions regarding the extent of coverage and amount of reimbursement to be provided are generally made on a plan-by-plan basis, meaning one third-party payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide similar coverage. As a result, the coverage determination process can require manufacturers to provide scientific and clinical support for the use of a product, and require providers to show medical necessity for use, to each payor separately. This process can be time-consuming, with no assurance that coverage and adequate reimbursement will be applied consistently or even obtained.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar challenges to obtaining coverage and reimbursement for pharmaceutical or biological products will apply to companion diagnostics. For example, for products administered under the supervision of a physician, the difficulty in obtaining coverage and adequate reimbursement may be increased because of the higher prices often associated with such drugs. Additionally, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement of the companion pharmaceutical or biological product. However, separate reimbursement for the product itself, the companion product, or the treatment or procedure for which the product is used may not be available, which, in turn, may also impact utilization.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payors are also increasingly reducing reimbursements for pharmaceutical products and services through continued implementation of cost-containment programs, including price controls and value-based care initiatives, requirements for substitution of generic products and restrictions on coverage and reimbursement, which could further limit sales of any product. In addition, payors continue to question safety and efficacy while also challenging the prices charged, examining medical necessity, and reviewing the cost effectiveness of pharmaceutical products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases of this nature surrounding reimbursement for any product or a decision by a government and third-party payor not to cover a product could result in reduced physician usage and patient demand for the product.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors&#8217; reimbursement policies will not adversely affect the ability of manufacturers to sell products profitably.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S. and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (&#8220;ACA&#8221;) was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the U.S. By way of example, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the Average Manufacturer Price (&#8220;AMP&#8221;) or the difference between AMP and &#8220;best price,&#8221; whichever is greater; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on each covered entity engaged in the business of manufacturing or importing branded prescription drugs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected (often referred to as &#8220;5i drugs&#8221;); expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its enactment, there have been judicial and Congressional challenges that would either repeal, or repeal and replace, all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have passed. For example, in 2017, Congress enacted the Tax Cuts and Jobs Act, which eliminated, effective January 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; In addition, the 2020 Consolidated Appropriations Act permanently eliminated, effective January 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 2021, also eliminated the health insurer tax. Other legislative changes have also been adopted since the ACA was enacted, including mandatory sequestration (e.g., aggregate reductions of certain Medicare payments of up to 2%), which will remain in effect through fiscal year 2031 absent Congressional action.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect such judicial and Congressional challenges to continue. There has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to reform government program reimbursement methodologies for pharmaceutical products and bring more transparency to product pricing and the relationship between pricing and manufacturer patient programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, which amends the FFDCA, among other things, provides a federal framework for certain patients to access certain investigational new product candidates that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its products available to eligible patients as a result of the Right to Try Act.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 9, 2021, former President Biden signed the &#8220;Executive Order on Promoting Competition in the American Economy,&#8221; which is focused on increasing competition in several industries, including the pharmaceutical and biotechnology industries. Among other things, the Executive Order directs the Department of Health and Human Services to increase support for generic and biosimilar drugs, continue to improve the approval framework for generics and biosimilars, to issue a comprehensive plan to combat high prescription drug prices and price gouging, identify efforts to impeded generic and biosimilar competition, and to standardize plan options in the National Health Insurance Marketplace to improve competition and consumer choice. The Executive Order also encourages the FTC to ban unfair anticompetitive conduct or agreements such as &#8220;pay for delay&#8221; and similar agreements, in which brand-name drug manufacturers pay generic drug manufacturers to stay out of the market, resulting in an estimated $3.5 billion increase in drug prices per year.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is unclear how the second Trump Administration may approach healthcare reform efforts, nor is it clear whether other legislative changes will be adopted, if any, or how such changes may impact healthcare reform efforts of prior Administrations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital Management</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 25 full-time employees plus 1 employee on leave of absence, zero part-time employees and zero full-time consultants. Among those employees, 2 had M.D. and 4 had Ph.D. degrees, 2 are Certified Public Accountants, and 1 has a J.D. degree. Of these full-time employees, 18 are engaged in research and development activities. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sets annual Corporate Goals and Objectives that are communicated to all employees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Part III of this Form 10-K for information about our Executive Officers, non-employee Directors and other key employees.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company was formed as a Delaware limited liability company in October 2014 and converted into a Delaware corporation in February 2021 in connection with our initial public offering (&#8220;IPO&#8221;). Our principal executive offices are located at 1951 NW 7</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Avenue, Suite 520 Miami, Florida 33136 and our telephone number is (305) 909-0840.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), are filed with the Securities and Exchange Commission (&#8220;SEC&#8221;). We are subject to the informational requirements of the Exchange Act, and we file or furnish reports, proxy statements and other information with the SEC. Such reports and other information we file with the SEC are available free of charge at our website www.longeveron.com when such reports are available on the SEC&#8217;s website. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. Longeveron periodically provides other information for investors on our corporate website, including press releases and other information about financial performance, information on corporate governance and presentations. Our website address is www.longeveron.com, and we make our filings with the SEC available on the Investor Relations page of our website. Our references to website URLs are intended to be inactive textual references only. The information found on, or that can be accessed from or that is hyperlinked to, our website does not constitute part of, and is not incorporated into, this Amendment. Our Class A common stock is traded on the Nasdaq Capital Market under the symbol &#8220;LGVN&#8221;.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factors Summary</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of the principal risks that could adversely affect our business, operations and financial results. Please refer to Item 1A &#8220;Risk Factors&#8221; of this 10-K below for additional discussion of the risks summarized in this Risk Factors Summary.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Relating to our Business</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse global conditions, including macroeconomic uncertainty, may negatively impact our financial results;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a history of losses, may not be able to achieve profitability going forward, and may not be able to raise additional capital necessary to continue as a going concern;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no FDA-approved allogeneic, cell-based therapies for Aging-related Frailty, AD, or other aging-related conditions, nor HLHS or other cardiac-related indications. This could complicate and delay FDA approval of our product candidate for these indications, or other indications we study or will study;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ethical and other concerns surrounding the use of stem cell therapy or human tissue may negatively affect public perceptions of us or our future products or product candidates, or may negatively affect regulatory approval of our future products or product candidates, thereby reducing demand for our future products, </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of our product candidates or future products in individuals may expose us to product liability claims, and we may not be able to obtain adequate product liability insurance coverage; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face risks related to our contract development and manufacturing business. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our trade secret and patent position does not adequately protect our product candidates and their uses, others could compete against us more directly, which could harm our business and have a material adverse effect on our business, financial condition, and results of operations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If certain license agreements are terminated, our ability to continue clinical trials and commercially market products could be adversely affected;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our proprietary information, trade secrets, and know-how, our competitive position could be impaired and our business, financial condition, results of operations, and prospects could be adversely affected;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our product development efforts; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Regulatory Approval and Other Government Regulations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to successfully develop and commercialize our product candidates and obtain the necessary regulatory approvals, we may not generate sufficient revenues to continue our business operations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot market and sell our product candidates in the U.S. or in other countries if we fail to obtain the necessary regulatory approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Final marketing approval of our product candidates by the FDA or other regulatory authorities for commercial use may be delayed, limited, or denied, any of which could adversely affect our ability to generate operating revenues; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to secure and maintain research institutions to conduct our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of Lomecel-B&#153; or any of our other product candidates, we will be subject to ongoing regulatory requirements and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may enter into arrangements with third-party collaborators to help us develop our product candidates and commercialize our products, and our ability to commercialize such products may be impaired or delayed if collaborations are unsuccessful.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim, &#8220;topline&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Class A Common Stock and the Securities Market</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The price of our Class A common stock has been, and may continue to be, volatile, which could result in substantial or total losses for investors.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation, as amended ("Certificate of Incorporation") and bylaws (the "Bylaws") and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our Class A common stock.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to maintain our share price above the minimum bid price requirement established by Nasdaq could result in the delisting of our Class A common stock on the Nasdaq Capital Market. The loss of our Nasdaq listing would in all likelihood make our Class A common stock significantly less liquid and adversely affect its value.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to successfully implement our plans and strategies, we will need to grow our organization, and we may experience difficulties in managing this growth.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In addition to the other information in this 10-K, the following risk factors should be considered carefully in evaluating us. You should carefully consider the risks and uncertainties described below and the other information in this report, including our financial statements and related notes appearing elsewhere in this 10-K and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our Class A common stock or to maintain or change your investment. Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our Class A common stock could decline and you could lose all or part of your investment. This 10-K also contains forward-looking statements that involve risks and uncertainties. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below. For a summary of these risk factors, please see &#8220;Risk Factors Summary&#8221; beginning on page 23 of this 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage biotechnology company with a limited operating history upon which you can evaluate our business and prospects. We have no products approved for commercial sale and have not generated any material revenue from product sales. To date, we have devoted substantially all of our resources and efforts to organizing and staffing our company, business planning, building and equipping our research and development laboratories, building and equipping our manufacturing suites, raising capital, acquiring raw materials for manufacturing, product candidate development and manufacturing, securing related intellectual property rights and conducting clinical trials of our Lomecel-B&#153; cellular therapy. We have not yet demonstrated our ability to obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability than if we had a longer operating history.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by clinical stage biotechnology companies in rapidly evolving fields, including but not limited to changes in FDA or foreign body regulatory oversight of products. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities. Such a transition may involve substantial additional capital requirements in order to launch and market a product, changes in the use of proceeds, and significant adjustment to personnel, compared to a clinical-stage development company. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the potential of our product candidates to treat diseases is not realized, the value of our technology and our development programs could be significantly reduced.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our team is currently exploring the potential of our product candidates to treat diseases. We have not yet proven in clinical trials that our product candidates will be a safe and effective treatment for any disease or condition. Our product candidates are susceptible to various risks, including undesirable and unintended side effects, unintended immune system responses, inadequate therapeutic efficacy, or other characteristics that may prevent or limit their marketing approval or commercial use. We have not yet completed all of the testing necessary to allow us to make a determination that serious unintended consequences will not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occur. If the potential of our product candidates to treat disease is not realized, the value of our technology and our development programs could be significantly reduced. Because our product candidates are based on mesenchymal stem cells, any negative developments regarding the therapeutic potential or side effects of our mesenchymal stem cells, or regarding scientific and medical knowledge about mesenchymal stem cells in general, could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product development programs are based on novel technologies and are inherently risky.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the risks of failure inherent in the development of product candidates based on new technologies. The novel nature of our product candidates creates significant challenges in regards to product development and optimization, manufacturing, government regulation, third-party reimbursement, and market acceptance. For example, although the FDA has approved several cell therapy products, the FDA has relatively limited experience with regulating these kinds of therapies, and its regulations and policies are still evolving. As a result, the pathway to regulatory approval for our product candidates may be more complex and lengthier.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, stem cells that are taken from one person and transplanted into a different individual may pose additional risks. For example, stem cells that are allogeneic (i.e., taken from one individual and given to a different person) and not autologous (i.e., taken from, and given to, the same individual) are subject to donor-to-donor variability, which can make standardization more difficult. As a result of these factors, the development and commercialization pathway for our therapies may be more complex and lengthier, and subject to increased uncertainty, as compared to the pathway for new conventional (i.e., new chemical entity) drugs.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There are no FDA-approved allogeneic, cell-based therapies for Aging-related Frailty, Alzheimer&#8217;s disease (AD), or other aging-related conditions, nor HLHS or other cardiac-related indications. This could complicate and delay FDA approval of our product candidate for these indications, or other indications we study or will study.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the FDA has approved several cell therapy products, there are no allogeneic cell-based or stem cell therapies currently approved by the FDA for the treatment of Aging-related Frailty or the other indications we are studying. There are also no conventional drugs or therapies currently approved by the FDA with stated indications for Aging-related Frailty, Aging, or Frailty.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">According to the FDA, &#8220;Aging-related Frailty&#8221; does not have a definition that is acceptable for characterizing the conditions for regulatory purposes, and there are no precedents for regulatory approvals of this indication. This could prevent, complicate and/or delay regulatory approval of our product candidate for these indications to the extent that the Company may continue to pursue this indication.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and the Japanese PMDA have both indicated that the concept of &#8220;Frailty&#8221; as an indication will require additional clinical data and discussion before future pivotal trials and marketing authorization. Because the condition of Frailty lacks consensus, there is no guarantee that PMDA, FDA or any regulatory agency will agree to an approvable indication, that these regulatory authorities will reach a consensus regarding the definition of the condition, or that they will agree on clinical endpoints that would be considered acceptable for demonstrating clinically meaningful benefit. More specifically, our ability to begin Phase 3 (i.e., pivotal) trials in a &#8220;Frailty&#8221; or &#8220;Aging-related Frailty&#8221; indication would depend on our subsequent interactions with FDA where we would discuss the size and scope of the next program, the appropriate target patient population (i.e., defining the indication), and agreement on one or more primary endpoints that demonstrate clinically meaningful outcome.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that the FDA may never recognize &#8220;aging&#8221; as a disease and may never agree to a definition of &#8220;Aging-related Frailty&#8221; primarily due to a lack of consensus on the definitions amongst clinicians, researchers and regulators, an insufficient understanding of the underlying pathophysiologic mechanisms that cause any or all of the manifestations, or both. To obtain FDA approval for any indication for the disease states we are studying, we will have to demonstrate, among other things, that our product candidates are safe and effective for that indication in the target population. The results of our clinical trials must be statistically significant, meaning that there must be sufficient data to indicate that it is unlikely the outcome occurred by chance. The FDA will also require us to demonstrate an appropriate dose (i.e., number of cells) and dosing interval for our product candidates, and to identify and define treatment responders, which may require additional clinical trials. As a result, the clinical endpoints, the criteria to measure the intended results of treatment, and the correct dosing for our cell-based therapeutic approaches for "Aging-related Frailty" may be difficult to determine. To the extent we decide to pursue this indication, these challenges may prevent us from developing and commercializing products on a timely or profitable basis, or at all.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not able to recruit and retain qualified management and scientific personnel, we may fail in developing our technologies and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends to a significant extent on the skills, experience, and efforts of the principal members of our scientific and management personnel. These members include Joshua M. Hare, M.D. and our staff of scientific consultants. Our co-founder, Dr. Hare, remains employed by UM, and provides services to us as a consultant on a limited basis. The loss of Dr. Hare or any or all of these individuals could harm our business and might significantly delay or prevent the achievement of research, development or business objectives. Competition for regulatory, clinical manufacturing and management personnel in the pharmaceutical industry is intense. We may be unable to recruit or retain personnel with sufficient management skills in the area of cell therapeutics or attract or integrate other qualified management and scientific personnel in the future.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates represent new classes of therapy that the marketplace may not understand or accept.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we successfully develop and obtain regulatory approval for our product candidates, the market may not understand or accept them. We are developing product candidates that represent novel treatment approaches and will compete with a number of more conventional products and therapies manufactured and marketed by others, including major pharmaceutical companies. The degree of market acceptance of any of our future developed and potential products will depend on a number of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical safety and effectiveness of our products and their perceived advantage over alternative treatment methods;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to demonstrate that our cell-based products have a clinically significant effect, initially for Aging-related Frailty, AD, HLHS, and other disease states for which we may seek marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ethical controversies that may arise regarding the use of stem cells or human tissue of any kind, including adult stem cells, adult bone marrow, and other adult tissues derived from donors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse events involving our product candidates or candidates of others that are cell based;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to supply a sufficient amount of our products to meet regular and repeated demand in order to develop a core group of medical professionals familiar with and committed to the use of our products; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of our products and the reimbursement policies of government and third-party payors.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the health care community does not accept our product candidates or future approved products for any of the foregoing reasons, or for any other reason, it could affect our sales or have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our dependence upon a limited supply of bone marrow donors and biologic growth media may impact our ability to produce sufficient quantities of our product candidates as needed to complete our clinical trials, and if our trials are successful and our products are approved, to meet product demand.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The population of acceptable bone marrow donors is limited to volunteers between the ages of 18 and 45. In addition, potential donors are prescreened for a variety of health conditions and are only allowed to donate bone marrow a total of six times in their lifetime, further limiting the total number of potential donors. The amount of bone marrow donated may be insufficient for us to mass produce our product candidates at a scale sufficient to meet our clinical trial needs or to produce a product, if approved, to meet future commercial demand at an acceptable cost. In addition, the expansion of mesenchymal stem cells through our proprietary manufacturing methods utilizes biologic growth media that may be in limited supply. Our product candidates will be inherently more difficult to manufacture at commercial-scale than conventional pharmaceuticals, which are manufactured using precise chemical formulations and operational methods. Cost-effective production at clinical trial or commercial scale quantities may not be achievable.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future government regulation or health concerns may also reduce the number of donors or otherwise limit the amount of bone marrow available to us. If we cannot secure quantities of bone marrow or biologic growth media sufficient to meet the manufacturing demands for our clinical trials, we might not be able to complete our clinical trials and obtain marketing approval for our product candidates. Moreover, even if our clinical trials are successful and we obtain marketing approval for our product candidates, our inability to secure enough bone marrow or biologic growth media to meet commercial product demand could limit our potential revenues.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mesenchymal stem cells are biological entities derived from human bone marrow and therefore have the potential for disease transmission and can pose risks to the recipient.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MSC therapies require many manufacturing steps. Cells must be harvested from donor tissue, isolated, and expanded in cell culture to produce a sufficient number of cells for use. Each step carries risks for contamination by other cells, microbes, or adventitious agents. The transfer of cells into a recipient can also carry risks and complications associated with the procedure itself, and a recipient may reject the transplanted cells.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the utilization of donated bone marrow creates the potential for transmission of cancer and communicable disease, including but not limited to human immunodeficiency virus (&#8220;HIV&#8221;), viral hepatitis, syphilis, Creutzfeldt-Jakob disease, and other viral, fungal, or bacterial pathogens. Although we and our suppliers are required to comply with federal and state regulations intended to prevent communicable disease transmission, we or our suppliers may fail to comply with such regulations. Further, even with compliance, our products might nevertheless be viewed by the public as being associated with transmission of disease, and a clinical trial subject or patient who contracts an infectious disease might assert that the use of our product candidate or products resulted in disease transmission, even if the individual became infected through another source.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any actual or alleged transmission of communicable disease could result in clinical trial subject or patient claims, litigation, distraction of management&#8217;s attention, increased expenses, and adverse regulatory authority action. Further, any failure in screening, whether by us or other manufacturers of similar products, could adversely affect our reputation, the support we receive from the medical community, and overall demand for our products. As a result, such actions or claims, whether or not directed at us, could have a material adverse effect on our reputation with our customers and our ability to market our products, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our processing and storage facility or our clinical manufacturing facilities are damaged or destroyed, our business and prospects could be negatively affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our processing and storage facility is located in a region which experiences severe weather, notably hurricanes, from time to time. If this facility in Miami, Florida or the equipment in the facility were to be significantly damaged or destroyed, we could suffer a loss of some, or all of the stored units of our product candidates and it could force us to halt our clinical trial processes. The risk of tropical storm and hurricane activity historically rises on or about June 1</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> each year and subsides on or about November 30</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each year. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major hurricane or tornado, flood, fire, earthquake, power loss, terrorist activity or other disasters and do not currently have a recovery plan for such disasters. If we underestimate our insurance needs, we will not have sufficient insurance to cover losses above and beyond the limits on our policies. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ethical and other concerns surrounding the use of stem cell therapy or human tissue may negatively affect public perception of us or our future products or product candidates, or may negatively affect regulatory approval of our future products or product candidates, thereby reducing demand for our future products.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of our product candidates will depend in part on general public acceptance of the use of MSC therapy for the prevention or treatment of human diseases. Although we do not use embryonic stem cells or fetal tissue, the public may not be able to, or may fail to, differentiate our use of adult mesenchymal stem cells from the use of embryonic stem cells or fetal tissue by others, which could result in a negative perception of our company or our future products or product candidates, thereby reducing demand, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may obtain mesenchymal stem cells from volunteer adult bone marrow donors from non-profit organizations that collect and process tissue donations. Bone marrow donors receive payment, but ethical concerns have been raised by some about the use of donated human tissue in a for-profit setting, as we are doing. Future adverse events in the field of stem cell therapy, changes in public policy, or changes to the FDA&#8217;s regulatory approval framework for these products could also result in greater governmental regulation of our product candidates or products, and potential regulatory delays relating to their testing or approval.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may eventually compete for product sales with other companies, many of which will have greater resources or capabilities than we have, or may succeed in developing better products or in developing products more quickly than we do, and we may not compete successfully with them.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We compete or may eventually compete with other companies and organizations that are marketing or developing therapies for our targeted disease indications, based on traditional pharmaceutical, medical device, or other non-cellular therapy and technologies. In addition, we have other potential competitors developing a variety of therapeutics, and in some cases, such as with AD, there may be tens or hundreds of companies seeking to commercialize therapeutics.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also face competition in the cell therapy field from academic institutions and governmental agencies. Many of our current and potential competitors have greater financial and human resources than we have, including more experience in research and development and more established sales, marketing, and distribution capabilities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that competition in our industry will increase. In addition, the health care industry is characterized by rapid technological change, resulting in new product introductions and other technological advancements. Our competitors may develop and market products that render product candidates under development by us now or in the future, or any products manufactured or marketed by us, non-competitive or otherwise obsolete.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of our products may involve a lengthy sales cycle.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many factors are expected to influence the sales cycle for products once they are approved. These factors include the future state of the market, the perceived value of our product candidate(s), the evolution of competing technologies, insurance coverage or prior authorization requirements and changes in medical practices. Any of these may adversely affect our sales cycles and the rate of market acceptance of our approved products.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have ongoing challenges with respect to our liquidity and access to capital.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we advance the preclinical and clinical development of our programs, we expect to continue to incur significant expenses and operating losses, for which we do not have offsetting revenue. We expect that our sales, research and development and general and administrative costs will increase in connection with conducting additional preclinical studies and clinical trials for our current and future programs and product candidates, contracting with contract research organizations (&#8220;CROs&#8221;) to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements, or other sources.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had $19.2 million in cash and cash equivalents. To date, we have financed our operations primarily through public and private equity financings, grant awards, and fees generated from clinical trial revenue and contract manufacturing services. There are no assurances that we will be able to continue to finance operations through these means, and our inability to generate sufficient revenue in the near term may have an adverse impact on our business, operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face risks related to health epidemics, pandemics, and outbreaks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global outbreaks of epidemics, pandemics, and other public health risks, such as COVID-19, continue to impact countries, communities, supply chains and markets. For example, the COVID-19 pandemic has impacted our Bahamas Registry Trial business. It is also possible that the COVID-19 pandemic or other public health risks could adversely affect our business, results of operations, financial condition or liquidity in the future. For example, they could impact the timing and enrollment of our collaborators&#8217; planned or ongoing clinical trials, delaying clinical site initiation, regulatory review and the potential receipt of regulatory approvals, payment of milestones under our license agreements and commercialization of one or more of our product candidates, if approved. Epidemics, pandemics, and other public health risks could also disrupt the production capabilities of our contract manufacturing facility. Further, the continued mutation of the virus causing COVID-19 may lead to ongoing illness in our workforce or contracting partners, which may leave individuals unable to work for periods of time. The impact of the epidemics, pandemics, and other public health risks are generally fluid and continue evolve over time, and therefore, we cannot currently predict the extent to which our business, clinical trials, results of operations, financial condition or liquidity would ultimately be impacted. In addition, epidemics, pandemics, and other public health risks could materially and adversely impact our operations due to, among other factors:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a general decline in business activity;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty accessing the capital and credit markets on favorable terms, or at all, and a severe disruption and instability in the global financial markets, or deteriorations in credit and financing conditions which could affect our access to capital necessary to fund business operations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential negative impact on the health of our employees, especially if a significant number of them or any of their family members are impacted or if any of our senior leaders are impacted for an extended period of time;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential negative impact on our ability to monitor the investigative sites participating in our clinical studies in person or even remotely, which could result in a deviation from pre-pandemic protocols and/or site monitoring and data management plans, and delays in our ability to perform data-related tasks dependent on communications with personnel at the investigative sites, such as resolution of open data queries, the cumulative effects of which could lead to delayed or missed identification of non-compliance with cGCPs, and/or unrecognized data errors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential delays in the preparation and submission of applications for regulatory approval of our products, as well as potential delays in FDA&#8217;s or another regulatory authority's ability to review applications in a timely manner consistent with past practices;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential difficulty in adequately overseeing and/or evaluating the manufacturing process at the facilities that will manufacture future commercial products; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a deterioration in our ability to ensure business continuity during a disruption.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse global conditions, including macroeconomic uncertainty, may negatively impact our financial results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global conditions, dislocations in the financial markets, or continuing inflation could adversely impact our business. In addition, the global macroeconomic environment has been and may continue to be negatively affected by, among other things, instability in global economic markets, increased U.S. trade tariffs and trade disputes with other countries, instability in the global credit markets, supply chain weaknesses, instability in the geopolitical environment as a result of the Russian invasion of the Ukraine, the Israeli-Palestinian conflict, the withdrawal of the United Kingdom from the European Union, other political tensions, and foreign governmental debt concerns. Such challenges have caused, and may continue to cause, uncertainty and instability in local economies and in global financial markets, which may adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a history of losses and may not be able to achieve profitability going forward, and may not be able to raise additional capital necessary to continue as a going concern.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have experienced significant losses since inception and, at December 31, 2024 and 2023, had an accumulated deficit of approximately $109.6 million and $85.0 million, respectively. We expect to incur additional losses in the future and expect the cumulative losses to increase. We expect our operating expenses to increase and it is not likely that our grant revenues will fully fund our clinical programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had cash and cash equivalents of $19.2 million. We currently believe that our cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025 based on our current operating budget and cash flow forecast. However, as a result of a successful Type C meeting with the U.S. FDA in August 2024 with respect to the HLHS regulatory pathway, we have started to ramp up Biologics License Application (BLA) enabling activities as we currently anticipate a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. Our operating expenses and capital expenditure requirements are expected to accelerate in 2025 as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness, and there will be a need to increase our current proposed spend and further increase our capital investments. We intend to seek additional financing/capital raises/non-dilutive funding options to support these activities, and current cash projections may be impacted by these ramped up activities and any financing transactions entered into. There can be no assurance we will be able to attain future financing at terms favorable to us or at all. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect. We currently have no credit facility or committed sources of capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To continue as a going concern, we will need to obtain additional capital, which we will likely obtain through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. There are no assurances that we would be able to raise additional capital or on terms favorable to us. Our recurring losses from operations and negative cash flow raise substantial doubt about our ability to continue as a going concern without sufficient capital resources and we have included an explanatory paragraph in the notes to our financial statements for the year ended December 31, 2024, with respect to this uncertainty. Further, the report of our independent registered public accounting firm with respect to our audited financial statements for the year ended December 31, 2024 included an emphasis of matter paragraph stating that our recurring losses from operations and continued cash outflows from operating activities raised substantial doubt about our ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial statements do not include any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adjustments that might result from the outcome of this going concern uncertainty and have been prepared under the assumption that we will continue to operate as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to continue as a going concern, we may be forced to liquidate our assets, which would have an adverse impact on our business and developmental activities. In such a scenario, the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. The reaction of investors to the inclusion of a going concern statement by our independent registered public accounting firm and our potential inability to continue as a going concern may materially adversely affect our stock price and our ability to raise new capital. Our ability to continue as a going concern is dependent on our available cash, how well we manage that cash, and our operating requirements. If we are unable to raise additional capital when needed, we would be forced to delay, reduce or eliminate our clinical trial programs, commercialization efforts and other business activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have been funded in part by government and non-profit association grant awards, which is not a guaranteed source of future funding.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The funding of government programs is dependent on budgetary limitations, congressional appropriations and administrative allotment of funds, and changes in national health and welfare priorities, all of which are inherently uncertain and may be affected by changes in U.S. government policies resulting from various political and military developments. Our continued receipt of government and non-profit association funding is also dependent on the ability to adhere to the terms and provisions of the original grant and contract documents and other regulations. We can provide no assurance that we will receive or continue to receive funding for the grants and contracts we have been awarded. The loss of government funds or non-profit association grant awards could have a material adverse effect on our clinical programs and on our business, financial condition, and results of operations. For additional detail regarding the grant awards, we have received from governmental and non-profit associations, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Awards&#8221; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on page 78 of this report</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The use of our product candidates or future products in individuals may expose us to product liability claims, and we may not be able to obtain adequate product liability insurance coverage.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the nature of our products, we face an inherent risk of product liability claims. None of our product candidates have been widely used over an extended period of time, and therefore our safety data are limited. We derive the raw materials for our product candidates from human donor sources, the manufacturing process is complex, and the handling requirements are specific, all of which increase the likelihood of quality failures and subsequent product liability claims. We will need to increase our insurance coverage if and when we receive approval for and begin commercializing our product candidates. We may not be able to obtain or maintain product liability insurance on acceptable terms with adequate coverage or at all. If we are unable to obtain insurance, or if claims against us substantially exceed our coverage, then our business could be adversely impacted. Whether or not we are ultimately successful in any product liability litigation, such litigation either before or after product approval and marketing could consume substantial amounts of our financial and managerial resources and could result in, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant awards against us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial litigation costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of products or termination of clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA withdrawal of marketing approval of products or suspension or revocation of an IND for a product candidate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial sites or investigators; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory action.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these results could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face risks with respect to our contract development and manufacturing business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We provide contract development and manufacturing services to a third-party and may, in the future, provide similar services to a limited number of customers that are developing their own cellular therapy treatments. Losing any customer of our contract</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development and manufacturing services could have a significant impact on the income generated from this division of our business. Whether we are developing and manufacturing our product candidates or products or product candidates for our customers, similar regulatory, ethical, supply chain, and demand risks apply. Assisting customers in developing a product or product candidate may result in incurring costs and expenses that are not reimbursable by the customer, including, if we are required to obtain regulatory approval that is specific to manufacturing a customer&#8217;s product or product candidate. Our success with respect to the contract manufacturing operations of our organization is largely dependent on forces outside of our control as our success in dependent on the success of our customers&#8217; products and product candidates. Our customers may have to overcome the same or similar obstacles that we face in bringing their product to market. We must maintain stringent quality control measures, as failure to do so could lead to manufacturing defective products. Failure to manufacture regulatory compliant products or product candidates could result in recalls, legal liabilities, and impact our relationship with current and future customers. The cell therapy development and manufacturing industry is highly competitive. New companies entering the market could result in pricing pressures, reduced margins, and the loss of market share. Our focus has been and will continue to be on developing our own product candidates, while our competitors may only be focused on manufacturing cell therapies for their customers. Splitting our focus may give other contract manufacturing companies a competitive edge. Furthermore, jurisdictions outside of the United States may have other regulatory requirements that we cannot meet without incurring costs and expenses. Customers looking to obtain regulatory approval in the jurisdictions may engage with competitors that already meet the regulatory requirements of such jurisdictions. Our ability to compete effectively depends on our reputation, quality of service, current technology, regulatory approval, and operational efficiency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trade secret and patent position does not adequately protect our product candidates and their uses, others could compete against us more directly, which could harm our business and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends, in large part, on our ability to obtain and maintain intellectual property protection for our product candidates. The patent position of biotechnology companies is generally highly uncertain, involves complex legal and factual questions, and continues to be the subject of much litigation. Our trade secrets attempt to bridge the gap that threatens patent exclusivity for the protection of products derived from mesenchymal stem cells. Our trade secrets also are intended to remain valid and enforceable without regard to limitations such as term restrictions that are imposed on patents. Our trade secrets and know-how are the subject of various license agreements and confidentiality agreements as further discussed below.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The claims of existing U.S. and foreign patent applications and patents, and those patents that may issue in the future, or those to be licensed to us, that are owned by the Company or under an obligation of assignment to the Company, may not confer on us significant commercial protection against competing products, methods, or processes. Furthermore, to the extent that the Company owns or is assigned or licenses patent rights covering its business, third parties may challenge or design around those patent rights, such as by asserting that the patents are invalid or arguing that the patent claims should be narrowly construed, and thereby avoid successful infringement actions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patent applications on MSC technology, in particular, include claims directed to therapeutic uses and kits comprising mesenchymal stem cells. Patents with such claims tend to be more vulnerable to challenge by other parties than patents with extremely narrow claims. Also, our pending patent applications may not issue, may issue with substantially narrower claims than currently pending claims, or we may not receive any additional patents. Further, the laws of foreign countries may not protect our intellectual property rights to the same extent as do the laws of the U.S. Our patents might not contain claims that are sufficiently broad to prevent others from practicing our technologies or from competing with us with their own technology in the fields of interest to us.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the Company has obligations of assignment and has been assigned patents and patent applications concerning stem cell products and their uses, none of those patents or presently pending applications has granted claims or pending claims that, if granted, would absolutely prevent a third party from commercializing their own allogeneic stem cell therapy for those indications that we are studying. Consequently, our competitors may independently develop competing products that do not infringe our patents or other intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Control over patented technology requires the Company to obtain formal assignment of patents and applications from third parties. Although the Company believes it has contracts requiring formal assignment of the patent properties in its patent portfolio, there is risk that the inventors and research partners now of record as owning these patent properties will refuse to execute documents confirming assignment of their rights to the Company or that litigation will be required to compel the execution of those documents. In the meantime, those inventors and research partners may claim to be co-owners of some of the patent portfolio.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the extensive time required for development, testing, and regulatory review of a potential product, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantages of the patent. To the extent our product candidates based on that technology are not commercialized ahead of this patent expiration, to the extent we have no other patent protection on such products, or to the extent that regulatory or patent extensions are not granted, those products might not have the robust protection we currently expect to enjoy. The background technologies used in the development of our product candidates are known in the scientific community, and it may be possible to duplicate the methods we use to create our product candidates, which makes us vulnerable to competition, without the ability to exclude others from potentially commercializing a similar product.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If certain license agreements are terminated, our ability to continue clinical trials and commercially market products could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a party to various agreements that give us rights to use specified technologies applicable to research, development, and commercialization of our product candidates. If these agreements are voided or terminated, our product development, research, and commercialization efforts may be altered or delayed. Certain aspects of our technology rely on inventions developed using university or other third-party resources. The universities or third parties may have certain rights, as defined by law or applicable agreements, and may choose to exercise such rights. If we fail to comply with any terms or provisions of these agreements, our rights and our access to the universities&#8217; or third parties&#8217; resources could be terminated. The Exclusive License Agreement with the University of Miami dated November 20, 2014, as amended on December 11, 2017, and on March 3, 2021, and the additional Exclusive License Agreement with the University of Miami, signed and effective as of July 18, 2024, require the Company to pay fees and royalties and to make commercially reasonable efforts to achieve milestones. The University of Miami may terminate the Exclusive License Agreement and the additional Exclusive License Agreement for material breach if the fees and royalties are not paid, or if the milestones are not met and an extension to achieve the milestones is not agreed upon.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our employees, including but not limited to Dr. Hare, are employed by third party employers in addition to being employed or engaged as a consultant by the Company. Such employees and consultants may owe obligations to the third-party employers related to that employment. Those third-party employers may assert that they are entitled to assignment of some or all rights of new inventions made by such employees or consultants. If we are unable to conclusively prove that we are entitled to assignment of those rights, we may be required to negotiate co-ownership to or a license of those rights, if such an arrangement is available at all.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our proprietary information, trade secrets, and know-how, our competitive position could be impaired and our business, financial condition, results of operations, and prospects could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As disclosed above, some aspects of our technology, especially regarding manufacturing processes, are unpatented and maintained by us as trade secrets. In an effort to protect these trade secrets, we require our employees, consultants, collaborators, and advisors to execute confidential disclosure agreements before the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. These agreements, however, may not provide us with adequate protection against improper use or disclosure of confidential information, and these agreements may be breached. A breach of confidentiality could affect our competitive position. In addition, in some situations, these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, collaborators, or advisors have previous employment or consulting relationships. Also, others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. The disclosure of our trade secrets could impair our competitive position and could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our product development efforts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates, methods of making product candidates, and methods of using product candidates may give rise to claims of infringement of the patent rights of others.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may sue us. We are aware of several U.S. patents held by third parties covering potentially similar or related products and their manufacture and use. Generally, conducting clinical trials and other acts relating to FDA approval are not considered acts of infringement in the U.S. If and when Lomecel-B&#153; mesenchymal stem cells are approved by the FDA, third parties may seek to enforce their patents by filing a patent infringement lawsuit against us. Patents issued in the U.S. by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. We may not be able to prove in litigation that any patent enforced against us is invalid.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, there may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. Some of those patent applications may not yet be available for public inspection. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidates unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. They might seek an exclusion order from the International Trade Commission to prevent import of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, which could be expensive and time consuming.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Litigation may be necessary to enforce patents issued or licensed to us, to protect trade secrets or know-how, or to determine the scope and validity of the proprietary rights. Litigation, opposition, or other patent office proceedings could result in substantial additional costs and diversion of management focus. If we are ultimately unable to protect our technology, trade secrets, or know-how, we may be unable to operate profitably. Competitors may infringe our patents or the patents of our collaborators or licensors. As a result, we may be required to file infringement claims to protect our proprietary rights, which can be expensive and time-consuming, particularly for a company of our size. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or is unenforceable, or may refuse to enjoin the other party from using the technology at issue. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly. Litigation or other patent office proceedings may fail and, even if successful, may result in substantial costs and distraction to our management. We may not be able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the U.S.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, though we could seek protective orders where appropriate, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments. If investors perceive these results to be negative, the market price for our Class A common stock could be significantly harmed.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our industry is highly competitive and subject to significant or rapid technological change.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology industry, including our fields of therapeutic interest, is highly competitive and subject to significant and rapid technological change. Accordingly, our success may depend, in part, on our ability to respond quickly to such change through the development and introduction of new products. Our ability to compete successfully against currently existing and future alternatives to our product candidates and systems and competitors who compete directly with us in the biopharmaceutical industry may depend, in part, on our ability to attract and retain skilled scientific and research personnel, develop technologically superior products, develop competitively priced products, obtain patent or other required regulatory approvals for our products, be an early entrant to the market and manufacture, market, and sell our products, independently or through collaborations. If a third party were to commercialize a competitive product, there is no assurance that we would have a basis for initiating patent infringement proceedings or that, if initiated, we would prevail in such proceedings.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our product candidates are approved by the FDA, then potential competitors who seek to introduce generic versions of our product candidates may seek to take advantage of the abbreviated approval pathway for biological products shown to be biosimilar to or interchangeable with our product candidates. The Biologics Price Competition and Innovation Act of 2009 might permit these potential competitors to enter the market using a shorter and less costly development program for a biosimilar product that competes with our products. As discussed, our ability to obtain one or more types of regulatory exclusivity upon product approval could impact the timing of approval of a competing biosimilar or interchangeable product.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If all of the Company&#8217;s intellectual property has not been properly assigned to the Company, our business, financial condition, results of operation, and prospects could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the Company believes that each patent application or patent has already been assigned or, if it has not yet been formally assigned, is under an obligation to be assigned to the Company either through direct employment agreements between the Company and the inventors, or through research agreements with a third party and the Company, if such is not the case, our business, financial condition, results of operations, and prospects could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors might not have been the first to make the inventions covered by the issued patents or patent application that we own or license;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or our licensors might not have been the first to file patent applications covering certain of our inventions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">some or all of our licensors&#8217; pending patent applications may not lead to issued patents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we own or license may be held invalid or unenforceable as a result of legal challenges by our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets or in commercial markets where we do not have patent rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our Class A common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the U.S. transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of that we also made even if we had made the invention before the invention was made independently by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1) file any patent application related to our product candidates or (2) invent any of the inventions claimed in our patents or patent applications.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review (PGR), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review (IPR), and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of a lower evidentiary standard necessary to invalidate a patent claim in USPTO proceedings compared to the evidentiary standard in U.S. federal courts, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a patent claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of any resulting issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors&#8217; ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, are limited. Even if patents directed to our product candidates are obtained, once the patent term has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents directed to our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or our licensors do not obtain patent term extension for our product candidates and/or methods of their use, our business may be materially harmed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates and their methods of use, one or more of our U.S. patents may be eligible for limited patent term restoration. These laws permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we or our licensors may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Patent term extension may also not be granted because the product candidates and/or methods of use are determined not to be the first permitted marketing or use of those drug candidates in the jurisdiction in question, or patent term extension may not be granted because the product candidates and/or methods of use are determined not to constitute an &#8220;active ingredient&#8221; or use of an &#8220;active ingredient&#8221; that is eligible for patent term extension. Moreover, if patent term extension is granted then the additional time period or the scope of patent protection afforded could be less than we request. If we or our licensors are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we have in-licensed issued patents and pending patent applications in the U.S. and certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our in-licensed inventions in all countries outside the U.S. or from selling or importing products made using our in-licensed inventions in and into the U.S. or other jurisdictions. Competitors may use our in-licensed technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors have patent protection but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our or our licensors' patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our or our licensors&#8217; patents or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our or our licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly and our or our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our licensors&#8217; efforts to enforce or defend our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has been granted. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Regulatory Approval and Other Government Regulations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not able to successfully develop and commercialize our product candidates and obtain the necessary regulatory approvals, we may not generate sufficient revenues to continue our business operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To generate sales revenue from our product candidates, we must conduct extensive preclinical studies and clinical trials to demonstrate that our product candidates are safe and effective, and we must obtain required regulatory approvals. Our early-stage product candidates may fail to perform as we expect. Moreover, our product candidates in later stages of development may fail to show the required safety and effectiveness for approval despite having progressed successfully through preclinical or initial clinical testing. We may need to devote significant additional research and development, financial resources, and personnel to develop commercially viable products. If our product candidates do not prove to be safe and efficacious in clinical trials, we will not obtain the required regulatory approvals. If we fail to obtain such approvals, we may not generate sufficient revenues to continue our business operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may experience numerous unforeseen events during, or as a result of, any future clinical trials that could delay or prevent our ability to receive marketing approval for, or to commercialize, our product candidates, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators, IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulatory authorities may disagree with our clinical trial protocol, which may delay or prevent us from initiating our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites, prospective CROs, and prospective local representatives which can be subject to extensive negotiation and may vary significantly among different local representatives, CROs and trial sites;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays and interruptions to our clinical trials could extend the duration of the trials and increase the overall costs to finish the trials as our fixed costs are not substantially reduced during delays;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may elect to, or regulators, IRBs, or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a   finding that the participants are being exposed to unacceptable health risks;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not have the financial resources available to begin and complete the planned trials, or the cost of clinical trials of any product candidates may be greater than we anticipate;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate to initiate or complete a given clinical trial; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA or other comparable foreign regulatory authorities may require us to submit additional data such as long-term toxicology studies or may impose other requirements before permitting us to initiate or complete a clinical trial.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development costs will increase if we experience delays in clinical trials or in obtaining marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. If we do not achieve our product development goals in the time frames we announce and expect, the approval and commercialization of our product candidates may be delayed or prevented entirely. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our products following approval and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition, and results of operations significantly.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval of a product candidate, that approval may be subject to limitations on the indicated uses for which it may be marketed. Even after granting regulatory approval, the FDA and regulatory authorities in other countries continue to review and inspect marketed products, manufacturers, and manufacturing facilities, which may create additional regulatory burdens. Later discovery of previously unknown problems with a product, manufacturer, or facility may result in restrictions on the product or manufacturer, including a withdrawal of the product from the market or a withdrawal of the approved application by the FDA. Furthermore, FDA may require post-approval studies or other post-approval requirements or commitments. Failure to comply with or meet those requirements or commitments could result in withdrawal of the approved application by FDA. Regulatory authorities may also establish additional regulations, policies, or guidance that could prevent or delay regulatory approval of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We cannot market and sell our product candidates in the U.S. or in other countries if we fail to obtain the necessary regulatory approvals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot sell our product candidates until regulatory authorities grant marketing approval. The process of obtaining regulatory approval is lengthy, expensive, and uncertain, and the legal requirements for obtaining approval may change. It is likely to take several years to obtain the required regulatory approvals for our lead product candidates, or we may never gain the necessary approvals. Any difficulties that we encounter in obtaining regulatory approval may have a substantial adverse impact on our operations. Moreover, because our product candidates are all based on only three platform technologies, any adverse events in any of our clinical trials for one of our product candidates could negatively impact the clinical trials and approval process for our other product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pathway to regulatory approval for mesenchymal stem cells may be more complex and lengthier than for approval of a new conventional drug. Similarly, to obtain approval to market our cell products outside of the U.S., we, together with our collaborative partners, will need to file appropriate applications and submit clinical data concerning our product candidates and receive regulatory approval from governmental agencies, which in certain countries includes approval of the price we intend to charge for our product. We may encounter delays or rejections if changes occur in regulatory agency regulations, policies or guidance during the period in which we develop a product candidate or during the period required for review of any application for regulatory agency approval. If we are not able to obtain regulatory approvals for use of our product candidates under development, we will not be able to commercialize such products, and therefore may not be able to generate sufficient revenues to support our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not able to conduct our clinical trials properly and on schedule, marketing approval by FDA and other regulatory authorities may be delayed or denied.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The completion of our clinical trials may be delayed or terminated for many reasons, including, but not limited to, if:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA does not grant INDs to test the product candidates in humans;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA does not grant, or suspends, permission to proceed with a clinical trial and places a trial on clinical hold;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are not able to identify sufficient clinical trial sites and/or clinical trial investigators to begin or complete a trial;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subjects do not enroll in our trials at the rate we expect;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subjects experience an unacceptable rate or severity of adverse side effects;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party clinical investigators do not perform our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Current Good Clinical Practices (cGCPs), cGMPs, Current Good Tissue Practices (cGTPs), and other regulatory requirements, or other third parties do not perform data collection and analysis in a timely or accurate manner;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party service providers acting as our local representative in communications with foreign regulatory authorities do not appropriately perform the services required or terminate a service agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inspections by the FDA or IRBs of clinical trial sites at research institutions participating in our clinical trials find regulatory violations that require us to undertake corrective action, suspend, or terminate one or more sites, or prohibit us from using some or all of the data in support of our marketing applications; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one or more IRBs suspends or terminates the trial at an investigational site, precludes enrollment of additional subjects, or withdraws its approval of the trial.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our development costs will increase if we have material delays in our clinical trials, or if we are required to modify, suspend, terminate, or repeat a clinical trial. If we are unable to conduct our clinical trials properly and on schedule, marketing approval may be delayed or denied by the FDA.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Final marketing approval of our product candidates by the FDA or other regulatory authorities for commercial use may be delayed, limited, or denied, any of which could adversely affect our ability to generate operating revenues.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Final marketing approval for our product candidates may be delayed, limited, or denied if, among other factors:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are unable to satisfy the significant clinical testing required to demonstrate safety and effectiveness of our product candidates before marketing applications can be filed with the FDA or another regulatory authority;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other regulatory authorities do not agree with our interpretation of data obtained from preclinical and nonclinical animal testing or human clinical trials, even though the data can be interpreted in different ways;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we fail at any stage of the development and testing of our product candidates, which may take years to complete;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we receive negative or inconclusive results or reports of adverse side effects during a clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA does not accept our application for filing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA issues us a complete response letter during its review of our filed application; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA requires us to expand the size and scope of the clinical trials or to conduct one or more additional trials.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If marketing approval for our product candidates is delayed, limited, or denied, our ability to market products, and our ability to generate product sales, could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There has been very little success in gaining FDA approval for an Alzheimer&#8217;s disease drug, and we have not had success to date in developing Alzheimer&#8217;s disease therapeutics.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite billions of dollars invested by the biopharmaceutical industry in research programs to develop novel therapeutics for AD, there are few FDA-approved treatments. For example, Aduhelm</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(aducanumab-avwa), an amyloid beta-directed antibody, was approved by FDA in June 2021 under FDA&#8217;s accelerated approval pathway based upon the drug&#8217;s effect on a surrogate endpoint. FDA has required confirmatory trials of clinical benefit, and there is ongoing public discussion of the drug&#8217;s clinical benefit. Leqembi</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#153; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(lecanemab-irmb), also an amyloid beta-directed antibody, was approved in January 2023 under the accelerated approval pathway as well and will therefore likewise require confirmatory trials.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many new types and classes of drugs have been developed and tested in AD, including monoclonal antibodies, g-secretase modulators and inhibitors, &#946;-site amyloid precursor protein cleaving enzyme (BACE) inhibitors, receptor for advanced glycation end-products (&#8220;RAGE&#8221;) inhibitors, nicotinic agonists, serotonin subtype receptor (5HT6) antagonists, and others. The vast majority of these scientific programs have failed in clinical testing. Moreover, we have not had any success to date in developing therapeutics for AD, and we may never do so.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to secure and maintain research institutions to conduct our clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on research institutions to conduct our clinical trials. Specifically, the limited number of bone marrow transplant centers further heightens our dependence on such research institutions for our future Phase 3 clinical trials. Our reliance upon research institutions, including hospitals and clinics, provides us with less control over the timing and cost of clinical trials and the ability to recruit subjects and delays may occur which may result in our incurring additional costs. If we are unable to reach agreement with suitable research institutions on acceptable terms, or if any resulting agreement is breached or terminated, we may be unable to quickly replace the research institution with another qualified institution on acceptable terms. Even if we do replace the institution, we may incur additional costs to conduct the trial at the new institution. We may not be able to secure and maintain suitable research institutions to conduct our clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves the use of hazardous materials that could expose us to environmental and other liability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have contract facilities in Florida that are subject to various local, state, and federal laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including chemicals, micro-organisms, and various radioactive compounds used in connection with our research and development activities. In the U.S., these laws include the Occupational Safety and Health Act, the Toxic Test Substances Control Act, and the Resource Conservation and Recovery Act. We cannot guarantee that accidental contamination or injury to our employees and third parties from hazardous materials will not occur. We do not have insurance to cover claims arising from our use and disposal of these hazardous substances other than limited clean-up expense coverage for environmental contamination due to an otherwise insured peril, such as fire.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of Lomecel-B&#153; or any of our other product candidates, we will be subject to ongoing regulatory requirements and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we receive for Lomecel-B&#153; or another product-candidate may require post-marketing surveillance to monitor the safety and efficacy of the product and may require us to conduct post-approval clinical studies. The FDA may also require a Risk Evaluation and Mitigation Strategy (REMS) program in order to approve our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use (ETASU), such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements can include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs, for any clinical trials that we conduct post-approval and applicable product tracking and tracing requirements. Compliance with ongoing and changing requirements takes substantial resources and, should we be unable to remain in compliance, our business could be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers and their facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, or the making of unsupported claims, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or product recalls;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, 483 observations, warning letters, untitled letters, or holds on clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or withdrawal of approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of our product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent decrees or injunctions or the imposition of civil or criminal penalties, or the invocation of the FDA's Application Integrity Policy.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is not inconsistent with the labeling. Companies may also share certain scientific and medical information about off-label uses of products in certain limited circumstances as part of scientific exchange. However, the policies of the FDA and of other regulatory authorities may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example, changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the ACA was enacted, other legislative changes have been proposed and adopted in the United States. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs, including aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013, and subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, or BBA, will remain in effect through 2030, unless additional congressional action is taken. However, these Medicare sequester reductions were suspended from May 1, 2020, through December 31, 2021, due to the COVID-19 pandemic. The BBA also amended the ACA, effective January 1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the federal level, the first Trump Administration&#8217;s budget for fiscal year 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the first Trump Administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. The first Trump Administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out-of-pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) issued a final rule that would allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. On July 24, 2020, President Trump signed four Executive Orders aimed at lowering drug prices. The Executive Orders direct the Secretary of HHS to: (1) eliminate protection under an AKS safe harbor for certain retrospective price reductions provided by drug manufacturers to sponsors of Medicare Part D plans or pharmacy benefit managers that are not applied at the point-of-sale; (2) allow the importation of certain drugs from other countries through individual waivers, permit the re-importation of insulin products, and prioritize finalization of the proposed rule to permit the importation of drugs from Canada; (3) ensure that payment by the Medicare program for certain Medicare Part B drugs is not higher than the payment by other comparable countries (depending on whether pharmaceutical manufacturers agree to other measures); and (4) require Federally Qualified Health Centers, or FQHCs, participating in the 340B drug program to provide insulin and injectable epinephrine to certain low-income individuals at the discounted price paid by the FQHC, plus a minimal administrative fee. On October 1, 2020, the FDA issued the final rule allowing importation of certain prescription drugs from Canada. On August 6, 2020, President Trump signed an additional Executive Order directing U.S. government agencies to encourage the domestic procurement of Essential Medicines, Medical Countermeasures, and Critical Inputs, which include among other things, active pharmaceutical ingredients and drugs intended for use in the diagnosis, cure, mitigation, treatment, or prevention of COVID-19. The FDA has been directed to release a full list of Essential Medicines, Medical Countermeasures, and Critical Inputs affected by this Order by November 5, 2020. On September 13, 2020, President Trump signed an Executive Order directing HHS to implement a rulemaking plan to test a payment model, pursuant to which Medicare would pay, for certain high-cost prescription drugs and biological products covered by Medicare Part B, no more than the most-favored-nation price (i.e., the lowest price) after adjustments, for a pharmaceutical product that the drug manufacturer sells in a member country of the Organization for Economic Cooperation and Development that has a comparable per-capita gross domestic product. Although a number of these and other measures may require additional authorization to become effective, Congress and the Trump Administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, on July 9, 2021, former President Biden issued an executive order directing the FDA to, among other things, continue to clarify and improve the approval framework for generic drugs and identify and address any efforts to impede generic drug competition. It is unclear how other healthcare reform measures of the former Biden Administration, the second Trump Administration, or other efforts, if any, to challenge or repeal the ACA will impact our business. Nor is it clear whether other legislative changes will be adopted, if any, or how such changes would impact healthcare reform efforts of prior Administrations, affect the demand for our product candidates or future products, or otherwise impact our business. Legislative and regulatory agendas, as they relate to the healthcare and pharmaceutical industries and the economy as a whole, of the second Trump Administration and the U.S. Congress currently remain uncertain. Any new laws and initiatives may result in additional reductions in Medicare and other healthcare funding, such as the proposed cap on CRO indirect cost reimbursements by the National Institute of Health (NIH), or impose additional regulatory requirements on drug development or approval, which could have a material adverse effect on our clinical trial sites that rely on collaborations with university hospitals and research institutions funded in whole or in part by NIH grants, our future customers and accordingly, our financial operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Additionally, we expect to experience pricing pressures in connection with the sale of any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare reform in the U.S. and other countries may materially and adversely affect us.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S. and in many foreign jurisdictions, the legislative landscape continues to evolve. Our revenue prospects could be affected by changes in healthcare spending and policies in our target markets. We operate in a highly regulated industry and new laws or judicial decisions, or new interpretations of existing laws or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could materially and adversely affect us.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is significant interest in promoting healthcare reform, as evidenced by the enactment in the U.S. of the ACA in 2010. It is likely that many governments will continue to consider new healthcare legislation or changes to existing legislation. We cannot predict the initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified, or how they may affect us. The continuing efforts of governments, insurance companies, managed care organizations and other third-party payors to contain or reduce healthcare costs may adversely affect:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for any products for which we may obtain regulatory approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to set a price that we believe is fair for our products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenues and achieve or maintain profitability; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the ACA, there are many programs and requirements for which details or consequences are still not fully understood. We are unable to predict what healthcare programs and regulations will ultimately be implemented at any level of government in or outside the U.S., but any changes that decrease reimbursement for our approved products, reduce volumes of medical procedures or impose new cost-containment measures could adversely affect us.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prescription Drug Pricing Reduction Act</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 16, 2022, the Inflation Reduction Act of 2022 was passed, which among other things, allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#8217; annual out-of-pocket drug expenses at $2,000. The effect of Inflation Reduction Act of 2022 on our business and the healthcare industry in general is not yet known. Additionally, it is not yet known whether, during the second Trump Administration, the Inflation Reduction Act of 2022 will be repealed or otherwise modified.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to serve as local representatives in foreign jurisdictions where we perform our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to provide us with services related to our clinical trials conducted domestically and in foreign jurisdictions. In foreign jurisdictions, such third parties may serve as our local representative. Such local representative may perform services that include corresponding with the foreign regulatory authority on our behalf. If such third party fails to comply with applicable laws, misrepresents our intentions, fails to adequately provide the necessary services, or terminates its relationship with us, our clinical trial process may be delayed as we engage a new service provider, which would increase our anticipated development and commercialization costs. Any prolonged disruption could have a significant negative impact on our ability to effectively communicate with regulatory authorities, which could delay our pre-clinical and clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to provide us with supplies to produce our product candidates. Any problems experienced by these third parties could result in a delay or interruption in the supply of our product candidates for our clinical trials and future approved products to our customers, which could have a material negative effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to provide us with supplies to produce our product candidates. If the operations of these third parties are interrupted or if they are unable to meet our delivery requirements due to capacity limitations or other constraints, we may be limited in our ability to fulfill our supply of product candidates. Any prolonged disruption in the operations of third parties could have a significant negative impact on our ability to produce our product candidates for pre-clinical and clinical trials or sell our future approved products, could harm our reputation and could cause us to seek other third-party contracts, thereby increasing our anticipated development and commercialization costs. In addition, if we are required to change third parties for any reason, we will be required to verify that the new third parties maintain facilities and procedures that comply with quality standards required by the FDA and with all applicable regulations and guidelines. The delays associated with the qualification of a new third party could negatively affect our ability to develop product candidates or receive approval for any product candidates in a timely manner.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently depend upon third parties for services and raw materials needed for the manufacture of our product candidates, and if these products are successfully commercialized, we may become dependent upon third parties for product distribution. If any of these third parties fail or are unable to perform in a timely manner, our ability to manufacture and deliver could be compromised.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To produce our product candidates for use in clinical studies, and to produce any of our product candidates that may be approved for commercial sale, we require biologic media, reagents, and other highly specialized materials in addition to the bone marrow aspirate used in the manufacture of our product candidates. These items must be manufactured and supplied to us in sufficient quantities and in compliance with the regulations governing cGMP and cGTP promulgated by the FDA. To meet these requirements, we have entered into supply agreements with firms that manufacture these components to meet cGMP and cGTP standards. Our requirements for these items are expected to increase if and when we transition to the manufacture of commercial quantities of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as we proceed with our clinical trial efforts, we must be able to demonstrate to the FDA that we can manufacture our product candidates with consistent characteristics. While we currently produce our product candidates in our own facility, scaling up the manufacturing process would require us to develop a larger facility, which could require significant time and capital investments to conform to applicable manufacturing standards. Alternatively, we may be required to outsource some or all of our manufacturing, which would cause us to be materially dependent on these suppliers for supply of cGMP- and cGTP-grade components of consistent quality. Our ability to complete ongoing clinical trials may be negatively affected in the event that we are forced to seek and validate a replacement source for any of these critical components. If we are not able to obtain adequate supplies of these items of consistent quality from our third-party suppliers, it will also be more difficult to manufacture commercial quantities of our product candidates that are approved for commercial sale.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if one or more of our product candidates is approved for commercial sale, we intend to rely on third parties for their distribution. Proper shipping and distribution require compliance with specific storage and shipment procedures (e.g., prevention of damage to shipping materials and prevention of temperature excursions during shipment). Failure to comply with such procedures will necessitate return and replacement, potentially resulting in additional cost and causing us to fail to meet supply requirements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of third-party manufacturers may increase the risk that we will not have adequate quantities of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may use a third-party manufacturer to supply our product candidates for clinical trials or other uses at some point. Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including reliance on the third party for regulatory compliance and quality assurance, possible breach of the manufacturing agreement by the third party or termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or inconvenient for us.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future contract manufacturers are or will be subject to all of the risks and uncertainties that we would be subject to if we manufactured the product candidates on our own. Similar to us, third-party manufacturers are subject to ongoing, periodic, and unannounced inspection by the FDA and corresponding state and foreign agencies or their designees to ensure strict compliance with cGMP and cGTP regulations and other governmental regulations and corresponding foreign standards. Although we do not control compliance by our contract manufacturers with these regulations and standards, we&#8212;as the manufacturer&#8212;assume the liabilities for our contract manufacturers&#8217; non-compliance. Our future contract manufacturers might not be able to comply with these regulatory requirements. If our third-party manufacturers fail to comply with applicable regulations, the FDA or other regulatory authorities could impose penalties on us, including fines, injunctions, civil penalties, consent decrees, invocation of FDA&#8217;s Application Integrity Policy, issuance of warning or untitled letters, denial of marketing approval of our product candidates, delays, suspensions, or withdrawals of approvals, license revocation, seizures or recalls of product candidates or our other products, operating restrictions, and criminal prosecutions. Any of these actions could significantly and adversely affect supplies of our product candidates or other products and could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize any potential product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend, or may depend in the future, upon third parties to conduct certain aspects of our preclinical studies and clinical trials, under agreements with universities, medical institutions, CROs, strategic collaborators and others. We expect to have to negotiate budgets and contracts with such third parties, which may result in delays to our development timelines and increased costs.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will rely especially heavily on universities, medical institutions, CROs and other third parties for the conduct of our clinical trials. While we are obligated to ensure compliance of third parties with our clinical trial protocols and other aspects of our clinical trials, and to have mechanisms in place to monitor our clinical trials, the sites at which they are conducted, and the investigators and other personnel involved in our clinical trials, we have limited control over these entities and individuals and limited visibility into their day-to-day activities, including with respect to their compliance with the approved clinical protocol. Our reliance on third parties does not relieve us of our regulatory responsibilities for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. We and these third parties are required to comply with cGCP requirements, for product candidates in clinical development. Regulatory authorities enforce cGCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with cGCP requirements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients meeting requirements for enrollment in the trial may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any third parties conducting aspects of our preclinical studies or clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other therapeutic development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons or if, due to federal or state orders, they are unable to meet their contractual and regulatory obligations, our development timelines, including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we decide to use third-party manufacturers in the future, they will likely be dependent upon their own third-party suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The operations of any future third-party manufacturers will likely be dependent upon their own third-party suppliers. A supply interruption or an increase in demand beyond a supplier&#8217;s capabilities could harm the ability of any future manufacturers to manufacture our product candidates or approved products until the manufacturer identifies and qualifies new sources of supply. Reliance on these third-party manufacturers and their suppliers could subject us to a number of risks that could harm our business, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of third-party manufacturers or suppliers to comply with their own legal and regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a lack of long-term supply arrangements for key components with our suppliers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty and cost associated with locating and qualifying alternative suppliers for components in a timely manner;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production delays related to the evaluation and testing of products from alternative suppliers, and corresponding regulatory qualifications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay in delivery due to suppliers prioritizing other customer orders over ours or those of our third-party manufacturers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage to our brand reputation caused by defective components produced by the suppliers; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuation in delivery by the suppliers due to changes in demand from us, our third-party manufacturers or their other customers.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any interruption in the supply of components of our product candidates or future products or materials, or our inability to obtain substitute components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demands of our clinical trials or of our future customers, which would have an adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will depend on third-party distributors in the future to market and sell our future products which will subject us to a number of risks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will depend on third-party distributors to sell, market, and service our future products in our intended markets. We are subject to a number of risks associated with reliance upon third-party distributors including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of day-to-day control over the activities of third-party distributors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of the third-party distributors to comply with their own legal and regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party distributors may not commit the necessary resources to market and sell our future products to our level of expectations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party distributors may terminate their arrangements with us on limited or no notice or may change the terms of these arrangements in a manner unfavorable to us; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreements with our future distributors could result in costly and time-consuming litigation or arbitration which we could be required to conduct in jurisdictions with which we are not familiar.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to establish and maintain satisfactory relationships with our future third-party distributors, our revenues and market share may not grow as anticipated, and we could be subject to unexpected costs which could harm our results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The successful commercialization of our current or future product candidates will depend on obtaining reimbursement from government and third-party payors, and price controls in foreign markets could adversely affect our future profitability.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we successfully develop and obtain necessary regulatory approvals, we intend to sell our product candidates in countries such as the U.S. and Japan. In the U.S., the market for any pharmaceutical product is affected by the availability of reimbursement from government and third-party payors, such as government health administration authorities, private health insurers, health maintenance organizations, and pharmacy benefit management companies. MSC therapies may be expensive compared with conventional pharmaceuticals, due to the higher cost and complexity associated with the research, development, and production of product candidates, the small size and large geographic diversity of the target patient population for some indications, and the complexity associated with distribution of signaling cell therapies which require special handling, storage, and shipment procedures and protocols. This, in turn, may make it more difficult for us to obtain adequate reimbursement from government and third-party payors, particularly if we cannot demonstrate a favorable cost-benefit relationship. Government and third-party payors may also deny coverage or offer inadequate levels of reimbursement for our potential products if they determine that the product has not received appropriate clearances from the FDA or other government regulatory authorities or is experimental, medically unnecessary or inappropriate.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some other countries where we may seek to market our products, such as Japan, the pricing of prescription pharmaceutical products and services and the level of government reimbursement are subject to governmental control. In these countries, pricing negotiations with governmental authorities can take six to twelve months or longer after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our potential future collaborators may be required to conduct one or more clinical trials that compare the cost effectiveness of our product candidates or products to other available therapies. Conducting one or more additional clinical trials would be expensive and could result in delays in commercialization of our product candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Managing and reducing health care costs has been of great concern in the U.S. and various foreign governments. Although we do not believe that any recently enacted or presently proposed legislation in any jurisdictions in which we currently operate should impact our business based on our current model, we might be subject to future regulations or other cost-control initiatives that materially restrict the pricing or reimbursement of our products. In addition, payors are continuing to limit reimbursements for newly approved health care products while also challenging the price and cost-effectiveness of medical products and services. In particular, payors may limit the indications for which they will reimburse patients who use any products that we may develop. Finally, cost control initiatives could decrease the price for products that we may develop, which could result in lower product revenues to us. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may enter into arrangements with third-party collaborators to help us develop our product candidates and commercialize our products, and our ability to commercialize such products may be impaired or delayed if collaborations are unsuccessful.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are parties to various collaborations with third parties, and we may enter into additional collaborations in the future. We are dependent upon the success of our current and any future collaborators in performing their responsibilities in connection with the relevant collaboration. If we fail to maintain these collaborative relationships for any reason, we would need to perform the activities that we currently anticipate would be performed by our collaborators on our own at our sole expense. This could substantially increase our capital needs, and we may not have the capability or financial capacity to undertake these activities on our own, or we may not be able to find other collaborators on acceptable terms, or at all. This may limit the programs we are able to pursue and result in significant delays in the development, sale, and manufacture of our product candidates and future approved products, and may have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our dependence upon our current and potential future collaborations exposes us to a number of risks, including that our collaborators (i) may fail to cooperate or perform their contractual obligations, including financial obligations, (ii) may choose to undertake differing business strategies or pursue alternative technologies, or (iii) may take an opposing view regarding ownership of clinical trial results or intellectual property.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to these factors and other possible events, we could suffer delays in the research, development, or commercialization of our product candidates and future approved products or we may become involved in litigation or arbitration, which could be time consuming and expensive. We additionally may be compelled to split revenue with our collaborators, which could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products or product candidates, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of our equity securities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assimilation of operations, intellectual property and products or product candidates of an acquired company, including difficulties associated with integrating new personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party to receive marketing approvals for their existing products or product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to generate revenue from acquired technology, product candidates and/or approved products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the U.S. and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing, patient support and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third- parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required to curtail or restructure our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union (EU). The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, &#8220;topline&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data. These results and related findings and conclusions are based on assumptions, estimations, calculations and conclusions, and are subject to change following the generation of additional data or a more comprehensive review of the data related to the particular study or trial. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data is available.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. For example, we have reported interim data from our ongoing clinical trials elsewhere in this report. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more subject data become available or as subjects from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on other product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The U.S. FDA, Japanese PMDA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are conducting several trials in the U.S., and previously entered into a sponsored clinical research agreement with the National Center for Geriatrics and Gerontology and Juntendo University Hospital in Japan to explore the safety and efficacy of Lomecel-B&#153; in older, frail Japanese subjects. This study in Japan was discontinued by the Company in 2024. The acceptance of study data by the U.S. FDA, Japanese PMDA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (1) the data are applicable to the U.S. population and U.S. medical practice; (2) the trials are performed by clinical investigators of recognized competence and pursuant to cGCP requirements; and (3) the FDA is able to validate the data through an on-site inspection or other appropriate means. The FDA may accept the use of some foreign data to support a marketing approval if the clinical trial meets certain requirements. Additionally, the FDA&#8217;s clinical trial requirements, including the adequacy of the subject population studied and statistical powering, must be met. Furthermore, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, PMDA or any applicable foreign regulatory authority will accept data from trials conducted outside of its respective jurisdiction. If the FDA, PMDA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining regulatory approval of a product in one jurisdiction does not mean that we will be successful in obtaining or maintaining regulatory approval in other jurisdictions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and maintaining regulatory approval of a product in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or PMDA grants marketing approval of a product, comparable regulatory authorities in other foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Moreover, product types or regulatory classifications, as well as approval procedures, vary among jurisdictions and can involve requirements and administrative review periods different from those in the U.S., including different or additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fails to comply with the regulatory requirements in international markets or fails to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory authorities strictly regulate the promotional claims that may be made about approved prescription products. In particular, an approved product may not be promoted for uses that are not approved by the FDA or such other regulatory authorities as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved labeling, which is within their purview as part of their practice of medicine. If we are found to have promoted such off-label uses, however, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal penalties against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. The FDA may also issue a public warning letter or untitled letter to the company. If we cannot successfully manage the promotion of our future approved products, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are required by the FDA to obtain approval of a companion diagnostic test in connection with approval of any of our product candidates, and we do not obtain or face delays in obtaining FDA approval of a diagnostic test, we will not be able to commercialize such future approved product and our ability to generate revenue will be materially impaired.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If safe and effective use of any of our product candidates depends on the use of an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostic test that is not otherwise commercially available, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates if at all. According to FDA guidance, if the FDA determines that a companion diagnostic is essential to the safe and effective use of a novel therapeutic product or indication, then the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to its own regulatory approval requirements. The process of obtaining or creating such a diagnostic is time consuming and costly.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable regulatory authorities. The approval of a companion diagnostic as part of the therapeutic product labeling limits the use of the therapeutic product to only certain patients for whom the companion diagnostic was developed.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA, PMDA or a comparable regulatory authority requires approval of a companion diagnostic for any of our product candidates, whether before or after it obtains marketing approval, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such product candidate. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval of a product candidate or continued marketing of an approved product.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials of a product candidate or commercializing an approved product on a timely or profitable basis, if at all.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through an expedited review program, and if we are unable to do so, then we could face increased expense to obtain, and delays in the receipt of, necessary marketing approvals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future seek approval for one or more of our product candidates under one of the FDA&#8217;s expedited review programs for serious conditions. These programs are available to sponsors of therapies that address an unmet medical need to treat a serious condition. The qualifying criteria and requirements vary for each expedited program. Prior to seeking review under one of these expedited programs for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive marketing approval through an expedited review program.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that, after our evaluation of the FDA&#8217;s feedback and other factors, we will decide to pursue one or more of these expedited review programs. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue one or more of these expedited programs, even if we initially decide to do so. Furthermore, the FDA could decide not to grant our request to use one or more of the expedited review programs for a product candidate, even if the FDA&#8217;s initial feedback is that the product candidate would qualify for such program(s). Moreover, the FDA can decide to stop reviewing a product candidate under one or more of these expedited review programs if, for example, the conditions that warranted expedited review no longer apply to that product candidate.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of these expedited programs (e.g., accelerated approval) also require post-marketing clinical trials to be completed and, if any such required trial fails, the FDA could withdraw the approval of the product. If one of our product candidates does not qualify for any expedited review program, then this could result in a longer time period to approval and commercialization of such product candidate, could increase the cost of development of such product candidate, and could harm our competitive position in the marketplace.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA&#8217;s Rare Pediatric Disease Designation for Lomecel-B&#153; for HLHS does not guarantee that we will receive a priority review voucher if the product is approved for this indication, nor does the receipt of Orphan Drug Designation for Lomecel-B&#153; for HLHS guarantee that we will receive seven years of market exclusivity if the product is approved for this indication.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As noted elsewhere in this report, the FDA has granted both Rare Pediatric Disease Designation and Orphan Drug Designation status for the use of Lomecel-B&#153; to treat HLHS. These designations were granted following our Phase 1 safety-focused ELPIS trial, However, even though the FDA has granted Lomecel-B&#153; Rare Pediatric Disease Designation for the treatment of HLHS, receipt of Rare Pediatric Disease Designation does not provide any guarantee that we would or will receive a priority review voucher (PRV) upon approval for this indication. This voucher program has been extended in the past, but there is no guarantee the Congress will extend it again in the future.As of December 20, 2024, the rare pediatric disease PRV program has expired and PRVs may no longer be awarded unless the drug has already received a Rare Pediatric Disease Designation as of that date, and the application is approved no later than September 30, 2026. If we do receive a PRV upon approval of Lomecel-B&#153; for this indication, then that voucher permits a future application to be treated as a priority review application by the FDA. The FDA does not guarantee that the future application will be reviewed in a particular period of time, and a future application that redeems a PRV must submit an additional user fee in addition to any regularly assessed user fees. Vouchers may be transferred, including by sale; accordingly, there is a market for these vouchers at prices that have historically fluctuated. If we receive a voucher, we cannot guarantee that we will use it or that there will be a market to transfer or sell the voucher. Further, receipt of Orphan Drug Designation does not guarantee that we will receive seven years of market exclusivity upon approval for this indication unless all appropriate statutory and regulatory criteria are met, the interpretation of which, as noted, has been in flux. Orphan Drug designation can also be rescinded in specific circumstances and, if the designation is withdrawn after drug approval, any orphan drug exclusivity awarded would be rescinded as well.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has also granted Fast Track Designation to Lomecel-B&#153; for the treatment of HLHS. A Fast Track designation by the FDA may not lead to a faster development or regulatory review or approval process, and does not necessarily increase the likelihood that our product candidates will receive marketing approval for this indication.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for Lomecel-B&#153; for mild AD does not guarantee that Lomecel-B will be developed or approved faster, or more successfully, than if these designations were not granted, and FDA could rescind these designations if the qualifying criteria are no longer met.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA has granted two designations to Lomecel-B&#153; for the treatment of mild AD based on the completion of certain clinical trials: Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation. RMAT Designation may be granted to a regenerative medicine therapy, including a cell therapy, that is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition. An RMAT Designation can provide earlier and more intensive interactions with FDA during the drug development process. However, these interactions may not lead to a faster or more successful Lomecel-B&#153; development program or approval for mild AD because FDA review priorities may change, or the designation could be withdrawn if the qualifying criteria for RMAT Designation are no longer met.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA has also granted Fast Track Designation to Lomecel-B&#153; for the treatment of mild AD. Products are eligible for this designation if they are intended to treat a serious or life-threatening disease or condition, and nonclinical or clinical data demonstrate the potential to address unmet medical needs for the disease or condition. Benefits of a Fast Track Designation can include more frequent interactions with FDA, as well as rolling review of portions of an application before the complete application is submitted. However, a Fast Track Designation does not guarantee that we will have a faster or more successful Lomecel-B&#153; development program or approval for mild AD because FDA review priorities may change, or the designation could be withdrawn if the qualifying criteria for Fast Track Designation are no longer met.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may face difficulties from changes to current regulations and future legislation, both in the U.S. as well as in other foreign jurisdictions where we may be operating.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing regulations and regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the ACA substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacted the U.S. pharmaceutical industry. Since its enactment, there have been judicial and Congressional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been adopted since the ACA was enacted, including mandatory sequestration (e.g., aggregate reductions of Medicare payments to providers up to 2%), which will remain in effect through fiscal year 2031 absent additional Congressional action. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and legislation designed, among other things, to reform government program reimbursement methodologies for pharmaceutical products and bring more transparency to product pricing and the relationship between pricing and manufacturer patient programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022, signed into law by former President Biden on August 16, 2022, contains several significant provisions regarding drug pricing, coverage, and reimbursement that could materially impact our business. Among the key provisions related to drug pricing, Title XI of the Social Security Act would be amended to direct the Secretary of the U.S. Department of Health and Human Services to establish a Drug Price Negotiation Program to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government for certain prescription drugs. Each year, under the Drug Price Negotiation Program, the Secretary would identify a small number of single-source brand name drugs or biologics, without generic or biosimilar competition, and for which certain periods of time have elapsed since drug approval, that are covered under Medicare Part D (starting in 2026) and Part B (starting in 2028). These selected drugs would be subject to negotiation to establish a maximum fair price charged to Medicare. Manufacturers that are noncompliant with the drug price negotiation program would be subject to an excise tax and other civil monetary penalties during noncompliance periods. Other important drug pricing provisions include a mandatory rebate for drug manufacturers of certain Medicare Part B and Part D drugs with prices increasing faster than inflation; caps on annual out-of-pocket spending for Medicare beneficiaries; and limits of $35 for monthly cost-sharing for insulin products under Medicare Part D and a cap of 20% of the Medicare-approved amount after reaching the Medicare Part B deductible.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the U.S. that could impact our future business and operations, including those that may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and accordingly, our business, financial condition, and results of operations. Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from third-party payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the future marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with healthcare professionals, clinical investigators, CROs and payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers and payors play a primary role in the recommendation and prescription of any product candidates for which we obtain future marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Although our products are not currently reimbursed by government healthcare programs such as Medicare or Medicaid, any future reimbursement from federal and/or state healthcare programs could expose our business to broadly applicable fraud and abuse laws and other healthcare laws and regulations that would regulate the business. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal Stark Law</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If in the future some of our revenues are derived from federal healthcare programs, we may be subject to the federal self-referral prohibitions, commonly known as the Stark Law. Where applicable, this law prohibits a physician from referring Medicare patients to an entity providing &#8220;designated health services&#8221; such as laboratory and other diagnostic services and prescription drugs that are furnished at an entity if the physician or a member of such physician&#8217;s immediate family has a &#8220;financial relationship&#8221; with the entity, unless an exception applies. A determination of liability under the Stark Law could have a material adverse effect on our business, financial condition and results of operations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal Anti-Kickback Statute</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We will also be subject to the federal Anti-Kickback Statute if any of our services become reimbursable by government healthcare programs. The Anti-Kickback Statute is broadly worded and prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (i) the referral of a person covered by Medicare, Medicaid or other governmental programs, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other governmental programs or (iii) the purchasing, leasing or ordering or arranging or recommending purchasing, leasing or ordering of any item or service reimbursable under Medicare, Medicaid or other governmental programs. Violations of the federal Anti-Kickback Statute may result in civil monetary penalties, criminal penalties and exclusion from participation in government healthcare programs, including Medicare and Medicaid. Imposition of any of these remedies could have a material adverse effect on our business, financial condition and results of operations, if in the future we provide services reimbursable by government healthcare programs.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">False Claims Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Both federal and state government agencies have continued civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and their executives and managers. Although there are a number of civil and criminal statutes that can be applied to healthcare providers, a significant number of these investigations involve the FCA. These investigations can be initiated not only by the government but also by a private party asserting direct knowledge of fraud. These &#8220;qui tam&#8221; whistleblower lawsuits may be initiated against any person or entity alleging such person or entity has knowingly or recklessly presented, or caused to be presented, a false or fraudulent request for payment from the federal government or has made a false statement or used a false record to get a claim approved. In addition, the improper retention of an overpayment for 60 days or more is also a basis for an FCA action, even if the claim was originally submitted appropriately. Penalties for FCA violations include fines and may provide the basis for exclusion from federally funded healthcare programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">State Fraud and Abuse Laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Several states have also adopted or may adopt similar self-referral, anti-kickback, fraud, whistleblower and false claims laws as described above. The scope of these laws and the interpretations of them vary by jurisdiction and are enforced by local courts and regulatory authorities, each with broad discretion. A determination of liability under such state fraud and abuse laws could result in fines and penalties and restrictions on our ability to operate in these jurisdictions.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Physician Payments Sunshine Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS starting in 2022 information regarding payments and other transfers of value to physicians, certain other healthcare providers and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported will be publicly available on a searchable website, with disclosure required annually; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The FCA established several separate criminal penalties for making false or fraudulent claims to insurance companies and other non-governmental payers of healthcare services. Under FCA, these two additional federal crimes are: &#8220;Healthcare Fraud&#8221; and &#8220;False Statements Relating to Healthcare Matters.&#8221; The Healthcare Fraud statute prohibits knowingly and recklessly executing a scheme or artifice to defraud any healthcare benefit program, including private payers. A violation of this statute is a felony and may result in fines, imprisonment, or exclusion from government sponsored programs. The False Statements Relating to Healthcare Matters statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact by any trick, </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">scheme or device or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. A violation of this statute is a felony and may result in fines or imprisonment. This statute could be used by the government to assert criminal liability if a healthcare provider knowingly fails to refund an overpayment. In addition, the Civil Monetary Penalties Law imposes civil administrative sanctions for, among other violations, inappropriate billing of services to federally funded healthcare programs and employing or contracting with individuals or entities who are excluded from participation in federally funded healthcare programs. Moreover, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of copayments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties. Furthermore, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and civil False Claims Act, which can impose additional penalties associated with the wrongful act. The routine waivers of copayments and deductibles offered to patients covered by commercial payers may also implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts, and statutory or common law fraud. Additionally, pharmaceutical and device manufacturers may be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business, including, without limitation, the Consumer Fraud Act, fee splitting, patient brokering, and other state and federal laws and regulations, as well as similar foreign laws in jurisdictions outside the U.S., where applicable involving various pharmaceutical regulation issues, fraud and abuse, price reporting, data privacy and security, and transparency.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Further state laws require biotechnology companies to report information on the pricing of certain drug products. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For instance, as previously stated, the collection and use of health data in the EU is governed by the GDPR, which extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles, creates new obligations for companies and new rights for individuals. Failure to comply with the GDPR may result in substantial fines and other administrative penalties. In addition, on June 28, 2018, the State of California enacted the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, temporary or permanent debarment, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A variety of factors, including inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, collection of user fees, and statutory, regulatory, and policy changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Average review times at the agency have fluctuated in recent years as a result of these and other factors. In particular, the FDA has relatively limited experience with regulating novel product candidates like ours, and this may add to its already fluctuating review times. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times, and certain regulatory authorities, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Separately, since March 2020 when foreign and domestic inspections of facilities were largely placed on hold in connection with the COVID-19 pandemic, the FDA has been working to resume pre-pandemic levels of inspections, including routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel or for other reasons, and the FDA does not determine that a remote interactive evaluation will be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to a pandemic and may experience delays in their regulatory activities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to identify or discover additional product candidates in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield viable product candidates for clinical development for a number of reasons, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to design such product candidates with the pharmacological properties that we desire or that result in attractive pharmacokinetics;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to design and develop a suitable manufacturing process; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify other suitable treatments for preclinical and clinical development, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, or if the laws and regulations regarding animal testing otherwise change, our research and development activities may be interrupted, delayed or become more expensive.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we further expand our operations outside of the U.S., we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third-party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. In recent years, the SEC and Department of Justice (DOJ) have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. On February 10, 2025, President Trump signed an executive order titled &#8220;Pausing Foreign Corrupt Practices Act Enforcement to Further American Economic and National Security. The executive order ordered the Attorney General of the United States to  (i) review in detail all existing FCPA investigations or enforcement actions, (ii) to take appropriate action to restore proper bounds on FCPA enforcement, and (iii) cease initiation of any new FCPA investigations or enforcement actions unless the Attorney General determines that an individual exception should be made. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. It is additionally uncertain whether our employees, agents, or contractors, or those of our affiliates, would meet the requirements of any individualized exception to the FCPA enforcement moratorium imposed by President Trump&#8217;s executive order. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, prospects, operating results and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our products and technology may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products and technology, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell access to our products would likely adversely affect our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Class A Common Stock and the Securities Market</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The price of our Class A common stock has been, and may continue to be, volatile, which could result in substantial or total losses for investors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our Class A common stock has been and may continue to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Broad market and industry factors may negatively affect the market price of our Class A common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and results, or perception of the results, of preclinical studies and clinical trials of our product candidates or those of our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or announcements by potential competitors of their product development efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory actions with respect to our or our competitors&#8217; product candidates or approved products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in our growth rate relative to our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the U.S. and other countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, or capital commitments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sector;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Class A common stock price and volume fluctuations attributable to inconsistent trading volume levels of our Class A common stock;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcement or expectation of additional financing efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our Class A common stock by us, our insiders, or our other stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expiration of market stand-off or lock-up agreements; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry and market conditions.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our Class A common stock. Additionally, in the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There may not be sufficient liquidity in the market for our securities in order for investors to sell their shares.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a small company that is relatively unknown to stock analysts, stockbrokers, institutional investors and others in the investment community that generate or influence sales volume, and even if we came to the attention of such persons, they tend to be risk-averse and may be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable. There may be periods of several days or more when trading activity in our shares is minimal as compared to a mature issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. It is possible that a broader or more active public</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading market for our common stock will not develop or be sustained, or that trading levels will not continue. These factors may materially adversely affect the market price of our Class A common stock, regardless of our performance.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to raise substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, scale back or discontinue some of our product candidate development programs or commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development of pharmaceutical drugs is capital intensive. We are currently advancing Lomecel-B</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into clinical development. Our current cash resources are insufficient to fund our planned operations or development plans beyond the fourth quarter of 2025, based on our current operating budget and cash flow forecast. We will require additional funds to advance further. If we are capital constrained, we may not be able to meet our obligations. If we are unable to meet our obligations, or we experience a disruption in our cash flows, it could limit or halt our ability to continue to develop our current product candidate or even to continue operations, either of which occurrence would have a material adverse effect on us. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we continue the research and development of, advance the preclinical and clinical activities of, and seek marketing approval for, our current product candidates. As a result of our Type C meeting with the U.S. FDA in August 2024 with respect to the HLHS regulatory pathway, we have started to ramp up Biologics License Application (BLA) enabling activities as we currently anticipate a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. Our operating expenses and capital expenditure requirements are expected to accelerate in calendar 2025 as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness, and there will be a need to increase our current proposed spend and further increase our capital investments. We intend to seek additional financing/capital raises/non-dilutive funding options to support these activities, and current cash projections may be impacted by these ramped up activities and any financing transactions entered into. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we obtain marketing approval for any of our current or future product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. We may also need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our current product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, we expect to continue to incur significant costs associated with operating as a public company. If we are unable to raise capital when needed, we could be forced to delay, scale back or discontinue the development and commercialization of one or more of our product candidates, delay our pursuit of potential licenses or acquisitions, or significantly reduce our operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the net proceeds from recent offerings, together with our existing cash, will be sufficient to fund our operations into the fourth quarter of 2025. Our future capital requirements will depend on and could increase significantly as a result of many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our current or future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential additional expenses attributable to adjusting our development plans (including any supply-related matters) in response to global geopolitical conditions and/or future public health crises;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, prioritization and number of our research and development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our current or future product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under any additional collaboration agreements we obtain;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we are obligated to reimburse, or are entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or license other current or future product candidates and technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of securing manufacturing arrangements for commercial production; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our current or future product candidates.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying potential current or future product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve drug sales.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our current or future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to continue to rely on additional funding to achieve our business objectives.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current or future product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions in the financial markets in general have made equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms favorable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our Class A common stock to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness could result in fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or current or future product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain funding on a timely basis, we may be required to significantly delay, scale back or discontinue one or more of our research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to maintain our share price above the minimum bid price requirement established by Nasdaq could result in the delisting of our Class A common stock on the Nasdaq Capital Market. The loss of our Nasdaq listing would in all likelihood make our Class A common stock significantly less liquid and adversely affect its value.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 18, 2025 our Class A common stock closing bid price was $1.58. In January 2025, the SEC approved Nasdaq&#8217;s proposal to modify its listing standards governing minimum bid price compliance periods and delisting processes, such that, among other matters, if a company fails to maintain a closing bid price of at least $1.00 per share (the &#8220;Minimum Bid Price Requirement&#8221;), and had previously executed a reverse stock split within the prior year, it would immediately receive a notification letter from the Nasdaq Listing Qualifications Department commencing delisting proceedings, with no compliance period. As previously disclosed, the Company undertook a reverse stock split on March 26, 2024.  As such, if our Class A common stock closing bid price drops below $1.00 prior to March 26, 2025, we would be subjected to immediate delisting proceedings.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a delisting from the Nasdaq Capital Market, our Class A common stock would likely be traded in the over-the- counter inter-dealer quotation system, more commonly known as the OTC. OTC transactions involve risks in addition to those associated with transactions in securities traded on the securities exchanges, such as the Nasdaq Capital Market, or Exchange-listed stocks. Many OTC stocks trade less frequently and in smaller volumes than Exchange-listed stocks. Accordingly, our Class A common stock would be less liquid than it would be otherwise. Also, the prices of OTC stocks are often more volatile than Exchange-listed stocks. Additionally, many institutional investors are prohibited from investing in OTC stocks, and it might be more challenging to raise capital when needed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The dual-class structure of our common stock may adversely affect the trading market for our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict whether our dual class structure will result in a lower or more volatile market price of our Class A common stock or in adverse publicity or other adverse consequences. For example, certain index providers have announced restrictions on including companies with dual class or multi-class share structures in certain of their indexes. Our dual class capital structure could make us ineligible for inclusion in certain indices and mutual funds, exchange-traded funds and other investment vehicles that attempt to passively track these indices will not be investing in our stock. These policies are still fairly new, and it is as of yet unclear what effect, if any, they will have on the valuations of publicly traded companies excluded from the indices, but it is possible that they may depress these valuations compared to those of other similar companies that are included. Furthermore, we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cannot assure you that other stock indices will not take a similar approach to S&amp;P, Dow Jones or FTSE Russell in the future. Exclusion from indices could make our Class A common stock less attractive to investors and, as a result, the market price of our Class A common stock could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Holders of our Class B common stock exert considerable control over the direction of our business and their ownership of our Class B common stock can prevent other stockholders from influencing significant decisions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For so long as holders of Class B common stock continue to hold their current shares, they will be able to significantly influence the composition of our Board of Directors (the "Board") and the approval of actions requiring stockholder approval through their voting power. Accordingly, for such period of time, these holders will have significant influence with respect to our management, business plans and policies. In particular, for so long as the Class B common stock remains outstanding, the holders may be able to cause or prevent a change of control of our Company or a change in the composition of our Board of Directors and could preclude any unsolicited acquisition of our Company. The concentration of ownership could deprive stockholders of an opportunity to receive a premium for shares of Class A common stock as part of a sale of our Company and ultimately might affect the market price of our Class A common stock. As of February 17, 2025, three holders of our Class B common stock, Joshua M. Hare, co-founder, Chief Science Officer and Chairman of the Board of Directors, Donald M. Soffer, co-founder and former member of our Board of Directors, and Rock Soffer, member of our Board of Directors, control voting rights over approximately 37% of the combined voting power of our Class A common stock and Class B common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports, or if they publish negative, adverse, or misleading research or reports, regarding us, our business or our market, our Class A common stock price and trading volume could decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our Class A common stock is influenced by the research and reports that securities or industry analysts publish about us, our business, or our market. We do not currently have significant research coverage and may never obtain significant research coverage by securities or industry analysts. If no or few securities or industry analysts provide coverage of us, the Class A common stock price could be negatively impacted. In the event we obtain significant, or any securities or industry analyst coverage and such coverage is negative, or adverse or misleading regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our Class A common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our Class A common stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective June 30, 2020, the SEC implemented Regulation Best Interest requiring that &#8220;A broker, dealer, or a natural person who is an associated person of a broker or dealer, when making a recommendation of any securities transaction or investment strategy involving securities (including account recommendations) to a retail customer, shall act in the best interest of the retail customer at the time the recommendation is made, without placing the financial or other interest of the broker, dealer, or natural person who is an associated person of a broker or dealer making the recommendation ahead of the interest of the retail customer.&#8221; This is a significantly higher standard for broker-dealers to recommend securities to retail customers than before under prior FINRA suitability rules. FINRA suitability rules do still apply to institutional investors and require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending securities to their customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information, and, for retail customers, determine that the investment is in the customer&#8217;s &#8220;best interest,&#8221; and meet other SEC requirements. Both SEC Regulation Best Interest and FINRA&#8217;s suitability requirements may make it more difficult for broker-dealers to recommend that their customers buy speculative, low-priced securities. They may affect investing in our Class A common stock, which may have the effect of reducing the level of trading activity in our securities. As a result, fewer broker-dealers may be willing to make a market in our Class A common stock, reducing a stockholder&#8217;s ability to resell shares of our Class A common stock.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our Certificate of Incorporation and Bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Certificate of Incorporation and bylaws contain provisions that could depress the market price of our Class A common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a classified Board of directors so that not all members of our Board are elected at one time;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">permit only the Board of directors to establish the number of directors and fill vacancies on the Board;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provide for a dual class common stock structure, which provides certain affiliates of ours, including our co-founder and members of our Board, individually or together, with the ability to significantly influence the outcome of matters requiring stockholder approval, even if they own significantly less than a majority of the shares of our outstanding common stock and Class B common stock;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our Board could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eliminate the ability of our stockholders to call special meetings of stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibit cumulative voting;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorize our Board to amend our Bylaws;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish advance notice requirements for nominations for election to our Board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require a super-majority vote of stockholders to amend some of the provisions described above.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Section 203 of the General Corporation Law of the State of Delaware prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any provision of our Certificate of Incorporation, Bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently an emerging growth company, or EGC, as defined in the JOBS Act, enacted in April 2012. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an EGC for up to five years following the year in which we completed our initial public offering, although circumstances could cause us to lose that status earlier. We will remain an EGC until the earlier of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering (i.e., December 31, 2026), (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior June 30th, and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may choose to take advantage of some, but not all, of the available exemptions. We cannot predict whether investors will find our Class A common stock less attractive if we rely on certain or all of these exemptions. If some investors find our Class A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">common stock less attractive as a result, there may be a less active trading market for our Class A common stock and our stock price may be more volatile.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the JOBS Act, EGCs can also delay adopting new or revised accounting standards until such time as those standards apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The issuance of additional stock in connection with acquisitions or otherwise will dilute all other stockholdings.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are not restricted from issuing additional shares of our Class A common stock, or from issuing securities that are convertible into or exchangeable for, or that represent the right to receive, Class A common stock. As of February 17, 2025, we had an aggregate of 84,295,000 shares of Class A common stock authorized and of that approximately 62,902,003 not issued, outstanding or reserved for issuance (for purposes of warrant exercise or under the Company&#8217;s current Second Amended and Restated 2021 Incentive Award Plan). We may issue all of these shares without any action or approval by our stockholders. We may expand our business through complementary or strategic business combinations or acquisitions of other companies and assets, and we may issue shares of Class A common stock in connection with those transactions. The market price of our Class A common stock could decline as a result of our issuance of a large number of shares of Class A common stock, particularly if the per share consideration we receive for the stock we issue is less than the per share book value of our Class A common stock or if we are not expected to be able to generate earnings with the proceeds of the issuance that are as great as the earnings per share we are generating before we issue the additional shares. In addition, any shares issued in connection with these activities, the exercise of warrants or stock options or otherwise would dilute the percentage ownership held by our investors. We cannot predict the size of future issuances or the effect, if any, that they may have on the market price of our Class A common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never commercialized an approved product, and we currently have no sales force, marketing or distribution capabilities, nor do any of our current employees have any experience in commercializing a regulated product. To achieve commercial success for our product candidates, if they are approved, which we may license to others, we will rely on the assistance and guidance of those collaborators. For future approved products for which we retain commercialization rights, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Factors that may affect our ability to commercialize our future approved products on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our products and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our future approved products. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our future approved products, we may not generate revenues from them or be able to reach or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In order to successfully implement our plans and strategies, we will need to grow our organization, and we may experience difficulties in managing this growth.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to successfully implement our development and commercialization plans and strategies, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing our internal development efforts effectively, including preclinical and clinical studies and investigations, as well as FDA, PMDA and other comparable foreign regulatory authorities review process for any current or future product candidates, while complying with any contractual obligations to contractors and other third parties we may have; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future financial performance and our ability to successfully develop and, if approved, commercialize, any current or future product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of our current and future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third-party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize our current and future product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our computer systems, or those of any of our CROs, manufacturers, other contractors, consultants, collaborators or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the implementation of security measures, our computer systems and those of our current and any future CROs and other contractors, consultants, collaborators and third-party service providers, are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as HIPAA, the Health Information Technology for Economic and Clinical Health Act and GDPR), it could result in a material disruption of our drug discovery and development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development, approval, and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our first year incurring NOLs was for the tax year ended 2021, the net operating loss carryforwards, or NOLs, could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Under the current Tax Act, federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely. It is uncertain if and to what extent various states will conform to the Tax Act.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change in our ownership by &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period), the corporation&#8217;s ability to use its pre-change NOLs and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">result of subsequent shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in ownership. Our ability to utilize those NOLs could be limited by an &#8220;ownership change&#8221; as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to seek regulatory approval of our product candidates outside of the U.S. and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing regulatory requirements and reimbursement regimes in foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential liability under the FCPA or comparable foreign regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The increasing use of social media platforms presents new risks and challenges.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Social media is increasingly being used to communicate about our clinical development programs and the diseases our therapeutics are being developed to treat, and we intend to utilize appropriate social media in connection with our commercialization efforts following approval of our product candidates, if any. Social media practices in the biotechnology and biopharmaceutical industries continue to evolve and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to off-label marketing or other prohibited activities and heightened scrutiny by the FDA, the SEC and other regulators. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. If such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking platform. In addition, we may encounter attacks on social media regarding our company, management, product candidates or future approved products. Finally, social media may aid in the social reform of current drug prices. For example, CVS&#8217;s recently proposed &#8220;CostVantage&#8221; program is regularly referred to on social media and may have an impact on how pharmaceutical products are priced in the future. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolved Staff Comments</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:nonNumeric id="F_4bdd1749-d690-4c4b-bd88-f5f9a989f985" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_4bdd1749-d690-4c4b-bd88-f5f9a989f985_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) recognizes the critical importance of maintaining the trust and confidence of our customers, clients, business partners and employees. The Board is actively involved in oversight of the Company&#8217;s risk management program, and cybersecurity represents an important component of the Company&#8217;s overall approach to enterprise risk management (&#8220;ERM&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f07aadfb-a845-49af-8aad-b26f8ded3db4" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cybersecurity policies, standards, processes, and practices are fully </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_796695d1-913a-498e-a0eb-cafc369d7e3c" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into the Company&#8217;s ERM program and are based on recognized frameworks established by the National Institute of Standards and Technology, the International Organization for Standardization and other applicable industry standards.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In general, the Company seeks to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that the Company collects and stores by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.</span></p><div><ix:nonNumeric id="F_205fc986-1dae-47cd-9331-b3c39cc3b99e" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true" continuedAt="F_205fc986-1dae-47cd-9331-b3c39cc3b99e_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As one of the critical elements of the Company&#8217;s overall ERM approach, the Company&#8217;s cybersecurity program is focused on the following key areas:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f294675-2f03-49d1-92bc-181b14bf6e28" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in more detail under the heading &#8220;Governance,&#8221; The Board&#8217;s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the &#8220;Audit Committee&#8221;), which regularly interacts with the Company&#8217;s General Counsel ("GC"), Chief Technology Officer ("CTO"), other members of management and relevant management committees, including Company&#8217;s Senior Leadership Team (&#8220;SLT&#8221;), regarding cybersecurity oversight and risk management.</span></div></div></ix:nonNumeric></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative Approach: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, through its </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a0588e6-2dcd-48be-84bc-d63f67ef2782" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information technology partner</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, has implemented a comprehensive, cross-functional approach to identifying, preventing, and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd82d109-c713-45ba-b710-6cc325e4332c" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Technical Safeguards: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, through its information technology partner, deploys technical safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti- malware functionality and access controls, which are evaluated and improved through vulnerability assessments, penetration testing, and cybersecurity threat intelligence.</span></ix:nonNumeric></span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incident Response and Recovery Planning: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, with its information technology partner, maintains comprehensive incident response and recovery plans that fully address the Company&#8217;s response to a cybersecurity incident.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Education and Awareness: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, through its information technology partner, provides regular, mandatory training for personnel regarding cybersecurity threats to equip the Company&#8217;s personnel with effective tools to address cybersecurity threats, and to communicate the Company&#8217;s evolving information security policies, standards, processes, and practices.</span></div></div><div><ix:nonNumeric id="F_8dbf9909-162c-4cd2-85ed-32ce1ac9bc38" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company engages in the periodic assessment and testing of the Company&#8217;s policies, standards, processes, systems, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability and penetration testing and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. The Company with our information technology partner regularly engages assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the CTO and GC who shares data with the SLT and Audit Committee, and the Company adjusts its cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_8bf9b296-64a8-4b58-b569-0a52b80af3d6" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true" continuedAt="F_8bf9b296-64a8-4b58-b569-0a52b80af3d6_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae4a9a2e-9be3-4d6f-8071-f1d8583c3680" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5cfd4b5-d765-4f90-a4ef-33412775af90" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTO, in coordination with the SLT, oversees the Company&#8217;s ERM process, including the management of risks arising from cybersecurity threats.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CTO and the SLT, through its information technology partner receives regular reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, the threat environment, technological trends and information security considerations.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e8a5ddb-e375-4fc1-8ad1-2902ac9f0702" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On an annual basis, the Audit Committee and the Board discuss the Company&#8217;s approach to cybersecurity risk management with the members of the SLT, which includes the Company&#8217;s CTO, GC, and Chief Financial Officer (&#8220;CFO&#8221;).</span></ix:nonNumeric></span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_4bdd1749-d690-4c4b-bd88-f5f9a989f985_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_205fc986-1dae-47cd-9331-b3c39cc3b99e_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8bf9b296-64a8-4b58-b569-0a52b80af3d6_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTO, in coordination with the SLT, works collaboratively across the Company to implement a program designed to protect the Company&#8217;s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company&#8217;s incident response and recovery plans. To facilitate the success of the Company&#8217;s cybersecurity risk management program, multidisciplinary teams are prepared to address cybersecurity threats and to respond to cybersecurity incidents. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57a946ff-e8e5-4567-a940-973c619eec69" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through ongoing communications with the Company&#8217;s information technology partner, these teams monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to the Company&#8217;s SLT and Audit Committee, when appropriate.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s information technology partner has worked in information technology and information security for over 30 years with over 300 employees with six locations in the United States. A virtual Chief Information Officer (&#8220;vCIO&#8221;) from the partner works directly with the Company to align business and technical strategies, decisions, and implementations. The CTO has nearly 20 years of experience in the pharmaceutical and biotech industry managing programs and projects across a variety of implementation methodologies and risk factors and holds undergraduate degrees and certifications in his respective field. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83f420be-fa44-401c-821b-ac5dadf397df" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Executive Officer, CFO and General Counsel each hold undergraduate and graduate degrees in their respective fields, and each have over 25 years of experience managing risks at similar companies, including risks arising from cybersecurity threats.</span></ix:nonNumeric></span></p></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity threats, including the results of any previous cybersecurity incidents, have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3866ff6f-cb48-4e1f-8c24-c1788c03700f" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not materially</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> affected or are reasonably likely to affect the Company, including its business strategy, results of operations or financial condition.</span></p></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Properties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal executive offices are located at 1951 NW 7th Avenue, Suite 520, Miami, Florida 33136. We rent approximately 15,000 ft</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of space, which includes our executive offices and cGMP manufacturing facility, and research and development operations. This property is used by the Company&#8217;s single operating segment focused on developing regenerative medicines to address unmet medical needs. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; on page 5 of this 10-K for additional details regarding our facilities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal Proceedings</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. While management does not currently believe that the ultimate disposition of these matters will have a material adverse impact on the Company&#8217;s results of operations, cash flows, or financial position, litigation is inherently unpredictable, and depending on the nature and timing of these proceedings, an unfavorable resolution could materially affect the Company&#8217;s future results of operations, cash flows or financial condition in a particular period.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Safety Disclosures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market for Common Stock; Holders</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Class A common stock is traded on The Nasdaq Capital Market under the under the symbol &#8220;LGVN.&#8221; Our Class B common stock is not listed or traded on any stock exchange or other market. Shares of Class A common stock are entitled to one (1) vote per share. Shares of Class B common stock are entitled to five (5) votes per share. Holders of our Class A common stock and Class B common stock generally vote together as a single class, unless otherwise required by law or our Certificate of Incorporation. Each share of our Class B common stock is convertible into one share of our Class A common stock at any time and converts automatically upon certain transfers. The Class A common stock is not convertible into Class B common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 17, 2025, there were 19 and 12 holders of record of our Class A and Class B common stock, respectively, based on information provided by our transfer agent, Colonial Stock Transfer Co., Inc. As of such date, 13,473,898 shares of our Class A common stock and 1,484,005 shares of our Class B common stock were issued and outstanding.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared nor paid any cash dividends, and currently intend to retain all our cash and any earnings for use in our business and, therefore, do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of the Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements and such other factors as the Board of Directors deems relevant.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities; Repurchases of Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ISSUER PURCHASES OF EQUITY SECURITIES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.292%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.158%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.678%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.158%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.158%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Period</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total <br/>Number of<br/>Shares (or Units)<br/>Purchased<br/>(a)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average Price Paid<br/>per <br/>Share (or<br/>Unit)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total <br/>Number of Shares <br/>Purchased as Part<br/>of Publicly <br/>Announced Plans <br/>or Programs</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maximum Number or Approximate Dollar Value of<br/>Shares that May <br/>Yet Be Purchased<br/>Under the Plans or<br/>Programs</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 1-31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,620</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.88</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 1-30, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.98</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1-31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,853</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.88</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes shares withheld from employees to satisfy minimum tax withholding obligations associated with the vesting of restricted stock units during the period.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information set forth under Part III, Item 12. &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters &#8211; Equity Compensation Plan Information&#8221; is incorporated herein.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. Reserved</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserved.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and related notes thereto and other financial information appearing elsewhere in this 10-K. This 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. See &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and Part I, Item 1A, &#8220;Risk Factors.&#8221; Readers are also urged to carefully review and consider these and other disclosures made by us which attempt to advise interested parties of the factors which affect our business. Operating results are not necessarily indicative of results that may occur in future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Introduction and Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company&#8217;s lead investigational product is Lomecel-B&#153;. Lomecel-B&#153; has multiple modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently pursuing three pipeline indications: Hypoplastic Left Heart Syndrome (&#8220;HLHS&#8221;), Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Aging-related Frailty. Our mission is to advance Lomecel-B&#153; and other cell-based product candidates into pivotal or Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Overview. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, the Company has primarily been engaged in organizational activities, including raising capital, and research and development activities. The Company does not yet have a product that has been approved by the FDA, and has only generated revenues from grants, the Bahamas Registry Trials and contract manufacturing. The Company has not yet achieved profitable operations or generated positive cash flows from operations. The Company has incurred recurring losses from operations since its inception, and as of December 31, 2024 the Company had an accumulated deficit of $109.6 million. The Company expects to continue to generate operating losses for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025 based on our current operating budget and cash flow forecast. However, as a result of our Type C meeting with the U.S. FDA in August 2024 with respect to the HLHS regulatory pathway, we have started to ramp up Biologics License Application (BLA) enabling activities as we currently anticipate a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. Our operating expenses and capital expenditure requirements are expected to accelerate in calendar 2025 as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness, and there will be a need to increase our current proposed spend and further increase our capital investments. We intend to seek additional financing/capital raises/non-dilutive funding options to support these activities, and current cash projections may be impacted by these ramped up activities and any financing transactions entered into. There can be no assurance we will be able to attain future financing at terms favorable to us or at all.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operational Overview</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. With respect to HLHS, we are exploring the possibility that Lomecel-B&#153; when administered directly to the myocardium of affected infants, can improve outcomes in this devastating rare pediatric disease. The standard of care in HLHS is a series of three heart surgeries (staged surgical palliation) that reconfigures the single right ventricle to support system circulation. Despite these life-saving surgical interventions, it is estimated that only 50 to 60 percent of affected individuals survive until adolescence. The pro-vascular, pro-regenerative and anti-inflammatory properties of Lomecel-B&#153; may improve the function of the right ventricle in these infants. A previous Longeveron Phase 1 open-label study indicated that such a benefit may exist when outcomes were compared to historical controls. Longeveron is currently conducting a controlled study to determine the actual benefit of Lomecel-B&#153; in these patients.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 17, 2025, we have completed five U.S. clinical studies of Lomecel-B&#153;: Phase 1 AD, Phase 1 HLHS, Phase 1/2 Aging-related Frailty (&#8220;HERA Trial&#8221;), Phase 2a AD (CLEAR MIND Trial&#8221;), and Phase 2b Aging-related Frailty. We currently have one clinical trial actively enrolling patients: Phase 2b HLHS (&#8220;ELPIS II&#8221; trial). Additionally, we sponsor a registry in The Bahamas under the approval and authority of the National Stem Cell Ethics Committee. The Bahamas Registry Trials may administer Lomecel-B&#153; to eligible participants at private clinics in Nassau for a variety of indications. While Lomecel-B&#153; is considered an investigational product in The Bahamas, under the approval terms from the National Stem Cell Ethics Committee, we are permitted to charge a fee to participate in the Registry Trial.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our founding in 2014, we have focused the majority of our time and resources on the following: organizing and staffing our company, building, staffing and equipping a cGMP manufacturing facility with research and development labs, business planning, raising capital, establishing our intellectual property portfolio, generating clinical safety and efficacy data in our selected disease conditions and indications, and developing and expanding our manufacturing processes and capabilities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We manufacture all of our own product candidates for clinical trials. In 2017 we opened a manufacturing facility comprised of eight clean rooms, two research and development laboratories, and warehouse and storage space. We have supply contracts with multiple third parties for fresh bone marrow, which we use to produce our product candidate for clinical testing and research and development. From time to time, we enter into contract development and manufacturing contracts or arrangements with third parties who seek to utilize our product development capabilities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the time that we became a publicly traded company in February 2021, we have sold 12,686,240 shares of Class A common stock through our IPO and subsequent follow-on public and private equity offerings and transactions. Additionally, as of December 31, 2024, warrants exercisable for an aggregate of up to 6,802,668 shares of a Company's Class A common stock remain outstanding at exercise prices ranging from $2.35 per share to $175.00 per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When appropriate funding opportunities arise, we routinely apply for grant funding to support our ongoing research and since 2016 we have received approximately $16.0 million in grant awards ($11.5 million of which has been directly awarded to us and is recognized as revenue when the performance obligations are met) from the National Institute on Aging (&#8220;NIA&#8221;) of the National Institutes of Health (&#8220;NIH&#8221;), the National Heart Lung and Blood Institute (&#8220;NHLBI&#8221;) of the NIH, the Alzheimer&#8217;s Association, and the Maryland Stem Cell Research Fund (&#8220;MSCRF&#8221;) of the Maryland Technology Development Corporation, or TEDCO.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Estimates</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The discussion and analysis of our financial condition and results of operations is based upon our condensed financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, (U.S. GAAP). The preparation of these financial statements requires that we make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. We base our estimates on historical experience, anticipated results and trends and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily available from other sources. By their nature, these estimates, judgments and assumptions are subject to an inherent degree of uncertainty, and management evaluates them on an ongoing basis for changes in facts and circumstances. Changes in estimates are recorded in the period in which they become known. Actual results may differ from our estimates under different assumptions or conditions. While our significant accounting policies and estimates are described in more detail in the accompanying Notes to the Condensed Financial Statements contained in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical due to the judgments and estimates used in the preparation of our financial statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue recognition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize revenue associated with our contract manufacturing services, which may require us to exercise considerable judgment in estimating revenue to be recognized, including judgments made on day one accounting and judgments associated with the amount of revenue to be recognized over time as performance obligations are satisfied.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant judgment is required to apply the authoritative accounting guidance at the outset of our contract manufacturing services agreement, and over time, as detailed below:</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. For our contract manufacturing services revenue, the contract generally includes the terms of the contract manufacturing services and related ancillary services or procedures to comply with regulatory requirements. We have determined, our performance obligations vary per contract and are accounted for as separate performance obligations when a product or services is delivered.  If a product or service is determined not to be delivered as in the case of an initial down payment that amount is deferred and combined with another related performance obligation. If a contract contains a single performance obligation, we allocate the entire transaction price to the single performance obligation. If a contract contains multiple performance obligations, we allocate consideration to each performance obligation using the &#8220;relative standalone selling price&#8221;. Generally, we utilize observable standalone selling prices in our allocations of consideration. If observable standalone selling prices are not available, we estimate the applicable standalone selling price using a cost-plus-margin approach or an adjusted market assessment approach, in each case, representing the amount that we believe the market is willing to pay for the applicable service or product. Revenue is recognized over time using an appropriate method of measuring progress towards</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fulfilling our performance obligation for the respective arrangement. Determining the measure of progress that consistently depicts our satisfaction of performance obligations within each of our revenue streams across similar arrangements requires judgment.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The identified performance obligations will impact most significantly the timing of revenue recognition, and is either at a point in time or an over-time mainly based transfer of control assessment performed at the outset of the arrangement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For revenue recognized over time, this is based on an underlying measure deemed to approximate the progress towards satisfaction of performance obligations for the respective arrangement. These underlying measures, such as costs incurred to date compared with total forecasted costs for a service, may include inherent estimates, which in turn can impact the timing of revenue recognition. For revenue recognized at a point in time, revenue is recognized once the performance obligation is satisfied, meaning the product is delivered or the service is completed, signifying the transfer of control at a specific point in time,  The satisfaction of performance obligations assessment is performed at each reporting period. To date, there have been no material true ups to revenue as a result of changes in the satisfaction of performance obligations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Going Concern Assessment</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recently faced significant losses over the previous years and expects to incur losses for the foreseeable future. As a result, the company&#8217;s management has conducted an assessment of its financial condition, including cash flow projections for the next twelve months from the date the financial statements will be issued. Based on this assessment, management has identified potential material uncertainties that could cast substantial doubt on the company&#8217;s ability to continue as a going concern.  This assessment includes significant assumptions and estimation of uses and forecasts of cash flows in future periods.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To address these uncertainties, management has developed a plan that includes among other things the potential for securing additional financing and non-dilutive funding such as grants. Cost reductions would also be evaluated if needed. The successful execution of these plans is contingent upon various factors some of which may be outside the Company&#8217;s control.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the significant judgment and subjectivity of these estimates involved in assessing the feasibility of these plans and their potential impact on future cash flows, management considers the going concern assessment to be a critical accounting estimate. The financial statements include a disclosure outlining the nature of these uncertainties, the assumptions made by management, and the potential impact on the company&#8217;s financial position and performance.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Our Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have generated revenue from three sources:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Bahamas Registry Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Participants in The Bahamas Registry Trial pay us a fee to receive Lomecel-B&#153;, imported into The Bahamas, and administered at one of two private medical clinics in Nassau. While Lomecel-B&#153; is considered an investigational product in The Bahamas, under the approval terms received from the National Stem Cell Ethics Committee, we are permitted to charge a fee for participation in the Registry Trial. The fee is recognized as revenue and is used to pay for the costs associated with manufacturing and testing of Lomecel-B&#153;, administration, shipping and importation fees, data collection and management, biological sample collection and sample processing for biomarkers and other data, and overall management of the Registry, including personnel costs. Lomecel-B&#153; is considered an investigational treatment in The Bahamas and is not licensed for commercial sale.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract development and manufacturing services. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we enter into fee-for-service agreements with third parties for our product development and manufacturing capabilities. These agreements may include research, process development, and manufacturing services tailored to customer needs. In February 2024, we entered into our first manufacturing services contract with a third-party biotechnology company. Revenue from this contract is recognized over time as the services are provided. Additionally, the customer pays a fixed monthly fee per suite to reserve and maintain a dedicated manufacturing suite and storage space. Additional suites may also be secured based on capacity needs, which are billed at a fixed fee per suite per month. </span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Extramural grant award funding, which is non-dilutive, has been a core strategy for supporting our ongoing clinical research. Since 2016 our clinical programs have received over $16.0 million in competitive extramural grant awards ($11.5 million which has been directly awarded to us and which are recognized as revenue when the performance obligations are met) from the NIH, Alzheimer&#8217;s Association, and MSCRF.</span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of Revenues</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record cost of revenues based on expenses directly related to revenue. For grants we record allocated expenses for research and development costs to a grant as a cost of revenues. For the clinical trial revenue, directly related expenses for that program are allocated and accrued as incurred. These expenses are similar to those described under &#8220;Research and Development Expenses&#8221; below. For contract manufacturing revenue, directly related expenses for the services and facilities provided under the contract are recorded as cost of revenues.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are charged to expense when incurred in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 730 Research and Development. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Those activities that should be identified as research and development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The elements of costs that should be identified with research and development activities, and the accounting for these costs; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statement disclosures related to them.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, equity-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. We accrue for costs incurred by external service providers, including contract research organizations (&#8220;CROs&#8221;) and clinical investigators, based on estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, subject enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, we may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently do not carry any inventory for our product candidates, as we have yet to launch a product for commercial distribution. Historically our operations have focused on conducting clinical trials, product research and development efforts, and improving and refining our manufacturing processes, and accordingly, manufactured clinical doses of product candidates were expensed as incurred, consistent with the accounting for all other research and development costs. Once we begin commercial distribution, all newly manufactured approved products will be allocated either for use in commercial distribution, which will be carried as inventory and not expensed, or for research and development efforts, which will continue to be expensed as incurred.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our research and development expenses will continue to be significant in the future as we increase our headcount to support increased research and development activities relating to our clinical programs, as well as incur additional expenses related to our clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of salaries and other related costs, including equity-based compensation, for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include public company related expenses; legal fees relating to corporate matters; insurance costs; professional fees for accounting, auditing, tax and consulting services; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Income and Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income consists of interest earned on cash equivalents and marketable securities. The increase in interest income for the current year was primarily driven by a higher balance of cash compared to the prior year.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No provision for income taxes has been recorded for the years ended December 31, 2024 and 2023. We may incur income taxes in the future if we have earnings. At this time the Company has not evaluated the impact of any future profits.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESULTS OF OPERATIONS</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMPARISON OF THE YEARS ENDED DECEMBER 31, 2024 AND 2023</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2024 and 2023, together with the changes in those items in dollars (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.28%;box-sizing:content-box;"/>
    <td style="width:1.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Decrease)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,392</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,683</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">508</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">488</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,884</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,663</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,269</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,184</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,915</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,137</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,066</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(929</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,406</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,844</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,522</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,029</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,507</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other income and (expense)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lawsuit expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(30</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(30</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other tax credits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">549</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(377</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">926</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income (expenses), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">549</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(384</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">933</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(15,973</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,413</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,440</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues, Cost of Revenues and Gross Profit: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues for the years ended December 31, 2024 and 2023 were $2.4 million and $0.7 million, respectively. 2024 revenues increased $1.7 million, or 237%, when compared to 2023 as a result of higher participant demand for our Bahamas Registry Trial and the addition of our manufacturing services contract. Clinical trial revenue, which is derived from the Bahamas Registry Trial, for the years ended December 31, 2024 and 2023 was $1.4 million and $0.7 million, respectively, reflecting an increase of $0.7 million, or 110%, when compared to 2023 as a result of increased participant demand. Contract manufacturing revenue for the year ended December 31, 2024 was $1.0 million, consisting of $0.5 million from our manufacturing lease services and $0.5 million from our manufacturing services contract.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related cost of revenues was $0.5 million and $0.5 million for the years ended December 31, 2024 and 2023, respectively. </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This resulted in a gross profit of approximately $1.9 million for the year ended December 31, 2024, an increase of $1.7 million, or 752%, when compared with a gross profit of $0.2 million for 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and Administrative Expense:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> General and administrative expenses for the year ended December 31, 2024 decreased to approximately $10.3 million compared to $12.2 million for the same period in 2023. The decrease of approximately $1.9 million, or 16%, was primarily due to lower personnel expenses as a result of reduced severance in 2024 and lower legal and other administrative expenses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Research and development expenses for the year ended December 31, 2024 decreased to approximately $8.1 million from approximately $9.1 million for the same period in 2023. This decrease of $1.0 million, or 10%, was primarily driven by a reduction of $2.3 million in expenses related to the completed CLEAR MIND Alzheimer&#8217;s disease clinical trial, reduced costs for the Aging-related Frailty clinical trial following our decision to discontinue trial activities in Japan, and a $0.9 million decrease in supply costs. These reductions were partially offset by $1.7 million in higher compensation and benefit costs and a $0.3 million increase in equity-based compensation expenses allocated to research and development.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consisted primarily of the following items (less those expenses allocated to the cost of revenues) (in thousands):</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial expenses-statistics, monitoring, labs, sites, etc.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,031</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,349</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Supplies and costs to manufacture Lomecel-B&#153;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,214</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee compensation and benefits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,554</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,861</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">825</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">555</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">735</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">722</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Travel</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">268</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,137</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,066</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Income (Expense), net:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Other income (expense) for the years ended December 31, 2024 and 2023 was an income of $0.6 million and an expense of $0.4 million, respectively. Net other income for 2024 was driven by a higher interest income, </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compared to net other expense for 2023 driven by realized losses on sales of marketable securities of $0.3 million, write-offs of intangible assets of $0.3 million and reduced benefit of tax credits of $0.3 million.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net loss decreased to approximately $16.0 million for the year ended December 31, 2024 from a net loss of $21.4 million for the same period in 2023. The decrease in the net loss of $5.4 million, or 25%, was for reasons outlined above.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our sources and uses of cash for the period presented for the (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,868</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,002</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(640</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,186</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,791</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,262</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,283</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,554</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred losses since inception. Net cash used in operating activities for the year ended December 31, 2024 was $13.9 million, consisting primarily of our net loss of $16.0 million and payments for accounts payable of $0.5 million and a decrease in deferred revenue of $0.5 million. This was partially offset by non-cash expenses of $2.3 million in equity-based compensation expenses and $1.0 million in depreciation and amortization. Net cash used in operating activities for the year ended December 31, 2023 was $19.0 million, consisting primarily of our net loss of $21.4 million and payments for accounts payable of $1.1 million and payment of the non-operating lawsuit of $1.4 million. This was partially offset by non-cash expenses of $2.0 million in equity-based compensation expenses, $0.9 million in depreciation and amortization, and $0.3 million for the write-off of intangible assets, as well as an increase in accrued expenses of $1.5 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2024 was $0.6 million consisting primarily of additions to intangible assets of $0.6 million and purchases of equipment of $0.3 million, which was partially offset by proceeds from the sale of marketable securities of $0.3 million. Net cash provided by investing activities for year ended December 31, 2023 was $8.2 million consisting primarily of proceeds from the sale of marketable securities of $8.9 million, which was partially offset by additions to intangible assets of $0.4 million and purchases of equipment of $0.3 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2024 was $28.8 million consisting primarily of proceeds from the issuance of common stock of $12.9 million and warrants exercised of $16.2 million, which was partially offset by the payment of taxes upon vesting of RSUs.  Net cash provided by financing activities for the year ended December 31, 2023 was $5.3 million consisting primarily of $5.4 million of net proceeds received from the October 2023 and December 2023 offerings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LIQUIDITY AND CAPITAL RESOURCES</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses as we advance the preclinical and clinical development of our programs. We expect that our sales, research and development and general and administrative costs will remain substantial in connection with conducting additional preclinical studies and clinical trials for our current and future programs and product candidates, contracting with CROs to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements, or other sources.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have financed our operations primarily through our IPO, registered and private placement equity financings, grant awards, and fees generated from the Bahamas Registry Trials and contract manufacturing services. Since we were formed, we have raised approximately $113.0 million in gross proceeds from the issuance of equity. As of December 31, 2024, the Company had cash and cash equivalents of $19.2 million and working capital of approximately $17.0 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently believe that our cash and cash equivalents as of December 31, 2024 will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025 based on our current operating budget and cash flow forecast. However, as a result of our successful Type C meeting with the U.S. FDA in August 2024 with respect to the HLHS regulatory pathway, we have started to ramp up Biologics License Application (BLA) enabling activities as we currently anticipate a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. Our operating expenses and capital expenditure requirements are expected to accelerate in calendar 2025 as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness, and there will be a need to increase our current proposed spend and further increase our capital investments. We intend to seek additional financing and non-dilutive funding options to support these activities, and the current cash projections may be impacted by these ramped up activities and any financing transactions entered into. There can be no assurance we will be able to attain future financing at terms favorable to us or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capital Raising Efforts</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the time that we became a publicly traded company in February 2021, we have sold 12,686,240 shares of Class A common stock through our IPO and subsequent follow-on public and private equity offerings and transactions. Additionally, as of December 31, 2024, warrants exercisable for an aggregate of up to 6,802,668 shares of a Company's Class A common stock remain outstanding at exercise prices ranging from $2.35 per share to $175.00 per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 8, 2024, the Company commenced a public offering of up to 639,872 shares of the Company&#8217;s Class A common stock, along with pre-funded warrants to purchase up to an aggregate 1,572,894 shares of Class A common stock (the &#8220;Pre-Funded Warrants&#8221;). The shares and Pre-Funded Warrants were sold together with warrants to purchase up to an aggregate of 2,212,766 shares of Class A common stock (the &#8220;Common Warrants&#8221;). The combined public offering price was $2.35 per share and related Common Warrant and $2.349 per Pre-Funded Warrant and related Common Warrant. Subject to certain limitations, the Pre-Funded Warrants were immediately exercisable and could be exercised at a nominal consideration of $0.001 per share of Class A common stock at any time until all of the Pre-Funded Warrants were exercised in full. The Common Warrants were immediately exercisable and expire on April 10, 2029.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As compensation to the placement agent the Company also issued to designees of the placement agent warrants to purchase up to 154,894 shares of Class A common stock, which had substantially the same terms as the Common Warrants, and with an exercise price of $2.9375 per share and a term of five years from the commencement of sales in the offering.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the offering, the Company also entered into an agreement with a holder of existing warrants to amend the holder&#8217;s existing Series A warrants and Series B warrants that were issued in a private placement as part of the Company's October 2023 registered direct offering to reduce the exercise price to $2.35 per share and (ii) amend the expiration date of the Series A Warrants to five and one-half (5.5) years following the closing of the public offering and the Series B warrants to eighteen (18) months following the closing of the public offering, in each case for a payment to the Company of $0.125 per amended warrant.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 16, 2024, the Company entered into inducement letter agreements with certain holders of its existing Series A warrants and Series B warrants, and Common Warrants issued on April 10, 2024, whereby the holders agreed to exercise the warrants for cash at the exercise price of $2.35 per share in consideration for payment of $0.125 per new warrant and for the Company&#8217;s agreement to issue new unregistered Class A common stock warrants to purchase up to 4,799,488 shares of Class A common stock at an exercise price of $2.35 per share, and which were immediately exercisable upon issuance. The warrants to purchase up to 2,399,744 shares of Class A common stock (the &#8220;Series C Warrants&#8221;) have a term of five (5) years from the issuance date, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the warrants to purchase up to 2,399,744 shares of Class A common stock (the &#8220;Series D Warrants&#8221;) have a term of twenty-four (24) months from the issuance date, with all of the Series C Warrants and Series D Warrants being immediately exercisable. All of the Series D Warrants were exercised in June 2024, pursuant to ordinary course exercise as well as a subsequent inducement transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company issued to the placement agent or its designees as compensation, warrants to purchase up to 167,982 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the inducement transaction, which had the same terms as the Series C Warrants, except that the placement agent warrants have an exercise price of $3.25 per share.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, upon exercise, if any, of the Series D Warrants for cash, the Company agreed to issue the placement agent or its designees, within five (5) business days of the Company&#8217;s receipt of the exercise price, warrants to purchase the number of shares of Class A common stock equal to 7.0% of the aggregate number of shares underlying such Series D Warrants that have been exercised, with such warrants to be in the same form and terms as the prior placement agent warrants.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 18, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-278995) registering the resale of an aggregate of 4,967,470 shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to 2,399,744 shares issuable upon the exercise of the Series C Warrants issued in the April 2024 warrant inducement transaction; (ii) up to 2,399,744 shares issuable upon the exercise of the Series D Warrants issued in the April 2024 warrant inducement transaction; and (iii) up to 167,982 shares issuable upon exercise of the warrants issued to the placement agent or its designees in the April 2024 warrant inducement transaction. The Form S-1 was subsequently amended by the Company and declared effective by the SEC on May 21, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 17, 2024, the Company entered into additional inducement letter agreements with the holders of its existing Series D Warrants to exercise the remaining 1,697,891 shares of Class A common stock underlying Series D Warrants that remained outstanding for cash at the exercise price of $2.35 per share in consideration for the Company&#8217;s agreement to issue new unregistered Class A common stock warrants (the "June Inducement Warrants"), for payment of $0.125 per new warrant, to purchase up to an aggregate of 3,395,782 shares of Class A common stock at an exercise price of $2.50 per share and which were immediately exercisable upon issuance and have a term of twenty-four (24) months from the issuance date.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also issued to the placement agent or its designees as compensation, (i) warrants to purchase up to 118,852 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the June inducement transaction and (ii) warrants to purchase up to an aggregate of 49,130 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Common Stock issued upon exercise of certain Series D warrants prior to the inducement transaction, which had substantially the same terms as the June Inducement Warrants, except that the warrants exercisable for 118,852 shares had an exercise price of $3.25 per share and the warrants exercisable for 49,130 shares had an exercise price $2.9375 per share, respectively (collectively, the "June placement agent warrants").</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon exercise, if any, of the June Inducement Warrants for cash, the Company agreed to issue within five (5) business days to the placement agent or its designees, warrants to purchase the number of shares of Class A common stock equal to 7.0% of the aggregate number of shares of Class A common stock underlying such June Inducement Warrants that have been exercised, with such warrants to be in the same form and terms as the June placement agent warrants.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance under the inducement offers represented $8.5 million in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders. The June Inducement Warrants expire on June 18, 2026.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-280577) registering the resale of an aggregate of 3,563,764 shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to 3,395,782 shares issuable upon the exercise of the June Inducement Warrants and (ii) up to 167,982 shares issuable upon the exercise of the June placement agent warrants. The Form S-1 was subsequently declared effective by the SEC on July 9, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2024, a holder exercised Series C warrants for 50,000 shares of Class A common stock for cash (the &#8220;July Series C warrant exercise&#8221;).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2024, certain holders of warrants issued in June of 2024 exercised warrants to purchase an aggregate of 150,000 shares of Class A common stock for cash (the &#8220;July 10 warrant exercise&#8221;). In addition, on July 17, 2024, we issued to the placement agent warrants to purchase up to 10,500 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued in the July 10 warrant exercise (the &#8220;first tranche July ordinary course placement agent warrants&#8221;). The first tranche July ordinary course placement agent warrants have substantially the same terms as the June</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">placement agent warrants, except that the first tranche July ordinary course placement agent warrants (i) have an exercise price of $3.125 per share and (ii) expire July 17, 2026.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 17, 2024, a holder of the June Inducement Warrants exercised the same to purchase 2,319,186 shares of Class A common stock for cash (the &#8220;July 17 warrant exercise&#8221; and together with the July 10 warrant exercise and the July Series C warrant exercise, collectively, the &#8220;July warrant exercises&#8221;). Accordingly, on July 24, 2024, we issued to the placement agent warrants to purchase up to 162,344 shares of Class A common stock, equal to 7.0% of the aggregate number of shares of Class A common stock issued in the July 17 warrant exercise (the &#8220;second tranche July ordinary course placement agent warrants&#8221;, and together with the first tranche July ordinary course placement agent warrants, the &#8220;July ordinary course placement agent warrants&#8221;, and collectively with the July offering placement agent warrants, the &#8220;July placement agent warrants&#8221;). The second tranche July ordinary course placement agent warrants have substantially the same terms as the first tranche July ordinary course placement agent warrants, except that the second tranche July ordinary course placement agent warrants expire July 24, 2026.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The gross proceeds to the Company from the July warrant exercises, inclusive of the payment consideration for such Series C warrants and June Inducement Warrants, were approximately $6.3 million, inclusive of the payment consideration for such warrants, before deducting placement agent fees payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 18, 2024, we entered into a securities purchase agreement with institutional and accredited investors relating to the registered direct offering and sale of an aggregate of 2,236,026 shares of our Class A common stock at a purchase price of $4.025 per share of Class A common stock and associated warrant (the &#8220;July registered direct offering&#8221;). The securities issued in the July registered direct offering were offered pursuant to a prospectus supplement, dated July 18, 2024, and accompanying prospectus, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-264142), which was declared effective by the SEC on April 14, 2022.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a concurrent private placement (the &#8220;July private placement&#8221; and together with the July registered direct offering, the &#8220;July offering&#8221;), we also sold unregistered Class A common stock warrants to purchase up to an aggregate of 2,236,026 shares of our Class A common stock (the &#8220;July private placement warrants&#8221;). The unregistered July private placement warrants have an exercise price of $3.90 per share, became exercisable on July 19, 2024, and expire on July 20, 2026. In addition, the Company granted the placement agent warrants, under similar terms, to purchase 156,522 shares of Class A common stock, at an exercise price of $5.0313 (the &#8220;July offering placement agent warrants&#8221;). The gross proceeds to the Company from the July offering were approximately $9.0 million, before deducting placement agent fees and other offering expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 6, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-281299) registering the resale of an aggregate of 2,565,392 shares of Class A common stock issuable upon exercise of certain warrants, of which (i) up to 2,236,026 shares are issuable upon the exercise of the July private placement warrants issued to the purchasers upon the closing of the July private placement; (ii) 156,522 shares are issuable upon exercise of the July offering placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of the current engagement Letter with Wainwright; and (iii) 172,844 shares are issuable upon exercise of the July ordinary course placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of a then-applicable engagement letter with Wainwright, in connection with previously exercised June Inducement Warrants. The Form S-1 was declared effective by the SEC on August 12, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company entered into additional inducement letter agreements with certain holders of its existing purchaser warrants issued as part of the Company&#8217;s 2021 private placement offering (the "Purchaser Warrants") to amend and reduce the exercise price of the Purchaser Warrants to $1.00 per share in consideration for the holders&#8217; cash exercise of all Purchaser Warrants held by such holder on or before September 27, 2024. In connection with the September 2024 inducement transaction, Purchaser Warrants were exercised for 114,077 shares of Class A common stock, resulting in gross proceeds to the Company of $114,077. In October 2024, the Company entered into additional inducement letter agreements with the remaining holders of its existing Purchaser Warrants issued as part of the Company&#8217;s 2021 private placement offering to amend and reduce the exercise price of the Purchaser Warrants to $1.00 per share in consideration for the holders&#8217; cash exercise of all Purchaser Warrants held by such holder. In connection with the October 2024 inducement transaction, Purchaser Warrants were exercised for 2,858 shares of Class A common stock. As of the date of this 10-K, the Purchaser Warrants have been exercised in full.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant Awards</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From inception through December 31, 2024, we have been awarded approximately $11.9 million in governmental and non-profit association grants, which have been used to fund our clinical trials, research and development, production and overhead. Grant awards are recognized as revenue, and depending on the funding mechanism, are deposited directly in our accounts as lump sums, which are staggered over a predetermined period or drawn down from a federal payment management system account for reimbursement of expenses incurred. Revenue recognition occurs when the grant related expenses are incurred or supplies and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materials are received. As of December 31, 2024, and 2023, the amount of unused grant funds that were available for us to draw was approximately $0.1 million and $0.1 million, respectively. The following table summarizes the grants awarded.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.211%;box-sizing:content-box;"/>
    <td style="width:1.46%;box-sizing:content-box;"/>
    <td style="width:21.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.778%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.46%;box-sizing:content-box;"/>
    <td style="width:13.317%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Longeveron Project</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Funding Agency</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Amount ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Status of <br/>Award</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aging-related frailty Phase 2b Trial</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SBIR (DHHS) NIA</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,957,813</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aging-related frailty Phase 2b Trial</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SBIR (DHHS) NIA</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">283,040</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alzheimer&#8217;s Disease Phase 1 Trial</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alzheimer&#8217;s Association</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alzheimer&#8217;s Disease Phase 1 Trial</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alzheimer&#8217;s Association</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Metabolic Syndrome Sub-Study</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">STTR (DHHS) NIA</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Metabolic Syndrome Sub-Study</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">STTR (DHHS) NIA</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">901,486</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aging-related frailty Influenza Vaccine Trial (&#8220;HERA&#8221;)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MSCRF - TEDCO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HLHS Phase 1 Trial</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MSCRF - TEDCO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HLHS Phase 2 Trial</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">UG3 (DHHS) NHLBI</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">477,566</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ongoing</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARDS Phase 1</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MSCRF - TEDCO</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">650,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complete</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,919,905</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SBIR=Small Business Innovation Research programs; STTR=Small Business Technology Transfer programs; DHHS=Department of Health and Human Services; NIA = National Institute on Aging; NHLBI=National Heart, Lung, and Blood Institute.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the grant award agreement with the Alzheimer&#8217;s Association, we may be required to make revenue sharing or distribution of revenue payments for products or inventions generated or resulting from this clinical trial program. The potential payments, although not currently defined, could result in a maximum payment of five times (5x) the award amount.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The HLHS Phase 2b clinical trial grant was awarded to Sunjay Kaushal, M.D., Ph.D, Ann and Robert H. Lurie Children&#8217;s Hospital of Chicago, and the trial will be conducted under our IND and will test Lomecel-B&#153;. The total award was $4.6 million, and we have received $0.3 million of the approximately $0.5 million apportioned to us.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Terms and Conditions of Grant Awards</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant projects are typically divided into periods (e.g., a three-year grant may have three one-year periods), and the total amount awarded is divided according to the number of periods. At pre-specified time points, which are detailed in the grant award notifications, we are required to submit interim financial and scientific reports to the granting agency totaling funds spent, and in some cases, detailing use of proceeds and progress made during the reporting period. After funding the initial period, receipt of additional grant funds is contingent upon satisfactory submission of our interim reports to the granting agency.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant awards arise from submitting detailed research proposals to granting agencies and winning a highly competitive and rigorous application review and process that is judged on the merits of the proposal. There are typically multiple applicants applying and competing for a finite amount of funds. As such we cannot be sure that we will be awarded grant funds in the future despite our past success in receiving such awards.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Funding Requirements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating costs will continue to be substantial for the foreseeable future in connection with our ongoing activities. In past years we have been able to fund a large portion of our clinical programs and our administrative overhead with the use of grant funding.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, we will incur expenses to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance the clinical development of Lomecel-B&#153; for the treatment of several disease states and indications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursue the preclinical and clinical development of other current and future research programs and product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in-license or acquire the rights to other products, product candidates or technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional personnel in research, manufacturing and regulatory and clinical development as well as management personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory approval for any product candidates that successfully complete clinical development; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">optimize our operational, financial and management systems and increase personnel, including personnel to support our operations as a public company.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently believe that our cash and cash equivalents as of December 31, 2024 will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025 based on our current operating budget and cash flow forecast. However, as a result of our successful Type C meeting with the U.S. FDA in August 2024 with respect to the HLHS regulatory pathway, we have started to ramp up Biologics License Application (BLA) enabling activities as the Company currently anticipates a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. Our operating expenses and capital expenditure requirements are expected to accelerate in calendar 2025 as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness, and there will be a need to increase our current proposed spend and further increase its capital investments. We intend to seek additional financing/capital raises/non-dilutive funding options to support these activities, and current cash projections may be impacted by these ramped up activities and any financing transactions entered into. There can be no assurance we will be able to attain future financing at terms favorable to us or at all.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of our product candidates, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, costs and results of our clinical trials for our programs for our cell-based therapies, and additional research and preclinical studies in other research programs we initiate in the future;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs we advance through preclinical and clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we in-license or acquire rights to other products, product candidates or technologies; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property-related claims.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our operating results may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, grant awards, collaboration agreements, other third-party funding, strategic alliances, licensing arrangements and marketing and distribution arrangements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no credit facility or committed sources of capital. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our biologic drug development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to meet our operational goals, we will need to obtain additional capital, which we will likely obtain through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of convertible debt or equity securities, current stockholder ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect stockholder rights. Such financing will likely result in dilution to stockholders, and may result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. In addition, we may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we have $1.4 million in operating lease obligations and no CRO payment obligations. We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore we believe that our non-cancelable obligations under these agreements are not material.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not included milestone or royalty payments or other contractual payment obligations if the timing and amount of such obligations are unknown or uncertain.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company Status</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, which is a law intended to encourage funding of small businesses in the U.S. by easing many of the country&#8217;s securities regulations, and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. We have elected to take advantage of the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. The JOBS Act also exempts us from having to provide an auditor attestation of internal control over financial reporting under Sarbanes-Oxley Act Section 404(b).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will remain an &#8220;emerging growth company&#8221; until the earliest of (1) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (2) the last day of the fiscal year following the fifth anniversary of the completion of our IPO, (3) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which generally is when a company has more than $700 million in market value of its reported class of stock held by non-affiliates and has been a public company for at least 12 months and have filed at least one Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our audited financial statements included in Item 8 of this 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosures about Market Risk.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We held cash and cash equivalents of approximately $19.2 million as of December 31, 2024. We generally hold our cash in interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 8 is contained in the audited financial statements and accompanying notes located at the end of this 10-K and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of December 31, 2024. Disclosure controls and procedures include, without limitation, controls and other procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC as well as accumulated and communicated to its management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management did not identify material weaknesses in our internal control over financial reporting, which is an integral component of our disclosure controls and procedures. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. However, we do believe we can design and maintain more effective controls in 2025. These may include additions to personnel and or consultants; and formalizing and improving our accounting policies, procedures and controls.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the evaluation of our disclosure controls and procedures as of December 31, 2024, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Responsibility for Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for the integrity and objectivity of all information presented in this 10-K. The financial statements were prepared in conformity with accounting principles generally accepted in the United States of America and include amounts based on management&#8217;s best estimates and judgments. Management believes the financial statements fairly reflect the form and substance of transactions and that the financial statements fairly represent the Company&#8217;s financial position and results of operations for the periods and as of the dates stated therein.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of the Board of Directors, which is composed solely of independent directors, meets regularly with our independent registered public accounting firm, Marcum LLP and representatives of management to review accounting, financial reporting, internal control, and audit matters, as well as the nature and extent of the audit effort. The Audit Committee is responsible for the engagement of the independent auditors. The independent auditors have free access to the Audit Committee.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control over financial reporting required by Rule 13a-15(d) and Rule 15d-15(d) of the Exchange Act that occurred during the fiscal quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including the Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. Management based this assessment on criteria for effective internal control over financial reporting described in &#8220;Internal Control-Integrated Framework 2013&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management determined that, as of December 31, 2024, we maintained effective internal control over financial reporting.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Information Required to be Disclosed on Form 8-K for the Fiscal Quarter Ended December 31, 2024, But Not Reported</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Insider Trading Policies and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1707753c-d0d0-4d12-9876-5fca4835b86a" contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a Statement of Policy on Insider Trading (the &#8220;insider trading policy&#8221; or &#8220;insider trading policy guidelines&#8221;) that describes our standards regarding the prohibition on trading, and causing the trading of securities while in possession of certain material nonpublic information, which the Company believes are reasonably designed to promote compliance with insider trading laws, rules and regulations, as well as any listing standards applicable to the Company (including Nasdaq listing standards). Our insider trading policy is applicable to all of our directors, officers, employees, consultants, certain of their family members, and entities under the control of such persons. The policy attempts to establish standards that will avoid even the appearance of improper transactions on the part of insiders to preserve the Company&#8217;s reputation for adhering to the highest standards of conduct.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The insider trading policy guidelines, among other things, prohibits the unauthorized disclosure of material nonpublic information about the Company or any company with which the Company deals. The insider trading policy prohibits trading in Company securities or &#8220;tipping&#8221; on the basis of material nonpublic information. These guidelines also provide certain specific exceptions for various transactions including, for example, (i) stock option exercises where no sale is made, (ii) the vesting of restricted stock awards or tax withholding requirements in connection therewith, (iii) bona fide gifts of securities, and (iv) Rule 10b5-1 plans. The insider trading policy further restricts trading and other transactions for a limited group of designated persons, including, for example, members of our Board of Directors, executive officers, and employees during certain &#8220;Blackout Periods&#8221; that follow the end of a given fiscal period. These designated persons are also required to pre-clear any trades in the Company&#8217;s securities in accordance with the insider trading policy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our insider trading policy guidelines further acknowledge that short sales, buying or selling publicly traded options, hedging transactions in the Company&#8217;s stock (including prepaid variable forwards, equity swaps, collars and exchange funds), margin accounts, pledged securities and standing and limit orders (outside of an approved Rule 10b5-1 plan) may permit a holder to continue to own our common stock obtained through benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, our directors, employees, and officers to whom our policy applies, may no longer have the same objectives as our other stockholders. As such, the Company&#8217;s employees, consultants and directors are prohibited from engaging in such transactions (except as otherwise may be approved in writing by the Company).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the Longeveron Inc. insider trading policy is filed as Exhibit 19.1 to this Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trading Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of the Company&#8217;s directors or &#8220;officers,&#8221; as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94ff215e-780e-40ff-a266-d4dafb868a31" contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_62f2e9b1-4d99-4237-bb66-56f2985693c6" contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71db1c6f-e3a2-43ee-8989-301fee8856a2" contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3" name="lgvn:Rule10b51ArrModifiedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_6eeaad0f-fa55-46bc-b8ef-68f98431f708" contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3" name="lgvn:NonRule10b51ArrModifiedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modified</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66854962-0436-4ffe-b23b-fcf98f828595" contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_7c79ab1d-af1c-457d-b84b-324644630442" contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K, during the Company&#8217;s fiscal quarter ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below contains information regarding the current members of the Board of Directors (the "Board") and executive officers. The ages of individuals are provided as of February 1, 2025:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:56%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Officers</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wa&#8217;el Hashad</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joshua M. Hare, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Co-Founder, Chief Science Officer, Chairman and Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa Locklear</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Treasurer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paul Lehr, J.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General Counsel, and Secretary</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nataliya Agafonova</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Medical Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Executive Employees</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Devin Blass</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Employee Directors</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Khoso Baluch</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Roger Hajjar, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Kender, M.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neha Motwani</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rock Soffer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ursula Ungaro, J.D.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;padding-right:0.011in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.011in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Officers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Wa&#8217;el Hashad</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">M.B.A., (Chief Executive Officer (&#8220;CEO&#8221;))</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was appointed in February 2023 as CEO of Longeveron Inc. Prior to this position, Mr. Hashad served as the President and CEO of Avanir Pharmaceuticals from 2017 until 2023. Prior to 2017, he served as the chairman of the strategic advisory board for Morningside Biopharma, a private incubator of several pharmaceutical/bio-tech companies, for three years. In addition, he has held vice president roles at Amgen Inc., Boehringer Ingelheim, and Eli Lilly and Company. Mr. Hashad earned an executive degree from the Wharton Business School, University of Pennsylvania, an M.B.A. degree from the University of Akron, and a Bachelor of Science degree from the University of Cairo.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joshua M. Hare, M.D., F.A.C.C., F.A.H.A. (Co-Founder, Chief Science Officer and Chairman)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> co-founded Longeveron in 2014 and has served on its Board of Directors and as its Chief Science Officer since that time. Longeveron obtained an exclusive license to cell production technologies developed by Dr. Hare at UM. Dr. Hare is a double-boarded cardiologist (Cardiology and Advanced Heart Failure and Transplantation) and is the founding director of the Interdisciplinary Stem Cell Institute at the UM Miller School of Medicine. He has obtained in excess of $25 million in funding from the National Institutes of Health over the past 15 years to support basic research of cell therapy strategies. He is also a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award, and is an elected member of the American Association of Physicians, The American Society for Clinical Investigation, an elected Fellow of the American Heart Association, and an elected member of the National Academy of Inventors. Dr. Hare has also served in numerous leadership roles at the American Heart Association, the Heart Failure Society of America, and at the Center for Scientific Review of the National Institutes of Health. Dr. Hare is also a co-founder of Vestion, Inc., and Heart Genomics, LLC, companies that hold cardio-related intellectual property. He received a B.A. from the University of Pennsylvania, his M.D. from The Johns Hopkins University School of Medicine, and completed fellowships at Johns Hopkins and Brigham and Women&#8217;s Hospital, and was a Research Fellow at Harvard Medical School.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lisa A. Locklear, C.P.A. (inactive), M.B.A. (Chief Financial Officer (&#8220;CFO&#8221;))</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> joined Longeveron as CFO on July 31, 2023. Prior to her time at Longeveron, Ms. Locklear served as Senior Vice President and CFO of Avanir Pharmaceuticals, a subsidiary of Otsuka, from to 2018 to 2022. During her time at Avanir, Ms. Locklear was instrumental in enhancing the financial and technology-related processes, systems, and people during a period of rapid growth. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company and Price Waterhouse (now PwC), with assignments in Paris and London. Ms. Locklear has been recognized by the Healthcare Businesswoman&#8217;s Association with the Luminary Award, an honor that underscores her dedication to fostering growth of other women&#8217;s careers and her unwavering commitment to the healthcare industry. In addition to her professional career, Ms. Locklear serves on several philanthropic boards. She currently chairs the Board of Governors of the Gemological Institute of America and serves on the boards of Pacific Marine Mammal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Center and the Orange County United Way, and is a member of the National Association of Corporate Directors. She holds and Bachelor of Science degree in plant science from the University of California, Davis, and an M.B.A. degree from the University of California, Irvine. She is a licensed Certified Public Accountant (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Paul Lehr, J.D. (General Counsel and Secretary)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> joined Longeveron in 2016 and serves as General Counsel and Corporate Secretary. Over the past 20 years, Mr. Lehr has held senior legal and executive positions in corporate, non-profit, and research settings. Mr. Lehr has also been the CEO of GroundUP Music Foundation, which organizes an annual music festival, since 2015. Mr. Lehr has also served since 2011 as CEO and co-founder of HeartGenomics, a biotech firm based on intellectual property Mr. Lehr licensed from the UM Miller School of Medicine. Mr. Lehr served as a law clerk for a United States Federal Judge and practiced law with experience in healthcare and business transactions and litigation at a leading Miami law firm for 5 years. Thereafter, Mr. Lehr focused his efforts in the cardiac rehabilitation field as President of a non-profit research foundation. With this research serving as the foundation of the for-profit arm of the cardiac rehabilitation program, Mr. Lehr negotiated a master franchise agreement with a leading Indian healthcare operator with 100+ facilities across India and the Middle East, then co-lead negotiations with the Centers for Medicare &amp; Medicaid Services to successfully secure reimbursement of their residential intensive cardiac rehabilitation program. Mr. Lehr has held senior legal and executive positions in corporate as well as educational and not-for-profit settings. He earned his B.A. from Brown University, and his J.D. with honors from University of Florida College of Law.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nataliya Agafonova, M.D. (Chief Medical Officer (&#8220;CMO&#8221;))</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> joined Longeveron in the role of CMO on July 1, 2023. Before Longeveron, Dr. Agafonova served as Clinical Development Lead, Senior Medical Director, and Product Development Chair at Otsuka Pharmaceuticals from 2021 to 2023. Previously, she was the Clinical Development Lead and Senior Medical Director at Bristol-Myers Squibb. Dr. Agafonova previously held several senior leadership positions in clinical development and pharmacovigilance at Ardea Bioscience, Biogen, Amgen and Genzyme Corporation. She has extensive experience in therapeutic areas such as autoimmune, hematology, neuroscience, and oncology. Her cross-therapeutic expertise in drug development helped to bring several products to the U.S. and EU markets. Prior to her industry experience, Dr. Agafonova served as a physician at the Ukrainian Research Institute of Oncology and Radiology. She earned her M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Executive Employees</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Devin Blass (Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> joined Longeveron on December 2, 2024 with over 15 years of  experience in the development and manufacture of advanced therapies. Prior to his time at Longeveron, Mr. Blass severed as the Senior Vice President of Comprehensive Cell Solutions, the contract development and manufacturing organization (CDMO) of New York Blood Center Enterprises (NYBCe), from November 2023 to December 2024. There, he oversaw the CDMO business unit, encompassing Technical Operations, Business Development, and Cell Sourcing. From November 2019 to October 2023, Mr. Blass held various roles at Talaris Therapeutics, where he ultimately served as the Vice President of Technical Operations and Site Head, managing the company&#8217;s technical operations and supply chain. His career also includes directing cell manufacturing operations at Bellicum Pharmaceuticals and serving as the Director of Commercial Program Manufacturing at Mesoblast. Mr. Blass&#8217;s industry experience is complemented by his significant contributions at MD Anderson Cancer Center, where he advanced through roles of increasing responsibility. There, he played a pivotal role in developing the infrastructure and systems necessary to obtain licensure for HPC and Cord Blood. Mr. Blass holds a B.S. In Biochemistry from Texas State University.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Employee Directors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Khoso Baluch</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was elected to Longeveron&#8217;s Board of Directors in June 2023. Mr. Baluch has over 36 years of experience across global geographies in the biopharmaceutical industry. Since 2012, he has served as an independent director of Poxel S.A., a French publicly traded biotech company, chairs its compensation committee and as of March 2023 became Chairman. He also currently serves as an independent director of Processa Pharmaceuticals, Inc (NASDAQ: PCSA), and serves on its audit and compensation committees. He served as the Chairman of the Board for Da Volterra, a French privately held company, from December 2021 until November 2022. From 2016 to 2021, Mr. Baluch served as the Chief Executive Officer and Board member of CorMedix, Inc., a publicly traded pharmaceutical company in the United States. Mr. Baluch also held various senior positions at UCB, S.A. between January 2008 to April 2016, including Senior Vice President and President Europe, Middle East &amp; Africa. Prior to joining UCB, Mr. Baluch worked for Eli Lilly and Company (NYSE: LLY) for 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, business development, market access and product leadership. Mr. Baluch holds a B.S. in Aeronautical Engineering from City University London and an M.B.A. from Cranfield School of Management.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Roger Hajjar, M.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was elected to the Longeveron Board of Directors in July 2024. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, and whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world. He was recently head of R&amp;D at Ring Therapeutics and was appointed as the inaugural director of the Gene and Cell Therapy Institute at Mass General Brigham. Dr. Hajjar also currently serves on the Board of Atamayo Therapeutics. He has initiated multiple clinical trials in gene therapy for a variety of cardiovascular diseases, authored over 500 publications, and received numerous awards for his achievements in the field of cardiac gene therapy. Dr. Hajjar is a co-founder of several biotechnology companies and, from 2019 to 2022, was involved in the creation of multiple gene therapy companies at Flagship Pioneering, Cambridge, MA. Dr. Hajjar earned his B.S. in Biomedical Engineering from Johns Hopkins University and his M.D. from Harvard Medical School.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Richard Kender </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was appointed to Longeveron&#8217;s Board of Directors in May 2024. Mr. Kender is a 35-year veteran in the pharmaceutical industry and spent his entire career at Merck &amp; Co., Inc. (&#8220;Merck&#8221;) in the U.S. Rich worked in various corporate areas in the company, including Vice President of Corporate Development, Sr. Vice President and head of Merck&#8217;s M&amp;A, Licensing, Financial Evaluation and Analysis and Global Competitive Intelligence. During his tenure he was actively involved in more than 100 transactions of various sizes and transaction types. He was most recently the Senior Vice President of Business Development and Corporate Licensing, before retiring from Merck in September 2013. Mr. Kender currently serves on the Board of Directors of Seres Therapeutics (NASDAQ: MCRB) in Cambridge, Massachusetts, and serves as the Chair of the Audit Committee and is a member of the Compensation Committee; POXEL SA (Euronext: POXEL), in Lyon, France and serves as the Chair of the Business Development Committee and is a member of the Audit Committee and the Chair of the Compensation Committee; and Bicycle Therapeutics (NASDAQ: BCYC) in Cambridge, United Kingdom and Cambridge, Massachusetts, and serves as the Chair of the Audit Committee and is a member of the Strategic Committee and member of the Compensation Committee. Mr. Kender holds a B.S. Degree in Accounting from Villanova University and an M.B.A. from Fairleigh Dickinson University.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neha Motwani </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was elected to Longeveron&#8217;s Board of Directors in July 2024 and has over 25 years of healthcare investment banking experience. Most recently, she served as Managing Director, Health Care Investment Banking at William Blair from 2021 to 2023. From 2017 to 2021 Ms. Motwani served as the Managing Director, Health Care Investment Banking at Truist Securities. She previously held investment banking roles of increasing responsibility with Oppenheimer and Company, Stifel Financial and Cowen and Company, where, collectively, she completed transactions raising over $6.8 billion. Ms. Motwani earned her B.A. in political science from Columbia University.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rock Soffer </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was elected to Longeveron&#8217;s Board of Directors in March 2020. Mr. Soffer is President, Special Project Division at Turnberry Associates, where he oversees leasing, asset acquisitions, zoning and site approvals, as well as the development of other specialty projects. He has experience in managing and securing financing for complex projects, as well as overseeing a number of developments in Florida, such as the redevelopment of an almost 200,000 square-foot open-air lifestyle shopping center in Aventura. In addition, Mr. Rock Soffer was tasked with overseeing the referendum for the new 800-key Miami Beach Convention Center luxury hotel. Upon completion, the privately funded property will be the cornerstone of the Convention Center District in Miami Beach. Mr. Rock Soffer is an advocate for responsible, environmentally sustainable development.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ursula Ungaro, J.D. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served on Longeveron&#8217;s Board of Directors since June 2021. She currently serves as partner of the law firm Boies Schiller Flexner LLP. Prior to joining Boies Schiller, Ms. Ungaro served 29 years as a federal judge. Ms. Ungaro was appointed to serve on the federal U.S. District Court for the Southern District of Florida in 1992 after being nominated by President George H.W. Bush and being confirmed by the U.S. Senate. In her time on the federal bench, she presided over and ruled in numerous major civil and criminal cases in legal domains ranging from constitutional principles, equal rights, securities issues, and the use of non-embryonic stem cell therapies, amongst many others. Following her graduation with honors from the University of Florida School of Law in 1975, Ms. Ungaro practiced law in Miami, Florida where in 1981 she became a partner in Tew, Critchlow, Sonberg, Traum &amp; Friedbauer, P.A. (later merged into Finley, Kumble, Wagner, Heine, Underberg, Manley, Myerson &amp; Casey, a national law firm). She subsequently joined Sparber, Shevin, Shapo &amp; Heilbronner, a prestigious local law firm. She practiced law mainly in the area of complex commercial litigation, including in the areas of securities, corporate and tax law. From 1987 to 1992, Ms. Ungaro served as a trial judge on the Eleventh Judicial Circuit of the State of Florida. She has authored published articles in the areas of administrative law, legal ethics, and civil procedure. She is the recipient of the ORT Jurisprudence Award and has been recognized on several occasions by other organizations for her achievements in the law and service to the community. Ms. Ungaro serves on the Board of Directors of Bradford Holdings, Inc., a private holding company and on the Board of Directors of RVR, Inc., a privately held company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no family relationships among our current directors or executive officers. Rock Soffer is the son of an investor in the Company who owns approximately 4.5% of total shares outstanding as of February 17, 2025.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Composition and Election of Directors</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board currently consists of eight members. Our directors will be elected by the vote of holders of our Class A common stock and Class B common stock, voting together as a single class, with holders of our Class B common stock having five (5) votes per share. Under our Bylaws, the number of directors on our Board will be determined from time to time by our Board.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Classified Board of Directors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with our Certificate of Incorporation and Bylaws, our Board is divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors are divided among the three classes as follows:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Class I director is Rock Soffer, and his term will expire at our annual meeting of stockholders to occur in 2025;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Class II directors are Wa&#8217;el Hashad, Khoso Baluch and Richard Kender, and their terms will expire at our annual meeting of stockholders to occur in 2026; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Class III directors are Joshua M. Hare, Ursula Ungaro, Roger Hajjar, and Neha Motwani and their terms will expire at the annual meeting of stockholders to occur in 2027.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Certificate of Incorporation and Bylaws provide that the authorized number of directors may be changed only by resolution of the Board. Any additional directorships resulting from an increase in the number of directors or the filling of vacancies will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of our Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of our outstanding voting stock entitled to vote in the election of directors.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CORPORATE GOVERNANCE</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors and Committees of the Board</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board, elected by stockholders, is the ultimate decision-making body of the Company, except with respect to those matters reserved to the stockholders. The Board acts as an advisor and counselor to executive management and oversees and monitors its performance.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board held nine (9) meetings during 2024. Each director attended either in person or via teleconference at least 75% of the aggregate of all Board and applicable committee meetings during fiscal 2024 for the period in which they served as director. Although we do not have a formal policy regarding attendance by members of the Board at our annual meeting of stockholders, directors are encouraged to attend our annual meetings. Two members of our Board were in attendance at our 2024 Annual Meeting of Stockholders, which was held virtually.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board has established a standing Audit Committee; Compensation Committee; and Nominating and Corporate Governance Committee. The Company has also established a Science and Strategy Committee. Each of these committees has adopted a written charter.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit Committee.    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee is comprised of three members: Mr. Baluch (chair), Mr. Kender and Ms. Motwani. The Board has determined that all of the members of the Audit Committee are independent within the meaning of the Nasdaq Stock Market listing standards as well as within the meaning of Rule 10A-3 of the Exchange Act, and that each Audit Committee member is able to read and understand fundamental financial statements. The Audit Committee&#8217;s responsibilities include appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; overseeing the work of our registered public accounting firm, including through the receipt and consideration of reports from such firm; reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related disclosures; coordinating our Board's oversight of our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; discussing our risk management policies; meeting independently with our internal auditing staff, if any, registered public accounting firm, and management; reviewing and approving or ratifying any related person transactions; and preparing the audit committee report required by SEC rules. The Board has adopted and approved a written charter for the Audit Committee. A current copy of this charter is posted on our website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">http://www.longeveron.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the Investor Relations section. Mr. Baluch is the Audit Committee Chair, and the Board has determined that Mr. Kender qualifies as an audit committee financial expert, as that term is described in SEC regulations. The Audit Committee held four (4) meetings during 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation Committee.    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee is comprised of three members: Ms. Ungaro (chair), Mr. Baluch  and Mr. Kender. The Board has determined that all the members of the Compensation Committee are independent within the meaning of the Nasdaq Stock Market listing standards and applicable SEC regulations and are &#8220;non-employee directors&#8221; as defined in Rule 16b-3 promulgated under the Exchange Act. The Compensation Committee&#8217;s responsibilities include reviewing and approving, or recommending for approval by the Board, the compensation of our CEO and our other executive officers; overseeing and administering our cash and equity incentive plans; reviewing and making recommendations to our Board with respect to director compensation; reviewing and discussing annually with management our &#8220;Compensation Discussion and Analysis,&#8221; to the extent required; and preparing the annual compensation committee report required by SEC rules, to the extent required. The Board of Directors has adopted and approved a written charter for the Compensation Committee. A current copy of this charter is posted on our website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">http://www.longeveron.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the Investor Relations section.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Compensation Committee&#8217;s primary objectives in structuring and administering our executive officer compensation program are to attract, motivate and retain talented and dedicated executive officers; tie annual and long-term cash and stock incentives to achievement of measurable corporate and individual performance objectives; and reinforce business strategies and objectives to enhance stockholder value. To achieve these goals, our Compensation Committee maintains compensation plans that tie a portion of executives&#8217; overall compensation to key strategic goals such as the Company&#8217;s financial and operational performance, as measured by metrics such as total revenue and non-GAAP operating expense. Our Compensation Committee evaluates individual executive performance along with our CEO (other than with respect to his own performance) as part of the review process.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Compensation Committee periodically reviews our executive officers&#8217; compensation to determine whether we provide adequate incentives and motivation to our executive officers and whether we adequately compensate our executive officers relative to comparable officers in other similarly situated companies. The Committee engaged Compensation Advisory Partners, a third-party compensation consulting firm, to advise the Compensation Committee with respect to executive compensation benchmarking and compensation and equity program structure in 2024. Management plays a significant role in the compensation-setting process for executive officers, other than the CEO, by evaluating employee performance, recommending business performance targets and establishing objectives, and recommending salary levels, bonuses and equity-based awards. The Compensation Committee held six (6) meetings during 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nominating and Corporate Governance Committee.    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Nominating and Corporate Governance Committee is comprised of three members: Dr. Hajjar(chair), Ms. Motwani, and Ms. Ungaro. The Board has determined that all the members of the Nominating and Corporate Governance Committee are independent within the meaning of the Nasdaq Stock Market listing standards and applicable SEC regulations. The Nominating and Corporate Governance Committee&#8217;s responsibilities include identifying individuals qualified to become Board members; recommending to our Board the persons to be nominated for election as directors and to each Board committee; developing and recommending to our Board corporate governance guidelines, and reviewing and recommending to our Board proposed changes to our corporate governance guidelines from time to time; and overseeing a periodic evaluation of our Board of directors. The Board has adopted and approved a written charter for the Nominating and Corporate Governance Committee. A current copy of this charter is posted on our website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">http://www.longeveron.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the Investor Relations section. The Nominating and Corporate Governance Committee held four (4) meetings during 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When considering a potential candidate for membership on our Board, our Nominating and Corporate Governance Committee considers relevant business and industry experience and demonstrated character and judgment. The Nominating and Corporate Governance Committee considers diversity in identifying candidates by generally seeking to achieve a diversity of occupational and personal backgrounds on the Board. However, the Nominating and Corporate Governance Committee has no formal policy regarding diversity. The Nominating and Corporate Governance Committee will consider stockholder nominations for directors submitted in accordance with the procedure set forth in Article II, Sections 2.5 and 2.6 of our Bylaws. The procedure provides that a notice relating to the nomination must be timely given in writing to our Corporate Secretary prior to the meeting. Such notice shall set forth (a) as to each person whom the stockholder proposes to nominate for election or re-election as a director, (i) the name, age, business address and residence address of each such person, (ii) the principal occupation or employment of such person, (iii) the class and number of shares of Longeveron Common Stock that are beneficially owned by such person and (iv) any other information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including, without limitation, such person&#8217;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected); and (b) as to the stockholder giving the notice (i) the name and address of such stockholder as they appear on our books and (ii) the class and number of shares of Longeveron common stock that are beneficially owned by such stockholder. There are no differences in the manner in which the Nominating and Corporate Governance Committee evaluates a candidate that is recommended for nomination for membership on our Board of Directors by a stockholder.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Science and Strategy Committee</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Science and Strategy Committee is comprised of three members: Dr. Hajjar (chair), Dr. Hare, and Mr. Kender. The Science and Strategy Committee&#8217;s purpose is to review and advise the full Board and the management of the Company with respect to scientific direction and opportunities deemed beneficial to the Company. The Science and Strategy Committee&#8217;s responsibilities include reviewing the scientific basis of the Company&#8217;s clinical programs, new products, or research areas under consideration by the Company, suggesting opportunities to refine or advance the Company&#8217;s therapeutic technologies, and advising the Company in consultation with management on resource allocation for new product avenues. The Board of Directors has adopted and approved a written charter for the Science and Strategy Committee. As a newly formed committee, no meetings of the Science and Strategy Committee were held in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Member Independence</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board of Directors has determined that each of Dr. Hajjar, Mr. Kender, Ms. Motwani, Ms. Ungaro, and Mr. Baluch are independent as defined in the Nasdaq Stock Market listing standards and applicable SEC regulations. Dr. Hare and Messrs. Soffer, and Hashad have been determined not to be independent under relevant standards.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Sessions</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independent directors meet in executive session without the presence of our non-independent directors or members of management to review the criteria upon which the performance of the CEO, to review the performance of the CEO against those criteria, to ratify the compensation of the CEO as approved by the Compensation Committee, and to discuss any other relevant matters.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Leadership Structure</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board&#8217;s current leadership structure is characterized by:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a combined Chairman of the Board and Chief Science Officer;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a robust Committee structure with oversight of various types of risks; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an engaged and majority independent Board.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board believes that its current leadership structure provides appropriate Board leadership and engagement while deriving the benefits from having our CSO also serve as Chairman of the Board. As an individual with primary responsibility for managing the Company&#8217;s scientific operations and in-depth knowledge and understanding of the Company as its co-founder, he is best positioned to chair regular Board meetings as we discuss key business and strategic issues. This combined structure provides independent oversight while avoiding unnecessary confusion regarding the Board&#8217;s oversight responsibilities and the day-to-day management of business operations. We do not have a lead independent director.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Oversight</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board oversees an enterprise-wide approach to risk management, designed to support the achievement of our strategic and organizational objectives, improve long-term organizational performance and enhance stockholder value. A fundamental part of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk oversight is to understand the risks our Company faces and the steps management is taking to manage those risks and to assess management&#8217;s overall appetite for risk. It is management&#8217;s responsibility to manage risk and bring material risks facing our Company to the Board&#8217;s attention. Our Board receives regular reports from management on matters relating to strategic and operational initiatives, financial performance and legal developments which are each integrated with enterprise-risk exposures. Our Board also approves our CEO&#8217;s performance goals for each year. In doing so, the Board has an opportunity to ensure that the CEO&#8217;s goals include responsibility for broad risk management. The involvement of the full Board in setting our strategic plan is a key part of its assessment of the risks inherent in our corporate strategy.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committees of the Board are also involved in evaluating and overseeing the management of risks particular to their respective areas of oversight. For example, the Audit Committee focuses on financial risk and internal controls, supports the Board&#8217;s oversight of cybersecurity risk management, and receives an annual risk assessment report from our external auditors. The Compensation Committee evaluates and sets compensation programs that encourage decision-making predicated upon a level of risk-taking consistent with our business strategy. The Compensation Committee also reviews compensation and benefit plans, and the risks associated with them. The Nominating and Corporate Governance Committee oversees governance and succession risk and evaluates director skills and qualifications to appoint particular directors to our standing committees based upon the needs of that committee. Each Committee reports its activities to the full Board of Directors to ensure that the Board is regularly informed about these risks.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Business Conduct and Ethics</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics that applies to all of our employees, executive officers and directors. We will provide a copy of the Code of Business Conduct and Ethics upon request made in writing to Longeveron Inc. at 1951 NW 7</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Avenue, Suite 520, Miami, Florida 33136, Attention: Investor Relations. The full text of our Code of Business Conduct and Ethics is posted on our website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.longeveron.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the Corporate Governance Documents section. We intend to disclose any amendment to the Code of Business Conduct and Ethics or waiver of a provision of the Code of Business Conduct and Ethics applicable to our executive officers or directors, including the name of the executive officer or director to whom the amendment applies or for whom the waiver was granted, at the same location on our website identified above. The inclusion of our website address herein does not include or incorporate by reference the information on our website into this 10-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board Communications</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders may communicate with members of the Board of Directors by mail addressed to the full Board, a specific member of the Board or a particular committee of the Board at our principal executive offices located at 1951 NW 7</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Avenue, Suite 520, Miami, Florida 33136, Attention: Legal Department.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy; Hedging Prohibition</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has adopted a Statement of Policy on Insider Trading (the &#8220;insider trading policy&#8221; or &#8220;insider trading policy guidelines&#8221;) that describes our standards regarding the prohibition on trading, and causing the trading of securities while in possession of certain material nonpublic information, which the Company believes are reasonably designed to promote compliance with insider trading laws, rules and regulations, as well as any listing standards applicable to the Company (including Nasdaq listing standards). Our insider trading policy is applicable to all of our directors, officers, employees, consultants, certain of their family members, and entities under the control of such persons. The policy attempts to establish standards that will avoid even the appearance of improper transactions on the part of insiders to preserve the Company&#8217;s reputation for adhering to the highest standards of conduct.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The insider trading policy guidelines, among other things, prohibit the unauthorized disclosure of material nonpublic information about the Company or any company with which the Company deals. The insider trading policy prohibits trading in Company securities or &#8220;tipping&#8221; on the basis of material nonpublic information. These guidelines also provide certain specific exceptions for various transactions including, for example, (i) stock option exercises where no sale is made, (ii) the vesting of restricted stock awards or tax withholding requirements in connection therewith, (iii) bona fide gifts of securities, and (iv) Rule 10b5-1 plans. The insider trading policy further restricts trading and other transactions for a limited group of designated persons, including, for example, members of our Board of Directors, executive officers, and employees during certain &#8220;Blackout Periods&#8221; that follow the end of a given fiscal period. These designated persons are also required to pre-clear any trades in the Company&#8217;s securities in accordance with the insider trading policy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our insider trading policy guidelines further acknowledge that short sales, buying or selling publicly traded options, hedging transactions in the Company&#8217;s stock (including prepaid variable forwards, equity swaps, collars and exchange funds), margin accounts, pledged securities and standing and limit orders (outside of an approved Rule 10b5-1 plan) may permit a holder to continue to own our common stock obtained through benefit plans or otherwise, but without the full risks and rewards of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ownership. When that occurs, our directors, employees, and officers to whom our policy applies, may no longer have the same objectives as our other stockholders. As such, the Company&#8217;s employees, consultants and directors are prohibited from engaging in such transactions (except as otherwise may be approved in writing by the Company).</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation Committee Interlocks and Insider Participation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No members of our Compensation Committee have ever been a current or former officer or employee. None of our executive officers serves or has served as a member of the Board of directors or a compensation committee (or other committee serving an equivalent function) of any entity that has one or more of its executive officer serving as one of our directors or on our Compensation Committee.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delinquent Section 16(a) Reports</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s directors and executive officers are required under Section 16(a) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) to file reports of ownership and changes in ownership of the Company&#8217;s common stock with the SEC. Based upon a review of filings with the SEC and written representations from our directors and executive officers, we believe that all of our directors and executive officers complied during fiscal 2024 with the reporting requirements of Section 16(a) of the Exchange Act, with the exception of the following: (i) a Form 4 filed on January 25, 2024 reporting 3,074 shares withheld to satisfy tax obligations in connection with vesting of restricted stock award units by Nataliya Agafonova on January 2, 2024; (ii) a Form 4 filed on January 25, 2024 reporting 992 shares withheld to satisfy tax obligations in connection with vesting of restricted stock award units by Paul T. Lehr on January 2, 2024; (iii) a Form 4 filed on January 25, 2024 reporting 5,123 shares withheld to satisfy tax obligations in connection with vesting of restricted stock award units by Wa&#8217;el Hashad on January 2, 2024; (iv) a Form 4 filed on January 25, 2024 reporting 4,098 shares withheld to satisfy tax obligations in connection with vesting of restricted stock award units by Lisa A. Locklear on January 2, 2024; (v) a Form 4 filed on March 20, 2024 reporting the payment of 80,200 performance shares to Wa&#8217;el Hashad and a withholding of 32,866 shares for tax purposes on March 12, 2024; (vi) a Form 4 filed on June 7, 2024 reporting 325 shares withheld to satisfy tax obligations in connection with vesting of restricted stock award units by Paul T. Lehr on June 3, 2024; (vii) a Form 4 filed on August 7, 2024 reporting a grant of 16,000 restricted stock units to Neha Motwani, who was elected to the Board of Directors on July 2, 2024; and (viii) a Form 4 filed on August 7, 2024 reporting a grant of 16,000 restricted stock units to Roger Hajjar, who was elected to the Board of Directors on July 2, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executive Compensation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Summary Compensation Table below summarizes the compensation of the executive officers named therein (our &#8220;named executive officers&#8221; or &#8220;NEOs&#8221;) during 2024 and 2023. Our NEOs for 2024 are as follows:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Wa&#8217;el Hashad, Chief Executive Officer (CEO)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lisa Locklear, Chief Financial Officer (CFO), Treasurer</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Paul Lehr, General Counsel and Corporate Secretary</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal elements of our executive compensation program are base salary, discretionary annual performance bonuses, and discretionary equity awards. Our NEOs are also entitled to participate in employee benefit plans and programs that we offer to our other employees, as described below. We view these components of compensation as related but distinct. Although our Compensation Committee does review total compensation, we do not believe that significant compensation derived from one component of compensation should negate or offset compensation from other components. Our executive compensation program is designed to attract, motivate, and retain talented and dedicated executive officers, who are critical to our success. The following highlights our approach to executive compensation:</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competitive Positioning: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to establish the overall compensation of our executive officers at levels that we believe are roughly comparable with the average levels of compensation of executives at other clinical state biotechnology companies of similar size.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual Bonus Compensation Tied to Performance: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive compensation program has three primary components: base salary; discretionary annual bonus compensation; and discretionary equity compensation; and other benefits and perquisites. Among these components, bonus compensation is tied in whole or in part to individual performance, company performance, or as otherwise determined appropriate by the Compensation Committee.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity-Based Incentives align our NEOs with our Stockholders: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our equity-based incentive awards are designed to align our interests and the interests of our stockholders with those of our employees and consultants, including our named executive officers. The Compensation Committee of the Board is responsible for approving equity grants.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We pay our NEOs a base salary to compensate them for the satisfactory performance of services rendered to us. The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. Base salaries for our NEOs have generally been set at lower levels than would normally be deemed necessary to attract and retain individuals with this level of talent. For more information, see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary Compensation Table &#8212; 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on page 93 of this Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bonus Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In order to retain and motivate our named executive officers and other executives, from time to time the Board upon recommendation of our Chief Executive Officer, may approve bonuses for our NEOs based on individual performance, company performance, or as other determined based on the Committee&#8217;s discretion. Estimated bonus amounts earned in 2024 and made under our executive incentive plan are reported in the &#8220;Non-equity incentive plan compensation&#8221; column of the Summary Compensation Table</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For more information, see </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary Compensation Table &#8212; 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on page 93 of this Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that for growth companies in the biotechnology sector, such as Longeveron, equity awards are a significant compensation-related motivator in attracting and retaining executive-level employees. Accordingly, we have provided our named executive officers and other executives with certain equity incentive awards that vest over several years to incentivize those individuals to stay with us, which in turn should provide us with greater stability over such periods than we would experience without such awards. Equity awards are granted for both restricted stock units and stock options, typically vesting quarterly over a three year period. In 2024, restricted stock unit awards were granted to our named executive officers and other executives and employees that vested in full upon grant, to provide a one-time catch up grant for past initial hire grants that were not in line with current award levels.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Elements of Compensation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Perquisites, Health, Welfare and Retirement Benefits.    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, group life, disability and accidental death and dismemberment insurance plans, in each case on generally the same basis as all of our other employees. We provide a 401(k) Plan to our employees, including our current named executive officers, as discussed in the section below titled &#8220;401(k) Plan.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">401(k) Plan. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a defined contribution employee retirement plan, or 401(k) Plan, for our employees. Our named executive officers are eligible to participate in the 401(k) Plan on the same basis as our other employees, if they are considered an employee and not a consultant. The 401(k) Plan is intended to qualify as a tax-qualified plan under Section 401(k) of the Internal Revenue Code. The 401(k) Plan provides that each participant may make pre-tax deferrals from his or her compensation up to the statutory limit, which is $23,000 for calendar year 2024, and other testing limits. Participants that are 50 years or older can also make &#8220;catch-up&#8221; contributions, which in calendar year 2024 may be up to an additional $7,500 above the statutory limit. The 401(k) Plan provides for discretionary matching and profit-sharing contributions, we currently provide 5% match to the 401(k) Plan. Participant contributions are held and invested, pursuant to the participant&#8217;s instructions, by the plan&#8217;s trustee.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonqualified Deferred Compensation. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, we entered into a deferred compensation agreement with the CSO to defer payment of the consulting fees earned for services rendered as our Chief Science Officer during 2024 totalling $265,000. The 2024 consulting fees will be paid in the form of a lump sum distribution in February 2027. We do not maintain any other nonqualified defined contribution plans or other nonqualified deferred compensation plans. Our Board may elect to provide our officers and other employees with non-qualified defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary Compensation Table &#8212; 2024 and 2023</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.86%;box-sizing:content-box;"/>
    <td style="width:1.1%;box-sizing:content-box;"/>
    <td style="width:7.64%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and principal position</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Salary<br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock<br/>awards<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>awards<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-equity<br/>incentive plan<br/>compensation<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All other<br/>compensation<br/>($)</span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total <br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wa&#8217;el Hashad,</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">570,973</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">765,675</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,725</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">389,550</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,816</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,848,739</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431,474</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">633,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">309,167</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,918</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,576,559</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa Locklear,</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">430,923</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">429,885</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,975</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,468</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,123,251</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer, Treasurer</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,539</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,400</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,840</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380,779</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paul Lehr,</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">420,150</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438,207</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,975</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">184,275</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144,089</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,226,696</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General Counsel and Corporate Secretary</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">372,346</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,459</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">554,055</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) The values set forth in this column are based on the aggregate grant date fair values of 2024 Restricted Stock Unit (RSU) awards computed in accordance with FASB ASC Topic 718. The grant date fair values of RSUs are computed based on the closing price per share of Longeveron Class A common stock on the date of grant. A discussion of the relevant assumptions made in the valuation of these awards is provided in Note 8 to the financial statements, Equity Incentive Plan, in this Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) The values set forth in this column represent the aggregate grant date fair value of stock option awards computed in accordance with FASB ASC Topic 718 (excluding the effect of estimated forfeitures). A discussion of the relevant assumptions made in the valuation of these awards is provided in Note 8 to the financial statements, Equity Incentive Plan, in this Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Includes performance payouts at target for Company performance in 2024 under our executive incentive plan, described as "Bonus Compensation" in the narrative above. The relevant performance measures for the annual performance awards were satisfied and thus reportable in 2024, even though final performance payout will be calculated and approved by the Compensation Committee in March 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) Other compensation represents 401(k) matching and health insurance costs paid by the Company. For Mr. Hashad, in 2024 this includes medical insurance of $34,566. For Mr. Lehr, in 2024 this includes medical insurance of $33,960 and a vacation accrual payout of $85,500 upon adoption of a new maximum vacation accrual limit policy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding Equity Awards at Fiscal Year End Table - 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth information with respect to outstanding equity awards for each of our NEOs as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.583%;box-sizing:content-box;"/>
    <td style="width:2.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.122%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.322000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.222%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.623%;box-sizing:content-box;"/>
    <td style="width:2.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.622%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.222%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.981%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options Awards</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock Awards</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Exercise<br/>Price ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Expiration<br/>Date</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares or<br/>Units of<br/>Stock That<br/>Have Not<br/>Vested (#)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Market<br/>Value of<br/>Shares or<br/>Units of<br/>Stock That<br/>Have Not<br/>Vested ($)</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wa&#8217;el Hashad,</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.20</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/1/2033</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,895</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">302,568</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,396</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,354</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.46</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/15/2034</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa Locklear, <br/>Chief Financial Officer, Treasurer</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,355</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,895</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.46</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/15/2034</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,520</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,500</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paul Lehr,</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,688</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">312</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.80</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/20/2031</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,687</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,309</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General Counsel and Corporate Secretary</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87.30</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/3/2032</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,573</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">712</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.00</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/16/2032</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,355</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,895</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.46</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/15/2034</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Based on the value of $1.73 per share, the closing market price of our common stock on December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) The option, granted March 1, 2023, fully vested on March 1, 2024.  The number of shares and the exercise price were adjusted for the March 26, 2024 1:10 reverse stock split (the "Reverse Split").</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) The option, granted on August 15, 2024, vests quarterly over 3 years beginning on October 1, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) Restricted Stock Unit awards granted on August 15, 2024, vests quarterly over various periods up to three years beginning on October 1, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) The option, granted July 20, 2021, vested one-eighth on date of grant, with quarterly vesting over four years thereafter. The number of shares and the exercise price were adjusted for the March 26, 2024 Reverse Split.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6) The option, granted June 3, 2022, was fully vested upon grant. The number of shares and the exercise price were adjusted for the March 26, 2024 1:10 reverse stock split.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7) The option, granted November 16, 2022, vests 25% on March 1, 2023, then 6.25% each quarter thereafter. The number of shares and the exercise price were adjusted for the March 26, 2024 Reverse Split.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grants of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our policies and practices regarding the grant of equity awards are designed to comply with applicable securities laws to and reflect the integrity of our executive compensation program. The Compensation Committee is responsible for determining the timing and terms of equity awards to eligible personnel. The timing of equity award grants is determined with consideration to a variety of factors, including ensuring that the Company is not in possession of material nonpublic information at the time of grant. While the Company&#8217;s equity compensation program seeks alignment with the Company&#8217;s strategic objectives, competitive aims, and the attraction and retention of qualified personnel, the equity compensation of each individual is generally considered on a case-by-case basis. The Company does not follow a predetermined schedule for the granting of all equity awards. Nevertheless, certain of the Company&#8217;s equity awards adhere to standard award timelines and vesting schedules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not grant equity awards in anticipation of the release of material nonpublic information and do not time the public release of such information based on equity award grant dates for the purpose of affecting the value of executive compensation. However, the Compensation Committee may consider material nonpublic information to ensure that grants of equity awards comply with applicable laws and regulations as well as Company policy. The Company&#8217;s procedures to prevent the improper use of material nonpublic information in connection with the granting of equity awards include oversight by internal and external legal counsel. We are committed to maintaining equity compensation practices that comply with evolving corporate governance standards, foster a competitive workforce, and serve the best interests of the Company and its stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth certain information regarding awards of options to our named executive officers during the fiscal year ended December 31, 2024 in the period beginning four business days before and ending one business day after the filing of a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">periodic report on Form 10-Q or Form 10-K or the filing or furnishing of a Current Report on Form 8-K that discloses material nonpublic information and ending one business day after the filing or furnishing of such report:</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.483%;box-sizing:content-box;"/>
    <td style="width:1.024%;box-sizing:content-box;"/>
    <td style="width:12.29%;box-sizing:content-box;"/>
    <td style="width:1.024%;box-sizing:content-box;"/>
    <td style="width:15.363%;box-sizing:content-box;"/>
    <td style="width:1.024%;box-sizing:content-box;"/>
    <td style="width:11.266%;box-sizing:content-box;"/>
    <td style="width:1.024%;box-sizing:content-box;"/>
    <td style="width:9.218%;box-sizing:content-box;"/>
    <td style="width:1.024%;box-sizing:content-box;"/>
    <td style="width:26.26%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:73.1pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(b)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities underlying the award</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(c)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise price of the award<br/>($)</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(d)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant date fair value of the award</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(e)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">information</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(f)</span></p></td>
   </tr>
   <tr style="height:11.75pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wa&#8217;el Hashad</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/15/2024</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,750</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$2.46</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$49,163</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5.75%)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.75pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Chief Executive Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:12.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa A. Locklear,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;8/15/2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,250</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$2.46</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$27,788</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5.75%)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:12.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Chief Financial Officer, Treasurer</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:11.75pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paul Lehr</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;8/15/2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,250</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$2.46</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$27,788</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5.75%)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General Counsel and Corporate Secretary</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreements/Letters with our NEOs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Wa&#8217;el Hashad</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Pursuant to the terms of the letter agreement dated February 21, 2023, as amended January 17, 2025 (&#8220;Agreement&#8221;) setting forth Mr. Hashad&#8217;s compensation as Chief Executive Officer of the Company starting on March 1, 2023, Mr. Hashad receives an annual salary of $556,500 and will be eligible for an annual cash bonus of up to seventy percent (70%) of his base salary, eighty percent (80%) of which will be based on the achievement of pre-established performance criteria and twenty percent (20%) of which will be discretionary. Mr. Hashad received a signing bonus of 5,000 Restricted Stock Units, which vested in quarterly installments on each of April 1, 2023, July 1, 2023, September 1, 2023, and December 31, 2024. Mr. Hashad will also be eligible to receive annual long-term equity incentive awards through 2026 consisting of 5,000 shares of time-based vesting stock options and up to 12,500 of performance share units, in accordance with the terms of the Longeveron Second Amended and Restated 2021 Incentive Award Plan.  Share numbers have been adjusted for the March 26, 2024 Reverse Split discussed in Note 2 to the financial statements, Summary of Significant Accounting Policies, in this Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of the Company&#8217;s termination of Mr. Hashad&#8217;s employment without Cause, as defined therein, he will be entitled to receive all unpaid but accrued bonuses for the prior year, three (3) months of base salary per each full year worked at the Company (with a minimum of 12 months of salary) payable in a lump sum, COBRA coverage for 18 months, and a bonus payment prorated based on date of termination. Mr. Hashad also entered into a Confidentiality and Nondisclosure Agreement simultaneously with this Agreement which imposed certain confidentiality, non-competition, non-disclosure obligations on Mr. Hashad.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ms. Lisa Locklear</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On July 14, 2023, the Company entered into a letter agreement (&#8220;Agreement&#8221;) with Ms. Lisa Locklear and hired her as Chief Financial Officer and Executive Vice President of the Company. Ms. Locklear receives an annual salary of $420,000 and is eligible to receive an annual cash bonus of up to forty-five percent (45%) of her base salary, eighty percent (80%) of which will be based on the achievement of pre-established performance criteria and twenty percent (20%) of which will be based on pre-established individual performance criteria. Ms. Locklear received a signing bonus of 4,000 Restricted Stock Units, which vested in quarterly installments on each of October 1, 2023, January 1, 2024, April 1, 2024, and July 1, 2024. Ms. Locklear will also be eligible to receive up to 10,000 of performance share units annually, eighty percent (80%) of which will be based on the achievement of pre-established performance criteria and twenty percent (20%) of which will be pre-established individual performance criteria. Share numbers have been adjusted for the March 26, 2024 Reverse Split discussed in Note 2 to the financial statements, Summary of Significant Accounting Policies, in this 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of employment, Ms. Locklear shall be entitled to receive accrued salary and benefits, unless terminated without Cause (as defined therein) or by Ms. Locklear for Good Reason (as defined therein), in which event, in addition to accrued amounts, Ms. Locklear shall also be entitled to receive earned but unpaid equity bonus amounts, an annual prorated cash bonus payment at target level, plus severance and reimbursement of COBRA premiums equal to three (3) months of base salary and premiums for each full year worked at the Company (not less than six months in any case), in all cases only if a release is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">executed and not revoked. Ms. Locklear also entered into a Confidentiality and Nondisclosure Agreement simultaneously with this Agreement that imposed certain confidentiality, non-competition, non-disclosure obligations on her.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mr. Paul Lehr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has an employment agreement with Mr. Lehr, entered into on May 3, 2022 with an initial term of one year, with automatic one-year renewals thereafter, unless either party terminates the Agreement by providing 60 days written notice prior to the end of the then current term. The Company may terminate the Agreement for Cause (as defined therein), and Mr. Lehr may terminate the Agreement for a Good Reason (as defined therein). Under the terms of the Agreement, Mr. Lehr receives an annual salary of $409,500 and is eligible for an annual bonus based on the achievement of pre-established metrics agreed by Mr. Lehr and the CEO and/or the Compensation Committee. Mr. Lehr is also eligible to participate in the Company&#8217;s Second Amended and Restated 2021 Incentive Award Plan.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of employment, Mr. Lehr shall be entitled to receive accrued salary and benefits, unless terminated without Cause (as defined therein) or by Mr. Lehr for Good Reason (as defined therein), in which event, in addition to accrued amounts, Mr. Lehr shall also be entitled to receive earned but unpaid equity bonus amounts, an annual prorated cash bonus payment at target level, severance equal to three months of base salary for each full year worked at the Company (not less than six months in any case), accelerated vesting of any unvested equity award, and 18 months of COBRA coverage, subject to execution and non-revocation of a standard release. The Agreement subjects Mr. Lehr to certain restrictive covenants which prohibit him from soliciting employees of the Company or working for businesses in competition with the Company for 24 months after the date of his employment termination with the Company. The Agreement also imposes certain confidentiality obligations on Mr. Lehr.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 6, 2024, the Compensation Committee approved, and on August 15, 2024, the Company issued certain additional equity awards to executive officers and other employees of the Company that served to recalibrate the equity holdings of those employees, as well as additional bonus discretionary equity awards above what was otherwise contractually owed pursuant to the terms of each individual's employment agreements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential Payments Upon Termination or Change in Control</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the Company&#8217;s Second Amended and Restated 2021 Incentive Award Plan (the &#8220;Plan&#8221;) provide that the shares subject to vesting granted under any equity award may automatically become fully vested, no longer subject to restrictions and freely transferable upon a &#8220;Change of Control&#8221; as such term is defined in our Plan. We provide this benefit in order to properly incentivize our executives to support a Change of Control that would be deemed beneficial to our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DIRECTOR COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director Compensation Table - 2024.    </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents summary information regarding the total compensation that was awarded to, earned by or paid to our non-employee directors for services rendered during the year ended December 31, 2024. Mr. Hashad, the Company&#8217;s Chief Executive Officer, does not receive any additional compensation for serving as a member of the Board of Directors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.52%;box-sizing:content-box;"/>
    <td style="width:1.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.540000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.200000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.540000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.34%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.76%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.200000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fees earned or <br/>paid in cash<br/>($)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stock<br/>Awards<br/>($)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Option<br/>Awards<br/>($)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Other<br/>Compensation<br/>($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total ($)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joshua M. Hare</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,771</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">543,122</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">640,393</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neil E. Hare</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,810</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,810</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rock Soffer</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,750</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,810</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,560</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ursula Ungaro</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,810</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,810</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Khoso Baluch</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,500</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,810</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,310</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Kender</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,946</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,280</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,226</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neha Motwani</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,250</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,880</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,130</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Roger Hajjar, M.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(8)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,375</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,880</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,255</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeffrey Pfeffer</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(9)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,575</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,575</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cathy Ross</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(10)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,283</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,283</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Douglas Losordo, M.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(11)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Amounts reflect fees paid relating to calendar 2024.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) The values set forth in this column represent the aggregate grant date fair value, computed in accordance with FASB ASC Topic 718 (excluding the effect of forfeitures), of the Board of Directors restricted stock unit awards granted to Dr. J. Hare, Mr. N. Hare, Mr. Soffer, Ms. Ungaro and Mr. Baluch on August 15, 2024.  Additionally, Mr. Kender received an onboarding restricted stock award on May 9, 2024, while Ms. Motwani and Mr. Hajjar received their onboarding restricted stock awards on July 1, 2024. A discussion of the relevant assumptions made in the valuation of these awards may be found in Note 8 to the financial statements, Equity Incentive Plan, in this Form 10-K. The number of unvested restricted stock units and unvested stock option awards outstanding as of December 31, 2024 was as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:59.596%;box-sizing:content-box;"/>
    <td style="width:1.01%;box-sizing:content-box;"/>
    <td style="width:18.747%;box-sizing:content-box;"/>
    <td style="width:1.01%;box-sizing:content-box;"/>
    <td style="width:19.636%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:28.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unvested Stock Awards</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unvested Option Awards</span></p></td>
   </tr>
   <tr style="height:14.15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joshua M. Hare, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,150</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:14.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neil E. Hare</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,333</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,150</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:14.15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rock Soffer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,333</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,150</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:14.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ursula Ungaro</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,333</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,150</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:14.15pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Khoso Baluch</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;15,457</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;900</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:14.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Kender</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;13,334</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
   </tr>
   <tr style="height:12.45pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neha Motwani</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14,667</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
   </tr>
   <tr style="height:12.45pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Roger Hajjar, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14,667</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) There were no stock options granted to directors in 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) Amounts set forth herein reflect compensation received as a director of the Company. "All Other Compensation" also includes compensation that Dr. Hare receives as the Chief Science Officer of the company, pursuant to the terms of that certain consulting agreement entered into with the Company. For additional information, see "Part III. Item 13. Certain Relationships and Related Party Transactions."</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) Includes estimated value of complimentary Bahamas Registry Trial treatments ($14,000) received by the director and his guest, in addition to compensation received as the Chief Science Officer of the company, pursuant to his consulting agreement. In 2024, this compensation includes consulting fees of $265,000, estimated 2024 incentive compensation award of $119,250, and stock and option awards totaling $144,872 related to his consulting services. In 2024, we entered into a deferred compensation agreement with the CSO to defer payment of the consulting fees earned for services rendered as our Chief Science Officer during 2024 totaling $265,000. The 2024 consulting fees will be paid in the form of a lump sum distribution in February 2027.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6) Mr. Neil Hare resigned from the Board on January 27, 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7) Mr. Kender was appointed to the Board of Directors to fill a vacancy on May 10, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(8) Ms. Motwani and Mr. Hajjar were elected to the Board of Directors on July 2, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(9) Mr. Pfeffer resigned from the Board on May 6, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(10) Ms. Ross resigned from the Board on May 8, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(11) Mr. Losordo did not stand for reelection to the Board so his term ended on July 2, 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Director Compensation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The director compensation program provides for annual retainer fees and/or long-term equity awards for our directors. </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the first half of 2024, each director received a prorated annual retainer of $35,000. A director serving as chairman of the Board or lead independent director received an additional prorated annual retainer of $15,000. Directors serving as the chairs of the audit, compensation and nominating and corporate governance, and finance committees received additional prorated annual retainers of $15,000, $10,000, $8,000, and $7,500, respectively. Directors serving as members of the audit, compensation, finance, and nominating and corporate governance committees received additional prorated annual retainers of $15,000, $10,000, $7,500 and $4,000, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Beginning on July 1, 2024, each director received a prorated annual cash retainer of $45,000. A director serving as chairman of the Board received an additional prorated annual retainer of $20,000. Directors serving as the chairs of the Audit, Compensation, Nominating  &amp; Corporate Governance, and Science &amp; Strategy (commencing in Q4 2024) committees</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">received additional prorated annual retainers of $15,000, $12,000, $10,000, and $7,500, respectively. Directors serving as members of the Audit, Compensation, Nominating and Corporate Governance, and Science &amp; Strategy (commencing in Q4 2024) committees received additional prorated annual retainers of $8,000, $6,000, $5,500, and $5,000, respectively. Annual equity grants, to be made following the Company&#8217;s annual meeting of stockholders, are 8,000 restricted stock units for each director, and initial grants upon joining the Board in 2024 are 16,000 restricted stock units of our Class A common stock, which shall be subject to vesting requirements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board or its authorized committee may modify the director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, subject to the annual limit on director compensation set forth in the Plan. As provided in the Plan, our Board or its authorized committee may make exceptions to this limit for individual directors in extraordinary circumstances, as the Board or its authorized committee may determine in its discretion.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_of_certain"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth certain information known to us as of February 17, 2025 (except where another date is noted below), with respect to beneficial ownership of our Common Stock by (i) each person (or group of affiliated persons) who is known by us to own beneficially more than five percent (5%) of our outstanding Common Stock and is not a director or executive officer, (ii) each of our named executive officers and current directors, and (iv) all current directors and executive officers as a group, together with the approximate percentages of outstanding Common Stock owned by each of them.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table is based upon information supplied by directors, executive officers, and principal stockholders. Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act. A person has beneficial ownership of shares if the person has the power to vote or dispose of such shares. This power can be exclusive or shared, direct or indirect. In addition, a person is considered by SEC rules to beneficially own shares underlying options and convertible securities that are presently exercisable or convertible or will become exercisable or convertible within 60 days of the date that beneficial ownership is calculated. Unless otherwise indicated the address of each beneficial owner is c/o Longeveron Inc., 1951 NW 7</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Ave, Suite 520, Miami, FL 33136, and none of the shares listed are pledged. The percentage of beneficial ownership is based on 13,473,898 shares of Class A common stock and 1,484,005 shares of Class B common stock as of February 17, 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23.145%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.182%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.241999999999999%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.182%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.241999999999999%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.182%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.822%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Affiliate</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class A<br/>Common<br/>Stock<br/>Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% of Class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class B<br/>Common<br/>Stock<br/>Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% of Class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% of<br/>Total<br/>Voting<br/>Power</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">% of<br/>Total<br/>Common<br/>Stock<br/>Beneficially<br/>Owned</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Greater than 5% Holder:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Donald M. Soffer</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,851</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">653,523</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.04</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.95</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.48</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lee Cohen Hare</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298,483</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.11</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0% </span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Named Executive Officers and<br/>&#160;&#160;&#160;Directors</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joshua M. Hare, M.D. </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407,256</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.99</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">462,808</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.19</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.98%</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.76</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rock Soffer </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">323,823</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.38</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,010</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.76</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.50</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.42</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ursula Ungaro </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,551</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Khoso Baluch</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(6)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,593</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Kender</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,333</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neha Motwani</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Roger Hajjar, M.D.</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(7)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wa&#8217;el Hashad</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(8)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168,073</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.25</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa Locklear</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(9)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,528</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Paul Lehr </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(10)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,719</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nataliya Agafonova</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(9)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,027</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Executive Officers and Directors as a Group<br/>&#160;&#160;&#160;(11 individuals)</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(9)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">:</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,206,903</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">8.90</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">503,818</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">33.95</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">34.66</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11.35</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Less than 1%.</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Percentage of total voting power represents voting power with respect to all shares of our common stock and Class B common stock, as a single class. The holders of our Class B common stock are entitled to five (5) votes per share, and holders of our common stock are entitled to one (1) vote per share.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to a Voting Agreement and Proxy entered into between Dr. Hare and Lee Cohen Hare, Dr. Hare&#8217;s former spouse holds 298,483 shares of Class B common stock, which are not included in the number of shares owned by Dr. Hare for purposes of this table, as he retains voting but not dispositive power with respect to such shares, for so long as such shares remain owned by his former spouse. Dr. Hare's voting power percentage is inclusive of the amounts owned by Lee Cohen Hare.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount includes 542 stock options and 148,936 warrants that are exercisable within 60 days of February 17, 2025. Amount also includes 533 shares held by an affiliated entity. Dr. Hare disclaims beneficial ownership except to the extent of his pecuniary interest. </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount includes 667 restricted stock units that may vest and 138,298 warrants that are exercisable within 60 days of February 17, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount includes 667 restricted stock units that may vest within 60 days of February 17, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount includes 2,000 restricted stock units that may vest within 60 days of February 17, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount includes 1,333 restricted stock units that may vest within 60 days of February 17, 2025.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount includes 26,354 restricted stock units that may vest and 2,396 stock options and 10,638 warrants that are exercisable within 60 days of February 17, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount includes 14,895 restricted stock units that may vest and 1,354 stock options that are exercisable within 60 days of February 17, 2025.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount includes 4,062 restricted stock units that may vest and 1,497 stock options that are exercisable within 60 days of February 17, 2025.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation Plan Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes information, as of December 31, 2024, for the equity compensation plans of the Company pursuant to which grants of options, restricted stock, restricted stock units or other rights to acquire shares may be granted from time-to-time:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.47%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.042%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.582%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.042%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity Compensation Plan Information</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Category</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities to be<br/>Issued Upon<br/>Exercise of<br/>Outstanding<br/>Options,<br/>Warrants and<br/>Rights<br/>(a)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price<br/>of Outstanding<br/>Options,<br/>Warrants and<br/>Rights<br/>(b)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Securities<br/>Remaining<br/>Available for<br/>Future Issuance<br/>Under Equity<br/>Compensation<br/>Plans<br/>(Excluding<br/>Securities<br/>Reflected<br/>in Column<br/>(a) (c)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by security holders</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">927,487</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.98</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205,704</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans not approved by security holders</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">927,487</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.98</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205,704</span></p></td>
    <td style="background-color:#cceeff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.24%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Represents outstanding awards pursuant to the Company&#8217;s Second Amended and Restated 2021 Incentive Award Plan. Represents shares of Class A common stock. Shares of Class B common stock are not authorized for issuance under the Plan.</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares of common stock that are subject to any award (e.g., options, restricted stock units, etc.) pursuant to the Plan will count against the aggregate number of shares of common stock that may be issued as one share for every share issued.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships">&#160;</p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related Transactions and Director Independence</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following includes a summary of transactions as of December 31, 2024 to which we have been a party in which the amount involved exceeded or will exceed $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock, or 5% Security Holders, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employment and Consulting Agreements with our NEOs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;. We also describe below certain other transactions with our directors, executive officers and stockholders.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following are the Company&#8217;s related party transactions as of December 31, 2024:</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CSO Consulting Agreements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into a consulting services agreement with Dr. Hare in November 2014 (the &#8220;Agreement&#8221;). The Agreement has an initial term of ten (10) years, with automatic renewals thereafter for four (4) year terms unless either party determines not to renew, provides for an initial annual fee structure of $265,000 and eligibility to participate in any incentive compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">programs that are established for the Company. Under the terms of the Agreement, if Dr. Hare&#8217;s employment is terminated without Cause (as defined below), Dr. Hare is entitled to receive a lump sum payment equal to the sum of (i) annual fees through the date of termination to the extent not previously paid, (ii) annual fees from the date of termination through the end of the Term (as though no termination had occurred), and (iii) any accrued but unpaid expenses. In the event Dr. Hare resigns for Good Reason (as defined below), then, subject to executing a release of claims and complying with 12-month non-solicit and non-compete covenants, Dr. Hare would be entitled to receive a lump sum payment equal to the sum of (i) annual fees through the date of termination to the extent not previously paid, (ii) annual fees from the date of termination through the end of the Term (as though no termination had occurred), plus an additional three (3) years, which shall include an annual increase in said fees of ten percent per year for each of the additional three (3) years, and (iii) any accrued but unpaid expenses. If Dr. Hare terminates the Agreement without Good Reason, then he shall receive the sum of (i) annual fees through the date of termination to the extent not previously paid, and (ii) any accrued but unpaid expenses. For purposes of this paragraph, Term is defined in the Agreement as the period commencing on the effective date and continuing through the tenth (10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) anniversary of the effective date. Upon Dr. Hare&#8217;s death or disability during the Term of the Agreement, he is entitled to receive any accrued and unremunerated fees or expenses; provided, however, that the Board has the discretion to choose to continue to pay fees for any period of time following a determination of disability.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The initial term of the agreement ended on November 22, 2024, however, the Company continues to operate under the same terms until a new agreement is executed. In addition, we entered into a deferred compensation agreement with the CSO to defer payment of the consulting fees earned for services rendered during 2024. The 2024 consulting fees will be paid in the form of a lump sum distribution in February 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Agreement acknowledges that Dr. Hare is employed by the University of Miami (&#8220;UM&#8221;), and remains subject to UM&#8217;s policies, and also acknowledges that he serves as a consultant to enumerated outside entities. The Agreement outlines Dr. Hare&#8217;s obligations with respect to confidentiality, ownership of information, inventions and original works, contains a non-competition covenant with respect to Dr. Hare&#8217;s associations during his time with the Company and for a period of two (2) years thereafter, and contains non-solicitation and non-disparagement obligations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 16, 2022, the Company accounted for but had not issued 48,140 RSUs with an aggregate value of $0.2 million as payment for accrued expenses under the Agreement with the CSO. These shares were issued on May 24, 2023. As of December 31, 2024 and 2023, the Company had accrued balances due to the CSO of approximately $0.3 million and $0.1 million, respectively, included in other long-term liabilities and accrued expenses, respectively, and less than $0.1 million and approximately $0.1 million, respectively, included in accrued expense and accounts payable in the accompanying balance sheets.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">JMHMD License Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a licensee under an exclusive license agreement with JMHMD Holdings, LLC, an affiliate of our CSO and director, for the use of CD271+ cellular therapy technology, a subpopulation of bone marrow-derived mesenchymal stem cells. We are required to pay a royalty of one percent of the annual net sales of the licensed product(s) used, leased, or sold by or for us by any sub-licensees. If we sublicense the technology, we are also required to pay an amount equal to 10% of the net sales of the sub-licensees. The agreement is to remain in effect until either the date all issued patents and filed patent applications have expired or been abandoned, or 20 years after the date of FDA approval of the last commercialized product or process arising from the patent rights, whichever comes later. Further, expenses related to the furtherance of the CD271 technology is being capitalized and amortized as incurred over 20 years. There were no license fees due during the years ended December 31, 2024 and 2023 pertaining to this agreement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Participation in Capital Markets Transactions</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 8, 2024, the Company commenced a public offering of up to 639,872 shares of the Company&#8217;s Class A common stock, along with Pre-Funded Warrants to purchase up to an aggregate 1,572,894 shares of Class A common stock. The shares and Pre-Funded Warrants were sold together with Common Warrants to purchase up to an aggregate of 2,212,766 shares of Class A common stock. The combined public offering price was $2.35 per share and related Common Warrant and $2.349 per Pre-Funded Warrant and related Common Warrant. The Common Warrants were immediately exercisable and expire on April 10, 2029. Dr. Hare, our Chairman and Chief Science Officer, Mr. Rock Soffer, a member of our Board, and Mr. Hashad, our Chief Executive Officer each participated in the transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specifically, Dr. Hare purchased approximately $350,000 of Class A common stock and accompanying Common Warrants in this transaction. Dr. Hare&#8217;s Common Warrants are exercisable for up to 148,396 shares of our Class A common stock at an exercise price of $2.35, a value of approximately $348,730.60, if such warrant is exercised at the exercise price. Mr. Rock Soffer</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchased approximately $325,000 of Class A common stock and accompanying Common Warrants in this transaction. Mr. Rock Soffer&#8217;s Common Warrants are exercisable for up to 138,298 shares of our Class A common stock at an exercise price of $2.35, a value of approximately $325,000.30, if such warrant is exercised at the exercise price. Mr. Hashad purchased approximately $25,000 of Class A common stock and accompanying Common Warrants in this transaction. Mr. Hashad&#8217;s Common Warrants are exercisable for up to 10,638 shares of our Class A common stock at an exercise price of $2.35, a value of $24,999.30, if such warrant is exercised at the exercise price.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification Agreements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us or will require us to indemnify each director and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services as a director or executive officer. For further information, see &#8220;Description of Capital Stock&#8212;Limitations on Liability and Indemnification Matters.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policies and Procedures for Related Person Transactions</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board has adopted a written related person transaction policy, which sets forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year and a related person had, has or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accountant_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accountant Fees and Services</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of the fees billed to Longeveron by Marcum, the Company&#8217;s current independent auditors, for professional services rendered for the fiscal years ended December 31, 2024 and 2023:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fee Category</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal 2024<br/>Fees</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal 2023<br/>Fees</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audit Fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">451,327</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">283,410</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,098</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All Other Fees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,085</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit Fees: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This category includes the fees billed by our principal accountants for professional services rendered for the audit of our annual financial statements, the quarterly review of our interim financial statements, and services provided in connection with regulatory filings.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Audit-Related Fees: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This category consists of assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under &#8220;Audit Fees.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Fees: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This category consists of fees billed for professional services rendered for tax compliance, tax advice and tax planning.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">All Other Fees: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This category consists of services billed not included in the categories above.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Approval Policies and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee has adopted a policy that requires advance approval of all audit services and permitted non-audit services to be provided by the independent auditor as required by the Exchange Act. The Audit Committee must approve the permitted service before the independent auditor is engaged to perform it. The Audit Committee approved all of the services described above in accordance with its pre-approval policies and procedures.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_and_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits and Financial Statements Schedules</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a. (1) Financial Statements:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements required to be filed by Item 8 of this Annual Report on Form 10-K and filed in this Item 15, are as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:9pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;(PCAOB #688)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:9pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Balance Sheets as of December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:9pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Operations for the Years Ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:9pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:9pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Cash Flows for the Years Ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:9pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="text-indent:-9pt;padding-left:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-1.695%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Financial Statement Schedules</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the financial statements and notes thereto.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description of Exhibit</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021018716/f10k2020ex2-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Plan of Conversion, incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 30, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021018716/f10k2020ex2-2_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Conversion of Longeveron LLC, incorporated by reference to Exhibit 2.2 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 30, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021009581/ea135545ex4-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Incorporation of Longeveron Inc., incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-8 filed on February 16, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024024003/ea020200901ex3-1a_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to Certificate of Incorporation of Longeveron Inc., incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed March 19, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021009581/ea135545ex4-2_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Bylaws of Longeveron Inc., incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-8 filed on February 16, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021006475/ea134523ex4-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Class A Common Stock Certificate evidencing the shares of Class A Common Stock, incorporated by reference to Exhibit 4.1 on Registrant&#8217;s Registration Statement No. 333-252234 filed February 3, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024017521/ea0200564ex4-2_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Annual Report on Form 10-K filed on February 27, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021018716/f10k2020ex4-3_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Underwriter Warrants issued February 17, 2021, incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 30, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021063408/ea151717ex10-4_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Purchaser Warrant, incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K filed December 3, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021063408/ea151717ex10-5_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Representative Warrant, incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K filed December 3, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000101376223003640/ea186688ex4-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed October 13, 2023</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000101376223003640/ea186688ex4-2_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Series A/B Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed October 13, 2023.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000101376223003640/ea186688ex4-3_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant, incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report Form 8-K filed October 13, 2023.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390023097862/ea190541ex4-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Warrant, incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed December 22, 2023.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.10</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390023097862/ea190541ex4-2_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant, incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed December 22, 2023.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.11</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024032239/ea020359401ex4-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant, incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed April 11, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024032239/ea020359401ex4-2_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Warrant, incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed April 11, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.13</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024032239/ea020359401ex4-3_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant, incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K filed April 11, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.14</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024034129/ea020404301ex4-1_long.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Series C/D Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed April 18, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.15</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024034129/ea020404301ex4-2_long.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed April 18, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.16</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024053828/ea020802801ex4-1_long.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of New Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed June 18, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.17</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024053828/ea020802801ex4-2_long.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed June 18, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.18</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024062766/ea020968201ex4-1_longe.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Warrant, incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed July 19, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.19</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024062766/ea020968201ex4-2_longe.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Placement Agent Warrant, incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed July 19, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.20</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024065710/ea021066401ex4-19_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Ordinary Course Placement Agent Warrant, incorporated by reference to Exhibit 4.19 of the Registrant&#8217;s Registration Statement on Form S-1 filed August 6, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex10-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive License Agreement dated November 20, 2014 between the University of Miami and Longeveron LLC, incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex10-1i_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Exclusive License Agreement dated December 11, 2017 between the University of Miami and Longeveron LLC, incorporated by reference to Exhibit 10.1.1 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1.2</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021014296/ea137297ex10-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Exclusive License Agreement dated March 3, 2021 between the University of Miami and Longeveron Inc., incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed March 9, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021014296/ea137297ex10-2_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Collaborative Research and Development Agreement dated March 3, 2021 between the University of Miami and Longeveron Inc., incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed March 9, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3*</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex10-2_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement dated December 22, 2016 between JMHMD Holdings, LLC and Longeveron LLC, incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex10-2i_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to License Agreement effective December 22, 2016, by and between JMHMD Holdings, LLC and Longeveron LLC, incorporated by reference to Exhibit 10.2.1 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex10-3_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consulting Services Agreement, dated November 20, 2014, by and between Longeveron LLC and Joshua M. Hare, M.D., incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex10-4_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, effective August 12, 2020 by and between Longeveron LLC and James Clavijo, incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5.1#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024017521/ea0200564ex10-5i_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation Agreement and General Release, effective June 9, 2023, by and between Longeveron Inc. and James Clavijo, incorporated by reference to Exhibit 10.5.1 to the Registrant&#8217;s Annual Report on Form 10-K filed on February 27, 2024.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6*</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex10-5_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease Agreement, dated October 6, 2015 by and between Wexford Miami, LLC and Longeveron LLC, incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7*</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex10-6_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Grant Agreement, dated October 1, 2020 by and between the Maryland Stem Cell Research Commission, acting by and through the Maryland Technology Development Corporation, and Longeveron LLC, incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex10-12_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2017 Longeveron LLC Incentive Plan, dated July 18, 2017, incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021006475/ea134523ex10-13_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Longeveron Inc. 2021 Incentive Award Plan, incorporated by reference to Exhibit 10.13 on Registrant&#8217;s Registration Statement No. 333-252234 filed February 3, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9.1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390023033867/def14a0423_longever.htm#T99006"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Longeveron Inc. 2021 Incentive Award Plan, incorporated by reference to Appendix A of the Registrant&#8217;s Definitive Proxy Statement, filed April 28, 2023</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9.2</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024045202/ea0206252-02.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amended and Restated Longeveron Inc. 2021 Incentive Award Plan, incorporated by reference to Appendix A to the Registrant's Definitive Proxy Statement filed on May 20, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021006475/ea134523ex10-14_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement for Officers and Directors, incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement No. 333-252234 filed February 3, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021063408/ea151717ex10-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement, incorporated by reference to Exhibit 10.1 to Registrant&#8217;s Current Report on Form 8-K filed December 3, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021063408/ea151717ex10-3_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Registration Rights Agreement, incorporated by reference to Exhibit 10.3 to Registrant&#8217;s Current Report on Form 8-K filed December 3, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390022018143/ea158049ex10-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between Longeveron Inc. and K. Chris Min, M.D., Ph.D., incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s current report on Form 8-K filed April 5, 2022.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13.1#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024017521/ea0200564ex10-13i_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Separation Agreement and General Release, effective March 31, 2023 between Longeveron Inc. and K. Chris Min, M.D. and Ph.D., incorporated by reference to Exhibit 10.13.1 to the Registrant&#8217;s Annual Report on Form 10-K filed on February 27, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/ea174406ex10-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between Longeveron Inc. and Wa&#8217;el Hashad, incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s current report on Form 8-K filed February 28, 2023.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024017521/ea0200564ex10-15_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between Longeveron Inc. and Paul Lehr dated May 3, 2022, incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Annual Report on Form 10-K filed on February 27, 2024</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024017521/ea0200564ex10-16_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement between Longeveron Inc. and Lisa Locklear, dated July 14, 2023, incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Annual Report on Form 10-K filed on February 27, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024017521/ea0200564ex10-17_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement between Longeveron Inc. and Nataliya Agafonova, M.D. dated June 21, 2023, incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Annual Report on Form 10-K filed on February 27, 2024</span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18**</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000101376223003640/ea186688ex10-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement, dated October 11, 2023, by and between the Company and the Purchaser signatory thereto, incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed October 13, 2023</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19**</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390023097862/ea190541ex10-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement, dated December 20, 2023, by and between the Company and the Purchaser signatory thereto, incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed December 22, 2023</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20**</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024032239/ea020359401ex10-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement, dated April 8, 2024, by and between the Registrant and the Purchasers signatory thereto, incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed April 11, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024032239/ea020359401ex10-2_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant Amendment Agreement, dated April 8, 2024, by and between the Registrant and the Holder, incorporated by reference to Exhibit 10.2 to Registrant&#8217;s Current Report on Form 8-K filed April 11, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024034129/ea020404301ex10-1_long.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Inducement Letter Agreement, dated April 16, 2024, by and between the Registrant and each Holder, incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed April 18, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024053828/ea020802801ex10-1_long.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Inducement Letter Agreement, dated June 17, 2024, by and between the Registrant and each Holder, incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed June 18, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24**</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024062766/ea020968201ex10-1_longe.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Securities Purchase Agreement, dated July 18, 2024, by and between the Company and the Purchasers signatory thereto, incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed July 19, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25#</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lgvn-ex10_25.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between Longeveron Inc. and Wa'el Hashad, dated February 21, 2023, as amended January 17, 2025, filed herewith.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lgvn-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Longeveron Inc. Statement of Policy on Insider Trading, filed herewith</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390021002924/ea133523ex21-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant, incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Registration Statement No. 333-252234 filed January 19, 2021</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lgvn-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lgvn-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of the Chief Executive Officer pursuant to SEC Rules 13a-14(a) and 15d-14(a) adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lgvn-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of the Chief Financial Officer pursuant SEC Rules 13a-14(a) and 15d-14(a) adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lgvn-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lgvn-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1721484/000121390024017521/ea0200564ex97-1_longeveron.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Policy Relating to Recovery of Erroneously Awarded Compensation, incorporated by reference to Exhibit 97.1 to the Registrant&#8217;s Annual Report on Form 10-K filed on February 27, 2024.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates management contract or compensatory plan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of any of the omitted schedules upon request by the SEC.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form 10-K Summary</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LONGEVERON INC</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">/s/ </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mohamed Wa&#8217;el Ahmed Hashad</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mohamed Wa&#8217;el Ahmed Hashad</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES AND POWER OF ATTORNEY</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated and, on the dates, indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:35%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:42%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:21%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mohamed Wa&#8217;el Ahmed Hashad</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mohamed Wa&#8217;el Ahmed Hashad</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(principal executive officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Lisa A. Locklear</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President and Chief Financial Officer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa A. Locklear</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(principal financial officer and principal accounting officer)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Joshua M. Hare</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joshua M. Hare</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Khoso Baluch</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Khoso Baluch</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Rock Soffer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rock Soffer</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Roger Hajjar</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Roger Hajjar</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard Kender</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Richard Kender</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Neha Motwani</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Neha Motwani</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Ursula Ungaro</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ursula Ungaro</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LONGEVERON, INC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:90%;box-sizing:content-box;"/>
    <td style="width:1.34%;box-sizing:content-box;"/>
    <td style="width:8.66%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB #</span><span><ix:nonNumeric id="F_726d5505-b0c2-45a8-89d5-c1ec3d7d45a9" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">688</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Balance Sheets as of December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Operations for the Years Ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Cash Flows for the Years Ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_registered_public"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and Board of Directors of</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longeveron Inc.</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34262a91-124c-41ca-9deb-92ff971fdf71" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longeveron Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related statements of operations, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, based on our audits, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years in the period ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in conformity with accounting principles generally accepted in the United States of America.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Explanatory Paragraph &#8211; Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations over the next 12 months. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_163d50a3-17a4-45cc-b1a6-35c286e8fa1f" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marcum </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">llp</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marcum </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">llp</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a82ba98-be63-458c-bf05-9f9aeb159867" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hartford, CT</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 28, 2025</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longeve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ron Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balance Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6607846-f235-487a-b511-5e1f2a4ed7d0" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,232</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e25fd67d-4f2f-43dc-b27b-8fd71173142e" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable equity securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88312f1e-32d0-465e-aafa-0adcebc2e4a0" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3fbbc65-cf90-4865-af80-808be0b2f86b" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7863e46-bc66-495a-b22f-93b3a4602ba5" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f830f5ff-00c5-4570-834b-bfaef84b05e0" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">376</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts and grants receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_658c1df8-52b4-42ad-9121-a32daa3a08c9" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d1ad11d-f033-419f-a063-dc0c49c6bf35" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97d08508-babe-4d0f-a092-b9e2246d1d82" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,624</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecc95d94-97b3-49e6-806a-84ad238df6e7" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,848</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89b856ca-21fc-4532-9762-9c41e25c6d3c" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,449</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab6fbcd2-0d5f-4e73-95b4-323a4b1102bb" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77b6b173-b8e0-4d89-82a0-01bf7438f95c" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,401</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5098eb6b-ce93-4f9b-ba5c-3082f3b4b186" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,287</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease asset</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_891acd17-cfe0-4542-84b7-2901b6b5ad83" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">882</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fc71622-8b00-4c61-ba60-fca9f723824c" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,221</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_546bc32e-d7b5-48df-8bfd-f82274b1498d" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_246d2ac3-2bb1-4c07-ac5c-4c98edd48a15" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_240f3147-33d3-428f-96f1-2607b3dd3aa8" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,558</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd44e6ef-4bc7-4b9d-9f84-3bca36cb7279" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,078</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cc720e6-6d3f-4484-8985-3784924aa328" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7acb88f4-3196-40f2-8ac7-a47a1faf3cf1" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">638</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35e42e7f-40d8-4aa6-9243-fe1e39139bd4" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,820</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae904991-7238-4ae4-b2b8-1317c99cf727" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,152</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of operating lease liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_283c66d3-a0f0-4724-adb5-1f8ee375f9fd" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">623</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fecbb5b-29b8-450b-b730-91f0fed1aec8" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">593</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8940340-345b-405e-8b20-db7c8375cbc5" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a1ed031-d79b-427f-8f1c-7d4bd0d8db7f" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9972d5-54d1-43ae-99ed-536a69ea8526" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,582</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5069f836-6baf-48b9-939b-1a28898d2c99" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,889</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of operating lease liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1089af2-cc6f-4da2-8cae-d6a7892522c6" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">824</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02e4657a-5b2b-43a1-b8c4-3635077f0cd6" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_281a130a-e6ef-4114-bd5a-a0954f3eff78" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_390d071f-96ea-437f-b1a2-6629d7b51ce9" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df9f8636-8179-4abd-ad31-1f6eb1ad4787" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,089</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a8aaa90-885b-48f0-9010-499d41594f0b" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d70dd09-d2dd-4d89-82ee-6a18741d817b" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,671</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aeea995-b90c-4e03-96bf-716ebdf2ab9b" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,337</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_67f6638a-5395-4219-9e87-130051a737fc;"><span style="-sec-ix-hidden:F_b32d22a7-f5c5-47a3-8a4b-a4ef13404364;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69a78db0-2e87-40fb-b27f-a7a1e4f217c1" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_875d8b66-936c-4e99-b6f4-8f8a46edfef8" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2017412e-2cae-4128-b568-8874d4df3d7c" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_efebd779-23ad-41c7-aa79-7336ece16a4b" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1580effe-f615-40c2-a445-5b2cf80e30bc" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_007b951d-7848-4163-987d-939904db7986" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_878bdf52-4c40-4b34-a1c0-66f28d7fe3b8" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e6cfed86-93eb-4702-9061-7c567f9f230d" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;issued and outstanding at December 31, 2024 and December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_e2b63699-fc70-43ef-83b0-3ec8d8d5c95b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_9969c8c5-df41-4078-a8e1-6b3423b5476c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4474f21d-c981-4ebf-a3a8-806eee0544ba" contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f51f35a3-60e2-4d55-92da-85a8cb04431e" contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e5fced3-214f-4a13-8cf3-904d5170235f" contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1495ce8a-8292-4715-a440-4c7db7fef72b" contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">84,295,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;authorized, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d1c37b0-69b6-4440-a57b-1f9932a82808" contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_30029745-3860-41a3-a996-835fdb1d52f4" contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,407,441</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024;<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e60aaf13-5295-4b47-a6bb-e1a232441b64" contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f1c04eda-5bcd-4b8e-a9ab-7cea033f8f45" contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,025,183</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;issued and outstanding at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1a5e853-6c53-4207-a1ef-6b355fd5d8f0" contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e917f54b-758b-48b9-8995-8ad22cde51ac" contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class B common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb0f5b0c-356c-46b5-b380-63f63b485772" contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_341d1c4f-56df-4c2f-9f8c-b9a50451d757" contextRef="C_c2617445-260c-4016-83d7-e383b81dadab" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db0e0e0f-1134-4c43-aee9-106829222185" contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_67625e4c-80f4-42b8-94b0-e1aefc3033f3" contextRef="C_c2617445-260c-4016-83d7-e383b81dadab" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,705,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized,<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22da5135-8a0c-4786-8c52-128a634c4121" contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1c562dc8-a0fe-4e83-902d-b188181509db" contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,484,005</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db74eaff-c19d-4b88-a04c-0d1f78b2d1aa" contextRef="C_c2617445-260c-4016-83d7-e383b81dadab" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_aa346b7b-6184-4503-8ed5-f1d3382a8fc1" contextRef="C_c2617445-260c-4016-83d7-e383b81dadab" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,485,560</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;&#160;issued and outstanding at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_848d2344-3dfc-4ccf-9e0c-36c8ea13d667" contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed43934f-f0fd-4d29-940e-3ace48fad624" contextRef="C_c2617445-260c-4016-83d7-e383b81dadab" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82767416-1dbb-4eba-b67a-e3b9e6292b15" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,480</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a290993-4767-4bf0-81e1-ad217611ccc2" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,823</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock subscription receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f634019-695b-41c5-be67-bafe517e35e7" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1919c4e4-4838-4b7c-bbc5-320c447c9b4e" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d88b0264-d95e-4bff-812d-9d7fcce4c779" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,607</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a6463d8-3905-4d81-8b78-59ab7abc550c" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84,984</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14e78ea1-9763-419e-9c02-225b6bd3989f" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,887</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6100881-4b7b-41be-97f8-25ffa8d7409c" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,741</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45287ee1-ef61-40a0-a347-e57a50eff13d" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,558</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f480c157-89be-427e-8d14-c2673a3a4f1a" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,078</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying Notes to the Financial Statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">everon Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except per share data)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.311%;box-sizing:content-box;"/>
    <td style="width:2.24%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.604%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:2.24%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:18.604%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenues</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_309e1c26-5b8f-454e-8c2d-787b70bcd077" contextRef="C_8e3349a5-e8ad-4d9f-932c-91af4f1b95ad" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,402</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c68e6185-9f72-4033-9f8d-9f474879e5d9" contextRef="C_cec0b67c-0b8b-4bc4-9170-1fbad94ea8f8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">668</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing lease revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22e2a2cc-d058-48c8-bf74-0599866ecce7" contextRef="C_88f70043-2bab-4fbd-a7ff-7ca163bafeae" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">503</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfcd95e0-04d4-44ed-9686-06bb001e569c" contextRef="C_9fa8323f-6ecb-4760-888b-b865f49ee572" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">487</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Grant revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44e2dabe-400d-40c6-9be5-8a041618d6f2" contextRef="C_4207ea7a-dee3-4ce6-b471-3464cadf1696" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92e1c7b0-13b5-414c-94a0-005e8d86e28f" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d4b45c2-f8b5-45f4-99b5-8863056de160" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2216930b-cf5a-47db-ac2f-b4519029b1fa" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">508</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12fa6fa4-3591-4187-94b6-806dda491abd" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">488</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9460d78-a6ae-447b-86da-801f540fa7f7" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,884</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbb8fbdf-ef5f-4487-bf04-bab2ef30fa3a" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38c781e5-2cd7-4a76-b316-cc7cd676fff4" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,269</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0861dc1d-0273-40e7-92cb-cf07fdc8174b" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,184</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53f06491-f813-4396-92c1-2b587340d8a7" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,137</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a7974cf-8ff6-4659-b904-a456e75719af" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,066</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46266856-edd1-44bb-b002-38a2c7761b52" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,406</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0d227cf-a917-442a-9192-76898d4c18a0" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8def8fc-6e52-4e38-b45f-8577aff49150" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,522</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f357a17b-b36f-4211-aeb2-5b9adcd107b5" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,029</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other income and (expense)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lawsuit expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f52754c6-e1a6-4515-9e7a-a64dcd099bde" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:LawsuitExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other refundable tax credits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8feab7bd-4169-4b5f-8626-c982e6bbc540" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:OtherRefundableTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1b5e320-70f6-4083-8b2d-f2235066e2af" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">549</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48128241-7c19-4309-a98c-499789872d06" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">377</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income (expenses), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a888f587-baef-460c-8f94-b7e07b797fbe" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">549</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ca14343-e686-4c2d-9740-7ed00e452958" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">384</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_737e3984-9258-4cde-8762-00ae6df800b6" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,973</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03270bb4-5a16-469f-9e57-9aa147fd0021" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,413</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deemed dividend - warrant inducement offers</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d225f212-cbc7-4ed6-88d7-0ecadac3496d" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:DeemedDividendWarrantInducementOffers" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,650</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_153d87e0-c4a9-482b-af08-51b35acc6dd6" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:DeemedDividendWarrantInducementOffers" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e751694-bb0a-46be-acfc-5ce4468f2aec" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,623</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91dab373-1a7d-4d6b-97ea-3e6112287434" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,211</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36cd6462-3caa-4c69-ae78-428e7eca9203" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_23fe0f46-b53e-44e5-ae9e-2403f601110c" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.62</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_060690f0-ccf5-4772-a1f3-ba759cf5ac9d" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_196d475d-d887-49d6-8c98-0ff6f7e3172a" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">10.22</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Basic and diluted weighted average common shares outstanding</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cae9456-3881-4a7b-a1cc-422c0312fce5" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c57db8aa-47c9-4f56-b86a-120956fd284f" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,411,164</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6209eda-27ce-430a-a19f-eb3c2d4f5011" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ca3f70bc-d8f7-4674-abdc-235e9c5b2acf" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,173,490</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying Notes to the Financial Statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longev</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eron Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.36%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.8%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4.3%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.68%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class A <br/>Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Class B<br/>Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subscription</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Shareholder&#8217;s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Receivable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at January 1, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58e9d9bc-0ca1-4816-9892-cbd4034b91e6" contextRef="C_7483a01b-1311-4461-aef8-66d710fd0bf5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">612,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66bbb643-07a8-4fd6-bb74-c8b314bff659" contextRef="C_7483a01b-1311-4461-aef8-66d710fd0bf5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d911f9a-dfb4-470a-95d9-e12a8a2853e7" contextRef="C_f492dbe2-0361-48ff-be3f-265ad6408614" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,489,109</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aecc3f46-0c67-4e43-af6e-e8b2a38459d3" contextRef="C_f492dbe2-0361-48ff-be3f-265ad6408614" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a56060e-801b-472b-9df8-f73bf92e44b1" contextRef="C_496249ae-e79a-4060-8ff9-4a44d6dcc042" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7ebc143-917a-4034-a2ab-198a1fcdd13f" contextRef="C_e5e6b360-d445-4c3e-bc79-675f33b37486" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,731</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7b3e280-213f-43eb-bf2f-9338f6329e64" contextRef="C_c17b9bfa-207b-4863-b527-d6ad7945f5f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62,773</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_182221f7-44b1-471f-9557-70b3c46542a6" contextRef="C_e11b48f3-b181-48a1-9aba-5a7956f22930" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">357</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f84f7ad1-b331-42d1-8b7d-5eb3bb3d73bc" contextRef="C_713a5589-63ed-440c-848f-a0dc06ed8d24" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,503</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of Class B common stock for<br/>&#160;&#160;&#160;Class A Common Stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b414aee-1975-46c0-b1de-19e9e77009b3" contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,555</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72f4c6a2-17c4-4a1e-b6d7-12f24bd2b423" contextRef="C_40dda296-3d9d-40bb-bc61-02fd395bf0f7" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">3,555</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock issued for RSUs vested</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78210ef0-0a39-4143-8725-2ad920e04c7c" contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154" name="lgvn:StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,308</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock, held for taxes on<br/>&#160;&#160;&#160;RSUs vested</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6830e358-d4d2-4f23-850a-c6a494303fb1" contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154" name="lgvn:StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">5,223</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41dc673e-da1d-42f4-a109-758376657a10" contextRef="C_12e07091-6e3f-4a59-802d-ada554263431" name="lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc507792-2af6-4646-8639-9b9453c453f4" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Class A common stock issued for stock rights offering, net of issuance cost of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ab4ff6e-eada-4e35-91e9-047b245c2b24" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:StockIssuedForStockRightsOfferingNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f9b0571-90dc-40e0-b095-ad702ccb3468" contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,850</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Class A common stock issued in direct placements, net of issuance costs of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c287005f-1fa5-441f-bbbc-3c1b8f3498e9" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,229</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d10992ab-ab03-43e2-938e-5bab71a8e2ef" contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">372,030</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76b1ba13-1819-40ba-b13b-22252afeab11" contextRef="C_12e07091-6e3f-4a59-802d-ada554263431" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,338</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abd7ad60-544f-445c-aa4f-d2d73e155b25" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,338</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2527aef7-606c-49d5-a67b-ce6adf68603b" contextRef="C_12e07091-6e3f-4a59-802d-ada554263431" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75cff404-81a1-4b5b-a827-9094a0206de8" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend attributable to down round feature of 2021 warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8051b982-54fc-4284-af91-0e562cc86fd4" contextRef="C_12e07091-6e3f-4a59-802d-ada554263431" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f38a893-e41a-4724-b1f7-29261853071c" contextRef="C_0f2e3a3d-a8c9-4849-8d99-8d26291368fd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock issued for prefunded warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aea2a3a-3bbd-4f5a-8916-178a2b3bfe06" contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154" name="lgvn:StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,924</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfda8a09-1af9-456b-93b6-2b18dffccb47" contextRef="C_12e07091-6e3f-4a59-802d-ada554263431" name="lgvn:StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b28ba54-3f83-4d4c-a2fe-27ce0f9055b3" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reverse stock split rounding adjustment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92c21624-b9a1-45d8-a8d3-c2c043c70c8d" contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d4f680b-d143-4aee-a69e-a0df940b459c" contextRef="C_40dda296-3d9d-40bb-bc61-02fd395bf0f7" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss attributable to change in market<br/>&#160;&#160;&#160;value of available-for-sale securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c97138bd-8d86-416f-81a6-7bea183c0071" contextRef="C_4c3eb97b-7e9e-414b-9078-9b9612c6aa90" name="lgvn:StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">357</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d528d387-7bd1-4f5b-963a-17ccc5827b07" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">357</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89b54892-6a24-4862-9414-93afca926bca" contextRef="C_0f2e3a3d-a8c9-4849-8d99-8d26291368fd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,413</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68139526-0bbf-4b45-8e70-8810aac1e74f" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,413</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7285797c-0658-4019-8a50-c83962662fbc" contextRef="C_cdf836e1-0f62-4f0e-af87-d9a88e484056" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,025,183</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e3d239d-b397-4a81-a2d4-da1cd42dce79" contextRef="C_cdf836e1-0f62-4f0e-af87-d9a88e484056" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b184485c-f779-4e75-b019-275c0ee2afe3" contextRef="C_c0f2353d-d121-47bf-acc8-b4e623af90e5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,485,560</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_104bf91d-ccd9-442d-a563-7c74afda0c77" contextRef="C_c0f2353d-d121-47bf-acc8-b4e623af90e5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03c9499b-3a37-42ff-9fa6-6ca270b7bcc8" contextRef="C_77ca1123-0343-4fd4-a5b4-64151b7b9e0f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c78eb76-2caa-4577-bf8e-7efafbeb1109" contextRef="C_fb198e78-e33b-404a-872e-c2d863686fc7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,823</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b3c8a89-e567-4090-afe0-1b769b535c03" contextRef="C_20a3ae2b-fe8d-415d-9a71-83546b838508" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84,984</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_943328a7-f5d4-4ade-8b0b-f44cabf55e22" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,741</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of Class B common stock for Class A common stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76106a15-aba9-427d-85bd-53a53dc3fa14" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,555</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14ff789c-3cc5-4da5-a012-81c0674ef651" contextRef="C_69d91da2-7bca-4bff-9cb8-c9cfd3c244e7" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">1,555</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock, issued for RSUs vested</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8d2ed62-734e-4b94-91c9-bc538fd41e29" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="lgvn:StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">566,904</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock, held for taxes on RSUs vested</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_780ff3c2-868c-4124-a8f0-a21c07e6bf42" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="lgvn:StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">142,306</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89b58709-3c76-488a-9ced-96b8ba770846" contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289" name="lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19910e5c-eadb-4400-a067-6350c89c610a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock, issued for PSUs vested</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a709003-66b2-470a-9e33-4a2119862e39" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="lgvn:StockIssuesDuringPeriodSharesForPSUsVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,020</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Class A common stock, held for taxes on PSUs vested</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c5dabf9-ef55-4adc-810f-1911f7d80b84" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="lgvn:StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">3,286</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6dd2bc3-eb33-4000-b6ce-44b89bec2f60" contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcb30fd6-0974-4a80-aec0-21f1497bc17a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collection of stock subscription receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c76c6fb4-b88d-4e5b-9a72-dcb3b8389c02" contextRef="C_313e3c1d-a177-40fe-a408-6990d730e5ec" name="lgvn:CollectionOfStockSubscriptionReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8523a07-a017-4e8f-a986-47c1d88aa813" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:CollectionOfStockSubscriptionReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57693813-938f-4486-bb4d-45e4e5b6c592" contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,328</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf079426-5522-4244-b8cc-24c4e0f1439f" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,328</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Class A common stock issued in public offering, net of issuance cost of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f1873e7-5b6b-445a-ab3e-c0534a8a15c1" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,064</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6eb4893b-1706-4934-ae49-d52dc4d890e1" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,448,792</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b68cff7-220d-40b9-ad0a-38bc0477106f" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_601499d6-c91b-4dad-a389-ceacb050f727" contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,862</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55dda0be-81fb-49c8-8544-419fc3dcaccc" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,866</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Class A common stock issue for warrants exercised, net of issuance cost of $</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4de4b047-faf2-4dca-999e-72215b8d88ff" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,855</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53695e26-5f5a-48ee-8e3c-c46ced15dba5" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,435,609</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da6add3d-9838-479d-bb33-d5e6859b1968" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ba47ea3-ebad-4778-b2b9-b6342e7e90ae" contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,183</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27f57723-2e63-4b69-9ec3-3ef34a89abfa" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,191</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deemed dividend &#8211; warrant inducement offers</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dd0eacf-4d80-4c56-8fe2-1bc1a7b488c3" contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,650</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f22bec2-a794-4bfc-b70c-192a403ba4d9" contextRef="C_32a5c33d-d25b-44e7-987a-deec4533967d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,650</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reverse stock split rounding adjustment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd873592-49a4-4c9d-ba23-54c5b05e249d" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">66,970</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_032327b5-62c4-40f0-870f-4791bed77fd6" contextRef="C_32a5c33d-d25b-44e7-987a-deec4533967d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,973</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_465170ab-2481-465b-9aab-4e91d18b3ed9" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,973</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61048633-c987-47f7-9ef8-e6ac53d30fbf" contextRef="C_ff6c86a5-5367-4252-82ff-f27f2520421d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,407,441</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a0c316e-e65a-41de-a25b-8b5e2280090a" contextRef="C_ff6c86a5-5367-4252-82ff-f27f2520421d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_361b09f8-4924-4527-b2c3-5bc9b32d5b3d" contextRef="C_c920b7f7-14c0-4ed4-8bef-d33b2189d204" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,484,005</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42f1a87a-9d1f-442b-9e3c-a43538b7b7cb" contextRef="C_c920b7f7-14c0-4ed4-8bef-d33b2189d204" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e59a6ffb-158f-4ea4-966f-f0dbdc6184c1" contextRef="C_ac111904-200e-4f5d-bf20-50cfa1be5544" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,480</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_224e6fb4-82ce-41b7-8338-902c25123bf1" contextRef="C_60e8ad0c-7547-4527-8724-24923bdc82a9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,607</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91e17de1-6a08-4922-ba7d-59244c3e45bc" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,887</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying Notes to the Financial Statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.63in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longev</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eron Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.713%;box-sizing:content-box;"/>
    <td style="width:1.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.363000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.78%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.363000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4153208a-f06e-48ce-a12d-e623e3a05585" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,973</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68c694ef-ffa6-4abd-926c-f37543028263" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,413</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cc4425a-9029-4638-9721-001e74f2b41e" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">958</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1366841-ae08-4a4f-b51c-dcc7d3f1c11c" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">946</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest earned on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7122d535-bfcc-4521-bedd-7c126e3e3fd0" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:InterestEarnedOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb0d186e-34a3-46f1-8540-cfc496fa84c0" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:InterestEarnedOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">220</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity-based compensation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e2f735b-66ad-45b9-8a9f-da86904cc709" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,328</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a0431f5-696a-4fa8-93ca-97e84adbac3f" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,032</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash write-off of intangible assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78ec13ba-f6c8-4b96-93ed-536cf1af768a" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts and grants receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7c7b292-87bd-4d10-ad08-71b751c84ebd" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9f3b648-4e4f-44fa-86ce-fa3e5739a9a0" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_224dc1d2-3c4c-4e6a-8881-56a0ee2273b9" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_096ffcc8-0cb6-4803-b2ec-afaebbbaff41" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7725bb2b-016a-4fa8-909c-b6df6981e746" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a0c7a25-55d5-4d02-8358-fd5043c35af7" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa18ce51-9f37-4572-8064-71a8ea26ad85" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">540</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef182f93-faa8-4e5a-8bee-b71fc00c96c2" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,113</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16efc132-5a7e-48bd-be77-24323f50cd4e" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">466</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-operating lawsuit expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ecb92cc-22a6-48c9-af7d-fd890f42411e" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,398</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8c1aed0-389d-498d-a503-2104003594d1" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">332</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ab805c6-f9d7-4f70-8011-3c649c0907c8" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,502</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease asset and liability</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6539c94-8be1-42a1-a654-5e522f294240" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0936de8-050d-487c-bc34-201da50c02df" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03f593a5-7787-454e-831d-42ef69023a85" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfb70f36-826d-41cc-8d40-ac3c3dfe8892" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,868</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0a3f346-b166-4210-af06-8efbf76634a2" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19,002</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the sale of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5882deb0-17b7-492b-b56e-9c62f4df7691" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_145f2672-701c-4cf3-bc7c-51051061d783" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,880</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bab2b89d-a52f-4e67-afe6-73cb464dc1d3" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b09529f1-0033-4e05-8f0a-2de315c3c789" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">301</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of intangible assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b726d80-37c5-4db0-8179-0c76aa0fa834" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">337</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccabd64b-2aa1-4354-8c6c-05b2e68faf3d" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7ab3321-3831-44e2-a418-12484f0c413a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">640</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26cf6ac3-7c66-4c4a-9e1c-e66655c063f6" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,186</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock, net of issuance cost</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66c3ddff-c766-41a8-89a3-ee2abdd52317" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,866</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1626dd7f-8c2d-4658-8fb0-b2b43758b949" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,338</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from warrants exercised, net of issuance cost</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c866400c-c57b-4f92-b670-8287be29485a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,191</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_905ca164-8d38-4c80-bddb-bbf8526354f0" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from stock subscription receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_329ca66a-923d-41c6-908e-62de9ab70dd5" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:ProceedsFromStockSubscriptionReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments for taxes on RSUs vested and PSUs vested</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b26c05d-c0c9-44f6-b36a-83f1de4014cd" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:PaymentsForTaxesOnRsusVestedAndPsusVested" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">366</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23999183-b48e-4cda-b6d7-8e48df413235" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:PaymentsForTaxesOnRsusVestedAndPsusVested" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">174</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_170acd26-9515-4fc7-9cd3-4a9fd00a78ca" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,791</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acbb95c0-0ca3-450b-bdf6-3a040ad95aba" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,262</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43390714-f609-4424-ae60-a07a6437682b" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,283</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6362bf6-2cd2-42c0-ac5b-8a8dbc5fa7fe" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,554</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d145596-c5ea-43f8-a2fc-6cfb5af431fa" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba4e0c8e-0bf2-41a2-8732-99bc8dc9502e" contextRef="C_713a5589-63ed-440c-848f-a0dc06ed8d24" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,503</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62811304-1a55-403f-95c3-c1340d5da7b5" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,232</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bb07738-cfbe-4230-b3ce-d5f27ee8ba9e" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of Non-cash Investing and Financing Activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of RSUs into Class A Common Stock</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61ac7825-a25e-4b85-8700-546272c7969a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:VestingOfRSUsAndPSUsIntoClassACommonStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,109</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce76cfd2-d003-464e-a53e-97512a90ac9c" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:VestingOfRSUsAndPSUsIntoClassACommonStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">777</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deemed dividend - warrant inducement offers</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5bc39e3-d9a2-485c-93e9-6dbf00c4ca16" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:DeemedDividendWarrantInducementOffers" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,650</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ad91bf8-5428-4a56-9e20-3024ae0c4c24" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:DeemedDividendWarrantInducementOffers" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">798</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying Notes to the Financial Statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longev</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eron Inc.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span></p>
  <div><ix:nonNumeric id="F_96055a76-8545-41a4-b337-665be0a2928a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" continuedAt="F_96055a76-8545-41a4-b337-665be0a2928a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Nature of Business, Basis of Presentation, and Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of Business:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longeveron LLC was formed as a Delaware limited liability company on October 9, 2014 and authorized to transact business in Florida on December 15, 2014. On February 12, 2021, Longeveron LLC converted its corporate form (the &#8220;Corporate Conversion&#8221;) from a Delaware limited liability company (Longeveron, LLC) to a Delaware corporation, Longeveron Inc. (the &#8220;Company,&#8221; &#8220;Registrant,&#8221; &#8220;Longeveron,&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;). The Company is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on licenses, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s product candidates are currently in development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from, among others, existing pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, partners and consultants.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern and Liquidity:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, the Company has primarily been engaged in organizational activities, including raising capital, and research and development activities. The Company does not yet have a product that has been approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), and has only generated revenues from grants, the Bahamas Registry Trials and contract manufacturing. The Company has not yet achieved profitable operations or generated positive cash flows from operations. The Company intends to continue its efforts to raise additional equity financing, develop its intellectual property, and secure regulatory approvals to commercialize its products. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, the Company&#8217;s future operations are dependent on the success of the Company&#8217;s efforts to raise additional capital, its research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of the Company&#8217;s products. These financial statements do not include adjustments that might result from the outcome of these uncertainties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred recurring losses from operations since its inception, including a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d88bde6-303d-445a-9f4a-dc2a78cf4194" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">16.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3da3446-e424-4d94-843c-638782c0f71e" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">21.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. In addition, as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92602bb7-9aa8-49ba-bb25-3106c93ec20f" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">109.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company expects to continue to generate operating losses for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c3c901-410c-4cd0-938b-f58f6c0f72ec" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company currently believes that its cash and cash equivalents as of December 31, 2024 will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025 based on its current operating budget and cash flow forecast. However, as a result of its successful Type C meeting with the U.S. FDA in August 2024 with respect to the HLHS regulatory pathway, the Company has started to ramp up Biologics License Application (BLA) enabling activities as the Company currently anticipates a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. The Company's operating expenses and capital expenditure requirements are expected to accelerate in calendar 2025 as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness, and there will be a need to increase the Company's current proposed spend and further increase its capital investments. The Company intends to seek additional financing/capital raises/non-dilutive funding options to support these activities, and current cash projections may be impacted by these ramped up activities and any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_96055a76-8545-41a4-b337-665be0a2928a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financing transactions entered into. There can be no assurance the Company will be able to attain future financing at terms favorable to the Company or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has prepared a cash flow forecast which indicates that it does not have sufficient cash to meet its minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore needs to raise additional funds to continue as a going concern. As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_1b138a75-e94e-4bac-a023-4a215483f330" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_1b138a75-e94e-4bac-a023-4a215483f330_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_617a6498-cf8d-4532-9e59-92d3c3c98c6e" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements of the Company were prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain reclassifications have been made to prior period amounts to conform to the current period presentation. These reclassifications had no impact on previously reported net loss for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b68c1e5-f448-4dce-9356-282dc32b7f38" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:ReverseStockSplitPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reverse Stock Split:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 26, 2024, the Company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4a0b75b5-4668-44fe-9ab3-6ac34d6f5dc3;"><span style="-sec-ix-hidden:F_2e46777d-d9ea-4884-a9bb-dd1d15ee5f6a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-10</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (1:10) basis (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split became effective at 11:59 p.m. Eastern Time on March 26, 2024 via a certificate of amendment to the Company&#8217;s Certificate of Incorporation filed with the Secretary of State of the State of Delaware. At the effective time of the Reverse Stock Split, every 10 shares of the Company&#8217;s Class A common stock and Class B common stock, whether issued and outstanding or held by the Company as treasury stock, were automatically combined and converted (without any further act) into one fully paid and nonassessable share of Class A common stock or Class B common stock, respectively, subject to rounding up of fractional shares to the nearest whole number of shares resulting from the Reverse Stock Split without any change in the par value per share. All share, per share, option, warrant, equity award, and other derivative security numbers and exercise prices appearing in this Annual Report on Form 10-K and the accompanying condensed financial statements have been adjusted to give effect to the Reverse Stock Split for all prior periods presented. However, the Company&#8217;s annual, other periodic, and current reports, and all other information and documents incorporated by reference into this Annual Report on Form 10-K that were filed prior to March 19, 2024, do not give effect to the Reverse Stock Split.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7797fa89-9de5-4aa0-8eee-d0a95dc2bb5e" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The presentation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_1f42eaf7-5ae4-44fa-b892-8aaa427abedf" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_1f42eaf7-5ae4-44fa-b892-8aaa427abedf_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Standard Updates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company&#8217;s financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, "Improvements to Reportable Segment Disclosures". The amendments in this ASU are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and by extending the disclosure requirements to entities with a single reportable segment. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_382d7ea9-fe54-4942-9ed3-f6ed091b8df0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is effective for the Company for the annual period of its fiscal year ending December 31, 2024. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29b93aca-9b94-4dae-a6b4-ad93d142ff46" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this standard as of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe662b55-0e55-42fb-af86-f9c2cdef65fa" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the adoption did not have a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4eed576-8e32-47fd-bff1-94398eff0aae" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material impact</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on its financial statements. See Note 13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for disclosures related to the adoption of ASU 2023-07.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_1b138a75-e94e-4bac-a023-4a215483f330_1" continuedAt="F_1b138a75-e94e-4bac-a023-4a215483f330_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1f42eaf7-5ae4-44fa-b892-8aaa427abedf_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, &#8220;Improvements to Income Tax Disclosures&#8221;. The amendments in this ASU change disclosure requirements for various items, including effective tax rate reconciliations and cash taxes paid. This ASU is effective for public companies for the financial reporting periods beginning on January 1, 2025, with early adoption permitted. The Company has not adopted ASU 2023-09 for its financial reporting period ending December 31, 2024, and does not anticipate the adoption of this ASU will have a material impact on its financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221;. The amendments in this ASU require additional disclosure about the nature of expenses included in the expense captions presented on the face of the income statement, including research and development and other operating expenses. This ASU is effective for public companies for the financial reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively, with the option for retrospective application, and early adoption is permitted. ASU 2024-03 will be effective for the Company for the annual period of its fiscal year ending December 31, 2027. The Company is currently evaluating the impact of adopting this ASU on its financial statements.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1fc26af-90cf-4544-81a7-bbc7eaae25c2" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers cash to consist of cash and cash equivalents and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a694c30a-99dd-42f1-b212-902923e83419" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b349f8ed-096d-421c-8a47-6d2332827bb5" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> marketable securities at December 31, 2024. Marketable securities at December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as available-for-sale securities and are thus marked to market and stated at fair value in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 820 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and / or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized gains and losses were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2d830fe-ac68-4f3c-99ec-380d7c22e323" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe49037e-d7a2-457d-8d75-597ee897419b" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2239d4e7-109e-464d-82f3-3016ebb84e98" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ReceivablesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and Grants Receivable:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of December 31, 2024 and 2023 are deemed to be collectible and no amount has been recognized for credit losses. In addition, for the clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the clinical trial revenue are recorded to deferred revenue. Advance contract manufacturing payments are recorded to deferred revenue.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c724d3f1-c058-426b-8145-34cf21f0cc43" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and grants receivable by source, as of (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58%;box-sizing:content-box;"/>
          <td style="width:2.06%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.939999999999998%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:2.06%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.939999999999998%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivables from customers</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f00af57b-1a95-468d-8ce7-fbefaaefa7af" contextRef="C_611dbbc0-e2ce-41b4-85bf-90180810a5c5" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5744f5b2-1f0f-4ed5-ac08-b9940c970074" contextRef="C_2e89703c-f1d8-47e0-91e2-c47b8050d0e4" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">National Institutes of Health &#8211; Grant</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4a5da50-0228-45d5-b351-20e09353ef52" contextRef="C_0d1788e0-51e1-4f67-b903-b27ef0e08ec1" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9caa1132-7e69-4661-91aa-47b2b3f9aff9" contextRef="C_c4442eac-31f6-4b65-9025-3e8e2289cc06" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dd739c9-dc07-4d1a-9485-78517528c049" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69969306-83ab-47db-bc90-7940e0bfd1ea" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_1b138a75-e94e-4bac-a023-4a215483f330_2" continuedAt="F_1b138a75-e94e-4bac-a023-4a215483f330_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e57c8f17-c722-4e4f-ab39-08dc41886ae0" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:DeferredOfferingCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Offering Costs:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of proceeds generated as a result of the offering.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d8d5c62-4f0e-4013-ae91-45b636a2f8cd" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, including improvements that extend useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the Statement of Operations as the assets are primarily related to the Company&#8217;s clinical programs.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb19efb5-4412-4bd4-81f0-acdd48630003" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible Assets:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets include payments on license agreements with the Company&#8217;s co-founder and Chief Scientific Officer (&#8220;CSO&#8221;) and the University of Miami (&#8220;UM&#8221;) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e652d62-f345-4be8-814d-f1828929c813" contextRef="C_7bec887e-3248-45a0-9092-39870e2cd880" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5625679f-2669-4307-8a3e-f5a68125916f" contextRef="C_44c40476-bff5-429e-a017-f12f5df662e4" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the statements of operations as the assets are primarily related to the Company&#8217;s clinical programs.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09cb9f4a-4fe4-4dd3-b206-a64ceb5fa105" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4893190-16cf-47a1-ae54-7bbbd2ab64db" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_0a1dd616-9e9e-46b4-bc9f-222cf64613f0" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment loss</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is reflected on the statements of operations. Upon evaluation, management determined that there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7e9ddd0-b263-4808-b325-c5a3945fe51e" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f988cf93-ded0-453d-ba42-e97f13448a05" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million impairment of long-lived assets during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c531d2a7-b443-4d32-888e-b3a1953ecb97" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Revenue:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unearned portion of advanced grant funds, contract manufacturing revenues, and prepayments for Clinical trial revenue, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the balance sheets. For the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_050d625c-b283-4d73-b8c5-134240d83d37" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal"><ix:nonFraction id="F_91e69c74-bcc6-4d69-8096-6e89804b1844" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of funds that were previously classified as deferred revenue. Due to the MSCRF &#8211; TEDCO &#8211; grant ARDS program being discontinued, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e683d840-c157-454f-8821-ce4939906ee1" contextRef="C_70201005-5bfe-4448-ba31-f3aebe56ae09" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recorded as deferred revenue was reversed when the funds were returned to MSCRF &#8211; TEDCO.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_023316e7-dc86-491f-b034-7d86c74ba422" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="F_023316e7-dc86-491f-b034-7d86c74ba422_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company recognizes revenue when performance obligations related to respective revenue streams are met. For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant received the treatment. For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and / or statement of work has been satisfied. Additionally, the Company's contract manufacturing agreements include a lease component, under which customers pay a fixed monthly fee per</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_1b138a75-e94e-4bac-a023-4a215483f330_3" continuedAt="F_1b138a75-e94e-4bac-a023-4a215483f330_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_023316e7-dc86-491f-b034-7d86c74ba422_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suite </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to reserve and maintain a dedicated manufacturing suite with one production line. Customers may also secure additional suites based on capacity needs, which are billed at a fixed fee per suite per month. furthermore, customers pay the Company a fixed fee per month for storage of in-process samples, vialed harvests for training, and in-process samples for product lots. As these arrangements grant customers the right to control the use of an identified space, the Company classifies the suite reservation fees and storage fees as lease revenue in accordance with ASC 842 Leases. Payment terms may vary depending on specific contract terms. In 2024, the Company derived </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e6492e6-0e30-4548-8e3f-604ad049d397" contextRef="C_f23ba838-5cb1-45db-a43c-3c3ea606ba58" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of its contract manufacturing revenue from a single customer, resulting in a significant concentration of revenue risk. Should this customer terminate their business relationship, the Company's contract manufacturing revenue could be materially adversely impacted.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a46a2ba7-7859-4e55-9ec3-385e2f6c5a69" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue by source (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.272%;box-sizing:content-box;"/>
          <td style="width:2%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.363%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:2%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.363%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6745d6bc-ecec-46ad-8576-570c68c05c86" contextRef="C_8e3349a5-e8ad-4d9f-932c-91af4f1b95ad" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,402</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f386bdca-4cd8-45af-ae37-36c0496e3e68" contextRef="C_cec0b67c-0b8b-4bc4-9170-1fbad94ea8f8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">668</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing lease revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6787d530-3c38-44ad-b2bc-53398f3b443a" contextRef="C_88f70043-2bab-4fbd-a7ff-7ca163bafeae" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">503</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_27ce6dd3-639b-41e2-9150-1333292d9101;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd66614b-fcaa-4ffc-b07a-e3b9684d3ce8" contextRef="C_9fa8323f-6ecb-4760-888b-b865f49ee572" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">487</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ab57fa60-fbf9-444e-8dc1-8543b8bc25bd;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">National Institute of Health - grant</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_491c5dcc-2520-4145-b055-747c1b012785;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e7804c6-78b7-480a-b20b-66564ddcd3e1" contextRef="C_75235aac-f968-4f7c-9c6b-79a7b4522881" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46b9470d-6f01-4530-827a-79f69db4a912" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39104671-9b17-48ff-9dec-6b58a15ac522" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records cost of revenues based on expenses directly related to revenue. For Grants, the Company records allocated expenses for Research and development costs to a grant as a cost of revenues. For the Clinical trial revenue directly related expenses for that program are expensed as incurred. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These expenses are similar to those described under &#8220;Research and development expense&#8221; below. For the contract manufacturing, the Company records costs incurred under the contract as cost of revenues.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0733008f-71c5-42dd-a0ec-f14540a43214" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expense:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are charged to expense when incurred in accordance with ASC 730 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af103952-8991-4c6f-886b-9be10582c93c" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities, and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_42ac54c8-1246-4f43-95db-1ff5328102a8" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_42ac54c8-1246-4f43-95db-1ff5328102a8_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company&#8217;s tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1b138a75-e94e-4bac-a023-4a215483f330_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_42ac54c8-1246-4f43-95db-1ff5328102a8_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provision </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bf9533d-28d3-446d-a8e1-d5c98ba1ad67" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fe0d1b1e-b667-41cb-b202-51e90288440e" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the uncertainty of realizing a benefit in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authority. It is the Company&#8217;s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc51c616-5121-4939-b81f-d47b101d15b9" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity-Based Compensation:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for equity-based awards based on estimated fair values on the date of grant. The fair value of the options is estimated at the date of the grant using the Black-Scholes option-pricing model.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the Company&#8217;s stock options nor its restricted stock units (&#8220;RSUs&#8221;) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company&#8217;s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the option was granted. The expected life is the period of time that the options granted are expected to remain outstanding. Options granted have a maximum term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1874156-cf40-4056-98dd-2d917c60f862" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company had insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_0d8d5a45-c280-41e7-86f3-ae721da3f0a9" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true" continuedAt="F_0d8d5a45-c280-41e7-86f3-ae721da3f0a9_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0705566-ab6d-4bfa-9ce4-c1ea915fd435" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:MarketableSecuritiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is summary of marketable securities that the Company measures at fair value (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.628%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.842%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.842%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.842%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.842%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e89db0d-7516-4cec-996c-1c90638f3e28" contextRef="C_130be5b2-21d0-478a-b3b4-fa7cffb2136b" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,877</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_5860e748-b626-4760-9959-04c8458de42e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b5db85cc-838d-40fc-a08f-983e2963015b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7605902-0fdc-48bc-ac79-49562b553579" contextRef="C_4dc5b1b6-411b-4ddf-9cb1-ffe97d305ce8" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,877</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_badff5da-4d0e-4ef0-94f6-a1fbe41c6fd7" contextRef="C_57c941b5-3999-414f-ab10-1d89c4034885" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_edf3cd8e-fee7-4f2b-bae4-3cb7da56e51c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_26429428-9ef1-47d7-90cc-f345882c97e5;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dffe4c30-2f57-4b19-97af-ed274527fdf3" contextRef="C_a40fe316-3a4c-45cf-a412-d4ebc66d9819" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d188004a-984b-4db3-83be-e84df965edfd" contextRef="C_0d186ce3-11b3-4bf0-afd5-6b860eabc151" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,902</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_261c32f6-80e4-43ac-b52b-25b87d6e73cb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_8adfe637-2df8-4137-b76b-d02b023f34c0;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ff5a749-c2ba-4edc-bdb2-0c4ac6845d10" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,902</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_7a05c076-4b13-4782-980f-f1db531e3014;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b268ce2c-1e85-44ea-8d20-00ce353ce432" contextRef="C_c3264d47-ea98-488c-addc-6cdd4c066842" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_1ae67987-286c-4292-ad79-4c71735dd6d9;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9716215b-948d-4dac-b33b-2e14adb69f26" contextRef="C_4dd328b2-e009-40a7-afa9-eeb63f4c4773" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e12fe2a-e38a-40fb-b7a3-505eb340170c" contextRef="C_a75f8163-8123-4c7b-8abf-018d61948b64" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,948</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b98a551e-dc71-4388-aafc-fbc75338dd46;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_382c332e-e576-4e25-b8f8-144ea2ba7f4f;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65783fe8-1f0d-4364-afe5-73df559ef586" contextRef="C_f5c01cc3-f4ac-4cac-b32c-b2eec7d32119" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,948</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cba38198-3e99-45ca-9665-f3cc596bcdad" contextRef="C_b5a79c7f-92c4-4fca-aa5a-8390eb7d7186" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_40e58eda-d3eb-4484-86f2-e1fe5a77793e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_588625ea-79fb-4a9a-8abb-1ccf786357c5;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c19e343-50ae-436e-bf54-ba2254e42790" contextRef="C_701daa93-ad26-4a44-8b06-338415e1f2ed" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_159e39de-0198-4362-9da8-e4b74615439c" contextRef="C_651c763b-11ca-4b66-a7a6-bbdd17189552" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,964</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9532fd7-2b43-40fe-b9d1-c47706148997" contextRef="C_3643e2ad-d20e-482f-b92d-71aace47a7e2" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_1809098a-d0f5-4df3-8175-e912d38dfd37;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56a25cbe-75b5-4eb1-93d7-479666065b80" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,376</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_f8479f6d-5b6c-4d05-a3d1-b92c863314eb" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the balance sheets.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company reported accrued interest receivable related to marketable securities and money market funds of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1068f3d0-9090-4ee7-b8e6-fe6dc5f18df9" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:AccruedInvestmentIncomeReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6760546c-a785-4096-9765-f3b410e694ad" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:AccruedInvestmentIncomeReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. These amounts are recorded in other assets on the Balance Sheets and are not included in the carrying value of the marketable securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b26cba1e-9958-461e-982b-b4dd5a0b84c1" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_dcad8ceb-cafa-4683-9fac-d417c33ed3be" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrealized losses attributable to changes in marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0d8d5a45-c280-41e7-86f3-ae721da3f0a9_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the amortized cost of these securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d4f0609-2290-46ae-9849-08052f14d8ff" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:TradingSecuritiesDebtAmortizedCost" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce1ae922-dd9f-4851-a7eb-b639b466ae7f" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:TradingSecuritiesDebtAmortizedCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p></ix:continuation></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_917fbe6a-8e56-4432-aa82-fb1f28d4b201" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Property and Equipment, Net</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff483b7e-0491-4eb0-9a3a-b01e146063b5" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major components of property and equipment are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Lives</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_021155dd-eadd-451f-b373-8caa0b212b77" contextRef="C_33ea8560-6aa0-4787-a29e-7ac5e23721b4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08d6636c-4626-42a3-bef4-a77a49a56b9a" contextRef="C_33ea8560-6aa0-4787-a29e-7ac5e23721b4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,402</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0692f37c-82e5-450d-81dc-40e1e5288365" contextRef="C_6366083b-23db-422d-a18f-92b5b0481e03" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture/Lab equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b87bcfe2-0485-4ea5-9f88-cb55547d9b8c" contextRef="C_852485d6-ba04-474c-a47e-395518e87aea" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_966cd728-c815-455d-ad25-c47b0c182857" contextRef="C_852485d6-ba04-474c-a47e-395518e87aea" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,063</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_646fb59b-934a-4d4e-b4f9-5534bb3c77a8" contextRef="C_2c7472b4-63fb-4213-8963-db0f9caec040" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ea37e1df-2769-402e-9e75-d59dbe34eb6c" contextRef="C_be58ec30-718f-49dc-9b0b-5da7ce7d3da6" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bcd407d-fcd7-4a64-b716-b7dacad30718" contextRef="C_be58ec30-718f-49dc-9b0b-5da7ce7d3da6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ef1c3fb-4fb4-408e-9749-28748d17720c" contextRef="C_9a653252-42fd-451f-b16d-80dfc3b20336" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software/Website</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8b413717-df3f-4066-ad57-d64c03c3c7f6" contextRef="C_25de8810-47ca-4f3b-b23d-79bd1ccf287e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f35d5978-b195-4c00-88ad-b79810d458fd" contextRef="C_25de8810-47ca-4f3b-b23d-79bd1ccf287e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe8ed69c-1fb1-4a03-a591-01c0c1959838" contextRef="C_192155e6-0c54-4184-b414-7318e5281259" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc0d91c-dbd6-448e-b866-78f51ebc5278" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,623</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2942373e-31b3-45d7-92ef-64b22c5029bf" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,969</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06f531c0-b279-42d9-bf4f-db76812e40f0" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,174</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_384de38f-eca7-48d7-86c1-b001658c40a0" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,440</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_638a04d5-a6ae-49eb-8d7a-46aaea9c4499" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,449</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9951e74f-1643-49fd-af12-723c2af9f735" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense amounted to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6a35599-d9b1-4fc3-b63c-bba9b70adb36" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4b6cc794-04c9-4ec8-b899-a1f5d0d69bc8" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f56c4925-f3fb-4fb9-a8ad-6392f198886e" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Intangible Assets, Net</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d72de460-4a0b-4c62-ac98-6652f0171c1c" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major components of intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.033%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:14.217%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.198%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.117%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.56%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.198%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Lives</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4304ac38-1f54-4b90-badb-ff677ad3b4e2" contextRef="C_d061083c-5970-4784-a095-643917174816" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a556f5f1-dff6-45ae-a88d-a5cb081d9a39" contextRef="C_d061083c-5970-4784-a095-643917174816" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,043</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e0224ac-ab49-4953-93c6-07d32f4deb54" contextRef="C_d061083c-5970-4784-a095-643917174816" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,132</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be87b54a-706c-4012-987c-fc3c4dad9371" contextRef="C_d061083c-5970-4784-a095-643917174816" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">911</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patent costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dda6a77-8f11-46a7-9ec2-36b5e52a00a7" contextRef="C_cdfee0ba-2fda-4acb-bf1e-85d83d8ae89f" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_93e3078f-8d95-4815-8772-dedb12df7e8d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6534939a-4c9b-4150-974f-dbf2f4c544d3" contextRef="C_cdfee0ba-2fda-4acb-bf1e-85d83d8ae89f" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trademark costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3937b6da-8783-4f51-b90e-7090c8a5e13b" contextRef="C_3d0dcccf-31cc-483e-b3d8-b27e06e3534a" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_76c75a36-7343-4618-abb0-0a79d6e55a20;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac9c0a31-9669-4a1f-bc7e-e2728aa37844" contextRef="C_3d0dcccf-31cc-483e-b3d8-b27e06e3534a" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58be5789-6730-4295-953c-35ff185a7a41" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,533</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54236db3-a517-4eca-a409-64c2dd8dd8b3" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,132</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e9280a7-efc5-4dd2-a50b-67a7621f644d" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,401</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major components of intangible assets as of December 31, 2023, are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.65%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:11.202%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.902000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Lives</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_92199f0a-3130-4748-bb8c-51b6987842d7" contextRef="C_e32174f8-44a9-4669-8a00-c469ea7d76ef" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28f76a24-2e1b-46ef-8365-f54602ac007e" contextRef="C_e32174f8-44a9-4669-8a00-c469ea7d76ef" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,043</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_477a654d-817d-4e0b-85f7-342ab32e57c1" contextRef="C_e32174f8-44a9-4669-8a00-c469ea7d76ef" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">909</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_584664ca-dce8-415c-8b73-2fdbe3749101" contextRef="C_e32174f8-44a9-4669-8a00-c469ea7d76ef" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,134</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patent costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25512b3b-af9f-43ac-bde1-754ec15e982c" contextRef="C_b35ec15a-1d7a-48da-bb29-ded77d1dd6e0" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_cfc4d707-5861-482b-84d7-64104ba53727;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5077571e-e4d2-47ab-8f06-d3120fb786b4" contextRef="C_b35ec15a-1d7a-48da-bb29-ded77d1dd6e0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trademark costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ffe80d8-f773-40a8-9b23-4f88d5f4ce22" contextRef="C_c92a5e48-5a59-41b6-85ff-8ee27a7ded47" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b8f1c0ca-aab8-4e72-a961-0a1daf3f73fb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dba1fe3d-c229-4598-9413-a4e41fc0b37d" contextRef="C_c92a5e48-5a59-41b6-85ff-8ee27a7ded47" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1ba7562-fc3e-48dd-942b-6f8c9b308b67" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,196</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4db9349b-1c1a-4c3c-a8de-05500a760f9a" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">909</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67426e55-937a-4bd5-b14c-b341aaa09562" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,287</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortization expense related to intangible assets amounted to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_664990c3-9a0b-417a-ad7a-f565a1e0e22a" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7723a499-bdc8-4164-a746-3e9a2f3798a6" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023. During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company wrote-off $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_377b97cf-e9bd-49c5-86b2-211997c68d96" contextRef="C_427d1b69-1c7f-4694-805f-39f18674b82e" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9504264-8fe6-4faa-b13a-a36df33344df" contextRef="C_72fb5ee4-e997-41b0-a33d-75e6db840ad0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, of abandoned patents that it was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0194928b-be57-45cc-bbc4-d45852f0bd0e" contextRef="C_427d1b69-1c7f-4694-805f-39f18674b82e" name="lgvn:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" format="ixt:fixed-true"><ix:nonNumeric id="F_3babea3c-3bd8-4f91-86fb-59e0b397ca86" contextRef="C_72fb5ee4-e997-41b0-a33d-75e6db840ad0" name="lgvn:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no longe</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r pursuing in several jurisdictions.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bca829b-76b2-4f69-80d7-71ec10a03683" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future amortization expense for intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is approximately as follows (in thousands):</span></p><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.88%;box-sizing:content-box;"/>
        <td style="width:2.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:25.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_843cca95-c0a9-497e-8788-d2316a031d4c" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fb50818-ce2a-40a3-bec5-8b0120e1ceee" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afc4de5b-894e-498a-9f50-9b8a46fbf1e8" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ee1b43e-a876-424e-8974-9ae3214d90dc" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_256208d9-a1c7-4ebb-a5ec-0bdc157ac157" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e6f2680-f137-4cf9-9291-5c154cfcebd6" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b71a32d-dc95-4603-b673-e71ef33b6e1a" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">911</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b282529-1ad3-445e-aaf2-cbcaff802f83" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records a right-of-use operating lease asset and a lease liability related to its operating leases (there are no finance leases). The Company&#8217;s corporate office lease expires in March 2027. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the operating lease asset and operating lease liability were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acddd209-1ad1-4942-8207-ff1fc65db4ab" contextRef="C_e584071b-f7ae-411b-be56-e2130dbedae5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66ba4011-3149-494a-8e3d-ca0f0ac9b06d" contextRef="C_e584071b-f7ae-411b-be56-e2130dbedae5" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the operating lease asset and operating lease liability were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94afdca4-061a-4b79-8dbf-cfdd06c2b613" contextRef="C_39a27885-81f0-4ba6-9f1c-ee208299badf" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_939164de-f414-4c2b-92b2-6b04ff3c6391" contextRef="C_39a27885-81f0-4ba6-9f1c-ee208299badf" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50600459-2912-432a-abd2-c13cd8be6448" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum payments under the operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows (in thousands):</span></p><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.823%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae6f81f5-19fa-493c-aae5-ac9e0a9da60c" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d2c42d3-9515-495f-b3a0-f585748827b1" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5a184ed-8b79-48c4-becc-a06d14d4e2bb" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39e38a3f-eb26-4e5e-ad19-fd5cc9fe2208" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,533</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less interest (</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ee5c9bb-7367-4122-a6a9-51460a52ba63" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% discount rate)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_911a21c9-b6f3-4221-adb9-9f2a19c3d1db" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee4e5f67-93c2-4e67-bb32-5b27d47f9def" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,447</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97fb450e-5f27-4f62-9f38-f3ec32609140" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ebc5636-894a-4d04-9290-057a65a0a96d" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:LeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, of total lease costs that are included in the general and administrative expenses in the statements of operations.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_54014ccb-3f79-47aa-a573-ca0e80661778" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_54014ccb-3f79-47aa-a573-ca0e80661778_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Class A and Class B Common Stock</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Class A common stock generally have rights identical to holders of Class B common stock, except that holders of Class A common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8b1ead3-4f81-4b75-b86b-e82d53c530c2" contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote per share and holders of Class B common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c1856ba-0e39-4919-930e-37e0b3b2f43d" contextRef="C_d1dbc3f6-3e73-4cc4-a7c7-bc22662d8467" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (5) votes per share. The holders of Class B common stock may convert each share of Class B common stock into one share of Class A common stock at any time at the holder&#8217;s option. Class B common stock is not publicly tradable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, stockholders exchanged </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd416ecc-d416-4f02-bf80-dccb66a60fec" contextRef="C_69d91da2-7bca-4bff-9cb8-c9cfd3c244e7" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">1,555</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class B common stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e862b149-e2c7-4b67-8db1-7386f495f84d" contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,555</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, stockholders exchanged </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2a54ba6-1176-404b-90a9-1191dd32e9e7" contextRef="C_40dda296-3d9d-40bb-bc61-02fd395bf0f7" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">3,555</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class B common stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1cf8ab4-7071-4c36-98c4-b4cb9606215e" contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,555</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Warrant Issuances</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the Company&#8217;s initial public offering (&#8220;IPO&#8221;), the underwriter received warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19a65127-8cfb-4de0-bde7-6af84493ef51" contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701" name="lgvn:WarrantsToPurchase" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,640</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. The warrants are exercisable at any time and from time to time, in whole or in part, during the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_80fc046b-9fe3-4c96-90ec-96afcbbbd494;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four and a half-year period</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> commencing </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e1b5ec8-5ab9-4144-b026-da05d9a26d8c" contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 12, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ec07b62-5a2a-43fc-ab58-474c2b4c13bb" contextRef="C_b9192f71-3161-4b98-9cf0-b50270b7d523" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">120.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the fair value of warrants was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6068a0bc-1987-4298-b3e9-73714fc05e1f" contextRef="C_bdba25ca-ce76-451a-a79b-72c6a6a68dbe" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. During 2021, the underwriters assigned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb3ae21f-2555-404e-aa0f-72667ae2cfd0" contextRef="C_4ba85633-032f-48ff-b8fd-3307bf64c707" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,576</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the warrants to its employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the Company&#8217;s 2021 private placement offering, the Company issued warrants to investors to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c68eef6-5cb8-4123-89e3-7c2332feee8b" contextRef="C_2196011d-eb59-453d-922a-463609b50727" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">116,935</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to the number of shares of Class A common stock purchased by such investor in the offering, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c376e98c-eff0-47bd-94cd-7e4a6f3f74c1" contextRef="C_f3787016-d57b-41d8-93d0-083f687dccac" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">175.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share , which were immediately exercisable, were set to expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0ee1c09-5b05-4b30-b9f4-4f2b19f9059a" contextRef="C_e7b06b06-de62-4546-8211-520778c26862" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance, and had certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail therein (the &#8220;Purchaser Warrants&#8221;). In addition, the Company granted the underwriters warrants, under similar terms, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e860cdd7-6311-4169-901c-1125bb11efa5" contextRef="C_f3787016-d57b-41d8-93d0-083f687dccac" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,679</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c1507aa-b130-40c8-a4ff-1ff67f366786" contextRef="C_f3787016-d57b-41d8-93d0-083f687dccac" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">175.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. On August 16, 2023, the Company announced its Stock Rights Offering, which triggered the downward pricing mechanism on the Purchaser Warrants, at which time these warrants were adjusted downward to an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fc19caa-0780-4ebc-bbf2-f752a08ec5c4" contextRef="C_8bd66a75-3699-4e56-8cd2-f92fabc91f0a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">52.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the period remaining through expiration. This resulted in a deemed dividend to common stockholders of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcd4ebc1-0049-45a4-a199-3f0a14edd939" contextRef="C_5cc56a11-ee4f-45a8-8b30-e4604e7cc25f" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the change in the fair value of the warrants using a Black-Scholes pricing model.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 15, 2021, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-261667) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1ade4af-c12c-453d-b293-a6c62ef13ae5" contextRef="C_8a695d29-400b-42bb-81da-34af6591dda8" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">238,535</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, including (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b44dc0ef-fe0f-4902-9e0a-9d5f4d931db9" contextRef="C_af1e0bf2-f9b3-4719-89f9-f37749bdfb82" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">116,935</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued to purchasers in the Company&#8217;s 2021 private placement offering; (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64b80d7d-d256-480b-ace6-78aa6bcc67e8" contextRef="C_27694a1f-8536-4e3a-90cb-ee31e0d92d39" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">116,935</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of the Purchaser Warrants; and (iii)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_54014ccb-3f79-47aa-a573-ca0e80661778_1" continuedAt="F_54014ccb-3f79-47aa-a573-ca0e80661778_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a5ac33d-1e7f-48da-a3f6-0cc90fe0e454" contextRef="C_09e3c48c-8324-4e5f-b8ba-e37b4bea78af" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,679</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of the underwriters warrants issued as part of the 2021 private placement offering. The Form S-1 was declared effective by the SEC on December 22, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of an October 2023 registered direct offering, the Company issued Series A warrants and Series B warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10397a1f-d5e6-4229-b879-2a359ad9edec" contextRef="C_800ca5b3-19a9-469b-ad8c-765f4cf802f8" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">242,425</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87597c0b-5336-4e34-84a4-df8b4669a971" contextRef="C_8fb325dd-2a4c-427e-b457-7d9e26d11251" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">242,425</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, shares of Class A common stock. Each series of warrants had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1315b97b-6502-4e2a-a77e-f61a6b28b92d" contextRef="C_800ca5b3-19a9-469b-ad8c-765f4cf802f8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, with the Series A warrants having a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_428f7fa2-6f69-4ce1-97cd-53b8e1f3b7a5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five and one-half (5.5) years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance, and the Series B warrants having a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d317f701-e4a6-46de-af03-196205d6c7fb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eighteen (18) months</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance. Both the Series A and Series B warrants became exercisable as of December 26, 2023, following stockholder approval. In addition, the Company granted the placement agent warrants, under similar terms, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e9a4a8f-5154-47f8-ba33-26a449b4f532" contextRef="C_ac1c02ac-9c7a-4aa5-b23c-caf1a6d79afb" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,971</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b79f47b-5e92-4ca8-9c3e-091c235e470a" contextRef="C_1ef16fb7-28d8-4b6f-b55c-d02b22740228" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">20.625</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 15, 2023, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-275578) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72fffb8a-6437-47d6-b303-46c6f73dab12" contextRef="C_3cf0423a-d017-4bc5-a03a-6a1be7ecd8b6" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">501,821</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, including (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88dd080d-44cc-4d09-ab01-0a9b71c778a2" contextRef="C_885350a8-cf29-4eb2-a100-dd267e1f76ed" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">242,425</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of issuable upon exercise of the Series A Warrants; (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24d8028f-d2f7-49e4-8c1a-8f36d0489377" contextRef="C_5c5570fa-1707-4ec0-bdd8-26e9735b80d7" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">242,425</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of the Series B Warrants; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a65290a-78f6-4de2-9352-2bb9d7044c1c" contextRef="C_cee66114-9a5c-4865-9e37-ed6c8eea4537" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,971</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of warrants granted to the placement agent as part of the October 2023 registered direct offering. The Form S-1 was declared effective by the SEC on November 21, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, the Series A Warrants and Series B Warrants were amended to reduce the exercise price to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5debf6bb-56d9-4861-b9af-e4272c291ceb" contextRef="C_375c44e5-dc70-4557-aa86-d4d7438ddb81" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series A Warrants and Series B Warrants were subsequently exercised in full in April 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of a December 2023 registered direct offering, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6b27dcc-56a6-4c26-8184-53cdf99419ed" contextRef="C_9dcd6c86-0172-4023-b693-3ddef2e87823" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">135,531</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. These warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc49d6db-59bb-483b-ac52-46863578112f" contextRef="C_9dcd6c86-0172-4023-b693-3ddef2e87823" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, became immediately issuable upon issuance, and expire on June 22, 2029. In addition, the Company granted the placement agent warrants, under similar terms, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f748efb-572f-45b2-907c-edc0b24f5613" contextRef="C_31c839fd-7132-4e3c-bef4-2e938e7520cc" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,489</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_687b7131-da4b-45f0-b94f-cd3b8765f76e" contextRef="C_31c839fd-7132-4e3c-bef4-2e938e7520cc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">21.813</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 29, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-276745) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83dd8c61-9bcc-437d-9594-81d31c4ee91d" contextRef="C_2d460a19-5b01-4993-8a57-12e7d78c57f5" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">145,020</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, including (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d24a701f-d71b-4835-aee2-00ddb3a79798" contextRef="C_7534eddc-bba5-4cf0-ba3e-08178e69ed62" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">135,531</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of warrants issued in a concurrent private placement in connection with the December 2023 registered direct offering and (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a30e8ffd-5638-47f3-b2c5-74d4a2d2be60" contextRef="C_ac41fb9d-662d-4175-a25e-3ade70bb7db8" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,489</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of warrants granted to the placement agent in connection with the December 2023 registered direct offering. The Form S-1 was subsequently amended by the Company on April 16, 2024 and declared effective by the SEC on April 17, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 8, 2024, the Company commenced a public offering of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27ecb787-316e-45a8-b4c3-c705758725cd" contextRef="C_17a45533-4b30-4885-b609-d19b1db34a37" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">639,872</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock, along with pre-funded warrants to purchase up to an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46d94874-8736-4a67-a339-3945fd0a9e33" contextRef="C_4d1774b7-d786-4c83-9da6-6f4a21fa76cb" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,572,894</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock (the &#8220;Pre-Funded Warrants&#8221;). The shares and Pre-Funded Warrants were sold together with warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07828cb9-e41a-422f-83b8-7fb6156cc3f0" contextRef="C_d68599d9-47e2-4ece-8323-0052aa98f47b" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,212,766</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock (the &#8220;Common Warrants&#8221;). The combined public offering price was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_704025c3-5f7a-455e-af07-f1775493a821" contextRef="C_c984fb4f-1fdc-4b32-b577-b0d95a9c9e4a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and related Common Warrant and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd05d98e-cc76-49a5-9e74-e73952649e2b" contextRef="C_e4cfce79-c2b0-4ca4-8408-3fc1d9f375ff" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.349</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Pre-Funded Warrant and related Common Warrant. Subject to certain limitations, the Pre-Funded Warrants were immediately exercisable and could be exercised at a nominal consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2309a1c-2d24-4d46-84c3-4853d7e52c7f" contextRef="C_4d1774b7-d786-4c83-9da6-6f4a21fa76cb" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of Class A common stock at any time until all of the Pre-Funded Warrants were exercised in full. The Common Warrants were immediately exercisable and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_757f9551-59f4-488d-9dfa-b2298e979316" contextRef="C_44e4401f-ab33-46f4-a549-74a0489db4c1" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 10, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As compensation to the placement agent the Company also issued to designees of the placement agent warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a5e0887-7cf9-4e88-b0df-4174443d7538" contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">154,894</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, which had substantially the same terms as the Common Warrants, and with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_799b49e8-f5ca-47d9-a3c2-614e234015d0" contextRef="C_9aa77719-3220-42ff-b34d-4e36497e3a08" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">2.9375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9607042c-a860-46f8-9dbf-eb6551c7666b" contextRef="C_c984fb4f-1fdc-4b32-b577-b0d95a9c9e4a" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the commencement of sales in the offering.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the offering, the Company also entered into an agreement with a holder of existing warrants to amend the holder&#8217;s existing Series A warrants and Series B warrants to reduce the exercise price to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75f9dc4d-24de-47d5-9141-b66996f31a8c" contextRef="C_375c44e5-dc70-4557-aa86-d4d7438ddb81" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and (ii) amend the expiration date of the Series A Warrants to five and one-half (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6354c5c3-fe3a-4216-b521-e2bcf98c2b11" contextRef="C_1a1782e7-88b3-418e-978c-52f25f9bd58c" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) years following the closing of the public offering and the Series B warrants to eighteen (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e536e70b-d1fa-4562-8952-b4950a63f736" contextRef="C_906ca24e-44d3-40ab-b91a-b4250b408e3c" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) months following the closing of the public offering, in each case for a payment to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64b037bd-8b51-4f13-97d5-e2fd77a2c5b0" contextRef="C_cdc2df3b-5c8c-44c7-a3c8-e65d385a5523" name="lgvn:PaymentPerWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per amended warrant.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 16, 2024, the Company entered into inducement letter agreements with certain holders of its existing Series A warrants and Series B warrants, and Common Warrants issued on April 10, 2024, whereby the holders agreed to exercise the warrants for cash at the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f344092-5491-4d1a-a3fe-0a3629de17ca" contextRef="C_6f844770-8d63-4c0a-b0d4-165e7185f787" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in consideration for payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ae0a784-237f-40a8-b442-b0bf305bceb4" contextRef="C_5e7f8a23-cf6b-4aa9-b4bd-dc4e77beffe6" name="lgvn:PaymentPerWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per new warrant and for the Company&#8217;s agreement to issue new unregistered Class A common stock warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35bb9ca5-e21f-4d54-a682-3311491afcec" contextRef="C_268ad250-3034-4601-a1f3-6fe024bad788" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,799,488</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ff09274-e591-41d2-8cec-3d5bf475a1d7" contextRef="C_268ad250-3034-4601-a1f3-6fe024bad788" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and which were immediately exercisable upon issuance. The warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c851637-0cc9-4243-9ac9-3b8a3a301517" contextRef="C_724dcd9a-d231-46d1-a3ea-7d375a83a614" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,399,744</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock (the &#8220;Series C Warrants&#8221;) have a term of five (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2eee12d-010c-4a71-9bf6-266df4241803" contextRef="C_7707aae5-ac5b-4ae5-9938-ac6e3ea965d6" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) years from the issuance date, and the warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0bdf1d9-4413-4df1-aaf3-25ee9cc72cc7" contextRef="C_e6f0b313-1ad4-4509-b95a-760e3a3d6430" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,399,744</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock (the &#8220;Series D Warrants&#8221;) have a term of twenty-four (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de9927bd-0eca-4830-8259-2dd006fb2bfc" contextRef="C_329d5c2e-7887-4b19-bf7f-646f3efde941" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months from the issuance date, with all of the Series C Warrants and Series D Warrants being immediately exercisable. All</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_54014ccb-3f79-47aa-a573-ca0e80661778_2" continuedAt="F_54014ccb-3f79-47aa-a573-ca0e80661778_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Series D Warrants were exercised in June 2024, pursuant to ordinary course exercise as well as a subsequent inducement transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company issued to the placement agent or its designees as compensation, warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75c81eab-409f-4373-a30b-28018495ed82" contextRef="C_682a89cb-47a9-46e1-bdd9-3cd1abe13dd7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">167,982</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bcca1c7-d808-4936-a04d-932a85ad5786" contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701" name="lgvn:PercentageOfAggregateNumberOfShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the inducement transaction, which had the same terms as the Series C Warrants, except that the placement agent warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_044a9476-38c7-462b-9837-9a81ea21577c" contextRef="C_134d5e58-28b4-43ed-938b-934bfff4116f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, upon exercise, if any, of the Series D Warrants for cash, the Company agreed to issue the placement agent or its designees, within five (5) business days of the Company&#8217;s receipt of the exercise price, warrants to purchase the number of shares of Class A common stock equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18bab890-8c46-4c46-9ccb-55a57d8c490d" contextRef="C_f8a92122-f474-4b31-b2b6-a0fe54800397" name="lgvn:PercentageOfAggregateNumberOfShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares underlying such Series D Warrants that have been exercised, with such warrants to be in the same form and terms as the prior placement agent warrants.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 18, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-278995) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95e4e659-63e3-4c03-bcc6-a6e840e6e193" contextRef="C_58e4471a-d2f1-4ec9-b6a9-d4b9eae6b4e6" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,967,470</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d54b840-2a83-4de3-baec-4687ad1d1fa2" contextRef="C_b5cc0db4-91de-465c-bb48-5b53ca7e01b1" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,399,744</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of the Series C Warrants issued in the April 2024 warrant inducement transaction; (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39866d1e-c056-4de6-8a06-96dabf34edc0" contextRef="C_5b5ba2d7-308e-4e38-ba50-2a15b6d0f5ec" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,399,744</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of the Series D Warrants issued in the April 2024 warrant inducement transaction; and (iii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97b80500-1375-4303-b189-adaa37c771f1" contextRef="C_31d229d0-f489-478a-b8c4-7a980e71248a" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">167,982</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of the warrants issued to the placement agent or its designees in the April 2024 warrant inducement transaction. The Form S-1 was subsequently amended by the Company and declared effective by the SEC on May 21, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 17, 2024, the Company entered into additional inducement letter agreements with the holders of its existing Series D Warrants to exercise the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f65165b5-377b-4281-83bc-21dd39e8884e" contextRef="C_8561f2ca-4d1a-475a-bc19-fcface1b15dc" name="lgvn:ExerciseOfRemainingShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,697,891</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock underlying Series D Warrants that remained outstanding for cash at the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b6fad1a-05f3-401d-8a05-726f1865f2b9" contextRef="C_aa3f1212-2350-4425-9290-9e78374aa7c6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in consideration for the Company&#8217;s agreement to issue new unregistered Class A common stock warrants (the "June Inducement Warrants"), for payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_745a8a72-ec17-4e1a-bbc5-d7270c8d7013" contextRef="C_c28d2aec-e976-4127-9697-03bb7896c0e0" name="lgvn:PaymentPerWarrant" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per new warrant, to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f845ca0-757f-458e-b447-17aa4f0a4172" contextRef="C_a5b385af-6f58-47c5-83db-6be10bedcad9" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,395,782</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2b4043c-12ea-4e10-8fcc-59ed773787c4" contextRef="C_a5b385af-6f58-47c5-83db-6be10bedcad9" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and which were immediately exercisable upon issuance and have a term of twenty-four (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1e7c6fb-39bb-4c36-9bd8-b74fb7e334f4" contextRef="C_a5b385af-6f58-47c5-83db-6be10bedcad9" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) months from the issuance date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also issued to the placement agent or its designees as compensation, (i) warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd0f4f7b-9266-4059-b090-25adde8a3087" contextRef="C_b9192f71-3161-4b98-9cf0-b50270b7d523" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">118,852</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02641f47-fe09-42f0-ba07-1d7329799863" contextRef="C_231d6559-39de-40e2-92ca-0ce4ccbeea1d" name="lgvn:PercentageOfAggregateNumberOfShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the June inducement transaction and (ii) warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2ecfcc6-288d-42bf-b623-7748dd53c851" contextRef="C_fcc6b1eb-c243-4fbc-8e56-d5caa3a5c35e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">49,130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26fb2e61-8023-474b-8d5c-348636f40d0e" contextRef="C_7b2a701b-185b-46d8-a802-15cd82f62888" name="lgvn:PercentageOfAggregateNumberOfShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Common Stock issued upon exercise of certain Series D warrants prior to the inducement transaction, which had substantially the same terms as the June Inducement Warrants, except that the warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d38345a4-ce25-4acd-adba-5ac174f564fa" contextRef="C_236ea03d-46b1-4bac-973b-e724dd4cb6ce" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">118,852</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18df0778-f1de-4f07-ba51-613d376fd03b" contextRef="C_236ea03d-46b1-4bac-973b-e724dd4cb6ce" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc6f30d3-1974-4d27-b538-472b014d0153" contextRef="C_0922a283-969e-4183-84f1-754212457538" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">49,130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73609b70-116a-4563-89cc-0b3ce253c0f5" contextRef="C_0922a283-969e-4183-84f1-754212457538" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">2.9375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively (collectively, the "June placement agent warrants").</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon exercise, if any, of the June Inducement Warrants for cash, the Company agreed to issue within five (5) business days to the placement agent or its designees, warrants to purchase the number of shares of Class A common stock equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55915a6c-ba9c-47f5-bf52-b66034a35a6d" contextRef="C_dfe8bcec-cbcf-444b-8845-a535ef3f03eb" name="lgvn:PercentageOfAggregateNumberOfShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock underlying such June Inducement Warrants that have been exercised, with such warrants to be in the same form and terms as the June placement agent warrants.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance under the inducement offers represented $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f194a6e-2438-45bd-9c74-742be2d324c6" contextRef="C_e1adbcb7-b9b2-43f3-afc8-b17cbfef377a" name="us-gaap:ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders. The June Inducement Warrants expire on June 18, 2026.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-280577) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9fc5e3d-feca-4179-928a-758f3f0840c3" contextRef="C_1265d1c0-07a0-47c5-a6e0-1db933689ef8" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,563,764</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02a8c3b5-38c8-4fd5-b66f-8e5cda67727e" contextRef="C_a7d1800f-a37a-45fd-8dea-2364d19b5d11" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,395,782</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of the June Inducement Warrants and (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04bdbbb7-a7fb-49d9-b933-2a350e2a763a" contextRef="C_89410ccd-0c4e-45f8-bf14-c2ca134fe7ba" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">167,982</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of the June placement agent warrants. The Form S-1 was subsequently declared effective by the SEC on July 9, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2024, a holder exercised Series C warrants for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06b78efe-c9a9-4225-b1b2-3f84993bdfe6" contextRef="C_2e7d7aea-3be2-4828-ad68-c7631d50cb13" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock for cash (the &#8220;July Series C warrant exercise&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2024, certain holders of warrants issued in June of 2024 exercised warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09ffab92-1c82-4934-8f39-bf81442288a7" contextRef="C_3f3103ec-1fd2-48ed-9be1-19cba6a04ef5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">150,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock for cash (the &#8220;July 10 warrant exercise&#8221;). In addition, on July 17, 2024, the Company issued to the placement agent warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dea5441-fdf0-462b-b683-5c63d77600ed" contextRef="C_5cfe12ec-4f6d-46c2-b279-5fb305736864" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8542c07-7564-44c0-ab95-03a48801e9c1" contextRef="C_924ecf1f-101e-4065-841a-2f62764b7c61" name="lgvn:PercentageOfAggregateNumberOfShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock issued in the July 10 warrant exercise (the &#8220;first tranche July ordinary course placement agent warrants&#8221;). The first tranche July ordinary course placement agent warrants have substantially the same terms as the June placement agent warrants, except that the first tranche July ordinary course placement agent warrants (i) have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4481c710-33b0-441c-8307-0164f5354459" contextRef="C_f620f41f-099b-4180-8d31-3b93f07907a0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">3.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and (ii) expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5293f134-2648-4284-83c8-798a10715d14" contextRef="C_711f128e-33db-462a-b513-6bbea4533ff0" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 17, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_54014ccb-3f79-47aa-a573-ca0e80661778_3" continuedAt="F_54014ccb-3f79-47aa-a573-ca0e80661778_4"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 17, 2024, a holder of the June Inducement Warrants exercised the same to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6f686de-a4bf-4fcf-a59e-559c26f9e36f" contextRef="C_b14e7beb-bb0f-4f7a-971e-b4f66076e0c5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,319,186</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock for cash (the &#8220;July 17 warrant exercise&#8221; and together with the July 10 warrant exercise</span><span style="color:#008080;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the July Series C warrant exercise,</span><span style="color:#008080;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collectively, the &#8220;July warrant exercises&#8221;). Accordingly, on July 24, 2024, the Company issued to the placement agent warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be1ea30b-ecec-4b76-a8c0-f9352d8dd601" contextRef="C_c3874ec0-4371-433c-8e08-3d6bcf9a60d5" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">162,344</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a13e6e04-1363-4e35-b3d8-cef31eb2db8a" contextRef="C_c3874ec0-4371-433c-8e08-3d6bcf9a60d5" name="lgvn:PercentageOfAggregateNumberOfShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock issued in the July 17 warrant exercise (the &#8220;second tranche July ordinary course placement agent warrants&#8221;, and together with the first tranche July ordinary course placement agent warrants, the &#8220;July ordinary course placement agent warrants&#8221;, and collectively with the July offering placement agent warrants, the &#8220;July placement agent warrants&#8221;). The second tranche July ordinary course placement agent warrants have substantially the same terms as the first tranche July ordinary course placement agent warrants, except that the second tranche July ordinary course placement agent warrants expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15e6aef2-88c1-402d-9d43-c217c2100713" contextRef="C_c2653ae9-c06d-4781-a567-ba19aae19693" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 24, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The gross proceeds to the Company from the July warrant exercises, inclusive of the payment consideration for such Series C warrants and June Inducement Warrants, were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5dd8b05-075f-4b6c-9897-c733885c3cd4" contextRef="C_ebecf041-4bf7-4e13-a8bb-d1dc47e42040" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, inclusive of the payment consideration for such warrants, before deducting placement agent fees payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 18, 2024, the Company entered into a securities purchase agreement with institutional and accredited investors relating to the registered direct offering and sale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26fd0578-18d2-453e-81e9-a5670ccc15f0" contextRef="C_d018a83c-69ba-4776-9f87-503309a9913d" name="us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,236,026</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our Class A common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df6aa026-ef5d-4115-aa14-61a823d9eef9" contextRef="C_3cb893e8-ebe9-452e-b2d1-71116392d51a" name="us-gaap:CommonStockOtherSharesOutstanding" unitRef="U_shares" scale="0" decimals="3" format="ixt:num-dot-decimal">4.025</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of Class A common stock and associated warrant (the &#8220;July registered direct offering&#8221;). The securities issued in the July registered direct offering were offered pursuant to a prospectus supplement, dated July 18, 2024, and accompanying prospectus, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-264142), which was declared effective by the SEC on April 14, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a concurrent private placement (the &#8220;July private placement&#8221; and together with the July registered direct offering, the &#8220;July offering&#8221;), the Company also sold unregistered Class A common stock warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6d02988-1759-45a1-802b-f5c5a5e68a26" contextRef="C_5fc20789-feae-4261-9107-524520b01c0f" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,236,026</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our Class A common stock (the &#8220;July private placement warrants&#8221;). The unregistered July private placement warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e01b485-5d66-4556-9935-6dce1c41590e" contextRef="C_7697e068-658d-48a3-9b3b-a722fcb2fa76" name="us-gaap:WarrantExercisePriceIncrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, became exercisable on July 19, 2024, and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52f40f1a-9853-4944-a532-42b4087f656f" contextRef="C_7697e068-658d-48a3-9b3b-a722fcb2fa76" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 20, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company granted the placement agent warrants, under similar terms, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4142430-d8c6-4a2f-a711-ddd5e1457683" contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">156,522</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_212c56d1-7e05-4a58-b77e-3da690bad326" contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701" name="us-gaap:WarrantExercisePriceIncrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">5.0313</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;July offering placement agent warrants&#8221;). The gross proceeds to the Company from the July offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59c81e23-663d-4608-81ac-c70dfd6d44b3" contextRef="C_e6f33f88-f256-4289-b5e6-07ec6c716dee" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting placement agent fees and other offering expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 6, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-281299) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64e97fe2-2273-41df-8222-59760f24799b" contextRef="C_972466ee-785c-4232-9930-fe53db2cddaf" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,565,392</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock issuable upon exercise of certain warrants, of which (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45ba9605-098a-4310-9272-b9639af89538" contextRef="C_d496e54d-c6ce-4319-8f1d-e8da390d52f5" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,236,026</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are issuable upon the exercise of the July private placement warrants issued to the purchasers upon the closing of the July private placement; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6c390dc-a187-4f17-b44e-8bd3ab537002" contextRef="C_1dcfeb4c-c36e-4113-9bd0-cb07f984983e" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">156,522</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are issuable upon exercise of the July offering placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of the current engagement Letter with Wainwright; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc2beef1-87a0-47f8-a91d-e8dcb0397d96" contextRef="C_77836947-2834-438d-856e-a46d1692ea17" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">172,844</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are issuable upon exercise of the July ordinary course placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of a then-applicable engagement letter with Wainwright, in connection with previously exercised June Inducement Warrants. The Form S-1 was declared effective by the SEC on August 12, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company entered into additional inducement letter agreements with certain holders of its existing Purchaser Warrants issued as part of the Company&#8217;s 2021 private placement offering to amend and reduce the exercise price of the Purchaser Warrants to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17c36cd0-dcef-4771-901d-d14b300a4b93" contextRef="C_fc09c49d-eaa5-4b33-8d36-7cb35209c791" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in consideration for the holders&#8217; cash exercise of all Purchaser Warrants held by such holder on or before September 27, 2024. In connection with the September 2024 inducement transaction, Purchaser Warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_483c2b3a-2005-4cca-bf10-de884e448c9e" contextRef="C_d059abac-e58b-43e2-a95a-5a8879af8f3d" name="us-gaap:WarrantExercisePriceIncrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:num-dot-decimal">114,077</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, resulting in gross proceeds to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acd71bc8-945e-47a7-b907-4d7b26df190e" contextRef="C_d059abac-e58b-43e2-a95a-5a8879af8f3d" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">114,077</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company entered into additional inducement letter agreements with the remaining holders of its existing Purchaser Warrants issued as part of the Company&#8217;s 2021 private placement offering to amend and reduce the exercise price of the Purchaser Warrants to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69638465-4e5d-49cb-8cff-c4c7af875d85" contextRef="C_c7555a19-6815-4308-a228-e63b0c8a4703" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in consideration for the holders&#8217; cash exercise of all Purchaser Warrants held by such holder. In connection with the October 2024 inducement transaction, Purchaser Warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a1b0658-f0ea-4cdd-b2e9-72dda511e288" contextRef="C_dde951fe-7b4d-4fe4-8fe2-29b317fefcff" name="us-gaap:WarrantExercisePriceIncrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:num-dot-decimal">2,858</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, resulting in gross proceeds to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d16685d-672a-4d08-85e9-fd5ca95844dd" contextRef="C_dde951fe-7b4d-4fe4-8fe2-29b317fefcff" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,858</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Purchaser Warrants have been exercised in full.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Warrants Outstanding</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, warrants exercisable for an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4079f040-49f6-4c56-b434-15e6e91d49f3" contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,802,668</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock remain outstanding. This includes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_54014ccb-3f79-47aa-a573-ca0e80661778_4"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IPO underwriter warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3d5f6ef-d537-4c57-8336-b87d93e58d75" contextRef="C_31e78a64-3bdd-47be-ac65-3b87c7c4e859" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,536</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_074fecb7-a2fa-418a-9718-97024ab248ed" contextRef="C_31e78a64-3bdd-47be-ac65-3b87c7c4e859" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">120.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cb45826-1b63-4be6-8db3-6eb57827b762" contextRef="C_0e8a73c4-ea0e-438b-b7f5-e4427532c51a" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 12, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Underwriter warrants issued in connection with the 2021 private placement offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62609572-4b2b-45d2-af9e-bc5061456ca8" contextRef="C_8b8d20b6-58a6-4f02-b93e-8d56eedb8243" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,679</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92f69a3b-0959-4152-85ef-109d81498923" contextRef="C_8b8d20b6-58a6-4f02-b93e-8d56eedb8243" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">175.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a992299-22df-462b-b449-0ea1854a1c6c" contextRef="C_2209f280-17a3-4fd1-94a9-c9d5d6bd6b30" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 1, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the October 2023 registered direct offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20a9c4d9-e5dd-41eb-a47c-cb5d70eba56c" contextRef="C_1ef16fb7-28d8-4b6f-b55c-d02b22740228" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,971</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c38c6ffe-8e6d-4462-bf6a-bbcc94a39b0a" contextRef="C_1ef16fb7-28d8-4b6f-b55c-d02b22740228" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">20.625</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c30588c-54a9-4305-a964-47d430a04b89" contextRef="C_5353b9ba-0648-487a-aefb-c0c16431821a" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 11, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor warrants issued in connection with the December 2023 registered direct offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_475c3739-56c7-41ed-87e7-9bf9a0a138c7" contextRef="C_68efe625-4084-44ea-8dd6-7181da4c1023" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">135,531</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0af66a1-24ce-4d5a-991f-6692a4d2c841" contextRef="C_68efe625-4084-44ea-8dd6-7181da4c1023" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f68509f-1360-48a0-b124-fca57a04e3cd" contextRef="C_0f3486fa-b30f-4c7f-a57a-ecbf7bf415e1" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 22, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the December 2023 registered direct offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78dd9522-0dd1-4fc6-b9a1-b2f02ca6c202" contextRef="C_b186b4ae-25c4-45b0-8e3c-637d9c03a871" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,489</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5563108f-923c-42cd-85c4-3b6ce0304634" contextRef="C_b186b4ae-25c4-45b0-8e3c-637d9c03a871" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">21.813</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_809bd342-ecc1-4ebb-b967-241d7987a53b" contextRef="C_65a27186-d86b-45fd-9ea9-84445417ac27" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 20, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Warrants issued in connection with the April 2024 public offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b35f230a-21df-49df-be6c-858e5de7bf26" contextRef="C_d8c195d2-126b-4a62-8221-e81b21de8e4a" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">297,872</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56a026e9-cb95-43fd-894f-83e3d64766a2" contextRef="C_d8c195d2-126b-4a62-8221-e81b21de8e4a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f510ab66-f971-4459-ae23-ac7e9a619dae" contextRef="C_58d502e3-e75a-4d67-9f49-bf40b468f239" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 10, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the April 2024 public offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2dbbfbb-6cbe-49a4-a65c-a2ff3dddd6a3" contextRef="C_681d8182-c08b-4f2c-b850-c94acff077c7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">154,894</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16e7c070-7cfe-4907-8a32-3ce9c12f9545" contextRef="C_681d8182-c08b-4f2c-b850-c94acff077c7" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">2.9375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b29fcf10-57d1-4f31-aa69-390312496f0c" contextRef="C_ad3fe0e4-e995-40c1-bc38-77db69fa7a3f" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 8, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Series C Warrants issued in connection with the April 2024 inducement transaction exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fb951fa-a75c-472a-8dba-b7adf6776402" contextRef="C_060bd5b3-20e9-452b-9a05-b0270d3c7018" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,349,744</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0325964e-46c0-4e53-b5e5-c6281a44456f" contextRef="C_060bd5b3-20e9-452b-9a05-b0270d3c7018" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9775129-f225-4591-a1d6-162f4dff65b6" contextRef="C_10494440-1436-4801-9d95-e37fad25c83b" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 18, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the April 2024 inducement transaction exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d4dc197-55f4-4162-a380-dbba91696c33" contextRef="C_682a89cb-47a9-46e1-bdd9-3cd1abe13dd7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">167,982</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d466ccb-c23e-4d06-beb9-036cdd36259f" contextRef="C_682a89cb-47a9-46e1-bdd9-3cd1abe13dd7" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6deeaab0-4809-4a27-8769-ab7918a5ef44" contextRef="C_231d6559-39de-40e2-92ca-0ce4ccbeea1d" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 18, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June placement agent warrants issued in the ordinary course prior to the June 2024 inducement transaction exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecd44336-ace2-4648-a9cf-b2872084aacd" contextRef="C_d928293f-8f03-4263-a9cb-8b1b15166f54" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">49,130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c9d26e3-59ce-4988-814b-ab90d1fdd167" contextRef="C_d928293f-8f03-4263-a9cb-8b1b15166f54" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">2.9375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_53db0637-f701-4587-99cb-7512bfa33590" contextRef="C_9474be27-a471-40f6-84ce-28e85ee32e08" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 18, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June Inducement Warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec052bb5-b397-4637-b637-3f1d1ddc9042" contextRef="C_5ad083cc-071f-4968-8655-4ec150277da0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">926,596</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_924866bf-2f1f-405d-bef0-4cc9113ec002" contextRef="C_5ad083cc-071f-4968-8655-4ec150277da0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5ef0b4a-a8c4-466c-b7e7-ec6d23abb38c" contextRef="C_d75ceeb2-ec46-49ab-a15a-5b9237a9730c" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 18, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the June 2024 inducement transaction exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d42db17-4e5d-425a-9b29-c8364c0189b7" contextRef="C_d5f7e310-6aa6-4ef9-ba0b-23c17f14bd5d" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">118,852</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6a71f6a-8f66-4621-b599-566e308e661f" contextRef="C_d5f7e310-6aa6-4ef9-ba0b-23c17f14bd5d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0336827-b2a2-496a-bae3-8db3b9908086" contextRef="C_66ab6a93-936f-44ff-be1a-6cfc54371b2d" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 18, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">First tranche July ordinary course placement agent warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7421afd7-dcd3-4ca0-873c-e8c02f27ccc0" contextRef="C_a3cf52d5-51ea-46c9-a0ff-4a136cfdc855" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46379618-4ebe-42e1-973e-5a41d646a4d2" contextRef="C_a3cf52d5-51ea-46c9-a0ff-4a136cfdc855" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">3.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c60c456-206d-405d-a5ce-ac18c0297495" contextRef="C_2e8cf413-7785-4109-aeb3-90e76b3f91b0" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 17, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Second tranche July ordinary course placement agent warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e511751d-7f16-4f61-9780-301acd046be8" contextRef="C_63c4202f-ab95-43b7-9ac7-8fc5f186cdb3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">162,344</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4375697b-4ec8-436a-9659-b290859a37c8" contextRef="C_63c4202f-ab95-43b7-9ac7-8fc5f186cdb3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">3.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4beace2e-24bb-4c5a-86e3-7ec80304842f" contextRef="C_c8996def-ed25-41c0-9cde-57e67fd24599" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 24, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July private placement warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e5616d1-51d7-4757-b6b9-b5ea4d40b0d5" contextRef="C_b988428e-be70-43a6-a20f-4a0d1af53866" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,236,026</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3714922-256f-4754-832e-aa51a1130ce0" contextRef="C_b988428e-be70-43a6-a20f-4a0d1af53866" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d62e4abc-6ecd-46be-8d52-fd2039131359" contextRef="C_0c05e440-f556-4213-b61b-eda6feaf9090" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 20, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July offering placement agent warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_443d05a3-09c0-4923-b871-167e53559055" contextRef="C_5be6c0a6-1868-4af2-89ef-106e0e069070" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">156,522</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12706212-7962-4ca2-9795-bd6a5293d9db" contextRef="C_5be6c0a6-1868-4af2-89ef-106e0e069070" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">5.0313</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_797502a9-3818-428b-9e89-52d142b681a1" contextRef="C_655c9a5e-6bc6-4cd8-9dec-b75e3ef72592" name="us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 20, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_c1ae2429-1400-4a5e-b6be-eb558f2d4347" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_c1ae2429-1400-4a5e-b6be-eb558f2d4347_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the Company&#8217;s IPO, the Company adopted and approved the 2021 Incentive Award Plan, which has been subsequently amended and restated twice (as accordingly amended and restated, the &#8220;2021 Incentive Plan&#8221;). Under the 2021 Incentive Plan, the Company may grant cash and equity incentive awards to employees and eligible service providers in order to attract, motivate and retain the talent for which the Company competes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs are taxable upon vesting based on the market value on the date of vesting. The Company is required to make mandatory tax withholding for the payment and satisfaction of income tax, social security tax, payroll tax, or payment on account of other tax related to withholding obligations that arise by reason of vesting of an RSU. The taxable income is calculated by multiplying the number of vested RSUs for each individual by the closing share price as of the vesting date and a tax liability is calculated based on each individual&#8217;s tax bracket. During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d7c979f-f01d-4bb1-abb7-3d98410a3d77" contextRef="C_a153ce10-2e61-4bc3-acd9-4005eae448d3" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">566,904</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs vested for Class A common stock shares. Of that amount, the Company withheld </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93e93216-a1de-41e1-8966-595a4105acc5" contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">142,306</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A common stock shares to satisfy employee tax liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_c1ae2429-1400-4a5e-b6be-eb558f2d4347_1" continuedAt="F_c1ae2429-1400-4a5e-b6be-eb558f2d4347_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bed3b16-f6f1-4d75-89a8-669ddb400199" contextRef="C_10a053c8-c2a2-4e48-84b4-b5ed263c95d5" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">25,308</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs vested for Class A common stock shares. Of that amount, the Company withheld </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34977355-7949-48c8-a9a8-c035f0247085" contextRef="C_d1bc4f98-b538-4530-9021-04474129f4f8" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,223</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class A common stock shares to satisfy employee tax liabilities. The shares withheld are available for reissuance pursuant to the Company&#8217;s Second Amended and Restated 2021 Incentive Award Plan. Each RSU grant made during 2024 and 2023 is expensed ratably over its respective vesting period, with prorated adjustments made as needed to align with grant dates and the applicable service periods.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed73e522-69a5-49b7-8da6-035339def906" contextRef="C_377db0af-954f-408b-bd6c-7c6b6d74118a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">806,001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d0c912a-75b6-4f42-b876-21e52ce7292e" contextRef="C_caeb366f-d29c-4739-90bc-fff7fe6667f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,239</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively RSUs outstanding (unvested).</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3dad03ac-bb7f-4eab-b3fe-bdb8b53754ab" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.18%;box-sizing:content-box;"/>
        <td style="width:2.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:25.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>RSUs</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding (unvested) at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_961e83d7-0be8-40fa-a246-81b04503ed6b" contextRef="C_caeb366f-d29c-4739-90bc-fff7fe6667f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,239</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4441bd2-f80b-4fb7-9dcb-a3f0f1316d5c" contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,394,774</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07d174a6-201b-4f66-ae9d-a6cdaef12a44" contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">566,904</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSU expired/forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3fec33e-d626-409f-88a9-17108463ffe4" contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">33,108</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding (unvested) at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdd15238-63cd-4b17-bffa-8eabf612bb21" contextRef="C_377db0af-954f-408b-bd6c-7c6b6d74118a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">806,001</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Options</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options may be granted under the 2021 Incentive Plan. The exercise price of options is equal to the fair market value of the Company&#8217;s Class A common stock as of the grant date. Options historically granted have generally become exercisable over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a211f642-62a5-42ee-bc71-d3f13e686a7e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d55492e-b216-43e2-a5d8-ef911eb8ef91" contextRef="C_573f4892-a8c0-49cb-b8bb-f89fab69086c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expire </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2d86f6c-b9cd-4349-8e31-4719cc762f02" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the Company granted options that vest quarterly over three years. Non-employee awards, including options granted to directors and certain third-party service providers, are granted similar to the Company&#8217;s employee awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2023, the Company granted options to executives and non-employee directors under various vesting schedules, including a four-year vesting period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d70dbe9-cab3-409c-9b0b-30bef3b11b11" contextRef="C_30abdd0a-27e1-4d75-a863-e2cce39841ab" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% vesting per year and a one-year cliff vesting for the CEO.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the options issued are estimated using the Black-Scholes option-pricing model. For 2024, the following assumptions were used: a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8c49644-71e2-41aa-9089-53bcafc1e992" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; an expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dda33eec-5d55-46ee-8cf8-8be9a6b83964" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years; volatility ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a003e88e-c6aa-4a7a-9eee-8ec0ab73d43b" contextRef="C_8828b9f4-08cf-4cd9-86ab-83a206aaab8c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16faf480-fc06-4471-9143-1c526ae0b1f5" contextRef="C_573f4892-a8c0-49cb-b8bb-f89fab69086c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; and risk-free interest rate based on the grant date ranging from of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89754cfd-4568-44a0-bab6-33d1d7a6ad49" contextRef="C_57e34a04-c6a3-42fb-8d4f-86889f99fd47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3baa48a5-bda5-4982-a434-2ea4e33433f9" contextRef="C_01ea16bf-996c-4f70-aec4-bfd677595c42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.52</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For 2023, the following assumptions were used: a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7657311c-7730-46a0-afe0-72ac5868b487" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; an expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69194715-30bd-4077-a20a-cbd1d1a6f53d" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years; volatility ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38bff53c-4baf-4a8c-a825-b7ed35511a4d" contextRef="C_c6d1288e-2e0f-44c3-bc7e-30f39c656ecc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bffcfe9-31c3-4d2e-b323-438004c3a102" contextRef="C_830ceff8-2513-4d56-879f-3cc26a4081b4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; and risk-free interest rate based on the grant date ranging from of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95e7a563-7896-4286-a465-748d8b2dddb2" contextRef="C_2165fc3d-60ff-463a-ac2e-ab3e6e0ab4ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_889b6030-e22b-4f6f-b168-25be811d0c43" contextRef="C_5fe7e291-90ef-457d-8a32-938bb17e4966" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. Each option grant made during 2024 and 2023, will be expensed ratably over the option vesting periods, with prorated adjustments made as needed to align with grant dates and applicable service periods.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has recorded issued and outstanding options to purchase a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bceb2ae-2fa3-428f-a65e-52be5579f9c4" contextRef="C_377db0af-954f-408b-bd6c-7c6b6d74118a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">121,186</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock pursuant to the 2021 Incentive Plan, at a weighted average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc2a6023-70e4-481d-9f3e-0214f7f4e596" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.09</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Also, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has recorded issued and outstanding options to purchase a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faee2cfe-7960-4d65-bc11-d2df1a04ffcb" contextRef="C_caeb366f-d29c-4739-90bc-fff7fe6667f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,786</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock pursuant to the 2021 Incentive Plan, at a weighted average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12761a46-9fc3-40d5-9059-1754e7422327" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.96</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ede4e436-f783-41e8-8190-184264382267" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options vested (based on ratable vesting)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2a4b780-d0b0-41bf-9288-4987d4a2267a" contextRef="C_966061df-c7de-4d04-b147-85979bffe716" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">31,713</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options unvested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75faa229-dcf3-47a9-a93a-83a4061246fd" contextRef="C_966061df-c7de-4d04-b147-85979bffe716" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">89,473</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock options outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b3f3517-7510-4fda-9f3e-f283c589c3f3" contextRef="C_966061df-c7de-4d04-b147-85979bffe716" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">121,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options vested (based on ratable vesting)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dde9c5bf-5aaf-4727-922c-29e0e8cb5f4d" contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,091</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options unvested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f40251bd-1519-47b3-aa66-dfe20a3f7c0e" contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,695</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock options outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e75203d0-73aa-478a-a284-129ab73643fb" contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_c1ae2429-1400-4a5e-b6be-eb558f2d4347_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25f70b64-40dc-4c1c-af2b-708b27cc31b6" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise <br/>Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2a6a528-c043-4c22-96a3-7b1aa687c630" contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,786</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c705f35-665a-418d-af09-7cc99f8512ac" contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">49.60</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea81121f-9dd0-44c4-b7c9-bd43177c2bbd" contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">88,625</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3afd0344-e82a-485f-99c7-7581077852dc" contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.46</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_d44a448c-95da-42af-9268-94b3f97749eb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_e72c3d8a-06d5-4f57-820b-ef886d45e808;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options expired/forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2dee0ff-810d-4f59-9bb7-22bc498c5e7e" contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c8550a8-a053-4162-9e20-359942a38f63" contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">50.20</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_536ec01e-ab2c-4bf8-bd48-9b1623af190d" contextRef="C_966061df-c7de-4d04-b147-85979bffe716" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">121,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_778d5fb9-79bc-4fd3-a15a-cd22953a4b21" contextRef="C_966061df-c7de-4d04-b147-85979bffe716" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.09</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the equity-based compensation expense amounted to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a5807e6-640e-4391-84a8-3cbeca978aba" contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_887d0c9a-b48b-403b-9126-84b5b7f38f95" contextRef="C_61e522cf-6101-40bb-b529-2e57609235e3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which is included in the research and development and general and administrative expenses in the statements of operations for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the remaining unrecognized RSUs compensation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e198f00-7fdd-4db0-96b9-8fc9b49197f4" contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be recognized over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7de8ce8b-985f-48b8-94e5-94a1dbb4600f" contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.08</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The remaining unrecognized stock options compensation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a458bc6-3dc8-4653-99d9-875891a4e74f" contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be recognized over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e358a5e2-00be-4186-a92e-a6ba63ef23db" contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.94</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_38aafd4a-cdbe-42e9-9041-8877cd905eb2" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_38aafd4a-cdbe-42e9-9041-8877cd905eb2_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Master Services and Clinical Studies Agreements:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company terminated its active master services agreements with third parties that were previously engaged to conduct its clinical trials and manage clinical research programs and clinical development services. This termination was due to the Company&#8217;s decision in April 2024 to discontinue trial activities in Japan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consulting Services Agreement:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 20, 2014, the Company entered into a ten-year consulting services agreement with Dr. Joshua Hare, its Chief Science Officer (CSO). Under the agreement, the Company has agreed to pay the CSO $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_192508a6-a1d5-4349-90d5-07f693a44c82" contextRef="C_309403c4-9ddf-4b25-a74d-ada45e629444" name="us-gaap:OtherExpenses" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">265,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annually. The compensation payments are for scientific knowledge, medical research, technical knowledge, skills, and abilities to be provided by the CSO to further develop the intellectual property rights assigned by the CSO to the Company. This agreement requires the CSO to also assign to the Company the exclusive right, title, and interest in any work product developed from his efforts during the term of this agreement. On November 16, 2022, the Company accounted for but had not issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5ee9b7e-385c-4d82-b67d-7798a80dd33c" contextRef="C_0bffd59a-5e1d-4d4e-8b68-f305bbb2e10c" name="lgvn:SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">48,140</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs convertible to unregistered shares of Class A common stock, with an aggregate value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9be8dbe3-9257-42ae-80f8-9d5457204e3a" contextRef="C_597c2a74-45ac-4076-9561-0e22ff41b523" name="us-gaap:AccruedLiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">207,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as payment for accrued expenses under a consulting agreement with the CSO. These shares were issued on May 24, 2023. The initial term of the agreement ended on November 22, 2024, however, the Company continues to operate under the same terms until a new agreement is executed. In addition, t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he Company entered into a deferred compensation agreement with the CSO to defer payment of the consulting fees earned for services rendered during 2024. The 2024 consulting fees will be paid in the form of a lump sum distribution in February 2027.  As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company had accrued balances due to the CSO of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d006307a-e19a-4566-aed8-c8e1ebf9d4d9" contextRef="C_003e9629-0270-4293-930d-9e35e517c34f" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43a1bdac-2629-45ac-aafb-ecbabff699c1" contextRef="C_a5052b3f-7b15-4f4e-a480-ac371b45c8fb" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, included in other long-term liabilities and accrued expenses, respectively, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bbe3ac0-899d-43e1-8fef-263769440292" contextRef="C_43ed4fe3-0d84-459e-a147-85ba5807b813" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d948a703-8584-4306-a2e8-c689a4f525b8" contextRef="C_a5052b3f-7b15-4f4e-a480-ac371b45c8fb" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, included in accrued expense and accounts payable in the accompanying balance sheets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing Services Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 21, 2024, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6427e7ac-5349-4837-9f0a-5ecf2e6c9287" contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9" name="lgvn:AgreementTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Supply Agreement with a third-party biotechnology company developing multiple, novel secretomes (&#8220;Secretome&#8221;), to address a spectrum of diseases driven by pathological processes , to manufacture, test, release, and supply Secretome with cardiac stem cells (the &#8220;Product&#8221;) to be used in Phase 1 and Phase 2 clinical trials (the &#8220;Secretome Agreement&#8221;).  The Company received an initial start-up payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_123dfaef-e1d1-4fd7-a1b5-9a6b464b81bb" contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9" name="lgvn:InitialStartUpPaymentReceived" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">242,400</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon signing of the  Secretome Agreement, which was comprised of (a) technology transfer, documentation preparation, training, and testing costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19bc04c1-dc31-4397-9474-34399235c52b" contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9" name="lgvn:TechnologyTransferDocumentationPreparationTrainingAndTestingCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">210,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (b) a ten-hour prepayment of project management fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98629cd3-2150-4134-a2ff-40c3a6b2f375" contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9" name="lgvn:ProjectManagementFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,400</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (c) a first month suite reservation fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48b7df1a-5c0c-4514-b297-5bbd6b019dc2" contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9" name="lgvn:SuiteReservationFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will bill Secretome on a variable fee basis for quality control, in process, release, and stability testing service items. For each Product lot, Secretome will pay the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f68ec7e4-927b-4f25-b0a9-4620f5d69aac" contextRef="C_5969aff3-9175-480f-9b07-995e126acd22" name="lgvn:PotentialAmountReceivableForEachProductLot" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">55,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per lot as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1aea0047-3b22-475f-b672-6420747bec32" contextRef="C_5969aff3-9175-480f-9b07-995e126acd22" name="lgvn:PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each additional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_38aafd4a-cdbe-42e9-9041-8877cd905eb2_1" continuedAt="F_38aafd4a-cdbe-42e9-9041-8877cd905eb2_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lot in excess of two initial &#8220;training run&#8221; lots. Secretome will also pay a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0e5a90a-7e74-4e51-869e-101dcdfc4b8c" contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9" name="lgvn:MonthlyManufacturingSuiteReservationFee" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> monthly manufacturing suite reservation fee to the Company as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2bfd67c-8265-4d45-8ebd-75dd85182100" contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9" name="lgvn:HourlyFeeForProjectManagementServices" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">240</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per hour hourly fee for project management services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secretome  has also agreed to compensate the Company for the value of all materials involved in manufacturing and quality control testing the Product, plus a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b11e38d8-51e9-4dac-9be3-b0cbac6ec7a9" contextRef="C_5969aff3-9175-480f-9b07-995e126acd22" name="lgvn:MarkupPercentageOnValueOfMaterialsCompensated" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent markup on these materials. For any outsourced testing, Secretome will be billed directly by the laboratory conducting the testing, plus a fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8671da9b-3d6f-4e8f-a3df-bb74229ea686" contextRef="C_5969aff3-9175-480f-9b07-995e126acd22" name="lgvn:OutsourcedTestingFeePerBatchReceivable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per batch payable to the Company. Furthermore, Secretome will pay the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed4fdc2a-1f72-4b9c-ae11-48985853505c" contextRef="C_5969aff3-9175-480f-9b07-995e126acd22" name="lgvn:MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> monthly for storage of in process samples, vialed harvests for training, and in process samples for Product lots. The Company will receive certain variable payments related to product packing, handling and shipping, with a standard fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65b3fb28-a914-4535-a82d-a3d6a708d824" contextRef="C_5969aff3-9175-480f-9b07-995e126acd22" name="lgvn:StandardFeeReceivableForProductPackingHandlingAndShipping" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with an increased fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6285d22f-c2e7-4fb0-9772-9833c9caaacd" contextRef="C_5969aff3-9175-480f-9b07-995e126acd22" name="lgvn:IncreasedFeeReceivableForExpeditedOrSpecialHourService" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for expedited or special hour service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the initial </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c723184-bf24-4a36-9f09-23a4e5e5abb5" contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9" name="lgvn:AgreementTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term, the Secretome Agreement may be renewed for additional successive two-year terms upon the mutual written agreement of the parties. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec429d7a-01bf-44e9-a365-0c069f782c22" contextRef="C_e577d4b1-7eb8-446b-9a4f-8502fde888f2" name="lgvn:AgreementTerminationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either party may terminate the agreement for cause and upon notice in the event of a material breach, within (i) 30 days of an uncured material breach that is not a payment default or (ii) 10 days for an uncured payment default. The Secretome Agreement further provides that either party may terminate the agreement at any time upon 90 days&#8217; notice to the other party.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, either party may terminate the agreement immediately in the event the other party seeks the protection of any bankruptcy court, becomes insolvent, makes an assignment for the benefit of creditors, or any debarment activity occurs with respect to that party. A force majeure provision also permits termination of the Secretome Agreement upon written notice to the other party as a result of a delay or interference of performance continuing for more than 60 days.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company has earned revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57e8b20a-b1ff-4bf5-a203-71b95aed125f" contextRef="C_e577d4b1-7eb8-446b-9a4f-8502fde888f2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Secretome Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is also a party to a Mutual Nondisclosure Agreement with Secretome, signed and effective as of October 24, 2023 (the &#8220;Nondisclosure Agreement&#8221;), by which both parties have agreed to maintain the strict confidentiality of, restrict access to, and not to disclose  any intellectual property, trade secrets, business dealings, customers, operations, products, research, clinical data, or other competitively sensitive or proprietary confidential information shared between them, subject to certain customary carve-outs for disclosures pursuant to applicable law or filings with regulatory or governmental agencies including the SEC. The Nondisclosure Agreement has a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0504fd9-a896-4ee7-9ca5-59c762622d5d" contextRef="C_2e7abbe2-22f9-4dec-88c2-e983a64471e1" name="lgvn:AgreementTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the later of (i) the effective date of the Nondisclosure Agreement, (ii) the date of the last disclosure of information under the Secretome Agreement, any &#8220;Quality Agreement&#8221; which may be entered into between the parties, or any scope of work; or (iii)  the expiration of any patents issued arising out of or resulting from the confidential information. The Nondisclosure Agreement will not terminate with respect to trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exclusive Licensing Agreements:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">UM Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 20, 2014, the Company entered into an Exclusive License Agreement with UM (the &#8220;UM License&#8221;) for the use of certain Aging-related Frailty Mesenchymal Stem Cell (&#8220;MSC&#8221;) technology rights developed by our CSO at UM. The UM License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how specifically related to the development of the culture-expanded mesenchymal stem cells for Aging-related Frailty used at the Human-induced pluripotent stem cell-derived mesenchymal stem cells (IMSCs&#8221;), all standard operating procedures used to create the IMSCs, and all data supporting isolation, culture, expansion, processing, cryopreservation and management of the IMSCs. The Company is required to pay UM (i) a license issue fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58440c37-b4e0-4903-80f1-6eba79df36d4" contextRef="C_309403c4-9ddf-4b25-a74d-ada45e629444" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (ii) a running royalty in an amount equal to three percent of annual net sales on products or services developed from the technology, payable on a country-by-country basis beginning on the date of first commercial sale through termination of the UM License Agreement, and which may be reduced to the extent we are required to pay royalties to a third party for the same product or process, (iii) escalating annual cash payments of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_223355e5-ad3f-4af6-8c79-2854de5442a0" contextRef="C_1603a247-a9e5-422a-846b-6d3ba3b022c6" name="us-gaap:OtherCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">fifty thousand</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dollars, subject to offset. The agreement extends for up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34a7ae85-c062-4b00-afa2-f1962d08ec77" contextRef="C_309403c4-9ddf-4b25-a74d-ada45e629444" name="lgvn:TermsOfAgreement" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the last date a product or process is commercialized from the technology and was amended in 2017 to modify certain milestone completion dates as detailed below. In 2021 the license fee was increased by an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2708f1a-ce33-42ac-ae6e-cb0c0be62b8a" contextRef="C_b2d83ae4-7a58-420c-b89e-bc88b246fd41" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to defray patent costs. In addition, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d54a0304-ba74-456f-a33e-124de993aba3" contextRef="C_54e1f014-5bac-4239-87f8-50bf65a2d3d8" name="us-gaap:ExcessStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">110,387</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unregistered shares of Class A common stock to UM.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The milestone payment amendments shifted the triggering payments to three payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06ab4de4-3356-45f8-9939-5fb9f86359c8" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:MilestoneOfTriggeringPayments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to be paid within six months of: (a) the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (b) the receipt by the Company of approval for the first new drug application (&#8220;NDA&#8221;), biologics application (&#8220;BLA&#8221;), or other marketing or licensing application for the product; and (c) the first sale following product approval. &#8220;Approval&#8221; refers to Product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successor agency. The amendments also provided for the Company&#8217;s license of additional technology, to the extent not previously included in the UM License, and granted the Company an exclusive option to obtain an exclusive license for (a) the Hypoplastic Left Heart Syndrome (&#8220;HLHS&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_38aafd4a-cdbe-42e9-9041-8877cd905eb2_2" continuedAt="F_38aafd4a-cdbe-42e9-9041-8877cd905eb2_3"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigational </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new drug application (&#8220;IND&#8221;) with ckit+ cells; and (b) UMP-438 titled &#8220;Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the right to terminate the UM License upon 60 days&#8217; prior written notice, and either party has the right to terminate upon a breach of the UM License. To date, the Company has made payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1b1683b-84cc-4fb3-9bda-6b633762ea97" contextRef="C_202c13b7-a778-4220-862c-5376ad67002b" name="us-gaap:PaymentsForFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to UM, and as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, in the accompanying balance sheets, the Company had accrued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df1375fc-6f97-43ff-a55e-7fcd9e43cdb7" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="lgvn:MilestoneFeesPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2573ce61-3feb-4196-87e9-234f25b21112" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="lgvn:MilestoneFeesPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in milestone fees payable to UM for both years, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fe290e5-b528-400c-b445-7c9535c76642" contextRef="C_1a4b8c2d-4195-4bab-8513-5d2b8c496ede" name="lgvn:MilestoneFeesPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_83b78866-ac43-4347-9c3b-d48b12275381" contextRef="C_dacd79be-b988-4527-b1bf-f17043f4b8a0" name="lgvn:MilestoneFeesPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for both years, respectively, for patent related reimbursements based on the estimated progress to date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also entered into an additional Exclusive License Agreement with UM, signed and effective as of July 18, 2024, for technology rights developed by our CSO at UM. This License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how, SOPs, data and other all other rights related to UMP-144, entitled &#8220;A method to derive GHRHR+ cardiomyogenic cells from pluripotent stem cells (PSCs) for therapeutic and pharmacologic applications&#8221; and having inventors Joshua Hare and Konstantinos Chatzistergos. UM retained a non-exclusive, royalty-free, perpetual, irrevocable, worldwide right to practice, make, and use the Patent Rights or Technology for any non-profit purposes, including educational, and research purposes. Pursuant to the terms of the license agreement, Longeveron must pay to UM: (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f37d97cd-70bc-420a-a2ed-966c31d436dc" contextRef="C_610cf94d-af47-4533-bd1a-06eb6eed02ed" name="us-gaap:PaymentsForFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within 30 days of the Effective Date; and (b) reimbursement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fde93c60-ff92-4508-b3a5-dc52e4148466" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:InvestmentCompanyExcessExpenseReimbursable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">21,307</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within 90 days of the Effective Date for previously incurred patent expenses; and (c) an annual $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38bfb497-36d3-4253-ada2-cd0ce71a73bc" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:RoyaltyExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> fee which is both creditable against other royalty payments for the applicable license year and is waived so long as Company is current on annual fee payments in accordance with the Exclusive License Agreement entered into November 20, 2014 between Company and UM. In addition to certain those certain other royalty payments that would be due should the Company&#8217;s sublicense of the technology result in revenue, Longeveron also agreed to the following additional milestones and payments: (c) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b42c5b1b-9afc-4f2e-be63-bc085e92ad46" contextRef="C_28896f23-6bbf-4287-b699-1d223de107ca" name="us-gaap:LoanRestructuringTrialModificationsAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">150,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon completion of the first Phase 3 Clinical Trial; and (d) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6433e54-f34a-48f0-9e77-a32c8473c439" contextRef="C_aab874c5-5eb9-44be-987c-9dfe72f5a008" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon issuance of a biologics license application or new drug application based on the licensed technology. The Company has the right to terminate the new UM License for convenience upon 90 days&#8217; prior written notice, and both parties have additional termination rights for material breach of the agreement. To date, the Company has made payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fda143c-d5bb-4531-beb4-f93e961f761f" contextRef="C_1a4b8c2d-4195-4bab-8513-5d2b8c496ede" name="us-gaap:PaymentsForFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to UM, and as of December 31, 2024, the Company had not yet accrued any milestone fees payable to UM.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CD271</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 22, 2016, the Company entered into an exclusive license agreement with an affiliated entity of Dr. Joshua Hare, JMH MD Holdings, LLC (&#8220;JMHMD&#8221;), for the use of CD271 cellular therapy technology. The Company recorded the value of the cash consideration and membership units issued to obtain this license agreement as an intangible asset. The Company is required to pay as royalty </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d654d0e1-4c72-4be2-907d-856045b64a7e" contextRef="C_7ebcdbcd-409e-4f2d-81dd-ac2a0d38a037" name="lgvn:AnnualNetSalesPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the annual net sales of the licensed product(s) used, leased, or sold by or for licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_226d6a59-08f7-4180-8460-3edaa7ffa97f" contextRef="C_7ebcdbcd-409e-4f2d-81dd-ac2a0d38a037" name="lgvn:NetSalesOfSubLicensees" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c841df1-e5b5-41b3-b682-0590d10c250c" contextRef="C_831b093d-c619-43f4-90d9-56df47a2666a" name="us-gaap:DebtInstrumentFeeAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to JMHMD, and issued to it </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a86e6c8b-bafc-4734-b237-8cc06473a37f" contextRef="C_8043ee3e-2733-4b91-a33a-2a0763fad881" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series C Units, valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fa6ef4b-3df2-4acc-8db5-4969772966b3" contextRef="C_8043ee3e-2733-4b91-a33a-2a0763fad881" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_191ee3de-bfbe-4bcb-aaa6-d4a0b89e41f2" contextRef="C_831b093d-c619-43f4-90d9-56df47a2666a" name="us-gaap:IndefiniteLivedLicenseAgreements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of value provided to JMHMD for the license agreement, along with professional fees of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe7d1ff8-1686-446f-9e36-c9303b9a2d17" contextRef="C_2a71fae8-4d00-48eb-bf4d-2a741ccb4f26" name="us-gaap:ProfessionalFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91bbe14c-e4f6-4c26-a1f8-83620559dbd3" contextRef="C_2a71fae8-4d00-48eb-bf4d-2a741ccb4f26" name="lgvn:licenseAgreementTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Further, expenses related to the furtherance of the CD271+ technology is being capitalized and amortized as incurred over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dce0a4cf-222a-42ac-bcde-d9abd63803ef" contextRef="C_2a71fae8-4d00-48eb-bf4d-2a741ccb4f26" name="lgvn:IncurredTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9c1e959-21f6-4da8-8641-3447fed90b41" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ba8ef68b-cc47-4dd4-b714-df6e740ac452" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:ProceedsFromLicenseFeesReceived" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> license fees due for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 pertaining to this agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Royalty</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the grant award agreement with the Alzheimer&#8217;s Association, the Company may be required to make revenue sharing or distribution of revenue payments for products or inventions generated or resulting from this clinical trial program. The potential payments, although not currently defined, could result in a maximum payment of five times (5x) the award amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87824492-d2b6-4c7c-b5e0-09571f1ff2d6" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingencies &#8211; Legal</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. For the year ended December 31, 2024, the Company is not aware of any legal proceedings or material developments requiring disclosure.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 13, 2021, the Company and certain of its directors and officers were named as defendants in a securities lawsuit filed in the U.S. District Court for the Southern District of Florida and brought on behalf of a purported class. The suit alleges there were materially false and misleading statements made (or omissions of required information) in the Company&#8217;s initial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_38aafd4a-cdbe-42e9-9041-8877cd905eb2_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offering materials and in other disclosures during the period from our initial public offering on February 12, 2021, through August 12, 2021, in violation of the federal securities laws. The action sought damages on behalf of a proposed class of purchasers of the Company&#8217;s common stock during said period. On July 12, 2022, all parties preliminarily agreed to settle the action for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_352abf6d-8914-4718-bf2f-f96af4c7f442" contextRef="C_c7147bf9-99b9-448b-938b-630f1b775c57" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which settlement was preliminarily approved by the Court on or about May 12, 2023, and which settlement amount was paid on May 24, 2023. Legal expenses incurred in ordinary business activities are reported within general and administrative expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On or about May 18, 2023, a former employee of the Company filed a charge with the Equal Employment Opportunities Commission (&#8220;EEOC&#8221;) and the Florida Commission on Human Relations alleging discrimination based on disability, and on or about August 15, 2023, the former employee filed a complaint in Miami-Dade Circuit Court alleging unpaid wages were outstanding.  Both matters were addressed and fully resolved and settled in a mediation between the Company and the former employee held on September 28, 2023, by which it was agreed that the former employee would be paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24c30cac-f689-43cd-ab00-50570e25ed3b" contextRef="C_f6a93e10-9d65-4c37-b7bd-599ff82c8e50" name="us-gaap:EmployeeStockOwnershipPlanESOPDividendsPaidToESOP" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">75,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e721a00-ccfc-4bce-bf20-ac096e0b0d20" contextRef="C_110002f2-7209-44ec-b8bb-e70434de6600" name="us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">35,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> towards this resolution was paid by the Company and all remaining costs were covered by the Company&#8217;s insurance carrier) and that the EEOC and FCHR charges were withdrawn and the action in the Miami-Dade Circuit Court was dismissed with prejudice.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cac39752-528d-4799-b638-f9f99be5b89c" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Employee Benefits Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sponsors a defined contribution employee benefit plan (the &#8220;Plan&#8221;) under the provisions of Section 401(k) of the Internal Revenue Code. The Plan covers substantially all full-time employees of the Company who are eligible upon date of hire. Contributions to the Plan by the Company are at the discretion of the Board of Directors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company contributed approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1cbac84-e0cb-478e-b996-f6f82fb1953f" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">154,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c61e2c70-f016-416c-91d9-5c84a06b3674" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">131,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the Plan during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_fd7f3412-1c11-4f74-9efe-245886f62583" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_fd7f3412-1c11-4f74-9efe-245886f62583_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62b6a939-a779-4def-b6e8-3b461f34f036" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences and net operating loss (&#8220;NOL&#8221;) carryforwards that gave rise to significant portions of the deferred tax assets and deferred tax liabilities were approximately as follows at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65e2cfab-04a0-4242-a4ce-2b0f794a0940" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,870</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9bf682b-ae58-45ab-9794-e02353616bc0" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,790</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASC 842 Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b288242-abfd-479d-8750-27ea5053acca" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="lgvn:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">361</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aca44d5-8ea3-465b-8ee3-371f14f9b7df" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="lgvn:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">514</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21bdd6c9-2c8f-4a6f-b3e0-e97ebb1dc0b8" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62c119fe-1616-4e2d-9003-214a15d91582" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">201</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_59df80b9-4b23-4957-add5-f538f80c9bb3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_4dd0ce9c-9e6c-48e8-8f65-86135e742a26;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c48e9e-16ab-46c8-9e85-ac6a7e06131c" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">158</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95f21ad2-63ba-4af6-bfa8-d8ac1a01c861" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research &amp; development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_272cc942-688a-45a2-bc25-b7229f41dabf" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,283</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c889e4e-69f2-47ce-ae4c-3fd15eebb780" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,830</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3eeeea6a-8af0-4d81-a4ab-583d153db130" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,866</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35708475-e23f-48b5-836b-b347d1434a5b" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,258</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrual to cash adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_08bd69a2-41d1-491f-a362-6162aa80c7fc;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_dc96f2f3-806d-4814-8f8e-b6e47d188ef7;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d21908d4-b8c2-455b-832c-060438e2bfa4" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">466</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acd4b58a-42e8-40c7-98ce-6233d8039074" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_102787ef-ab3b-451d-acb1-3c336de4015f" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,248</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff0c422f-da98-4403-b730-91195ada0736" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,167</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e729121b-811f-4ac7-9dfa-3388fa66c10b" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,014</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_354df90c-9004-4a71-89c1-6570f35e91d9" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,776</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bd98d9a-23de-499d-9674-345dc3213a69" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">234</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9cb8399-27d9-4dfd-bd35-39c1358b3b05" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">391</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASC 842 Right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f12e39b1-ce2a-4777-9cfc-68c7acdb14d2" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="lgvn:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_469c56c1-2a7b-402f-897e-f07cacff2ea1" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="lgvn:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">307</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cddac2d-8c2c-45d1-8f22-334d8b35e058" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="lgvn:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8c0fedc-98e2-4652-9672-3d475724c76f" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="lgvn:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d59f022-7ae9-4170-b671-1d5a61be739b" contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">234</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_978fc027-832b-4396-bd53-46d4231d8573" contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">391</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_5f5fbe24-614b-499f-aced-c5af13aee5ae;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_fd5c8872-fbff-42c3-a6e0-bd84c28f075d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had NOL carryforwards for federal purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdc854b8-c0b3-44ac-8b8c-ea7f8e98f2f9" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">43.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, all of which have no expiration. The Company also had state NOL carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6fcd523-e3e0-4460-bb7e-6910223f26d9" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, all of which have no expiration. However, these NOLs are subject to various limitations under Internal Revenue Code (&#8220;IRC&#8221;) Section 382. IRC Section 382 limits the use of NOLs to the extent there has been an ownership change of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_229dc1bf-4c98-4f62-9851-5e2ba9527c27" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percentage points in shares owned by any </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5902b89a-694b-44c1-8c9a-5627537e28a7" contextRef="C_747cbc79-ca1c-46c7-be44-ba004328f6dd" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">owner. In addition, the NOL carry forwards are subject to examination by the taxing authority and could be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_fd7f3412-1c11-4f74-9efe-245886f62583_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adjusted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or disallowed due to such exams. Although the Company has not undergone an IRC Section 382 analysis, it is likely that the utilization of the NOLs may be substantially limited.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bff388b7-0157-4871-be20-46063579cbcb" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reconciliations of the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.343%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.343%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal tax at statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9976c18-ce29-4b44-8366-7043301e3d65" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6907fc8f-9a2b-4a4a-bbb6-8b852919b8d5" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax benefits, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6577065-ce27-401f-b44d-7c766cd127c7" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c5c1a2c-c5d5-494f-81fe-e16be3657c8f" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bdb0dd3-d420-442f-9cd2-ec51fccc633d" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd57664e-a719-445b-becd-45353612f015" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29da5302-a5e4-4926-ab33-fbdfcdb939e4" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">26.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3649e7e9-c113-4f94-9550-24f7b68ecf42" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">26.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_903b8dcc-7d05-4cc8-8ed2-00092d584312;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_9b1b95a1-5cfc-4117-a2c2-f442d0b99222;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2024, there were no uncertain positions. The Company&#8217;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from 2021, the earliest year with a net operating loss carryover, because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023.</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8bf2382-08eb-4f37-8699-2fce28f412f1" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share have been computed using the weighted-average number of shares of common stock outstanding during the period. We have outstanding equity-based awards that are not used in the calculation of diluted net loss per share because to do so would be anti-dilutive.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be074b5a-6a8b-46ba-94f0-23b38220894f" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following instruments (in thousands) were excluded from the calculation of diluted net loss per share because their effects would be antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fec4d67-369b-4346-89f1-5b5977ef4a17" contextRef="C_0a31e712-6c10-4d5f-a17e-78ce49207e63" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">806</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03be1e83-76b8-4c30-b5a1-707e0d0a4964" contextRef="C_5b020284-3c22-456d-94b9-311e885fa6b5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PSUs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ca18ef5-2515-4560-bfc1-67fa6c6c4da6" contextRef="C_f62d3e71-2071-4235-baa6-e8487a08b092" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">125</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdfd19f1-175b-4ecd-a7a3-65ebbb78ffcd" contextRef="C_b94a44e3-eb07-42c8-b01e-5d44090f5b4d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_669c50ef-d492-4796-ba56-81d59ddbcdc6" contextRef="C_2af1430d-300c-4a83-ab6c-f2efb9b2b469" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">438</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae183cf3-d693-497b-882c-d3054e41dea7" contextRef="C_554ff09e-61fb-4eb8-892c-14e2e6d7f3cb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,803</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_882483f6-daca-4d0a-9302-717fbf8aa351" contextRef="C_a24d65d6-9396-4617-9b12-342686401195" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d991f407-dcb8-4597-9ca3-48fcda707214" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,730</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_769aa368-7775-4a19-b3e5-e8bcfd93e825" contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,415</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_5e6d8fc8-7de4-4d03-823a-e4471a5371e5" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_5e6d8fc8-7de4-4d03-823a-e4471a5371e5_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Segment Information</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which discrete financial information is available and regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) to allocate resources and assess performance. The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_eb2962d5-c458-43df-b1ef-4f45299e5db3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM is its Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_13fc1c78-4d1d-440f-aa75-9a7f20b97683;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment focused on developing regenerative medicines to address unmet medical needs. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d2ff9e2-e9ec-4891-b0f9-7d869d1e9486" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company&#8217;s measure of segment profit or loss is net loss. The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company&#8217;s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adcd7300-1e3e-48b8-bdd8-e3653d2fbef3" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_577d3f24-3615-4da2-a77f-a18b9428fc43;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating expenses</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are used to monitor budget versus actual results.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  All material long-lived assets of the Company are located in the United States and Company&#8217;s revenues are derived from the United States, the Bahamas and Israel. The total assets of the one reporting segment are disclosed on the balance sheets as of December 31, 2024 and 2023.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:continuation id="F_5e6d8fc8-7de4-4d03-823a-e4471a5371e5_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a19976de-89c0-4c8d-bfbf-51e247c35fcd" contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company&#8217;s single reportable segment:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.953%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.903%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.903%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fe7344d-dc91-49e0-aee7-d442e2d389dd" contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0775914-fe76-4600-af8b-6b08dc8dac74" contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a60c8288-0084-40e9-a69c-c78344db5801" contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">508</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e208ffd-4204-46ec-85de-1aba2131ae16" contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">488</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68c40c4e-72da-4111-a80c-2a6b9a5d361f" contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,799</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1506c981-952d-431b-9ae9-0eee92cf20a8" contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,704</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">G&amp;A costs</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b0064f9-c27c-44e2-9b5c-e6fbce2f3e7f" contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,646</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79c07512-b711-4832-aae8-da319894fc9a" contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,869</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1e54a54-2fef-4b3f-9eb7-bbe5f27d191f" contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af" name="lgvn:PersonnelCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,002</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28d74d80-ba84-4ec2-b668-ae0a233df880" contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75" name="lgvn:PersonnelCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,731</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be21a908-5147-465a-b102-ef2722d341f4" contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5e1e494-ef20-49f0-8135-b7dfd7673fce" contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,330</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de7d4c32-1111-461e-8d50-dea872572a6f" contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,973</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_551f98a6-33d2-4b92-8f6a-18a71655fd77" contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,413</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_affce6d7-8e57-4056-a01d-c9ca371ee566" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Contract Manufacturing and Clinical Trial revenue</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </span><ix:footnote id="FNT_f578064d-d204-42b8-aee5-f8e88fc6a93c" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Clinical Development, Research &amp; Discovery, CMC</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </span><ix:footnote id="FNT_a97c71f4-761d-4b7e-8797-b7ae4e3b378b" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Executive, Finance, Legal, Business Operations</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) </span><ix:footnote id="FNT_cc02af35-7765-4878-8a7d-93447031342c" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes compensation, benefits and equity-based compensation</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) </span><ix:footnote id="FNT_e02994b6-ff61-46f2-aac1-3e0c30130e6b" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes depreciation and amortization, (interest income) and other specific charges</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>2
<FILENAME>lgvn-ex10_25.htm
<DESCRIPTION>EX-10.25
<TEXT>
<html>
 <head>
  <title>EX-10.25</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.25</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img156238889_0.jpg" alt="img156238889_0.jpg" style="width:433px;height:93px;"></p>
  <p style="margin-left:0.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 21, 2023, as amended January 17, 2025</font></p>
  <p style="font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dear Wa&#x2019;el:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This letter agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) sets forth the terms and conditions of your employment with Longeveron Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which shall be effective as of March 1, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). This Agreement will govern your employment with the Company following the Effective Date on the following terms and conditions:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__term___the_term_of_your_employment_wi"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The term of your employment with the Company will terminate upon delivery to you by the Company of notice to such effect, which notice may be given for any or no reason, or upon your earlier resignation, death or Disability. You acknowledge that no provision contained in this Agreement will entitle you to remain in the employment of the Company for any specific period of time or affect the right of the Company to terminate your employment hereunder at any time for any reason, subject to compliance with the termination provisions set forth herein. The period during which you are employed by the Company pursuant to this Agreement shall be referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; For purposes of this Agreement, &#x201c;Disability&#x201d; shall mean your inability, due to physical or mental incapacity, to perform the essential functions of the your job, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period or one hundred twenty (120) consecutive days or receiving any disability benefits under a Company plan for a period of one hundred twenty (120) consecutive days or longer.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__position__duties_and_reporting___your"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Position, Duties and Reporting</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Your position will be Chief Executive Officer of the Company and you will join the Company Board of Directors when such position is available without violating any requirements under Nasdaq, and without any additional payment for such position. You will report directly to the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) of the Company. You shall be employed by the Company on a full-time basis and shall perform such duties and responsibilities on behalf of the Company as are consistent with your position, as may be designated from time to time by the Board. You will be required to devote all of your business time to the business and affairs of the Company and to the promotion of its interests. Notwithstanding the foregoing, you may engage in other activities such as personal investments or business ventures that do not involve a conflict of interest or civic and charitable activities, so long as: (i) such activities do not interfere or conflict with your duties and obligations hereunder and (ii) such activities are disclosed in advance to the Board. In addition, you shall be permitted to serve as a director on up to two (2) other company&#x2019;s Board of Directors so long as they do not compete with Company and subject to the prior consent of the Board (which will not be unreasonably withheld).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__compensation_and_benefits_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation and Benefits.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;" id="a__base_salary___during_the_term__your_a"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary. During the Term, your annual base salary will be Five Hundred and Thirty Thousand Dollars ($530,000.00) per year and will be payable in accordance with the Company&#x2019;s normal payroll practices, less the applicable taxes and elective withholdings. Your base salary may be subject to review and adjustment on an annual basis, as determined by the Board or the Compensation Committee of the Board (the </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Compensation Committee&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;" id="b__incentive_bonus_eligibility___during_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incentive Bonus Eligibility. During the Term, you will be eligible for an annual cash bonus pursuant to the Company&#x2019;s annual cash bonus program. Your initial aggregate target bonus will be in an amount up to 70% of your base salary (&#x201c;Target Bonus&#x201d;). With respect to the Target Bonus, eighty percent (80%) of the Target Bonus amount will be based on the achievement of performance criteria established by the Compensation Committee for the applicable fiscal year, which may include both corporate goals and individual criteria; twenty percent (20</font><font style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%) of the Target Bonus amount will be at the discretion of the Board or the Compensation Committee. The actual amount of any bonus earned shall be determined in the discretion of and by the Compensation Committee or the Board based on achievement of the applicable performance criteria and the program terms and discretionary considerations after the end of the applicable fiscal year. Except as otherwise provided herein, you will be entitled to receive any earned bonus for a </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fiscal year of the Company following certification of the same by the Compensation Committee so long as you remain actively employed by the Company on the payment date for such bonus.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;" id="c__long_term_incentive___you_will_be_eli"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-Term Incentive. You will be eligible to receive long-term equity incentive awards pursuant to the terms of the Longeveron 2021 Incentive Award Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2021 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (or any successor plan thereto). Initial long-term equity incentive awards will be granted in accordance with Appendix A attached hereto and incorporated herein. Additional long-term incentive awards may be granted at the discretion of the Compensation Committee and in accordance with market guidelines for your role as approved by the Compensation Committee.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;" id="d__benefits___during_your_employment_wit"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits. During your employment with the Company, you will be eligible for participation in employee health and welfare benefits programs, retirement programs, and other fringe benefits maintained by the Company, to the extent consistent with applicable law and the terms of the applicable plans and programs available to similarly situated executives of the Company. The Company retains all rights to amend or terminate any such benefit plans and programs, subject to the terms of such employee benefit plans and programs and applicable law, and nothing contained herein shall obligate the Company to continue any benefit plans or programs in the future. You will be eligible to receive vacation in accordance with the terms of the Company&#x2019;s vacation/Paid Time Off &#x201c;PTO&#x201d; policy.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;" id="e__business_expenses___during_the_term__"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Expenses. During the Term, the Company will reimburse you for reasonable business expenses, including travel, entertainment, and other expenses (including a mobile phone and data service) incurred by you in the furtherance of the performance of your duties hereunder, in accordance with the Company&#x2019;s Travel and Entertainment policy as in effect from time to time.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;" id="f__all_payments_made_under_this_agreemen"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All payments made under this Agreement shall be reduced by any tax or other amounts required to be withheld under applicable law.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">g.</font><div style="width:100%;display:inline;" id="g__place_of_duty__you_will_be_allowed_to"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Place of Duty; You will be allowed to work from your current residence in California as long as you are present in Miami for business needs and as required by the job. You will be reimbursed for reasonable travel expenses in accordance with the Company&#x2019;s typical reimbursement practices.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__termination_and_severance_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination and Severance.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;" id="a__upon_your_termination_of_employment_f"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon your termination of employment for any reason, the Company shall pay to you (i) your base salary earned through the date of such termination, (ii) amounts for accrued but unused vacation days, (iii) all compensation and employee benefits, if any, that are due and owing to you under the terms of the Company's employee benefit plans and programs, in each case, in accordance with and subject to the terms and conditions of the applicable employee benefit plan, and (iv) any unreimbursed business expenses to which you would be entitled in accordance with the Company&#x2019;s reimbursement policy, not later than thirty (30) business days after the customary documentation regarding such expenses has been received and only to the extent that such expenses are submitted within one year of your termination (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Amounts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). For avoidance of doubt, your rights and obligations with respect to equity awards, if any, shall be controlled by, and subject to, the terms and conditions set forth in the 2021 Plan and the applicable award agreements.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;" id="b__in_the_event_your_employment_is_termi"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event your employment is terminated during the Term by the Company without Cause (as defined below) or by you for Good Reason (as defined below), in addition to the Accrued Amounts, you will be entitled to receive, subject to your timely execution and non-revocation of a Release (as defined below) (i) any earned but unpaid bonus for any prior completed fiscal year, payable when such payments would otherwise be paid, (ii) a cash payment equal to severance benefits in the amount of three (3) months of your then existing Base Salary for every year you have worked full time for Longeveron (which, for the avoidance of doubt, commenced on March 1, 2023, and prorated for partial years, provided, however, that in no case shall the severance benefit under this section be less than twelve (12) months of your then existing Base Salary payablein one lump sum; and (iii) if you are eligible for and timely elect to continue health benefits under COBRA, the Company will pay the applicable COBRA premiums until the earlier of twelve eighteen (18) months following your termination date, the date you cease to be eligible for COBRA continuation coverage, or the date you become eligible for substantially equivalent health coverage from another employer, and (iv) annual cash bonus payment for current year, at target level and prorated based on date of termination.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.459%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.9014788270327565%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;" id="c__notwithstanding_the_foregoing__upon_a"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, upon a termination of your employment by the Company without Cause or by you for Good Reason within six (6) months following a Change in Control (as defined in the 2021 Plan), in addition to the Accrued Amounts, you will be entitled to receive, subject to your timely execution and non-revocation of a Release (i) a lump sum payment equal to the sum of twelve (12) months of your base salary as of immediately prior to the Change in Control and 100% of your then-current annual cash bonus (at target level), (ii) if you are eligible for and timely elect to continue health benefits under COBRA, the Company will pay the applicable COBRA premiums until the earlier of twelve (12) months following your termination date, the date you cease to be eligible for COBRA continuation coverage, or the date you become eligible for substantially equivalent health coverage from another employer and (iii) full vesting of any equity awards then outstanding held by you (with any performance-based equity awards vesting at &#x201c;target&#x201d; levels) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exercise period of any stock option continuing for a one-year period following your termination of employment. Notwithstanding anything to the contrary set forth herein, to the extent that there is a conflict between any of the terms set forth in this Agreement and any terms set forth in an award agreement relating to the grant of equity awards to you, the terms of this Agreement shall prevail.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;" id="d__in_the_event_that_your_employment_is_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that your employment is terminated by the Company for Cause, or on account of your death, Disability or voluntary resignation, other than for reasons described in subsection (b) above, other than the amounts specified in subsection (a) above, you will not be entitled to receive any payments under this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;" id="e__payment_of_any_severance_payments_or_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment of any severance payments or benefits pursuant to subsection (b) above is expressly conditioned upon your (i) execution of a general waiver and release of claims in such form and substance as reasonably required by the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), within twenty-one (21) days of your termination unless additional time is required by law, and the Release becoming effective upon the expiration of the revocation period (which is seven days after the Release is executed and returned to the Company) and (ii) continued compliance with this Agreement and the Covenant Agreement (as defined below). If an executed Release is not returned to the Company within twenty-one (21) days of termination unless additional time is required by law or the Release is revoked by you, the Company shall be relieved of all obligations to pay you severance under this Agreement. The payment described in subsection 4(b)(ii) shall be paid in the form of salary continuation and shall be made in substantially equal installments, at least monthly, commencing on or before the 60th day following your termination date. The first such payment shall include payment of all severance benefits that otherwise would have been due prior to such date, applied as though such payments commenced on the next normal pay date immediately following your termination date. The payment described in subsection 4(b)(iv) and subsection 4(c)(i) shall be paid on or before the 60th day following your termination date.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;" id="f__for_purposes_of_this_agreement_"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Agreement:</font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall include, but not be limited to: (i) the executive&#x2019;s unauthorized use or disclosure of confidential information or trade secrets of the Company or any subsidiary, or any material breach of a written agreement between the executive and the Company or any of its subsidiaries, including without limitation a material breach of any employment, confidentiality, non-compete, non-solicit or similar agreement; (ii) the executive&#x2019;s commission of, indictment for or the entry of a plea of guilty or </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">nolo contendere </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by the executive to, a felony under the laws of the United States or any state thereof or any crime involving dishonesty or moral turpitude (or any similar crime in any jurisdiction outside the United States); (iii) the executive&#x2019;s gross negligence or willful misconduct which is injurious to the Company or any of its subsidiaries, or the executive&#x2019;s willful or repeated failure or refusal to substantially perform assigned duties; (iv) any act of fraud, embezzlement, material misappropriation or dishonesty committed by the executive against the Company or any of its subsidiaries; (v) the material violation by the executive of any rule or policy of the Company or any of its subsidiaries of which the executive had written notice; or (v) any acts, omissions or statements by a executive which the Company reasonably determines to be materially detrimental or damaging to the reputation, operations, prospects or business relations of the Company or any subsidiary.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) a change in the executive&#x2019;s position with the Company that materially reduces the executive&#x2019;s authority, duties or responsibilities or the level of management to which he or she reports, (ii) a material diminution in the executive&#x2019;s level of compensation (including base salary, fringe benefits and target bonuses under any corporate performance-based incentive programs), excluding any reduction that applies generally to similarly situated employees of the Company, and excluding any change made in connection with the termination of your employment for Cause, or on account of your death or Disability, or temporarily as a result of your Disability or other absence for an extended period; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that you will not have the right to resign for Good Reason pursuant to this provision of the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason definition due to a change in authority, duties or responsibilities solely as a result of the Company no longer being a publicly traded company,, provided further, that Good Reason shall not be deemed to exist unless (A) the executive provides written notice to the Company of the event giving rise to Good Reason within thirty (30) days of the occurrence of such event (setting forth the nature of such event and the corrective action reasonably sought by the executive); (B) the Company fails to cure the event giving rise to Good Reason within forty-five (45) days after written notice thereof is given by the executive to the Company (the &#x201c;Cure Period&#x201d;); and (C) the executive terminates the executive&#x2019;s service within thirty (30) days following the last day of the Cure Period.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">g.</font><div style="width:100%;display:inline;" id="g__effective_as_of_the_date_of_your_term"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective as of the date of your termination of employment, unless otherwise requested by the Company in writing, you will, automatically and without further action on your part or any other person or entity, resign from all offices, boards of directors (or similar governing bodies) and committees of the Company. You agree that you will, at the request of the Company, execute and deliver such documentation as may be required to effect such resignations, and authorize any member of the Company to file (or cause to be filed) such documentation, as necessary, with any applicable governmental authority.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">h.</font><div style="width:100%;display:inline;" id="h__in_consideration_for_the_promises_and"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In consideration for the promises and payments by the Company pursuant to this Agreement, at the request of the Company, for a one-year period following your termination of employment for any reason, you agree to cooperate to the fullest extent possible with respect to matters involving any member of the Company about which you have or may have knowledge, including any such matters which may arise before or after the Term; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such cooperation shall not unreasonably interfere with any obligations you may have to your current employer at the time. The Company will compensate you for your time at a reasonable rate to be agreed to, reimburse you for any reasonable, properly documented out-of-pocket expenses, including your travel expenses and attorneys&#x2019; fees that you actually incur in connection with such cooperation.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;" id="i__the_company_shall_provide_director_an"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company shall provide Director and Officers (D&amp;O) insurance coverage from the start date of employment in accordance with its existing policies. In addition, you will be eligible to sign a stand-alone indemnification agreement in form and substance the same as other Directors and Executive Officers.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__section_409a___this_agreement_is_inte"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement is intended to comply with Section 409A of the Code (&#x201c;Section 409A&#x201d;) or an exemption thereunder and shall be administered and interpreted accordingly. Each payment under this Agreement, including each installment payment, shall be considered a separate and distinct payment. For purposes of this agreement, each payment is intended to be excepted from Section 409A to the maximum extent provided as follows: (i) each payment made within the applicable 2&frac12; month period specified in Treas. Reg. &#167; 1.409A-1(b)(4) is intended to be excepted under the short-term deferral exception; (ii) post-termination medical benefits are intended to be excepted under the medical benefits exceptions as specified in Treas. Reg. &#167; 1.409A- 1(b)(9)(v)(B); and (iii) to the extent payments are made as a result of an involuntary separation, each payment that is not otherwise excepted under the short-term deferral exception or medical benefits exception is intended to be excepted under the involuntary pay exception as specified in Treas. Reg. &#167; 1.409A-1(b)(9)(iii). With respect to any payment subject to Section 409A (and not excepted therefrom), if any, it is intended that each payment is paid on a permissible distribution event and at a specified time consistent with Section 409A. You shall have no right to designate the date of any payment under this Agreement. In the event the terms of this Agreement would subject you to the imposition of taxes and penalties under Section 409A (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">409A Penalties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Company and you shall cooperate diligently to amend the terms of this Agreement to avoid such 409A Penalties, to the extent possible; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that, for the avoidance of doubt, you shall be solely liable for any 409A Penalties incurred by you.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All references in this Agreement to your termination of employment shall mean your &#x201c;separation from service&#x201d; within the meaning of Section 409A of the Code and Treas. Reg. &#167; 1.409A-1(h). Whether you have had a separation from service will be determined based on all of the facts and circumstances and in accordance with the guidance issued under Section 409A.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding any other provision of this Agreement to the contrary, if any payment or benefit provided to you in connection with your termination of employment is determined to constitute &#34;nonqualified deferred compensation&#34; within the meaning of Section 409A and you are determined by the Company to be a &#34;specified employee&#34; as defined in Section 409A(a)(2)(b)(i), then such payment or benefit shall not be paid until the first payroll date following the six-month anniversary of your termination date or, if earlier, on your death (the &#34;Delayed Payment Date&#34;). The aggregate of</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any payments that would otherwise have been paid before the Delayed Payment Date shall be paid (without interest) to you (or your estate or beneficiaries) in a lump sum on the Delayed Payment Date and thereafter, any remaining payments shall be paid without delay in accordance with their original schedule.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to any taxable expense reimbursements , in-kind benefits and/or cash allowances provided or paid by the Company under this Agreement, such reimbursement shall be made in accordance with and subject to the following terms and conditions: (i) reimbursements shall only be made to the extent that the expense was actually incurred and reasonably substantiated; (ii) reimbursements of eligible expenses shall be made on or before the last day of your taxable year following the taxable year in which you incurred the expense; (iii) the amount of any expenses eligible for reimbursement or the amount of any in-kind benefits provided, as the case may be, under this Agreement during any calendar year shall not affect the amount of expenses eligible for reimbursement or the amount of any in-kind benefits provided during any other calendar year; and (iv) the right to reimbursement or to any in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding any provision of this Agreement to the contrary, you acknowledge and agree that the Company and its employees, officers, directors and affiliates are not providing you with any tax advice with respect to Section 409A of the Code or otherwise and are not making any guarantees or other assurances of any kind to you with respect to the tax consequences or treatment of any amounts paid or payable to you under this Agreement. Nothing provided or contained in this Agreement will be construed to obligate or cause the Company and/or its employees, officers, directors, subsidiaries and affiliates to be liable for, any tax, interest or penalties imposed on you related to or arising with respect to any violation of Section 409A.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__section_280g___if_the_present_value_o"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 280G</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the present value of your severance benefits, either alone or together with other payments which you have the right to receive from the Company (the &#x201c;Benefits&#x201d;) constitute a &#x201c;parachute payment&#x201d; as defined in Section 280G of the Code, then your Benefits shall be either (i) provided to you in full, or (ii) provided to you only as to such lesser extent that would result in no portion of such Benefits being subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;Excise Tax&#x201d;), whichever of the foregoing amounts, taking into account the applicable federal, state, and local income and employment taxes and the Excise Tax, results in the receipt by you, on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such Benefits may be taxable under the Excise Tax.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the Company and you otherwise agree, any determination required under section shall be made in writing in good faith by the Company&#x2019;s independent accounting firm or such other nationally or regionally recognized accounting firm selected by the Company (the &#x201c;Accountants&#x201d;), whose determination shall be conclusive and binding upon you and the Company for all purposes. In the event that a reduction to the Benefits under this section, the reduction shall apply first to the Benefits that are not deferred compensation subject to Section 409A of the Code and you shall be given the choice, subject to approval by the Company, of which of such Benefits to reduce; provided, that such reduction achieves the result specified in clause (ii) above of this section. If a reduction in the Benefits that are subject to Section 409A of the Code is required, such Benefits shall be reduced pro rata, but with no change in the time at which such Benefits shall be paid. For purposes of making the calculations required by this section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Code. The Company and you shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this section.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__restrictive_covenant_obligations___yo"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictive Covenant Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You acknowledge and agree that you will be subject to the Company&#x2019;s existing policies regarding confidentiality, non-disclosure, non-use, non-competition, non-solicitation or other covenants pursuant to the terms of that certain Confidentiality and Nondisclosure agreement with the Company, which shall be executed prior to the Effective Date (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covenant Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Notwithstanding any provision in this Agreement, the Covenant Agreement or otherwise to the contrary, nothing in this Agreement, the Covenant Agreement or otherwise precludes or otherwise limits your ability to (A) communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or any other federal, state or local governmental agency or commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Agency</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or self-regulatory organization regarding possible legal violations, without disclosure to the Company, or (B) disclose information which is required to be disclosed by applicable law, regulation, or order or requirement (including without </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitation, by deposition, interrogatory, requests for documents, subpoena, civil investigative demand or similar process) of courts, administrative agencies, the SEC, any Government Agency or self-regulatory organizations, provided that, if permissible by law, you provide the Company with prior notice of the contemplated disclosure and cooperate with the Company in seeking a protective order or other appropriate protection of such information. The Company may not retaliate against you for any of these activities.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__representation_regarding_prior_commit"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representation Regarding Prior Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You represent that your performance of all of the terms of this Agreement and the performance of the services for the Company does not and will not breach or conflict with any agreement with a third party, including an agreement not to compete or to keep in confidence any proprietary information of another entity acquired by you in confidence or in trust prior to the date of this Agreement. You agree that you will not enter into any agreement that conflicts with this Agreement during the term of your employment with the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__governing_law__forum_and_venue___this"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law, Forum and Venue</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement shall be governed, construed, interpreted and enforced in accordance with its express terms, and otherwise in accordance with the substantive laws of the State of Florida, without reference to the principles of conflicts of law or choice of law of the State of Florida, or any other jurisdiction, and where applicable, the laws of the United States. All questions pertaining to the validity, construction, execution and performance of this Agreement shall be construed and governed in accordance with the laws of the State of Florida, without giving effect to principles of conflicts or choice of law. Jurisdiction and venue for any disputes shall be, as appropriate, in the state courts in Miami-Dade County, FL, or the federal courts in the Southern District of Florida.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="x0__validity___the_invalidity_or_unenfor"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Validity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. You were advised to seek counsel with regard to this Agreement and all employment terms, and you were represented by counsel.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;" id="x1__final_agreement___the_terms_of_this_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Final Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The terms of this Agreement and the Covenant Agreement are intended by the parties to be the final expression of their agreement with respect to your employment by the Company and supersede, effective as of the Effective Date, all prior understandings and agreements with respect to your employment by the Company, whether written or oral. For the avoidance of doubt, if the Effective Date does not occur, this Agreement will be void </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ab initio</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Any other signed written agreements, including referenced herein that are not in contradiction with this Agreement are in full force and effect.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;" id="x2__assignment___the_rights_and_benefits"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The rights and benefits under this Agreement are personal to you and such rights and benefits shall not be subject to assignment, alienation or transfer, except to the extent such rights and benefits are lawfully available to your estate or any of your beneficiaries upon your death. The Company may assign this Agreement to any affiliate or subsidiary at any time and shall require any entity which at any time becomes a successor, whether by merger, purchase, or otherwise, or otherwise acquires all or substantially all of the assets, membership interests or business of the Company, to expressly assume this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;" id="x3__counterparts___this_agreement_may_be"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement. Signatures delivered by facsimile shall be deemed effective for all purposes.</font></div></div>
  <p style="font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">[Signature page follows]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Please sign and date this Agreement in the space indicated and return it to my attention to evidence your understanding and acceptance of the terms set forth herein.</font></p>
  <p style="margin-left:0.96%;text-indent:6.731%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55%;box-sizing:content-box;"></td>
    <td style="width:4%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:8%;box-sizing:content-box;"></td>
    <td style="width:32%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sincerely,</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Longeveron Inc.</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Joshua Hare</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joshua Hare</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Position:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman, Chief Science Officer</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15%;box-sizing:content-box;"></td>
    <td style="width:82.5%;box-sizing:content-box;"></td>
    <td style="width:2.5%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Agreed to and Accepted:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Wa&#x2019;el Hashad</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wa&#x2019;el Hashad</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix A</font></p>
  <p style="margin-left:0.027%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.037%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-Term Incentive Equity Awards</font></p>
  <p style="font-size:10pt;margin-top:11pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For so long as employee remains employed as Chief Executive Officer (CEO), he will be entitled to receive the following equity incentive awards:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__upon_the_effective_date_of_employment"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the Effective Date of employment as CEO, he will receive an award of 50,000 Restricted Stock Units (RSUs), which shall vest in four quarterly installments on each of April 1, July 1, September 1 and December 31, 2023.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__for_each_of_calendar_2023__2024__2025"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For each of calendar 2023, 2024, 2025 and 2026, CEO will receive, in accordance with the grant schedule established by the Compensation Committee and commensurate with other executive officers, the following equity awards:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;" id="a__stock_option_award__exercisable_for_5"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option Award, exercisable for 50,000 shares of common stock. The Award will have time-based vesting, and will vest 100% on the first anniversary of the date of grant.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:11pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;" id="b__125_000_performance_share_units__psus"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125,000 Performance Share Units (PSUs). The performance metrics applicable to earn the PSUs will be established annually by the Compensation Committee and communicated to the award recipient at the time of grant. The PSU awards will be structured to allow for partial satisfaction and payment of award, with a minimum &#x201c;floor&#x201d; of 25,000 PSUs to be paid so long as CEO remains employed on the date of payout. Payout of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSU awards shall occur no later than the end of the first quarter following the year of grant, following certification by the Compensation Committee of the degree to which the applicable performance criteria have been met.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>lgvn-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 19.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img51003162_0.jpg" alt="img51003162_0.jpg" style="width:320px;height:59px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement Of Policy On Insider Trading</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Introduction</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is the policy of Longeveron Inc. (collectively any present or future subsidiaries, the &#x201c;Company&#x201d;) that its employees, consultants and members of its Board of Directors (&#x201c;Company Personnel&#x201d;) comply fully with the insider trading securities laws and regulations of the United States. Company Personnel must maintain a basic familiarity with the principles and purposes of these laws as they may be applied to the Company and avoid any activity that might violate these laws or give any appearance either of violation or intention to violate. Compliance with this Statement of Policy on Insider Trading (this &#x201c;Policy&#x201d;) defines the scope of employment for Company employees. Conduct that violates or does not comply with this Policy is outside the scope of employment for Company employees. Any employee who fails to comply with this Policy will be subject to appropriate disciplinary action, which may include suspension or termination.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy is not a description of all applicable securities statutes, but rather is intended to set forth a course of conduct and guiding principles designed to ensure that the employees and directors of the Company do not engage in any activity that violates the spirit of the insider trading provisions of the securities laws, is unfair to the Company&#x2019;s public stockholders or other stakeholders, or creates an appearance of a violation.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons Subject To The Policy</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part I of this Policy applies to all members of the Company&#x2019;s Board of Directors and to all of the Company&#x2019;s employees and consultants. We refer collectively to those covered by this Policy as &#x201c;Company Personnel&#x201d;. The Company may also determine that other persons should be subject to this Policy, such as contractors or consultants who have access to material nonpublic information. This Policy also applies to family members, other members of a person&#x2019;s household and entities controlled by a person covered by this Policy, as described below.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain Company Personnel are subject to additional guidelines as it relates to transactions in the Company&#x2019;s securities, as outlined in Part II of this Policy. If your job title or category is listed on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">then the additional requirements set forth in Part II of this Policy apply to you.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are unsure as to whether you are subject to the additional guidelines set forth in Part II of this Policy, please</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contact the Company&#x2019;s General Counsel or Chief Financial Officer to discuss.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Longeveron Inc. Statement Of Policy On Insider Trading</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to the following categories of securities (collectively, they are referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;):</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This includes the Company&#x2019;s common stock (NASDAQ: LGVN), Class B common stock, options to purchase common stock, restricted common stock, restricted stock units, or any other type of securities that the Company may issue, including derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to Company Securities; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities of Companies with whom the Company Transacts Business</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This would include securities of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> company about which you have material, nonpublic information that you obtained through or in connection with your employment with or work at Longeveron. We refer to those companies in this Policy as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Associated Companies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NO TRADING ON OR TIPPING OF MATERIAL NONPUBLIC INFORMATION</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Company Personnel may trade, directly or indirectly through family members or other persons or entities in Company Securities if they are aware of material nonpublic information (except as set forth under &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transactions For Which this Policy Does Not Apply</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Company Personnel may recommend the purchase or sale of any Company security or disclose such information to others to others who might use it for trading or might pass it along to others who might trade. This practice, known as &#x201c;tipping,&#x201d; also can result in same penalties as trading even though you did not trade and did not gain any benefit from another trader</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Company Personnel may disclose material nonpublic information to persons outside of the Company, including, but not limited to, family, friends, business associates, investors, or other third parties, unless the disclosure is made in accordance with the Company&#x2019;s policies.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Personnel may not trade, directly or indirectly, through family members or other persons or entities, in securities of any other organization (including, without limitation, an Associate Company) unless they are sure they do not possess any material nonpublic information about the organization which they obtained in the course of their employment with the Company, such as information about a major contract being negotiated. Information that is not material to the Company may nevertheless be material to the other organization.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Company Personnel may assist anyone engaged in any of the above activities.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also important that when you disclose material nonpublic information to persons within the Company you do so in a manner that is consistent with directives and the confidentiality restrictions that have been provided to you with that information.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consequences For Violation</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purchase or sale of Securities (including Company Securities) while aware of material, nonpublic information with respect to the issuer of such securities, or the disclosure of material, nonpublic information to others who then trade in Securities of such issuer (including Company Securities), is prohibited by federal and state laws. Insider trading violations are pursued vigorously by the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;), U.S. Attorneys and state enforcement authorities, as well as the laws of foreign jurisdictions. Punishment for insider trading violations is severe and could include significant fines and imprisonment. While the regulatory authorities concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the federal securities laws also impose potential liability on companies and other &#x201c;controlling persons&#x201d; if they fail to take reasonable steps to prevent insider trading by company personnel.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. securities laws impose severe penalties for trading on material non-public information and communicating knowledge of material, non-public information to another person or company (other than in the necessary course of business) who thereafter purchases or sells securities, which can include disgorgement of the unlawful profits, civil penalties of up to three</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Longeveron Inc. Statement Of Policy On Insider Trading</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">times the profit gained or loss avoided, criminal fines of up to $5,000,000 and/or jail terms of up to 20 years. Similar legislation imposes similar penalties in other jurisdictions.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, an individual&#x2019;s failure to comply with this Policy may subject the individual to Company- imposed sanctions, including dismissal for cause, whether or not the failure to comply results in a violation of law. Needless to say, a violation of law, or even an investigation by the SEC that does not result in prosecution, can tarnish a person&#x2019;s reputation and irreparably damage a career. This Policy sets forth the Company&#x2019;s policy against insider trading. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Company Personnel must comply</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no exceptions to this Policy, except as specifically noted herein. Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure), or small transactions, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are not excepted from this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The securities laws do not recognize any mitigating circumstances, and in any event, even the appearance of an improper transaction must be avoided to preserve the Company&#x2019;s reputation for adhering to the highest standards of conduct.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Information: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All information that a reasonable investor would consider important in deciding whether to buy, sell, or hold Securities is considered material. As it relates to Company Securities, information that could be expected to affect the Company&#x2019;s stock price, whether it is positive or negative, should be considered material. There is no &#x201c;bright line&#x201d; standard for assessing materiality; rather, materiality is based on an assessment of all facts and circumstances and is often evaluated by enforcement authorities with the benefit of hindsight. Examples of some types of material information are: (i) trial or study results, or other information regarding the efficacy or safety of the Company&#x2019;s products; (ii) financial results for the quarter or the year; (iii) financial forecasts, projections or other information, including projection of earnings (or other financial metrics) or other types of financial guidance; (iv) changes to previously announced earnings (or other financial metrics) guidance; (v) possible mergers, acquisitions, joint ventures, and other purchases and sales of companies and investments in companies; (vi) obtaining or losing important contracts, licenses, or regulatory approvals; (vii) information about vendor relationships; (viii) major financing developments (including new equity, debt or bank financings or grants); (ix) major personnel changes; (x) major litigation developments; (xi) the establishment of a repurchase program for Securities; (xii) changes in the Company&#x2019;s auditors or a notification from its auditors that the Company may no longer rely on the auditors&#x2019; audit report; (xiii) the imposition of a trading ban on Company Securities or the securities of another company; (xiv) major events regarding Company Securities; and/or (xv) changes in dividends or to a dividend policy.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unauthorized Disclosure of Material, Nonpublic Information Prohibited</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Rule. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Director, Officer or Employee may disclose material, nonpublic information about Longeveron or any company with which Longeveron deals to anyone, unless such disclosure is in the necessary course of business. Questions regarding what constitutes disclosure in the necessary course of business shall be decided by the General Counsel and/or the Chief Financial Officer.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tipping. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the U.S. federal securities laws, you can be held responsible not only for your own insider trading, but also for securities transactions by anyone to whom you disclose material, nonpublic information. Even if those to whom you disclose such information do not trade while aware of the information, you can be responsible for the trades of persons who received material, nonpublic information indirectly from you, if you are the ultimate source of their information.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discussing or Recommending Longeveron Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We recognize that employee enthusiasm for Longeveron and its business prospects is a vital element of our success. You should, however, use extreme caution when discussing our business or our securities with anyone. In the course of discussing our business or our securities, accidental disclosure of material, nonpublic information can occur and can be viewed as &#x201c;tipping.&#x201d; Likewise, recommendations of our securities can also result in embarrassing situations for you or the Company if you make a recommendation at a time when there is a pending announcement of material, nonpublic information by the Company, even if you are unaware of that information.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chat Rooms and Internet Postings</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. No Director, Officer or Employee may disclose information about Longeveron&#x2019; or its securities on the Internet (regardless of whether such information is material or already public), and, more specifically, in discussion forums or chat rooms where companies and their prospects are discussed. Messages in these forums are typically made by unsophisticated investors who are sometimes poorly informed, and generally are carelessly stated or, in some cases, malicious or manipulative and intended to benefit their own stock positions. In addition, disclosures of material nonpublic</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Longeveron Inc. Statement Of Policy On Insider Trading</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information through this type of forum may amount to a &#x201c;tip&#x201d; or leak of such information, in violation of this Policy and applicable law. Accordingly, no Director, Officer or Employee of Longeveron may discuss the Company or Company-related information in such a forum, regardless of the situation. Despite any inaccuracies that may exist in these forums, postings in these forums can result in the disclosure of information that may be harmful to the Company and expose you to liability for violating U.S. federal securities laws.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees and/or Contracted Employees who encounter a discussion pertaining to the Company in such forums should advise the General Counsel immediately, so the discussion may be monitored.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Authorization to Disclose Material, Nonpublic Information Outside the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We authorize only certain Directors and Officers to make public disclosures of material, nonpublic information or to confer with persons outside the Company regarding such information (for example, our auditors, outside counsel and other advisors). Unless you are authorized to do so by the CEO, the President, the CFO or the General Counsel, you should refrain from discussing material, nonpublic information with anyone not in the Company. Even in discussions with others subject to this Policy, you should consider the consequences of disclosing material, nonpublic information to them. For example, by doing so, you would preclude those persons from trading in Longeveron&#x2019; securities until the information is publicly disclosed. Accordingly, you should restrict the communication of material, nonpublic information to those Directors, Officers or Employees and/or Contracted Employees having a need to know in order to serve Longeveron&#x2019; interests.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sele</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ctive Disclosure. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are SEC rules and regulations banning selective disclosure of information relating to public companies. Generally, these regulations provide that when a public company (such as Longeveron) discloses material, nonpublic information, it must provide broad, non-exclusionary public access to the information (for example, through press releases, conference calls or webcasts). Violations of these regulations can result in enforcement actions, resulting in injunctions and severe monetary penalties. The Company&#x2019;s Disclosure Policy provides that a limited group of senior Officers and Directors are the only Company personnel authorized to communicate information regarding the Company with securities market professionals, shareholders or members of the media. Such persons are aware of the rules and regulations banning selective disclosure and have been trained in how to comply with such rules and regulations. No other Longeveron Directors, Officers or Employees and/or Contracted Employees are authorized to communicate information regarding the Company with securities market professionals, shareholders or members of the media because of the risk that such communications might violate the ban on selective disclosure.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Disclosure Agreements. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors, Officers or Employees and/or Contracted Employees involved in transactions or other negotiations that require disclosure of material, nonpublic information with parties outside Longeveron should generally have those to whom such information is being disclosed sign a non-disclosure agreement. The non-disclosure agreement will require that the recipient of information not disclose the information to others, other than in the necessary course of business, and require the recipient not to trade in Longeveron securities while in possession of such information. You should confer with the General Counsel whenever a non- disclosure agreement may be needed.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information that is likely to affect the price of Securities is almost always material.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Public Information: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information is considered to be nonpublic </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unless</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it has been effectively disclosed to the public by the Company. Examples of effective disclosure include public filings with the SEC, Company press releases, Company meetings with members of the press and the public dissemination of information through Dow Jones &#x201c;broad tape,&#x201d; news wire services, broadcast on widely- available radio or television programs, and publications in widely available newspapers, magazines or news websites. By contrast, information would likely not be considered widely disseminated if it is available only to Company Personnel, or if it is only available to a select group of analysts, brokers or institutional investors. The information must not only be publicly disclosed; there must also be adequate time for the market as a whole to digest the information. Generally, at least one full trading day of general availability may be required for information to be considered public. For example, if the Company were to make an announcement of material information on a Monday at 8:00 a.m. (local time), you should not trade in Company Securities until Tuesday at 8:00 a.m. (local time). Depending on the particular circumstances, the Company may determine that a longer or shorter period should apply to the release of specific material nonpublic information.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Longeveron Inc. Statement Of Policy On Insider Trading</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Prohibited Transactions</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to recent developments and legal changes, the Company has determined that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy engage in certain types of transactions. It therefore is the Company&#x2019;s policy that Company Personnel may not engage in any of the following transactions without first consulting with and obtaining clearance from the Company (which clearance may be denied for any reason): (i) short sales; (ii) publicly-traded options, (iii) hedging transactions (including prepaid variable forwards, equity swaps, collars and exchange funds), (iv) margin accounts and pledged securities; and (v) standing and limit orders (except standing and limit orders under approved Rule 10b5-1 Plans).</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Guidance</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions by Family Members and Others</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy applies to (i) your family members who reside with you, (ii) anyone else who lives in your household, (iii) any family members who do not live in your household but whose transactions in Company Securities are directed by you or are subject to your influence or control ((i), (ii) and (iii) collectively, &#x201c;Family Members&#x201d;), and (iv) any entities that you influence or control, including any corporations, partnerships or trusts. You are responsible for the transactions of these other persons or entities and therefore should make them aware of the need to confer with you before they trade in Company Securities, and you should treat all such transactions for the purposes of this Policy and applicable securities laws as if the transactions were for your own account. However, this Policy does not apply to personal securities transactions of Family Members where the investment decision is made by a third party not controlled by, influenced by or related to you or your Family Members.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions For Which this Policy Does Not Apply</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy does not apply in the case of the following transactions, except as specifically noted (collectively referred to as &#x201c;Excepted Transactions&#x201d;):</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Exercises Where No Sale is Made</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Policy does not apply to the exercise of a stock option acquired pursuant to the Company&#x2019;s plans, or to the exercise of a tax withholding right pursuant to which a person has elected to have the Company withhold shares subject to an option to satisfy tax withholding requirements; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, this Policy does apply to any sale of stock as part of a broker assisted cashless exercise of an option, or any other market sale related to an option exercise, whether for the purpose of generating the cash needed to pay the exercise price of an option, to satisfy tax withholding requirements or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy does not apply to the vesting of restricted stock, or the exercise of a tax withholding right pursuant to which a person has elected to have the Company withhold shares of stock to satisfy tax withholding requirements upon the vesting of any restricted stock; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, this Policy does apply to any market sale or other disposition of restricted stock.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bona Fide Gifts of Securities. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gifts of securities are not transactions subject to this Policy, unless the person making the gift has reason to believe that the recipient intends to sell the Securities while the person making the gift is aware of material, nonpublic information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plans Approved in Accordance with this Policy. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) provides a defense from insider trading liability under Rule 10b-5. In order to be eligible to rely on this defense, a person subject to this Policy must enter into a plan for transactions in Company Securities that meets the requirements of Rule 10b5-1 (a &#x201c;Rule 10b5-1 Plan&#x201d;). Under a Rule 10b5-1 Plan, Company Securities may be purchased or sold without regard to certain insider trading restrictions. To comply with this Policy, a Rule 10b5-1 Plan must be approved by the General Counsel and the Chief Financial Officer and meet the requirements of Rule 10b5-1.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mutual Fund Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Transactions in mutual funds that are invested in Company Securities are also not subject to this Policy.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Longeveron Inc. Statement Of Policy On Insider Trading</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividend Reinvestment. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently the Company does not maintain a Company sponsored dividend reinvestment plan; however, if you choose through your broker or another third party to participate in a non-Company sponsored dividend reinvestment program, then, so long as you enter such a program at a time when you are not aware of material nonpublic information concerning the Company, your participation in such a program and the purchases of Company Securities under the program are not subject to this Policy. Nevertheless, this Policy applies to your sale or other disposition of any Company Securities purchased pursuant to such a program.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Termination Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Because the prohibitions on insider trading are mandated in the law, the restrictions contained in this Policy continue to apply to you even after termination of your service with the Company. You will be solely responsible for complying with these requirements after your service with the Company is over. If an individual is in possession of material, nonpublic information regarding the Company or another company when his or her service terminates, that individual may not trade in Company Securities or securities of such other company until that information has become public or is no longer material in accordance with this Policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Any person subject to Section 16 under the Exchange Act should be aware that acquisitions of Company Securities made through non-Company sponsored dividend reinvestment programs are not exempt from Section 16(b) of the Exchange Act and those acquisitions are potentially matchable with any non-exempt &#x201c;opposite-way&#x201d; disposition transactions within the past six months. As such, Section 16 officers and members of the Board of Directors are strongly discouraged from participating in non-Company sponsored dividend reinvestment programs.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Longeveron Inc. Statement Of Policy On Insider Trading</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:5.6%;font-size:10pt;margin-top:13pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.667%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Provisions of this Policy that Apply to Certain Company Personnel Only</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN ADDITION TO THE GENERAL REQUIREMENTS OF THIS POLICY THAT ARE APPLICABLE TO ALL COMPANY PERSONNEL, THERE ARE SPECIAL ADDITIONAL REQUIREMENTS THAT ARE APPLICABLE TO SPECIFIC GROUPS OF COMPANY PERSONNEL. IF YOU ARE IN ONE OF THE CATEGORIES OF COMPANY PERSONNEL THAT HAVE THESE ADDITIONAL RESTRICTIONS THEN YOU MUST COMPLY WITH THESE ADDITIONAL RESTRICTIONS.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Blackout Periods Which is Applicable Only To &#x201c;Designated&#x201d; Persons</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain employees and advisors routinely possess or have access to material, nonpublic information and those job titles or categories are listed on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Schedule A </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hereto (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designated Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The trading window portion of this Policy applies to transactions by Designated Persons in Company Securities.</font></p>
  <p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-indent:7.2pt;border-left:0.5pt solid;padding-right:0.01in;"><p style="margin-left:1.333%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As more fully described below, Designated Persons are prohibited from engaging in transactions involving Company Securities during the Blackout Period. The &#x201c;Blackout Period&#x201d; means (i) the period commencing on the calendar day marking the end of any fiscal quarter (including the end of the fiscal year) and ending two full trading days after the Company&#x2019;s earnings release has been made public for that period and (ii) any other period deemed a &#x201c;Blackout Period&#x201d; that is event driven, as described below.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of illustration only, if the Company&#x2019;s fiscal quarter ended on September 30 (i.e. the last day of the fiscal quarter is September 30, and the next quarter started October 1), the Blackout Period would be in effect starting at 12:01 a.m. on September 30 and would end two full trading day following the Company&#x2019;s earnings release for that quarter.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the quarterly Blackout Periods set forth above, from time to time an event may occur that is material to the Company and is known by only select directors, officers or employees. In that situation, the Chief Executive Officer, Chief Financial Officer, General Counsel or their designees will notify these select persons that they should not trade in Company Securities; provided, however, that if you are not specifically notified by the Company of an event-specific Blackout Period, but nevertheless are in possession of material, nonpublic information, you should refrain from trading until such information becomes public in accordance with Part I of this Policy. The existence of an event-specific Blackout Period generally will not be announced to the Company as a whole and should not be communicated to any other person. The appropriate officers of the Company or their designees will provide additional notification when such event-specific Blackout Period is lifted.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These prohibitions shall not apply to any Excepted Transactions (as defined in Part I of this Policy); however, the prohibition on engaging in transactions in Company Securities </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extend</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to and shall preclude any such Designated Persons from engaging in transactions other than Excepted Transactions.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance Policy Applicable To Designated Persons</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Personnel who are Designated Persons are also required to pre-clear any trades in Company Securities. (See Pre- Clearance Request Form on the last page).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#d9d9d9;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-indent:7.2pt;border-left:0.5pt solid;padding-right:0.01in;"><p style="margin-left:1.333%;text-indent:0;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;margin-right:1.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Designated Persons are required to (i) provide the Company written notice of any proposed transaction in Company Securities and (ii) receive clearance prior to entering into that proposed transaction, in each case as set forth below.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Longeveron Inc. Statement Of Policy On Insider Trading</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To prevent inadvertent violations of this Policy and to avoid even the appearance of an improper transaction (which could result, for example, where a Designated Person engages in a transaction while unaware of a pending major development), any Designated Person who proposes to undertake a transaction in Company Securities, which includes any acquisition, disposition or other transfer for value, whether through the Company&#x2019;s stock plan administrator or another broker (other than Excepted Transactions), must obtain pre-clearance through the following process:</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Step One</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Provide a written request for clearance to transact in Longeveron securities, which request must provide all relevant information needed for the Company to assess said request.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Step Two</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Email the request to the Chief Financial Officer or General Counsel.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Step Three</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Approval for your request will be solicited from the Company&#x2019;s Chief Executive Officer, Chief Financial Officer or General Counsel. Notice of approval (or denial if applicable) will be communicated back to you via email.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Step Four</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: If approved, unless otherwise determined by the General Counsel&#x2019;s office, you will have until the earlier of (i) five (5) trading days from the date of approval (inclusive of the date you receive approval) and (ii) the commencement of a Blackout Period (the &#x201c;Open Period&#x201d;) to conduct your transaction(s). After the Open Period expires, you must repeat the pre-clearance process (as outlined above) prior to conducting any further transactions. Any sell/buy orders that are outstanding as of the end of the Open Period must be cancelled unless you have requested and received approval for an additional Open Period in accordance with the procedures herein.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When a request for pre-clearance is made, the Designated Person should carefully consider whether he or she may be aware of any material, nonpublic information about the Company, as further discussed in this Policy, and should fully describe those circumstances in his or her request. If the Designated Person is subject to Section 16 under the Exchange Act, the Designated Person should also determine whether he or she has effected any non-exempt &#x201c;opposite-way&#x201d; transactions within the past six months, and should be prepared to review any Form 4 or Form 5 that will be required to be filed in connection with such transaction. The requestor should also be prepared to comply with SEC Rule 144 and file Form 144, if necessary, at the time of any sale.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even though gifts of securities are not transactions subject to the Policy generally, as a best practice we encourage Designated Persons to provide prior notice of any gift transaction to the Chief Financial Officer and General Counsel. The Company makes this request because in some circumstances where a donor knows that a charitable gift recipient (usually a charitable organization) will typically sell the donated stock soon after the gift is made, any such sale that is made while the donor is aware of material non-public information could result in potential claims of conflict of interest and the appearance of impropriety.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In all cases, the ultimate responsibility for adhering to this Policy rests with you. Any action on part of the Company, the Company&#x2019;s Chief Executive Officer, Chief Financial Officer or General Counsel or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your failure to observe this Policy could lead to significant legal problems, as well as having other serious consequences, including termination of your employment.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy Effective: February 12, 2021</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended Effective: February 27, 2025</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dfsfsd</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img51003162_1.jpg" alt="img51003162_1.jpg" style="width:320px;height:59px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement Of Policy On Insider Trading</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Effective As Of February 12, 2021;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revised As of February 27, 2025)</font></p>
  <p style="font-size:10pt;margin-top:2.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Designated Persons)</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Members of the Board of Directors</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO, CFO, CSO, General Counsel</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Employees</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any other individual who may from time to time be designated as a Designated Person by the Chief Executive Officer or the General Counsel of the Company</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Longeveron Inc. Statement Of Policy On Insider Trading</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Effective As Of February 12, 2021;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revised As of February 27, 2025)</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img51003162_2.jpg" alt="img51003162_2.jpg" style="width:320px;height:59px;"></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRE-CLEARANCE REQUEST FORM</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14%;box-sizing:content-box;"></td>
    <td style="width:86%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Longeveron, Inc. (the &#x201c;Company&#x201d;)</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">General Counsel and Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">From:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Re:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proposed transaction in the Company&#x2019;s Securities</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0.3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This is to advise you that the undersigned intends to execute a transaction in the Company&#x2019;s securities on ___________ _____, 20 _____ AND THEREAFTER UNTIL THE TRADING WINDOW SHALL CLOSE AND DOES HEREBY REQUEST THAT THE Company pre-clear the transaction as required by the Company&#x2019;s Insider Trading Policy (the &#x201c;Policy&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general nature of the transaction is as follows (i.e. open market purchase of 10,000 shares of common stock through NASDAQ, privately negotiated sale of warrants for the purchase of 5,000 shares of common stock, etc.):</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:33.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:33.333%;text-align:left;"><font style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned is not in possession of Material Nonpublic Information (as defined in the Insider Trading Policy) about the Company and will not enter into the transaction if the undersigned comes into possession of Material Nonpublic Information about the Company between the date hereof and the proposed trade execution date.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned has read and understands the Policy and certifies that the above proposed transaction will not violate the Policy.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned agrees to advise the Company promptly if, as a result of future developments, any of the foregoing information becomes inaccurate or incomplete in any respect. The undersigned understands that the Company may require additional information about the transaction and agrees to provide such information upon request.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"></td>
    <td style="width:20%;box-sizing:content-box;"></td>
    <td style="width:74%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Very truly yours,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:6%;box-sizing:content-box;"></td>
    <td style="width:44%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[Signature]</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[Print Name]</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52%;box-sizing:content-box;"></td>
    <td style="width:48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">A</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">PPROVED</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-style:italic;font-kerning:none;min-width:fit-content;">PPROVED</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">:</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">General Counsel</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>lgvn-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Independent Registered Public Accounting Firm&#x2019;s Consent</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the Registration Statement of Longeveron Inc. on Forms S-1 File Nos. 333-252234, 333-253029, 333-261667, 333-272946, 333-275578, 333-278073, 333-276745, 333-278995, 333-280577, and 333-281299, S-3 File No. 333-264142 and S-8 File Nos. 333-253141, 333-272938, and 333-280747 of our report dated February 28, 2025, which includes an explanatory paragraph as to the Company&#x2019;s ability to continue as a going concern, with respect to our audits of the financial statements of Longeveron Inc as of December 31, 2024 and 2023 and for the years ended December 31, 2024 and 2023, which report is included in this Annual Report on Form 10-K of Longeveron Inc. for the year ended December 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Marcum LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hartford, CT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 28, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>lgvn-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 13a-14(a)/15(d)-14(a) Certifications</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Wa&#x2019;el Hashad, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this annual report on Form 10-K of Longeveron Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant &#x2018;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60%;box-sizing:content-box;"></td>
    <td style="width:40%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 28, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Wa&#x2019;el Hashad</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wa&#x2019;el Hashad<br>Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>lgvn-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 13a-14(a)/15(d)-14(a) Certifications</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Lisa A. Locklear, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this annual report on Form 10-K of Longeveron Inc.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant &#x2018;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60%;box-sizing:content-box;"></td>
    <td style="width:40%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 28, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Lisa A. Locklear</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa A. Locklear<br>Executive Vice President and Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>lgvn-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO U.S.C. SECTION 1350</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSANT TO SECTION 206 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Longeveron Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Wa&#x2019;el Hashad, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60%;box-sizing:content-box;"></td>
    <td style="width:40%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 28, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Wa&#x2019;el Hashad</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wa&#x2019;el Hashad<br>Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>lgvn-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO U.S.C. SECTION 1350</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSANT TO SECTION 206 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Longeveron Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Lisa A. Locklear, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60%;box-sizing:content-box;"></td>
    <td style="width:40%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 28, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Lisa A. Locklear</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lisa A. Locklear<br>Executive Vice President and<br>Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img51003162_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img51003162_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ 4 # 2(  A$! Q$!_\0
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MK+DA^?Y:'+F7$%+!5?J]&'//MT7EUN_)'Z^6_P 8/ EU,(8?&GA^64\!%U.
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M .O]?_1E?N*.E>YQ1_RX_P"WOT/G>$?^7_\ V[^IQ_QB\7R> ?A5XL\0P?\
M'QIVFSSP_P#70(=G_CV*_'KX;>$+GXI?$S0O#WGL)M8OXX9;ACN90S?.YSU(
M&3^%?KC^T5H5QXE^!7CK3K12]S+I-PT:#JS*I<*/KMQ^-?E%\ ?&-K\/_C3X
M0UZ_8)8V>HQFX<_P1L=KM^"L3^%:\.WCA*\Z?Q_\#3\3/B>TL;AX5?@_X.OX
M6/V)\'^$-(\!^&['0M#LH[#3+*,1Q0QC'3J2>['J2>2236O)&DT;1R*'1@59
M6&00>H(I(I4GB22-UDC<!E=3D,#T(-/KX*4G)N4GJ?HT8QC%1BK)'Y0?MO\
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MW$W[=GQ/_P"%B?'6_L;:7S--\/I_9D(4Y4R*<S-]=Y*_1!7VY^Q-\*O^%8?
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M'][",I/?Y?2N0_8"\:W%O;_$KPH\K&TNM#FU&.,]%DC78Q'N5D&?]P>E>O\
M_!2OQO9Z?\-=!\+"5&U'4=0%X8L_,L,2,NXCMEG 'KAO2O"/V"-!GN_$GQ!U
M8 _9K+PQ<PNV.-\A7:/RC?\ *ON\,Y5,D?MNFWR:M^.A^=XJ,:6?KV'7>W=Q
M=_PU/GOX?:+:^(_B#X;TF]#&SO\ 4[:TF"'#;))51L'L<$UT'Q6^'NM_L_\
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03$RJ8:45%ZV=].^R>A__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img51003162_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img51003162_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ 4 # 2(  A$! Q$!_\0
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MK+DA^?Y:'+F7$%+!5?J]&'//MT7EUN_)'Z^6_P 8/ EU,(8?&GA^64\!%U.
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M .O]?_1E?N*.E>YQ1_RX_P"WOT/G>$?^7_\ V[^IQ_QB\7R> ?A5XL\0P?\
M'QIVFSSP_P#70(=G_CV*_'KX;>$+GXI?$S0O#WGL)M8OXX9;ACN90S?.YSU(
M&3^%?KC^T5H5QXE^!7CK3K12]S+I-PT:#JS*I<*/KMQ^-?E%\ ?&-K\/_C3X
M0UZ_8)8V>HQFX<_P1L=KM^"L3^%:\.WCA*\Z?Q_\#3\3/B>TL;AX5?@_X.OX
M6/V)\'^$-(\!^&['0M#LH[#3+*,1Q0QC'3J2>['J2>2236O)&DT;1R*'1@59
M6&00>H(I(I4GB22-UDC<!E=3D,#T(-/KX*4G)N4GJ?HT8QC%1BK)'Y0?MO\
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MW$W[=GQ/_P"%B?'6_L;:7S--\/I_9D(4Y4R*<S-]=Y*_1!7VY^Q-\*O^%8?
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M'][",I/?Y?2N0_8"\:W%O;_$KPH\K&TNM#FU&.,]%DC78Q'N5D&?]P>E>O\
M_!2OQO9Z?\-=!\+"5&U'4=0%X8L_,L,2,NXCMEG 'KAO2O"/V"-!GN_$GQ!U
M8 _9K+PQ<PNV.-\A7:/RC?\ *ON\,Y5,D?MNFWR:M^.A^=XJ,:6?KV'7>W=Q
M=_PU/GOX?:+:^(_B#X;TF]#&SO\ 4[:TF"'#;))51L'L<$UT'Q6^'NM_L_\
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03$RJ8:45%ZV=].^R>A__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img51003162_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img51003162_2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ 4 # 2(  A$! Q$!_\0
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MK+DA^?Y:'+F7$%+!5?J]&'//MT7EUN_)'Z^6_P 8/ EU,(8?&GA^64\!%U.
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M .O]?_1E?N*.E>YQ1_RX_P"WOT/G>$?^7_\ V[^IQ_QB\7R> ?A5XL\0P?\
M'QIVFSSP_P#70(=G_CV*_'KX;>$+GXI?$S0O#WGL)M8OXX9;ACN90S?.YSU(
M&3^%?KC^T5H5QXE^!7CK3K12]S+I-PT:#JS*I<*/KMQ^-?E%\ ?&-K\/_C3X
M0UZ_8)8V>HQFX<_P1L=KM^"L3^%:\.WCA*\Z?Q_\#3\3/B>TL;AX5?@_X.OX
M6/V)\'^$-(\!^&['0M#LH[#3+*,1Q0QC'3J2>['J2>2236O)&DT;1R*'1@59
M6&00>H(I(I4GB22-UDC<!E=3D,#T(-/KX*4G)N4GJ?HT8QC%1BK)'Y0?MO\
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MW$W[=GQ/_P"%B?'6_L;:7S--\/I_9D(4Y4R*<S-]=Y*_1!7VY^Q-\*O^%8?
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M'][",I/?Y?2N0_8"\:W%O;_$KPH\K&TNM#FU&.,]%DC78Q'N5D&?]P>E>O\
M_!2OQO9Z?\-=!\+"5&U'4=0%X8L_,L,2,NXCMEG 'KAO2O"/V"-!GN_$GQ!U
M8 _9K+PQ<PNV.-\A7:/RC?\ *ON\,Y5,D?MNFWR:M^.A^=XJ,:6?KV'7>W=Q
M=_PU/GOX?:+:^(_B#X;TF]#&SO\ 4[:TF"'#;))51L'L<$UT'Q6^'NM_L_\
MQ9O=&>:6"\TNY6XL+Y/E,D>=T,RGL< 'V(([5F?"'_DKG@O_ +#EE_Z4)7Z-
M_MS? '_A;'PZ/B#2K;S/$WA^-IHP@^:XMNLD7N1]]1ZA@/O5[6,QZPF,I4JG
MP337H[Z/]&>#@<N>-P-6K3^.#37FK:K]5_P3T7]FOXV6OQV^%]AKH9$U>'_1
M=3MEX\NX4#) [*PPP]CCJ#7Y%>-?^1PUS_K]F_\ 0S7K/[(?QX?X'?%*WDO9
MF7PUJQ6TU-"?E1<_)-]4)S_NEAWKR3QC*DWBW6I(G66-KR9E=#E6&\X(/I6.
M79?]0Q5917N2LU^.GR_*QOFF9?VC@Z#D_?C=/\+/Y_G<AN+Q]/\ $,EU&%,D
M-R9%#="0V1FOJ+_AY7\3/^@-X8_\!)__ (_7U--^QQ\'I9G=_!D99F))^WW7
M7/\ UUIG_#&GP<_Z$R/_ ,#[K_X[7E5\XRW$V]O2<K;72_S/8P^29KA.;ZO6
MC&^]F_\ Y$^=/"/_  4J\6MXCL4\4:#HLV@/($O!I\$J3B,\$J6E921UP1SC
M&1G->7?M,? $^!]17QIX1_XF_P -]=/VK3]0M 62VWG/DOC[N#D#/4#'W@0/
MMS_AC3X.?]"9'_X'W7_QVO3OAM\+/"W@/PY?^'M%TE8-#G??)87$TES"2PPW
MRRLV <#('!KB6;8/"357!4W'HUI9K[W9KH=_]C8[&P=''5%+K&6K:?W*Z?57
M/SL^"G[=/C?X1Z)!H5W;V_BC1;90EO%?.R30*.B+(,_*.P8''08'%=?X[_X*
M3>,M?TB:R\/:#8>&IY5*F],K7,J CJF0J@^Y!KO?VL_V>/AWX2M3J.C>&+?3
M+J8;F^S32I'G)Z1[]J_@!7EW[,'P6\&>/_$L=OK^BKJ$.\?(;B9._P#L.*]5
M/*Z]-XZ5'S?_  U['CN.;X>JLOC7\EZ>MKH\6^%?PF\6_M!>.QI^EQS7ES<2
M^=?ZI<[FC@5CEI97]>IQG+'IDU][?M7> ]-^&/[%]UX7TE2+'3390JS##2-]
MH0L[>[,68^YKZ/\ "7@O0? >D1Z7X>TFTT:P3D06D00$^IQRQ]SDU2^)'@?0
M_B+X2NM#\16 U+2IV1Y+=I'C#%6#*<H0>" >M?/8G.WBL32GRVIP:=NNG]:'
MTV$R%8/"5H<UZDXM7Z*_3OZOJ?G!_P $[O\ DXF'_L%W7_LM?ICXJ\,:=XT\
M-ZEH6KVZW6FZA UO/$W=6&./0CJ#V(!KS7X8?L[?#SX9^*%UGPUX<33-3$+Q
M"<74\GRMC(P[L.WI7K]<6;8Z&,Q2KT;JR6^]UZ'?DV7SP.$>'K6=V]MK.W=(
M_%?XV_"?4O@M\1]5\+Z@&<6[[[6Y(P+B!N8Y!]1U'8@CM78_L7?\G.>!?^OB
M?_TFEK]+?BY\$/ _Q8GTZY\5Z!%JUQ:*T<,IFEB95/)7,;*2,\X.<9..IKG/
M ?[,7PR\"^+M.UW0O"Z6&JV;,T%P+RX<H2I4\-(0>&(Y'>OHI<04JV#E3J1?
M.XM:6M>UK[_H?,1X:K4,=&K2DN1235[WM>]MOU/G_P#;U_9>U'5]4E^)/A6R
M>\+Q :S96ZYD!48%PJCDC: &QTV@]V(^:O@3^U%XS^ ,LL&CRQ7^BSOYDVDW
MP+0EL8+(004; '(.#@9!P*_8*OFO]I;]G;X<:CH-WXAD\)V4.L$EFN;1GM]Y
MP>66-E5C[D$UQ9=F].5)8+&0YH[+]+^G1G?F>25(5I8_ U.26[7YVMWZIGAE
M]_P4]UR2R9;3P-I\%V5XEFO9)$!]=H52?^^J^1_B%X\U7XH>-=4\4:SY)U/4
M9!)-]GCV("%"@*O.  H%>@^$/ &@ZIXM%E=6 EMO-V[/-D'&?4-FOT.^#?[-
M7PQ\,:99ZM8^#K ZC]X7%WONF4^J^:S!3[C%>Y4Q& R7WJ5)\S_K=MGS]+#9
MEGON5JRY8]_\DE<^/OVO$:/X"_L_JZLC#1&RK#!'[JV[5YC\"?VIO%7[/NF:
MK8^'K'2;N+494FE.HPR.P*@@;=LB\<GKFOTY^+OP9\&_%D:6/%>BIJPL?,%M
MNGEB\O?MW?ZMESG:O7TKSG_AC3X.?]"9'_X'W7_QVO+PV<8/ZJJ&(IMZMM:6
MUDWW1ZV*R3'?7'B,+44;))/6^D4NS/ES_AY7\3/^@-X8_P# 2?\ ^/U](?L;
M?M.>*/VA;_Q3#XBLM*M$TN*W>$Z=%(A8R&0-NWNW]P8QCO6G_P ,:?!S_H3(
M_P#P/NO_ ([7H7PB^"G@OX2W&IR^$]$72)+Y8UN&6XEEWA2Q4?O';&-QZ>M<
M&-Q>65,/*.'HN,^CLN_J>C@,'FU+$PGB:ZE!7NKOMZ+J=_J^E6NNZ5>Z;>Q"
M>SO(7MYXFZ.CJ58?B":_%+XJ^ [KX8_$7Q!X7N\F73;MX5<_\M(\Y1_^!*5;
M\:_;BO'_ (G_ +.?PZ^)/BAM;\1^&HM1U22%(WN/M,\18+PN0CJ#@<9QG@5S
MY+F<<OJ251-QDNG=?TSJSW*99G3@Z32E%]>S]+^1XA_P3;^%7]C>#=8\=WD.
M+G5Y/L5DS#D6\9^=A[-)Q_VRK[/K)\)^&M,\'^&M.T71K1+'3+*%8K>W0DA%
M';)))]<DDFM:O+QV*>,Q,Z[ZO3TZ'KY=A%@<+##KHM?7K^)^-_[4?'[0WC__
M +"\_P#Z%7IGA+_@H/\ $/P=X6TC0;+2?#LEIIEI%9PO-:S%V2- JEB)@"<#
MG %?9_B_]E;X6>+?$^IZSJWA2.[U*]G:>XG-[<IO=CDG"R #\!61_P ,:?!S
M_H3(_P#P/NO_ ([7V#S?+ZU&G2Q%)RY4NB[>I\.LES.A7J5<-5C'F;ZO:]_Y
M3Y<_X>5_$S_H#>&/_ 2?_P"/UV/[9'C>^^)'[*GPN\3:G%!#?ZG?"XFCME*Q
MJQAE'R@DD#CN37N7_#&GP<_Z$R/_ ,#[K_X[7<>)_@/X$\3?#W0/"VI: ESH
M.DL&LK,W,RB$X8?>5PQX8]2>M<4LPRZG6I5</2<>5W>BVL_,[X9=FE2A6I8F
MLI<T;+5Z.Z\CY)_X)A?\C?XX_P"O"W_]&-6S_P %'_@G_P @_P")6EP==MAJ
MP0=^D,I_] )_ZYU]1_"/X(>"/A-?ZA<^%-#729[R)8YW6XFEWJ"2!^\=L<^E
M=OXM\-:9XQ\-:CHNLV:7^EWL+13V\A(#K]000<@$$$$$9%<E7-DLS^NTD^71
M-/>UDG_P#MI9-*64_4:S7-JTULG=M=/O/S__ .">?Q\_X1GQ)+\.M9N=NF:M
M(9=,>0\0W6.8_82 #'^T!W8UU'[>G[+NHZKJLWQ)\*V3WGF1@:S90+EU*C N
M%4<D;0 V.FT'N2/:+7]D'X1Z?<PW5MX16"YA<21RQZA=AD8'((/F\$$5]"Q_
MZM>_ ZU>(S2G3QJQN$35_B3MK]S>_P":N9X;**M7 / XV2:7PM7NOO2V_)V/
MQ_\ @1^U'XS^ ,LMOI$L5_HL[^9-I-\"T);&"Z$$%&QCD'!P,@X%>[:M_P %
M.O$,^G/'IW@K3;.]92%GGNY)D4^NP*N?^^J]W_:7_9V^'&HZ!>>(9/"=E#K!
M)9KFT9[?><=66-E5C[D$U\3_  Q^&WASQ!XYCT_4--%Q9F3:8_.D7CZA@:^A
MIU,MS*+Q52CJM_Z35_F?-5:>:95)82G7]U[?TT[?(\_UO6_&GQ_^(7VJZ-WX
MD\2ZG((XXH4R<?PHBCA47T& !DGN:_2OX&? -?@%\ -<TZZ:.;Q!J%E/=:G-
M$<J'\E@L2GNJ#C/<ECWKTCX7?!_P9\+M+C'A;P]9Z0\\2^;/&I>:3C.&D<EB
M/8G%=EJ-G#J&GW-K<)YEO/$T4B9(W*P((X]C7SF99S];4:%&/+35OG;\$O(^
MHRO(_J;EB*\^>K)/7HK[[ZMON?BG\(?^2N>"_P#L.67_ *4)7[:5X!H?[)'P
MFT;6]/U&S\(QPWMI<1W$,OVZY.R16#*<&4@X(!YKW^L\ZS"EF$X2I)JR>]OT
M;-,ARRMEM.I&JT^9K:_ZI'Y6_MO? $_"#XD-K&E6WE^%]?=KBW"#Y;>;.9(?
M89.Y?8X'W37S=7[<?$SX>>'?B;X6ET;Q/I<>K:=YBS"&1F0JZGA@RD,#R1P>
MA(Z&O'O^&-/@Y_T)D?\ X'W7_P =KW,#Q%3IX>,,1%N2TNK:]MVM3Y_,.&*M
03$RJ8:45%ZV=].^R>A__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img156238889_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img156238889_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" != ;$# 2(  A$! Q$!_\0
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M-$',MA<#:^?7:X4K[FOHHUQOQ@^']O\ %#X9^(_#%QMQJ-F\4;MT24?-&_\
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M'Z U^-L\UUK.HO+,\EW>7,I9W)W/(['D^Y)-?II_P45EEB_9]*QDA)-7M5D
M[KMD/\PM? '[/MM:7OQP\!P7JJ]J^M6@=6Z-^]7 /XXKZOAZ,:."J8C=W?\
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M^;S[%QQ%;#XE+1Q3M_V\S]JD^$G@H#_D5M)S_P!>B?X4\_"7P61@^%M)'O\
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M>'X9J*HG7FN5=KZ_@>QB>*J;I-8>#YGWZ%'7=:NO$NNW^JWK^9>WUQ)<SO\
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=BHG.527--W?F:0A"G'E@K+L@HHHJ"PHHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img237815897_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img237815897_0.jpg
M_]C_X  02D9)1@ ! @$"6 )8  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M P,# P,# P,# P,# P,# P,# P,#_\  $0@#C! B P$1  (1 0,1 ?_$ /T
M 0 ! P4! 0             '!@@+ P0%"0H" 0$! 0$!  (# 0$
M  $" P0(!@<)!0H0   % P(# P4)"0L'!P<!&0 " P0% 08'$0@2$Q0A%0DQ
M%M:76$$B51=7&!D*&E$R(]/4E9;7F&$S4S0EU;9WMW@Y<5(D-38W.(%"8K,F
M=KB1<D5EM:C8@U169H8GB%E$9,A):7FI.H)#A.>96NBYV2H1 0 ! @(##@0$
M P0(! 8 !P !$0(#!!)4!2$QT9+24Y/3E!46!Q<805%2!F&A(E4RHA-Q0G,(
M@;%B<K(4-#4CLW4V\)'!,T,D@F/Q">'"1/_:  P# 0 "$0,1 #\ ]_
M
M
M
M
M
M
M
M
M
M
M
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M^.%;B06EI%=99*:H5YR42J2#-X4M:&/U/O4VU2]E?*;[@FE&E7X+3<HI3%V
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M;H2<M(R"+<Q)7B02>O%G*:)N!2A-4B*4+73L[.P6+X^1HI?S5BF;R=YM=S7
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M;F1S!HJK^"+2FAS&I[OE'2^(B(HS;,SOKL!S:
M
M                                     6GV]DN]GVXB4L5U-<VU6SN:
M31B^[8DG 1I$J.FY>N38$D3<M<M#:U6K6ODKK3L'28C0K\6:SI4^"[ <V@
M %I^Y/)=[6 ^M-&TIKNE.3:RZCXO=L2_YYVJS J!M9-@\,GP%7-V$J6E=>W7
M2@Z66Q.^S=,QO+L!S:
M                                      6GV7DN]I;/MRV5(3746S'N
M[E3:1G=L2ER21ZG"T+UJ#!.04Y-/=,J:IO\ G:CI,1H5^+,3-:+L!S:    6
MG[@<EWM9%TV?'6O-=V,I5H91^CW;$O>>>DBFA0W,D6#M5+\$:M-"&+3W?*.E
MD1,35FZ9C>78#FT
M
M
M                                     "V[<A?UVV#"6T[M.6[I<2$H
M[;.U.@C7W-12:%5(3@DF;PB?">NNI:%K7[HW9$3.ZS=-(W$Y6H]=25KVW(O5
M><\D("'>NUN!-/FNG4<V775Y:1$TD^8JI6O"4I2TUTI2E!F=]J-YSX@  "T]
MYDN]DMR9+ 3FN&TJNF*=8GNV)K[Q:S6\JH7KS,*R?OGYZJ:\[6FO#3WO8.FC
M&A7XLUG2I\%V YM
M
M               -J^4.BQ>+)FX5$FKA1,VE*\)R(G,0VAJ5+70U/)6E:! M
MDVTY'O/('GKYW3/>W=/FYW?_ "=%,.GZ_O[J_P#5C%ES>;T27W_%P\/9IK77
MI?$12C-LS.^NE'-H   !:?;V2[V?;B)2Q74US;5;.YI-&+[MB2<!&D2HZ;EZ
MY-@21-RURT-K5:M:^2NM.P=)B-"OQ9K.E3X+L!S:
M
M                                        6GYQR7>UGY#LN"MR:[NB
MI9I'*2#7NV)=]0=><79JFY[Y@Z<I<;8E"Z$.6E--:=O:.EL1,3,LS,U78#FT
M  ""L4W7BNX)NX&M@VWW)*,T"GEW'<[*-ZI*KLR="\YLY6.OHXI4VAJ4^Z-7
M1=$;N\D3'P3J,J                              #82LBWAXR1EW:;]9
MI%,'DBY2BHJ3G9-5NQ;J.5DXZ$A&<A,S#\Z:5:(M6C==TX4K1-),ZABEJ'43
MF[QYO#&VS.(5GN0ROGG;Z[N-%5S;S7-VP?Q!<4.)YNB=1)9>%0OS:W JRB*2
MJ1BF.A10I3%K2M=:5 0-]J.\"CVYO_=FWA__  ^@);PY]8/\)_<3<JME[?L]
M9;SI>*+11^M:>'-CV_7)URI,4DUEE7BL%9.V2;E$VB23=0QE*I4(4I#5K72E
M= [=+!O>&R39MO7U;S*[XZ$N>.3E(UC?V/K]Q3>39LJ8Y"I7#CK*-M6=D&T9
M&E25XF<M%LG9*:5,G2E:5J%7@        .L+=/XQ>P+9),/8C=9D/-&$46MP
M/;7;75>&R_>R7&UQ3<<1%1XULC*\9MWD<99 123<$-1Q!RT@V.4U*E4K2H"S
M[[4=X%'MS?\ NS;P_P#X?0'>/C+(]F9BQOC[+N.)GSBQYE.R+4R/8=P=W2L1
MW[9E\0+"YK7F>Z9UC%SD7WI!RB"_3O&S=VAQ\"R2:A3$H%ON]??/MC\/3"$E
MN"W6Y(:8ZQZSDVEO1=21\A.W)=]V22#MS%VC9ML0[=W+7!<#]!BLKRTDZ(MV
MR*KERH@V156('5'L#^LU^&?XA6<(/;M83K-F$LJWDM5ACN%W%V79EIQV19W@
M*HE;%K7#8.2<FP2=R/4^/I&<DXCU'RJ?);<U<Z22@>A4
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MM]]RCQ QXAQW.RDNE2H[*G4O.<N43H:N*T-H6E?NC5L73&YO),Q\4ZC*@
M
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MC:7!*W$:WSLGI2:R[*(?46*:E6W#H<P=D8
M                                                        AC,U
MT8]M>,A5\A6RM<S-T^<(QR",;&R56KDC>AU53$DGS$B5#I=FI:FK7[@U;$S.
MXDTC?2C N6+R"A7<6WJTC743'.8YH9--(S5BNS15:-S))'422JBW,4M2E,8I
M=-*5K3M&5<L   " W-XXO)F@MK+6@N?(=5VI*7/W3$F1HJI;B+Y _>9I&DE^
M#B#%0UY&M*TX:>]]\-TNT:UW$K%:?%/@PH
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MQ\K866(:.26*BI+^8UV-(R3GK?1,JC163B.\8UNHX225<)KGY0#LG
M                                  :#HZ2;9P=<O&@1!4ZQ-*&XTBIF
MJH7AKI0W$2E::>Z AC#=T8PN7SC^+>W>X.B[H[Y_DAG%=7U/>G=W\4<+\_D<
MA?[[3AX^S76HU=%T?Q)$Q.\FX94   !!43=>*W&6GMO1]M\C(*2\B1U.=SLD
MN8JBP.L]-WF5R9T?FM*5+K4GOO)7L&J7:-?@E8K^*=1E0
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MJ3E!-_'++$;R,<Y(9!XT6Y;IDY3.BNFFJ0Y"A*(
M                   ""LEW7BN#NVW(^]K;[WN!Z@S/#/NYV4ATB2DFJ@W+
MU+ARDJARWI3'T*6NFNOE&K8NIN;R3,5_%.HRH  +>\/89D\:3]R3#Z:82:<X
MW*BDBT;N$CH5H].ZXE#+5X34X3:=GNC=UU8HD11<(,*
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MOWEQE:QD<\HE)H))NE'"*)5D>,/8R
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M),57"#"@
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MBLHN9>L6A55:TI552B"!>(U?OJ]H#*9?4^?\'N._O,YO_P"JLT!ZEP
M                 >?#?(X^L5Y^Q[=;78_8^R_9/#HM[@*T+D[,TGE;=M>#
M9FQI6.;VNM#X@N;;%C-[<?-503(ZEY99!Q1%6DM'E(<YPQ/6?<GYYRWE>\+K
MW+7[DK(V94Y>1A+SG<M7)/W/>S65AY%XV?04D]N-V\D618:1YR16=*D2:UH8
MA"$I30!D,?J1O_!OO,_O,VU_99!@/;&
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ML#J&:6WE&S)>0LO(T2S(OHZ2BO.R!=.(ZBOX0\:NW4K4U#T-4.P,
M                               &W=HU<-7+<IJ%JNW61H:O;0M54S$H
M:M*=M:4J8!!>#\/R6*/.?O&88RW?_<O)Z)!PCT_=?>W,YG/K[[F]XETT\G#7
M4;NNTDB*)\&%    6]PV&9.,S,_R>I-,%6#QQ*+%BR-W%'9*/XX[(A3+5KR:
MU3.;BK]V@W-WZ=%*;M5P@PH
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MUEZ)F615^"JO02+<R9UD:5H119L@<VM4BZ!C2MN7_$+@?^N;%_\ 3># 9Y(
M                      '1'XB-M[O_ !#,]/O#3V^75DC:GM>MVR("\]]V
M[^(@I&&NJ];;R"D^I:.U[;/-2*+1C,35UQ,<Y<7C--3+Q\9'K)LG!U#U=1,@
M$(_9-?!1^++S"^(3)OG5W=T7QU_.$R_\9O4]=U??'=7G1\37>/(_T;A\TNDY
M';R.=^% 8\7QHO"DO?PC]WCW!<C<;O(6)+YM]/(^!,G/&"$=(W183R0=QCF&
MNAHR.I'-+YLF:9*L)(J%2).DJ-I B+9)\DV2#N+^IU[S<N8U\0.4V9I7!)R>
M"]Q^/;^N9]9+MTLO#6UE'&EMUNR*O^#:JK\F*DY.UX-Y$2-4"4[P24:57H?H
MFU4@R?(                                        "WO*N&9/(5Y6Q
M<[.:81Z$"W9(K-7+=PJLXJUE5I QDSI5X"T,13AIK[M!NVZD428K-5P@PH
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MZ;,E-'B45,]"K5G(M#NXQT9-1--P99%9-,,4( SC?AF?X;WA]_W(MJ/]@]A
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MXG;XOG<8:_+6A/BDSGD+O2U*XSL>WZ2O>6+,97Q$,OY7AW*/(<.$7/X/CY?
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MLV6WOR:7HQ+'Q%NW78]]Y*LE&7FG+RK=@RD9)@\>ND3(HI'440*L'H5
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M6*<2R*!V1ZN"QZSQ-(QN]$Z:K4;&H2M>#_.]P=+*4EFY>H.;0
M
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M4 >][ZD;_P &^\S^\S;7]ED& ]L8
M                                                  M0W7-YAQ;]
MITB$))=0LR]JM2-2=*G*2K(M"U5HU*8U"5-Y->S4=,.E=UF[>7%6654MG6F5
M<JA5BVU!%6*K0U%2JTBVM%"J4/[^BE#ZZTKVZ^48G?6-Y4HB@  LK?M9VN[(
MC@K>6K#];'5YY47G=O#2PVI#?A:%Z72CC6E>W[_L\HZ;G]/\6?[R]0<V@
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M<$;;9E3=I3][P< A(IUI6NB+TA:Z&I6E ]$
M               -E(U-2/?U+K0U&3JI:EUXJ&Y!].'3MUU\@1OBT3:4YFW'
MQ@=\.)5?@\U>F[S5=J\/%YR<[D=48W#Q<)>+A\NE-?<'3$IN49M7D#FT
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M)QKB62:'9157)&*SQ-N8U;B<E/5<K<U$S5JG2E*\7_-_<'2RFC+,[Z]0<V@
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MW>TZ^E)R4[K@XM!#J'CEP[7X.-9510QCU#UQ_5<?!\\.CQ&-I&X7)V\K;O\
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MY<3I8R[VY;WLTKFP[NN:15,FEK)W'<5L.7SFA2T(5PX/0GO:4J ['P
M                          $!1&:'4GF!]B\T @B@S7DT:3%)!0ZRE&$>
M=[0U656A2%YM2\-?PE=/+VC<V_ITDKNT3Z,*    @/-&:'6*'4 W;P"$U2:0
MD%C&6D%&-6]6*C0E"EH1HYYG,ZG7MTTT&[;=))FB?!A0        !Y6_KB&2
M9.Q?""\UV#Q1LUS-NFPGC::1(K5,LA&1<5D',"3-8E.Q=,DSBEHXH6O90Z!3
M>4M &*K 97#ZH+;,? ^#G;,JR1*FYO7<5G.YI8Y:ZU<2#1_;]FIK'IP$X3%B
MK2:IZ:F["4KKVZ4#U$      #$>?6*/&6OWQ)]U=W8DQS=LC'[*]OUWR]I8K
MM.*D#$@\HW/;CQY#3>=;E3;5(2<<W&Y35+;Q%^(D9!52JFFDZ=OS+![TOJ\?
MAWXCV>^%S@%TI8%LN\K[JL36YFW/5T2L*SD)VZD,Q0#6Z;?Q].N)&/(Z\V;-
ML688Q9H8W$P(\3=K<!U7*ZJH8]#QML))^%UXTN;V&T1_(X0CK(O/&^?,#N+%
M<&@U\:.[\LVVK_<1MI$:UY,7 VU>TC)LH]D4O3)Q:*3:J=4=2 ,G=X/^_1/Q
M)?#WV_;J9!NRCK^N2!?6CF&&CFYFC"+R[8$BXM:^#QS2IUBLX6XG\>69CD**
MK50C9-NF<]52'I0/";];#\7V\MQFY>Z/#JPU=KN+VW;:[@0B,RIP4BJDWS%G
M^&42<SD;<IFRB?6VOAB5H6+;1:Q>46Y6;UVK14Z$>9J'9S]2YV08F<8#S_OO
MO.Q;=N/++_-ZV#\4W+<4,QE)3']J6%9%J75<\Q9#IXW5-!O;TG,BE9/72!BN
M3)P94BF(F92BP1+]=,V/XCM&!VS;[+#L^&M'(MZY$G<$9CD8",9QB>1%']LR
MU_V%<EQD9D0(^NN$);$VV4D%"*.WK1RBDLI4C-N4H0)]4E\8;(%AYSAO#$SY
M>TC<6&<L,I=3; ]N:3=/E<4Y1AVCRX'>,H-T\JI2.L/),0W>JM6-52MVEQ-T
M2-$J*2CFI@]T?B0[R8;P_-CNX_=_,1;*>4PQC]:5MFVY%TLRC[GR!<$I&V;C
M:V9!VVH9VVCI^_KBCFKE5$IE4FZISEI6I: ,*=N(W$YGW7YEOO/^X&_I[)>5
M\CS2TW=%U7 [.Y<*J&T291<:WK7I8:W8-B1-I&QS4B3./9(IMT$TTDREH&93
M\,;P_P#;QM#\/G"6W6VL460XC[KPS8C_ #PI-6I"22V9+^N2U&,E?4WD5)^A
M($N9.0FY1VFW:/3NF[!A5-FAH@D0H#$]>,UM6M+93XH6\S;;C^-+"8_L?*]9
MRP+?3.NHWMJQ,HVQ;V6K-MAFHZ(5TJPMJVKZ:L&YU:J*&1;EJ954U:JG#V3?
M5E=C'A$;Y=M^,]U2^RV.LW>MLRS=9[6Z;PB,];H%HF1R?CAS;N2<59JC+,D\
MVR-H(ISRB#=9Y%+LE8HTO&O2%:E8'2;T#T#?6#[8@;K\&;?\PN&+92S6.PK6
MYV*+UNBY*TGK3NVV;CM^4;T6(>B+V+F8Q%=)0NAR')2M*TJ PS8#W7V%L&WL
M_68MNV*[Y:YNCMI.QO9SA"QMN^TFR;NM>9O;X_,YXEQG;5F9+RK=,/#7-;B%
MN6[.76Q<1:-Q\,N[AX]'H6L4X<$DU5@Z$+&^KP>+3/[M87:W/;0\P6=4UZM8
M.?STZM.76V[P-L(RB24G?['-J+<F/IN,9Q/$^;LVL@:7=4*5 C7J:U1H&1Q^
ML)^(+D?PU?#-O[+^%W709IR#=]HX!Q5>#QNC)ULBYKZC[@E9.^ZLG39PQ?S4
M!9=H2RT;1R0S4LO5LHNFND0[=8,=_P#5Z]S^!\:^+=BF[]Z..8[< 7<+,NL3
M0E_Y.3I?LMCO/F8;SMI"T\UR9;J[T2GI5Y.F6BI"1=U,[9(3B\B5:AVYBJA[
MW/K0.U3"V<_"7W,97O&P;7?Y<V^V_9^0<4Y-4B6*=ZVFK&9%MME/0;"Y2-%)
M:MMW';4])-G4892K%99=->I"N$$%D@Q2VWS/V6-K6:<;[@L'7?)V+E3%5T1U
MV6C<46X70.B^8*_AXZ12061I)V_.,3JLI)@K6K:0CW"S98ITE3EJ&=0Q#?J>
M5,38OR>DU39)9'QW95^I,T5C.$6B=X6U&7"1JDN8I#+IH%D:$*>I:5-2FNE-
M0'BG^N_6= .<!;$,@*1S2MTP^8,LV<TEJ($H^+ 7+9=NS4C'&=4T4,T-(VHU
M5HG74I3TK6FE:FX@\'FRZ!S7=6[O;):NVV>\U-P5TYWQ9;.%+JZANS\ULH7!
M></#V1<O6.DUFS+S?N%ZW><Y0AR(\GCJ4U"Z5#+5X0^KV^%9BO;K3!-];5,6
M;@[CN"#41REN#S):C&Y\_P"0[QE4N9=-]-LJO5'5^8ZDYN545<I(V[)QZ;'C
MI1.IC\:APQ5/B<;.7&P'?KN=VC5>2,E#X?R0Z965+2Y24EI?&MT1D;?&,965
M,BDBW5E7^/[FC5'9TB%2,Y,IP4H72E R+/U4'Q/KUWQ;-KOV\YON=[=N<=G#
MVU[:1NV>DUI&YKZPK=K:5^+F5FW3I,KF3F;1<V\^@W3HRBZRK5LQ5<',X7.=
M0._;Q _^ O>Y_=$W)_V-7H P80#(0>!GX#%F>(-M"V^;LO%*NJ]<[XLCL>RV
M/-F^UR-R!<MB6!C?#,7<]P-7%RW$_P 9REJW.6Y+LO!)W)(-V$FU,9"B2TFH
M\.J1JQ#RU>/'L'QEX;WB49AVXX3/-%PV:!L#)&,XRXI=2>F[=M^_+79R#^VG
MDTXI1Y)MH*ZD)%NQ6<U.[-'$;]0JNOS%U ],'U)'<]?3N>WD[/)J>>R>/8VV
M;+W 6# O'CA5M:4_WZK8N1%85L?C1;-[M1EH$[HE*E+1:.(<I:F55-4/8MXF
M6PS&?B1[-,Q;6<C1\=UEVVZ]D\7W<[:I+/<;9?A63IQCZ^XMP9)1TU[KFS%1
MD"(&3.^B'#MF8]$W)P&$OR)8%WXHR!?.+<@PCNV;]QK>-S6!>]MO^"CZW[OL
MZ:>V[<L(\Y1U$^KBIF.604X3&+QIUTK6@#*E?5*=VMJ[@/"BL_"K7HF-_P"S
MZ][OQ3=\0V;T:J.;>O&XIO*%@7?1)-15([:=970]CS*UJFJL_A79S)TI4IU
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MGW!NVVL529HGT84
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M]-[G][O<G_;+>@#WM?4C?^#?>9_>9MK^RR# >V,
M
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MKX\L6VV-*E9P-H69",;=MR';<5:FJC'1$<BD6M:U-6A-:UK74!7(
M                               -!TM5LU<N*%XZH(++4+6NE#523,?A
MUTKIKPZ (1PKF)SEGSEZB!0A.X.YN#DOU'W4]Z]Z\7%QM6W*Y/=M--.+BX_<
MT[=W6Z*1-4ZC"@   ("B,T.I/,#[%YH!!%!FO)HTF*2"AUE*,(\[VAJLJM"D
M+S:EX:_A*Z>7M&YM_3I)7=HGT84
M      !AX_K,W^.+OO\ ^\6%?_#1A@!)'U9/?5M6\/;Q"+ZSCN_RE\46+IG:
MSD7'$;='F1D:_NIO.>R-AZ>BH;N7&%H7K<2/51-JOU>H4:%:$Y'"=4ISIE.'
MI)\7?ZVUM94V_9'P5X:\E>.6\L92M>4LJNX"8LJY\;X]Q? 71"&8SER6K#Y!
MBK>R#<V0H]N_5;1R3F&CXUH\+UAEW2:";9T'B-V->&#OB\1>]6%H[5<!WG>\
M2I(H,+ARI(QCRW<+V*11;@7=WGE&4;)6M%J-D"*K%CTEG$P\305*S9N5253
M9:GP?/"UQKX3.T6%V_6E,)WOD2Y)4U^YTRG5A2//?N2)!@T8N.ZFA^)U'69;
M$>T380[14YE"-TSKJ_Z2Y<5,'4U]<@_PC8'^]WAG^AV6@&+SQPI=J.0[#5L%
M/FWVE>=KJ64EPL3\R[23C$UN)\$G6D:?CF*(TT<5Y%?_ -I[S4!E$,/?54]H
M61,/WC=_B.W5E7='OTSRV=7?E_<FEEJ]X%2P<DW T4.^3Q5 PS^(M2=BK;76
M3104NB+F47-&A:HM630Q&*08O')5D2&,LBW]C>671=2N/KUNJR)-TVIHW<R%
MJ3K^!>KH4XU-$5G+ QB>^K[VM.VH#+:?5@-SU];H/" P5)9*GGMTWAABYK^V
M_NKCE'CA]+2<!CZ4;O+$2DW+G515Q!8_N.*C"'J8YE$&*9SFJH8X"V3ZV)XE
M69=BFS#&6(MOEQ2=@9.WB71>UF2&38-PLSN2SL4V%"0CG(;>SY) I58&[;I=
M7K$L$I-)0KIBP4>':\MW5!TV#S%?5 L_[:+!\0FY<*9JP]:]UYCW$VVU;[;\
MVST0QG)C&%XXSB[SOR[+5C5)5%R6WC9+@&M%B2K0R+PK^#;M*U4*]IR@[]?K
MEFU3"T_L+L/=BC8-KQF>L>;@K"LY7)D;$L8^[;DQ[>UL7;%R5GW++M6A7ERQ
MC.5AHITP(\4/6.JU4HV,F5PX36#PH>$GNZRILH\0G:]F7%MS/X/GY;L.Q,BQ
M"+YRVA[ZQ3?%VPL#?MEW*U2/1O(1DC#.C+(<Y-4K*2;MGJ9>>V2,4,VR PV7
MU@W>-D/>)XK.[*1NV<?N[.P1E>]]MF([:.Y=UAK5LC#%SRED.%(=@ZX>B6O.
MYX=].OJU+0ZCN0-2OO$TRD#(_>#-E'PU=[WA@8CP]M[L7#-P8MM3%5I8^SYM
MBN>U;5F7EK7X6V6<9>J&6+#FVCVERJ7A,M73I.X'J#E*XRG,XHNHKSB)AYTL
MT>#A:WA:?6$_#*SGMVA'L-L^W+;B"P]L6\59Y+(8;RR:UYUO/8Q)(23E\_5M
MFX6$AWK '<JF73;E?-:5,6/*JH'O/OZ^;4Q?8MZ9+OR9:6Y8^.[2N.^;SN%^
M8Q6,#:EI0[R?N*9>&*4QBM(N(CUEU*TI6M")U[ &&A\7/Q3LZ>+ENTF<C7 Z
MN*.Q%$3SRU=L^"B.SK1E@V:Y>IL8M12,9FJSD<D7KRD74W(?A5EW:A6J1Z,F
MS1%(,K-LA\,?;1M'V#V7L96Q/CN[K+D<9Q]N[A&LU;D7.QV<;WF8I.N1KEOD
MTC')JW0G-S[ES5G1V2O0,"MVS<J*3=(A Q0F4KLROX-OBW9R5VJW?*VC<&TK
M=#D^U,>.GCIT[0N7&,-><DTAK1OQL5R0UQV[>%@U;M)AJJI_I!%CU*8BM"*$
M#,+;1=R-G;P=L&!=T-A(K-+5SMBRSLDQ\6Z/11[ +W'#MGDO:\BJ4A$U9.UI
MDSB.<G3U2.X:GJF8Q*E-4+B@   ><CQN\^>/EB6#NA/PQ]LN++QP^A:[1T_S
M%8\@7,.Z:+<K1J]9LUMX NAA Q"<G&2A*HM&T3&Y"</6]4')2(*J+M688G7)
M=T9#O;(=\7;ER:NNXLI7%=<]+9#G+Z=23R\Y.\WDDX5N-W=+F8J:54GE)4RO
M5=1^&*MQ4-2E:: /7=]68\>S+F ,ZXI\/C=-?,OD#;!F*X(7&>%+BNV36DIS
M;SD>?<M8:QH.+G'YEWBF'[KE3MXE6)75HT@7+A!ZT,U;D?I.@R:8
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M^K0N%W7@?;#E7"AE5"VOF%N4QO+1!GN.S$T;)TTT]ZBV0(2G[A: .]8
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M3SAM^'ZU*KLJU3]/+M'"[G1>E"ZIU+3MT\HU;-T1N),1.^G494
M
M           >.#ZZ_P#X;VVC^^[:G]@^>@&,F 9MVT_"F\+I2V[:>*>&WL&.
M[/!PSD[H^SS;P9P=P9@V5,N9<V.JJF6,K7BJ>M>*INW74!?)96,L;XV1D&^.
ML?618*$LHW6E$+*M2!M9&26:%5(U5D$X)@P(\4;$7/1,RE#5)0YJ4TUJ K<
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M*ER$.5NU8N5*K$(>A*<'$4,E,     P87B!_\>F]S^]WN3_MEO0![VOJ1O\
MP;[S/[S-M?V608#VQ@
M                                       "&,S1V,)&,A29/DUHQ@F^
M<&BSHJO4JJNZMZ46(:K)JZ-6E$>WWU*4&K=+^ZDT^*48%..2@H5*(4JM$IQ,
M<G%JFJ>IE8XC-$K)0U5"D4K4[:A:UJ:E*]O;2E1F=]7+    @)S%X?KF@LBO
M+KERASVM2QE%I#D\XMN(HMZ<JC.K+WT)0I_WWRUU\O8-UNT?]E-ROXI]&%
M                                      >=_P"M4?X'6[;_ +Q;;_\
MQ+XE 8B<!E_/"G\,_P .'(GAE[ ;]R!X?VR2^KYO+9]MYN:[[TO':G@FY[LN
MNY)O%MLR$S<%R7'-V&^F)V<EW[A1=T[=+*KN%CF.<YC5K6H=T^-\$X0PXB@W
MQ#AO%6*T&L*SMQLAC?'EHV.BWMZ/*W(P@4$[8B(LB4*Q(T2HBU+2B"5$B4*6
MG#30)5  &%*\;+_%R\1G^]WFK^F,B ]C_P!1_P#^'K?I_7-A[^A%U@*B^N[_
M /";LE_O$7S_ &:J@/%!X."RR'BQ>&\=!51$YM[.VQ$QTCF3-5%QEBUV[A*I
MB5I6J:Z"IB'+Y#$-6E=:5K0!FTP'DY\4WZJ%M]\0S<E=^Z?%NY"YMJF2,I2+
M:;RU#_%8PS)8-V7(DQJR?W7#0!L@XNE[4N*X:HMUI$]))XS<.$U%BMDUEU5*
MA2%F[X_"+^K/[>E=B>$;[O?>+NB?7Y(7#>V,L5%BKLR??&;KE;0-M43R)-Q!
M36/BI-!K$QL8SMY)1].-&J)#%CWSI5=PX#Q$^.UF7=9N!\06[,P[Q]N[#:IE
MZ^<88GEVF"49=S-S=CX^4M9%.PD+U>NUNI)>LE D([?MU6T:X:&7*BX8LW":
MR! [UOJ1O_&1O,_NS6U_:G!@/7SX]WAS7'XG/AR9)P1CL[+XY[%N*!SM@YI)
M*I-V$WDC'T?/L/-)=VN9)!@YO>RKHF85FY542;M7\@@JN>C<BH##EWO9%XXT
MO"YL?9#M:X+'OJRYR2MJ[K/NN)?0-RVS<,.Z492L+.0LF@VD(R3CW:)DUD5D
MR*$.6M*T >D3P:OK+FZ#PWG%I8/SLI/;E]E[-RC'ELJ6D"NLK8<B#D2:\_#%
MW3#DM%H&)23(H2U)16L0<J=4F*T2=99P<,G-LXROM5W!8.A=QFSM7'<CB3<'
M*R^6G=RX\MR)M<UVW[<*J32]9W($;'L(Z0^-4DI%]%<%99/OA)ZSJ@[KS$M*
M!BV/K5F3YK(GC8[F82256/%XAM+ ^,+527/4U6T*7#%E9"D$DR<:A$45;PR#
M*K$*6M.*BO'6E#&-2@7 _5RL_P#C4XLL+=-;OA,[0MMVYV!=W?BZ:S=(9ON.
M"M^6M"7=0UY,;$9PG?6Z+;UU<=,,XV4.IRV\GRU6_OE$>(I5 [7_ !&\=?6N
M/$]VTR6UC/WA?[2K5L"3O&T[X/-XER[AF#O5I,V<Y<N8TK&2O3?M?\*@T<T=
MJ)N*5CC*G2/4I%":UK4+1O!)\"/QE=D'BA[3MRN7=IBE@XEL.Z[M8Y-NDFX+
M;+<*499=[8UO2Q9==Q;UEYIN*Y9M-*ER$.5NU8N5*K$(>A*<'$4,E,     \
M%?UG_?EE#>OGW&/@8;#XB7RK?\[>MN2^XB/LQ5F\1N._&A$KEL?#SA_S2LHZ
M(QHW;5NJ[G;E5)C&+H,^H60-&/RD#T@>"IX0&*?".VQM[#C#Q5Y[B\FMH2X=
MR.86K8Y:71=+)LN9A9EIJNT47[7&5@'D7+>)35(BJ\55<2"Z2*SLR"(=R@
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M9=(J:ICJIE35/6E"FK4U*4TK6M0')@
M         @K)=C8RN6[;<EKQO'N"=CD&A(B,\X;?BNN21DU7*!^CE&B[QUS7
MAC)ZI&+0VG#3WW:-6S=$;F\DQ%4ZC*@  M(V\8]O*SKKO)_<L&O%,Y)H5-BN
MJNR5*X/2246J4I6SE<Y?P5:5]]2@Z7S$Q%&;8F%VXYM
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M '3>'A_6)N)_HUB4!Y)/ E_QA/#O_O,V)_UKH!F'-TO_  R;C/ZB,N_V?W"
MP/P#,.?5F?\  ZV(?]W<U?\ B7S. [W
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M*\;E>EJYD'Z].8NL;2E")E33(&(M 9U_97_P;[2_[LV!_P"RRU0'DD^N[_\
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MX-=O;;YW<ZC64,NR,DL1\IJT,5)-R=R7G4\FI*:>[H.DS&A3XLQ$UJNW'-H
M  !:1N'Q[>5XW79K^VH->59QK0R;Y=)=DD5N>LDFM0IBN7*!S?@J5K[VE1TL
MF(B:LW1,KMQS:
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MU4+N7M@YB4-3C*0^+88I#&+KQ4*<R9J4KY*U+7[E0'ME
M
M      %O6X3'%S9'A[=96RDS57C9-TZ=4>.R-"T26:T2)4ACE-0YN.GD&[)B
MV=U)BJ:;88.(JVK>BW="%=QL'$L'5$S4.2CAFP;MUJ$/3L.2BB==*^[08G?6
M'.    M>=XINY;<.3)!$6/FQ1TR5JK5\G1YP(6BWAU/]$X>/6CU.M*=O:7M&
M]*-#1^+-/U570C#0                                       #SO\
MUJC_  .MVW_>+;?_ .)?$H#$3@,VOX.O^$_X;O\ <BVS?V0VF [(0   84KQ
MLO\ %R\1G^]WFK^F,B ]C_U'_P#X>M^G]<V'OZ$76 J+Z[O_ ,)NR7^\1?/]
MFJH#Q.>#K_BP>&[_ 'W=LW]KUI@,VN QQGUDGZQ/FZX\VY9\/39%?<KBG%&)
MYZ6QOGS,]DRCJ+O_ "O?,4FK%7WCJVKB:5;R-GX[M&9,XB)$[(R3V;?LUR]1
MW97EO N.^IY>%;BF>L"YO$_S);49>-_-<A3N--L4=,($?1V/D+39-$;YRHU9
MKIG;*7C+3,J>(BW-:<V*0CW:B?X1V0Z0=*'UM[_&@RQ_4S@+^@+4!?\ _4C?
M^,C>9_=FMK^U.# >^7>)O,PWL9QS9F6L[J7!'X]N[-&*L).KEA&L,Y865+9;
MN1.UX6\KT/,3T%5C8, ^6*K+.FE'KUJUU43:+4*:E ZXO%X\!+:%XL5O/;MN
M)D7"VZV*@ZQME;DK+BD%I5V5H@DE%0.6[9(XC6>4K2:$;)I(4<+-Y:-2IP,7
MS=(RR*P8LWQ%?#:W1>&#GI[@;<W:2,>[=HNY?'F1+<5<R>-\M6BW>59ENFQ)
M]=JS5<HIJU(5XP=(M92-54(1VW2JHE4X>N[ZD-G/(*T[OBVUNY91YBUA"XUS
M;!0BYJF3@+[D7\G8US2,;2E*<'G5 L(M-Y0U:TK6(;U+0M>/B#IK^MEX5F<5
M>,[FF\GK1PA"[A,98/R];"JI%*MW#*/QS#X<F:MESU-S=+JQ._.<NOX,RFE*
M4)P4 7"?4_=\EH;:/$"OK;AD29;6_;&]BR+?LFTY-XJ1!DIG#',M*3.,H)XN
MK0J:'G5"W/<,8RU/0R\NZ9-B%,=P70,I" M;RQO#PGAS<%MMVNW/*R\EF[=/
M)WLWQK95JQ-;@D6%O8\M"7N^Z\@WLBV<$<6KCV.2BBL*2:J9TU))VDD4M2%<
M*(!=(   #SQ_6$?&GMWPK-NA;(QA*PTIO1SW"R,9ARWG)DWOQ86N[+(1,KG^
MZHJJ+DJL5;+]NHW@VBY#$EIPG#REVK.0*0.COP3][OU>GPPK"FLIY1W^M,V;
M]<X(N9K<!GZ4VU;S9MQ'O+A?4GYO'V/):9V]5ERVW6<4JXEI5:B<C<\D3JW=
M$TB,V;0.].5^M,^!A'QDB_:;T7\Z[8L'CQM"16VK=@C)S#ALW461BHY6;P=#
MPR3^04)1%$SMVU:E4/2JJR2?$<H1)X+OB67YXN6_;Q ]S5I2&2+-V8X0QW@K
M &W;$MSS#QE&34O<DW?]XWMENZ+,BY9]::>39,UKMR&<5HN[CH-^S8$7/0KD
MR@>F@                                       &T?IG58O4DR\2BK1
MRFF6FE*F.=$Y2EUK6E*:FJ$;XM>VQV#=]C>>_G7"+P_>GFUT'.79K=1T7?\
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M38"Y,J.4D.:W@\-V,]0NO*$L]5.0[5MQ6G%N&C3GZ)+R3ILWUJ=8A:AFX
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M:>L'<4O/6G$MF%M0=P=UR+1A)1J,]'PI'B3=T@DZ127*18A5:'I0/13]3_\
M$0VG[.K\WF8BW2YJQ[@8N=F&"[CQM>649]O9EDOI+&2N5X^Z8*7O:;,VM&WW
M:K._F#AI61>,B*T07*0RAM"E#W,>*_X;V-?%,V:9 VOWVZ;VY<JZB-ZX8R.H
MRH_7QEF"WF4@C:MT]/2G.=0KI&1<QDPV2,15U#2#I-(Z2U4E4PQ;>'X#=_\
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MLTUB+^?PDCF&_<BQ=WVE;TFHVD+PM>EJ7HQJ\>QI'2#!W15%Q5(Q:4J'J=
M                               6KP&4;R?[@I.P7,@@>V&SJ9219TCV
M1%BD9Q2CI"E7A4:.C<*Q:5KJ;M\E>P;FV-"OQ9K.E3X+J!AH   !:ON-RC>6
M.WMJ(VK((,DY1K+*O:+1[)[50[15@1"I:NT5:I\)5S?>Z:Z]HZ66Q.^S=,QO
M+J!S:          !U/>+%X/>U[Q;L.-+$S,U<V1E:S$W:V&]P=IQS1U?>-7S
MQ1%9['+-7*S1M>-ASAVY2R4&\6326I^&;+,WI$7:08V#=9X-7BV>##FZ W"V
MK8]XW%;^%[Q;W[C7=MMUC9&^+-A*VY(&=1D[?,8T8/IG'**S8A$I)C<[!.'=
ME<*LZ+OVYSU4#U3; OKEFU:_;-MZTO$)QY>>!LKQ\=&LY_*V+K9?Y%PK=CPK
MQJPD)WS8B'#W)]AN5$776FC46%PH41;N.6\YM6S54.R7(/UKGP1K,MY6:MS<
MS>^6I)-10A+1Q]MUSW&W"N4C%Z[*LDYRIC[&=IT357:D:EH>4(?GN4ZF+1&B
MRJ08YOQ ,C7KXN/B5;H-Q>SO;QN"OZ*S+>L%-6KCJ QO+7]E%A#1EEV[9T8I
M<=MXNI>[9A)R_FHJXZ=LZ>))<1DR+K<NIZAZBOJV?@%^(GM2WO8^WR;IL?VO
M@;'EAVEDZ"8X^NR\(R8R]=KR_+%E[0CGK*U[--<D3;<1'KRQU'/?4E'2-.26
MB;-0BM%2AD#P&,&^LG> ?F+;/G[*F^3:QCF<O[:9F"X);)&186R8=Q+2FW6_
M+A='D[T+.0D6DJY;XHGIYRO(1LFBB5C#T<FCG/((BT6=AYN]E6^S=+X>N9F6
M=]I^4Y7&5])LNY9U))NRF+6O>UE'K1^]M"^K4ET'<+<UNOG#),]4UDN<V6(1
MPU50<II+$#U@[=O%W^L*^/$Z3V@[=X3$6WK'\XW4MG/FZO"6+,@V>UL6R9%L
MP:W"[N;*%Y9%O]I;MU.XQ8ZD?&VE2'N)^HX/TE4D"'6:A[TMDFS_ !)L+VNX
M@VHX28*-K$Q);*4.E)O$FZ<U=UPO5UI6[;YN0[4B:*]Q7C<CUS(.ZDI1)-1?
ME)%(BFF0H>37ZT!X F2=UEQF\0G9!8CF]\VMX&/A=QV$K8:%6NW*T1;;!K%V
MODW'T8B0J]QY MV :)QDG$IU4>2T:U9U8IF=-E$7@=4'U:+QQ,$^%S#9WV8;
M\#7SBG&UT9/<Y/M>_:V/=5S5QEDDEO15EY!M#(%CVY"RN16*,TSLZ)Z8S&.>
M&:/VJY'""=%S+$",?K('B]8Y\8C+VV[;%L(MK)&7,;8CE;REH^<CL?76WN?-
MV4[S0C(QBC8.-W,52_SP-K6Q!*],9Y'LI%XXE'5#LTTVR2JP>@_ZLEX!=Z;#
MD'V^/>3;C:$W27[:JUN8CQ0Y4;OI' F/KB13/<,Q=RJ)UV;7+-],Z)M3LT#&
M4@(>JS5=6KM^]:,0]2&[3+,_@3:MN8SI:D&:Y[IPOM]S-EFVK:(@=T>X9_'.
M.;DO"&@RMDSIJ.#2TC#IMZ$*8ICU4TI6E:Z@,,_L]\3+<!M0\0VT?$DDEFF>
M,YQ5XW[=UZGRD]?."Y%7RC:5T63?%)26CZI/HA^[@KN=="NU+1)@L1&A4%&R
M=6QP]<WVYS_\5W_[[/\ _:. JBSOKR-E/9Q%O?\ X;5T6S;1D7!G$M9VZF)O
MF<2<%2K5HDC;TUM_QXP<(KK:%44-)IF2+[XI%*^]J'I \+WQU-B7BNGD[3P3
M<EU6'F^W8'SCN3 >8(F.MS("<(BXHR?S]JNX>7G[4ONW63VI>:K&/U7C-%=!
M1\T9573)4+3?K,F_G:]@3PV-U.VBZLPV'7<MG7%T/:N/,#LYUI)9,DHR[;U@
M(YY=TC:T>NK(VU:D=!-I)ZE)296C-X>.50;'7<%Y%0Q)H#,9^!MXD6S3=9L:
MV;X;Q5GG'+W/F+=K>(L>9!P%(W3&168(">P_CJV;'O5\VL*5587+/VDUE(FJ
MJ4PQ:KQQVSA$QE2&/P4#O% >0_ZXYM5S'G?8#B+,&*K;FKRAML.8I*\LL05O
MLU9&1A\=7=:#R"=Y$5CVR2KQS"V9,,FB<@=&ANB92*CQ8I6K9PLB&-HVT;A<
MC[3MP&(-R>(G[2.R3A2_K>R#:2TBVZV+<24 ^3=&BYEE11$SV#FFE%&;U$IT
MS*M%U"4.6M:&H&13W-P_BZ>/GX;.2W]V[;Y'P[L.P6(IS)-IX#I=$K>N<]^>
M8K0BD+HQW"'B[BLBP7V'\"/)9CU3"/D&[V3G);H#D749%(](&-(DHV1AI%_$
M2[![%2T4]=1LI%R35=C(QLBQ74:O6#]DZ32<LWK-RD9-5)0I3IG+4IJ4K2M
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M=F4/203;TJ51RBJ=/\$:M/>UH-VVQ,35FZ9C>74##0
M
M ".\JY>Q-@FQI?)^;\H8[PWC6WU(U&>R'E6];:QY8T(M,R;2%ATI>[+NDXB
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M%+DLF8G(8DNP;R""BS:JU%DB+IF,6E#EK4)7
M                                                         6Q;
MG+PN:T(*UW-LS+R&7>2SQ!TJS,0IEDDV95")GJ8A]2E/74;LB)G=9NFD)[M%
MTX?6G;#UVJ==V\MV%=.EU*TJ=9PXC6RJRIZTI2E3J*'K6O[M1F=]J-Y40@
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M'D*PZL=MFP:V<HR\?B.V&-OI)6K;DK,R2:3J7:0Y"L&542(D,HY4D7#L/0X
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MAC?%MG6]85C6Q&$X&4):]K1;:'AH]*M:U46,BR:$XU5*F564XCG,8YC&J$A
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MR8:QRK]%6/9.CJG<3:[)6I5G"*BJ7$W)2GO:TTKV^4;MMB8F99F9JNH&&@
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M$VW/,"/6JS%Z5G,0]ALY!J5VR<J(JT(H6BB2AB&U*:M*A>V
M                             (*B9W$:N6WL3'0W*R.1>1*[D^[UR<:R
M; ZCZO656JD;F,Z5+][V^0:F+M'\$W*_BG494   !!68IW$<.Y@2Y-AN]5UT
M'YH@W=Z[WDI)J-:/*:I+)43XSG3\NNN@U;%T_P *33XIU&5
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M;%U-S>2:?%.HRH
M                                                 "W/-NSS:1N7
M?Q$KN.VM;<]P$I -E&<#)9MPCC/*K^$:+'JHJUB'E]VQ/.(ULJI6IC$1,0IJ
MUUK34!-5IVA:=A6]&VC8MKV[9=J0J:R,/;%IPD;;EO1*+ARL]72C86';,XUB
MFN\<J*G*DD2AE5#&KJ8U:U"ALQX P1N)MI*R]P.%,29TLY%VF_1M/,>-[.R=
M;23Y)1%9)XE!7M#3<6F[25;IF*I1*ARF(6M*ZTIH##N ,$;=[;/9NW_"F),&
M6@HL9RI:N'<;V=C*VU'!W#MV=<\'94-"1AUC.GZZM3U2XJJ+*&UU.:M0JB\,
M<8\R$O9SJ_K#LR^'..KSC<CX^<7A:\'<J]BY#AHZ6B(B_+.5FF+U2V+SBHF?
M?M6THRJ@^0;O5TR*E(LH4P4SE[ >"MP=O4M'/>%L39OM0O'PVQE['-GY*MXO
M,<L'JFD+><--1M.-Y%-5:_@NU5LD:OODR5H' X5VM;9-MC:09;=-N>",!,Y9
M19:5:85Q%C_%C:36<494<*R"%BV]!)/5%Z1K?C,I0U3=.GKKP%T"=P !".9M
MLVV_<;'MHG<+M]PAGB*9\KI(W,V*+#RA'M>0N9RATS.]X&<;(<EP<RA.$M.$
M]:FIVUU <3A7:1M3VV*2"NW3;)M[P$K+<[O57"N%\<8L4D^H*R*X[P/8MMP1
MGO/+&MZ'YE3<5&Z>NO 70+A
M                                                       0QF:^
M[8L2,A7=SVHC=2#]\X;M6ZS>/<4:*I-Z*G6+2016(6IR5X=2TI4:MB9WDF8C
M?2C O6\C!0L@S;49-'\3'/6K,I2%*T;NF:*Z#8I4J%2+1!(]"TH6E"TT[.P9
MG?5RP   ("<Y(M!+-!;#/9:"ET57:ITNNK:+JM0ZUN(RB9^HJAWA^#9'HA]_
MKI32GO>P;T9T:_!*Q6GQ3Z,*
M                  "$\U[:=N.Y2)BX'<9@#">?H.$=G?PL+FO%5B94B8A\
MJ2A%7D7'7U SK-@[4(6E#*)$(>M*:5J JK&.),4X2M-G86&<98]Q'8T>8AV%
MEXQLNV[!M-B=-FTCR&9VY:L;$P[8Q&$>@A2I$2UHB@F3[TA:4#7R3BS&.9K0
ME,>Y@QS8>5K!G$ZHS=CY)M"W[ZM"81J11*J4I;5T1\I"R"=4U3%X5D#TX35I
MY*U 1_A/:IM>VTHRK?;CMNP)M_0G%#K3:&$\/8\Q4C,+*%9D45E4[$MV!)(*
M')'-Z5,M0]:T03I7[PN@21D#'&/,LVJ^L3*EAV9DNR)-[!24E9N0+7@[RM60
MD;7GXNZ[9?OK>N-C)1#M[;MTPC*28*J(F.TD&:#A*I%DDSE#1R+B_&F7[7>V
M/EK'EC91LN2*L21M#(MI0%[6O($<LG<:X*]@+ECY.)=%7CI!PW/11$U#(+J$
MKJ4YJ5"(<,[+MG6W&6>3^WG:=MHP-.R)4R2$UAG!&+<72S\B*#QJD5Y)61:L
M&\=%2;2+A,M#G-0I%U"T[#FI4+EP !".9MLVV_<;'MHG<+M]PAGB*9\KI(W,
MV*+#RA'M>0N9RATS.]X&<;(<EP<RA.$M.$]:FIVUU <3A7:1M3VV*2"NW3;)
MM[P$K+<[O57"N%\<8L4D^H*R*X[P/8MMP1GO/+&MZ'YE3<5&Z>NO 70+A
M                                               !H.C)%;.#.*<2
M!4%3+%TUXDJ)FJI32G;74FH"&,-S>*)CSC^+"([JZ;NCOS_0%F//YW>G=O[\
MLKS>5RG'DTX>+]T:NBZ/XDBGP3<,J    @J)G<1JY;>Q,=#<K(Y%Y$KN3[O7
M)QK)L#J/J]95:J1N8SI4OWO;Y!J8NT?P3<K^*=1E0
M                                 !QTO#Q-P14C!3T7'3<)+LG,;+0\
MNR;245*1SQ(R#MA(Q[U)9H]9.D#F(HDJ0Q#DK6AJ5I4!;GB+9+LRV_7.ZO;
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M="0D0R;1L3#Q#)M&Q47',TBH-&$='LDD6C)DU0(4B:21"D(2E*%I2E '(@
M IF[K*LW($(O;5^6E;-[6XZ416<V_=T#%7)".%FYN-!5>*F6CU@LHB:NI#&3
MK4M?)H LSC?"O\,*&D6$O$>'%L-BI:*>M9*+E(W:#M\8R,;(L5TW3)^P>M<>
M).6;UFY2*HDJF8ITSEH8M:5I2H"]:V[9MNSH5C;5H6_!VK;L858D; 6W$L(.
M%CR.'*SQP5C%1C=JQ:%7=N%%3T33+0RAS&KJ8U:U#G
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M/_VE\+^FH!](5L$]N+9_^TOA?TU /I"M@GMQ;/\ ]I?"_IJ ?2%;!/;BV?\
M[2^%_34 ^D*V">W%L_\ VE\+^FH!](5L$]N+9_\ M+X7]-0#Z0K8)[<6S_\
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M/_VE\+^FH!](5L$]N+9_^TOA?TU /I"M@GMQ;/\ ]I?"_IJ ?2%;!/;BV?\
M[2^%_34 ^D*V">W%L_\ VE\+^FH!](5L$]N+9_\ M+X7]-0#Z0K8)[<6S_\
M:7POZ:@'TA6P3VXMG_[2^%_34!P& I#%V5LIWEEW#6=\*YHM9O*2[264Q+D.
MW<A=Q/IXE7;%A-/+5?2D='/3MJ<RB2BI3F)[XM*T[1N;HFW19B-VJ]\8:
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MTU /I"M@GMQ;/_VE\+^FH!](5L$]N+9_^TOA?TU /I"M@GMQ;/\ ]I?"_IJ
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M^TOA?TU /I"M@GMQ;/\ ]I?"_IJ ?2%;!/;BV?\ [2^%_34 ^D*V">W%L_\
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M+^FH!](5L$]N+9_^TOA?TU /I"M@GMQ;/_VE\+^FH!](5L$]N+9_^TOA?TU
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M/_VE\+^FH!](5L$]N+9_^TOA?TU /I"M@GMQ;/\ ]I?"_IJ ?2%;!/;BV?\
M[2^%_34 ^D*V">W%L_\ VE\+^FH!](5L$]N+9_\ M+X7]-0#Z0K8)[<6S_\
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MTU /I"M@GMQ;/_VE\+^FH!](5L$]N+9_^TOA?TU /I"M@GMQ;/\ ]I?"_IJ
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M^TOA?TU /I"M@GMQ;/\ ]I?"_IJ ?2%;!/;BV?\ [2^%_34 ^D*V">W%L_\
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M1?1P8:/FG[IO9JS_ .IO(OHX ?-/W3>S5G_U-Y%]' #YI^Z;V:L_^IO(OHX
M?-/W3>S5G_U-Y%]' #YI^Z;V:L_^IO(OHX ?-/W3>S5G_P!3>1?1P ^:?NF]
MFK/_ *F\B^C@!\T_=-[-6?\ U-Y%]' #YI^Z;V:L_P#J;R+Z. 'S3]TWLU9_
M]3>1?1P ^:?NF]FK/_J;R+Z. 'S3]TWLU9_]3>1?1P ^:?NF]FK/_J;R+Z.
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MF\B^C@!\T_=-[-6?_4WD7T< /FG[IO9JS_ZF\B^C@!\T_=-[-6?_ %-Y%]'
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MF]FK/_J;R+Z. 'S3]TWLU9_]3>1?1P ^:?NF]FK/_J;R+Z. 'S3]TWLU9_\
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M[-6?_4WD7T< /FG[IO9JS_ZF\B^C@!\T_=-[-6?_ %-Y%]' #YI^Z;V:L_\
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M:L_^IO(OHX ?-/W3>S5G_P!3>1?1P ^:?NF]FK/_ *F\B^C@!\T_=-[-6?\
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MWD7T< /FG[IO9JS_ .IO(OHX ?-/W3>S5G_U-Y%]' #YI^Z;V:L_^IO(OHX
M?-/W3>S5G_U-Y%]' #YI^Z;V:L_^IO(OHX ?-/W3>S5G_P!3>1?1P ^:?NF]
MFK/_ *F\B^C@!\T_=-[-6?\ U-Y%]' #YI^Z;V:L_P#J;R+Z. 'S3]TWLU9_
M]3>1?1P ^:?NF]FK/_J;R+Z. 'S3]TWLU9_]3>1?1P ^:?NF]FK/_J;R+Z.
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MF\B^C@!\T_=-[-6?_4WD7T< /FG[IO9JS_ZF\B^C@!\T_=-[-6?_ %-Y%]'
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MF]FK/_J;R+Z. 'S3]TWLU9_]3>1?1P ^:?NF]FK/_J;R+Z. 'S3]TWLU9_\
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M[-6?_4WD7T< /FG[IO9JS_ZF\B^C@!\T_=-[-6?_ %-Y%]' #YI^Z;V:L_\
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M:L_^IO(OHX ?-/W3>S5G_P!3>1?1P ^:?NF]FK/_ *F\B^C@!\T_=-[-6?\
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MB^C@!\T_=-[-6?\ U-Y%]' #YI^Z;V:L_P#J;R+Z. 'S3]TWLU9_]3>1?1P
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MWD7T< /FG[IO9JS_ .IO(OHX ?-/W3>S5G_U-Y%]' #YI^Z;V:L_^IO(OHX
M?-/W3>S5G_U-Y%]' #YI^Z;V:L_^IO(OHX ?-/W3>S5G_P!3>1?1P ^:?NF]
MFK/_ *F\B^C@!\T_=-[-6?\ U-Y%]' #YI^Z;V:L_P#J;R+Z. 'S3]TWLU9_
M]3>1?1P ^:?NF]FK/_J;R+Z. 'S3]TWLU9_]3>1?1P ^:?NF]FK/_J;R+Z.
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MT84
M
M  ! 41FAU)Y@?8O- ((H,UY-&DQ204.LI1A'G>T-5E5H4A>;4O#7\)73R]HW
M-OZ=)*[M$^C"@   (#S1FAUBAU -V\ A-4FD)!8QEI!1C5O5BHT)0I:$:.>9
MS.IU[=--!NVW229HGP84
M                                       ! 5M9H=3^69K&IX!!LA$K
MS2)98L@HJJO2)/PE,9G5H0A.?[OX2O#^Z-S;2W22)W:)]&%    0%ES-#K&4
M[;L.A (2Y9U RQUU9!1F9M6CPC7A*F1HXHIV&XNVM/N#=MM8JDS1/HPH
M
M
M
M
M
M                           #0=+5;-7+BA>.J""RU"UKI0U4DS'X==*Z
M:\.@"$<*YB<Y9\Y>H@4(3N#N;@Y+]1]U/>O>O%Q<;5MRN3W;333BXN/W-.W=
MUNBD35.HPH   " HC-#J3S ^Q>: 0109KR:-)BD@H=92C"/.]H:K*K0I"\VI
M>&OX2NGE[1N;?TZ25W:)]&%
M
M                       0%E#-#K'EWVU:Z, A*)SZ#-8[Q604:G;5=2BL
M?4I42-%RJ\!4^+M,76M=/W1NVVL3*3-)HGT84  $!8CL3'EISMQ/K.O9"Z)"
M00*G),DIB#DC,$Z/#K4.9&+I19#5:M2:J=G9IY1NZ9F-V$B(C>3Z,*
M
M                                                      @*(L3'
MC3,#Z[F=[(.KT77DU'%JTF(-19%1S'G;NB5C4J=ZDZ=O6IZT-VETUKV#<S.C
M2FXE(K7XI]&%    0'FBQ,>7DZ@%;XO9"T56"$@G')K3$'%U?)N%&AG)REEZ
M5,MR#)$IJ3L+Q=OEH-VS,;T528B=]/@PH
M                                                    " K:L3'D
M;EF:NJ+O9"0O!XO-*/K8+,0:ZK11Z?5\0T<WIWHET=>RM#]I/^<-S,Z-*;B1
M$5_%/HPH   " LN6)CR[)VW7UXWLA:\A'H&3C62LQ!QIGZ=7A%JG*C*4JLOH
MM2A-4^SMT\HW;,Q&Y"3$3OI]&%
M
M
M
M
M                                                          :#
MI--5JY26/RTE$%DU5*U*6B:9TS%.?B-[TO 6M:ZU[* (1PK8]@69YR^8UYH7
M=WEW-WIR9:%E.[^C[UZ+B[GI3D=7U2VG,^^Y7O?(8;NF9WXHD1$;R=1A0
M$!1%B8\:9@?7<SO9!U>BZ\FHXM6DQ!J+(J.8\[=T2L:E3O4G3MZU/6ANTNFM
M>P;F9T:4W$I%:_%/HPH
M
M                  " LH6)CRYKOMJ7NN]D+<FHU!FG%Q2LQ!L#R":,HJY0
M.5M)4J[7YKL]4]4^RM::4[1NV9B)I"3$53Z,*  "T#;G8MW6K=EZ/;B@7\2T
MD&A",EW9"%(X/2246J5.I3FK6O+KK_D'2^8F(HS;$QOKOQS:
M
M                                                6@6W8MW--R<M
M=CF!?HVVN[G#I3!R$Z0Y',.J@@8IJ'J;15:M"T[/*.DS&A3XLTG2K\%WXYM
M   +0=S]BW=>#^SU+8@7\RFP:3)'AF9"&HW.NM'&1*IQG)I52B1M/\@Z63$;
M[-T3.\N^'-H
M                              !:!8UBW=';A[HNE] OVUO/'=T':RRA
M"4:+$>*:M3$-0]35HM3[WL'29C0I\68B:U7?CFT    M W&6+=UU799;VW8%
M_+-(]H<CU=H0AB-SUDDUJ%4J8Y:TKRZ:_P"0=+)B(FK-T3.\N_'-H
M
M
M
M
M
M                        !M) AU6#U-,M3J*-')"%IY3'.B<I2T_=K6H0
M+5]KMDW79WGSYSP3Z%[Q\V>AZTA"=3T?G!U/+X#GUY/5)Z_^?0=+YB:49MB8
MWUV8YM    +0+;L6[FFY.6NQS OT;;7=SATI@Y"=(<CF'500,4U#U-HJM6A:
M=GE'29C0I\6:3I5^"[\<V@
M
M                     %H&>K%NZY<DV-+0,"_E(V.:1A'SQL0AD6QT9YPY
M4*I4QRUI4B!J&KV>2HZ63$1-69B:KOQS:  !:O@/*-Y7Y<]W1ERR"#QG$M2J
ML4TH]DT,F>L@HWK4RC9%(ZGX(M*>^K4;NMB(BC-LS.^NH&&@
M
M                                               %J\!E&\G^X*3L
M%S(('MALZF4D6=(]D18I&<4HZ0I5X5&CHW"L6E:ZF[?)7L&YMC0K\6:SI4^"
MZ@8:    6K[C<HWECM[:B-JR"#).4:RRKVBT>R>U4.T58$0J6KM%6J?"5<WW
MNFNO:.EEL3OLW3,;RZ@<V@
M                                         %J]FY1O*8SQ<=C/Y!!6
MVXYU<B35H6/9)*D)'*<+2AG::)7)^73RZFKQ>Z-S;&C7XLQ,UHNH&&@   %J
M^?,HWE8=SVC&6U((,V<LU,J^35CV3LRAZ2";>E2J.453I_@C5I[VM!NVV)B:
MLW3,;RZ@8:
M
M
M
M
M                                          ;5\J=!D\63KHHBU<*D
MK6E*TH=-(YRUK2O970U %M>W#)EWY%\\O.M^@^[G\W>@Y+!FRY7>'?O5<72(
MI<WCZ%/3BUX=.SRU&[[8MI1FV9G?7/##0   "U> RC>3_<%)V"YD$#VPV=3*
M2+.D>R(L4C.*4=(4J\*C1T;A6+2M=3=ODKV#<VQH5^+-9TJ?!=0,-
M
M                                                     +5\V91O
M*R\@6; 6_((-8R8:QRK]%6/9.CJG<3:[)6I5G"*BJ7$W)2GO:TTKV^4;MMB8
MF99F9JNH&&@  0%B.4P^_G;B2QQ$+QTLB@6LTJLC()E61ZPY:4*9X\<IF_TG
M6OO:%K_R#5VE3=WDBGP3Z,J
M
M                       @*(E,/J9@?1\;$+IY**O)T=R-49"B)UB1YSOJ
MT5.\,SKQL]:4T2I37R:5[1J=+1_V4W*_BGT94   ! 6:)3#\<Z@"Y0B%Y-=5
M"0K#F11D%:(HD4:4>T-T3QK0O&<R?WVOD[-!NV+O[J33XI]&%
M
M         0%;4IA];+,TQ@HA=#(B:\U24D#(R!4E5DS_ ,J5*HJ\4:5YIO)P
MITI7W-!J=+1W=Y(I7<WT^C*@   ("RY*8?83MNI9'B%Y&660-6%511D%"HH]
M80M:&,S>-DR_Z3I7WU#5_P"0:MTJ;F\DT^*?1E0
M
M
M
M
M
M          &@ZJB5JY,XIQ(406JN6FM:F1HF:JE*:5I7M)KY $(X5D\2R/G+
M\5L4O&<GN;OWG(OTN?S.]>[.'K7;KBY7 XUX>'3B[=>S35VE_>2*?!.HRH
M " HB4P^IF!]'QL0NGDHJ\G1W(U1D*(G6)'G.^K14[PS.O&SUI31*E-?)I7M
M&ITM'_93<K^*?1E0
M
M               $!90E,/LKPMIO?T0N^N59!G6"<I(R"A$$32BI&U#&:O$$
M2\+^AC>^*:NGE[.P:MTJ;F\DTKN[Z?1E0  6VX3P[<V-[BNB7G'T$[;3;8J+
M0D2ZD%UTS4?'<UJX*\C&*9"\LVGO3'[?W.T;NNB8B(9B*+DAAH
M
M                                                 !;;"8=N:-SC
M(Y,7?01X%VYEEDVB3J0-+E*_C%&:-#H'C$V=#%5-J;1Q70ODUKV#<W1HZ/Q9
MINU7)##0   "VW/6';FRD[MIQ;[Z"9DAFTFBZI,.I!N90SU5D=*J%&49(4,4
MM&QN+BJ736FFON;LNBW?9F*KDAAH
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MCXQ,1,?&'V)ELUE\Y@QF,K?;?@W;TQ_J_"?G$[L?%7X\QY
M                                                      #;/$3.
M&CIN2I:'7;+HDJ:M:%H95(Q"U-6E#5H6E3=NE*@+?L!8CN3%?G9YPO8-YW[W
M%TG<SE^XY?=??/4=3UT;'<''WB3@X>/70VNFE-=WW1=O,VQ1<4,-    +;83
M#MS1N<9')B[Z"/ NW,LLFT2=2!I<I7\8HS1H= \8FSH8JIM3:.*Z%\FM>P;F
MZ-'1^+--VJY(8:
M
M              6VY>P[<U_WQ:=RPSZ";,()LQ1=I2;J01=J&:RZS]2K9-K&
M/43EJBI2E.)0GONRNE.T;MNB(F)9F*S5<D,-   LKVQ3T[+7C?2$K-2TF@W9
M$,W1D)%X]20-WJH3B13<K*$2KP4TU+2G9V#I?&Y#-J]0<V@
M
M                                              %E=KSTZMNDF(A6
M:EE8DCVX"DBU)%X>.(5*$543*1D9:K8M$U*<1:4+V5[:=HZ3'_AL_P!Y>H.;
M0   "RO=C/3L-(626'FI:)*X93AERQLB\8E6,FO&43,M1JLE12I*'KI6NNFM
M=!UPXW)9N7J#DT
M                                  LKL">G7.Y>[(ES-2SB+1>W:5&-
M7D7BL>D5%71$J3-18S=.B5/O:4+3A]P=)C]$,Q_$O4'-H   !97N=GIV)O&Q
M4(J:EHQ!PR.9PC'R+QDDN;O5,G$LFV63(K7@KIJ:E>SL'2R-R6;EP^:_]S>6
MOZLK\_HK*CP\W_TN+_AW?ZI<\Q_T]_\ N7?ZI8[,>E3UW
M
M
M
M
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M=_\ &V?[T?G'QBFZ[%Q\T?(@
M                              ;*1,8D>_,4U2F*R=&*8M:T,4U$#UH8
MM::5I6E:=E0C?%HFTJ=FYKXP.^)B5ENF\U>F[SD';_I^=YR<[D=4LKRN;RB\
M7#IQ<--?)0=,3X,VKR!S:    65VO/3JVZ28B%9J65B2/;@*2+4D7AXXA4H1
M51,I&1EJMBT34IQ%I0O97MIVCI,?^&S_ 'EZ@YM
M
M                                       +*]Q$].Q>4; 9QLU+1S1R
MRBC.&K&1>-&[@Q[B<I',N@W6325J=*E"UJ:E=2TT\@Z61^F69WUZ@YM   @+
M$>8&N1YVXHE"T4+=-"H%6.[2DTWQGM*O#MN R9(B.JEI4O%K4Y_N?NC=UM(J
MD35/HPH
M
M      " HC,#62S ^QJ6T4&R[1>31K<=)--196K&/.\J>K"D0F<O/H7@K3J:
MZ:Z]OD&YM_35*[M$^C"@   (#S1F!KB]U (.+10N:LPA(+%46DTX^K.C-1H2
MI"E/$2?-YW4:ZTJ33A]W7LW;;I?%)FB?!A0
M                                                      $!6UF!
MK.Y9FL=DM%!BO%KS2)KA+)IK*NJQ9^$QS,:1"!T^J]VG4&X?^D-S;^FJ1.[1
M/HPH   " LN9@:XXG;=B5[10N(TT@98CM6338F94H\(VX"IGB)&JNM3<6M#D
M^Y^Z-VVUBJ3-%89K_P!S>6OZLK\_HK*CQ,W_ -+B_P"'=_JERS'_ $]_^Y=_
MJECLQZ5/7<
M
M
M
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M/PF'-CJV
M            T'2U&[5RO4G,H@@LM5.M>&AZ)IF/P<6AM.+ATUTJ A'"N6FV
M4O.7I[40MCN+N;CY,DG(==WGWKP\7!$Q?)Z;N^NFO'Q<S_FZ=N[K='XI$U3J
M,*    @*(S UDLP/L:EM%!LNT7DT:W'233465JQCSO*GJPI$)G+SZ%X*TZFN
MFNO;Y!N;?TU2N[1/HPH
M
M                  " LH9@:V#=]M6TM:*$\I.H,UB22LFFS.QHYE%6%"%0
M/$/S+<LR?,UHH36M=.SRC=MM8F4F:31/HPH  (*Q3CFQK,F[@D+5N[SB>R:!
M4Y!IWE#O>B3H[,O0_+C2%52U5K4NI^SW/*-73,QNI$1&\G494
M
M                                                !!43CFQF66GM
M[-+NZF['"\BHM;G>4.?E*.F!VSDG0IDI)%Y"!JGTK76FFM>P:K.C3X)2*U^*
M=1E0   $%9BQS8U].8%6\+N\V5(U!^FQ3[RAV'6$<J-3+GTE"',KR3(EIJ3L
MIQ=OEH-VW3&\DQ$[Z=1A0
M                                        $%6YCFQHK*<S>4==W772
M_7F5'EO=Y0ZO2J/SZO"=$@2DBGTM>S0U=2_\X:F9T:?!(B*_BG494   !!65
ML<V-><W;\A=5W>;KV,0,G'M.\H=EUJ=795ZGY<D0RJNBM*%U)V>YY1JV9B-Q
M)B)WU49K_P!S>6OZLK\_HK*CQ<W_ -+B_P"'=_JERS'_ $]_^Y=_JECLQZ5/
M7<
M
M
M
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MU:3N/MO9.V\CMC"TLM=3&B/U63_%;PQ^,;GSI.XO#'R1_7
M                                                !H.DR+-G"2I^
M6FJ@JFHIK0O 0Z9BG/J;WM.$M==:]@"&,-X]LFQ/./S.NOSG[U[H[Q_E&)?]
M#T/>G2?ZK(3E=3UBO[Y]]R_>^2HU==,[Z1$1O)N&5    05$XYL9EEI[>S2[
MNINQPO(J+6YWE#GY2CI@=LY)T*9*21>0@:I]*UUIIK7L&JSHT^"4BM?BG494
M
M                                                           !
M!62\<V-=MVVY-W+=W<4M%(,TXZ-[RAV?7)H2:KM$_(?D,Y5YKD]4]4ZZ5TTI
MVC5LS$4A)B*IU&5  !:!MSL6[K5NR]'MQ0+^):2#0A&2[LA"D<'I)*+5*G4I
MS5K7EUU_R#I?,3$49MB8WUWXYM
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M >VRP3D;V?&N%M,QBU]N+B4[@HTCWR+PD6],LHW*1&JX7>@
M                               +0+;L6[FFY.6NQS OT;;7=SATI@Y"
M=(<CF'500,4U#U-HJM6A:=GE'29C0I\6:3I5^"[\<V@   %H.Y^Q;NO!_9ZE
ML0+^938-)DCPS,A#4;G76CC(E4XSDTJI1(VG^0=+)B-]FZ)G>7?#FT
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M^-<+:9C%K[<7$IW!1I'OD7A(MZ991N4B-5PN]
M          6@6-8MW1VX>Z+I?0+]M;SQW=!VLLH0E&BQ'BFK4Q#4/4U:+4^]
M[!TF8T*?%F(FM5WXYM    +0-QEBW==5V66]MV!?RS2/:'(]7:$(8C<]9)-:
MA5*F.6M*\NFO^0=+)B(FK-T3.\G+-?\ N;RU_5E?G]%94>'F_P#I<7_#N_U2
MYYC_ *>__<N_U2QV8]*GKN
M
M
M
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M6L*H
M   #:2!#JL'J:9:G44:.2$+3RF.=$Y2EI^[6M0@6K[7;)NNSO/GSG@GT+WCY
ML]#UI"$ZGH_.#J>7P'/KR>J3U_\ /H.E\Q-*,VQ,;Z[,<V@   %H%MV+=S3<
MG+78Y@7Z-MKNYPZ4P<A.D.1S#JH(&*:AZFT56K0M.SRCI,QH4^+-)TJ_!=^.
M;0
M
M "T#/5BW=<N2;&EH&!?RD;'-(PCYXV(0R+8Z,\X<J%4J8Y:TJ1 U#5[/)4=+
M)B(FK,Q-5WXYM   M>P1E:[L@7-=D7<2S%5I#M2JLJ-&)&IRGK(';UYAR&K5
M2G++_P"4;NMB(BC,35=",-
M     ^3D(H0R:A2G3.4Q#D.6AB'(:E2F*8IJ5*8IBUTK2O96@#"3>+]BRT,*
M^*+OUQC8$+'6U9-L;HLM$M>VX=N1G#V["RUT/9UC Q#)(A$6,5#(RE&S9!.E
M$T4$BD+[TM &8BV"8ML?"NR':7B_'%OQEL6=:6WG$K.+B8EF@Q;5</+*AY29
MEG":!2T<2]PSC]S(2#D_$L\?.EEU3'54.>H7<@+,?$7Q):.==A>\7%5\0$9<
M<#=NVS,K7H)5LBY1;3+2P9V2MN;:56*;HY>W;B9M7[%T3A5:/&R:R9BG(6M
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M267*PE$73,RAE&QZ@,CR
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MS(R,Q99"QM<K>QIZPKW8H<UP@B:9M]ZD5ZW267*PE$73,RAE&QZ@,CR
M                            M>L_*UW36<[BL)\LQ-;T:ZN))JFFQ(FZ
MH2-4X6O&ZH:ICUI3[[L[1N;8T:_%F)W:+H1AH   !:]G?*UW8_N:TXNW5F*3
M28:F5>T=L2.CF/20(WIRSG-2J=.6;_RC=ML3$U9F:)4S7_N;RU_5E?G]%94>
M)F_^EQ?\.[_5+GF/^GO_ -R[_5+'9CTJ>NX
M
M
M
M
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MGX3,)\']=YX
M         -J]5.@S=KIZ441:N%2:TUIQII'.76GNTUH MQV[91NS)7GAYSK,
M5>Y?-_H>C9$9\/>/??4\S@,;F:] GIKY-*_=&[[8MI1FV:KF!AH   !:] Y6
MNZ0S[)X\<K,:VVU=3"221&)".Z$91:CM#B=T-QFK18M->SMIV#<VQH5^+-?U
M470C#0
M
M     "U[-&5KNL>_K/MZ!68IQLTUCU7Q7+$CE4QW$RNQ5Y:IC4JG2J"=*4T\
ME>T;MMB8F99F:31=",-   @K%+[#;N;N F-6?32Z:!:SA^GFD>-'JS4I3BDS
MF1-_I6M?>=O_ "#5VE3=WDBGP3J,J
M             PMGCM?XPGB(?WF;[_ZUJ S#FUK_ (9-N?\ 41B+^S^W@$[@
M((W2_P##)N,_J(R[_9_<(#$"_5_?\9?P^?Z]V?\ 1>Y0&9Q 0SN-_P"'K/']
M3.4/Z$3@##I>!+_C">'?_>9L3_K70#-)@    /+1]<&_P>Y'^\SA#_JKR =$
M?U(3_B;WS_U$8R_M DP&1S  &.,^N]_\3>QC^HC)O]H$8 [_ +ZHI_@T8_\
MZ]\\?TH:@/21?UL'O6Q;TLU.06B5+MM*X[8)*MM>HC#ST.\BBR"'"8IN<R,[
MYA-*TKQ%IV@,*!M"W+Y]\(7Q![8S''VHFEE[:_DV\+&R1C&Y%GL4RN)DV-,X
M^RECN8<IMU',=WK%.'K=L]Z=?H7E$'A45:HE3,&73\.'Q3=H/BBXB0R=MGR
MV<W!%LF1\E88N=9E%9=Q-*NB%I5C>-JD=.%%(I9Q4R;.98G=PTA4ARH.3*I+
M))!V,@.H_*>R^^9/QH]J&_*TK-:/+#M_9CN$V^9FO5*6MQB[@Y7SRL^Z<-1S
MN%>S#6Y9\L\>Z+F*FNP8NTF-&5:.U4:*MJ'#MP
M                       05$OL-GRT]:1C/AR:5>1H[<]/-%U6*P.9_7G*
MGK%UXF6M.RFE?<[1K]6C_LIN5_%.HRH   ""LQ/L-LW,#3*C/JG"B#^L-7IY
MI?@1*HUZVFL4<I2\1ZI_?]M=.SW1NV+O[J33XIU&%
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MT^*J,U_[F\M?U97Y_165'BYO_I<7_#N_U2Y9C_I[_P#<N_U2QV8]*GKN
M
M
M
M
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M.CEL[3"SL[D?1?/X3.]/^S,_V3.\[CA]E/F
M                                 T'54:-G%7%-6]$%:KTT-75&B9N;
M30OOJZDU\G: AC#;[$+SSC^*IGTO+[H[^_T>80YG'WIW7_K8YN+AX7/[WY-?
M?>X-7:7]Y(I\$W#*@   (*B7V&SY:>M(QGPY-*O(T=N>GFBZK%8',_KSE3UB
MZ\3+6G932ON=HU^K1_V4W*_BG494
M
M                           !!62WV&VUVVXED!GU%S*(,ZP*O3S2O+1K
M)JE:TXX\Y6I=)"AJ_A*:_=[!JW2IN;R32N[OIU&5  !;;A/#MS8WN*Z)><?0
M3MM-MBHM"1+J0773-1\=S6K@KR,8ID+RS:>],?M_<[1NZZ)B(AF(HN2&&@
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M&49(4,4M&QN+BJ736FFON;LNBW?9F*KDAAH
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MS%4BYK_W-Y:_JROS^BLJ/$S?_2XO^'=_JESS'_3W_P"Y=_JECLQZ5/7<
M
M
M
M
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M&'VCE<WEL]@QF,I?;?@W?&/]4QOQ/SB:3"1QYKR0
M                                  ;9XB9PT=-R5+0Z[9=$E35K0M#*
MI&(6IJTH:M"TJ;MTI4!;]@+$=R8K\[/.%[!O._>XND[F<OW'+[K[YZCJ>NC8
M[@X^\2<'#QZZ&UTTIKN^Z+MYFV*+BAAH   !;;"8=N:-SC(Y,7?01X%VYEED
MVB3J0-+E*_C%&:-#H'C$V=#%5-J;1Q70ODUKV#<W1HZ/Q9INU7)##0
M
M                                                     "VW+V';
MFO\ OBT[EAGT$V8039BB[2DW4@B[4,UEUGZE6R;6,>HG+5%2E*<2A/?=E=*=
MHW;=$1,2S,5FJY(8:  !9EMHNFYIZ\+X;3EQ3LRV:,R&:-Y:7D)%!L:LHHG4
MS=)XX631-RZ<.I:4[.SR#I?$1$49M7FCFT
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M0Q3%,6M2F*8M=:5IV5H ^@
M     696S=-S.-STQ +W%.K0*3R>*G"*R\@I$)E1A5542DC3N#,R%25IQ%I0
MGO3=M.T=)B-"OQ9_O+S1S:    69;J[IN:W9"RR6_<4[!$=,YLSHD/+R$85R
M9)>-HD9<K)PA18R=%#4+4VNG%73RCKAQ$QNLW+S1R:
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M0A5$S%.F<I3D.0U#$.0U*&*8IBUJ4Q3%KK2M.RM 'T
M             "S*PKIN9YN2NN"=W%.NH1L\NLK>'<R\@O%(%;*:-RHQZK@S
M1(J%/O*%)3A]S0=)B-"OQ9C^)>:.;0   "S+<O=-S0-X6.V@[BG89L[9G,[;
MQ,O(1R#DU)1-.AG"3-PBFL;EUX=34KV=GD'2R(F)JS<N S7_ +F\M?U97Y_1
M65'AYO\ Z7%_P[O]4N>8_P"GO_W+O]4L=F/2IZ[@
M
M
M
M
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M1TF(T*_%G^\O-'-H
M
M               !9EN$NFYH7)UA,(:XIV)8/&<69VRC)>08-'1E+@<HJ&<M
MFKA)%<QT2T)6IBUU+32O8.ED1-LU9G?7FCFT  ""L4Y>C,BS=P1+&U^X585
MJRKGJF[CJZ5=F;</"BR:F)H8O%VU,-76S$)$U3J,J
M                         PMGCM?XPGB(?WF;[_ZUJ S#FUK_ (9-N?\
M41B+^S^W@$[@((W2_P##)N,_J(R[_9_<(#$"_5_?\9?P^?Z]V?\ 1>Y0&9Q
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MM87Q; 7<1^?F/BW/#V/!1T^5XIQJ\;LLJV5HI7B-J?7MKY0$T
M                                 @J)R]&2.6GN-T[7Y#]HO(HFG^J;
MFYM6+ [PYNG*R*M3G%+P?OM=/W?(-:,Z-?@E=VB=1E0   $%9BR]&8Q<P*$A
M:_G%680?K)'ZINVZ6C-1J0Y=%V3NI^;5Q2O9PZ</NC=MLSO),T3J,*
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MGA['@HZ?*\4XU>-V65;*T4KQ&U/KVU\H":
M      05;F7HR<RG,X\1M?HWT6O,HJ3O5-S]16+/PJ&Y!62:Q>I_=5KI[NHU
M-LZ-?@D3NT3J,J    @K*V7HS'4W;\2^M?OY6:0,LDYZINWZ2E'96W#PK,G1
MCZF-Q=E2C5MLS"3-%49K_P!S>6OZLK\_HK*CQ<W_ -+B_P"'=_JERS'_ $]_
M^Y=_JECLQZ5/7<
M
M
M
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M#+X66LT,**1^<_VRNJ'D.P
M                -!TM1NV<+F+QT0056J373CHFF8]2ZUI6E.*A= $,8;RQ
M&Y0\X^[[9\W>X^Z.=_I3=SUG>?>G+_>&;3@Z?N\WEXM>/LTT[=76S;OI$U3<
M,J    @J)R]&2.6GN-T[7Y#]HO(HFG^J;FYM6+ [PYNG*R*M3G%+P?OM=/W?
M(-:,Z-?@E=VB=1E0
M
M               $%9+R]&6'=MN6V\M?OI><09K(O^J;H='1S)JL"EY:K)P<
M_+.GQ]ARZZZ?NC5MLS%4F:31.HRH  (*Q1BVV;#F[@DX.Z_.!S+(%2=M>9'G
MZ,M'9W%#Z,U5%*:J&X??4I_Y1JZZ9C=2(HG494
M                    %CFY/Q,?#ZV@+WA%;D-Y&W7%=XV)$,9RY,7SV5;1
M7S*VCI5JU?1*C'#$5)R&4YE:68O4G#5)G$+JKMU*+$+5+4] PT_B ;C(W=UO
M?W8;FX-F_CK;SCGW)^1+3CI4B:<K'V;<%UR3JSF$J1$QD2R;*UZM$G%"5J6B
MQ3:5K0!E0?"N\<KPV=QVT';O'3>[3!F%<SVMC+%F,<A8=SEDBT\07BQR7#VW
M'6N^CK/:9 D[=;9&A9F5C*K1SR!4D$S-W3=)Q1L\,HT3#OZ >>?Q>?&[\.G
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M(,SR:*3BY6K!JFDFHP56<'#(#@
M          (*B<6VRPRV]O\ 0NOJ)YRO(JJ6[S(^O*,\8':K$X"*U>?@4C<?
M:7W.WL&ING1I\$INU3J,J    @K,6+;9R(Y@5K@NOS;/%(/TFI.9'DZLKM1J
M=4_^FJIUKR:H%I[W7[[M&K;IC>28JG494
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M2$'(Y,M*T[XG[;L[(;^*;-F:"3V?@HU(JKE-(B<F="K].G+=% =QX
M                     ""K<Q;;,/E.9OII=?6S<BO,JN(#F1]>F-(GXG!.
M!)4SNG35[/?%I^Z-3=.C3X)3=JG494   !!65\6VS?DW;\G.77YON8E R31K
MS(\G6%J[(XJ?1XJFI710O#[VE?\ RC5MTQ&XDQ55&:_]S>6OZLK\_HK*CQ<W
M_P!+B_X=W^J7+,?]/?\ [EW^J6.S'I4]=P
M
M
M
M
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M=N@D4B2*"*1*%(0M*%*6E*4IH/DF\_N-<
M                             !H.DBKMG")S\LBR"J1S]GO"J)F(8_;V
M>]I77M 0QAO&5MXY\X_-ZZ?.7OCNCJ_PC _1=W]Z=/\ Q%533J>N/]]I^]]G
MNC5UTW;Z1%$W#*@   (*B<6VRPRV]O\ 0NOJ)YRO(JJ6[S(^O*,\8':K$X"*
MU>?@4C<?:7W.WL&ING1I\$INU3J,J
M
M                             @K)>+;9O2[;<GYFZ^XW\.@S2:1W,CR]
M:5O)JO4SZ.E2+5YBQZD][2OD[.T:MNF(I"3%9JG494  %G.VVSKJMN[KV>3]
MORT.U?,R$9N)!DLU2<FI)J*U*B=4I:'KRZ\79[@Z7S$Q%&;5XPYM
M
M "D+"Q]86*[1A,?XPLBT,;V%;+95G;=D6%;4-9]HV^T7=+OEFL);=O,HZ&BF
MRSUTJL8B"*93*J&/6G$:M:A'N9=L>VS<8R0C=PFWO!V=XYJ5N1LPS+B>PLH,
MFY&CA5VU*@UO> G$$2MG2YU4Z%+2A%#F-32M:U 41B38MLDP#/'NG!&SK:OA
M2YU#-CJ7'B3;WB3&\\H=E1S1F8\O9UHPT@8S2CQ;E5JIJGS3\.G$;4+J
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M*";5DP8,FJ:39FR9MDBII))E*1,A:%+2E*4H WH
M       "SFQ+.NIAN,NFXWMORS6!=/+J.VEUV2R<>N5TIJV,DY,6B9Z+T^]T
MKVCI,QH4^+,?Q+QAS:    6<[DK.NJY+NLEY 6_+3#5BS.1XXCV2SI)L:LFF
MK0JQTBFH2O+IQ=ON#I9,1$U9N3SFO_<WEK^K*_/Z*RH\/-_]+B_X=W^J7/,?
M]/?_ +EW^J6.S'I4]=P
M
M
M
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M^E\XRN3P<K;3#C]7QF=^?_CY.PT>:\H
M                             &SD"'48/DR%J<YV;DA"%IJ8QS(G*4I:
M>[4U:Z4"-\6H[5[1NBU?/OSD@96#Z_S7Z+O-FLTZKI?.+J.1S2EYG)ZA/BT\
MG'3[HZ7S$THS;"[H<V@   %G-M6==3;<S+W,XM^61MY9Y.G2F5&2Q8Y0J\,J
MBB8KJI>56BJM>$O;VU[!TF8T*?%G^\O&'-H
M
M                                  !9SG^SKJN#)=B2<);\M*Q[!G&$
M>O&+)9PW:F2GW#A0JRJ9:E3J1 U#UU\A:ZCI9,1$U9G?7C#FT  "V7!V7+JR
M)<EU14^G$D:PS8JS.L>S6;*U/5^=M7G'5=N*'IRR^Y2G:-W6Q$1,,VS5<T,-
M
M
M+98++EU2.=Y+'#A.)I;S1S+HI'39K%D>!C&*/$>-S5V9*M:JEIQ?@Z:T^X-S
M;&A7XLU_51<T,-    +9=P.7+JQD\MA"W$XDY)=M**N^\F:SHU#,U61$>35)
MVVH2FC@VNNNO8.EEL7;[-TS"YH<V@
M                                                %LMHY<NJ;S;<
M&/7J<32!C'-PHMCH,UB2%219^%MS7!G9TS5K3[[1.FO[@W-L:-?BS$[M%S0P
MT    MESCERZL=W):L5 )Q)VLRV,L\K(,UG*M#T?D;4Y)TG;>A*<LWNTKVC=
MML3$S+-TT2;FO_<WEK^K*_/Z*RH\3-_]+B_X=W^J7/,?]/?_ +EW^J6.S'I4
M]=P
M
M
M
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M@
M-L]5,W9NUR:<:+9=4G%34O$FD<Y>*E*TK6FI>T!;OM\RO=&3_.[SD3BB=Q]P
M=%W8T6:Z]Y=]=1S^:Z<\>G=Z?#IPZ=OEU[-WVQ;2C-LU7(C#0   "V6"RY=4
MCG>2QPX3B:6\T<RZ*1TV:Q9'@8QBCQ'C<U=F2K6JI:<7X.FM/N#<VQH5^+-?
MU47-##0
M
M      "V7,>7+JL2^[1MR$3B3Q\VV8+/3/F:R[BAW,PLP4Y"B;M I*<A.FFI
M3:&[?W!NVV)B9EF9I-%S0PT  ""L4_$GWW<'Q7_ZYY!>_O\ :W]YZLVG^T/^
MB_QK7]Y[?^0:NTJ?JWDBGP3J,J
M
M                          @J)^)/XVGO=?\ O4Y\CUG^UO[]T!^\/XQ_
MV<_B.OWG9_F^^&OU:/\ LIN5_%.HRH   ""LQ?$GU,#\;7\8Y#_N3_:W]YYC
M7KO]FO>??\K]^[?\WW1NW2_NI-/BG484
M                                                   !!5N?$G\:
M<SYO_P"\WGS/>_\ M;^_<?\ *_\ '?\ L_\ ??P79_F#4Z6CN_PI%*[F^G49
M4   !!65OB3[[M_XT/\ 7/(-W#_M;^\]677_ &>_T7^-:?OW;_R#5NE3].\D
MT^*J,U_[F\M?U97Y_165'BYO_I<7_#N_U2Y9C_I[_P#<N_U2QV8]*GKN
M
M
M
M
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MY.X(?TWG
M           T'7)Z9QU/\7Y"O4??_O/+-S?WOW_WFOWO;]P!#&&_B9_[1_%'
M_P"J/.#_ &J_]:=T_P"TW_[S^\?_ *__ #!J[2_O)%/@FX94   !!43\2?QM
M/>Z_]ZG/D>L_VM_?N@/WA_&/^SG\1U^\[/\ -]\-?JT?]E-ROXIU&5
M
M                                                      05DOXD
M_.VW/C&_VIY#3S?_ -K?WGO-7I/]1?R=_K'B_?\ M^[[W0:MTJ;F\DTKN[Z=
M1E0  6RX.Q'=6.[DNJ5GU(D[69;%19TCWBSE6AZ/SN:\XBK1O0E.6;W*U[1N
MZZ)B(AFV*+FAAH
M
M             !;+!8CNJ.SO)9'<*1-;>=N9=9(B;Q8TCP/HQ1FCQMJM"I4K
M14U.+\)72GW1N;HT*?%FGZJKFAAH   !;+N!Q'=637EL+VXI$D)$-I1)WWD\
M6:FJ9XJR.CR:)-'-#TT;FUUTT[!TLNBW?9NB97-#FT
M
M  MEM'$=U0F;;@R$]4B:P,FYN%9L1!XL>0H24/Q-N:W,T(F6M*??:*5T_=&Y
MNC1I\68C=JN:&&@   %LN<<1W5D2Y+5E8!2)(UAFQD7E)!XLV5J>K\CFG)(D
MT<4/3EE]VM.T;MNB(F)9NBJ3<U_[F\M?U97Y_165'B9O_I<7_#N_U2YYC_I[
M_P#<N_U2QV8]*GKN
M
M
M
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M(LCX0E0=&P
M             &V>I&<,W:!-.-9LND3BKH7B42.0O%6E*UI34W: MWV^8HNC
M&'G=YR*11^_.X.B[L=K.M.[>^NHY_-:MN#7O!/ATXM>WR:=N[[HNI1FV*+D1
MAH   !;+!8CNJ.SO)9'<*1-;>=N9=9(B;Q8TCP/HQ1FCQMJM"I4K14U.+\)7
M2GW1N;HT*?%FGZJKFAAH
M
M                   !;+F/$=U7W?=HW'"*1)(^$;,$7I7SQ9!Q4[:86?J<
MA--HN4].0I334Q=3=G[HW;=$1,2S,5FJYH8:  !9SMMO&ZKDNZ]F<_<$M,-6
M+,AV;>0>K.DFQJR:B53(D5,:A*\NG#V>X.E\1$11FU>,.;0
M
M                                              "SFVKQNISN9E[9
M<7!++6\B\G2)0RCU8T<F5"&561*5K4W*I1)6G$7L[*]HZ3$:%?BS_>7C#FT
M   LYW2WC=5K/[-3MRX):$(\9S1W9(UZLT*X.BM'%2,M1(Q>.J=%#4IKY-:C
MI9$3&ZS<O&'-H
M                                !9S8EXW4_P!QETVX]N"6=0+5Y=1&
MT0N]64CT"M5-&Q4FQC53)1"GWNE.P=)B-"OQ9C^)>,.;0   "SG<E>-U6W=U
MDLX"X):':OF9SO&\>]6:I.34DTTJ&6(D8M#UY=>'M]P=+(B8FK-R><U_[F\M
M?U97Y_165'AYO_I<7_#N_P!4N>8_Z>__ '+O]4L=F/2IZ[@
M
M
M
M
M     X6X+B@[5BG4Y<4HSAXIF3B</7JM$TRUTKPIIE[5%W"M::$23*910W84
MM:]@\C+97,9S&C+Y6RZ_&NWHC_7/PB/G,[D?%TPL'%Q[XP\&V;KY^$+:+%)N
M?W[Y1;[?MF&-KJN21D"55E9.-(G'JL((JI&[FX;MNARLA"8]M!)54I#.73E%
M190Z:)3U56*V/]K_ &Y]D6X>);B9JV,?.[^COV6?C-=^8^<[D3O16DOF>ROM
M[]<3B1_4S'R_NV_V_/\ MG<^3V<^%E]7_P!OVQJEO9@SC6$W"[I6M$9!K/R$
M>9QC#%<CHDN4F-;:ED..3N"/=%]Y<DFE1]2I"G9-XZM5:*_<NS]C8.4IB8M+
M\Q^4?V1_]9_T4?8>3V9A9:E^)2[&_*/[.'_4]"(_LOZ@
M                                                  -G('.FP?*$
M-4AR,W)R'+70Q3E1.8IBU]RI:TUH$;XM1VKW==%U>??G)/2LYT'FOT7>;Q9W
MTO5><74<CFF-R^=TZ?%IY>"GW!TOB(I1FV5W0YM    +.;:O&ZG.YF7MEQ<$
MLM;R+R=(E#*/5C1R94(959$I6M3<JE$E:<1>SLKVCI,1H5^+/]Y>,.;0
M
M                                                       "SG/]
MXW5;^2[$C(2X):*CW[.,.]9L7JS=NZ,K/N&ZAEDDS4*I4Z!:$KKY2TT'2R(F
M)JS.^O&'-H  $%8HRE;-^3=P1D':GF^YB4"JNW7+CR=86KL[>A-6:2:E=%"\
M7OJU_P#*-76S$;J1-4ZC*@
M
M                     (*B<I6R_P MO; 0M3IYYLO(I*7%RX^G-,S8'=+'
MXR)4>?ADB\':;W>WL&IMG1K\$KNT3J,J    @K,64K9QVY@4;@M3SD/*H/U6
MI^7'GZ0K11J14G^FI*5ISJKEK[W3[WM&K;9G>29HG494
M
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MX>&,?FL'^7@.XL?Z,/\ +@/LW7BZ_P !C3U](?DX>&,?FL'^7@.XL?Z,/\N
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M^7@.XL?Z,/\ +@/LW7BZ_P !C3U](?DX>&,?FL'^7@.XL?Z,/\N ^S=>+K_
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MTA^3AX8Q^:P?Y> [BQ_HP_RX#[-UXNO\!C3U](?DX>&,?FL'^7@.XL?Z,/\
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MX>&,?FL'^7@.XL?Z,/\ +@/LW7BZ_P !C3U](?DX>&,?FL'^7@.XL?Z,/\N
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M^7@.XL?Z,/\ +@/LW7BZ_P !C3U](?DX>&,?FL'^7@.XL?Z,/\N ^S=>+K_
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MTA^3AX8Q^:P?Y> [BQ_HP_RX#[-UXNO\!C3U](?DX>&,?FL'^7@.XL?Z,/\
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MX>&,?FL'^7@.XL?Z,/\ +@/LW7BZ_P !C3U](?DX>&,?FL'^7@.XL?Z,/\N
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M^7@.XL?Z,/\ +@/LW7BZ_P !C3U](?DX>&,?FL'^7@.XL?Z,/\N ^S=>+K_
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MTA^3AX8Q^:P?Y> [BQ_HP_RX#[-UXNO\!C3U](?DX>&,?FL'^7@.XL?Z,/\
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M/]?]JYL>0[
M                  -!TJ5!LX6.3F$1055.3L]^5-,QS$[>SWU*:=H"&,-Y
M-MO(WG'YO6MYM=S]T=7^#8$ZWO#O3I_XBDGKTW0G^^U_?.SW1JZV;=](FJ;A
ME0   $%1.4K9?Y;>V A:G3SS9>124N+EQ].:9FP.Z6/QD2H\_#)%X.TWN]O8
M-3;.C7X)7=HG494
M
M              !!62\I6S9=VVY 3-J=^/YA!FJTD>7'FZ(KB359)DU=)'6I
MRUB5/[VM/+V=HU;;,Q6$F:31.HRH  ("Q'BN"L&=N*4BKQ0N1>70*DX:(I,R
M&9%H\.XXS5;/W9ZZG-P^^*7R#5UTS"1%$^C*@
M
M                                    ("B,5P4?F!]D!*\4',LZ7DU3
MVS1)G19$SR/.T4)50K\[G\ F;CKJC3LIVZ4[1J;IT:?!*;M4^C*@   ("S1B
MN"R,Z@%IB\4+6-%(2"2":R3-2KPKM1H=0Y>J?LJTY-4*4][0WWW;H-VW3&\D
MQ5/HPH
M                         " K:Q7!0V69J^VUXH/Y617FE5K<*DSHJU-)
M'XEB&.F_5<UZ6O975(NONZ#4W3HT^"1&[5/HRH   " LN8K@K^G;=E)6\4+;
M7B$#)-VBR3,YGI:O"..,M7+]H>FAR\/O2F\HU;=,0DQ5/HRH
M
M
M
M
M
M                   #0=)%7:N43'Y95D%DC*5TT(51,Q*GKK6E/>TKKY:
M(1PKC"$QQYR]S7<A=7?/<W4\E-HGT'=W>O)XNE?/=>JZXVG%P_O?9KVZ:NNF
M[?2(HG494   ! 41BN"C\P/L@)7B@YEG2\FJ>V:),Z+(F>1YVBA*J%?G<_@$
MS<==4:=E.W2G:-3=.C3X)3=JGT94
M
M                           ! 64,5P5[7A;5P2=XH0#N&09I-HQ5)F<[
M\K>45>D.4SA^U5IS55*I^](;MI[M>P:MNF(HDQ6:I]&5  !9EMHM:YH&\+X<
MSENSL,V=LR%:.):(D(Y!R:DHHI4K=5XW136-RZ\6A:U[.WR#I?,3$49M7FCF
MT
M
M LRMFUKF;[GIB?7MV=1@57D\9.;5B)!.(4*M"JI(F))';E9G*JK7A+6A_?&[
M*=HZ3,:%/BS_ 'EYHYM    +,MU=K7-<4A99[?MV=G2-6<V5T>'B)"3*V,JO
M&U2*N9DW7HB92B9JEH;37AKIY!UPYB(W6;EYHY-
M                                                           +
M,K"M:YF>Y*ZYUW;LZUA'+RZS-YAS$2"$4N5RIJW,C(*MRM%2KT^\J4]>+W-1
MTF8T*?%F/XEYHYM    +,MR]K7-/7A8[F#MV=F6S1F<KMQ$Q$A(H-C5E$U*%
M<*LVZR:)N73BT-6G9V^0=+)B(FK-R\T<V@
M
M
M
M
M
M     &SD2F/'OB$*8YSLW12$+2IC&,9 ]"E*6FM3&-6NE*4\H1OBTK:A;-R6
MYY^^<-OSD%UGFMTG?,2_B^JZ?SCZCINN;H<_D<\G'PZ\/&7736@Z8DQ-*,VK
MP1S:    696S:US-]STQ/KV[.HP*KR>,G-JQ$@G$*%6A54D3$DCMRLSE55KP
MEK0_OC=E.T=)F-"GQ9_O+S1S:
M
M                         69;A+6N::R=83^&MV=EF#-G%E=O8R(D'[1J
M9.X'*RA7+EJW510,1$U#UH8U-"UUKV#I9,1;-69WUYHYM   MEP=ERZLB7)=
M45/IQ)&L,V*LSK'LUFRM3U?G;5YQU7;BAZ<LON4IVC=UL1$3#-LU7-##0
M
M                                                        "V6"
MRY=4CG>2QPX3B:6\T<RZ*1TV:Q9'@8QBCQ'C<U=F2K6JI:<7X.FM/N#<VQH5
M^+-?U47-##0   "V7<#ERZL9/+80MQ.).27;2BKOO)FLZ-0S-5D1'DU2=MJ$
MIHX-KKKKV#I9;%V^S=,PN:'-H
M                                            !;+:.7+JF\VW!CUZ
MG$T@8QS<*+8Z#-8DA4D6?A;<UP9V=,U:T^^T3IK^X-S;&C7XLQ.[1<T,-
M +9<XY<NK'=R6K%0"<2=K,MC+/*R#-9RK0]'Y&U.2=)VWH2G+-[M*]HW;;$Q
M,RS=-%S0PT
M
M
M
M
M                                          VSU4S=F[7)IQHMEU2<
M5-2\2:1SEXJ4K2M::E[0%N^WS*]T9/\ .[SD3BB=Q]P=%W8T6:Z]Y=]=1S^:
MZ<\>G=Z?#IPZ=OEU[-WVQ;2C-LU7(C#0   "V6"RY=4CG>2QPX3B:6\T<RZ*
M1TV:Q9'@8QBCQ'C<U=F2K6JI:<7X.FM/N#<VQH5^+-?U47-##0
M
M                                                 "V7,>7+JL2^
M[1MR$3B3Q\VV8+/3/F:R[BAW,PLP4Y"B;M I*<A.FFI3:&[?W!NVV)B9EF9I
M-%S0PT  " L1HX73G;BKC)TNXF#(%[]*J6XZ%(CUAZTJ7OILBWK_ *5K^]5K
M7_D&[M*F[O)%/@GT84
M
M                 ! 40CA>F8'RD8Z7-E"J\GUC>I;CY-%JQYZ2%*&7;%A/
M>LM:TX3UI_F]HW.EH_[*;E?Q3Z,*    @/-".%U74!\:[I=LXHA(=RT1+<9J
M'1JHTZZINXFRY*:'HE^^:5_S?=&[=+^ZDT^*?!A0
M                                                           $
M!6TCA<N69I2 =+GR55>:[V0,6XZ)%6J?^5J%JZ;$AO>F\G+/6G^;J-SI:.[_
M  I%*_BGT84   ! 67$<+J3MNUR:Z7;S!4#=Q%2+<=2G1ZPE:U-W*V6;T_TK
M3]]K2O\ R#=NE3<WDFGQ3Z,*
M
M
M
M
M                                                        T'7)
MZ5SU-=&_(6Y]:<6M$>6;FU]YJ?[S7R=OW $(X52PZEYR_%,Z7<\7<W?_ #BW
M"7@T[U[JX>_FZ&O%JYUY6OD]]I[T;NTO[R13X)U&%    0%$(X7IF!\I&.ES
M90JO)]8WJ6X^31:L>>DA2AEVQ83WK+6M.$]:?YO:-SI:/^RFY7\4^C"@
M
M                                                       ("R@C
MA=2[[:-D-TNA=!4&?<":1;CJ0Z-)16K6IJQ#99E360XJ?A34KIY?>Z#=NE2:
M;R32N[OI]&%  !:]@C%-W8_N:[)2XD6*328:E295:/B.CF/20.XKS"$+2J=.
M6;_RC=UT3$49B*+H1AH
M
M                  !:] XINZ/S[)Y#<HL:6VZ=3"J2I'Q#NZD>Q:C1#B:4
M+QEK58U->WLIVC<W1H4^+-/U570C#0   "U[</BF[LD/+67MA%BJG$M95)YU
MCY-I4IW:K$Z/+H<IN.E:-S:_<&[+HMWV;HJNA&&@
M                                                           %
MKUGXINZ%SG<5^OD6);>DG5Q*M5$WQ%'5222G$UXVM"T,2M:??=O8-S=&C3XL
MQ&[5=",-    +7L[XIN[(%S6G*6ZBQ5:0[4R3VKM\1J<IZR!'%.60Y:U4IRR
M_P#E&[;HB)JS,570C#0
M
M
M
M
M                                                  #:O4CKLW:"
M>E5%FKA(FM=*<:B1R%UK[E-:@+<=NV+KLQKYX><Z+%+OKS?Z'HWI'G%W=WWU
M/,X"EY>G7IZ:^76OW!N^Z+J49MBBY@8:    6O0.*;NC\^R>0W*+&EMNG4PJ
MDJ1\0[NI'L6HT0XFE"\9:U6-37M[*=HW-T:%/BS3]55T(PT
M
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M]'"ZSM-1#F,%DT-"%0+733BIQ=ON"6VQ,5F29F-Y4OQEW;\2?QC>;B'G3_\
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M7B]_6M.W[HU=$Q&ZD3$[R?1E0
M
M                        $!1&2+/>Y@?60VLM!K<K=>335NBC:+*LL=I'
MG<KGJNFA1_7J$2U)74^M:5[>P:F)T:_!*Q6GQ3Z,J    @+-&2+0L-U (W19
M:%UJ22$@HS46;1;BK(C91H58A:R""QB\\RQ:^]TI7A[?<&[;9G>29B-]/HPH
M
M                   " K:R19\KEF:LQC9:#"XF"\TFZN4K:+(J[.P/HZ.9
M=% KXW5U[:\1ZUK[NHU,3HU^"1,5I\4^C*@   ("RYDBS[*G;=CKCLM"YG<H
M@91D\6;1:YF)*/"(5(4S]!54NJIN+WE:4[/NC5L3,;B3,1OI]&5
M
M
M
M
M
M                       :#I0B+5RLH3F)I(+*'3K2E:*$(F8QB5H;4M>(
MM-.WL 0CA7(=I7[YR^:]G(6GW5W-UW);1C?K^N[UZ;B[N01X^EZ-33CUTYG9
MY:C5ULQOI$Q.\G494   ! 41DBSWN8'UD-K+0:W*W7DTU;HHVBRK+':1YW*Y
MZKIH4?UZA$M25U/K6E>WL&IB=&OP2L5I\4^C*@
M
M                                     ("RADBS[1O"VH2?LM"X9*50
M9J,915M%K'8$7E%6B1"J/4%7!.4X)53WE:4UKV=HU;$S%829BJ?1E0  05BG
M$,9CJ;N"68W1W\K-(%15;=*W;])2CLSGBXD7KHQ]3&X>VA1JZZ9A(BB=1E0
M
M                                                          $%
M1.(8R.RT]R0G='/?NUY%8T!TK<O*J^8'9G+U!7IEJ\DIN/\ >J:_N>4:TIT:
M?!*;M4ZC*@   (*S%B&,R<Y@5Y"Z/-VL.@_12)TK=SU5'BC4YS:KO6E2<JK>
ME.SBUXO<&[;IC>28JG484
M                                        !!5N8AC(/*<SD-&Z.L?2
MB\RLI!=*W)T]90_$H7GE>J+&Z;]U*FONZ#4W3HT^"1&[5.HRH   ""LK8AC,
MBS=ORSZZ.X585 R*3;I6[CJZ5=E<\7$L]:F)H8O#V4,-6W3$),53J,J
M
M
M
M
M
M                           T'2-'#9P@8W!1=!5&I]->"BB9B5-I6M*5
MX:&U 0QAO$\;B_SC[ON;SB[\[HYW^BMVW1]V=Z<O]X>.^/J.\#>7ATX.S77L
MU==-V^D11-PRH   ""HG$,9'9:>Y(3NCGOW:\BL: Z5N7E5?,#LSEZ@KTRU>
M24W'^]4U_<\HUI3HT^"4W:IU&5
M
M                          05DO$,9?EVVY<CRZ.Y5X-!FBBPZ5NOUE&T
MFJ_*;F*O6YR<PZG!V$-IIK^X-6W3$428K-4ZC*@  LRVT6M<T#>%\.9RW9V&
M;.V9"M'$M$2$<@Y-2444J5NJ\;HIK&Y=>+0M:]G;Y!TOF)B*,VKS1S:
M
M                                                       696S:
MUS-]STQ/KV[.HP*KR>,G-JQ$@G$*%6A54D3$DCMRLSE55KPEK0_OC=E.T=)F
M-"GQ9_O+S1S:    69;J[6N:XI"RSV_;L[.D:LYLKH\/$2$F5L95>-JD5<S)
MNO1$RE$S5+0VFO#73R#KAS$1NLW+S1R:
M                                                    696%:US,
M]R5USKNW9UK".7EUF;S#F(D$(I<KE35N9&05;E:*E7I]Y4IZ\7N:CI,QH4^+
M,?Q+S1S:    69;E[6N:>O"QW,';L[,MFC,Y7;B)B)"10;&K*)J4*X59MUDT
M3<NG%H:M.SM\@Z63$1-6;EYHYM
M
M
M
M
M                                                          -G
M(E,>/?$(4QSG9NBD(6E3&,8R!Z%*4M-:F,:M=*4IY0C?%I6U"V;DMSS]\X;?
MG(+K/-;I.^8E_%]5T_G'U'3=<W0Y_(YY./AUX>,NNFM!TQ)B:49M7@CFT
M LRMFUKF;[GIB?7MV=1@57D\9.;5B)!.(4*M"JI(F))';E9G*JK7A+6A_?&[
M*=HZ3,:%/BS_ 'EYHYM
M
M                   +,MPEK7--9.L)_#6[.RS!FSBRNWL9$2#]HU,G<#E9
M0KERU;JHH&(B:AZT,:FA:ZU[!TLF(MFK,[Z\T<V@  6VX3S%<V2+BNB(G&,$
MT;0C8JS0\2UD$%U#5?';5HX,\DWR9R\LNOO2D[?W.P;NMB(B89B:KDAAH
M
M                                                        !;;"
M9BN:2SC(XS78P1(%HYED4W:360++F*PC%'B-3KGDU&=3&5+H;1O34ODTKVC<
MVQHZ7Q9KNT7)##0   "VW/68KFQ:[MIO;[&">$F6TFLZK,-9!P9,S)5D1*B%
M64G'T*4U')N+BH;72FFGN[LMB[?9F:+DAAH
M                                                      !;;:>8
MKFG<T3^.7;&"3A(IS/HMW39K($E3EBC\+>JRZLFLT,8]/O\ A0+K[F@W-L1;
MI?%F)W:+DAAH   !;;FS,5S8WN*UXB#8P3MM-MC+.SRS60773-1\1M2C<S.3
M8ID+RS:^^*?M_<[!NVV)B9EF9HN2&&@
M
M
M
M
M
M  &V>+&;M'3@E"U.@V76)0U*U+4R21CEH:E*EK4M:E[=*T 6_8"RY<F5/.SS
MA90;/N+N+I.YFS]OS.].^>HZGKI*1X^#NXG!P\&FIM==::;OMBW>9MFJXH8:
M    6VPF8KFDLXR.,UV,$2!:.99%-VDUD"RYBL(Q1XC4ZYY-1G4QE2Z&T;TU
M+Y-*]HW-L:.E\6:[M%R0PT
M
M                      MMR]F*YK OBT[:AF,$Y83K9BL[5DVL@L[3,ZEU
MF"E&RC639(D+1%.E:<29_?=M=:=@W;;$Q,RS,TFBY(8:  !!6*6.&VDW<!\:
MO.IEU$"TG"=1-+<"/5FK2O#)D*B7_2M:>\[?^0:NTJ;N\D4^"=1E0
M
M                                                    $%1+'#9,
MM/7<8\XLFF7D:NVW431M%C,#E?TY*I*1=.%EK7LKI3W.T:_5H_[*;E?Q3J,J
M    @K,3'#;QS URH\Z5PF@_I#4ZB:0XT3*->MKI%$,4W">B?W_;37L]T;MF
M[^ZDT^*=1A0
M                              $%6XQPVGE.9=0+SF9'.O,UE6W431N!
M8Y_Y5IR7!*1I> W^972G_-&ITM'=WDBE?Q3J,J    @K*S'#;N;M\^2GG32Z
M:!J09.HFD>-'JRUK7AC"&1-_I6E/?]O_ "#5NE3<WDFGQ3J,J
M
M
M
M
M
M                     T'5$:MG%'%=&]4%:+UU-31&J9N;74OOJ:$U\G:
MAC#;'$+/SC^*IYU7,[H[^_TB87Y?!WIW7_K8A>'BXG/[WY=/?>X-7:7]Y(I\
M$W#*@   (*B6.&R9:>NXQYQ9-,O(U=MNHFC:+&8'*_IR524BZ<++6O972GN=
MHU^K1_V4W*_BG494
M
M               !!62V.&W-VVXKD!YT]S)H,Z0*74327,1I)JF:UX(\AFIM
M9"IJ?A*Z_=[!JW2IN;R32N[OIU&5  !:]@C%-W8_N:[)2XD6*328:E295:/B
M.CF/20.XKS"$+2J=.6;_ ,HW==$Q%&8BBZ$8:
M
M                                     6O0.*;NC\^R>0W*+&EMNG4P
MJDJ1\0[NI'L6HT0XFE"\9:U6-37M[*=HW-T:%/BS3]55T(PT    M>W#XIN[
M)#RUE[818JIQ+652>=8^3:5*=VJQ.CRZ'*;CI6C<VOW!NRZ+=]FZ*KH1AH
M
M                 !:]9^*;NA<YW%?KY%B6WI)U<2K51-\11U4DDIQ->-K0
MM#$K6GWW;V#<W1HT^+,1NU70C#0   "U[.^*;NR!<UIRENHL56D.U,D]J[?$
M:G*>L@1Q3ED.6M5*<LO_ )1NVZ(B:LS%5T(PT
M
M
M
M
M
M         VKU(Z[-V@GI519JX2)K72G&HD<A=:^Y36H"W';MBZ[,:^>'G.BQ
M2[Z\W^AZ-Z1YQ=W=]]3S. I>7IUZ>FOEUK]P;ONBZE&;8HN8&&@   %KT#BF
M[H_/LGD-RBQI;;IU,*I*D?$.[J1[%J-$.)I0O&6M5C4U[>RG:-S=&A3XLT_5
M5=",-
M
M     +7LT8INZ^+^L^X8%%BI&PK6/2?&<OB-E2G;S*[Y7EI&+6JE*(*4K33R
MU[!NVZ(B8EF8K-5T(PT  "T#;G?5W75=EZ,KBGG\LTCVA#LD'9R&(W/6241J
M9.A2%K2O+II_D'2^(B(HS;,SOKOQS:
M
M                              6@6W?5W.]R<M:;F>?K6V@[G")0YSDZ
M0A&T.JN@4I:$H;1):E#4[?*.DQ&A7XLUG2I\%WXYM    +0=S]]7=9[^ST[8
MGG\,F_:3)WA69R%HX.@M'%1,IQD/K5.BIM/\HZ61$[[-TS&\N^'-H
M
M            !:!8U]7=([A[HM9]//W-O,W=T$:Q*AR5:(D9J:-2D+0E#4HC
M3[WM'28C0K\68F:T7?CFT    M W&7U=UJW99;*W9Y_$M)!H<[U!H<A2.#TD
MDT:&4H8AJUKRZZ?Y!TLB)B:LW3,;R[\<V@
M
M
M
M
M
M     &TD#G28/5$S5(HFT<G(:GE*<B)S%-3]VE:! M7VNWM==X^?/G/.OIKN
M[S9Z'K3D/TW6><'4\O@(33G=*GK_ .90=+XB*49MF9WUV8YM    +0+;OJ[G
M>Y.6M-S//UK;0=SA$H<YR=(0C:'570*4M"4-HDM2AJ=OE'28C0K\6:SI4^"[
M\<V@
M
M   %H&>KZNZVLDV-$P,\_BXV1:1AWS-L<A47)UIYPV4,I0Q#5K4Z!:%KV^2@
MZ61$Q-69F:KOQS:  !!6*<C6-><W<$?:MH^;KV,0*I(.^[8=EUJ=79D*$YD:
M<RJNBM*FT/V>[Y1JZ)B-U(F)WDZC*@
M
M                             (*B<C6,]RT]LEI:/378W7D4UKC[MAR<
MU1JP.Y<GZY,]9(W/0+4FM::UUTKV#5)T:_!*Q6GQ3J,J    @K,61K&L5S I
M7A:/G,I)(/U&*G=L._Z,C91J5<FLH<ADN<98M="=E>'M\E!NVV9WDF8C?3J,
M*
M                     @JW,C6-*Y3F;-CK1Z&Z6"\RF\N'NV'2ZI1@?1X?
MK4#UD5.JKVZFIJ;_ )PU,3HU^"1,5_%.HRH   ""LK9&L:S)NWX^ZK1\XGLF
M@92/=]VP[WHDZ.RH5)S)(Y54M5:T-H3L]WRC5L3,;B3,1OIU&5
M
M
M
M
M
M                      :#I0B+9PJJ3F)I(*J*)Z4-QD(F8QR:&][7B+33
M2O8 AC#>0K)OOSC\SK4\V.ZNZ.\?Y.B6'7==WITG^JSGYO3=&K^^?>\SWOEJ
M-76S&^D3$[R;AE0   $%1.1K&>Y:>V2TM'IKL;KR*:UQ]VPY.:HU8'<N3]<F
M>LD;GH%J36M-:ZZ5[!JDZ-?@E8K3XIU&5
M
M                                 05DO(UC6E=MN0ERVCW[+2J#-2.D
MN[8=YT*:\FJT1)SWYRN4N4Y)531.FE-=:=HU;$S%829BJ=1E0  05BG"OQ8S
M=P3/G+WWWZ@5'INYN[>ET=F=<7.[UD.?]]PZ<)/N_N#5UVE%$B*)U&5
M
M                                                       05$X5
M[KRT]REYR\_K%Y%;N+N;E<OO!@=EP]Y]ZJ<?)X^+7IZ<7D[/*-:7Z=%*;M4Z
MC*@   (*S%A7XV7,"X\Y>X.Y$'Z/!W-WKU/7*-3\7%WK&\GE=-IIH?BXO<T[
M=VW:*3%4ZC"@
M                               (*MS"OF_E.9R7YR]7WLO,K=R]S<CI
M^]C\7#WEWJMS>G^[TY>/]P:FZMNBD12:IU&5    05E;"OQG3=OS/G+W)W$@
M9'INYN\NJU=E=<7.[UC^1][PZ<)_N_N#5MVC%$F*IU&5
M
M
M
M
M
M                :#I'J6SAOQ<'/051X].+@YJ9B<7#J7BX>+736FH"&,-X
M;^*7SC_[1^<'G!W1_P"B.ZND[J[T_P#6DES^?WE_T.'@]W7LU==I)$43<,J
M   @J)PKW7EI[E+SEY_6+R*W<7<W*Y?># [+A[S[U4X^3Q\6O3TXO)V>4:TO
MTZ*4W:IU&5
M
M          05DO"OQB7;;ET><O<_F^@T1Z'N;O#J^EDU9'BZGO5CR.9S.#3E
MGTTU[?(-6W4BB3%9JG494  %E>V*!G8F\;Z7E866C$'#(A6ZTA'/&22YN]5#
M\**CE%,BM>"NNA:U[.T=+YW(9M7J#FT
M
M                               LKM>!G4=TDQ+JPLLE$G>W 8DHI'/"
M1QRJPBJ:9B/3(T;&HHI7A+6ANVO93M'29_\ #9_O+U!S:    65[L8&=F9"R
M30\++2Q6[*<*N:-CGCXJ)E%XRJ95JM45:)U/0E=*5TUTKH.N'.Y+-R]0<F@
M
M                  %E=@0,ZVW+W9+.866;Q:SV[3(R2\<\2CU2K*ZHF2>*
M(E;J45I][6AJ\7N#I,_HAF/XEZ@YM    +*]SL#.RUXV*O%0LM)H-V1RN%H^
M.>/4D#=ZIGX5E&R*A$J\%-=#5IV=HZ63N2S<O4'-H
M
M
M
M
M
M            !LI$ICQ[\I2U,8S)T4I2TK4QC50/2A2TIK6M:UKV4"-\6B;2
MH*;A?C [XAY6)ZGS5Z;O./=L.HY/G)SN1U2*7-Y7-+Q<.O#Q4U\M!TQ/@S:O
M('-H   !97:\#.H[I)B75A99*).]N Q)12.>$CCE5A%4TS$>F1HV-112O"6M
M#=M>RG:.DS_X;/\ >7J#FT
M
M                      LKW$0,[*91L!Y&PLM(M&S***X=,8YX[;MS$N)R
MJ<JZ[=%1)*I$JT-6AJTT+77R#I9/Z99G?7J#FT  "W3#&9)W)5P7-$2L7$L$
M(-N59NK'T>456-5Z=KHMU+E<FG 77WM*=HW=;$15F)JN+&&@
M
M                                               %ND+F2=D\UR&,
ME8N)3B6;B51(_3H\[Q,5A&G>IU-4SDS;4ZA=#:)^3R=HW-L:.DS7=HN+&&@
M  %NF=,R3N*W=N-X>+B9$LRWDEES25'E3)&9*,R)T1Z5RWIH>CFNNNODIH-V
MVZ3,S1<6,-
M                              +=+6S).SV8YW'#F+B48N*<3R*+Y"CS
MO!0L4?A1JK51R=OJI3[[0E/W-!N;8BW29B=VBXL8:    6Z9GS).XUN"V8B*
MBXE^A.-S+.%9"CRJJ)J/2-=$>F<H$TX#:^^I7M&[;8F*LS-$U7=)J0MJ7/,H
MKI-58FWIJ32<K\ODMU&$:Y=$76YWX'E(F2H8W%[W2G;V#MDL*S&SF#@XD5LO
MQ;;9_LFZ(EPSN+?@Y/&QL.:8EF%==']L6S,/#W]-_P"(M\K5K^JG&_HV/TB]
MM_E-J./VG,=8_-7W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_RFU''[3F.L/<
MGYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_ "FU''[3F.L/<GYMZ_@=FR_5GTW_
M (BWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[
M;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;
M>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_P IM1Q^TYCK#W)^;>OX'9LOU9]-_P"(
MM\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_R
MFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^
M!V;+]6?3?^(M\K5K^JG&_HV'MO\ *;4<?M.8ZP]R?FWK^!V;+]6?3?\ B+?*
MU:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\IM1
MQ^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=F
MR_5GTW_B+?*U:_JIQOZ-A[;_ "FU''[3F.L/<GYMZ_@=FR_5GTW_ (BWRM6O
MZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_*;4<?M
M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU
M9]-_XBWRM6OZJ<;^C8>V_P IM1Q^TYCK#W)^;>OX'9LOU9]-_P"(M\K5K^JG
M&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_RFU''[3F.
ML/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3
M?^(M\K5K^JG&_HV'MO\ *;4<?M.8ZP]R?FWK^!V;+]6?3?\ B+?*U:_JIQOZ
M-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\IM1Q^TYCK#W
M)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B
M+?*U:_JIQOZ-A[;_ "FU''[3F.L/<GYMZ_@=FR_5GTW_ (BWRM6OZJ<;^C8>
MV_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?F
MWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWR
MM6OZJ<;^C8>V_P IM1Q^TYCK#W)^;>OX'9LOU9]-_P"(M\K5K^JG&_HV'MO\
MIM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_
M@=FR_5GTW_B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K
M^JG&_HV'MO\ *;4<?M.8ZP]R?FWK^!V;+]6?3?\ B+?*U:_JIQOZ-A[;_*;4
M<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9
MLOU9]-_XBWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JI
MQOZ-A[;_ "FU''[3F.L/<GYMZ_@=FR_5GTW_ (BWRM6OZJ<;^C8>V_RFU''[
M3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]
M6?3?^(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^
MC8>V_P IM1Q^TYCK#W)^;>OX'9LOU9]-_P"(M\K5K^JG&_HV'MO\IM1Q^TYC
MK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GT
MW_B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'
MMO\ *;4<?M.8ZP]R?FWK^!V;+]6?3?\ B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]
MR?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_X
MBWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_
M "FU''[3F.L/<GYMZ_@=FR_5GTW_ (BWRM6OZJ<;^C8>V_RFU''[3F.L/<GY
MMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\
MK5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_P I
MM1Q^TYCK#W)^;>OX'9LOU9]-_P"(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>O
MX'9LOU9]-_XBWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:
M_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\ *;4<
M?M.8ZP]R?FWK^!V;+]6?3?\ B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V
M;+]6?3?^(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ
M<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_ "FU''[3
MF.L/<GYMZ_@=FR_5GTW_ (BWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_
M5GTW_B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_
MHV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_P IM1Q^TYCK
M#W)^;>OX'9LOU9]-_P"(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]
M-_XBWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A
M[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\ *;4<?M.8ZP]R
M?FWK^!V;+]6?3?\ B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^
M(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_
MRFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_ "FU''[3F.L/<GYM
MZ_@=FR_5GTW_ (BWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?
M*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\IM
M1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_P IM1Q^TYCK#W)^;>OX
M'9LOU9]-_P"(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6
MOZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_*;4<?
MM.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\ *;4<?M.8ZP]R?FWK^!V;
M+]6?3?\ B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^J
MG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_RFU''[3F
M.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_ "FU''[3F.L/<GYMZ_@=FR_5
MGTW_ (BWRM6OZJ<;^C8>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQO
MZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\IM1Q^TYCK#
MW)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8>V_P IM1Q^TYCK#W)^;>OX'9LOU9]-
M_P"(M\K5K^JG&_HV'MO\IM1Q^TYCK#W)^;>OX'9LOU9]-_XBWRM6OZJ<;^C8
M>V_RFU''[3F.L/<GYMZ_@=FR_5GTW_B+?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?
MFWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\ *;4<?M.8ZP]R?FWK^!V;+]6?3?\
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M?*U:_JIQOZ-A[;_*;4<?M.8ZP]R?FWK^!V;+]6?3?^(M\K5K^JG&_HV'MO\
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MM1Q^TYCK#W)^;>OX'9LOU:Z/;#]8 SQ9]S]#NEMR*R_8<DY)5>;LV&A;-O\
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MU_OG9\;1^V<WAYC#B(T[/X<7"F?[N+AS2^R=^(F8T;J5LNNC=7#CXH^6
M           V[M8S=HZ<%I0QD&ZRQ2FUX:F23,>E#:5I72M2]H"!,$Y>F\J^
M=7?$9%1W</<?3=V4=TYW>G?'.Y_5.7'[WW<7AX=/OJZZ]FF[K=%F)JN#&&@
M  %ND+F2=D\UR&,E8N)3B6;B51(_3H\[Q,5A&G>IU-4SDS;4ZA=#:)^3R=HW
M-L:.DS7=HN+&&@
M
M             %NF6<R3N/[UM:V8V+B7K2>;L5G#A]1Y5PB9U++1YZ(].Y12
MT*DG0U.(M???N#=ML3%69FDT7%C#0  (*Q1!8CBINX%\=S/>4LX0*691[P7>
M<A'JSGI7EJHIE3_TFM:=E:_<&KININ[R13X)U&5
M
M                                       05$P6(TLMO9:.F>;D<Z\B
M9W&=X+GX%E&!TWU.CJC1(O+9UJ;[[L\HU,W:/X)N5_%.HRH   ""LQ06(YAS
M FR;,]U+H(/RQ!>\%V7.244:U>5T215HIP'(GY=--1JV;H_A2:?%.HRH
M
M               ""K<@L1MLIS,I!S//R$LO,FDX[O!=7E++'UE*=(9$J1.4
M;[AJ\(U,W:.[O)N5_%.HRH   ""LKP6(Y6;M]?(DSW;+-T#%AD>\%V?/1ZLA
MZUY:2*A5/])I2G;6GW!JV;J;F\DT^*I<W_[ELO?U7W__ $4EAYNR_P#N>6_Q
M\/\ XX>%M3_MF8_P,3_@EC/1^R+\8@
M
M
M
M
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MU-]]V>4:F;M'\$W*_BG494
M
M                     !!62X+$<E=MN.[[F>[[C;(,RPC;O!=KST22:JK:
MO)314*KQ/ZF+VUIKIH-6S=3<WDFE=W?3J,J  "U? >+KRL.Y[ND[ECT&;.6:
ME28J)2#)V90])!1Q6ADVRRIT_P $:E??4H-W71,11FV)C?74##0
M
M                                                  "U> Q=>3#<
M%)W\YCT"6PY=3*J+RD@R.L8CR*4:H5JS*M5T7B6-2E=2]GEKV#<W1H4^+-)T
MJ_!=0,-    +5]QN+KRR(]M1:U8]!ZG%M99)[5:09,JIG=JL#H4+1VLE53B*
M@;[W733M'2RZ(WV;HF=Y=0.;0
M                                            "U>S<77E#YXN.^7\
M>@E;<BZN15J[+(,E53DD5.)I4S1-8SDG,IY=2TX?=&YNC1I\68B:U74##0
M "U?/F+KRORY[1D[:CT'C.):F2?**R#)H9,]9!-Q2A4W*R1U/P1:U][2HW;=
M$1-6;HF=Y+&;_P#<ME[^J^__ .BDL/,V7_W/+?X^'_QP\/:G_;,Q_@8G_!+&
M>C]D7XQ
M
M
M
M
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MM]LS$Q,4F)C<F)B=Z8^,/9>R^S$LC$PYBZRZ(F)B:Q,3NQ,3&_$_"6L,M
M      #:ODCKLGB*=-5%FKA(E*UI2E3J)'(6E:U[*:FJ MKVX8SN_'7GEYUL
M$&/?'F[T')?LWO-[O[]ZKBZ197E<'7)Z<6G%KV>2HW?=%U*,VQ,;ZYX8:
M 6KP&+KR8;@I._G,>@2V'+J951>4D&1UC$>12C5"M695JNB\2QJ4KJ7L\M>P
M;FZ-"GQ9I.E7X+J!AH
M
M                 !:OFS%UY7ID"S9^WX]!U&0[6.2?K*R#)J=([>;7>JT*
MBX6355X6YZ5][2NM>SRC=MT1$Q+,Q-5U PT  "TC;QD*\KQNN\F%RSB\JSC6
MA5&*"J#)(K<]9)1&IBF;-D#F_!4I3WU:CI?$1$49MF97;CFT
M
M                                                M(MW(5Y/-QLK
M9CF<75MAN[FTT8FJ#*B)"-8A1P@6BQ6Q75>6L6AJ:J5U]WL'28C0K\6:SI4^
M"[<<V@   %I&YG(5Y60^M%*U9Q>'3D6DPH]*B@R6HN=LM'E0,:KMLXJ7EE6-
M][IY>T=+(B8W6;IF-Y=N.;0
M                                          "TBR,A7E*;@KFM!_.+
MN+;8N[G3:Q9D&14D2,5-&A2JIMB.3<FGDU/77W=1TF(T*_%F)FM%VXYM
M+2-P^0KRLZZ[-86U.+Q3.2:&4?()(,E2N#TDDT:&,9RV7.7\%6M/>UH.ED1,
M35FZ9A,^;_\ <ME[^J^__P"BDL/+V7_W/+?X^'_QP\/:G_;,Q_@8G_!+&>C]
MD7XQ
M
M
M
M
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MV@
M
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MP7->2<S(+/&YI:.=0*;!#G-UZO:40#MI
M     05;E\XRD<IS-K1%G=!>S->9)(7'YO6^UZI5F?20/WNV=GEU^J-VZG3I
M4_\ SM!J8NT:_!(F*_BG494   !!65KYQE:LW;[*^+.\Y)*00,>*=^;UOS'1
M)4=E1J3J)=VW7;:KUH;1.AJ=FOE&K8NF-Q)F(WU2YO\ ]RV7OZK[_P#Z*2P\
MW9?_ '/+?X^'_P </"VI_P!LS'^!B?\ !+&>C]D7XQ
M
M
M
M
M
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MIA3GM:5)J9.E3:Z&TH-4NT:_!*Q6GQ3J,J
M
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MG-NDY$[A/_2UCE#*&$(1,A4TRE(F0I2$(0M"D(0M*%*4I2TH4I2EII2E.RE
M$/Y\V_X8W18FO+!FX#'5LY4Q5?T4XB+FL^ZX\CY@Z163.1%\Q6]X]A9Z+5/1
M=A),E6[^/=$(NV626(0] \(?A"^';*^%_P#6?,F;7:/)&:QXAMFRYD3!]TRM
M4SR%SX;O@]KN[5<2*J238KF:MI\S?0$DL5%!)Q*0[E5(E$3IZAD'@
M                         $!6UA=U 99FLE'GT'*$LO-+%B2QZB2J%)8_
M$4IGE79R'Y'N_@Z<7[@W-U;=%(C=JGT84   ! 67,+NLFSMNS"$^A$%@D#(G
M05CU'AG-:O".N(JA';>B?87A[:5^Z-VW4BB3%56YO_W+9>_JOO\ _HI+#S-E
M_P#<\M_CX?\ QP\+:G_;,Q_@8G_!+&>C]D7XQ
M
M
M
M
M
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M$63H_CSLJ%J]J[,0W*J;BK^#IKY.P;F[].BE-VJ?1A0
M
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M,Y6(EXKP[V\A&2L9(-TW;"1CG[3,ZS1\P?-%B*HK)',FJF:ABUK2M*@-1_\
M6 V,6Q>2<GX,?CYQT;'-'#^0D'_AV(LV+!BS1.X=O'CMQF9-NU:-6Z9CJ*',
M4A"%J8U:4I6H"SBPOKC7AR92O>T<;8[VO>(M>5^W]<D+9]F6E;^(-O,A-W)<
M]Q2#>*A(2*9([J:J.7\E(NDTDB4\IC4\E.T!WH^+%_A9>)9_< WD?^'7(P#'
M._4^?\82._NS9O\ ^MLT!ZR/$B^M@;%-CF0+EPMAJT+DWH9@L]VM&763'5VP
M5GX8MN=:*42?VS(9A<Q]WJRMP1RM:D<EA8*79MEB*(+.4W*2J) IWPQ/K8VT
M[?KFVU-N.9<+71L_RODJ<;6WBM[+9"BLL8IN^Y'QSHQ5I2%_)VGC67M:[;B=
M&20BT7,&=@\='Z?K4W!VZ3@/5V V$K*QD%&2,W-R+"'AH=@\E9>7E7C>/C(J
M,CVZCM_(R+]VHBT8L&+1$ZJRRIRII)EJ8U:4I6H#HP>^-J_S]<-^VKX4^Q;/
M/B8EQP_6@KBS1;=X8[VT;2G%UM%R$DK1MC<5G!\S97I.1#<BBR]8>&?,U$E6
MBK5=RW=D7*'7C?WUJ"Z=G^=FV$O% \*3<9LI7D%"&BKBMG+%I;@&4Q%)K/H^
M4N>WG1K(Q#:-[VI#RQ&J2SZVIN<(9-1>J93K(I-W(>G';-NAP%O'PU:6X#;1
MDZW<M8DO9N=:#NNW3NDZ)N4.$K^%G8:4;,)^UKFB%3T3?1<FU:2+)7WBR)#=
M@"*-WGB*[(=AD 6X-VNY7&&&JN&BSV+MB;FC2V1;A:MR5.LO:V+[8;SF1;G1
M2KPE.HPBW":9U"%,8M3DI4.DG9Q]:+VZ[]_$BPKL/VV;<\GO+*RXMEELIN#R
M9=4'8J\:?&.(+[RHW?0.(HJ&O1]<$1=%;$59IGD)V">-$G*;A1K4]#M:!Z9+
MOO*T,>VU,7I?UU6W8]G6\TJ_G[LN^<B[:MJ#8T431J\F)V:=,HN,:455*7F+
M*D)Q&I376M 'FCWR?6RO#"VJ><%K84G+DWL94B2J-FT1A.B<7B0DMR.H00F,
MZW$UK;KR(52,2AG]K,;L(FH>B=2<9%2IAV,P/C#;7[3\-;!?B4;K)F(VT6)F
M_',)>D1CUQ<3G(UT.KDG63QZSQS8M(VVK=F<BW(LFR-4IF\2T332H9=S1LV3
M56('FWO;Z\/AMA?Y8['/A[Y-NK%E9%!(]Y7MG^UK O\ +$FE%DG+TN-(+&.2
MK=/(I0I4W!&M;L*DHZ,9O5P1,M')P]0?AB>*QM6\5[#$GEG;?+SD=,6:_CX/
M*F)KZ:L(O(V,IV3:JNHY.;81LA*1TC;\ZFU7-%RS)PLS?%;K$U2<H.6Z =5O
MB4?6J]A.PZ^[BPKBV N;>5FZTG,C&7=$XNN&$MG$=F7'&%=MW5HW/F&1;3Y7
M%S-91-)%VC PL\@PKU";I9%ZV,R.%J>R3ZY9M*W!Y8M[%VZ+;G=NSQG>,XRM
MZW<GI94B\U8RB9"379M(]QDB7-8.)YRR(-9VN=-602CI1HRI0BSHZ#;G+MP]
MDR*R+A%)PW537073(L@NB<JJ*R*I:'3524)4Q%$U"&I4IJ5K2M*ZT ;25E8R
M"C)&;FY%A#PT.P>2LO+RKQO'QD5&1[=1V_D9%^[41:,6#%HB=5994Y4TDRU,
M:M*4K4!T8/?&U?Y^N&_;5\*?8MGGQ,2XX?K05Q9HMN\,=[:-I3BZVBY"25HV
MQN*S@^9LKTG(AN119>L/#/F:B2K15JNY;NR+E#KQO[ZU!=.S_.S;"7B@>%)N
M,V4KR"A#15Q6SEBTMP#*8BDUGT?*7/;SHUD8AM&][4AY8C5)9];4W.$,FHO5
M,IUD4F[D/3CMFW0X"WCX:M+<!MHR=;N6L27LW.M!W7;IW2=$W*'"5_"SL-*-
MF$_:US1"IZ)OHN3:M)%DK[Q9$ANP!8KOE\;_ ,,[P]RR\3GO<K:DEDV'<G8+
M8/Q*8F5,PEE$EE$EXR8M6UEG#6Q7*)6ZIC*7*\A6U:IU3HK58Z29PM@\)_Q_
M\.>*?,[UIJ+PY)[;<(;/K;QW>KC*N7<FVXJ^N&SKS99&>SMP7O;<=!M[:Q:T
MLQOCEPJN<MR3R"K97F&50Y9BU#JBS)]=>VI63GMU8V)=I&4\TX"BI>L8^SN?
M(\1CJYIEJW,=)W/6/AF<L:44EHAPH3C8TF;BMYXN@:AEV[0^J5 ]AF#,TX\W
M'8:Q=GS$LUYQ8SS%8=L9&L:9,W59KOK:NV):S,6=XQ7I1Q'2*39W1-RV5I15
MLX(=(]*')6E MUWW[A=RF L70==H^TN[=W.?,D7(>QK#M9E.0EFXQL*0<0\@
M_+D;.5]SDC'(VWCF!.T+S$FYJ/)1P9-FBJV,MU*06E>%SX:-_;7KPSAO0WEY
M'@<]^(_N\4C5<YY/MMBLRL3'-CQ*,4G;. \-MGC=H\;X_M=*$8IK.CH-59*L
M<R*=*A62)C!VU7U?5F8QLRZ<B9$NF!LBP[(@92Z+ON^Z)1I"V[;5NPK15_+3
M4U+/U46<?'1[-$ZBJJARE*4H#SVVAX[F?]WLE<LGX4OA.Y]WUX:M*<DX!YN#
MR%FS&.RS$]UO8E1NW>UQC-9BAYM6]#-W3DM%6BA(^3;)UXUVJ7DH$!9Q^M$U
MV1OE+(\17PK=Z&U?+$A#3KBS8*#G\3Y<QC>\Y!O'#)=I;.:5IS&UNW+;+=0S
M3JY:%:2]6W54K1JJ3DG7#T=;3LZ?.@VL;:=R_FMYC_.(V_X;SIYE=]^<WF?\
M;>.K<O\ \UO./NBW_.#S?\X.DZ[H&/5\GF].CQ<LH3^   #IX\1KQO-F?APW
M5;^&;P4R!GO=9?*;!.P=J6W6VR9 R_,R$_5%O:B4^T*]91=G-[C?/$*-$G2Q
MYA\W4JM'1S^A*DJ%H5Z>,CXI6*+/<9LRS]7SW#6_MS8&DI*5NZR]W.'<HYLA
M+0;-95ZSN.>VS6K8)K^@3(M(\JLLD]<MVL.D8YU72A2)\X/#M]9=W^[:_$HW
MD;;-RVUNZ9.X;#>;',>6A<$5<<.I;]Y6#?D/GK<E*S=AWM"57>MF%R1,;<#%
MP?I73QBX;/$5VSA=!5-0P9*SP=?\)_PW?[D6V;^R&TP$0[YO'<\,/P^RSL-F
MG<C;MV92@TU"J8,PCR,L9:/)$3,L6#E8FWWE+;L.571+QD+=,K!(F(8E>92B
MB?$$1>"[XXMI^,M<>[AK8NW>XL'VEMF<82+!S=V9$C;NN/(C3,:66*U7E;6A
M[2B8RPW%N+XM.7E(S$\5X1[0W,0JE4J@=[@#H8S[XZ5JM-R]X;*_#VVH9@\2
M_=)C@QFV4(3#]QVOCK!F*)4CY&-5A<E[B+O1E+4MA^SD%3-G2W1N(YF^349K
M.B/$ED$@M\S1X^>[;9#"EOOQ(O!.W/[<<35=PZ:^3\&Y_P ([O[4AVTLY?1R
M-+KN"T$,?V;9\NYET$6[1E)2[8[NK@M:')4R!%P['/"4\4W'_BXX+R_N)Q7B
MR\<58]Q]N.NO ]J,L@3$*_O.[HRV<:XFR 6]+AA[<H\@[+?OELG'95B6TI.)
MI%8%7Z\]7%44 [3@'2EDKQJ+ N',M[[:?#TVVYJ\3+.^-.L9Y,-@-[9=D[=,
M4W&CSD&=I9,W29/F83&D/<4D_)RR(Q=)HB=&[PISE=,EFH#K3W"?68=RNPC(
MEL6UXE/@NYYVMV-=)DD8K(MA;E,=[AXJ9>T-'/'\5:DU#X[L/$ESSD;;[E9T
MNP1O)-X@JFFBNDB54ZR(>@O8SX@.U+Q&L--LY;3<H,,@VFF[)$71#.&KJ!OG
M'MR\GG+6M?\ 9TH1&7MR73+0QD3F*HRD$2]0Q<.FIB+F"\X!YT,N?6-\!RFY
M:4V8>'AMVS1XF6YF)+<23Z,P:^MFS\)1;ZVN:SD^^<YW4L\C&MMQDX=JV>W$
MWBWEMH%=$JD_<+53;J! FY;ZPKODV#I0-V^('X&V9-O^&YM9!A7*V.MX&)]Q
MT)'S4@HZ2B(.2?V%C:-L6&EY2L>O5%I)7%'O%"IT,FBH4U*@.Z_P[_$NVG>*
M#A=?->U6\Y&7CX210@[^L*[XM*W,FXPN%T@H[9PE]6VB_E6;9209I&5:/6#R
M0BGI4U*-W2IT5RIA?V Z&,^^.E:K3<O>&ROP]MJ&8/$OW28X,9ME"$P_<=KX
MZP9BB5(^1C587)>XB[T92U+8?LY!4S9TMT;B.9ODU&:SHCQ)9!(+?,T>/GNV
MV0PI;[\2+P3MS^W'$U7<.FOD_!N?\([O[4AVTLY?1R-+KN"T$,?V;9\NYET$
M6[1E)2[8[NK@M:')4R!%P['/"4\4W'_BXX+R_N)Q7BR\<58]Q]N.NO ]J,L@
M3$*_O.[HRV<:XFR 6]+AA[<H\@[+?OELG'95B6TI.)I%8%7Z\]7%44 [3@'2
MEDKQJ+ N',M[[:?#TVVYJ\3+.^-.L9Y,-@-[9=D[=,4W&CSD&=I9,W29/F83
M&D/<4D_)RR(Q=)HB=&[PISE=,EFH#K3W"?68=RNPC(EL6UXE/@NYYVMV-=)D
MD8K(MA;E,=[AXJ9>T-'/'\5:DU#X[L/$ESSD;;[E9TNP1O)-X@JFFBNDB54Z
MR(>@O8SX@.U+Q&L--LY;3<H,,@VFF[)$71#.&KJ!OG'MR\GG+6M?]G2A$9>W
M)=,M#&1.8JC*01+U#%PZ:F(N8+S@         !9':T7)I[JIE^I'/B,#/;AJ
M5Z=HX*T-0\&J4E2N:IT1K0YJZ4]]VU'2?_ML_P!Y>X.;0   "R/=Q%R<C(V.
M:/CGSZB3*=HK5FT<.:)U.O&5+12J"9Z$J:A:Z:Z:Z#KAS%)9N7N#DT
M                       ,,_\ 6%O\:#Q OZYF?] ;- 9<?97_ ,&^TO\
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MR+\8@
M
M
M
M
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M1TG_ .VS_>7N#FT
M
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MNCP0PL+=AM1GYZW8#<K>.58C-%MH33YJTN?+F/TK%;PDC%VZ=R<KNXG.+Y.
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M,E&9$Z(]*Y;TT/1S7777R4T&[;=)F9HN+&&@
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M_P""6,]'[(OQB
M
M
M
M
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M;B51(_3H\[Q,5A&G>IU-4SDS;4ZA=#:)^3R=HW-L:.DS7=HN+&&@
M
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MS%J'7-]9F_P.M]__ '=PK_XE\, /-[]1L_VL\2K_ +N[3O\ VEN) 9!X
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M.6SX8GAK65<EOWE9OAZ;'+2N^TIR)N:U;JMG:9@2!N2V;D@7[>5@[@M^<BK
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MF!(&Y+9N2!?MY6#N"WYR*L!I*0LY"RC1)RT=ME4UVRZ9%$SE.6E:!?&
M     ("B+=Q,CF!]-1UQ+K9$47DS.H2KXAT4U58\Z;TM&E&)#%Y32M34_#5T
MKV]OD&IF[1I\$I%:_%/HRH   " LT6[B:==0!\E7$O!+MD) L21%\1G1RDHH
MTJ\,:AF+SF<LY$Z>4NG%[HW;-T?PI,1.^GT84
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MTC%RC)K(QL@S5(NT?,'R";EF\:KIU,FLV<MU2G(<M:T,4U*T[ &]
M                       ! 5M6[B9KEF:F(6XEW5_KKS1I.',^(HD@JN?6
M3*5K1BF8G(-Y/PIM/W1J9NT?P2(BOXI]&5    0%ERW<33,[;KC(-Q+PTJV0
M,6';HOB-2N4NL(>IC$,Q=U4_TFE"_?%&K9NIN;R3$?%5N;_]RV7OZK[_ /Z*
M2P\W9?\ W/+?X^'_ ,</"VI_VS,?X&)_P2QGH_9%^,0
M
M
M
M
M
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MDS.H2KXAT4U58\Z;TM&E&)#%Y32M34_#5TKV]OD&IF[1I\$I%:_%/HRH
M
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M7]5WMPW'5JI5 B,%%N5):><IF*K-W"]JW:4XW+%H4,K+LKV=84V%;:<8;6L
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MYG_P>;@@&7Z 8TCZ[3_QZ;3?[HA/[9<E@/:EX$O^#WX=_P#=FL3_ *IT O\
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MN-W[N$(QG.FL?'2MH%M3 F.U98R:R=K7G>&3+KCIMP@55&13A6S4]4S-I#B
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MN+ V8XP6D+OS]?,Y'+)N$H!2[H"W5X"!=.>GJNZ.]6:',LP,4!VT@
M  "T^WL:7LQW$2E].H7E6JY=S2B,IWE$GXR.XE1JW-T*;\\B7F+FH72J-*T\
MM=*=HZ3,:%/BS2=*OP78#FT    M/W)XTO:_WUIK6E"][)QC673?&[RB6'(.
MZ68&0+I)OV9E.,J!NTE#4IIVZ:T'2RZ(WV;HF=Y=@.;0
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MM*S(6 DE4G/"7J$U'D>>I5-*<=*ZZ=H"70
M     6GV7C2]HG/MRWK(0O3VS(.[E4:2?>42KSB2"G$T-T2#]203YU/<,D6I
M?^=H.DS&A3XLQ$UJNP'-H   !:?N!QI>U[W39\C:\+WFRBFADWZW>42RY!ZR
M*:]"\N1?M%5?P1:UU(4U/<\HZ63$1-6;HF=Y,&;_ /<ME[^J^_\ ^BDL/+V7
M_P!SRW^/A_\ '#P]J?\ ;,Q_@8G_  2QGH_9%^,0
M
M
M
M
M
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M>8N:A=*HTK3RUTIVCI,QH4^+-)TJ_!=@.;0
M
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M@'L%\8NX&%V^#3OYNJ*;SC2+N;91E2X(UK<ULW)95R-F$UC]S),V]P6;>43
MW?:4XBW<E*[C)5BRDF"]#H.4$5TSIE#RG^#EXY6Z+PR, 6;M2\5;97O*M?;]
MCJUTGN%-QCW >28F;L'%[IRL6 MJ^(.]H*W"W/C6.=G.T@IN/>&6CVQ48^C5
MPW32.U#NKSS]9MV67?C6Z;2\,EKFKQ -W-Q0,G%8KQ5B#;;GQHS@+KDJ-XJW
MKMR,ZR!C2T5$K,BY61(LJ2.0D5W1D.G/1L5:CD@0W]69\"C(?AIVW?>ZC=:V
MB([=1F^SF%DP>.(UTTF5,'XJ4D6%R3$)<%P,%G$4_OZ]YZ+CU9%!BHX:1C:*
M;I$=+*KNDT0[S_$K\/#"GB?;3[XVL9LJ[B&<TLUN?'N08AHV>W'BK)\$W>I6
MM?T$U=*((/S,2R#AH_9&50I)1+QTTYR%5Z+IAB=M[?A&^)9X466',]?.,<FQ
MEOV!/4F\?[M<$I7=(8R5K$UK(Q5UPF3K9;-)''$\W2;F7*TEZQ$NV,@HH5.J
M1*+&"[W;?XVGUCW<*TC=N^V7<3N*SM(G10MI)C9.W_$^4\CM$ILTFZ1>3^5U
M<-SV1HLQ4&;Q?OB2FTC,FC152KE)!L8R8>W#P&?!IS!LK>9%WM^(#?TGFCQ%
M]Q$96*NJ;NB[E,FO\.6*J[1>.+.2R&]?S!KIO6Y5V+52;D&C@\<V0:-XY@91
MNBLZ>A//UB/PS[T\3OP])W&^'FK)_G_#5[P^<<-0KURWCB7I,0$1.V[<V/*2
M[MPV91CF[+0N5Y5B=Q6C4\PT9$7.@B8[A(,?+X37BH;X_ PW$9%Q"[VXW??<
M;E.5A(')^S_)L9>.-KZ=W[!R+B(MZ<L8ZEK3=QVCD#55S%&_D:3:R:"E$UFB
MZS9DJV#V&3&._&.\>7!E^*;@[/?^%;LEN&QKC=6?MEMN;>/-T&Z>X#P<DK:D
M!ER^[GAK5=6#@Z2EU&Z4@U<0<(XF6Q3T.P5:KMGZ >*GP;<K;RO#L\4RUY'&
M6RK*>X3<)9C"^L77WM1+%7-9605(^[V#>WY#OB1+9EVO<<HV]-/HUZO+/XM2
M/0;EISSIH+<XH9!S=[:N\Z+\#KQ0[\WX7C:DAGC,F!,\9'/B/'/"XQEMDLIS
MBN,@+5P)9T]SW*UZN;<1@E9";G3G,21GI1YR*G:I(*J!T*>#EXY6Z+PR, 6;
MM2\5;97O*M?;]CJUTGN%-QCW >28F;L'%[IRL6 MJ^(.]H*W"W/C6.=G.T@I
MN/>&6CVQ48^C5PW32.U#NKSS]9MV67?C6Z;2\,EKFKQ -W-Q0,G%8KQ5B#;;
MGQHS@+KDJ-XJWKMR,ZR!C2T5$K,BY61(LJ2.0D5W1D.G/1L5:CD@0W]69\"C
M(?AIVW?>ZC=:VB([=1F^SF%DP>.(UTTF5,'XJ4D6%R3$)<%P,%G$4_OZ]YZ+
MCU9%!BHX:1C:*;I$=+*KNDT0[S_$K\/#"GB?;3[XVL9LJ[B&<TLUN?'N08AH
MV>W'BK)\$W>I6M?T$U=*((/S,2R#AH_9&50I)1+QTTYR%5Z+IAB=M[?A&^)9
MX466',]?.,<FQEOV!/4F\?[M<$I7=(8R5K$UK(Q5UPF3K9;-)''$\W2;F7*T
MEZQ$NV,@HH5.J1*+&"[W;?XVGUCW<*TC=N^V7<3N*SM(G10MI)C9.W_$^4\C
MM$ILTFZ1>3^5U<-SV1HLQ4&;Q?OB2FTC,FC152KE)!L8R8>W#P&?!IS!LK>9
M%WM^(#?TGFCQ%]Q$96*NJ;NB[E,FO\.6*J[1>.+.2R&]?S!KIO6Y5V+52;D&
MC@\<V0:-XY@91NBLZ>AZ50         !:1;N0KR>;C96S',XNK;#=W-IHQ-4
M&5$2$:Q"CA M%BMBNJ\M8M#4U4KK[O8.DQ&A7XLUG2I\%VXYM    +2-S.0K
MRLA]:*5JSB\.G(M)A1Z5%!DM1<[9:/*@8U7;9Q4O+*L;[W3R]HZ61$QNLW3,
M;R[<<V@                            !U/>,#X3.&/%SVS4PSD&44L+)
MMBR+^[L#9E81Q)21QS>;Q@5B^;2495=F>X+#NUL@BA-1=%T*N*-V[A)1-TT;
M*$#Q_>'[=?C+?5J,E7GA;<-LFR]NGV&W[=ZTW*S>WF-F<JVW;4^G5C UREB:
M[H!DZ8V<]O!JHS2=6U>C.WG4Y5FARNA61664#T>6?]:H\$V>A4WMX;F+YP_<
M1%E6LKC_ "/MLW$+WA /&]"%=,IBN.,:9#M5-VU<U.@H1"47J55(]/O>$Q@H
MG(?C\9*W#M:V#X07AX;KMY&1KDCHY:VLWY0Q1<6"MHULM;E<NV]KW;<-^7RX
MMR2E8J19LE'[=L\-;2#UG6ADG_&FY30"X3PK/"6OK;1E#*&_O?EE2.W-^)EN
M-9$;9#R2S9I4L+#%I&1:-D,687;*1D49K'(1<:S9NGZ;-@GT3-%@S;(-4UE'
MP=[ #HL^L>?/!^B;S_\ ,M^,3XP>\;*^,3XI.]?C)^(SOPGQF^;'F]_VFZ;H
MN1WSW?\ A?-WO#F_Z+U #R>_4N/G@_.QSGYL>?GS)/BAG?C4[R[U^*CXZN_+
M/^+SS>Y_\C_&KW/U_-Z7\-W'SNJ[.C 9)4!C#_"&\*[QR,'Q]F>+-X>BV"I%
MGD"3OZ-:;?+XR8O W/G3$\==TRWE82];>GH>W\<)6==\_9Y21JBUWQLPU=](
M_2Z0A:.B!ZV+>^L-X3P[$M8CQ/-K>[OPU\CQK9BC=+O)V"<D96P.^DWC;C;K
M8WS3AVUKM2O:%D'A3-D5NZVM2.RG0-J9)0] B3./UH3:+/VQ-VSX9>*=Q7B4
M;B'D8V0M&R</;>LX1%FPMPS/?",6KD9_=5B6]?"$8SK%5<&0B89ZH_*8J*2Z
M'^DN&@6.>#3X VXNYMW4[XMOB_-F2^X^Y,B/,T8QP$=[%2B]NY&E'])F(R;D
MSN)])0,*XLS5'S8M5JX7-#G1;J/3(.&9&10]JP#&9_7*_GC?/JQEY\_&1\SO
MXKK.^;QTO?'Q1?&/_+OQE<OHO^SGQQ=X:]3S_P"6.XN@T_T3D@/9A]7Z^=W]
M$_M<^>QY[_''W5=G=7QH=Y_&=\5'GC-_%/Y]]]?ROWKYE=+TG5_Z7W1T?4?A
M^8 [G                             %I%D9"O*4W!7-:#^<7<6VQ=W.F
MUBS(,BI(D8J:-"E53;$<FY-/)J>NONZCI,1H5^+,3-:+MQS:    6D;A\A7E
M9UUV:PMJ<7BF<DT,H^0209*E<'I))HT,8SELN<OX*M:>]K0=+(B8FK-TS"9\
MW_[ELO?U7W__ $4EAY>R_P#N>6_Q\/\ XX>'M3_MF8_P,3_@EC/1^R+\8@
M
M
M
M
M
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MVFC$U0941(1K$*.$"T6*V*ZKRUBT-352NON]@Z3$:%?BS6=*GP7;CFT
M
M                                                       M(SMD
M*\K4R-9,-;\XO&QDHTC5'[1)!DJ1P=>=<-53&.X;+*EXVY*%]Z:G93[HZ6Q$
MQ-69F:KMQS:  ! 6([QQ=<D[<32Q+07MV39(%/+.U8F)CRO4JO#I4(56/D7J
MJVCBE3:'*6GN^7L&[HNB-U(F/@GT84
M
M                             ! 41>.+G.8'ULL+07;7\BO)D<W)6)B4
MT554(\ZSP])%.1/(GY[6E24K5"E3:Z5TIVC<Q=HU^"5BM/BGT84   ! >:+Q
MQ?:SJ 3R':"]SK/$) \6HC$Q,G1FDBHT*[(8TE(L3(\XZB=="4-2O#VZ:4UW
M;%T[TI,Q&^GP84
M                                 ! 5M7CBY_EF:MR'M!=C?+5>:)(W
M":)B4$G2K4^DB<L@A(JR"O5&[:5,B6IO^=H-S%VC7X)$Q7\4^C"@   ("RY>
M.+K;G;=:7W:"]Q2;U QXEVE$Q,@5DE1X1*I#*R$BR51U<5H;0A34]WR]@W;%
MTQN),Q\56YO_ -RV7OZK[_\ Z*2P\S9?_<\M_CX?_'#PMJ?]LS'^!B?\$L9Z
M/V1?C$
M
M
M
M
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M\$K%:?%/HPH
M
M          " LH7CBZ N^VHR]+07GI]\@S/#R243$OB,4E915NW(9R^D6CA#
ME/2F4T(0]*4KK36O8-VQ=,33>29BOXI]&%  !;WA[#,GC2?N28?33"33G&Y4
M4D6C=PD="M'IW7$H9:O":G";3L]T;NNK%$B*+A!A0
M
M                                        %O<-AF3C,S/\GJ33!5@\
M<2BQ8LC=Q1V2C^..R(4RU:\FM4SFXJ_=H-S=^G12F[5<(,*    M[S=AF3RJ
MZMYQ'S3"*I"MY%%4KQ!PM5:KU1F<ADZH5T+0E&U==?NC=MVBDQ5<(,*
M
M               M[MC#,G Y>G,DK33!PQE7$XLG&IMW!7:5)8_$F4ZIJ\DU
M4O\ G:>7W!N;JVZ*1%)JN$&%    6]YAPS)Y+G[;F&,TPC$X-N9%5%VW<*G7
MK5Z1UQ)F1KPEIPET[?=&[;J11)BJM,W_ .Y;+W]5]_\ ]%)8>9LO_N>6_P ?
M#_XX>%M3_MF8_P #$_X)8ST?LB_&(
M
M
M
M
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MP_)8H\Y^\9AC+=_]R\GHD'"/3]U][<SF<^OON;WB733R<-=1NZ[22(HGP84
M  !;W#89DXS,S_)ZDTP58/'$HL6+(W<4=DH_CCLB%,M6O)K5,YN*OW:#<W?I
MT4INU7"#"@
M
M         +>\JX9D\A7E;%SLYIA'H0+=DBLU<MW"JSBK656D#&3.E7@+0Q%.
M&FONT&[;J11)BLU7"#"@  LKVQ-9U"\;Z-*MY9% [(E&YI!%XFD8W>BE=$:N
M2T)6O!_F^X.E]*0S:O4'-H
M
M                     !97:[6=+NDF'"K>6+$U>W!4BRB+RD=4IH16B=2*
M&+TU:5/V%TKY?(.DTT/Q9_O+U!S:    65[LFLZXD+)K#MY9<I64Y1>L:B\5
M*4U5XSE\[I2FI2M:4KIK^[H.F'2FZS<O4'-H
M                                                       !978#
M6=)N7NU=PWEB19GMVU1661>%CS%,K^!JDH<M&]:&_P";I7M]P=)IH?BS'\2]
M0<V@   %E>YUK.KWC8IHIO++($9'HX-'HO%$BF[T3KHM5L6I*5X/\[W!TLI2
M6;EPF;_]RV7OZK[_ /Z*2P\O9?\ W/+?X^'_ ,</#VI_VS,?X&)_P2QGH_9%
M^,0
M
M
M
M
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M(ZI30BM$ZD4,7IJTJ?L+I7R^0=)IH?BS_>7J#FT
M
M                                       LKW$-9U;*-@*1K>65:$91
M5')V*+Q1N4U+B<F/1<S<M4RUHG6E:\7_ #?W!TLIHRS.^O4'-H  %O>'LS2>
M2Y^Y(=]"L(Q.#;E626:.'"IUZU>G:\*A5J<):<)=>SW1NZVD52)JN$&%
M
M                                                        6]PV
M9I.3S,_Q@I"L$F#-Q*(EE".'%79Z,(X[TAC(UIR:54.7AK]R@W-OZ=)*[M%P
M@PH   "WO-V9I/%3JWF\?"L)6DTWD5E3/%W"-4:LE&9"%3HA30U#T<UUU^X-
MVVZ23-%P@PH
M                              "WNV,S2<]EZ<QLM"L&[&*<3B*<DFX<
M&=JTB3\*9CI&IR2U5_YVGD]P;FVENDD36:+A!A0   %O>8<S2>-)^VX=C"L)
M-.<;F656=N'"1T*T>D:\*94:<)J<)M>WW1NVVL529HK3-_\ N6R]_5??_P#1
M26'F;+_[GEO\?#_XX>%M3_MF8_P,3_@EC/1^R+\8@
M
M
M
M
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M'S-Y-W9TN!UYC1W)-"8W8*<:A"TC$ROSMS\IR\=4IK7UWVW]U[6VY,V8U_\
M3R?PP[*Q;_\ Q3OW3_;N5WHA[)[ ^SMC?;\1B8%G]7._'%OI-W_\,;UD?V;M
M-R9EVW#XR^5@          V[M:K=JY<%+0U4&ZRU"U[*&JDF8]"UK3MI2M2@
M(+P?F"2ROYS]XP[&)[@[EY/1+N%NH[T[VYG,Y]/>\KNXNFGEXJZC=UNBD35/
M@PH   "WN&S-)R>9G^,%(5@DP9N)1$LH1PXJ[/1A''>D,9&M.32JAR\-?N4&
MYM_3I)7=HN$&%
M
M             6]Y5S-)X]O*V+89PK"00GF[)99TY<.$EF]74JM'F*F1*G :
MA2)\5-?=J-VVUBJ3-)HN$&%  !!6*;4Q7;\W<#JP;D[[E'B!22[?OAE)=*E1
MV92AN2V;(G0U<5J74U:_<&KINF-W>2(CX)U&5
M
M                                     05$VIBMOEI[<,?<G/R"JO(G
M=0??#)7EJK,#HO2]V%;%=$Y32M3:5/[WRU[!JMVC3X)2*_BG494   !!68K4
MQ7<CF!/D>Y.X5VB#\D43OAG%]2DLHUJ[-PNFZ]5N4=-.FI=.'B[?*-VS='\*
M3$3OIU&%
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MYE>EP^4=Q;<U/-]#B<D\X8#X<A_SFR_'AWYL77,KTN'RCN+;FIYOH<3DGG#
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MS*]+A\H[BVYJ>;Z'$Y)YPP'PY#_G-E^/#OS8NN97I</E'<6W-3S?0XG)/.&
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MH[BVYJ>;Z'$Y)YPP'PY#_G-E^/#OS8NN97I</E'<6W-3S?0XG)/.& ^'(?\
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MZ7NPK8KHG*:5J;2I_>^6O8-5NT:?!*17\4ZC*@
M
M                                     (*R7:F*YR[;<D+VN3NBX&2#
M,D,Q[X91_5I)R:J[<W3.&RJJ_,>F,34IJ:Z:>4:MFZFYO),17\4ZC*@  M/V
M_8TO:R+IO"1NB%[L92K0J;!;O*)>\\])%1>I>7'/W:J7X(U*ZG*6GN>4=+YB
M8BC-L3&^NP'-H
M
M            !:?;V-+V8[B)2^G4+RK5<NYI1&4[RB3\9'<2HU;FZ%-^>1+S
M%S4+I5&E:>6NE.T=)F-"GQ9I.E7X+L!S:    6G[D\:7M?[ZTUK2A>]DXQK+
MIOC=Y1+#D'=+,#(%TDW[,RG&5 W:2AJ4T[=-:#I9=$;[-T3.\NP'-H
M
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M^>1+S%S4+I5&E:>6NE.T=)F-"GQ9I.E7X+L!S:
M
M                                      6GYQQI>UX9#LN=MR%[QBHE
MI')R#KO*):=.="<7>*EY#Y^U<J\#8]#:D(:E==*=O8.ELQ$3$LS$U78#FT
M"T_;]DN]KWNF\(ZZ)KO-E%-"J,$>[8EER#UD5$*FYD<P:*J_@BTIH<QJ>[Y1
MTOB(B*,VS,[Z[ <V@
M
M                %I]O9+O9]N(E+%=37-M5L[FDT8ONV))P$:1*CIN7KDV!
M)$W+7+0VM5JUKY*ZT[!TF(T*_%FLZ5/@NP'-H   !:?N3R7>U@/K31M*:[I3
MDVLNH^+W;$O^>=JLP*@;638/#)\!5S=A*EI77MUTH.EEL3OLW3,;R[ <V@
M
M                 %I]EY+O:6S[<ME2$UU%LQ[NY4VD9W;$I<DD>IPM"]:@
MP3D%.33W3*FJ;_G:CI,1H5^+,3-:+L!S:    6G[@<EWM9%TV?'6O-=V,I5H
M91^CW;$O>>>DBFA0W,D6#M5+\$:M-"&+3W?*.ED1,35FZ9C>78#FT
M
M
M
M
M
M                         VKY0Z+%XLF;A42:N%$S:4KPG(B<Q#:&I4M=
M#4\E:5H$"V3;3D>\\@>>OG=,][=T^;G=_P#)T4PZ?K^_NK_U8Q9<WF]$E]_Q
M</#V::UUZ7Q$4HS;,SOKI1S:    6GV]DN]GVXB4L5U-<VU6SN:31B^[8DG
M1I$J.FY>N38$D3<M<M#:U6K6ODKK3L'28C0K\6:SI4^"[ <V@
M
M                                                %I^<<EWM9^0[
M+@K<FN[HJ6:1RD@U[MB7?4'7G%V:IN>^8.G*7&V)0NA#EI336G;VCI;$3$S+
M,S-5V YM   @K%-UXKN";N!K8-M]R2C- IY=QW.RC>J2J[,G0O.;.5CKZ.*5
M-H:E/NC5T71&[O)$Q\$ZC*@
M
M                      (*B;KQ6XRT]MZ/MOD9!27D2.ISN=DES%46!UGI
MN\RN3.C\UI2I=:D]]Y*]@U2[1K\$K%?Q3J,J    @K,5UXKMMS DR/;??R[M
M!^>*/W.SE.F214:T=EXG3A"J/-.HG70NO%P]OD&[8NG^%)F(WTZC"@
M
M             (*MRZ\5O<IS,!#6WTE^-EYDDE-=SLD.H5;'TDC=XIN3N5>H
M-[M24X_=T&IB[1K\$B8K^*=1E0   $%96NO%=OS=OM;^MOON4>(&/$..YV4E
MTJ5'94ZEYSERB=#5Q6AM"TK]T:MBZ8W-Y)F/BG494
M
M
M
M
M
M            !H.CI)MG!UR\:!$%3K$TH;C2*F:JA>&NE#<1*5II[H"&,-W1
MC"Y?./XM[=[@Z+NCOG^2&<5U?4]Z=W?Q1POS^1R%_OM.'C[-=:C5T71_$D3$
M[R;AE0   $%1-UXK<9:>V]'VWR,@I+R)'4YW.R2YBJ+ ZSTW>97)G1^:TI4N
MM2>^\E>P:I=HU^"5BOXIU&5
M
M                       05DNZ\5P=VVY'WM;?>]P/4&9X9]W.RD.D24DU
M4&Y>I<.4E4.6]*8^A2UTUU\HU;%U-S>29BOXIU&5  !;WA[#,GC2?N28?33"
M33G&Y44D6C=PD="M'IW7$H9:O":G";3L]T;NNK%$B*+A!A0
M
M                                              %O<-AF3C,S/\GJ
M33!5@\<2BQ8LC=Q1V2C^..R(4RU:\FM4SFXJ_=H-S=^G12F[5<(,*    M[S
M=AF3RJZMYQ'S3"*I"MY%%4KQ!PM5:KU1F<ADZH5T+0E&U==?NC=MVBDQ5<(,
M*
M                     M[MC#,G Y>G,DK33!PQE7$XLG&IMW!7:5)8_$F4
MZIJ\DU4O^=IY?<&YNK;HI$4FJX084   !;WF'#,GDN?MN88S3",3@VYD547;
M=PJ=>M7I'7$F9&O"6G"73M]T;MNI%$F*KA!A0
M
M
M
M
M
M        &W=HU<-7+<IJ%JNW61H:O;0M54S$H:M*=M:4J8!!>#\/R6*/.?O&
M88RW?_<O)Z)!PCT_=?>W,YG/K[[F]XETT\G#74;NNTDB*)\&%    6]PV&9.
M,S,_R>I-,%6#QQ*+%BR-W%'9*/XX[(A3+5KR:U3.;BK]V@W-WZ=%*;M5P@PH
M
M                                                           "
MWO*N&9/(5Y6Q<[.:81Z$"W9(K-7+=PJLXJUE5I QDSI5X"T,13AIK[M!NVZD
M428K-5P@PH  +*]L3J=7O&^BRKB660(R)5N606>*)%-WHI35&CDU24KP?YON
M#I?2D,VKU!S:
M
M            65VNZG3;I)ANJXEC1-'MP4(BHL\K'4*6$5JG0B9C=-2E#]I=
M*>7R#I--#\6?[R]0<V@   %E>[)U.MY"R:0[B60*9E.57I&K/$BF-1>,Y?.Z
M4Q:5K2E:Z:_NZ#IATINLW+U!S:
M                                              65V ZG3[E[M0<.
M)8\65[=M$45EGAH\I2J_@:))G-5O2A?^;I3L]P=)IH?BS'\2]0<V@   %E>Y
MUU.H7C8I8IQ+(H'9'JX+'K/$TC&[T3IJM1L:A*UX/\[W!TLI26;EZ@YM
M
M
M
M
M
M                            -E(U-2/?U+K0U&3JI:EUXJ&Y!].'3MUU
M\@1OBT3:4YFW'Q@=\.)5?@\U>F[S5=J\/%YR<[D=48W#Q<)>+A\NE-?<'3$I
MN49M7D#FT    LKM=U.FW23#=5Q+&B:/;@H1%19Y6.H4L(K5.A$S&Z:E*'[2
MZ4\OD'2::'XL_P!Y>H.;0
M
M                    "RO<0ZG4<HV G&N)9)H=E%5<D8K/$VYC5N)R4]5R
MMS43-6J=*4KQ?\W]P=+*:,LSOKU!S:  ! 6(\T.LFSMQ0Z\ A$%@D"K$72D%
M'AG-:O#M>$R9VC>B?87B[*U^X-W6TBJ1-4^C"@
M
M                                     ("B,T.I/,#[%YH!!%!FO)HT
MF*2"AUE*,(\[VAJLJM"D+S:EX:_A*Z>7M&YM_3I)7=HGT84   ! >:,T.L4.
MH!NW@$)JDTA(+&,M(*,:MZL5&A*%+0C1SS.9U.O;IIH-VVZ23-$^#"@
M
M              ("MK-#J?RS-8U/ (-D(E>:1++%D%%55Z1)^$IC,ZM"$)S_
M '?PE>']T;FVENDD3NT3Z,*    @++F:'6,IVW8=" 0ERSJ!ECKJR"C,S:M'
MA&O"5,C1Q13L-Q=M:?<&[;:Q5)FB?1A0
M
M
M
M
M
M   &@Z6JV:N7%"\=4$%EJ%K72AJI)F/PZZ5TUX= $(X5S$YRSYR]1 H0G<'<
MW!R7ZC[J>]>]>+BXVK;E<GNVFFG%Q<?N:=N[K=%(FJ=1A0   $!1&:'4GF!]
MB\T @B@S7DT:3%)!0ZRE&$>=[0U656A2%YM2\-?PE=/+VC<V_ITDKNT3Z,*
M
M                                                           @
M+*&:'6/+OMJUT8!"43GT&:QWBL@HU.VJZE%8^I2HD:+E5X"I\7:8NM:Z?NC=
MMM8F4F:31/HPH  (*Q38V,K5F[@>V/>/G))2"!22K3SAM^8Z)*CLRU#]/$-&
MZ[;5>M2ZJ5-3LT\HU=-TQNI$1&\G494
M
M                              !!438V,FF6GMV,;QZF^UUY$[FV?.&W
MUN2JY8'0=D[F1:%F$^0UK4^AE*U+IJ;6@U6[1I\$I%:_%.HRH   ""LQ6-C.
M\',"ID"\?-99@@_)&)^<-OPG6)+J-3.C\$TT=&<<DR1*:IZ4+Q=OEH-VS=&]
M"3$3OIU&%
M                             05;EC8RCLIS-TQ%X]?>SQ>9/(6YYPV^
MZZ55X?60)W0V:$ET.E-V:'4K4G_.U&IF[1I\$B(K^*=1E0   $%96L;&5U3=
MOO;XO'S;DH] Q(IIYPV_#]:E5V5:I^GEVCA=SHO2A=4ZEIVZ>4:MFZ(W$F(G
M?3J,J
M
M
M
M
M                                     T'1$E6SA-8_+1405(JIQ%)P
M)'3,50_&>E2EX2UK76O90!#&&[)QO9WG'\7UW>=/>/='>_\ +\#.=!TG>G0?
MZD:->EZKJEOWWBX^7[W3A-KJZ;IWTB(C>3<,J    @J)L;&33+3V[&-X]3?:
MZ\B=S;/G#;ZW)5<L#H.R=S(M"S"?(:UJ?0RE:ETU-K0:K=HT^"4BM?BG494
M
M                                                          !!
M62[&QE<MVVY+7C>/<$['(-"1$9YPV_%=<DC)JN4#]'*-%WCKFO#&3U2,6AM.
M&GONT:MFZ(W-Y)B*IU&5  !:1MXQ[>5G77>3^Y8->*9R30J;%=5=DJ5P>DDH
MM4I2MG*YR_@JTK[ZE!TOF)B*,VQ,+MQS:
M
M                                 6D6[CV\F>XV5O-S!KI6PX=S:B,M
M5=E5$Y'40HW0-1$KDSJG,6-0M-4Z:>[V#I,QH4^+-)TJ_!=N.;0   "TC<SC
MV\KW?6BK:L&O,)QS283>F179(T0.Y6CS(%-1VY;U-S"HF^]U\G:.EDQ$;K-T
M3.\NW'-H
M                           !:19&/;RB]P5S7>_@UV]MOG=SJ-90R[(R
M2Q'RFK0Q4DW)W)>=3R:DII[N@Z3,:%/BS$36J[<<V@   %I&X?'MY7C==FO[
M:@UY5G&M#)OETEV216YZR2:U"F*Y<H'-^"I6OO:5'2R8B)JS=$RNW'-H
M
M
M
M
M
M                           !M'Z9U6+U),O$HJT<IIEII2ICG1.4I=:U
MI2FIJA&^+7ML=@W?8WGOYUPB\/WIYM=!SEV:W4=%W_U7#TCEQP\GJT]>+37B
M[->W3I?,32C-L3&^NL'-H   !:1;N/;R9[C96\W,&NE;#AW-J(RU5V543D=1
M"C= U$2N3.J<Q8U"TU3II[O8.DS&A3XLTG2K\%VXYM
M
M                                          +2,[8]O*Z\C63,V_!K
MR49%M(U-^[279)$;G0G7#I4IB.'**IN!N>AO>EKV5^Z.ELQ$35F8FJ[<<V@
M 6KX#RC>5^7/=T9<L@@\9Q+4JK%-*/9-#)GK(*-ZU,HV12.I^"+2GOJU&[K8
MB(HS;,SOKJ!AH
M
M            !:O 91O)_N"D[!<R"![8;.IE)%G2/9$6*1G%*.D*5>%1HZ-P
MK%I6NINWR5[!N;8T*_%FLZ5/@NH&&@   %J^XW*-Y8[>VHC:L@@R3E&LLJ]H
MM'LGM5#M%6!$*EJ[15JGPE7-][IKKVCI9;$[[-TS&\NH'-H
M
M      !:O9N4;RF,\7'8S^005MN.=7(DU:%CV22I"1RG"TH9VFB5R?ET\NIJ
M\7NC<VQHU^+,3-:+J!AH   !:OGS*-Y6'<]HQEM2"#-G+-3*ODU8]D[,H>D@
MFWI4JCE%4Z?X(U:>]K0;MMB8FK-TS&\NH&&@
M
M
M
M
M
M       &U?*G09/%DZZ*(M7"I*UI2M*'32.<M:TKV5T-0!;7MPR9=^1?/+SK
M?H/NY_-WH.2P9LN5WAW[U7%TB*7-X^A3TXM>'3L\M1N^V+:49MF9WUSPPT
M  M7@,HWD_W!2=@N9! ]L-G4RDBSI'LB+%(SBE'2%*O"HT=&X5BTK74W;Y*]
M@W-L:%?BS6=*GP74##0
M
M                  "U?-F4;RLO(%FP%OR"#6,F&L<J_15CV3HZIW$VNR5J
M59PBHJEQ-R4I[VM-*]OE&[;8F)F69F:KJ!AH  $%8HG<1RLW<"&.X;NV6;H%
M-,K=WKL^>CU9R4IS%5E"J?Z32M>RE/NC5T74W=Y(I\$ZC*@
M
M                                              (*B9W$:N6WL3'0
MW*R.1>1*[D^[UR<:R; ZCZO656JD;F,Z5+][V^0:F+M'\$W*_BG494   !!6
M8IW$<.Y@2Y-AN]5UT'YH@W=Z[WDI)J-:/*:I+)43XSG3\NNN@U;%T_PI-/BG
M494
M                      !!5N3N(W.4YF+@X;D9"17F2R<CW>NES5D3Z2E>
MK,L9(_--]PM.(:F+M'=WDW*_BG494   !!65YW$<5-V^AD2&[REG"!C0RW=Z
M[SD(]60E:<Q)9,J?^DUI7MI7[HU;%U-S>2:?%.HRH
M
M
M
M
M
M            #0=&2*V<&<4XD"H*F6+IKQ)43-52FE.VNI-0$,8;F\43'G'\
M6$1W5TW='?G^@+,>?SN].[?WY97F\KE./)IP\7[HU=%T?Q)%/@FX94   !!4
M3.XC5RV]B8Z&Y61R+R)7<GW>N3C638'4?5ZRJU4C<QG2I?O>WR#4Q=H_@FY7
M\4ZC*@
M
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M?.$FC*Y[=>.UST30:M9J-<.%CUI6M")(I.3J*'K2GDI2M1:25A;UN#L)O?\
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M-II6M*_<$I*UAK=^PG=G?7?$5W-\+=X-.[/XQTG\?YW2_P :_!??_OGO?+V
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MF*)HPJ3)F 8C)EQDN-]<$E&+$C6L;1LT:M5DJD;*N52J\:U:'XS5<UI6GD[
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M-G;BAUX!"(+!(%6(NE(*/#.:U>':\)DSM&]$^PO%V5K]P;NMI%4B:I]&%
M
M                                                         0%$
M9H=2>8'V+S0""*#->31I,4D%#K*481YWM#595:%(7FU+PU_"5T\O:-S;^G22
MN[1/HPH   " \T9H=8H=0#=O (35)I"06,9:048U;U8J-"4*6A&CGF<SJ=>W
M330;MMTDF:)\&%
M                                  0%;6:'4_EF:QJ> 0;(1*\TB66+
M(**JKTB3\)3&9U:$(3G^[^$KP_NC<VTMTDB=VB?1A0   $!9<S0ZQE.V[#H0
M"$N6=0,L==6049F;5H\(UX2ID:.**=AN+MK3[@W;;6*I,T3Z,*
M
M
M
M
M
M                      T'2U6S5RXH7CJ@@LM0M:Z4-5),Q^'72NFO#H A
M'"N8G.6?.7J(%"$[@[FX.2_4?=3WKWKQ<7&U;<KD]VTTTXN+C]S3MW=;HI$U
M3J,*    @*(S0ZD\P/L7F@$$4&:\FC28I(*'64HPCSO:&JRJT*0O-J7AK^$K
MIY>T;FW].DE=VB?1A0
M
M                 $!90S0ZQY=]M6NC (2B<^@S6.\5D%&IVU74HK'U*5$C
M1<JO 5/B[3%UK73]T;MMK$RDS2:)]&%  ! 6([$QY:<[<3ZSKV0NB0D$"IR3
M)*8@Y(S!.CPZU#F1BZ460U6K4FJG9V:>4;NF9C=A(B(WD^C"@
M
M                                                ("B+$QXTS ^N
MYG>R#J]%UY-1Q:M)B#4614<QYV[HE8U*G>I.G;UJ>M#=I=-:]@W,SHTIN)2*
MU^*?1A0   $!YHL3'EY.H!6^+V0M%5@A()QR:TQ!Q=7R;A1H9R<I9>E3+<@R
M1*:D["\7;Y:#=LS&]%4F(G?3X,*
M                                               @*VK$QY&Y9FKJ
MB[V0D+P>+S2CZV"S$&NJT4>GU?$-'-Z=Z)='7LK0_:3_ )PW,SHTIN)$17\4
M^C"@   ("RY8F/+LG;=?7C>R%KR$>@9.-9*S$'&F?IU>$6J<J,I2JR^BU*$U
M3[.W3RC=LS$;D),1.^GT84
M
M
M
M
M                                                     !H.DTU6
MKE)8_+2406354K4I:)IG3,4Y^(WO2\!:UKK7LH A'"MCV!9GG+YC7FA=W>7<
MW>G)EH64[OZ/O7HN+N>E.1U?5+:<S[[E>]\AANZ9G?BB1$1O)U&%    0%$6
M)CQIF!]=S.]D'5Z+KR:CBU:3$&HLBHYCSMW1*QJ5.]2=.WK4]:&[2Z:U[!N9
MG1I3<2D5K\4^C"@
M
M              ("RA8F/+FN^VI>Z[V0MR:C4&:<7%*S$&P/()HRBKE Y6TE
M2KM?FNSU3U3[*UII3M&[9F(FD),15/HPH  +0-N=BW=:MV7H]N*!?Q+20:$(
MR7=D(4C@]))1:I4ZE.:M:\NNO^0=+YB8BC-L3&^N_'-H
M
M                                           !:!;=BW<TW)RUV.8%
M^C;:[N<.E,'(3I#D<PZJ"!BFH>IM%5JT+3L\HZ3,:%/BS2=*OP7?CFT    M
M!W/V+=UX/[/4MB!?S*;!I,D>&9D(:C<ZZT<9$JG&<FE5*)&T_P @Z63$;[-T
M3.\N^'-H
M                           !:!8UBW=';A[HNE] OVUO/'=T':RRA"4:
M+$>*:M3$-0]35HM3[WL'29C0I\68B:U7?CFT    M W&6+=UU799;VW8%_+-
M(]H<CU=H0AB-SUDDUJ%4J8Y:TKRZ:_Y!TLF(B:LW1,[R[\<V@
M
M
M
M
M
M                    &TD"'58/4TRU.HHT<D(6GE,<Z)RE+3]VM:A M7VN
MV3==G>?/G/!/H7O'S9Z'K2$)U/1^<'4\O@.?7D]4GK_Y]!TOF)I1FV)C?79C
MFT    M MNQ;N:;DY:[',"_1MM=W.'2F#D)TAR.8=5! Q34/4VBJU:%IV>4=
M)F-"GQ9I.E7X+OQS:
M
M                 6@9ZL6[KER38TM P+^4C8YI&$?/&Q"&1;'1GG#E0JE3
M'+6E2(&H:O9Y*CI9,1$U9F)JN_'-H  %J^ \HWE?ESW=&7+((/&<2U*JQ32C
MV30R9ZR"C>M3*-D4CJ?@BTI[ZM1NZV(B*,VS,[ZZ@8:
M
M                                           6KP&4;R?[@I.P7,@@
M>V&SJ9219TCV1%BD9Q2CI"E7A4:.C<*Q:5KJ;M\E>P;FV-"OQ9K.E3X+J!AH
M   !:ON-RC>6.WMJ(VK((,DY1K+*O:+1[)[50[15@1"I:NT5:I\)5S?>Z:Z]
MHZ66Q.^S=,QO+J!S:
M                                     6KV;E&\IC/%QV,_D$%;;CG5
MR)-6A8]DDJ0D<IPM*&=IHE<GY=/+J:O%[HW-L:-?BS$S6BZ@8:    6KY\RC
M>5AW/:,9;4@@S9RS4RKY-6/9.S*'I()MZ5*HY15.G^"-6GO:T&[;8F)JS=,Q
MO+J!AH
M
M
M
M
M                                     !M7RIT&3Q9.NBB+5PJ2M:4K
M2ATTCG+6M*]E=#4 6U[<,F7?D7SR\ZWZ#[N?S=Z#DL&;+E=X=^]5Q=(BES>/
MH4].+7AT[/+4;OMBVE&;9F=]<\,-    +5X#*-Y/]P4G8+F00/;#9U,I(LZ1
M[(BQ2,XI1TA2KPJ-'1N%8M*UU-V^2O8-S;&A7XLUG2I\%U PT
M
M                                                 M7S9E&\K+R!
M9L!;\@@UC)AK'*OT58]DZ.J=Q-KLE:E6<(J*I<3<E*>]K32O;Y1NVV)B9EF9
MFJZ@8:  ! 6(Y3#[^=N)+'$0O'2R*!:S2JR,@F59'K#EI0IGCQRF;_2=:^]H
M6O\ R#5VE3=WDBGP3Z,J
M
M                    @*(E,/J9@?1\;$+IY**O)T=R-49"B)UB1YSOJT5.
M\,SKQL]:4T2I37R:5[1J=+1_V4W*_BGT94   ! 6:)3#\<Z@"Y0B%Y-=5"0K
M#F11D%:(HD4:4>T-T3QK0O&<R?WVOD[-!NV+O[J33XI]&%
M
M      0%;4IA];+,TQ@HA=#(B:\U24D#(R!4E5DS_P J5*HJ\4:5YIO)PITI
M7W-!J=+1W=Y(I7<WT^C*@   ("RY*8?83MNI9'B%Y&660-6%511D%"HH]80M
M:&,S>-DR_P"DZ5]]0U?^0:MTJ;F\DT^*?1E0
M
M
M
M
M
M       &@ZJB5JY,XIQ(406JN6FM:F1HF:JE*:5I7M)KY $(X5D\2R/G+\5L
M4O&<GN;OWG(OTN?S.]>[.'K7;KBY7 XUX>'3B[=>S35VE_>2*?!.HRH   "
MHB4P^IF!]'QL0NGDHJ\G1W(U1D*(G6)'G.^K14[PS.O&SUI31*E-?)I7M&IT
MM'_93<K^*?1E0
M
M            $!90E,/LKPMIO?T0N^N59!G6"<I(R"A$$32BI&U#&:O$$2\+
M^AC>^*:NGE[.P:MTJ;F\DTKN[Z?1E0  6VX3P[<V-[BNB7G'T$[;3;8J+0D2
MZD%UTS4?'<UJX*\C&*9"\LVGO3'[?W.T;NNB8B(9B*+DAAH
M
M                                              !;;"8=N:-SC(Y,
M7?01X%VYEEDVB3J0-+E*_C%&:-#H'C$V=#%5-J;1Q70ODUKV#<W1HZ/Q9INU
M7)##0   "VW/6';FRD[MIQ;[Z"9DAFTFBZI,.I!N90SU5D=*J%&49(4,4M&Q
MN+BJ736FFON;LNBW?9F*KDAAH
M                                            !;;:>';F@LT3^1G;
MZ"4A)5S/K-VK9U('E2%E3\3>BR"L8BT*8E/O^%<VGN:C<W1-NC\68C=JN2&&
M@   %MN;,.W-DBXK7EX-]!-&T(V,B[)+.I!!=0U7Q'-*MRLXQ\F<O++I[XQ.
MW]SM&[;HB)B69BJY(8:
M
M
M
M
M                                                   ;9XB9PT=-
MR5+0Z[9=$E35K0M#*I&(6IJTH:M"TJ;MTI4!;]@+$=R8K\[/.%[!O._>XND[
MF<OW'+[K[YZCJ>NC8[@X^\2<'#QZZ&UTTIKN^Z+MYFV*+BAAH   !;;"8=N:
M-SC(Y,7?01X%VYEEDVB3J0-+E*_C%&:-#H'C$V=#%5-J;1Q70ODUKV#<W1HZ
M/Q9INU7)##0
M
M          "VW+V';FO^^+3N6&?039A!-F*+M*3=2"+M0S676?J5;)M8QZB<
MM45*4IQ*$]]V5TIVC=MT1$Q+,Q6:KDAAH  %E>V*>G9:\;Z0E9J6DT&[(AFZ
M,A(O'J2!N]5"<2*;E90B5>"FFI:4[.P=+XW(9M7J#FT
M
M                                           LKM>>G5MTDQ$*S4LK
M$D>W 4D6I(O#QQ"I0BJB92,C+5;%HFI3B+2A>RO;3M'28_\ #9_O+U!S:
M 65[L9Z=AI"R2P\U+1)7#*<,N6-D7C$JQDUXRB9EJ-5DJ*5)0]=*UUTUKH.N
M'&Y+-R]0<F@
M                              %E=@3TZYW+W9$N9J6<1:+V[2HQJ\B\
M5CTBHJZ(E29J+&;IT2I][2A:</N#I,?HAF/XEZ@YM    +*]SL].Q-XV*A%3
M4M&(.&1S.$8^1>,DES=ZIDXEDVRR9%:\%=-34KV=@Z61N2S<O4'-H
M
M
M
M
M
M                        !LI$QB1[\Q35*8K)T8IBUK0Q340/6ABUII6E
M:5IV5"-\6B;2IV;FOC [XF)66Z;S5Z;O.0=O^GYWG)SN1U2RO*YO*+Q<.G%P
MTU\E!TQ/@S:O('-H   !97:\].K;I)B(5FI96)(]N I(M21>'CB%2A%5$RD9
M&6JV+1-2G$6E"]E>VG:.DQ_X;/\ >7J#FT
M
M                                  LKW$3T[%Y1L!G&S4M'-'+**,X:
ML9%XT;N#'N)RD<RZ#=9-)6ITJ4+6IJ5U+33R#I9'Z99G?7J#FT  " L1Y@:Y
M'G;BB4+10MTT*@58[M*33?&>TJ\.VX#)DB(ZJ6E2\6M3G^Y^Z-W6TBJ1-4^C
M"@
M
M (*B<U=Z9:>XM\VN1T:\BCW[WSS>9W>P.]XN[.ZD^#G<'#IU%>'R]OD&M'].
MDE=VB=1E0   $%9BS5\4SF!;^;7?_?:#];C[Y[JZ;H5&I.'A[JDN=S>IUUU)
MP\/NZ]F[;=))FB=1A0
M                                     $%6YFKS@RG,XT\VND[I7F4>
M^N^>?U'=)^'B[M[J1Y74?<Z@W!^Z-3;2W22)K-$ZC*@   (*RMFKXL9NWX;S
M:[[[]0,MU/?/=O2Z.RM>'D]U2'/^^XM>(GW/W1JVW2BJ3-$ZC*@
M
M
M
M
M
M                      -!TMTS9PXX>/D(*K<&O#Q\I,Q^'BT-P\7#IKI7
M0!#&&\R?&UYQ_P#9SS?\W^Z/_2_>O5]Z]Z?^JXWD<CNW_I\7'[FG;JZW12)J
MFX94   !!43FKO3+3W%OFUR.C7D4>_>^>;S.[V!WO%W9W4GP<[@X=.HKP^7M
M\@UH_ITDKNT3J,J
M
M               @K)>:OB[NVW+7\VN^/.!!HMUW?/=_2=5)JQW#TW=3[G\O
ME\>O,)KKIV>4:MMK%4F:31.HRH  (*Q3CFQK,F[@D+5N[SB>R:!4Y!IWE#O>
MB3H[,O0_+C2%52U5K4NI^SW/*-73,QNI$1&\G494
M
M                                       !!43CFQF66GM[-+NZF['"
M\BHM;G>4.?E*.F!VSDG0IDI)%Y"!JGTK76FFM>P:K.C3X)2*U^*=1E0   $%
M9BQS8U].8%6\+N\V5(U!^FQ3[RAV'6$<J-3+GTE"',KR3(EIJ3LIQ=OEH-VW
M3&\DQ$[Z=1A0
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MM=:::U[!JLZ-/@E(K7XIU&5
M
M                       05DO'-C7;=MN3=RW=W%+12#-..C>\H=GUR:$F
MJ[1/R'Y#.5>:Y/5/5.NE=-*=HU;,Q%(28BJ=1E0  6@;<[%NZU;LO1[<4"_B
M6D@T(1DN[(0I'!Z22BU2IU*<U:UY==?\@Z7S$Q%&;8F-]=^.;0
M
M                                                 "T"V[%NYIN3
MEKL<P+]&VUW<X=*8.0G2'(YAU4$#%-0]3:*K5H6G9Y1TF8T*?%FDZ5?@N_'-
MH   !:#N?L6[KP?V>I;$"_F4V#29(\,S(0U&YUUHXR)5.,Y-*J42-I_D'2R8
MC?9NB9WEWPYM
M                                +0+&L6[H[</=%TOH%^VMYX[N@[66
M4(2C18CQ35J8AJ'J:M%J?>]@Z3,:%/BS$36J[\<V@   %H&XRQ;NNJ[++>V[
M OY9I'M#D>KM"$,1N>LDFM0JE3'+6E>737_(.EDQ$35FZ)G>3=G'_<KF#^J[
M(']$Y8>#GO\ HL;_  K_ /AE\B^TO_=6S/\ U#+_ /G6,9F/0]_L?
M
M
M
M
M
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M(<CF'500,4U#U-HJM6A:=GE'29C0I\6:3I5^"[\<V@
M
M                                         %H&>K%NZY<DV-+0,"_E
M(V.:1A'SQL0AD6QT9YPY4*I4QRUI4B!J&KV>2HZ63$1-69B:KOQS:  !:]@C
M*UW9 N:[(NXEF*K2':E594:,2-3E/60.WKS#D-6JE.67_P HW=;$1%&8FJZ$
M8:
M
M  6O0.5KND,^R>/'*S&MMM74PDDD1B0CNA&46H[0XG=#<9JT6+37L[:=@W-L
M:%?BS7]5%T(PT    M>W#Y6N[&[RUD+868I)RS655>=8Q3=U,=HJQ(CRZG,7
M@I2C@VOW1NRV+M]FZ:+H1AH
M                                          !:]9^5KNFLYW%83Y9B
M:WHUU<235--B1-U0D:IPM>-U0U3'K2GWW9VC<VQHU^+,3NT70C#0   "U[.^
M5KNQ_<UIQ=NK,4FDPU,J]H[8D=',>D@1O3EG.:E4Z<LW_E&[;8F)JS,T2AG'
M_<KF#^J[(']$Y8>%GO\ HL;_  K_ /AE\B^TO_=6S/\ U#+_ /G6,9F/0]_L
M?
M
M
M
M
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M_JHNA&&@
M
M       %KV:,K7=8]_6?;T"LQ3C9IK'JOBN6)'*ICN)E=BKRU3&I5.E4$Z4I
MIY*]HW;;$Q,RS,TFBZ$8:  !!6*7V&W<W<!,:L^FETT"UG#]/-(\:/5FI2G%
M)G,B;_2M:^\[?^0:NTJ;N\D4^"=1E0
M
M                             $%1+[#9\M/6D8SX<FE7D:.W/3S1=5BL
M#F?UYRIZQ=>)EK3LII7W.T:_5H_[*;E?Q3J,J    @K,3[#;-S TRHSZIPH@
M_K#5Z>:7X$2J->MIK%'*4O$>J?W_ &UT[/=&[8N_NI-/BG484
M
M        !!5N/L-J93F6L"SY>1R+S-)5ST\T7C6(?^5:\YP>L:;C-_F4TK_S
M1J=+1W=Y(I7\4ZC*@   (*RL^PVTF[?)DIGU,NH@:L&?IYI;@1ZLM*TXHPY4
M2_Z5I7W_ &_\@U;I4W-Y)I\529Q_W*Y@_JNR!_1.6'AY[_HL;_"O_P"&7R'[
M2_\ =6S/_4,O_P"=8QF8]#W^Q\
M
M
M
M
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MHV6=Z*<OV:^R_,K9WW'HY#:.CEML[T17]&+/_P#+F=ZZ?HF9GZ9NW:?Y_O\
M-9_D)^]_(J[,?>/V1.8V]Y61,W78L65SF0LK6(SF'AQ2_"MC<_YS"MMP]R?Z
MV'@5MTNYL?9[\^@    !H.JHT;.*N*:MZ(*U7IH:NJ-$S<VFA??5U)KY.T!#
M&&WV(7GG'\53/I>7W1W]_H\PAS./O3NO_6QS<7#PN?WOR:^^]P:NTO[R13X)
MN&5    05$OL-GRT]:1C/AR:5>1H[<]/-%U6*P.9_7G*GK%UXF6M.RFE?<[1
MK]6C_LIN5_%.HRH
M
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M;0OB[YFYF;RS*9*NA[)7%,1ERPT6H\3CWSIW1AW9JUHW355*J'M_
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MNN8OR_3L;]MJ5F;DL^3O2Y'4A<T_'6](1*+MG5^Z<JM4Y0S=,Y6R2"*0>O
M     6VPF';FC<XR.3%WT$>!=N999-HDZD#2Y2OXQ1FC0Z!XQ-G0Q53:FT<5
MT+Y-:]@W-T:.C\6:;M5R0PT    MMSUAVYLI.[:<6^^@F9(9M)HNJ3#J0;F4
M,]59'2JA1E&2%#%+1L;BXJETUIIK[F[+HMWV9BJY(8:
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MWZ_A+9QZP([(S.RF&)I9257,^:5HW:T3#UA
M        +;;3P[<T%FB?R,[?02D)*N9]9NU;.I \J0LJ?B;T605C$6A3$I]_
MPKFT]S4;FZ)MT?BS$;M5R0PT    MMS9AVYLD7%:\O!OH)HVA&QD79)9U((+
MJ&J^(YI5N5G&/DSEY9=/?&)V_N=HW;=$1,2S,52#G'_<KF#^J[(']$Y8>%GO
M^BQO\*__ (9?(OM+_P!U;,_]0R__ )UC&9CT/?['P
M
M
M
M
M
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M5I7MI6@]B,OF<OF\"W,Y6^W$R]\5MNMF)MNB?C$QN2_#S;FPMM?;.U\Q]O\
MW%E,QD=N93%G#QLOCX=V%C86);OV8F'?$76W1\IC>I.]*H1V?R@  ;9XB9PT
M=-R5+0Z[9=$E35K0M#*I&(6IJTH:M"TJ;MTI4!;]@+$=R8K\[/.%[!O._>XN
MD[F<OW'+[K[YZCJ>NC8[@X^\2<'#QZZ&UTTIKN^Z+MYFV*+BAAH   !;;"8=
MN:-SC(Y,7?01X%VYEEDVB3J0-+E*_C%&:-#H'C$V=#%5-J;1Q70ODUKV#<W1
MHZ/Q9INU7)##0
M
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MES(V4UHZ<\Y_)83R O-7+BR0/S.$]4[>?M)JWDTR4,1NPB&=#&U4I0!ZP@
M      '#7%;EO7A S%JW; PMTVQ<,<[AY^W+BBV,W SD2_1.W?1<Q#R:#J/D
MXYZW.8BJ"R9TE"5J4Q:TKH H/#V"<(;>+1\P, 8;Q5@VPZ2+N8I9.'L>6CC.
MT:2TA4E7\IYMV5$0D-WB]JD7G+\GFJ<-.(U=* )5
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MY8++6XZ1N"R[BM&"M*YL=WI(UR7-)QEVR$?.TD+CCD&21(E-1FL=QR- R)(
M   "S*V;IN9QN>F(!>XIU:!2>3Q4X167D%(A,J,*JJB4D:=P9F0J2M.(M*$]
MZ;MIVCI,1H5^+/\ >7FCFT    LRW5W3<UNR%EDM^XIV"(Z9S9G1(>7D(PKD
MR2\;1(RY63A"BQDZ*&H6IM=.*NGE'7#B)C=9N7FCDT
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M  R^1?:7_NK9G_J&7_\ .L8S,>A[_8^
M
M
M
M
M                                                        .PC8
MQXD6>]C-QII6D_K>N(Y.1(\N[#EQOEB6])&/4I'4G;3_ )+MS9=T'0II1XU3
M.BN8I.K;NB)ID+\R^T_O?:_VGCTRT_U=FW75OP;I_3/SFV=V;+_]J-R=S2MN
MI$/5?_,G_E'\L?\ ,ELF;]NX7=WWU@X4V97:N!9$X^'3=MP\Q96VW-Y>)_\
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M7FCFT
M
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MR=3)F*:H71'.1,AE%#%(F0ICG.<U"D(0M*F,8QC5H4I2EIK6M>RE 'D"S?\
M6%-QV\O?6Q\-SP/\:XHR1>3:7N"/R%NZSE2:E,16_"6@LFA>U[6;!0#R.YE@
MV>YIRJ7"\K*EGUUDV\3%.3.&+AT%QF=MK7UES"V,Y3,N$_%DP_NUR+:T'*71
M*;5;GV(X#Q!;-UKI1*KAU96/\D02$M==P2;1RJH2%[Q7MWKUV[>CMRD594E
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MQI9>3(*D ^N2S[ D&L9#6I>+!@FP3A8YC&=+5HR1HS00K4,FG:'VH3NFU_\
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MM&:C4ARZ+LG=3\VKBE>SATX?=&[;9G>29HG484
M       89_ZPM_C0>(%_7,S_ * V: RX^RO_ (-]I?\ =FP/_99:H"YD  >.
M#ZZ__AO;:/[[MJ?V#YZ >MO$/^Z;%_\ 5W97]&HP!(@  VC]BSE&+R,D6R+V
M/D6CAB^9N4RJMW;-VB=NZ;+I'I4JB*Z"AB'+7LJ6M: ,*GXG^P/.GA+;Y[PQ
M%)^=MKQ]N7B?(^V/,4.YDX5>[,>-Y\TICR^K1NB/72=,KMM95NBWD*MG!745
M-LU*4-V)*G#U[>#M];KM&XHRTMO/BHJ^:MWH=!;]N;P;?AZGM&YJ&HFT9USK
M:,&UYUGS)EJ%HM<,.V5B%N;11XSC4T5GBP>YFRKXLK)5J05^8YN^U[_L>Z&"
M<K;-YV5<$3=5J7%&+&,5*1@KB@G;^(EV"IB&H59NLHF:M*Z5[ $&7GM/QE?&
MZW"&\:3=W0SRQ@7&&8L26LUBWL*A:D[:>:GMBR,_2[F3J >3C]_;[NPD3Q!F
MDBQ1;U?/.>DYYB7)"YL                                !!5N9>C)S
M*<SCQ&U^C?1:\RBI.]4W/U%8L_"H;D%9)K%ZG]U6NGNZC4VSHU^"1.[1.HRH
M   ""LK9>C,=3=OQ+ZU^_E9I RR3GJF[?I*4=E;</"LR=&/J8W%V5*-6VS,)
M,T5)G'_<KF#^J[(']$Y8>'GO^BQO\*__ (9?(?M+_P!U;,_]0R__ )UC&9CT
M/?['P
M
M
M
M
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MC*@
M
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M84ESE3*\@=\V,5$%JHT.L9M)80W%,7;,BO&6J":ZID%35T-Q5;EII[M L/\
MJ7NT.W+TL/,^\V_9$MU.\-9@O'$NWRS)! J\=BJ\;_QKBN3SOE2+363.D2[<
MAV6RM.WT7:=2KM(V,?(TKRWRE*AZU=Q?A->'-NTSQ9.YK<3M-QEE#.%@*1:D
M-?$Q2X8\\Q2#JW[D0R';T!.Q%J9:90R35-)HWNIA,H-FY*(ID*E[P!Y1OKJV
M]ZZ+8M7;/X?UG3;F+A\ELI#<1FMBS>D14N&WK<GU;6Q#!23=,G4.($UW0\Y)
MJ)*'H@H_B6:M"F4;%,0.V';=XR%H;=MOF$<#V!X)WCVM;,P]BJP\<6V6*\.
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MOB,_W1,U?T.D0'AI^I0?XD.Y?^Y%=?\ ;Q@4!DV0&(%^M'?XZ^^;_P"MF_\
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MXC"+$:/+SQ1<M$F)<A6,W=K))NC],TDXE99--XU(DJT=.P[S0
M                     $%6YBVV8?*<S?32Z^MFY%>95<0',CZ],:1/Q."<
M"2IG=.FKV>^+3]T:FZ=&GP2F[5.HRH   ""LKXMMF_)NWY.<NOS?<Q*!DFC7
MF1Y.L+5V1Q4^CQ5-2NBA>'WM*_\ E&K;IB-Q)BJI,X_[E<P?U79 _HG+#P\]
M_P!%C?X5_P#PR^0_:7_NK9G_ *AE_P#SK&,S'H>_V/@
M
M
M
M
M
M          /TIC%-0Q:U*8M:&*8M:T,4U*ZTK2M.VE:5!)B)BD[L2]"OAU^-
MU>6'S0>(-V[Z:R'BTG2QD%E2O/EL@6"V+0B""5QET4>WU;#8M*:J5J:7:DH;
M@,[+1- GW-]E>:F:V;H;-^XYNQMG[D6XN_B8<?[7QQ+8X\?#2W(?E;_FO_\
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MKZB><KR*JEN\R/KRC/&!VJQ. BM7GX%(W'VE]SM[!J;IT:?!*;M4ZC*@
M
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MX#+*607/6K_2J-+ZO1U(F6X7!D]VR4[/J/*J',N5,U"J\=*FJ8I>S7L 9J
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MM^61MY9Y.G2F5&2Q8Y0J\,JBB8KJI>56BJM>$O;VU[!TF8T*?%G^\O&'-H
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M_P#.L8S,>A[_ &/@
M
M
M
M
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MPRJ*)BNJEY5:*JUX2]O;7L'29C0I\6?[R\8<V@
M
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M2O>Z(2U%GS%=LE+/VC6-7=-U4$US*I*$*%Y.+<IXXS=CNS\M8BO:V\CXTO\
M@VER69>]H2K6:MVXH5\6M4'T;(LSJ(JEH<IDU"5T416(=-0I5"&+0*^
M                        6RVCERZIO-MP8]>IQ-(&,<W"BV.@S6)(5)%G
MX6W-<&=G3-6M/OM$Z:_N#<VQHU^+,3NT7-##0   "V7..7+JQW<EJQ4 G$G:
MS+8RSRL@S6<JT/1^1M3DG2=MZ$IRS>[2O:-VVQ,3,LW31).<?]RN8/ZKL@?T
M3EAX6>_Z+&_PK_\ AE\B^TO_ '5LS_U#+_\ G6,9F/0]_L?
M
M
M
M
M
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MYET4CILUBR/ QC%'B/&YJ[,E6M52TXOP=-:?<&YMC0K\6:_JHN:&&@
M
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MBU8.YK@?VE;<U<B+!PI!Q-P75%6S>LI;,'(RA4D7<@VAI==D@<ZR;)T<E$%
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M[D_VM_>>8UZ[_9KWGW_*_?NW_-]T;MTO[J33XIU&%
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MIZTE)QZ[6EYKAU-T;=4[*@=_P#P=?64O $\03?%O:A=W>S>TX'/-N7OC>R;
MNS'[K(]@XYNO&4Q8B$FRI(H'RG<]G6O,V1.L5T%TZL)!623DU715&5$N6X4#
MTS>"9L/R/X;OAQ8,VK9=NV,NS)=L+7Q=UYUMYZZ?VI;4UD6\YJ\U[.M9V\0;
M+.HRW22Y45W%$R)NY'J7"9:)JEI0.U\                            !
M!5N?$G\:<SYO_P"\WGS/>_\ M;^_<?\ *_\ '?\ L_\ ??P79_F#4Z6CN_PI
M%*[F^G494   !!65OB3[[M_XT/\ 7/(-W#_M;^\]677_ &>_T7^-:?OW;_R#
M5NE3].\DT^*I,X_[E<P?U79 _HG+#P\]_P!%C?X5_P#PR^0_:7_NK9G_ *AE
M_P#SK&,S'H>_V/@
M
M
M
M
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M
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MH^<TJ4Q'3=FV?H'Y#\M 'I
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M]Y/%FIJF>*LCH\FB31S0]-&YM==-.P=++HMWV;HF5S0YM
M
M     +9;1Q'=4)FVX,A/5(FL#)N;A6;$0>+'D*$E#\3;FMS-")EK2GWVBE=/
MW1N;HT:?%F(W:KFAAH   !;+G'$=U9$N2U96 4B2-89L9%Y20>+-E:GJ_(YI
MR2)-'%#TY9?=K3M&[;HB)B6;HJDG./\ N5S!_5=D#^B<L/"SW_18W^%?_P ,
MOD7VE_[JV9_ZAE__ #K&,S'H>_V/@
M
M
M
M
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M\6:?JJN:&&@
M
M          %LN8\1W5?=]VC<<(I$DCX1LP1>E?/%D'%3MIA9^IR$TVBY3TY"
ME--3%U-V?NC=MT1$Q+,Q6:KFAAH  %G.VV\;JN2[KV9S]P2TPU8LR'9MY!ZL
MZ2;&K)J)5,B14QJ$KRZ</9[@Z7Q$1%&;5XPYM            +(-^OAV;3_$
MIPT?".Z_&Z-YP#)VO+6==44[- Y$QK<2Z)$#W%C^\&R2CV#?JII)E<MSE<1T
MBFF1-ZV<I%HF \8&</J6&=;!O%Y?&P_?K;K9S'.4'UAQ^<(.\,8WC;*RB[9D
M\;O,O8;1O%1ZY3B5G2Q'S.V(VJJE2-3-R$,=U0*\QU]7K^LI,',/;ER^-M-6
M#8,3%$C&-,=;X-^UTN85I&,B-86)A[/?VAC:%1BD$T2(%*210*U1+3EIGH6A
M '<!LN^K([9,,9,@]P^^+.>8/$VW&VZ_7E(*Z-QSV46Q= R9Y9W,HR[;%\[=
M>0).YI<KY^LLMYR7!.1BKL_5IL$'5"JE#TQ          "R#?KX=FT_Q*<-'
MPCNOQNC>< R=KRUG75%.S0.1,:W$NB1 ]Q8_O!LDH]@WZJ:297+<Y7$=(IID
M3>MG*1:)@/&!G#ZEAG6P;Q>7QL/WZVZV<QSE!]8<?G"#O#&-XVRLHNV9/&[S
M+V&T;Q4>N4XE9TL1\SMB-JJI4C4S<A#'=4"O,=?5Z_K*3!S#VY<OC;35@V#$
MQ1(QC3'6^#?M=+F%:1C(C6%B8>SW]H8VA48I!-$B!2DD4"M42TY:9Z%H0!W
M;+OJR.V3#&3(/</OBSGF#Q-MQMNOUY2"NC<<]E%L70,F>6=S*,NVQ?.W7D"3
MN:7*^?K++><EP3D8J[/U:;!!U0JI0],0
M                                        #QU^//\ 5E,F>);N;)O"
MVHYHQ98&4;OM>UK5RW8V<E+LAK.FU[)BVUN6Y>5MW?8-FWW--).MK,FK!U'N
MHE5(_1)*IND^(R= YGP>OJHN']CF1K2W+[S+]M?<YGZR'</<6.K%MB&DVN"<
M5WHP33<ENHA[E29SV5[D@)4O-A7DC&P[-@JF1WW<9Z1LNT#U]@
M   "SFVKQNISN9E[9<7!++6\B\G2)0RCU8T<F5"&561*5K4W*I1)6G$7L[*]
MHZ3$:%?BS_>7C#FT    LYW2WC=5K/[-3MRX):$(\9S1W9(UZLT*X.BM'%2,
MM1(Q>.J=%#4IKY-:CI9$3&ZS<O&'-H
M                                                 !9S8EXW4_W&
M73;CVX)9U M7EU$;1"[U92/0*U4T;%2;&-5,E$*?>Z4[!TF(T*_%F/XEXPYM
M    +.=R5XW5;=W62S@+@EH=J^9G.\;Q[U9JDY-2332H98B1BT/7EUX>WW!T
MLB)B:LW)USC_ +E<P?U79 _HG+#P<]_T6-_A7_\ #+Y%]I?^ZMF?^H9?_P Z
MQC,QZ'O]CX
M
M
M
M
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M>T=)B-"OQ9_O+QAS:
M
M                 6<Y_O&ZK?R78D9"7!+14>_9QAWK-B]6;MW1E9]PW4,L
MDF:A5*G0+0E=?*6F@Z61$Q-69WUXPYM   @K%&4K9OR;N",@[4\WW,2@55VZ
MY<>3K"U=G;T)JS234KHH7B]]6O\ Y1JZV8C=2)JG494
M
M                                          ! 41E2"D,P/L?I6<@V
MEFJ\FD>YJ*LZK+&9QYW:AZIE8$<_ATR\%=5J]E>W6G8-3;.C7X)7=HGT94
M ! 6:,J06.74 C,6<A=)I5"0504659IU9E:*-"*$+U3![6O.JO2OO:E^][=1
MNVV9WDF:)]&%
M                                0%;65(*9RS-6(VLY!A*QR\TDM<95
M6=571HT_"L<Q$V"3FG55[:ZJFT]W4:FV=&OP2)W:)]&5    0%ES*D%8,[;L
M7*V<A<B\N@95N[659D,R+1X1OP%HY8.SUU.;B]Z8OD&K;9F$F:*LSC_N5S!_
M5=D#^B<L/#SW_18W^%?_ ,,OD/VE_P"ZMF?^H9?_ ,ZQC,QZ'O\ 8^
M
M
M
M
M
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MLZK+&9QYW:AZIE8$<_ATR\%=5J]E>W6G8-3;.C7X)7=HGT94
M
M                                               ! 64,J05DWA;5
MOR=G(3[N909JMI-55F0[ KB459$(4KA@Z5KRE4ZJ>].7MK[E>T:MMF8JDS2:
M)]&5  ! 6(\5P5@SMQ2D5>*%R+RZ!4G#1%)F0S(M'AW'&:K9^[/74YN'WQ2^
M0:NNF82(HGT94
M
M            ! 41BN"C\P/L@)7B@YEG2\FJ>V:),Z+(F>1YVBA*J%?G<_@$
MS<==4:=E.W2G:-3=.C3X)3=JGT94   ! 6:,5P61G4 M,7BA:QHI"0203629
MJ5>%=J-#J'+U3]E6G)JA2GO:&^^[=!NVZ8WDF*I]&%
M
M  0%;6*X*&RS-7VVO%!_*R*\TJM;A4F=%6II(_$L0QTWZKFO2U[*ZI%U]W0:
MFZ=&GP2(W:I]&5    0%ES%<%?T[;LI*WBA;:\0@9)NT629G,]+5X1QQEJY?
MM#TT.7A]Z4WE&K;IB$F*JLSC_N5S!_5=D#^B<L/#SW_18W^%?_PR^0_:7_NK
M9G_J&7_\ZQC,QZ'O]CX
M
M
M
M
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MGT94
M
M   ! 64,5P5[7A;5P2=XH0#N&09I-HQ5)F<[\K>45>D.4SA^U5IS55*I^](;
MMI[M>P:MNF(HDQ6:I]&5  !9EMHM:YH&\+X<SENSL,V=LR%:.):(D(Y!R:DH
MHI4K=5XW136-RZ\6A:U[.WR#I?,3$49M7FCFT
M
M                                     LRMFUKF;[GIB?7MV=1@57D\
M9.;5B)!.(4*M"JI(F))';E9G*JK7A+6A_?&[*=HZ3,:%/BS_ 'EYHYM    +
M,MU=K7-<4A99[?MV=G2-6<V5T>'B)"3*V,JO&U2*N9DW7HB92B9JEH;37AKI
MY!UPYB(W6;EYHY-
M                                   +,K"M:YF>Y*ZYUW;LZUA'+RZS
M-YAS$2"$4N5RIJW,C(*MRM%2KT^\J4]>+W-1TF8T*?%F/XEYHYM    +,MR]
MK7-/7A8[F#MV=F6S1F<KMQ$Q$A(H-C5E$U*%<*LVZR:)N73BT-6G9V^0=+)B
M(FK-RX/,S59[A_*S-N6AW#O&M]-4"U-0E#++VO*))%J8U:%+2ISTIK7LH/#S
M=LWY3%LM_BG#NB/],2_N_;6/AY7[CV?F<::8.'G<"ZZ=^D6XMLSN1O[D,5Y\
MXK%/PX\_,DM^2#TR\);;YNSCV\+_ %0>Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>
M$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'
MY!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMO
MF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G
M%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q
M[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/
MPX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PG
MN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''G
MYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E
M!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM
M^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S
M/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/
M"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C
M\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VW
MS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'S
MBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX
M]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BG
MX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3
MW0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS
M\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R
M@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26
M_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NY
MGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('
MA+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ
M^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;
MYNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#Y
MQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<
M>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3
M\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)
M[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY
M^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y
M0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+
M?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<
MSV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#
MPEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX
M_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM
M\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\
MXK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[.
M/;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I
M^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$
M]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\
M_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\
MH-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDE
MOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN
M9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!
MX2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<
M?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V
M^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^
M<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G
M'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4
M_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O"
M>Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>
M?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>
M4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2
MWY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW
M,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_)
M\);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN
M/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;
M?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?
M.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNS
MCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*
M?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA
M/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\./
M/S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/
M*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9)
M;\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[
MF>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@
M>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7
M'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEM
MOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/
MG%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9
MQ[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%
M/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;P
MGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''
MGYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'
ME!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,D
MM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=
MS/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0
M/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+
MC\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2V
MWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'
MSBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;L
MX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5B
MGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX
M3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#C
MS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#
MR@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F2
M6_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&N
MYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY(
M'A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]E
MQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);
M;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#
MYQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V
M<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q
M3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\
M)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQ
MY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!
MY0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)
M+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7
M<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D
M#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>R
MX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$M
MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!
M\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[
M./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8
MI^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>
M$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX
M\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@
M\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYD
MEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!K
MN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2
M!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9
M<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6
MV^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@
M^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=
MG'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL
M4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O
M">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<
M>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0
M>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R
M2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@U
MW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_)
M \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGL
MN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+
M;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0
M?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YN
MSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6
M*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>W
MA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.
M//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H
M/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9
M);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:
M[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D
M@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV
M7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PE
MMOF[./;PGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(
M/G%8I^''GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W
M9Q[>$]T'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK
M%/PX\_,DM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;
MPGN@\H-=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^'
M'GYDEOR0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T
M'E!KN9[+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,
MDM^2!X2VWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-
M=S/9<?D'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR
M0/"6V^;LX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[
M+C\@^<5BGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2
MVWS=G'MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D
M'SBL4_#CS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;
MLX]O">Z#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5
MBGX<>?F26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'M
MX3W0>4&NYGLN/R#YQ6*?AQY^9);\D#PEMOF[./;PGN@\H-=S/9<?D'SBL4_#
MCS\R2WY('A+;?-V<>WA/=!Y0:[F>RX_(/G%8I^''GYDEOR0/"6V^;LX]O">Z
M#R@UW,]EQ^0?.*Q3\.//S)+?D@>$MM\W9Q[>$]T'E!KN9[+C\@^<5BGX<>?F
M26_) \);;YNSCV\)[H/*#7<SV7'Y!\XK%/PX\_,DM^2!X2VWS=G'MX3W0>4&
MNYGLN/R'$3FY;'K&,<N(95].292Z-(ZC%Y'IJJFUX3+O';<A$4"5^^J6AS_<
M+7W.^6^S]J8F-%N8T,/!^-U8NG_1$;\__*/Q?Q?N#_-;Y;Y#96+F-@_\SG]K
M1%,/!G"OP;9NGXWXE]M+;(^.C%UT[D1;OS'9'X:_@I[H/$_GH'-F=W<]@O:5
M59-ZPNE:.HVNG(\717B5B\,6W*$.C6.=D3Y2ESR":D>F8W$@22425;D^Z/M7
M[)MC!C^G;.%DIW[Y_CQ/[.'^&/A$[S\GO\Q'^:[.YW:F)=M',6[0^Z+:QA96
MR9C*Y*)^%T1,TF-RMD3.-B4C^K?;6VYD -LVUK VSW%$'A;;OCJ#QS84&7FF
M9Q:-596X)8Z22+RY;NGW55IBZKFD"($HL^?+++F(0B9:E2333)]NY3)Y;(X,
M9?*VQ9AQ_P#.9^<SOS/XR_-O[B^Y-M?=6T[]K[>S%^8SM_QG^&VWX666Q^FR
MR*[EML1&_._,S-P(\E_#         &SD2F/'OB$*8YSLW12$+2IC&,9 ]"E*
M6FM3&-6NE*4\H1OBTK:A;-R6YY^^<-OSD%UGFMTG?,2_B^JZ?SCZCINN;H<_
MD<\G'PZ\/&7736@Z8DQ-*,VKP1S:    696S:US-]STQ/KV[.HP*KR>,G-JQ
M$@G$*%6A54D3$DCMRLSE55KPEK0_OC=E.T=)F-"GQ9_O+S1S:
M
M                                                 69;A+6N::R=
M83^&MV=EF#-G%E=O8R(D'[1J9.X'*RA7+EJW510,1$U#UH8U-"UUKV#I9,1;
M-69WUYHYM   MEP=ERZLB7)=45/IQ)&L,V*LSK'LUFRM3U?G;5YQU7;BAZ<L
MON4IVC=UL1$3#-LU7-##0
M
M                    "V6"RY=4CG>2QPX3B:6\T<RZ*1TV:Q9'@8QBCQ'C
M<U=F2K6JI:<7X.FM/N#<VQH5^+-?U47-##0   "V7<#ERZL9/+80MQ.).27;
M2BKOO)FLZ-0S-5D1'DU2=MJ$IHX-KKKKV#I9;%V^S=,PN:'-H
M
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M2.FS6+(\#&,4>(\;FKLR5:U5+3B_!TUI]P;FV-"OQ9K^JBYH8:
M
M                                                  6RYCRY=5B7
MW:-N0B<2>/FVS!9Z9\S67<4.YF%F"G(43=H%)3D)TTU*;0W;^X-VVQ,3,LS-
M)HN:&&@  0%B-'"Z<[<5<9.EW$P9 O?I52W'0I$>L/6E2]]-D6]?]*U_>JUK
M_P @W=I4W=Y(I\$^C"@
M
M                  ("B$<+TS ^4C'2YLH57D^L;U+<?)HM6//20I0R[8L)
M[UEK6G">M/\ -[1N=+1_V4W*_BGT84   ! >:$<+JNH#XUW2[9Q1"0[EHB6X
MS4.C51IUU3=Q-ER4T/1+]\TK_F^Z-VZ7]U)I\4^#"@
M
M ("MI'"Y<LS2D Z7/DJJ\UWL@8MQT2*M4_\ *U"U=-B0WO3>3EGK3_-U&YTM
M'=_A2*5_%/HPH   " LN(X74G;=KDUTNWF"H&[B*D6XZE.CUA*UJ;N5LLWI_
MI6G[[6E?^0;MTJ;F\DT^*?1A0
M
M
M
M
M                                                        &@ZY
M/2N>IKHWY"W/K3BUHCRS<VOO-3_>:^3M^X A'"J6'4O.7XIG2[GB[F[_ .<6
MX2\&G>O=7#W\W0UXM7.O*U\GOM/>C=VE_>2*?!.HPH   " HA'"],P/E(QTN
M;*%5Y/K&]2W'R:+5CSTD*4,NV+">]9:UIPGK3_-[1N=+1_V4W*_BGT84
M
M                                                       ! 64$
M<+J7?;1LANET+H*@S[@32+<=2'1I**U:U-6(;+,J:R'%3\*:E=/+[W0;MTJ3
M3>2:5W=]/HPH  +7L$8IN[']S79*7$BQ2:3#4J3*K1\1T<QZ2!W%>80A:53I
MRS?^4;NNB8BC,11=",-
M
M                   +7H'%-W1^?9/(;E%C2VW3J8525(^(=W4CV+4:(<32
MA>,M:K&IKV]E.T;FZ-"GQ9I^JJZ$8:    6O;A\4W=DAY:R]L(L54XEK*I/.
ML?)M*E.[58G1Y=#E-QTK1N;7[@W9=%N^S=%5T(PT
M
MM>L_%-W0N<[BOU\BQ+;TDZN)5JHF^(HZJ224XFO&UH6AB5K3[[M[!N;HT:?%
MF(W:KH1AH   !:]G?%-W9 N:TY2W46*K2':F2>U=OB-3E/60(XIRR'+6JE.6
M7_RC=MT1$U9F*KH1AH
M
M
M
M
M                                                 !M7J1UV;M!/
M2JBS5PD36NE.-1(Y"ZU]RFM0%N.W;%UV8U\\/.=%BEWUYO\ 0]&](\XN[N^^
MIYG 4O+TZ]/37RZU^X-WW1=2C-L47,##0   "UZ!Q3=T?GV3R&Y18TMMTZF%
M4E2/B'=U(]BU&B'$TH7C+6JQJ:]O93M&YNC0I\6:?JJNA&&@
M
M                                               %KV:,4W=?%_6?
M<,"BQ4C85K'I/C.7Q&RI3MYE=\KRTC%K52E$%*5IIY:]@W;=$1,2S,5FJZ$8
M:  !9SMMO&ZKDNZ]F<_<$M,-6+,AV;>0>K.DFQJR:B53(D5,:A*\NG#V>X.E
M\1$11FU>,.;0
M
M           "SFVKQNISN9E[9<7!++6\B\G2)0RCU8T<F5"&561*5K4W*I1)
M6G$7L[*]HZ3$:%?BS_>7C#FT    LYW2WC=5K/[-3MRX):$(\9S1W9(UZLT*
MX.BM'%2,M1(Q>.J=%#4IKY-:CI9$3&ZS<O&'-H
M                                                         !9S
M8EXW4_W&73;CVX)9U M7EU$;1"[U92/0*U4T;%2;&-5,E$*?>Z4[!TF(T*_%
MF/XEXPYM    +.=R5XW5;=W62S@+@EH=J^9G.\;Q[U9JDY-2332H98B1BT/7
MEUX>WW!TLB)B:LW+QAS:
M
M
M
M
M                                                    ;.0.=-@^
M4(:I#D9N3D.6NABG*B<Q3%K[E2UIK0(WQ:CM7NZZ+J\^_.2>E9SH/-?HN\WB
MSOI>J\XNHY'-,;E\[IT^+3R\%/N#I?$12C-LKNAS:    6<VU>-U.=S,O;+B
MX)9:WD7DZ1*&4>K&CDRH0RJR)2M:FY5*)*TXB]G97M'28C0K\6?[R\8<V@
M
M                                                         %G.
M?[QNJW\EV)&0EP2T5'OV<8=ZS8O5F[=T96?<-U#+))FH52IT"T)77REIH.ED
M1,35F=]>,.;0  ("Q'DBS[UG;BCK<LM"V7<6@51Z\1;1:!GQ*O#H4(8S!!)4
MVBI>+W]:T[?NC5T3$;J1,3O)]&5
M
M                           0%$9(L][F!]9#:RT&MRMUY--6Z*-HLJRQ
MVD>=RN>JZ:%']>H1+4E=3ZUI7M[!J8G1K\$K%:?%/HRH   " LT9(M"PW4 C
M=%EH76I)(2"C-19M%N*LB-E&A5B%K((+&+SS+%K[W2E>'M]P;MMF=Y)F(WT^
MC"@
M                      ("MK)%GRN69JS&-EH,+B8+S2;JY2MHLBKL[ ^C
MHYET4"OC=77MKQ'K6ONZC4Q.C7X)$Q6GQ3Z,J    @++F2+/LJ=MV.N.RT+F
M=RB!E&3Q9M%KF8DH\(A4A3/T%52ZJFXO>5I3L^Z-6Q,QN),Q&^GT94
M
M
M
M
M
M                         !H.E"(M7*RA.8FD@LH=.M*5HH0B9C&)6AM2
MUXBTT[>P!".%<AVE?OG+YKV<A:?=7<W7<EM&-^OZ[O7IN+NY!'CZ7HU-./73
MF=GEJ-76S&^D3$[R=1E0   $!1&2+/>Y@?60VLM!K<K=>335NBC:+*LL=I'G
M<KGJNFA1_7J$2U)74^M:5[>P:F)T:_!*Q6GQ3Z,J
M
M                                        @+*&2+/M&\+:A)^RT+AD
MI5!FHQE%6T6L=@1>45:)$*H]05<$Y3@E5/>5I36O9VC5L3,5A)F*I]&5  !!
M6*<0QF.INX)9C='?RLT@5%5MTK=OTE*.S.>+B1>NC'U,;A[:%&KKIF$B*)U&
M5
M
M 05$XAC([+3W)"=T<]^[7D5C0'2MR\JKY@=F<O4%>F6KR2FX_P!ZIK^YY1K2
MG1I\$INU3J,J    @K,6(8S)SF!7D+H\W:PZ#]%(G2MW/54>*-3G-JN]:5)R
MJMZ4[.+7B]P;MNF-Y)BJ=1A0
M                                           $%6YB&,@\IS.0T;HZ
MQ]*+S*RD%TK<G3UE#\2A>>5ZHL;IOW4J:^[H-3=.C3X)$;M4ZC*@   (*RMB
M&,R+-V_+/KH[A5A4#(I-NE;N.KI5V5SQ<2SUJ8FAB\/90PU;=,0DQ5.HRH
M
M
M
M
M
M                             #0=(T<-G"!C<%%T%4:GTUX**)F)4VE:
MTI7AH;4!#&&\3QN+_./N^YO.+OSNCG?Z*W;='W9WIR_WAX[X^H[P-Y>'3@[-
M=>S5UTW;Z1%$W#*@   (*B<0QD=EI[DA.Z.>_=KR*QH#I6Y>55\P.S.7J"O3
M+5Y)3<?[U37]SRC6E.C3X)3=JG494
M
M                            !!62\0QE^7;;ER/+H[E7@T&:*+#I6Z_6
M4;2:K\IN8J];G)S#J<'80VFFO[@U;=,11)BLU3J,J  "S+;1:US0-X7PYG+=
MG89L[9D*T<2T1(1R#DU)112I6ZKQNBFL;EUXM"UKV=OD'2^8F(HS:O-'-H
M
M                                                         !9E
M;-K7,WW/3$^O;LZC JO)XR<VK$2"<0H5:%521,22.W*S.556O"6M#^^-V4[1
MTF8T*?%G^\O-'-H   !9ENKM:YKBD++/;]NSLZ1JSFRNCP\1(296QE5XVJ15
MS,FZ]$3*43-4M#::\-=/(.N',1&ZS<O-')H
M                                                      !9E85K
M7,SW)77.N[=G6L(Y>769O,.8B00BERN5-6YD9!5N5HJ5>GWE2GKQ>YJ.DS&A
M3XLQ_$O-'-H   !9EN7M:YIZ\+'<P=NSLRV:,SE=N(F(D)%!L:LHFI0KA5FW
M631-RZ<6AJT[.WR#I9,1$U9N7FCFT
M
M
M
M
M
M V<B4QX]\0A3'.=FZ*0A:5,8QC('H4I2TUJ8QJUTI2GE"-\6E;4+9N2W//WS
MAM^<@NL\UND[YB7\7U73^<?4=-US=#G\CGDX^'7AXRZZ:T'3$F)I1FU>".;0
M   "S*V;6N9ON>F)]>W9U&!5>3QDYM6(D$XA0JT*JDB8DD=N5F<JJM>$M:']
M\;LIVCI,QH4^+/\ >7FCFT
M
M                      LRW"6M<TUDZPG\-;L[+,&;.+*[>QD1(/VC4R=P
M.5E"N7+5NJB@8B)J'K0QJ:%KK7L'2R8BV:LSOKS1S:  !;;A/,5S9(N*Z(B<
M8P31M"-BK-#Q+60074-5\=M6C@SR3?)G+RRZ^]*3M_<[!NZV(B)AF)JN2&&@
M
M                                                           %
MML)F*YI+.,CC-=C!$@6CF613=I-9 LN8K",4>(U.N>349U,94NAM&]-2^32O
M:-S;&CI?%FN[1<D,-    +;<]9BN;%KNVF]OL8)X29;2:SJLPUD'!DS,E61$
MJ(592<?0I34<FXN*AM=*::>[NRV+M]F9HN2&&@
M                                                         %MM
MIYBN:=S1/XY=L8).$BG,^BW=-FL@25.6*/PMZK+JR:S0QCT^_P"% NON:#<V
MQ%NE\68G=HN2&&@   %MN;,Q7-C>XK7B(-C!.VTVV,L[/+-9!==,U'Q&U*-S
M,Y-BF0O+-K[XI^W]SL&[;8F)F69FBY(8:
M
M
M
M
M
M     ;9XL9NT=."4+4Z#9=8E#4K4M3))&.6AJ4J6M2UJ7MTK0!;]@++ER94\
M[/.%E!L^XNXND[F;/V_,[T[YZCJ>NDI'CX.[B<'#P::FUUUIIN^V+=YFV:KB
MAAH   !;;"9BN:2SC(XS78P1(%HYED4W:360++F*PC%'B-3KGDU&=3&5+H;1
MO34ODTKVC<VQHZ7Q9KNT7)##0
M
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MJU^Y0*2/M5ZS;FX%W;9$^E#<"JZ29N&NM*&X3G+72M:>4!]=4VY/4]0AT_\
M\T<U/D_?\O\ ?>+@^_\ >^7R]@#Y2>LW!N!!VV6/I4W DNDH;AII2IN$AS5T
MI6OE ?!Y!@F<Q%'S,AR5J4Y#N42G*:GE*8ICTJ6M/N5"DC55=-D"D.LX01(I
M]X=55-,I^S7WACFI0W9V]@ BZ;.*&,@X07H33CJBJFI0FNM:<52&-0NM*>Z
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MR$/Q4XJ<!S&H4VI>VFGN "+ILYXNG<(+\&G'R54U>#BUX>+@,;AXN&NFOET
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M8AW*)#EK]PQ3'I6E0H-11TV1(155P@DFIIRU%%4R$/Q4XJ<!S&H4VI>VFGN
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M3AIQ5XSE-4I="]M=?< :9)!@J<J:;UHHH>NA2$<HG.:OW"E*>M:U"@_57K-
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MK]**42+:35Q5[;7?/&ZYVY_/GN[OI\=[T/FSUG3<9"$Y?4^<#7G:<'EY9/\
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M-MYCXP./D2J4GTWFKP\7*=E=<CG><AN'BX>'BX:Z>73W!?ZFY2B:*3,P8/\
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MWM*R$GTWFKSNGZ]VLZY'.\Y$N;RN;P\7"7BTUTIY!?ZGX&BEK,F&_C:\W/\
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MZ'S?[QX>C(8G,ZGOMAKS.+73ETT^[42V_1BE";:JJ?8;ZS$+/%7G'R^EZ?\
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MW01)XO\ BG>C/IN;Q\S]]4X?O>WRC-MU)JLQ6*&&\-_%+YQ_]H_.#S@[H_\
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MS?[QX>C(8G,ZGOMAKS.+73ETT^[42V_1BE";:JC5PKS<.M<3><O#TRYEN_\
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MWM*R$GTWFKSNGZ]VLZY'.\Y$N;RN;P\7"7BTUTIY!?ZGX&BEK,F&_C:\W/\
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M.U%](I0T=VJY\8:
M
M
M
M
M
M
M
M
M
M
E                                             !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>lgvn-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-28T13:18:10.4380+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://LongeveronInc.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:lgvn="http://LongeveronInc.com/20241231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails2" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Future Minimum Payments Under the Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals" id="StatementBalanceSheetsParentheticals">
        <link:definition>100030 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>100040 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss" id="StatementStatementsOfComprehensiveLoss">
        <link:definition>100050 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>100060 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParentheticals" id="StatementStatementsOfStockholdersEquityParentheticals">
        <link:definition>100070 - Statement - Statements of Stockholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>100080 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>100090 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_NatureofBusinessBasisofPresentationandLiquidity" id="lgvn_r_NatureofBusinessBasisofPresentationandLiquidity">
        <link:definition>995457 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPolicies" id="lgvn_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995467 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecurities" id="lgvn_r_MarketableSecurities">
        <link:definition>995477 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNet" id="lgvn_r_PropertyandEquipmentNet">
        <link:definition>995487 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNet" id="lgvn_r_IntangibleAssetsNet">
        <link:definition>995497 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_Leases" id="lgvn_r_Leases">
        <link:definition>995507 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_StockholdersEquity" id="lgvn_r_StockholdersEquity">
        <link:definition>995517 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlan1" id="DisclosureEquityIncentivePlan1">
        <link:definition>995527 - Disclosure - Equity Incentive Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_CommitmentsandContingencies" id="lgvn_r_CommitmentsandContingencies">
        <link:definition>995537 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995547 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_EmployeeBenefitsPlan" id="lgvn_r_EmployeeBenefitsPlan">
        <link:definition>995557 - Disclosure - Employee Benefits Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShare" id="lgvn_r_LossPerShare">
        <link:definition>995567 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995577 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995587 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPoliciesTables" id="lgvn_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>995597 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecuritiesTables" id="lgvn_r_MarketableSecuritiesTables">
        <link:definition>995607 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNetTables" id="lgvn_r_PropertyandEquipmentNetTables">
        <link:definition>995617 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNetTables" id="lgvn_r_IntangibleAssetsNetTables">
        <link:definition>995627 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LeasesTables" id="lgvn_r_LeasesTables">
        <link:definition>995637 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanTables" id="DisclosureEquityIncentivePlanTables">
        <link:definition>995647 - Disclosure - Equity Incentive Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995657 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShareTables" id="lgvn_r_LossPerShareTables">
        <link:definition>995667 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995677 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails" id="DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails">
        <link:definition>995687 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995697 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails">
        <link:definition>995707 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts and Grants Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails">
        <link:definition>995717 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>995727 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
        <link:definition>995737 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails">
        <link:definition>995747 - Disclosure - Property and Equipment, Net - Schedule of Major Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>995757 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails" id="DisclosureIntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>995767 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails" id="DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails">
        <link:definition>995777 - Disclosure - Intangible Assets, Net - Schedule of Major Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" id="DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
        <link:definition>995787 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense for Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995797 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails">
        <link:definition>995807 - Disclosure - Leases - Schedule of Future Minimum Payments Under the Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesParentheticalDetails" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesParentheticalDetails">
        <link:definition>995817 - Disclosure - Leases - Schedule of Future Minimum Payments Under the Operating Leases (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995827 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails" id="DisclosureEquityIncentivePlanAdditionalInformationDetails">
        <link:definition>995837 - Disclosure - Equity Incentive Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails" id="DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails">
        <link:definition>995847 - Disclosure - Equity Incentive Plan - Schedule of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails" id="DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails">
        <link:definition>995857 - Disclosure - Equity Incentive Plan - Schedule of Issued and Outstanding Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails" id="DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails">
        <link:definition>995867 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995877 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEmployeeBenefitsPlanAdditionalInformationDetails" id="DisclosureEmployeeBenefitsPlanAdditionalInformationDetails">
        <link:definition>995887 - Disclosure - Employee Benefits Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995897 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails" id="DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails">
        <link:definition>995907 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences and Net Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails">
        <link:definition>995917 - Disclosure - Income Taxes - Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails" id="DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails">
        <link:definition>995927 - Disclosure - Loss Per Share - Schedule of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>995937 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails" id="DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails">
        <link:definition>995947 - Disclosure - Segment Information - Schedule of Significant Expense Categories Provided to CODM (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://LongeveronInc.com/20241231/role/Anchoring" id="Anchoring">
        <link:definition>999009 - Disclosure - Anchoring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lgvn-20241231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets" xlink:href="lgvn-20241231.xsd#StatementBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals" xlink:href="lgvn-20241231.xsd#StatementBalanceSheetsParentheticals" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations" xlink:href="lgvn-20241231.xsd#StatementStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="lgvn-20241231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="lgvn-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails" xlink:href="lgvn-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails" xlink:href="lgvn-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="lgvn-20241231.xsd#DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails" xlink:href="lgvn-20241231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureIntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails" xlink:href="lgvn-20241231.xsd#DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureEquityIncentivePlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails" xlink:href="lgvn-20241231.xsd#DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails" xlink:href="lgvn-20241231.xsd#DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails" xlink:href="lgvn-20241231.xsd#DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails" xlink:href="lgvn-20241231.xsd#DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails" xlink:href="lgvn-20241231.xsd#DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/role/Anchoring" xlink:href="lgvn-20241231.xsd#Anchoring" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:href="lgvn-20241231.xsd#StatementStatementsOfComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParentheticals" xlink:href="lgvn-20241231.xsd#StatementStatementsOfStockholdersEquityParentheticals" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="lgvn-20241231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_NatureofBusinessBasisofPresentationandLiquidity" xlink:href="lgvn-20241231.xsd#lgvn_r_NatureofBusinessBasisofPresentationandLiquidity" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPolicies" xlink:href="lgvn-20241231.xsd#lgvn_r_SummaryofSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecurities" xlink:href="lgvn-20241231.xsd#lgvn_r_MarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNet" xlink:href="lgvn-20241231.xsd#lgvn_r_PropertyandEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNet" xlink:href="lgvn-20241231.xsd#lgvn_r_IntangibleAssetsNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_Leases" xlink:href="lgvn-20241231.xsd#lgvn_r_Leases" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_StockholdersEquity" xlink:href="lgvn-20241231.xsd#lgvn_r_StockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlan1" xlink:href="lgvn-20241231.xsd#DisclosureEquityIncentivePlan1" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_CommitmentsandContingencies" xlink:href="lgvn-20241231.xsd#lgvn_r_CommitmentsandContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="lgvn-20241231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_EmployeeBenefitsPlan" xlink:href="lgvn-20241231.xsd#lgvn_r_EmployeeBenefitsPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShare" xlink:href="lgvn-20241231.xsd#lgvn_r_LossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:href="lgvn-20241231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lgvn-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPoliciesTables" xlink:href="lgvn-20241231.xsd#lgvn_r_SummaryofSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecuritiesTables" xlink:href="lgvn-20241231.xsd#lgvn_r_MarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNetTables" xlink:href="lgvn-20241231.xsd#lgvn_r_PropertyandEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNetTables" xlink:href="lgvn-20241231.xsd#lgvn_r_IntangibleAssetsNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LeasesTables" xlink:href="lgvn-20241231.xsd#lgvn_r_LeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanTables" xlink:href="lgvn-20241231.xsd#DisclosureEquityIncentivePlanTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="lgvn-20241231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShareTables" xlink:href="lgvn-20241231.xsd#lgvn_r_LossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="lgvn-20241231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:href="lgvn-20241231.xsd#DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails" xlink:href="lgvn-20241231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesParentheticalDetails" xlink:href="lgvn-20241231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEmployeeBenefitsPlanAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureEmployeeBenefitsPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails" xlink:href="lgvn-20241231.xsd#DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails" xlink:href="lgvn-20241231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="lgvn-20241231.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails2" xlink:href="lgvn-20241231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails2" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueConsensusPricingModelMember" xlink:label="us-gaap_ValuationTechniqueConsensusPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod" xlink:label="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ProjectManagementFees" xlink:label="lgvn_ProjectManagementFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" xlink:label="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PlacementAgentWarrantsMember" xlink:label="lgvn_PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PreFundedWarrantMember" xlink:label="lgvn_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncurredTerms" xlink:label="lgvn_IncurredTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TwoThousandTwentyOnePIPEOfferingMember" xlink:label="lgvn_TwoThousandTwentyOnePIPEOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesCUnitsMember" xlink:label="lgvn_SeriesCUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesCWarrantsMember" xlink:label="lgvn_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingRevenueMember" xlink:label="lgvn_ContractManufacturingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CommonWarrantsMember" xlink:label="lgvn_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping" xlink:label="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MilestoneFeesPayable" xlink:label="lgvn_MilestoneFeesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" xlink:label="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_UnderwritersMember" xlink:label="lgvn_UnderwritersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyRegisteredDirectOfferingMember" xlink:label="lgvn_JulyRegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockOptionAwardFourYearVestingPeriodMember" xlink:label="lgvn_StockOptionAwardFourYearVestingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AnnualNetSalesPercentage" xlink:label="lgvn_AnnualNetSalesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts" xlink:label="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyPrivatePlacementMember" xlink:label="lgvn_JulyPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoteWarrantMember" xlink:label="us-gaap_NoteWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClinicalTrialRevenueMember" xlink:label="lgvn_ClinicalTrialRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SecretomeTherapeuticsIncorporatedMember" xlink:label="lgvn_SecretomeTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncomeTaxesTable" xlink:label="lgvn_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AgreementTerminationDescription" xlink:label="lgvn_AgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MasterServicesAgreementsMember" xlink:label="lgvn_MasterServicesAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfRevenueAbstract" xlink:label="lgvn_ScheduleOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TechnologyServicesAgreementMember" xlink:label="lgvn_TechnologyServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LongeveronMember" xlink:label="lgvn_LongeveronMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested" xlink:label="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OtherRefundableTaxCredits" xlink:label="lgvn_OtherRefundableTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots" xlink:label="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts" xlink:label="lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ExerciseOfRemainingShares" xlink:label="lgvn_ExerciseOfRemainingShares"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TwoThousandTwentyOneIncentivePlanMember" xlink:label="lgvn_TwoThousandTwentyOneIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedLicenseAgreements" xlink:label="us-gaap_IndefiniteLivedLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_HourlyFeeForProjectManagementServices" xlink:label="lgvn_HourlyFeeForProjectManagementServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OutsourcedTestingFeePerBatchReceivable" xlink:label="lgvn_OutsourcedTestingFeePerBatchReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PlacementAgentWarrants1Member" xlink:label="lgvn_PlacementAgentWarrants1Member"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract" xlink:label="lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" xlink:label="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClassACommonStockWarrantsMember" xlink:label="lgvn_ClassACommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LeasesDetailsTable" xlink:label="lgvn_LeasesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PaymentPerWarrant" xlink:label="lgvn_PaymentPerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_UMAgreementsMember" xlink:label="lgvn_UMAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesRestrictedAbstract" xlink:label="us-gaap_EquitySecuritiesRestrictedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_Rule10b51ArrModifiedFlag" xlink:label="lgvn_Rule10b51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredTaxAssetsLeaseLiability" xlink:label="lgvn_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingMember" xlink:label="lgvn_ContractManufacturingMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_firstPhase3ClinicalTrialMember" xlink:label="lgvn_firstPhase3ClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested" xlink:label="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TermsOfAgreement" xlink:label="lgvn_TermsOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockholdersEquityDetailsTable" xlink:label="lgvn_StockholdersEquityDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyOrdinaryCoursePlacementAgentMember" xlink:label="lgvn_JulyOrdinaryCoursePlacementAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanRestructuringTrialModificationsAmount" xlink:label="us-gaap_LoanRestructuringTrialModificationsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:label="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncomeTaxesLineItems" xlink:label="lgvn_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NondisclosureAgreementMember" xlink:label="lgvn_NondisclosureAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfStockOptionActivityAbstract" xlink:label="lgvn_ScheduleOfStockOptionActivityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_RockSofferMember" xlink:label="lgvn_RockSofferMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_BiologicsLicenseMember" xlink:label="lgvn_BiologicsLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_December2023OfferingMember" xlink:label="lgvn_December2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ReverseStockSplitPolicyTextBlock" xlink:label="lgvn_ReverseStockSplitPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:label="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfDilutedNetLossPerShareAbstract" xlink:label="lgvn_ScheduleOfDilutedNetLossPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PhantomShareUnitsPSUsMember" xlink:label="us-gaap_PhantomShareUnitsPSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingLeaseRevenueMember" xlink:label="lgvn_ContractManufacturingLeaseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" xlink:label="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesDWarrantsMember" xlink:label="lgvn_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock" xlink:label="lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ChiefScienceOfficerMember" xlink:label="lgvn_ChiefScienceOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfMarketableSecuritiesAbstract" xlink:label="lgvn_ScheduleOfMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AgreementTerm" xlink:label="lgvn_AgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NeilHareMember" xlink:label="lgvn_NeilHareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_InvestorWarrantsMember" xlink:label="lgvn_InvestorWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PotentialAmountReceivableForEachProductLot" xlink:label="lgvn_PotentialAmountReceivableForEachProductLot"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredOfferingCostsPolicyTextBlock" xlink:label="lgvn_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NonRule10b51ArrModifiedFlag" xlink:label="lgvn_NonRule10b51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts" xlink:label="lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AprilTwoThousandTwentyFourPublicOfferingMember" xlink:label="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" xlink:label="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_UnderwritersWarrantsMember" xlink:label="lgvn_UnderwritersWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NationalInstitutesOfHealthGrantMember" xlink:label="lgvn_NationalInstitutesOfHealthGrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="lgvn_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PercentageOfAggregateNumberOfShares" xlink:label="lgvn_PercentageOfAggregateNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_licenseAgreementTerm" xlink:label="lgvn_licenseAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeReceivableMember" xlink:label="us-gaap_AccruedIncomeReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OwnershipMember" xlink:label="lgvn_OwnershipMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SuiteReservationFee" xlink:label="lgvn_SuiteReservationFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining" xlink:label="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NetSalesOfSubLicensees" xlink:label="lgvn_NetSalesOfSubLicensees"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_GrantRevenueMember" xlink:label="lgvn_GrantRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MilestoneOfTriggeringPayments" xlink:label="lgvn_MilestoneOfTriggeringPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:label="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract" xlink:label="lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MonthlyManufacturingSuiteReservationFee" xlink:label="lgvn_MonthlyManufacturingSuiteReservationFee"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LawsuitExpenses" xlink:label="lgvn_LawsuitExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeemedDividendWarrantInducementOffers" xlink:label="lgvn_DeemedDividendWarrantInducementOffers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract" xlink:label="lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SupplyAgreementMember" xlink:label="lgvn_SupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingSecuritiesDebtAmortizedCost" xlink:label="us-gaap_TradingSecuritiesDebtAmortizedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService" xlink:label="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" xlink:label="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OperatingSegmentMember" xlink:label="lgvn_OperatingSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesAAndSeriesBWarrantsMember" xlink:label="lgvn_SeriesAAndSeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CustomerOneMember" xlink:label="lgvn_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyOfferingPlacementMember" xlink:label="lgvn_JulyOfferingPlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract" xlink:label="lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" xlink:label="us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_October2023RegisteredDirectOfferingMember" xlink:label="lgvn_October2023RegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JunePlacementAgentWarrantsMember" xlink:label="lgvn_JunePlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MarketableSecuritiesDetailsTable" xlink:label="lgvn_MarketableSecuritiesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ProceedsFromStockSubscriptionReceivable" xlink:label="lgvn_ProceedsFromStockSubscriptionReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MarkupPercentageOnValueOfMaterialsCompensated" xlink:label="lgvn_MarkupPercentageOnValueOfMaterialsCompensated"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_InitialStartUpPaymentReceived" xlink:label="lgvn_InitialStartUpPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PersonnelCosts" xlink:label="lgvn_PersonnelCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" xlink:label="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AccountsReceivableFromCustomersMember" xlink:label="lgvn_AccountsReceivableFromCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfRsuActivityAbstract" xlink:label="lgvn_ScheduleOfRsuActivityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OtherComprehensiveLossAbstract" xlink:label="lgvn_OtherComprehensiveLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuesDuringPeriodSharesForPSUsVested" xlink:label="lgvn_StockIssuesDuringPeriodSharesForPSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsTable" xlink:label="lgvn_EquityBasedCompensationDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_WarrantsToPurchase" xlink:label="lgvn_WarrantsToPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JuneInducementWarrantsMember" xlink:label="lgvn_JuneInducementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CommitmentsandContingenciesDetailsTable" xlink:label="lgvn_CommitmentsandContingenciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm" xlink:label="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_InterestEarnedOnMarketableSecurities" xlink:label="lgvn_InterestEarnedOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CollectionOfStockSubscriptionReceivable" xlink:label="lgvn_CollectionOfStockSubscriptionReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueConsensusPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique, Consensus Pricing Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueConsensusPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black-Scholes pricing model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of Class B common stock for Class A common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A common stock, issued for RSUs vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class ACommon Stock Issued For RSUs Vested During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, issued for RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease asset and liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ProjectManagementFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Project management fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ProjectManagementFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Project Management Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ProjectManagementFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Project management fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Security, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest earned on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First tranche july ordinary course placement agent warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Tranche July Ordinary Course Placement Agent Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity-Based Compensation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plan [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partners' Capital Account, Units, Sold in Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 (remaining three months)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement agent warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrant Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncurredTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incurred terms.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncurredTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incurred Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncurredTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incurred term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful Lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intangible assets estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TwoThousandTwentyOnePIPEOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty One PIPE Offering Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TwoThousandTwentyOnePIPEOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One PIPEOffering Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TwoThousandTwentyOnePIPEOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 private placement offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TwoThousandTwentyOnePIPEOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2021 PIPE Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesCUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series CUnits Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesCUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross (in Dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Other Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business, Basis of Presentation, and Liquidity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesCWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series CWarrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesCWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Manufacturing Revenue Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract manufacturing revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract Manufacturing Revenue Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contract manufacturing revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenditures amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Standard fee receivable for product packing, handling and shipping.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Standard Fee Receivable for Product Packing, Handling and Shipping</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Standard fee receivable for product packing, handling and shipping</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MilestoneFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone fees Payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MilestoneFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Fees Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MilestoneFeesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone fees payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Abandoned patents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Patents, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant, Exercise Price, Increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Change in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of unrealized loss attributable to change in market value of available-for-sale securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Unrealized Loss Attributable To Change In Market Value Of Available For Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain attributable to change in market value of available for sale investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_UnderwritersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriters Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_UnderwritersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyRegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">July registered direct offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyRegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July Registered Direct Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockOptionAwardFourYearVestingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Award Four Year Vesting Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockOptionAwardFourYearVestingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option award four year vesting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">UM License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AnnualNetSalesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual net sales percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AnnualNetSalesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Net Sales Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AnnualNetSalesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual net sales percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Technology transfer, documentation preparation, training, and testing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Technology Transfer, Documentation Preparation, Training, and Testing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technology transfer, documentation preparation, training, and testing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">July Private Placement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July Private Placement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Stock Options, Outstanding at ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Stock Options, Outstanding at Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option issued and outstanding (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stock options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets and liabilities, net of valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend &#8211; warrant inducement offers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoteWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Note Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoteWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Warrant Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual royalty fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split rounding adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Life Settlement Contracts, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Life Settlement Contracts, Fair Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income and (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Price per share (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ClinicalTrialRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Revenue Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ClinicalTrialRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trial revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ClinicalTrialRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Clinical trial revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SecretomeTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Secretome Therapeutics, Incorporated.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SecretomeTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secretome Therapeutics, Incorporated [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SecretomeTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secretome Therapeutics, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SecretomeTherapeuticsIncorporatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Secretome [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts and Grants Receivable [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSU granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Major Components of Property and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of RSU Activity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expenses), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, held for taxes on PSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement termination description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding (unvested) at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested shares (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding (unvested) at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Master Services Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Master Services Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ScheduleOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Revenue Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts and Grants Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issue for warrants exercised, net of issuance cost (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Stock Options, Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TechnologyServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Technology Services Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TechnologyServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technology Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company contributed amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">G&amp;A costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_LongeveronMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Longeveron Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_LongeveronMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Longeveron [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TrademarksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trademarks [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TrademarksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trademark costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of option right of use vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Share Based Payment Award Options RSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued RSUs shares (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options unvested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend attributable to down round feature of 2021 warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OtherRefundableTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Refundable Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OtherRefundableTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other refundable tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OtherRefundableTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other refundable tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options expired/forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Weighted Average Exercise Price, Options expired/forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Major Components of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments receivable for each additional product lot in excess of initial training run lots.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Receivable for Each Additional Product Lot in Excess of Initial Training Run Lots</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments receivable for each additional product lot in excess of initial training run lots</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of common stock issued for  warrants exercised, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value For Warrants Exercised Net Of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issued for warrants exercised, issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research &amp; development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ExerciseOfRemainingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ExerciseOfRemainingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Remaining Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ExerciseOfRemainingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of remaining shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TwoThousandTwentyOneIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TwoThousandTwentyOneIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty One Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TwoThousandTwentyOneIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_HourlyFeeForProjectManagementServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hourly fee for project management services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_HourlyFeeForProjectManagementServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hourly Fee for Project Management Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_HourlyFeeForProjectManagementServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hourly fee for project management services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Major Components of Intangible Assets [Line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OutsourcedTestingFeePerBatchReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outsourced testing fee per batch receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OutsourcedTestingFeePerBatchReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outsourced Testing Fee per Batch Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OutsourcedTestingFeePerBatchReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outsourced testing fee per batch receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PlacementAgentWarrants1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent warrants one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PlacementAgentWarrants1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Warrants 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PlacementAgentWarrants1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement Agent Warrants June 2024 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Issued And Outstanding Options Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual to cash adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash write-off of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Payments Under the Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of RSU Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Expensed and Capitalized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized equity based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Deferred Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonoperating lawsuit expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standard Updates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders&#8217; Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issued in direct placements/public offering, issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSU expired/forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares Class A common stock, held for taxes on PSUs vested shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Class A Common Stock Held For Taxes On PSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, held for taxes on PSUs vested (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A common stock, held for taxes on RSUs vested shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Perios Shares Class ACommon Stock Held For Taxes On RSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, held for taxes on RSUs vested (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ClassACommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class ACommon Stock Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ClassACommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_LeasesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PaymentPerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment per warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PaymentPerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Per Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PaymentPerWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment per warrant (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_UMAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UMAgreements Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_UMAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UM Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issued in public offering, net of issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issue for warrants exercised, net of issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesRestrictedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, Restricted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_Rule10b51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_Rule10b51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b51 ArrModified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-term Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">R&amp;D costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Stock Options, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842 Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Issued and Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Manufacturing Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract manufacturing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_firstPhase3ClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">first Phase3 Clinical Trial Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_firstPhase3ClinicalTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">first Phase 3 Clinical Trial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for taxes on RSUs vested and PSUs vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Taxes On RSUs Vested and PSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments for taxes on RSUs vested and PSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price per share (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TermsOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Terms of agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TermsOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Terms Of Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_TermsOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants or rights exercisable date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Patents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Diluted Net Loss per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockholdersEquityDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders&#8217; Equity (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyOrdinaryCoursePlacementAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">July Ordinary Course Placement Agent Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyOrdinaryCoursePlacementAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July Ordinary Course Placement Agent Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyOrdinaryCoursePlacementAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July Ordinary Course Placement Agent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoanRestructuringTrialModificationsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Restructuring, Trial Modifications, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoanRestructuringTrialModificationsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Completion of trial</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collection of stock subscription receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A common stock issued for stock rights offering, net of issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A common stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Class A Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class B Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class B Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class B common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Class B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company value amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock Option Activity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NondisclosureAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nondisclosure agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NondisclosureAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nondisclosure Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NondisclosureAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nondisclosure Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ScheduleOfStockOptionActivityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock Option Activity Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_RockSofferMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rock soffer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_RockSofferMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rock Soffer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_RockSofferMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rock Soffer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite lived intangible assets, wrote-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_BiologicsLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biologics License Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_BiologicsLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biologics license [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts and Grants Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_December2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December2023 Offering Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_December2023OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2023 registered direct offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of Reverse Stock Split.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reportable Segment, Aggregation before Other Operating Segment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reportable Segment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ScheduleOfDilutedNetLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Diluted Net Loss Per Share Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PhantomShareUnitsPSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phantom Share Units (PSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PhantomShareUnitsPSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingLeaseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Manufacturing Lease Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingLeaseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract manufacturing lease revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingLeaseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract manufacturing lease revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ContractManufacturingLeaseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contract manufacturing lease revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Class A Common Stock Issued For Prefunded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value class A common stock issued for prefunded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issued for prefunded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of contract manufacturing revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series DWarrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of vesting of RSU and PSUs into class A common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of RSUs And PSUs Into Class ACommon Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of RSUs and PSUs into Class A common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ChiefScienceOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Science Officer Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ChiefScienceOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Science Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders&#8217; Equity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Issued and Outstanding Options [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Warrants and Series D warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Warrants and Series D warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ScheduleOfMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Marketable Securities Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NeilHareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Neil Hare [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NeilHareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NeilHare [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NeilHareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NeilHare [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finite-Lived Intangible Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issued in direct placements, net of issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_InvestorWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investor warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_InvestorWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investor warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Class B common stock for Class A common stock (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders shares converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PotentialAmountReceivableForEachProductLot_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential amount receivable for each product lot.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PotentialAmountReceivableForEachProductLot_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Amount Receivable for Each Product Lot</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PotentialAmountReceivableForEachProductLot_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential amount receivable for each product lot</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity-Based Compensation (Details) - Schedule of RSU Activity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits Plan [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NonRule10b51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Rule10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NonRule10b51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Rule 10b51 ArrModified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued For Stock Rights Offering Net Of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued for stock rights offering net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Common Stock issued for stock rights offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split rounding adjustment (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">April Two Thousand Twenty Four Public Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">April Two Thousand Twenty Four Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">April 2024 Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend to common stockholders (in Dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A common stock, issued for RSUs vested shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issues Suring Period Class ACommon Stock Issued For RSUs Vestedin Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, issued for RSUs vested (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issued in public offering, net of issuance cost (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_UnderwritersWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriters Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_UnderwritersWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NationalInstitutesOfHealthGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institutes Of Health Grant Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NationalInstitutesOfHealthGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">National Institutes of Health &#8211; Grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NationalInstitutesOfHealthGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">NIH - grant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">ASC 842 Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less interest (5% discount rate)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PercentageOfAggregateNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate number of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PercentageOfAggregateNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Number Of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PercentageOfAggregateNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fee Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial fee paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Other Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to UM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic weighted average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Payments Under the Operating Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee tax liabilities shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Useful Lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock, net of issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense related to intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted maximum term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_licenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">license agreement term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_licenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">license Agreement Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_licenseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from warrants exercised, net of issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OwnershipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OwnershipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SuiteReservationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Suite reservation fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SuiteReservationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Suite Reservation Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SuiteReservationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Suite reservation fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Amortization Expense for Intangible Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-cash Investing and Financing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership change more than percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly payment receivable for in process samples and vialed harvests for training.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monthly Payment Receivable for In Process Samples and Vialed Harvests for Training</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly payment receivable for in process samples and vialed harvests for training</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Major Components of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized equity-based compensation term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NetSalesOfSubLicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net sales of sub licensees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NetSalesOfSubLicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales Of Sub Licensees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_NetSalesOfSubLicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales of sub licensees percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity-Based Compensation (Details) - Schedule of Stock Option Activity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants (in Dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax benefits, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_GrantRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Revenue Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_GrantRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MilestoneOfTriggeringPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of milestone of triggering payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MilestoneOfTriggeringPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Of Triggering Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MilestoneOfTriggeringPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from License Fees Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Investment Income Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable related to marketable securities and money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excess Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unregistered shares (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercisable term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payments term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software Website [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accounts And Grants Receivable Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MonthlyManufacturingSuiteReservationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monthly manufacturing suite reservation fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MonthlyManufacturingSuiteReservationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monthly Manufacturing Suite Reservation Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MonthlyManufacturingSuiteReservationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly manufacturing suite reservation fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_LawsuitExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lawsuit expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_LawsuitExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lawsuit expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_LawsuitExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lawsuit Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_LawsuitExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lawsuit expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeemedDividendWarrantInducementOffers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of deemed dividend warrant inducement offers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeemedDividendWarrantInducementOffers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Dividend Warrant Inducement Offers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeemedDividendWarrantInducementOffers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend &#8211; warrant inducement offers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeemedDividendWarrantInducementOffers_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deemed dividend - warrant inducement offers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Stock Options, Options expired/forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Major Components Of Intangible Assets Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingSecuritiesDebtAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Trading, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingSecuritiesDebtAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities of amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Debt, Net of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds (in Dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Business, Basis of Presentation, and Liquidity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, held for taxes on PSUs vested (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class A common stock issued for stock rights offering, net of issuance cost (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increased fee receivable for expedited or special hour service.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increased Fee Receivable for Expedited or Special Hour Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increased fee for expedited or special hour service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Company, Reimbursable Excess Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A common stock, held for taxes on RSUs vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Class ACommon Stock Held For Taxes On RSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, held for taxes on RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OperatingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OperatingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OperatingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating segment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesAAndSeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series AAnd Series BWarrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SeriesAAndSeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A and Series B Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Tax Effects of Temporary Differences and Net Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer One.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyOfferingPlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">July Offering Placement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyOfferingPlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July Offering Placement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JulyOfferingPlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July Offering Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Major Components Of Property And Equipment Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Ownership Plan (ESOP), Dividends Paid to ESOP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Expiration or Due Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expire date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_October2023RegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">October2023 Registered Direct Offering Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_October2023RegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October 2023 registered direct offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JunePlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">June Placement Agent Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JunePlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">June Placement Agent Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JunePlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June Placement Agent Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MarketableSecuritiesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 (remaining three months)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ProceedsFromStockSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of proceeds from stock subscription receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ProceedsFromStockSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Subscription Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ProceedsFromStockSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from stock subscription receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized gains and losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MarkupPercentageOnValueOfMaterialsCompensated_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Markup percentage on value of materials compensated.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MarkupPercentageOnValueOfMaterialsCompensated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Markup Percentage on Value of Materials Compensated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_MarkupPercentageOnValueOfMaterialsCompensated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage markup on the value of materials compensated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_InitialStartUpPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial start-up payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_InitialStartUpPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Start-Up Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_InitialStartUpPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial start-up payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_PersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Subscriptions Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock subscription receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second tranche July ordinary course placement agent warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Tranche July Ordinary Course Placement Agent Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Tranche July Ordinary Course Placement Agent Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables from Stockholder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AccountsReceivableFromCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable From Customers Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_AccountsReceivableFromCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable from customers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ScheduleOfRsuActivityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Rsu Activity Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OtherComprehensiveLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Loss Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_OtherComprehensiveLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivables [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, issued for PSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts and Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts and grants receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Amortization Expense for Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuesDuringPeriodSharesForPSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of stock issued for PSUs vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuesDuringPeriodSharesForPSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issues During Period Shares For PSUs Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuesDuringPeriodSharesForPSUsVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, issued for PSUs vested (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property and Equipment, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted weighted average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Significant Expense Categories Provided to CODM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts and grants receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options vested (based on ratable vesting)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_EquityBasedCompensationDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity-Based Compensation (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_EquityBasedCompensationDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_WarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_WarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_WarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JuneInducementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">June Inducement Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_JuneInducementWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">June Inducement Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_CommitmentsandContingenciesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies (Details) [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issued in direct placements, net of issuance cost (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of expiration of stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Stock Option Expiration Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option expiration term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding at ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding at Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price (in Dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Class A Common Stock Issued For Prefunded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares class A common stock issued for prefunded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock issued for prefunded warrants (in Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Other, Accumulated Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_InterestEarnedOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest earned on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_InterestEarnedOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Earned On Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_InterestEarnedOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest earned on marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_CollectionOfStockSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collection of stock subscription receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_CollectionOfStockSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collection Of Stock Subscription Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_CollectionOfStockSubscriptionReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collection of stock subscription receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized losses on available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity-Based Compensation (Details) - Schedule of Issued and Outstanding Options [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation And Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation and amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueConsensusPricingModelMember" xlink:to="us-gaap_ValuationTechniqueConsensusPricingModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod" xlink:to="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ProjectManagementFees" xlink:to="lgvn_ProjectManagementFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" xlink:to="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_PlacementAgentWarrantsMember" xlink:to="lgvn_PlacementAgentWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_PreFundedWarrantMember" xlink:to="lgvn_PreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_IncurredTerms" xlink:to="lgvn_IncurredTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_TwoThousandTwentyOnePIPEOfferingMember" xlink:to="lgvn_TwoThousandTwentyOnePIPEOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SeriesCUnitsMember" xlink:to="lgvn_SeriesCUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SeriesCWarrantsMember" xlink:to="lgvn_SeriesCWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ContractManufacturingRevenueMember" xlink:to="lgvn_ContractManufacturingRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_CommonWarrantsMember" xlink:to="lgvn_CommonWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping" xlink:to="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_MilestoneFeesPayable" xlink:to="lgvn_MilestoneFeesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" xlink:to="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_UnderwritersMember" xlink:to="lgvn_UnderwritersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_JulyRegisteredDirectOfferingMember" xlink:to="lgvn_JulyRegisteredDirectOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockOptionAwardFourYearVestingPeriodMember" xlink:to="lgvn_StockOptionAwardFourYearVestingPeriodMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_AnnualNetSalesPercentage" xlink:to="lgvn_AnnualNetSalesPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts" xlink:to="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_JulyPrivatePlacementMember" xlink:to="lgvn_JulyPrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoteWarrantMember" xlink:to="us-gaap_NoteWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:to="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBMember" xlink:to="us-gaap_SeriesBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ClinicalTrialRevenueMember" xlink:to="lgvn_ClinicalTrialRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SecretomeTherapeuticsIncorporatedMember" xlink:to="lgvn_SecretomeTherapeuticsIncorporatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_IncomeTaxesTable" xlink:to="lgvn_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_AgreementTerminationDescription" xlink:to="lgvn_AgreementTerminationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_MasterServicesAgreementsMember" xlink:to="lgvn_MasterServicesAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ScheduleOfRevenueAbstract" xlink:to="lgvn_ScheduleOfRevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_TechnologyServicesAgreementMember" xlink:to="lgvn_TechnologyServicesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_LongeveronMember" xlink:to="lgvn_LongeveronMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested" xlink:to="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_OtherRefundableTaxCredits" xlink:to="lgvn_OtherRefundableTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots" xlink:to="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts" xlink:to="lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ExerciseOfRemainingShares" xlink:to="lgvn_ExerciseOfRemainingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_TwoThousandTwentyOneIncentivePlanMember" xlink:to="lgvn_TwoThousandTwentyOneIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedLicenseAgreements" xlink:to="us-gaap_IndefiniteLivedLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_HourlyFeeForProjectManagementServices" xlink:to="lgvn_HourlyFeeForProjectManagementServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_OutsourcedTestingFeePerBatchReceivable" xlink:to="lgvn_OutsourcedTestingFeePerBatchReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_PlacementAgentWarrants1Member" xlink:to="lgvn_PlacementAgentWarrants1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract" xlink:to="lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAMember" xlink:to="us-gaap_SeriesAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested" xlink:to="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" xlink:to="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ClassACommonStockWarrantsMember" xlink:to="lgvn_ClassACommonStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_LeasesDetailsTable" xlink:to="lgvn_LeasesDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_PaymentPerWarrant" xlink:to="lgvn_PaymentPerWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_UMAgreementsMember" xlink:to="lgvn_UMAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesRestrictedAbstract" xlink:to="us-gaap_EquitySecuritiesRestrictedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_Rule10b51ArrModifiedFlag" xlink:to="lgvn_Rule10b51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_DeferredTaxAssetsLeaseLiability" xlink:to="lgvn_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ContractManufacturingMember" xlink:to="lgvn_ContractManufacturingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_firstPhase3ClinicalTrialMember" xlink:to="lgvn_firstPhase3ClinicalTrialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested" xlink:to="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_TermsOfAgreement" xlink:to="lgvn_TermsOfAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="lgvn_StockholdersEquityDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_JulyOrdinaryCoursePlacementAgentMember" xlink:to="lgvn_JulyOrdinaryCoursePlacementAgentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanRestructuringTrialModificationsAmount" xlink:to="us-gaap_LoanRestructuringTrialModificationsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:to="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_IncomeTaxesLineItems" xlink:to="lgvn_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_NondisclosureAgreementMember" xlink:to="lgvn_NondisclosureAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ScheduleOfStockOptionActivityAbstract" xlink:to="lgvn_ScheduleOfStockOptionActivityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_RockSofferMember" xlink:to="lgvn_RockSofferMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_BiologicsLicenseMember" xlink:to="lgvn_BiologicsLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesMember" xlink:to="us-gaap_AccruedLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_December2023OfferingMember" xlink:to="lgvn_December2023OfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ReverseStockSplitPolicyTextBlock" xlink:to="lgvn_ReverseStockSplitPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:to="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="lgvn_ScheduleOfDilutedNetLossPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PhantomShareUnitsPSUsMember" xlink:to="us-gaap_PhantomShareUnitsPSUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ContractManufacturingLeaseRevenueMember" xlink:to="lgvn_ContractManufacturingLeaseRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" xlink:to="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SeriesDWarrantsMember" xlink:to="lgvn_SeriesDWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock" xlink:to="lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ChiefScienceOfficerMember" xlink:to="lgvn_ChiefScienceOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:to="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ScheduleOfMarketableSecuritiesAbstract" xlink:to="lgvn_ScheduleOfMarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_AgreementTerm" xlink:to="lgvn_AgreementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_NeilHareMember" xlink:to="lgvn_NeilHareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMember" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_InvestorWarrantsMember" xlink:to="lgvn_InvestorWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_PotentialAmountReceivableForEachProductLot" xlink:to="lgvn_PotentialAmountReceivableForEachProductLot_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_DeferredOfferingCostsPolicyTextBlock" xlink:to="lgvn_DeferredOfferingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_NonRule10b51ArrModifiedFlag" xlink:to="lgvn_NonRule10b51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts" xlink:to="lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember" xlink:to="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" xlink:to="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_UnderwritersWarrantsMember" xlink:to="lgvn_UnderwritersWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_NationalInstitutesOfHealthGrantMember" xlink:to="lgvn_NationalInstitutesOfHealthGrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lgvn_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_PercentageOfAggregateNumberOfShares" xlink:to="lgvn_PercentageOfAggregateNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_licenseAgreementTerm" xlink:to="lgvn_licenseAgreementTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeReceivableMember" xlink:to="us-gaap_AccruedIncomeReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_OwnershipMember" xlink:to="lgvn_OwnershipMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SuiteReservationFee" xlink:to="lgvn_SuiteReservationFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining" xlink:to="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_NetSalesOfSubLicensees" xlink:to="lgvn_NetSalesOfSubLicensees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_GrantRevenueMember" xlink:to="lgvn_GrantRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_MilestoneOfTriggeringPayments" xlink:to="lgvn_MilestoneOfTriggeringPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInvestmentIncomeReceivable" xlink:to="us-gaap_AccruedInvestmentIncomeReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:to="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract" xlink:to="lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_MonthlyManufacturingSuiteReservationFee" xlink:to="lgvn_MonthlyManufacturingSuiteReservationFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_LawsuitExpenses" xlink:to="lgvn_LawsuitExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_DeemedDividendWarrantInducementOffers" xlink:to="lgvn_DeemedDividendWarrantInducementOffers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract" xlink:to="lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SupplyAgreementMember" xlink:to="lgvn_SupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingSecuritiesDebtAmortizedCost" xlink:to="us-gaap_TradingSecuritiesDebtAmortizedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService" xlink:to="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" xlink:to="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_OperatingSegmentMember" xlink:to="lgvn_OperatingSegmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SeriesAAndSeriesBWarrantsMember" xlink:to="lgvn_SeriesAAndSeriesBWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_CustomerOneMember" xlink:to="lgvn_CustomerOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_JulyOfferingPlacementMember" xlink:to="lgvn_JulyOfferingPlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract" xlink:to="lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" xlink:to="us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_October2023RegisteredDirectOfferingMember" xlink:to="lgvn_October2023RegisteredDirectOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_JunePlacementAgentWarrantsMember" xlink:to="lgvn_JunePlacementAgentWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_MarketableSecuritiesDetailsTable" xlink:to="lgvn_MarketableSecuritiesDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ProceedsFromStockSubscriptionReceivable" xlink:to="lgvn_ProceedsFromStockSubscriptionReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_MarkupPercentageOnValueOfMaterialsCompensated" xlink:to="lgvn_MarkupPercentageOnValueOfMaterialsCompensated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_InitialStartUpPaymentReceived" xlink:to="lgvn_InitialStartUpPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_PersonnelCosts" xlink:to="lgvn_PersonnelCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" xlink:to="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_AccountsReceivableFromCustomersMember" xlink:to="lgvn_AccountsReceivableFromCustomersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ScheduleOfRsuActivityAbstract" xlink:to="lgvn_ScheduleOfRsuActivityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_OtherComprehensiveLossAbstract" xlink:to="lgvn_OtherComprehensiveLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuesDuringPeriodSharesForPSUsVested" xlink:to="lgvn_StockIssuesDuringPeriodSharesForPSUsVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="lgvn_EquityBasedCompensationDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_WarrantsToPurchase" xlink:to="lgvn_WarrantsToPurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_JuneInducementWarrantsMember" xlink:to="lgvn_JuneInducementWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="lgvn_CommitmentsandContingenciesDetailsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm" xlink:to="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherCorporateBondsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants" xlink:to="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_InterestEarnedOnMarketableSecurities" xlink:to="lgvn_InterestEarnedOnMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_CollectionOfStockSubscriptionReceivable" xlink:to="lgvn_CollectionOfStockSubscriptionReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClinicalTrialRevenueMember" xlink:label="lgvn_ClinicalTrialRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LawsuitExpenses" xlink:label="lgvn_LawsuitExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeemedDividendWarrantInducementOffers" xlink:label="lgvn_DeemedDividendWarrantInducementOffers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingLeaseRevenueMember" xlink:label="lgvn_ContractManufacturingLeaseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OtherRefundableTaxCredits" xlink:label="lgvn_OtherRefundableTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingRevenueMember" xlink:label="lgvn_ContractManufacturingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_GrantRevenueMember" xlink:label="lgvn_GrantRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ClinicalTrialRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lgvn_LawsuitExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lgvn_DeemedDividendWarrantInducementOffers" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_CostOfRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_GrossProfit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingLeaseRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lgvn_OtherRefundableTaxCredits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_GrantRevenueMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OtherComprehensiveLossAbstract" xlink:label="lgvn_OtherComprehensiveLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lgvn_OtherComprehensiveLossAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_OtherComprehensiveLossAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod" xlink:label="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" xlink:label="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" xlink:label="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" xlink:label="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuesDuringPeriodSharesForPSUsVested" xlink:label="lgvn_StockIssuesDuringPeriodSharesForPSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CollectionOfStockSubscriptionReceivable" xlink:label="lgvn_CollectionOfStockSubscriptionReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" xlink:label="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" xlink:label="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_30"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_31"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuesDuringPeriodSharesForPSUsVested" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_CollectionOfStockSubscriptionReceivable" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_30" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_31" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParentheticals" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts" xlink:label="lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts" xlink:label="lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock" xlink:label="lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeemedDividendWarrantInducementOffers" xlink:label="lgvn_DeemedDividendWarrantInducementOffers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_InterestEarnedOnMarketableSecurities" xlink:label="lgvn_InterestEarnedOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ProceedsFromStockSubscriptionReceivable" xlink:label="lgvn_ProceedsFromStockSubscriptionReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested" xlink:label="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lgvn_DeemedDividendWarrantInducementOffers" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lgvn_InterestEarnedOnMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lgvn_ProceedsFromStockSubscriptionReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_RockSofferMember" xlink:label="lgvn_RockSofferMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NeilHareMember" xlink:label="lgvn_NeilHareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_Rule10b51ArrModifiedFlag" xlink:label="lgvn_Rule10b51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NonRule10b51ArrModifiedFlag" xlink:label="lgvn_NonRule10b51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="lgvn_RockSofferMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="lgvn_NeilHareMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="lgvn_Rule10b51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="lgvn_NonRule10b51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_NatureofBusinessBasisofPresentationandLiquidity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_Leases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_StockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlan1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_CommitmentsandContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_EmployeeBenefitsPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ReverseStockSplitPolicyTextBlock" xlink:label="lgvn_ReverseStockSplitPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredOfferingCostsPolicyTextBlock" xlink:label="lgvn_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lgvn_ReverseStockSplitPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lgvn_DeferredOfferingCostsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesRestrictedAbstract" xlink:label="us-gaap_EquitySecuritiesRestrictedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesRestrictedAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesRestrictedAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesRestrictedAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CustomerOneMember" xlink:label="lgvn_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:label="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="lgvn_CustomerOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AccountsReceivableFromCustomersMember" xlink:label="lgvn_AccountsReceivableFromCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract" xlink:label="lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NationalInstitutesOfHealthGrantMember" xlink:label="lgvn_NationalInstitutesOfHealthGrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="lgvn_AccountsReceivableFromCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="lgvn_NationalInstitutesOfHealthGrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClinicalTrialRevenueMember" xlink:label="lgvn_ClinicalTrialRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfRevenueAbstract" xlink:label="lgvn_ScheduleOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingLeaseRevenueMember" xlink:label="lgvn_ContractManufacturingLeaseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingRevenueMember" xlink:label="lgvn_ContractManufacturingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingMember" xlink:label="lgvn_ContractManufacturingMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NationalInstitutesOfHealthGrantMember" xlink:label="lgvn_NationalInstitutesOfHealthGrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ClinicalTrialRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_ScheduleOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingLeaseRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DeferredRevenueArrangementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_NationalInstitutesOfHealthGrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MarketableSecuritiesDetailsTable" xlink:label="lgvn_MarketableSecuritiesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingSecuritiesDebtAmortizedCost" xlink:label="us-gaap_TradingSecuritiesDebtAmortizedCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="lgvn_MarketableSecuritiesDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_MarketableSecuritiesDetailsTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AccruedInvestmentIncomeReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_TradingSecuritiesDebtAmortizedCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfMarketableSecuritiesAbstract" xlink:label="lgvn_ScheduleOfMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeReceivableMember" xlink:label="us-gaap_AccruedIncomeReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_ScheduleOfMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_AccruedIncomeReceivableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract" xlink:label="lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:label="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedPatentsGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract" xlink:label="lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LeasesDetailsTable" xlink:label="lgvn_LeasesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_LeasesDetailsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lgvn_LeasesDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_LeasesDetailsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockholdersEquityDetailsTable" xlink:label="lgvn_StockholdersEquityDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueConsensusPricingModelMember" xlink:label="us-gaap_ValuationTechniqueConsensusPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_UnderwritersMember" xlink:label="lgvn_UnderwritersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TwoThousandTwentyOnePIPEOfferingMember" xlink:label="lgvn_TwoThousandTwentyOnePIPEOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_October2023RegisteredDirectOfferingMember" xlink:label="lgvn_October2023RegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_WarrantsToPurchase" xlink:label="lgvn_WarrantsToPurchase"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PlacementAgentWarrantsMember" xlink:label="lgvn_PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_December2023OfferingMember" xlink:label="lgvn_December2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_InvestorWarrantsMember" xlink:label="lgvn_InvestorWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoteWarrantMember" xlink:label="us-gaap_NoteWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesAAndSeriesBWarrantsMember" xlink:label="lgvn_SeriesAAndSeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AprilTwoThousandTwentyFourPublicOfferingMember" xlink:label="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_UnderwritersWarrantsMember" xlink:label="lgvn_UnderwritersWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyRegisteredDirectOfferingMember" xlink:label="lgvn_JulyRegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PreFundedWarrantMember" xlink:label="lgvn_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CommonWarrantsMember" xlink:label="lgvn_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClassACommonStockWarrantsMember" xlink:label="lgvn_ClassACommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesCWarrantsMember" xlink:label="lgvn_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesDWarrantsMember" xlink:label="lgvn_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PaymentPerWarrant" xlink:label="lgvn_PaymentPerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PercentageOfAggregateNumberOfShares" xlink:label="lgvn_PercentageOfAggregateNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JuneInducementWarrantsMember" xlink:label="lgvn_JuneInducementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ExerciseOfRemainingShares" xlink:label="lgvn_ExerciseOfRemainingShares"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JunePlacementAgentWarrantsMember" xlink:label="lgvn_JunePlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PlacementAgentWarrants1Member" xlink:label="lgvn_PlacementAgentWarrants1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyPrivatePlacementMember" xlink:label="lgvn_JulyPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyOfferingPlacementMember" xlink:label="lgvn_JulyOfferingPlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyOrdinaryCoursePlacementAgentMember" xlink:label="lgvn_JulyOrdinaryCoursePlacementAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" xlink:label="us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" xlink:label="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" xlink:label="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="lgvn_StockholdersEquityDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueConsensusPricingModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_UnderwritersMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_SeriesBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_TwoThousandTwentyOnePIPEOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_SeriesAMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_October2023RegisteredDirectOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lgvn_WarrantsToPurchase" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_PlacementAgentWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_December2023OfferingMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_InvestorWarrantsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_NoteWarrantMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SeriesAAndSeriesBWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_UnderwritersWarrantsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_JulyRegisteredDirectOfferingMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_PreFundedWarrantMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_CommonWarrantsMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_ClassACommonStockWarrantsMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SeriesCWarrantsMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SeriesDWarrantsMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lgvn_PaymentPerWarrant" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lgvn_PercentageOfAggregateNumberOfShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JuneInducementWarrantsMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lgvn_ExerciseOfRemainingShares" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JunePlacementAgentWarrantsMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_PlacementAgentWarrants1Member" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JulyPrivatePlacementMember" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JulyOfferingPlacementMember" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JulyOrdinaryCoursePlacementAgentMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TwoThousandTwentyOneIncentivePlanMember" xlink:label="lgvn_TwoThousandTwentyOneIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockOptionAwardFourYearVestingPeriodMember" xlink:label="lgvn_StockOptionAwardFourYearVestingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsTable" xlink:label="lgvn_EquityBasedCompensationDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm" xlink:label="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lgvn_TwoThousandTwentyOneIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="lgvn_StockOptionAwardFourYearVestingPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lgvn_EquityBasedCompensationDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfRsuActivityAbstract" xlink:label="lgvn_ScheduleOfRsuActivityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_ScheduleOfRsuActivityAbstract" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract" xlink:label="lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfStockOptionActivityAbstract" xlink:label="lgvn_ScheduleOfStockOptionActivityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_ScheduleOfStockOptionActivityAbstract" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SupplyAgreementMember" xlink:label="lgvn_SupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LongeveronMember" xlink:label="lgvn_LongeveronMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_UMAgreementsMember" xlink:label="lgvn_UMAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SecretomeTherapeuticsIncorporatedMember" xlink:label="lgvn_SecretomeTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CommitmentsandContingenciesDetailsTable" xlink:label="lgvn_CommitmentsandContingenciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ChiefScienceOfficerMember" xlink:label="lgvn_ChiefScienceOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NondisclosureAgreementMember" xlink:label="lgvn_NondisclosureAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested" xlink:label="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesCUnitsMember" xlink:label="lgvn_SeriesCUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MasterServicesAgreementsMember" xlink:label="lgvn_MasterServicesAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TechnologyServicesAgreementMember" xlink:label="lgvn_TechnologyServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_firstPhase3ClinicalTrialMember" xlink:label="lgvn_firstPhase3ClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AgreementTerm" xlink:label="lgvn_AgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_BiologicsLicenseMember" xlink:label="lgvn_BiologicsLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_InitialStartUpPaymentReceived" xlink:label="lgvn_InitialStartUpPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts" xlink:label="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ProjectManagementFees" xlink:label="lgvn_ProjectManagementFees"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SuiteReservationFee" xlink:label="lgvn_SuiteReservationFee"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PotentialAmountReceivableForEachProductLot" xlink:label="lgvn_PotentialAmountReceivableForEachProductLot"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots" xlink:label="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MonthlyManufacturingSuiteReservationFee" xlink:label="lgvn_MonthlyManufacturingSuiteReservationFee"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_HourlyFeeForProjectManagementServices" xlink:label="lgvn_HourlyFeeForProjectManagementServices"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MarkupPercentageOnValueOfMaterialsCompensated" xlink:label="lgvn_MarkupPercentageOnValueOfMaterialsCompensated"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OutsourcedTestingFeePerBatchReceivable" xlink:label="lgvn_OutsourcedTestingFeePerBatchReceivable"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining" xlink:label="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping" xlink:label="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService" xlink:label="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AgreementTerminationDescription" xlink:label="lgvn_AgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TermsOfAgreement" xlink:label="lgvn_TermsOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MilestoneOfTriggeringPayments" xlink:label="lgvn_MilestoneOfTriggeringPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MilestoneFeesPayable" xlink:label="lgvn_MilestoneFeesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanRestructuringTrialModificationsAmount" xlink:label="us-gaap_LoanRestructuringTrialModificationsAmount"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AnnualNetSalesPercentage" xlink:label="lgvn_AnnualNetSalesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NetSalesOfSubLicensees" xlink:label="lgvn_NetSalesOfSubLicensees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedLicenseAgreements" xlink:label="us-gaap_IndefiniteLivedLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_licenseAgreementTerm" xlink:label="lgvn_licenseAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncurredTerms" xlink:label="lgvn_IncurredTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lgvn_SupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="lgvn_LongeveronMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="lgvn_UMAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lgvn_SecretomeTherapeuticsIncorporatedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lgvn_CommitmentsandContingenciesDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lgvn_ChiefScienceOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lgvn_NondisclosureAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lgvn_SeriesCUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lgvn_MasterServicesAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lgvn_TechnologyServicesAgreementMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_LicenseMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="dei_LegalEntityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lgvn_firstPhase3ClinicalTrialMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_AgreementTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lgvn_BiologicsLicenseMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_InitialStartUpPaymentReceived" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_ProjectManagementFees" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_SuiteReservationFee" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_PotentialAmountReceivableForEachProductLot" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MonthlyManufacturingSuiteReservationFee" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_HourlyFeeForProjectManagementServices" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MarkupPercentageOnValueOfMaterialsCompensated" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_OutsourcedTestingFeePerBatchReceivable" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_AgreementTerminationDescription" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_TermsOfAgreement" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MilestoneOfTriggeringPayments" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForFees" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MilestoneFeesPayable" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LoanRestructuringTrialModificationsAmount" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_AnnualNetSalesPercentage" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_NetSalesOfSubLicensees" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IndefiniteLivedLicenseAgreements" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProfessionalFees" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_licenseAgreementTerm" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_IncurredTerms" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEmployeeBenefitsPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OwnershipMember" xlink:label="lgvn_OwnershipMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncomeTaxesTable" xlink:label="lgvn_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncomeTaxesLineItems" xlink:label="lgvn_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="lgvn_OwnershipMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_IncomeTaxesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lgvn_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_IncomeTaxesTable" xlink:to="lgvn_IncomeTaxesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="lgvn_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredTaxAssetsLeaseLiability" xlink:label="lgvn_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lgvn_DeferredTaxLiabilitiesRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lgvn_DeferredTaxAssetsLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ScheduleOfDilutedNetLossPerShareAbstract" xlink:label="lgvn_ScheduleOfDilutedNetLossPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PhantomShareUnitsPSUsMember" xlink:label="us-gaap_PhantomShareUnitsPSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lgvn_ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PhantomShareUnitsPSUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OperatingSegmentMember" xlink:label="lgvn_OperatingSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:label="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PersonnelCosts" xlink:label="lgvn_PersonnelCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="lgvn_OperatingSegmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="lgvn_PersonnelCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfitLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClinicalTrialRevenueMember" xlink:label="lgvn_ClinicalTrialRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LawsuitExpenses" xlink:label="lgvn_LawsuitExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeemedDividendWarrantInducementOffers" xlink:label="lgvn_DeemedDividendWarrantInducementOffers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingLeaseRevenueMember" xlink:label="lgvn_ContractManufacturingLeaseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OtherRefundableTaxCredits" xlink:label="lgvn_OtherRefundableTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingRevenueMember" xlink:label="lgvn_ContractManufacturingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_GrantRevenueMember" xlink:label="lgvn_GrantRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ClinicalTrialRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lgvn_LawsuitExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lgvn_DeemedDividendWarrantInducementOffers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_GrossProfit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingLeaseRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lgvn_OtherRefundableTaxCredits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_GrantRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod" xlink:label="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" xlink:label="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" xlink:label="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" xlink:label="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuesDuringPeriodSharesForPSUsVested" xlink:label="lgvn_StockIssuesDuringPeriodSharesForPSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CollectionOfStockSubscriptionReceivable" xlink:label="lgvn_CollectionOfStockSubscriptionReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" xlink:label="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants" xlink:label="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" xlink:label="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuesDuringPeriodSharesForPSUsVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_CollectionOfStockSubscriptionReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_RockSofferMember" xlink:label="lgvn_RockSofferMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NeilHareMember" xlink:label="lgvn_NeilHareMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="lgvn_RockSofferMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="lgvn_NeilHareMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CustomerOneMember" xlink:label="lgvn_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:label="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="lgvn_CustomerOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AccountsReceivableFromCustomersMember" xlink:label="lgvn_AccountsReceivableFromCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NationalInstitutesOfHealthGrantMember" xlink:label="lgvn_NationalInstitutesOfHealthGrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="lgvn_AccountsReceivableFromCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="lgvn_NationalInstitutesOfHealthGrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClinicalTrialRevenueMember" xlink:label="lgvn_ClinicalTrialRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingLeaseRevenueMember" xlink:label="lgvn_ContractManufacturingLeaseRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingRevenueMember" xlink:label="lgvn_ContractManufacturingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ContractManufacturingMember" xlink:label="lgvn_ContractManufacturingMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NationalInstitutesOfHealthGrantMember" xlink:label="lgvn_NationalInstitutesOfHealthGrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ClinicalTrialRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingLeaseRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_ContractManufacturingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lgvn_NationalInstitutesOfHealthGrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MarketableSecuritiesDetailsTable" xlink:label="lgvn_MarketableSecuritiesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="us-gaap_AccruedInvestmentIncomeReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingSecuritiesDebtAmortizedCost" xlink:label="us-gaap_TradingSecuritiesDebtAmortizedCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="lgvn_MarketableSecuritiesDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AccruedInvestmentIncomeReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_TradingSecuritiesDebtAmortizedCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeReceivableMember" xlink:label="us-gaap_AccruedIncomeReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_AccruedIncomeReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:label="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedPatentsGross" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LeasesDetailsTable" xlink:label="lgvn_LeasesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lgvn_LeasesDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_LeasesDetailsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockholdersEquityDetailsTable" xlink:label="lgvn_StockholdersEquityDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueConsensusPricingModelMember" xlink:label="us-gaap_ValuationTechniqueConsensusPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_UnderwritersMember" xlink:label="lgvn_UnderwritersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBMember" xlink:label="us-gaap_SeriesBMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TwoThousandTwentyOnePIPEOfferingMember" xlink:label="lgvn_TwoThousandTwentyOnePIPEOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_October2023RegisteredDirectOfferingMember" xlink:label="lgvn_October2023RegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_WarrantsToPurchase" xlink:label="lgvn_WarrantsToPurchase"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PlacementAgentWarrantsMember" xlink:label="lgvn_PlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_December2023OfferingMember" xlink:label="lgvn_December2023OfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_InvestorWarrantsMember" xlink:label="lgvn_InvestorWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoteWarrantMember" xlink:label="us-gaap_NoteWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesAAndSeriesBWarrantsMember" xlink:label="lgvn_SeriesAAndSeriesBWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AprilTwoThousandTwentyFourPublicOfferingMember" xlink:label="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_UnderwritersWarrantsMember" xlink:label="lgvn_UnderwritersWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyRegisteredDirectOfferingMember" xlink:label="lgvn_JulyRegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PreFundedWarrantMember" xlink:label="lgvn_PreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CommonWarrantsMember" xlink:label="lgvn_CommonWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ClassACommonStockWarrantsMember" xlink:label="lgvn_ClassACommonStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesCWarrantsMember" xlink:label="lgvn_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesDWarrantsMember" xlink:label="lgvn_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PaymentPerWarrant" xlink:label="lgvn_PaymentPerWarrant"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PercentageOfAggregateNumberOfShares" xlink:label="lgvn_PercentageOfAggregateNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JuneInducementWarrantsMember" xlink:label="lgvn_JuneInducementWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ExerciseOfRemainingShares" xlink:label="lgvn_ExerciseOfRemainingShares"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JunePlacementAgentWarrantsMember" xlink:label="lgvn_JunePlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PlacementAgentWarrants1Member" xlink:label="lgvn_PlacementAgentWarrants1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyPrivatePlacementMember" xlink:label="lgvn_JulyPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyOfferingPlacementMember" xlink:label="lgvn_JulyOfferingPlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_JulyOrdinaryCoursePlacementAgentMember" xlink:label="lgvn_JulyOrdinaryCoursePlacementAgentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" xlink:label="us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" xlink:label="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" xlink:label="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lgvn_StockholdersEquityDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueConsensusPricingModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_UnderwritersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_SeriesBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_TwoThousandTwentyOnePIPEOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_SeriesAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_October2023RegisteredDirectOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lgvn_WarrantsToPurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_PlacementAgentWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_December2023OfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_InvestorWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_NoteWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SeriesAAndSeriesBWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_UnderwritersWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lgvn_JulyRegisteredDirectOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_PreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_CommonWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_ClassACommonStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SeriesCWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SeriesDWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lgvn_PaymentPerWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lgvn_PercentageOfAggregateNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JuneInducementWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="lgvn_ExerciseOfRemainingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JunePlacementAgentWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_PlacementAgentWarrants1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JulyPrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JulyOfferingPlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_JulyOrdinaryCoursePlacementAgentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsTable" xlink:label="lgvn_EquityBasedCompensationDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TwoThousandTwentyOneIncentivePlanMember" xlink:label="lgvn_TwoThousandTwentyOneIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StockOptionAwardFourYearVestingPeriodMember" xlink:label="lgvn_StockOptionAwardFourYearVestingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm" xlink:label="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lgvn_EquityBasedCompensationDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lgvn_TwoThousandTwentyOneIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="lgvn_StockOptionAwardFourYearVestingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" xlink:label="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_CommitmentsandContingenciesDetailsTable" xlink:label="lgvn_CommitmentsandContingenciesDetailsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SupplyAgreementMember" xlink:label="lgvn_SupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LongeveronMember" xlink:label="lgvn_LongeveronMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TechnologyServicesAgreementMember" xlink:label="lgvn_TechnologyServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_UMAgreementsMember" xlink:label="lgvn_UMAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SecretomeTherapeuticsIncorporatedMember" xlink:label="lgvn_SecretomeTherapeuticsIncorporatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ChiefScienceOfficerMember" xlink:label="lgvn_ChiefScienceOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NondisclosureAgreementMember" xlink:label="lgvn_NondisclosureAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested" xlink:label="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SeriesCUnitsMember" xlink:label="lgvn_SeriesCUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MasterServicesAgreementsMember" xlink:label="lgvn_MasterServicesAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_firstPhase3ClinicalTrialMember" xlink:label="lgvn_firstPhase3ClinicalTrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_BiologicsLicenseMember" xlink:label="lgvn_BiologicsLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AgreementTerm" xlink:label="lgvn_AgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_InitialStartUpPaymentReceived" xlink:label="lgvn_InitialStartUpPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts" xlink:label="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ProjectManagementFees" xlink:label="lgvn_ProjectManagementFees"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_SuiteReservationFee" xlink:label="lgvn_SuiteReservationFee"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PotentialAmountReceivableForEachProductLot" xlink:label="lgvn_PotentialAmountReceivableForEachProductLot"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots" xlink:label="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MonthlyManufacturingSuiteReservationFee" xlink:label="lgvn_MonthlyManufacturingSuiteReservationFee"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_HourlyFeeForProjectManagementServices" xlink:label="lgvn_HourlyFeeForProjectManagementServices"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MarkupPercentageOnValueOfMaterialsCompensated" xlink:label="lgvn_MarkupPercentageOnValueOfMaterialsCompensated"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OutsourcedTestingFeePerBatchReceivable" xlink:label="lgvn_OutsourcedTestingFeePerBatchReceivable"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining" xlink:label="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping" xlink:label="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService" xlink:label="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AgreementTerminationDescription" xlink:label="lgvn_AgreementTerminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_TermsOfAgreement" xlink:label="lgvn_TermsOfAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="us-gaap_ExcessStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MilestoneOfTriggeringPayments" xlink:label="lgvn_MilestoneOfTriggeringPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_MilestoneFeesPayable" xlink:label="lgvn_MilestoneFeesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanRestructuringTrialModificationsAmount" xlink:label="us-gaap_LoanRestructuringTrialModificationsAmount"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_AnnualNetSalesPercentage" xlink:label="lgvn_AnnualNetSalesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_NetSalesOfSubLicensees" xlink:label="lgvn_NetSalesOfSubLicensees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedLicenseAgreements" xlink:label="us-gaap_IndefiniteLivedLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_licenseAgreementTerm" xlink:label="lgvn_licenseAgreementTerm"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncurredTerms" xlink:label="lgvn_IncurredTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_CommitmentsandContingenciesDetailsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lgvn_SupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="lgvn_LongeveronMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lgvn_TechnologyServicesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="lgvn_UMAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lgvn_SecretomeTherapeuticsIncorporatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lgvn_ChiefScienceOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lgvn_NondisclosureAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lgvn_SeriesCUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccruedLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lgvn_MasterServicesAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lgvn_firstPhase3ClinicalTrialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lgvn_BiologicsLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_AgreementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_InitialStartUpPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_ProjectManagementFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_SuiteReservationFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_PotentialAmountReceivableForEachProductLot" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MonthlyManufacturingSuiteReservationFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_HourlyFeeForProjectManagementServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MarkupPercentageOnValueOfMaterialsCompensated" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_OutsourcedTestingFeePerBatchReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_AgreementTerminationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_TermsOfAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MilestoneOfTriggeringPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_MilestoneFeesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LoanRestructuringTrialModificationsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_AnnualNetSalesPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_NetSalesOfSubLicensees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IndefiniteLivedLicenseAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProfessionalFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_licenseAgreementTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lgvn_IncurredTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncomeTaxesLineItems" xlink:label="lgvn_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_IncomeTaxesTable" xlink:label="lgvn_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OwnershipMember" xlink:label="lgvn_OwnershipMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lgvn_IncomeTaxesLineItems" xlink:to="lgvn_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="lgvn_OwnershipMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lgvn_IncomeTaxesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lgvn_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PhantomShareUnitsPSUsMember" xlink:label="us-gaap_PhantomShareUnitsPSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PhantomShareUnitsPSUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OperatingSegmentMember" xlink:label="lgvn_OperatingSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" xlink:label="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PersonnelCosts" xlink:label="lgvn_PersonnelCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="lgvn_OperatingSegmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="lgvn_PersonnelCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/role/Anchoring">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeemedDividendWarrantInducementOffers" xlink:label="lgvn_DeemedDividendWarrantInducementOffers"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lgvn_DeemedDividendWarrantInducementOffers" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="5" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="lgvn_LawsuitExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lgvn_DeemedDividendWarrantInducementOffers" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="lgvn_OtherRefundableTaxCredits" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_LawsuitExpenses" xlink:label="lgvn_LawsuitExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeemedDividendWarrantInducementOffers" xlink:label="lgvn_DeemedDividendWarrantInducementOffers"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_OtherRefundableTaxCredits" xlink:label="lgvn_OtherRefundableTaxCredits"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lgvn_ProceedsFromStockSubscriptionReceivable" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lgvn_InterestEarnedOnMarketableSecurities" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="14" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_ProceedsFromStockSubscriptionReceivable" xlink:label="lgvn_ProceedsFromStockSubscriptionReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested" xlink:label="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_InterestEarnedOnMarketableSecurities" xlink:label="lgvn_InterestEarnedOnMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lgvn_DeferredTaxLiabilitiesRightOfUseAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lgvn_DeferredTaxAssetsLeaseLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="lgvn_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_DeferredTaxAssetsLeaseLiability" xlink:label="lgvn_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_CostOfRevenue" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="lgvn_PersonnelCosts" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="5" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lgvn-20241231.xsd#lgvn_PersonnelCosts" xlink:label="lgvn_PersonnelCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lgvn_NeilHareMember" name="NeilHareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_ExerciseOfRemainingShares" name="ExerciseOfRemainingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_UnderwritersWarrantsMember" name="UnderwritersWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_StockIssuesDuringPeriodSharesForPSUsVested" name="StockIssuesDuringPeriodSharesForPSUsVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_AprilTwoThousandTwentyFourPublicOfferingMember" name="AprilTwoThousandTwentyFourPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ProceedsFromStockSubscriptionReceivable" name="ProceedsFromStockSubscriptionReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_OwnershipMember" name="OwnershipMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_TechnologyServicesAgreementMember" name="TechnologyServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ScheduleOfDilutedNetLossPerShareAbstract" name="ScheduleOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_MilestoneFeesPayable" name="MilestoneFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_MarketableSecuritiesDetailsTable" name="MarketableSecuritiesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_OperatingSegmentMember" name="OperatingSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_PersonnelCosts" name="PersonnelCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock" name="VestingOfRSUsAndPSUsIntoClassACommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_UnderwritersMember" name="UnderwritersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_NetSalesOfSubLicensees" name="NetSalesOfSubLicensees" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_SeriesAAndSeriesBWarrantsMember" name="SeriesAAndSeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_StockholdersEquityDetailsTable" name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_AgreementTerm" name="AgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_LawsuitExpenses" name="LawsuitExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_WarrantsToPurchase" name="WarrantsToPurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_CollectionOfStockSubscriptionReceivable" name="CollectionOfStockSubscriptionReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_December2023OfferingMember" name="December2023OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_MarkupPercentageOnValueOfMaterialsCompensated" name="MarkupPercentageOnValueOfMaterialsCompensated" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_ClinicalTrialRevenueMember" name="ClinicalTrialRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_firstPhase3ClinicalTrialMember" name="firstPhase3ClinicalTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_licenseAgreementTerm" name="licenseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" name="StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_JulyOfferingPlacementMember" name="JulyOfferingPlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_StockOptionAwardFourYearVestingPeriodMember" name="StockOptionAwardFourYearVestingPeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ScheduleOfRevenueAbstract" name="ScheduleOfRevenueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_MonthlyManufacturingSuiteReservationFee" name="MonthlyManufacturingSuiteReservationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_Rule10b51ArrModifiedFlag" name="Rule10b51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" name="SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ScheduleOfRsuActivityAbstract" name="ScheduleOfRsuActivityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" name="StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_ChiefScienceOfficerMember" name="ChiefScienceOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_October2023RegisteredDirectOfferingMember" name="October2023RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract" name="ScheduleOfAccountsAndGrantsReceivableAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_SummaryofSignificantAccountingPoliciesDetailsTable" name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_SeriesCUnitsMember" name="SeriesCUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_SeriesCWarrantsMember" name="SeriesCWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract" name="ScheduleOfIssuedAndOutstandingOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_SupplyAgreementMember" name="SupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract" name="ScheduleOfMajorComponentsOfIntangibleAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_CommitmentsandContingenciesDetailsTable" name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" name="StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_SecretomeTherapeuticsIncorporatedMember" name="SecretomeTherapeuticsIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_AnnualNetSalesPercentage" name="AnnualNetSalesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots" name="PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_TwoThousandTwentyOneIncentivePlanMember" name="TwoThousandTwentyOneIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts" name="TechnologyTransferDocumentationPreparationTrainingAndTestingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_JunePlacementAgentWarrantsMember" name="JunePlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_JuneInducementWarrantsMember" name="JuneInducementWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ScheduleOfMarketableSecuritiesAbstract" name="ScheduleOfMarketableSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_AgreementTerminationDescription" name="AgreementTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping" name="StandardFeeReceivableForProductPackingHandlingAndShipping" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_CommonWarrantsMember" name="CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_MilestoneOfTriggeringPayments" name="MilestoneOfTriggeringPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_ContractManufacturingMember" name="ContractManufacturingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" name="FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants" name="StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_ContractManufacturingRevenueMember" name="ContractManufacturingRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_PotentialAmountReceivableForEachProductLot" name="PotentialAmountReceivableForEachProductLot" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_LongeveronMember" name="LongeveronMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_PlacementAgentWarrants1Member" name="PlacementAgentWarrants1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ScheduleOfStockOptionActivityAbstract" name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" name="EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" name="EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_IncurredTerms" name="IncurredTerms" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_LeasesDetailsTable" name="LeasesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" name="EquityBasedCompensationDetailsScheduleofStockOptionActivityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested" name="StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_AccountsReceivableFromCustomersMember" name="AccountsReceivableFromCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_NondisclosureAgreementMember" name="NondisclosureAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_OtherComprehensiveLossAbstract" name="OtherComprehensiveLossAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_PercentageOfAggregateNumberOfShares" name="PercentageOfAggregateNumberOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_PreFundedWarrantMember" name="PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_RockSofferMember" name="RockSofferMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" name="ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_InitialStartUpPaymentReceived" name="InitialStartUpPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts" name="StockIssuedForStockRightsOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_TermsOfAgreement" name="TermsOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_OutsourcedTestingFeePerBatchReceivable" name="OutsourcedTestingFeePerBatchReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_OtherRefundableTaxCredits" name="OtherRefundableTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_GrantRevenueMember" name="GrantRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_DeemedDividendWarrantInducementOffers" name="DeemedDividendWarrantInducementOffers" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_ProjectManagementFees" name="ProjectManagementFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService" name="IncreasedFeeReceivableForExpeditedOrSpecialHourService" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_MasterServicesAgreementsMember" name="MasterServicesAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" name="StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_UMAgreementsMember" name="UMAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod" name="ClassACommonStockIssuedForRSUsVestedDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems" name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_BiologicsLicenseMember" name="BiologicsLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_NonRule10b51ArrModifiedFlag" name="NonRule10b51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_HourlyFeeForProjectManagementServices" name="HourlyFeeForProjectManagementServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts" name="StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_SuiteReservationFee" name="SuiteReservationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_InterestEarnedOnMarketableSecurities" name="InterestEarnedOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_PaymentPerWarrant" name="PaymentPerWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_ContractManufacturingLeaseRevenueMember" name="ContractManufacturingLeaseRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ClassACommonStockWarrantsMember" name="ClassACommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable" name="EquityBasedCompensationDetailsScheduleofRSUActivityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" name="StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_EquityBasedCompensationDetailsTable" name="EquityBasedCompensationDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining" name="MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lgvn_CustomerOneMember" name="CustomerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_NationalInstitutesOfHealthGrantMember" name="NationalInstitutesOfHealthGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested" name="SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_InvestorWarrantsMember" name="InvestorWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_SeriesDWarrantsMember" name="SeriesDWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract" name="ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_SeriesCWarrantsAndSeriesDWarrantsMember" name="SeriesCWarrantsAndSeriesDWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_JulyRegisteredDirectOfferingMember" name="JulyRegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_JulyOrdinaryCoursePlacementAgentMember" name="JulyOrdinaryCoursePlacementAgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_JulyPrivatePlacementMember" name="JulyPrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested" name="PaymentsForTaxesOnRsusVestedAndPsusVested" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" name="ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lgvn_TwoThousandTwentyOnePIPEOfferingMember" name="TwoThousandTwentyOnePIPEOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501816663728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 17, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LONGEVERON INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001721484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2174146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,438,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1951 NW 7th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Miami<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">909-0840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum llp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Hartford, CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longeveron Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related statements of operations, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, based on our audits, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years in the period ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in conformity with accounting principles generally accepted in the United States of America.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,473,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,454,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814986176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,232,000<span></span>
</td>
<td class="nump">$ 4,949,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">412,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">308,000<span></span>
</td>
<td class="nump">376,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts and grants receivable</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,624,000<span></span>
</td>
<td class="nump">5,848,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,449,000<span></span>
</td>
<td class="nump">2,529,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,401,000<span></span>
</td>
<td class="nump">2,287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">1,221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">202,000<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,558,000<span></span>
</td>
<td class="nump">12,078,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">99,000<span></span>
</td>
<td class="nump">638,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,820,000<span></span>
</td>
<td class="nump">2,152,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">623,000<span></span>
</td>
<td class="nump">593,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">506,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,582,000<span></span>
</td>
<td class="nump">3,889,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liability</a></td>
<td class="nump">824,000<span></span>
</td>
<td class="nump">1,448,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">1,089,000<span></span>
</td>
<td class="nump">1,448,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,671,000<span></span>
</td>
<td class="nump">5,337,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">131,480,000<span></span>
</td>
<td class="nump">91,823,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Stock subscription receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(109,607,000)<span></span>
</td>
<td class="num">(84,984,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">21,887,000<span></span>
</td>
<td class="nump">6,741,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">25,558,000<span></span>
</td>
<td class="nump">12,078,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501816657680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">84,295,000<span></span>
</td>
<td class="nump">84,295,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">13,407,441<span></span>
</td>
<td class="nump">1,025,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">13,407,441<span></span>
</td>
<td class="nump">1,025,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">15,705,000<span></span>
</td>
<td class="nump">15,705,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,484,005<span></span>
</td>
<td class="nump">1,485,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,484,005<span></span>
</td>
<td class="nump">1,485,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820220768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 2,392<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,269<span></span>
</td>
<td class="nump">12,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,137<span></span>
</td>
<td class="nump">9,066<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,406<span></span>
</td>
<td class="nump">21,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(16,522)<span></span>
</td>
<td class="num">(21,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income and (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_LawsuitExpenses', window );">Lawsuit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_OtherRefundableTaxCredits', window );">Other refundable tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">549<span></span>
</td>
<td class="num">(377)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses), net</a></td>
<td class="nump">549<span></span>
</td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,973)<span></span>
</td>
<td class="num">(21,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_DeemedDividendWarrantInducementOffers', window );">Deemed dividend - warrant inducement offers</a></td>
<td class="num">(8,650)<span></span>
</td>
<td class="num">(798)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (24,623)<span></span>
</td>
<td class="num">$ (22,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (2.62)<span></span>
</td>
<td class="num">$ (10.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (2.62)<span></span>
</td>
<td class="num">$ (10.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding</a></td>
<td class="nump">9,411,164<span></span>
</td>
<td class="nump">2,173,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding</a></td>
<td class="nump">9,411,164<span></span>
</td>
<td class="nump">2,173,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgvn_ClinicalTrialRevenueMember', window );">Clinical trial revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,402<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgvn_ContractManufacturingLeaseRevenueMember', window );">Contract manufacturing lease revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">503<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgvn_ContractManufacturingRevenueMember', window );">Contract manufacturing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 487<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgvn_GrantRevenueMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_DeemedDividendWarrantInducementOffers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of deemed dividend warrant inducement offers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_DeemedDividendWarrantInducementOffers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_LawsuitExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lawsuit expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_LawsuitExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_OtherRefundableTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other refundable tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_OtherRefundableTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgvn_ClinicalTrialRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgvn_ClinicalTrialRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgvn_ContractManufacturingLeaseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgvn_ContractManufacturingLeaseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgvn_ContractManufacturingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgvn_ContractManufacturingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgvn_GrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgvn_GrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917445776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,973)<span></span>
</td>
<td class="num">$ (21,413)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501816261280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Common Stock </div>
<div>Class A</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class B</div>
</th>
<th class="th"><div>Subscription Receivable</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Gain</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 20,503<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="nump">$ 83,731<span></span>
</td>
<td class="num">$ (62,773)<span></span>
</td>
<td class="num">$ (357)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,732<span></span>
</td>
<td class="nump">1,489,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Class B common stock for Class A common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,555<span></span>
</td>
<td class="num">(3,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares', window );">Class A common stock, issued for RSUs vested (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested', window );">Class A common stock, held for taxes on RSUs vested</a></td>
<td class="num">(174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested', window );">Class A common stock, held for taxes on RSUs vested (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Class A common stock issued for stock rights offering, net of issuance cost (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Class A common stock issued in direct placements, net of issuance cost</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Class A common stock issued in direct placements, net of issuance cost (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation</a></td>
<td class="nump">2,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Dividend attributable to down round feature of 2021 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="num">(798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants', window );">Class A common stock issued for prefunded warrants</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants', window );">Class A common stock issued for prefunded warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split rounding adjustment (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities', window );">Unrealized gain attributable to change in market value of available for sale investments</a></td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">6,741<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">91,823<span></span>
</td>
<td class="num">(84,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025,183<span></span>
</td>
<td class="nump">1,485,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Class B common stock for Class A common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="num">(1,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares', window );">Class A common stock, issued for RSUs vested (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested', window );">Class A common stock, held for taxes on RSUs vested</a></td>
<td class="num">(349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested', window );">Class A common stock, held for taxes on RSUs vested (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuesDuringPeriodSharesForPSUsVested', window );">Class A common stock, issued for PSUs vested (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Class A common stock, held for taxes on PSUs vested</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested', window );">Class A common stock, held for taxes on PSUs vested (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_CollectionOfStockSubscriptionReceivable', window );">Collection of stock subscription receivable</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Equity-based compensation</a></td>
<td class="nump">2,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Class A common stock issued in public offering, net of issuance cost</a></td>
<td class="nump">12,866<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Class A common stock issued in public offering, net of issuance cost (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,448,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Class A common stock issue for warrants exercised, net of issuance cost</a></td>
<td class="nump">16,191<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Class A common stock issue for warrants exercised, net of issuance cost (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,435,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Deemed dividend &#8211; warrant inducement offers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,650<span></span>
</td>
<td class="num">(8,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split rounding adjustment (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 21,887<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,480<span></span>
</td>
<td class="num">$ (109,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,407,441<span></span>
</td>
<td class="nump">1,484,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_CollectionOfStockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collection of stock subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_CollectionOfStockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class A common stock, held for taxes on RSUs vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares Class A common stock, held for taxes on PSUs vested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares class A common stock issued for prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of unrealized loss attributable to change in market value of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value class A common stock issued for prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class A common stock, held for taxes on RSUs vested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuesDuringPeriodSharesForPSUsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued for PSUs vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuesDuringPeriodSharesForPSUsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class A common stock, issued for RSUs vested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501821351088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts', window );">Class A Common Stock issued for stock rights offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Class A common stock issued in direct placements/public offering, issuance costs</a></td>
<td class="nump">$ 2,064<span></span>
</td>
<td class="nump">$ 1,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts', window );">Class A common stock issued for warrants exercised, issuance costs</a></td>
<td class="nump">$ 1,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock issued for  warrants exercised, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued for stock rights offering net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820230304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,973,000)<span></span>
</td>
<td class="num">$ (21,413,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">958,000<span></span>
</td>
<td class="nump">946,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Interest earned on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_InterestEarnedOnMarketableSecurities', window );">Interest earned on marketable securities</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">2,328,000<span></span>
</td>
<td class="nump">2,032,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Non-cash write-off of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts and grants receivable</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(540,000)<span></span>
</td>
<td class="num">(1,113,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(466,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability', window );">Nonoperating lawsuit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,398,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(332,000)<span></span>
</td>
<td class="nump">1,502,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Operating lease asset and liability</a></td>
<td class="num">(254,000)<span></span>
</td>
<td class="num">(254,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,868,000)<span></span>
</td>
<td class="num">(19,002,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from the sale of marketable securities</a></td>
<td class="nump">352,000<span></span>
</td>
<td class="nump">8,880,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(655,000)<span></span>
</td>
<td class="num">(301,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="num">(337,000)<span></span>
</td>
<td class="num">(393,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(640,000)<span></span>
</td>
<td class="nump">8,186,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of issuance cost</a></td>
<td class="nump">12,866,000<span></span>
</td>
<td class="nump">5,338,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants exercised, net of issuance cost</a></td>
<td class="nump">16,191,000<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_ProceedsFromStockSubscriptionReceivable', window );">Proceeds from stock subscription receivable</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested', window );">Payments for taxes on RSUs vested and PSUs vested</a></td>
<td class="num">(366,000)<span></span>
</td>
<td class="num">(174,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">28,791,000<span></span>
</td>
<td class="nump">5,262,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="nump">14,283,000<span></span>
</td>
<td class="num">(5,554,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,949,000<span></span>
</td>
<td class="nump">10,503,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">19,232,000<span></span>
</td>
<td class="nump">4,949,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock', window );">Vesting of RSUs and PSUs into Class A common stock</a></td>
<td class="num">(1,109,000)<span></span>
</td>
<td class="num">(777,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_DeemedDividendWarrantInducementOffers', window );">Deemed dividend &#8211; warrant inducement offers</a></td>
<td class="nump">$ 8,650,000<span></span>
</td>
<td class="nump">$ 798,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_DeemedDividendWarrantInducementOffers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of deemed dividend warrant inducement offers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_DeemedDividendWarrantInducementOffers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_InterestEarnedOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest earned on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_InterestEarnedOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for taxes on RSUs vested and PSUs vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_ProceedsFromStockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds from stock subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_ProceedsFromStockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of vesting of RSU and PSUs into class A common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501815221024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) recognizes the critical importance of maintaining the trust and confidence of our customers, clients, business partners and employees. The Board is actively involved in oversight of the Company&#8217;s risk management program, and cybersecurity represents an important component of the Company&#8217;s overall approach to enterprise risk management (&#8220;ERM&#8221;). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cybersecurity policies, standards, processes, and practices are fully </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into the Company&#8217;s ERM program and are based on recognized frameworks established by the National Institute of Standards and Technology, the International Organization for Standardization and other applicable industry standards.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In general, the Company seeks to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that the Company collects and stores by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.</span></p><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As one of the critical elements of the Company&#8217;s overall ERM approach, the Company&#8217;s cybersecurity program is focused on the following key areas:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in more detail under the heading &#8220;Governance,&#8221; The Board&#8217;s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the &#8220;Audit Committee&#8221;), which regularly interacts with the Company&#8217;s General Counsel ("GC"), Chief Technology Officer ("CTO"), other members of management and relevant management committees, including Company&#8217;s Senior Leadership Team (&#8220;SLT&#8221;), regarding cybersecurity oversight and risk management.</span></div></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative Approach: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, through its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information technology partner</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, has implemented a comprehensive, cross-functional approach to identifying, preventing, and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Technical Safeguards: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, through its information technology partner, deploys technical safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti- malware functionality and access controls, which are evaluated and improved through vulnerability assessments, penetration testing, and cybersecurity threat intelligence.</span></span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incident Response and Recovery Planning: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, with its information technology partner, maintains comprehensive incident response and recovery plans that fully address the Company&#8217;s response to a cybersecurity incident.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Education and Awareness: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, through its information technology partner, provides regular, mandatory training for personnel regarding cybersecurity threats to equip the Company&#8217;s personnel with effective tools to address cybersecurity threats, and to communicate the Company&#8217;s evolving information security policies, standards, processes, and practices.</span></div></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company engages in the periodic assessment and testing of the Company&#8217;s policies, standards, processes, systems, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability and penetration testing and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. The Company with our information technology partner regularly engages assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the CTO and GC who shares data with the SLT and Audit Committee, and the Company adjusts its cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTO, in coordination with the SLT, oversees the Company&#8217;s ERM process, including the management of risks arising from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CTO and the SLT, through its information technology partner receives regular reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, the threat environment, technological trends and information security considerations.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On an annual basis, the Audit Committee and the Board discuss the Company&#8217;s approach to cybersecurity risk management with the members of the SLT, which includes the Company&#8217;s CTO, GC, and Chief Financial Officer (&#8220;CFO&#8221;).</span></span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTO, in coordination with the SLT, works collaboratively across the Company to implement a program designed to protect the Company&#8217;s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company&#8217;s incident response and recovery plans. To facilitate the success of the Company&#8217;s cybersecurity risk management program, multidisciplinary teams are prepared to address cybersecurity threats and to respond to cybersecurity incidents. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through ongoing communications with the Company&#8217;s information technology partner, these teams monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to the Company&#8217;s SLT and Audit Committee, when appropriate.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s information technology partner has worked in information technology and information security for over 30 years with over 300 employees with six locations in the United States. A virtual Chief Information Officer (&#8220;vCIO&#8221;) from the partner works directly with the Company to align business and technical strategies, decisions, and implementations. The CTO has nearly 20 years of experience in the pharmaceutical and biotech industry managing programs and projects across a variety of implementation methodologies and risk factors and holds undergraduate degrees and certifications in his respective field. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Executive Officer, CFO and General Counsel each hold undergraduate and graduate degrees in their respective fields, and each have over 25 years of experience managing risks at similar companies, including risks arising from cybersecurity threats.</span></span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity threats, including the results of any previous cybersecurity incidents, have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not materially</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> affected or are reasonably likely to affect the Company, including its business strategy, results of operations or financial condition.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s cybersecurity policies, standards, processes, and practices are fully </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into the Company&#8217;s ERM program and are based on recognized frameworks established by the National Institute of Standards and Technology, the International Organization for Standardization and other applicable industry standards.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As one of the critical elements of the Company&#8217;s overall ERM approach, the Company&#8217;s cybersecurity program is focused on the following key areas:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in more detail under the heading &#8220;Governance,&#8221; The Board&#8217;s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the &#8220;Audit Committee&#8221;), which regularly interacts with the Company&#8217;s General Counsel ("GC"), Chief Technology Officer ("CTO"), other members of management and relevant management committees, including Company&#8217;s Senior Leadership Team (&#8220;SLT&#8221;), regarding cybersecurity oversight and risk management.</span></div></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative Approach: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, through its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information technology partner</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, has implemented a comprehensive, cross-functional approach to identifying, preventing, and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Technical Safeguards: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, through its information technology partner, deploys technical safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti- malware functionality and access controls, which are evaluated and improved through vulnerability assessments, penetration testing, and cybersecurity threat intelligence.</span></span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incident Response and Recovery Planning: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, with its information technology partner, maintains comprehensive incident response and recovery plans that fully address the Company&#8217;s response to a cybersecurity incident.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Education and Awareness: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, through its information technology partner, provides regular, mandatory training for personnel regarding cybersecurity threats to equip the Company&#8217;s personnel with effective tools to address cybersecurity threats, and to communicate the Company&#8217;s evolving information security policies, standards, processes, and practices.</span></div></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company engages in the periodic assessment and testing of the Company&#8217;s policies, standards, processes, systems, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability and penetration testing and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. The Company with our information technology partner regularly engages assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the CTO and GC who shares data with the SLT and Audit Committee, and the Company adjusts its cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTO, in coordination with the SLT, oversees the Company&#8217;s ERM process, including the management of risks arising from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CTO and the SLT, through its information technology partner receives regular reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, the threat environment, technological trends and information security considerations.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On an annual basis, the Audit Committee and the Board discuss the Company&#8217;s approach to cybersecurity risk management with the members of the SLT, which includes the Company&#8217;s CTO, GC, and Chief Financial Officer (&#8220;CFO&#8221;).</span></span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTO, in coordination with the SLT, works collaboratively across the Company to implement a program designed to protect the Company&#8217;s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company&#8217;s incident response and recovery plans. To facilitate the success of the Company&#8217;s cybersecurity risk management program, multidisciplinary teams are prepared to address cybersecurity threats and to respond to cybersecurity incidents. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through ongoing communications with the Company&#8217;s information technology partner, these teams monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to the Company&#8217;s SLT and Audit Committee, when appropriate.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s information technology partner has worked in information technology and information security for over 30 years with over 300 employees with six locations in the United States. A virtual Chief Information Officer (&#8220;vCIO&#8221;) from the partner works directly with the Company to align business and technical strategies, decisions, and implementations. The CTO has nearly 20 years of experience in the pharmaceutical and biotech industry managing programs and projects across a variety of implementation methodologies and risk factors and holds undergraduate degrees and certifications in his respective field. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Executive Officer, CFO and General Counsel each hold undergraduate and graduate degrees in their respective fields, and each have over 25 years of experience managing risks at similar companies, including risks arising from cybersecurity threats.</span></span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity threats, including the results of any previous cybersecurity incidents, have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not materially</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> affected or are reasonably likely to affect the Company, including its business strategy, results of operations or financial condition.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in more detail under the heading &#8220;Governance,&#8221; The Board&#8217;s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the &#8220;Audit Committee&#8221;), which regularly interacts with the Company&#8217;s General Counsel ("GC"), Chief Technology Officer ("CTO"), other members of management and relevant management committees, including Company&#8217;s Senior Leadership Team (&#8220;SLT&#8221;), regarding cybersecurity oversight and risk management.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company engages in the periodic assessment and testing of the Company&#8217;s policies, standards, processes, systems, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability and penetration testing and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. The Company with our information technology partner regularly engages assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the CTO and GC who shares data with the SLT and Audit Committee, and the Company adjusts its cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTO, in coordination with the SLT, oversees the Company&#8217;s ERM process, including the management of risks arising from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CTO and the SLT, through its information technology partner receives regular reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, the threat environment, technological trends and information security considerations.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On an annual basis, the Audit Committee and the Board discuss the Company&#8217;s approach to cybersecurity risk management with the members of the SLT, which includes the Company&#8217;s CTO, GC, and Chief Financial Officer (&#8220;CFO&#8221;).</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTO, in coordination with the SLT, works collaboratively across the Company to implement a program designed to protect the Company&#8217;s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company&#8217;s incident response and recovery plans. To facilitate the success of the Company&#8217;s cybersecurity risk management program, multidisciplinary teams are prepared to address cybersecurity threats and to respond to cybersecurity incidents. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Through ongoing communications with the Company&#8217;s information technology partner, these teams monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to the Company&#8217;s SLT and Audit Committee, when appropriate.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s information technology partner has worked in information technology and information security for over 30 years with over 300 employees with six locations in the United States. A virtual Chief Information Officer (&#8220;vCIO&#8221;) from the partner works directly with the Company to align business and technical strategies, decisions, and implementations. The CTO has nearly 20 years of experience in the pharmaceutical and biotech industry managing programs and projects across a variety of implementation methodologies and risk factors and holds undergraduate degrees and certifications in his respective field. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Executive Officer, CFO and General Counsel each hold undergraduate and graduate degrees in their respective fields, and each have over 25 years of experience managing risks at similar companies, including risks arising from cybersecurity threats.</span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTO, in coordination with the SLT, oversees the Company&#8217;s ERM process, including the management of risks arising from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The CTO and the SLT, through its information technology partner receives regular reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, the threat environment, technological trends and information security considerations.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Chief Executive Officer, CFO and General Counsel each hold undergraduate and graduate degrees in their respective fields, and each have over 25 years of experience managing risks at similar companies, including risks arising from cybersecurity threats.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On an annual basis, the Audit Committee and the Board discuss the Company&#8217;s approach to cybersecurity risk management with the members of the SLT, which includes the Company&#8217;s CTO, GC, and Chief Financial Officer (&#8220;CFO&#8221;).</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814803856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (15,973)<span></span>
</td>
<td class="num">$ (21,413)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917197728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_Rule10b51ArrModifiedFlag', window );">Rule 10b51 ArrModified Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_NonRule10b51ArrModifiedFlag', window );">Non-Rule 10b51 ArrModified Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_NonRule10b51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_NonRule10b51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_Rule10b51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_Rule10b51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917334864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820259968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business, Basis of Presentation, and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business, Basis of Presentation, and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business, Basis of Presentation, and Liquidity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Nature of Business, Basis of Presentation, and Liquidity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of Business:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Longeveron LLC was formed as a Delaware limited liability company on October 9, 2014 and authorized to transact business in Florida on December 15, 2014. On February 12, 2021, Longeveron LLC converted its corporate form (the &#8220;Corporate Conversion&#8221;) from a Delaware limited liability company (Longeveron, LLC) to a Delaware corporation, Longeveron Inc. (the &#8220;Company,&#8221; &#8220;Registrant,&#8221; &#8220;Longeveron,&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;). The Company is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on licenses, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s product candidates are currently in development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from, among others, existing pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, partners and consultants.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern and Liquidity:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, the Company has primarily been engaged in organizational activities, including raising capital, and research and development activities. The Company does not yet have a product that has been approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), and has only generated revenues from grants, the Bahamas Registry Trials and contract manufacturing. The Company has not yet achieved profitable operations or generated positive cash flows from operations. The Company intends to continue its efforts to raise additional equity financing, develop its intellectual property, and secure regulatory approvals to commercialize its products. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, the Company&#8217;s future operations are dependent on the success of the Company&#8217;s efforts to raise additional capital, its research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of the Company&#8217;s products. These financial statements do not include adjustments that might result from the outcome of these uncertainties.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has incurred recurring losses from operations since its inception, including a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. In addition, as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company expects to continue to generate operating losses for the foreseeable future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company currently believes that its cash and cash equivalents as of December 31, 2024 will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025 based on its current operating budget and cash flow forecast. However, as a result of its successful Type C meeting with the U.S. FDA in August 2024 with respect to the HLHS regulatory pathway, the Company has started to ramp up Biologics License Application (BLA) enabling activities as the Company currently anticipates a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. The Company's operating expenses and capital expenditure requirements are expected to accelerate in calendar 2025 as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness, and there will be a need to increase the Company's current proposed spend and further increase its capital investments. The Company intends to seek additional financing/capital raises/non-dilutive funding options to support these activities, and current cash projections may be impacted by these ramped up activities and any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financing transactions entered into. There can be no assurance the Company will be able to attain future financing at terms favorable to the Company or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has prepared a cash flow forecast which indicates that it does not have sufficient cash to meet its minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore needs to raise additional funds to continue as a going concern. As a result, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814327392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements of the Company were prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain reclassifications have been made to prior period amounts to conform to the current period presentation. These reclassifications had no impact on previously reported net loss for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reverse Stock Split:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 26, 2024, the Company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4a0b75b5-4668-44fe-9ab3-6ac34d6f5dc3;"><span style="-sec-ix-hidden:F_2e46777d-d9ea-4884-a9bb-dd1d15ee5f6a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-10</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (1:10) basis (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split became effective at 11:59 p.m. Eastern Time on March 26, 2024 via a certificate of amendment to the Company&#8217;s Certificate of Incorporation filed with the Secretary of State of the State of Delaware. At the effective time of the Reverse Stock Split, every 10 shares of the Company&#8217;s Class A common stock and Class B common stock, whether issued and outstanding or held by the Company as treasury stock, were automatically combined and converted (without any further act) into one fully paid and nonassessable share of Class A common stock or Class B common stock, respectively, subject to rounding up of fractional shares to the nearest whole number of shares resulting from the Reverse Stock Split without any change in the par value per share. All share, per share, option, warrant, equity award, and other derivative security numbers and exercise prices appearing in this Annual Report on Form 10-K and the accompanying condensed financial statements have been adjusted to give effect to the Reverse Stock Split for all prior periods presented. However, the Company&#8217;s annual, other periodic, and current reports, and all other information and documents incorporated by reference into this Annual Report on Form 10-K that were filed prior to March 19, 2024, do not give effect to the Reverse Stock Split.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The presentation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Standard Updates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company&#8217;s financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, "Improvements to Reportable Segment Disclosures". The amendments in this ASU are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and by extending the disclosure requirements to entities with a single reportable segment. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_382d7ea9-fe54-4942-9ed3-f6ed091b8df0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is effective for the Company for the annual period of its fiscal year ending December 31, 2024. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this standard as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the adoption did not have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on its financial statements. See Note 13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for disclosures related to the adoption of ASU 2023-07.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, &#8220;Improvements to Income Tax Disclosures&#8221;. The amendments in this ASU change disclosure requirements for various items, including effective tax rate reconciliations and cash taxes paid. This ASU is effective for public companies for the financial reporting periods beginning on January 1, 2025, with early adoption permitted. The Company has not adopted ASU 2023-09 for its financial reporting period ending December 31, 2024, and does not anticipate the adoption of this ASU will have a material impact on its financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221;. The amendments in this ASU require additional disclosure about the nature of expenses included in the expense captions presented on the face of the income statement, including research and development and other operating expenses. This ASU is effective for public companies for the financial reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively, with the option for retrospective application, and early adoption is permitted. ASU 2024-03 will be effective for the Company for the annual period of its fiscal year ending December 31, 2027. The Company is currently evaluating the impact of adopting this ASU on its financial statements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers cash to consist of cash and cash equivalents and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> marketable securities at December 31, 2024. Marketable securities at December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as available-for-sale securities and are thus marked to market and stated at fair value in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 820 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and / or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized gains and losses were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and Grants Receivable:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of December 31, 2024 and 2023 are deemed to be collectible and no amount has been recognized for credit losses. In addition, for the clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the clinical trial revenue are recorded to deferred revenue. Advance contract manufacturing payments are recorded to deferred revenue.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and grants receivable by source, as of (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58%;box-sizing:content-box;"></td>
          <td style="width:2.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.939999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.939999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivables from customers</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">National Institutes of Health &#8211; Grant</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Offering Costs:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of proceeds generated as a result of the offering.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, including improvements that extend useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the Statement of Operations as the assets are primarily related to the Company&#8217;s clinical programs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible Assets:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets include payments on license agreements with the Company&#8217;s co-founder and Chief Scientific Officer (&#8220;CSO&#8221;) and the University of Miami (&#8220;UM&#8221;) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the statements of operations as the assets are primarily related to the Company&#8217;s clinical programs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment loss</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is reflected on the statements of operations. Upon evaluation, management determined that there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million impairment of long-lived assets during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Revenue:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unearned portion of advanced grant funds, contract manufacturing revenues, and prepayments for Clinical trial revenue, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the balance sheets. For the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of funds that were previously classified as deferred revenue. Due to the MSCRF &#8211; TEDCO &#8211; grant ARDS program being discontinued, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recorded as deferred revenue was reversed when the funds were returned to MSCRF &#8211; TEDCO.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company recognizes revenue when performance obligations related to respective revenue streams are met. For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant received the treatment. For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and / or statement of work has been satisfied. Additionally, the Company's contract manufacturing agreements include a lease component, under which customers pay a fixed monthly fee per</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suite </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to reserve and maintain a dedicated manufacturing suite with one production line. Customers may also secure additional suites based on capacity needs, which are billed at a fixed fee per suite per month. furthermore, customers pay the Company a fixed fee per month for storage of in-process samples, vialed harvests for training, and in-process samples for product lots. As these arrangements grant customers the right to control the use of an identified space, the Company classifies the suite reservation fees and storage fees as lease revenue in accordance with ASC 842 Leases. Payment terms may vary depending on specific contract terms. In 2024, the Company derived </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of its contract manufacturing revenue from a single customer, resulting in a significant concentration of revenue risk. Should this customer terminate their business relationship, the Company's contract manufacturing revenue could be materially adversely impacted.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue by source (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.272%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,402</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">668</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing lease revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_27ce6dd3-639b-41e2-9150-1333292d9101;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">487</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ab57fa60-fbf9-444e-8dc1-8543b8bc25bd;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">National Institute of Health - grant</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_491c5dcc-2520-4145-b055-747c1b012785;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,392</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records cost of revenues based on expenses directly related to revenue. For Grants, the Company records allocated expenses for Research and development costs to a grant as a cost of revenues. For the Clinical trial revenue directly related expenses for that program are expensed as incurred. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These expenses are similar to those described under &#8220;Research and development expense&#8221; below. For the contract manufacturing, the Company records costs incurred under the contract as cost of revenues.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expense:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are charged to expense when incurred in accordance with ASC 730 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities, and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company&#8217;s tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provision </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the uncertainty of realizing a benefit in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authority. It is the Company&#8217;s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity-Based Compensation:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for equity-based awards based on estimated fair values on the date of grant. The fair value of the options is estimated at the date of the grant using the Black-Scholes option-pricing model.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the Company&#8217;s stock options nor its restricted stock units (&#8220;RSUs&#8221;) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company&#8217;s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the option was granted. The expected life is the period of time that the options granted are expected to remain outstanding. Options granted have a maximum term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company had insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814927488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is summary of marketable securities that the Company measures at fair value (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.628%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_5860e748-b626-4760-9959-04c8458de42e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b5db85cc-838d-40fc-a08f-983e2963015b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_edf3cd8e-fee7-4f2b-bae4-3cb7da56e51c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_26429428-9ef1-47d7-90cc-f345882c97e5;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,902</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_261c32f6-80e4-43ac-b52b-25b87d6e73cb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_8adfe637-2df8-4137-b76b-d02b023f34c0;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,902</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_7a05c076-4b13-4782-980f-f1db531e3014;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_1ae67987-286c-4292-ad79-4c71735dd6d9;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b98a551e-dc71-4388-aafc-fbc75338dd46;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_382c332e-e576-4e25-b8f8-144ea2ba7f4f;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_40e58eda-d3eb-4484-86f2-e1fe5a77793e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_588625ea-79fb-4a9a-8abb-1ccf786357c5;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,964</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_1809098a-d0f5-4df3-8175-e912d38dfd37;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the balance sheets.</span></div></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company reported accrued interest receivable related to marketable securities and money market funds of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. These amounts are recorded in other assets on the Balance Sheets and are not included in the carrying value of the marketable securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrealized losses attributable to changes in marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the amortized cost of these securities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501923360352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Property and Equipment, Net</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major components of property and equipment are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Lives</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,328</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture/Lab equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,063</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software/Website</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,623</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,440</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,449</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,529</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense amounted to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917435488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Intangible Assets, Net</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major components of intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.033%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:14.217%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.198%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.117%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.198%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Lives</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">911</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patent costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_93e3078f-8d95-4815-8772-dedb12df7e8d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trademark costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_76c75a36-7343-4618-abb0-0a79d6e55a20;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,401</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major components of intangible assets as of December 31, 2023, are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.65%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:11.202%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Lives</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,043</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,134</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patent costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">959</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_cfc4d707-5861-482b-84d7-64104ba53727;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">959</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trademark costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b8f1c0ca-aab8-4e72-a961-0a1daf3f73fb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,196</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,287</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortization expense related to intangible assets amounted to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023. During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company wrote-off $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, of abandoned patents that it was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no longe</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r pursuing in several jurisdictions.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future amortization expense for intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is approximately as follows (in thousands):</span></p><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.88%;box-sizing:content-box;"></td>
        <td style="width:2.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:25.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">911</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814347616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Leases</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records a right-of-use operating lease asset and a lease liability related to its operating leases (there are no finance leases). The Company&#8217;s corporate office lease expires in March 2027. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the operating lease asset and operating lease liability were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the operating lease asset and operating lease liability were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum payments under the operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows (in thousands):</span></p><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less interest (</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% discount rate)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,447</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company incurred approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, of total lease costs that are included in the general and administrative expenses in the statements of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814940672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Class A and Class B Common Stock</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Class A common stock generally have rights identical to holders of Class B common stock, except that holders of Class A common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vote per share and holders of Class B common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (5) votes per share. The holders of Class B common stock may convert each share of Class B common stock into one share of Class A common stock at any time at the holder&#8217;s option. Class B common stock is not publicly tradable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, stockholders exchanged </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,555</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class B common stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,555</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, stockholders exchanged </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,555</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class B common stock for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,555</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Warrant Issuances</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the Company&#8217;s initial public offering (&#8220;IPO&#8221;), the underwriter received warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,640</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. The warrants are exercisable at any time and from time to time, in whole or in part, during the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_80fc046b-9fe3-4c96-90ec-96afcbbbd494;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four and a half-year period</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> commencing </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 12, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the fair value of warrants was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. During 2021, the underwriters assigned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,576</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the warrants to its employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the Company&#8217;s 2021 private placement offering, the Company issued warrants to investors to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,935</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to the number of shares of Class A common stock purchased by such investor in the offering, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share , which were immediately exercisable, were set to expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance, and had certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail therein (the &#8220;Purchaser Warrants&#8221;). In addition, the Company granted the underwriters warrants, under similar terms, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,679</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. On August 16, 2023, the Company announced its Stock Rights Offering, which triggered the downward pricing mechanism on the Purchaser Warrants, at which time these warrants were adjusted downward to an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the period remaining through expiration. This resulted in a deemed dividend to common stockholders of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the change in the fair value of the warrants using a Black-Scholes pricing model.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 15, 2021, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-261667) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,535</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, including (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,935</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued to purchasers in the Company&#8217;s 2021 private placement offering; (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116,935</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of the Purchaser Warrants; and (iii)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,679</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of the underwriters warrants issued as part of the 2021 private placement offering. The Form S-1 was declared effective by the SEC on December 22, 2021.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of an October 2023 registered direct offering, the Company issued Series A warrants and Series B warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242,425</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242,425</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, shares of Class A common stock. Each series of warrants had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, with the Series A warrants having a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_428f7fa2-6f69-4ce1-97cd-53b8e1f3b7a5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five and one-half (5.5) years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance, and the Series B warrants having a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d317f701-e4a6-46de-af03-196205d6c7fb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eighteen (18) months</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of issuance. Both the Series A and Series B warrants became exercisable as of December 26, 2023, following stockholder approval. In addition, the Company granted the placement agent warrants, under similar terms, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,971</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.625</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 15, 2023, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-275578) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">501,821</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, including (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242,425</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of issuable upon exercise of the Series A Warrants; (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242,425</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of the Series B Warrants; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,971</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of warrants granted to the placement agent as part of the October 2023 registered direct offering. The Form S-1 was declared effective by the SEC on November 21, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, the Series A Warrants and Series B Warrants were amended to reduce the exercise price to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The Series A Warrants and Series B Warrants were subsequently exercised in full in April 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of a December 2023 registered direct offering, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,531</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock. These warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, became immediately issuable upon issuance, and expire on June 22, 2029. In addition, the Company granted the placement agent warrants, under similar terms, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,489</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.813</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 29, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-276745) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,020</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, including (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,531</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of warrants issued in a concurrent private placement in connection with the December 2023 registered direct offering and (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,489</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of warrants granted to the placement agent in connection with the December 2023 registered direct offering. The Form S-1 was subsequently amended by the Company on April 16, 2024 and declared effective by the SEC on April 17, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 8, 2024, the Company commenced a public offering of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">639,872</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock, along with pre-funded warrants to purchase up to an aggregate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,572,894</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock (the &#8220;Pre-Funded Warrants&#8221;). The shares and Pre-Funded Warrants were sold together with warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,212,766</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock (the &#8220;Common Warrants&#8221;). The combined public offering price was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and related Common Warrant and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.349</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per Pre-Funded Warrant and related Common Warrant. Subject to certain limitations, the Pre-Funded Warrants were immediately exercisable and could be exercised at a nominal consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of Class A common stock at any time until all of the Pre-Funded Warrants were exercised in full. The Common Warrants were immediately exercisable and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 10, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As compensation to the placement agent the Company also issued to designees of the placement agent warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,894</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, which had substantially the same terms as the Common Warrants, and with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9375</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the commencement of sales in the offering.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the offering, the Company also entered into an agreement with a holder of existing warrants to amend the holder&#8217;s existing Series A warrants and Series B warrants to reduce the exercise price to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and (ii) amend the expiration date of the Series A Warrants to five and one-half (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) years following the closing of the public offering and the Series B warrants to eighteen (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) months following the closing of the public offering, in each case for a payment to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per amended warrant.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 16, 2024, the Company entered into inducement letter agreements with certain holders of its existing Series A warrants and Series B warrants, and Common Warrants issued on April 10, 2024, whereby the holders agreed to exercise the warrants for cash at the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in consideration for payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per new warrant and for the Company&#8217;s agreement to issue new unregistered Class A common stock warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,799,488</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, and which were immediately exercisable upon issuance. The warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,399,744</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock (the &#8220;Series C Warrants&#8221;) have a term of five (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) years from the issuance date, and the warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,399,744</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock (the &#8220;Series D Warrants&#8221;) have a term of twenty-four (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months from the issuance date, with all of the Series C Warrants and Series D Warrants being immediately exercisable. All</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Series D Warrants were exercised in June 2024, pursuant to ordinary course exercise as well as a subsequent inducement transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company issued to the placement agent or its designees as compensation, warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,982</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the inducement transaction, which had the same terms as the Series C Warrants, except that the placement agent warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, upon exercise, if any, of the Series D Warrants for cash, the Company agreed to issue the placement agent or its designees, within five (5) business days of the Company&#8217;s receipt of the exercise price, warrants to purchase the number of shares of Class A common stock equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares underlying such Series D Warrants that have been exercised, with such warrants to be in the same form and terms as the prior placement agent warrants.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 18, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-278995) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,967,470</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,399,744</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of the Series C Warrants issued in the April 2024 warrant inducement transaction; (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,399,744</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of the Series D Warrants issued in the April 2024 warrant inducement transaction; and (iii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,982</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon exercise of the warrants issued to the placement agent or its designees in the April 2024 warrant inducement transaction. The Form S-1 was subsequently amended by the Company and declared effective by the SEC on May 21, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 17, 2024, the Company entered into additional inducement letter agreements with the holders of its existing Series D Warrants to exercise the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,697,891</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock underlying Series D Warrants that remained outstanding for cash at the exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in consideration for the Company&#8217;s agreement to issue new unregistered Class A common stock warrants (the "June Inducement Warrants"), for payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per new warrant, to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,395,782</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and which were immediately exercisable upon issuance and have a term of twenty-four (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) months from the issuance date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also issued to the placement agent or its designees as compensation, (i) warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,852</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the June inducement transaction and (ii) warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Common Stock issued upon exercise of certain Series D warrants prior to the inducement transaction, which had substantially the same terms as the June Inducement Warrants, except that the warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,852</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and the warrants exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9375</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively (collectively, the "June placement agent warrants").</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon exercise, if any, of the June Inducement Warrants for cash, the Company agreed to issue within five (5) business days to the placement agent or its designees, warrants to purchase the number of shares of Class A common stock equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock underlying such June Inducement Warrants that have been exercised, with such warrants to be in the same form and terms as the June placement agent warrants.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance under the inducement offers represented $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders. The June Inducement Warrants expire on June 18, 2026.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 28, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-280577) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,563,764</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,395,782</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of the June Inducement Warrants and (ii) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,982</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issuable upon the exercise of the June placement agent warrants. The Form S-1 was subsequently declared effective by the SEC on July 9, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2024, a holder exercised Series C warrants for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock for cash (the &#8220;July Series C warrant exercise&#8221;).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2024, certain holders of warrants issued in June of 2024 exercised warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock for cash (the &#8220;July 10 warrant exercise&#8221;). In addition, on July 17, 2024, the Company issued to the placement agent warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock issued in the July 10 warrant exercise (the &#8220;first tranche July ordinary course placement agent warrants&#8221;). The first tranche July ordinary course placement agent warrants have substantially the same terms as the June placement agent warrants, except that the first tranche July ordinary course placement agent warrants (i) have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and (ii) expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 17, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 17, 2024, a holder of the June Inducement Warrants exercised the same to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,319,186</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock for cash (the &#8220;July 17 warrant exercise&#8221; and together with the July 10 warrant exercise</span><span style="color:#008080;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the July Series C warrant exercise,</span><span style="color:#008080;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collectively, the &#8220;July warrant exercises&#8221;). Accordingly, on July 24, 2024, the Company issued to the placement agent warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,344</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate number of shares of Class A common stock issued in the July 17 warrant exercise (the &#8220;second tranche July ordinary course placement agent warrants&#8221;, and together with the first tranche July ordinary course placement agent warrants, the &#8220;July ordinary course placement agent warrants&#8221;, and collectively with the July offering placement agent warrants, the &#8220;July placement agent warrants&#8221;). The second tranche July ordinary course placement agent warrants have substantially the same terms as the first tranche July ordinary course placement agent warrants, except that the second tranche July ordinary course placement agent warrants expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 24, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The gross proceeds to the Company from the July warrant exercises, inclusive of the payment consideration for such Series C warrants and June Inducement Warrants, were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, inclusive of the payment consideration for such warrants, before deducting placement agent fees payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 18, 2024, the Company entered into a securities purchase agreement with institutional and accredited investors relating to the registered direct offering and sale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,236,026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our Class A common stock at a purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of Class A common stock and associated warrant (the &#8220;July registered direct offering&#8221;). The securities issued in the July registered direct offering were offered pursuant to a prospectus supplement, dated July 18, 2024, and accompanying prospectus, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-264142), which was declared effective by the SEC on April 14, 2022.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a concurrent private placement (the &#8220;July private placement&#8221; and together with the July registered direct offering, the &#8220;July offering&#8221;), the Company also sold unregistered Class A common stock warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,236,026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our Class A common stock (the &#8220;July private placement warrants&#8221;). The unregistered July private placement warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, became exercisable on July 19, 2024, and expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 20, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company granted the placement agent warrants, under similar terms, to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,522</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0313</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;July offering placement agent warrants&#8221;). The gross proceeds to the Company from the July offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting placement agent fees and other offering expenses payable by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 6, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-281299) registering the resale of an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,565,392</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock issuable upon exercise of certain warrants, of which (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,236,026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are issuable upon the exercise of the July private placement warrants issued to the purchasers upon the closing of the July private placement; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,522</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are issuable upon exercise of the July offering placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of the current engagement Letter with Wainwright; and (iii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172,844</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are issuable upon exercise of the July ordinary course placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of a then-applicable engagement letter with Wainwright, in connection with previously exercised June Inducement Warrants. The Form S-1 was declared effective by the SEC on August 12, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company entered into additional inducement letter agreements with certain holders of its existing Purchaser Warrants issued as part of the Company&#8217;s 2021 private placement offering to amend and reduce the exercise price of the Purchaser Warrants to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in consideration for the holders&#8217; cash exercise of all Purchaser Warrants held by such holder on or before September 27, 2024. In connection with the September 2024 inducement transaction, Purchaser Warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,077</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, resulting in gross proceeds to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,077</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, the Company entered into additional inducement letter agreements with the remaining holders of its existing Purchaser Warrants issued as part of the Company&#8217;s 2021 private placement offering to amend and reduce the exercise price of the Purchaser Warrants to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share in consideration for the holders&#8217; cash exercise of all Purchaser Warrants held by such holder. In connection with the October 2024 inducement transaction, Purchaser Warrants were exercised for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,858</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock, resulting in gross proceeds to the Company of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,858</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Purchaser Warrants have been exercised in full.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Warrants Outstanding</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, warrants exercisable for an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,802,668</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s Class A common stock remain outstanding. This includes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IPO underwriter warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,536</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 12, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Underwriter warrants issued in connection with the 2021 private placement offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,679</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 1, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the October 2023 registered direct offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,971</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.625</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 11, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investor warrants issued in connection with the December 2023 registered direct offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,531</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 22, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the December 2023 registered direct offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,489</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.813</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 20, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Warrants issued in connection with the April 2024 public offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">297,872</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 10, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the April 2024 public offering exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,894</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9375</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 8, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Series C Warrants issued in connection with the April 2024 inducement transaction exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,349,744</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 18, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the April 2024 inducement transaction exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,982</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 18, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June placement agent warrants issued in the ordinary course prior to the June 2024 inducement transaction exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9375</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 18, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June Inducement Warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">926,596</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 18, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Placement agent warrants issued in connection with the June 2024 inducement transaction exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,852</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 18, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">First tranche July ordinary course placement agent warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 17, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Second tranche July ordinary course placement agent warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,344</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 24, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July private placement warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,236,026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 20, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July offering placement agent warrants exercisable for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,522</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0313</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, which expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">July 20, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501920298320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity Incentive Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Equity Incentive Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the Company&#8217;s IPO, the Company adopted and approved the 2021 Incentive Award Plan, which has been subsequently amended and restated twice (as accordingly amended and restated, the &#8220;2021 Incentive Plan&#8221;). Under the 2021 Incentive Plan, the Company may grant cash and equity incentive awards to employees and eligible service providers in order to attract, motivate and retain the talent for which the Company competes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs are taxable upon vesting based on the market value on the date of vesting. The Company is required to make mandatory tax withholding for the payment and satisfaction of income tax, social security tax, payroll tax, or payment on account of other tax related to withholding obligations that arise by reason of vesting of an RSU. The taxable income is calculated by multiplying the number of vested RSUs for each individual by the closing share price as of the vesting date and a tax liability is calculated based on each individual&#8217;s tax bracket. During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">566,904</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs vested for Class A common stock shares. Of that amount, the Company withheld </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,306</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A common stock shares to satisfy employee tax liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,308</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs vested for Class A common stock shares. Of that amount, the Company withheld </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,223</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Class A common stock shares to satisfy employee tax liabilities. The shares withheld are available for reissuance pursuant to the Company&#8217;s Second Amended and Restated 2021 Incentive Award Plan. Each RSU grant made during 2024 and 2023 is expensed ratably over its respective vesting period, with prorated adjustments made as needed to align with grant dates and the applicable service periods.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">806,001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,239</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively RSUs outstanding (unvested).</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.18%;box-sizing:content-box;"></td>
        <td style="width:2.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:25.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>RSUs</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding (unvested) at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,394,774</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">566,904</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSU expired/forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding (unvested) at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">806,001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Options</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options may be granted under the 2021 Incentive Plan. The exercise price of options is equal to the fair market value of the Company&#8217;s Class A common stock as of the grant date. Options historically granted have generally become exercisable over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a211f642-62a5-42ee-bc71-d3f13e686a7e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and expire </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the Company granted options that vest quarterly over three years. Non-employee awards, including options granted to directors and certain third-party service providers, are granted similar to the Company&#8217;s employee awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2023, the Company granted options to executives and non-employee directors under various vesting schedules, including a four-year vesting period with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% vesting per year and a one-year cliff vesting for the CEO.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the options issued are estimated using the Black-Scholes option-pricing model. For 2024, the following assumptions were used: a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; an expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years; volatility ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; and risk-free interest rate based on the grant date ranging from of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% - </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.52</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For 2023, the following assumptions were used: a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; an expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years; volatility ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; and risk-free interest rate based on the grant date ranging from of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.89</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. Each option grant made during 2024 and 2023, will be expensed ratably over the option vesting periods, with prorated adjustments made as needed to align with grant dates and applicable service periods.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has recorded issued and outstanding options to purchase a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,186</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock pursuant to the 2021 Incentive Plan, at a weighted average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.09</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Also, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has recorded issued and outstanding options to purchase a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,786</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Class A common stock pursuant to the 2021 Incentive Plan, at a weighted average exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.96</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options vested (based on ratable vesting)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,713</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options unvested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock options outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options vested (based on ratable vesting)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,091</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options unvested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock options outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise <br/>Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.60</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,625</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.46</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_d44a448c-95da-42af-9268-94b3f97749eb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_e72c3d8a-06d5-4f57-820b-ef886d45e808;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options expired/forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.09</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the equity-based compensation expense amounted to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, which is included in the research and development and general and administrative expenses in the statements of operations for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the remaining unrecognized RSUs compensation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be recognized over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.08</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. The remaining unrecognized stock options compensation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be recognized over approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.94</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917407024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Master Services and Clinical Studies Agreements:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Company terminated its active master services agreements with third parties that were previously engaged to conduct its clinical trials and manage clinical research programs and clinical development services. This termination was due to the Company&#8217;s decision in April 2024 to discontinue trial activities in Japan.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consulting Services Agreement:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 20, 2014, the Company entered into a ten-year consulting services agreement with Dr. Joshua Hare, its Chief Science Officer (CSO). Under the agreement, the Company has agreed to pay the CSO $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">265,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annually. The compensation payments are for scientific knowledge, medical research, technical knowledge, skills, and abilities to be provided by the CSO to further develop the intellectual property rights assigned by the CSO to the Company. This agreement requires the CSO to also assign to the Company the exclusive right, title, and interest in any work product developed from his efforts during the term of this agreement. On November 16, 2022, the Company accounted for but had not issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,140</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RSUs convertible to unregistered shares of Class A common stock, with an aggregate value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as payment for accrued expenses under a consulting agreement with the CSO. These shares were issued on May 24, 2023. The initial term of the agreement ended on November 22, 2024, however, the Company continues to operate under the same terms until a new agreement is executed. In addition, t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he Company entered into a deferred compensation agreement with the CSO to defer payment of the consulting fees earned for services rendered during 2024. The 2024 consulting fees will be paid in the form of a lump sum distribution in February 2027.  As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company had accrued balances due to the CSO of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, included in other long-term liabilities and accrued expenses, respectively, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, included in accrued expense and accounts payable in the accompanying balance sheets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing Services Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 21, 2024, the Company entered into a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Supply Agreement with a third-party biotechnology company developing multiple, novel secretomes (&#8220;Secretome&#8221;), to address a spectrum of diseases driven by pathological processes , to manufacture, test, release, and supply Secretome with cardiac stem cells (the &#8220;Product&#8221;) to be used in Phase 1 and Phase 2 clinical trials (the &#8220;Secretome Agreement&#8221;).  The Company received an initial start-up payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242,400</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon signing of the  Secretome Agreement, which was comprised of (a) technology transfer, documentation preparation, training, and testing costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (b) a ten-hour prepayment of project management fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,400</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (c) a first month suite reservation fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company will bill Secretome on a variable fee basis for quality control, in process, release, and stability testing service items. For each Product lot, Secretome will pay the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per lot as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each additional</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lot in excess of two initial &#8220;training run&#8221; lots. Secretome will also pay a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> monthly manufacturing suite reservation fee to the Company as well as a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">240</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per hour hourly fee for project management services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secretome  has also agreed to compensate the Company for the value of all materials involved in manufacturing and quality control testing the Product, plus a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent markup on these materials. For any outsourced testing, Secretome will be billed directly by the laboratory conducting the testing, plus a fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per batch payable to the Company. Furthermore, Secretome will pay the Company $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> monthly for storage of in process samples, vialed harvests for training, and in process samples for Product lots. The Company will receive certain variable payments related to product packing, handling and shipping, with a standard fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with an increased fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for expedited or special hour service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the initial </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term, the Secretome Agreement may be renewed for additional successive two-year terms upon the mutual written agreement of the parties. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Either party may terminate the agreement for cause and upon notice in the event of a material breach, within (i) 30 days of an uncured material breach that is not a payment default or (ii) 10 days for an uncured payment default. The Secretome Agreement further provides that either party may terminate the agreement at any time upon 90 days&#8217; notice to the other party.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, either party may terminate the agreement immediately in the event the other party seeks the protection of any bankruptcy court, becomes insolvent, makes an assignment for the benefit of creditors, or any debarment activity occurs with respect to that party. A force majeure provision also permits termination of the Secretome Agreement upon written notice to the other party as a result of a delay or interference of performance continuing for more than 60 days.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, the Company has earned revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million under the Secretome Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is also a party to a Mutual Nondisclosure Agreement with Secretome, signed and effective as of October 24, 2023 (the &#8220;Nondisclosure Agreement&#8221;), by which both parties have agreed to maintain the strict confidentiality of, restrict access to, and not to disclose  any intellectual property, trade secrets, business dealings, customers, operations, products, research, clinical data, or other competitively sensitive or proprietary confidential information shared between them, subject to certain customary carve-outs for disclosures pursuant to applicable law or filings with regulatory or governmental agencies including the SEC. The Nondisclosure Agreement has a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the later of (i) the effective date of the Nondisclosure Agreement, (ii) the date of the last disclosure of information under the Secretome Agreement, any &#8220;Quality Agreement&#8221; which may be entered into between the parties, or any scope of work; or (iii)  the expiration of any patents issued arising out of or resulting from the confidential information. The Nondisclosure Agreement will not terminate with respect to trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exclusive Licensing Agreements:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">UM Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 20, 2014, the Company entered into an Exclusive License Agreement with UM (the &#8220;UM License&#8221;) for the use of certain Aging-related Frailty Mesenchymal Stem Cell (&#8220;MSC&#8221;) technology rights developed by our CSO at UM. The UM License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how specifically related to the development of the culture-expanded mesenchymal stem cells for Aging-related Frailty used at the Human-induced pluripotent stem cell-derived mesenchymal stem cells (IMSCs&#8221;), all standard operating procedures used to create the IMSCs, and all data supporting isolation, culture, expansion, processing, cryopreservation and management of the IMSCs. The Company is required to pay UM (i) a license issue fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (ii) a running royalty in an amount equal to three percent of annual net sales on products or services developed from the technology, payable on a country-by-country basis beginning on the date of first commercial sale through termination of the UM License Agreement, and which may be reduced to the extent we are required to pay royalties to a third party for the same product or process, (iii) escalating annual cash payments of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">fifty thousand</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dollars, subject to offset. The agreement extends for up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years from the last date a product or process is commercialized from the technology and was amended in 2017 to modify certain milestone completion dates as detailed below. In 2021 the license fee was increased by an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to defray patent costs. In addition, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,387</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unregistered shares of Class A common stock to UM.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The milestone payment amendments shifted the triggering payments to three payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to be paid within six months of: (a) the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (b) the receipt by the Company of approval for the first new drug application (&#8220;NDA&#8221;), biologics application (&#8220;BLA&#8221;), or other marketing or licensing application for the product; and (c) the first sale following product approval. &#8220;Approval&#8221; refers to Product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successor agency. The amendments also provided for the Company&#8217;s license of additional technology, to the extent not previously included in the UM License, and granted the Company an exclusive option to obtain an exclusive license for (a) the Hypoplastic Left Heart Syndrome (&#8220;HLHS&#8221;)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigational </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new drug application (&#8220;IND&#8221;) with ckit+ cells; and (b) UMP-438 titled &#8220;Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has the right to terminate the UM License upon 60 days&#8217; prior written notice, and either party has the right to terminate upon a breach of the UM License. To date, the Company has made payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to UM, and as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, in the accompanying balance sheets, the Company had accrued $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in milestone fees payable to UM for both years, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for both years, respectively, for patent related reimbursements based on the estimated progress to date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company also entered into an additional Exclusive License Agreement with UM, signed and effective as of July 18, 2024, for technology rights developed by our CSO at UM. This License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how, SOPs, data and other all other rights related to UMP-144, entitled &#8220;A method to derive GHRHR+ cardiomyogenic cells from pluripotent stem cells (PSCs) for therapeutic and pharmacologic applications&#8221; and having inventors Joshua Hare and Konstantinos Chatzistergos. UM retained a non-exclusive, royalty-free, perpetual, irrevocable, worldwide right to practice, make, and use the Patent Rights or Technology for any non-profit purposes, including educational, and research purposes. Pursuant to the terms of the license agreement, Longeveron must pay to UM: (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within 30 days of the Effective Date; and (b) reimbursement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,307</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> within 90 days of the Effective Date for previously incurred patent expenses; and (c) an annual $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> fee which is both creditable against other royalty payments for the applicable license year and is waived so long as Company is current on annual fee payments in accordance with the Exclusive License Agreement entered into November 20, 2014 between Company and UM. In addition to certain those certain other royalty payments that would be due should the Company&#8217;s sublicense of the technology result in revenue, Longeveron also agreed to the following additional milestones and payments: (c) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon completion of the first Phase 3 Clinical Trial; and (d) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon issuance of a biologics license application or new drug application based on the licensed technology. The Company has the right to terminate the new UM License for convenience upon 90 days&#8217; prior written notice, and both parties have additional termination rights for material breach of the agreement. To date, the Company has made payments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to UM, and as of December 31, 2024, the Company had not yet accrued any milestone fees payable to UM.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">CD271</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 22, 2016, the Company entered into an exclusive license agreement with an affiliated entity of Dr. Joshua Hare, JMH MD Holdings, LLC (&#8220;JMHMD&#8221;), for the use of CD271 cellular therapy technology. The Company recorded the value of the cash consideration and membership units issued to obtain this license agreement as an intangible asset. The Company is required to pay as royalty </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the annual net sales of the licensed product(s) used, leased, or sold by or for licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to JMHMD, and issued to it </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Series C Units, valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of value provided to JMHMD for the license agreement, along with professional fees of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Further, expenses related to the furtherance of the CD271+ technology is being capitalized and amortized as incurred over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> license fees due for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 pertaining to this agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Royalty</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the grant award agreement with the Alzheimer&#8217;s Association, the Company may be required to make revenue sharing or distribution of revenue payments for products or inventions generated or resulting from this clinical trial program. The potential payments, although not currently defined, could result in a maximum payment of five times (5x) the award amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingencies &#8211; Legal</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. For the year ended December 31, 2024, the Company is not aware of any legal proceedings or material developments requiring disclosure.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 13, 2021, the Company and certain of its directors and officers were named as defendants in a securities lawsuit filed in the U.S. District Court for the Southern District of Florida and brought on behalf of a purported class. The suit alleges there were materially false and misleading statements made (or omissions of required information) in the Company&#8217;s initial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offering materials and in other disclosures during the period from our initial public offering on February 12, 2021, through August 12, 2021, in violation of the federal securities laws. The action sought damages on behalf of a proposed class of purchasers of the Company&#8217;s common stock during said period. On July 12, 2022, all parties preliminarily agreed to settle the action for approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which settlement was preliminarily approved by the Court on or about May 12, 2023, and which settlement amount was paid on May 24, 2023. Legal expenses incurred in ordinary business activities are reported within general and administrative expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On or about May 18, 2023, a former employee of the Company filed a charge with the Equal Employment Opportunities Commission (&#8220;EEOC&#8221;) and the Florida Commission on Human Relations alleging discrimination based on disability, and on or about August 15, 2023, the former employee filed a complaint in Miami-Dade Circuit Court alleging unpaid wages were outstanding.  Both matters were addressed and fully resolved and settled in a mediation between the Company and the former employee held on September 28, 2023, by which it was agreed that the former employee would be paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> towards this resolution was paid by the Company and all remaining costs were covered by the Company&#8217;s insurance carrier) and that the EEOC and FCHR charges were withdrawn and the action in the Miami-Dade Circuit Court was dismissed with prejudice.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917283024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences and net operating loss (&#8220;NOL&#8221;) carryforwards that gave rise to significant portions of the deferred tax assets and deferred tax liabilities were approximately as follows at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,870</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASC 842 Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_59df80b9-4b23-4957-add5-f538f80c9bb3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_4dd0ce9c-9e6c-48e8-8f65-86135e742a26;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research &amp; development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,283</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,866</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrual to cash adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_08bd69a2-41d1-491f-a362-6162aa80c7fc;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_dc96f2f3-806d-4814-8f8e-b6e47d188ef7;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,014</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,776</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">391</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASC 842 Right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">391</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_5f5fbe24-614b-499f-aced-c5af13aee5ae;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_fd5c8872-fbff-42c3-a6e0-bd84c28f075d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had NOL carryforwards for federal purposes of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, all of which have no expiration. The Company also had state NOL carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, all of which have no expiration. However, these NOLs are subject to various limitations under Internal Revenue Code (&#8220;IRC&#8221;) Section 382. IRC Section 382 limits the use of NOLs to the extent there has been an ownership change of more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percentage points in shares owned by any </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">owner. In addition, the NOL carry forwards are subject to examination by the taxing authority and could be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adjusted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or disallowed due to such exams. Although the Company has not undergone an IRC Section 382 analysis, it is likely that the utilization of the NOLs may be substantially limited.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reconciliations of the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal tax at statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax benefits, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_903b8dcc-7d05-4cc8-8ed2-00092d584312;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_9b1b95a1-5cfc-4117-a2c2-f442d0b99222;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2024, there were no uncertain positions. The Company&#8217;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from 2021, the earliest year with a net operating loss carryover, because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814432032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefits Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefits Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Employee Benefits Plan</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company sponsors a defined contribution employee benefit plan (the &#8220;Plan&#8221;) under the provisions of Section 401(k) of the Internal Revenue Code. The Plan covers substantially all full-time employees of the Company who are eligible upon date of hire. Contributions to the Plan by the Company are at the discretion of the Board of Directors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company contributed approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the Plan during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501920298320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Loss Per Share</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share have been computed using the weighted-average number of shares of common stock outstanding during the period. We have outstanding equity-based awards that are not used in the calculation of diluted net loss per share because to do so would be anti-dilutive.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following instruments (in thousands) were excluded from the calculation of diluted net loss per share because their effects would be antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">806</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PSUs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,803</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,730</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,415</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917370672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Segment Information</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which discrete financial information is available and regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) to allocate resources and assess performance. The Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_eb2962d5-c458-43df-b1ef-4f45299e5db3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM is its Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_13fc1c78-4d1d-440f-aa75-9a7f20b97683;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment focused on developing regenerative medicines to address unmet medical needs. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The company&#8217;s measure of segment profit or loss is net loss. The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company&#8217;s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_577d3f24-3615-4da2-a77f-a18b9428fc43;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating expenses</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are used to monitor budget versus actual results.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  All material long-lived assets of the Company are located in the United States and Company&#8217;s revenues are derived from the United States, the Bahamas and Israel. The total assets of the one reporting segment are disclosed on the balance sheets as of December 31, 2024 and 2023.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company&#8217;s single reportable segment:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.953%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.903%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.903%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">488</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,799</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">G&amp;A costs</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,002</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,731</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,973</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,413</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Contract Manufacturing and Clinical Trial revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Clinical Development, Research &amp; Discovery, CMC</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Executive, Finance, Legal, Business Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes compensation, benefits and equity-based compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes depreciation and amortization, (interest income) and other specific charges</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501815889008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis of Presentation:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements of the Company were prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain reclassifications have been made to prior period amounts to conform to the current period presentation. These reclassifications had no impact on previously reported net loss for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reverse Stock Split:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 26, 2024, the Company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_4a0b75b5-4668-44fe-9ab3-6ac34d6f5dc3;"><span style="-sec-ix-hidden:F_2e46777d-d9ea-4884-a9bb-dd1d15ee5f6a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-for-10</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (1:10) basis (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split became effective at 11:59 p.m. Eastern Time on March 26, 2024 via a certificate of amendment to the Company&#8217;s Certificate of Incorporation filed with the Secretary of State of the State of Delaware. At the effective time of the Reverse Stock Split, every 10 shares of the Company&#8217;s Class A common stock and Class B common stock, whether issued and outstanding or held by the Company as treasury stock, were automatically combined and converted (without any further act) into one fully paid and nonassessable share of Class A common stock or Class B common stock, respectively, subject to rounding up of fractional shares to the nearest whole number of shares resulting from the Reverse Stock Split without any change in the par value per share. All share, per share, option, warrant, equity award, and other derivative security numbers and exercise prices appearing in this Annual Report on Form 10-K and the accompanying condensed financial statements have been adjusted to give effect to the Reverse Stock Split for all prior periods presented. However, the Company&#8217;s annual, other periodic, and current reports, and all other information and documents incorporated by reference into this Annual Report on Form 10-K that were filed prior to March 19, 2024, do not give effect to the Reverse Stock Split.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The presentation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standard Updates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Standard Updates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company&#8217;s financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, "Improvements to Reportable Segment Disclosures". The amendments in this ASU are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and by extending the disclosure requirements to entities with a single reportable segment. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_382d7ea9-fe54-4942-9ed3-f6ed091b8df0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is effective for the Company for the annual period of its fiscal year ending December 31, 2024. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this standard as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and the adoption did not have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on its financial statements. See Note 13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for disclosures related to the adoption of ASU 2023-07.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, &#8220;Improvements to Income Tax Disclosures&#8221;. The amendments in this ASU change disclosure requirements for various items, including effective tax rate reconciliations and cash taxes paid. This ASU is effective for public companies for the financial reporting periods beginning on January 1, 2025, with early adoption permitted. The Company has not adopted ASU 2023-09 for its financial reporting period ending December 31, 2024, and does not anticipate the adoption of this ASU will have a material impact on its financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU No. 2024-03, &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221;. The amendments in this ASU require additional disclosure about the nature of expenses included in the expense captions presented on the face of the income statement, including research and development and other operating expenses. This ASU is effective for public companies for the financial reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively, with the option for retrospective application, and early adoption is permitted. ASU 2024-03 will be effective for the Company for the annual period of its fiscal year ending December 31, 2027. The Company is currently evaluating the impact of adopting this ASU on its financial statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers cash to consist of cash and cash equivalents and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> marketable securities at December 31, 2024. Marketable securities at December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as available-for-sale securities and are thus marked to market and stated at fair value in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 820 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and / or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized gains and losses were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts and Grants Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and Grants Receivable:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of December 31, 2024 and 2023 are deemed to be collectible and no amount has been recognized for credit losses. In addition, for the clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the clinical trial revenue are recorded to deferred revenue. Advance contract manufacturing payments are recorded to deferred revenue.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and grants receivable by source, as of (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58%;box-sizing:content-box;"></td>
          <td style="width:2.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.939999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.939999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivables from customers</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">National Institutes of Health &#8211; Grant</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Offering Costs:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of proceeds generated as a result of the offering.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and Equipment:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, including improvements that extend useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the Statement of Operations as the assets are primarily related to the Company&#8217;s clinical programs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible Assets:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets include payments on license agreements with the Company&#8217;s co-founder and Chief Scientific Officer (&#8220;CSO&#8221;) and the University of Miami (&#8220;UM&#8221;) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the statements of operations as the assets are primarily related to the Company&#8217;s clinical programs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment loss</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is reflected on the statements of operations. Upon evaluation, management determined that there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million impairment of long-lived assets during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Deferred Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred Revenue:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unearned portion of advanced grant funds, contract manufacturing revenues, and prepayments for Clinical trial revenue, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the balance sheets. For the years ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of funds that were previously classified as deferred revenue. Due to the MSCRF &#8211; TEDCO &#8211; grant ARDS program being discontinued, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million recorded as deferred revenue was reversed when the funds were returned to MSCRF &#8211; TEDCO.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company recognizes revenue when performance obligations related to respective revenue streams are met. For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant received the treatment. For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and / or statement of work has been satisfied. Additionally, the Company's contract manufacturing agreements include a lease component, under which customers pay a fixed monthly fee per</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suite </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to reserve and maintain a dedicated manufacturing suite with one production line. Customers may also secure additional suites based on capacity needs, which are billed at a fixed fee per suite per month. furthermore, customers pay the Company a fixed fee per month for storage of in-process samples, vialed harvests for training, and in-process samples for product lots. As these arrangements grant customers the right to control the use of an identified space, the Company classifies the suite reservation fees and storage fees as lease revenue in accordance with ASC 842 Leases. Payment terms may vary depending on specific contract terms. In 2024, the Company derived </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of its contract manufacturing revenue from a single customer, resulting in a significant concentration of revenue risk. Should this customer terminate their business relationship, the Company's contract manufacturing revenue could be materially adversely impacted.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue by source (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.272%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,402</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">668</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing lease revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_27ce6dd3-639b-41e2-9150-1333292d9101;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">487</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ab57fa60-fbf9-444e-8dc1-8543b8bc25bd;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">National Institute of Health - grant</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_491c5dcc-2520-4145-b055-747c1b012785;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,392</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records cost of revenues based on expenses directly related to revenue. For Grants, the Company records allocated expenses for Research and development costs to a grant as a cost of revenues. For the Clinical trial revenue directly related expenses for that program are expensed as incurred. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These expenses are similar to those described under &#8220;Research and development expense&#8221; below. For the contract manufacturing, the Company records costs incurred under the contract as cost of revenues.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expense:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs are charged to expense when incurred in accordance with ASC 730 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities, and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company&#8217;s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company&#8217;s tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provision </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the uncertainty of realizing a benefit in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2023, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authority. It is the Company&#8217;s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity-Based Compensation:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for equity-based awards based on estimated fair values on the date of grant. The fair value of the options is estimated at the date of the grant using the Black-Scholes option-pricing model.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither the Company&#8217;s stock options nor its restricted stock units (&#8220;RSUs&#8221;) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company&#8217;s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the option was granted. The expected life is the period of time that the options granted are expected to remain outstanding. Options granted have a maximum term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company had insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Reverse Stock Split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814432032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts and Grants Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts and grants receivable by source, as of (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:58%;box-sizing:content-box;"></td>
          <td style="width:2.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.939999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.06%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.939999999999998%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivables from customers</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">National Institutes of Health &#8211; Grant</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue by source (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.272%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,402</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">668</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing lease revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_27ce6dd3-639b-41e2-9150-1333292d9101;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract manufacturing revenue</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">487</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_ab57fa60-fbf9-444e-8dc1-8543b8bc25bd;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">National Institute of Health - grant</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_491c5dcc-2520-4145-b055-747c1b012785;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,392</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917432752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is summary of marketable securities that the Company measures at fair value (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.628%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.842%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_5860e748-b626-4760-9959-04c8458de42e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b5db85cc-838d-40fc-a08f-983e2963015b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_edf3cd8e-fee7-4f2b-bae4-3cb7da56e51c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_26429428-9ef1-47d7-90cc-f345882c97e5;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,902</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_261c32f6-80e4-43ac-b52b-25b87d6e73cb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="-sec-ix-hidden:F_8adfe637-2df8-4137-b76b-d02b023f34c0;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,902</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_7a05c076-4b13-4782-980f-f1db531e3014;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_1ae67987-286c-4292-ad79-4c71735dd6d9;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b98a551e-dc71-4388-aafc-fbc75338dd46;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_382c332e-e576-4e25-b8f8-144ea2ba7f4f;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_40e58eda-d3eb-4484-86f2-e1fe5a77793e;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_588625ea-79fb-4a9a-8abb-1ccf786357c5;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,964</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">412</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_1809098a-d0f5-4df3-8175-e912d38dfd37;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,376</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the balance sheets.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814421120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Major Components of Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major components of property and equipment are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Lives</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,328</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture/Lab equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,063</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,483</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software/Website</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,623</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,174</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,440</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,449</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,529</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814355200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Major Components of Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major components of intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.033%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:14.217%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.198%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.117%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.56%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.198%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Lives</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,043</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">911</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patent costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_93e3078f-8d95-4815-8772-dedb12df7e8d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trademark costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_76c75a36-7343-4618-abb0-0a79d6e55a20;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,132</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,401</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Major components of intangible assets as of December 31, 2023, are as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.65%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:11.202%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.902000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Lives</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Amortization</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License agreements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,043</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,134</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Patent costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">959</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_cfc4d707-5861-482b-84d7-64104ba53727;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">959</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trademark costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b8f1c0ca-aab8-4e72-a961-0a1daf3f73fb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8211;</span></span></span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,196</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">909</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,287</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense for Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future amortization expense for intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is approximately as follows (in thousands):</span></p><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.88%;box-sizing:content-box;"></td>
        <td style="width:2.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:25.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">911</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501919554336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments Under the Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum payments under the operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows (in thousands):</span></p><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.823%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,533</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less interest (</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">% discount rate)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,447</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814763680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesRestrictedAbstract', window );"><strong>Equity Securities, Restricted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.18%;box-sizing:content-box;"></td>
        <td style="width:2.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:25.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>RSUs</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding (unvested) at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,239</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,394,774</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">566,904</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSU expired/forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,108</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding (unvested) at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">806,001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Schedule of Issued and Outstanding Options</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options vested (based on ratable vesting)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,713</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options unvested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock options outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options vested (based on ratable vesting)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,091</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options unvested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,695</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock options outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Option activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.98%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted <br/>Average<br/>Exercise <br/>Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,786</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.60</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,625</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.46</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_d44a448c-95da-42af-9268-94b3f97749eb;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_e72c3d8a-06d5-4f57-820b-ef886d45e808;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options expired/forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.09</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesRestrictedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesRestrictedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814352064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Tax Effects of Temporary Differences and Net Operating Loss Carryforwards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences and net operating loss (&#8220;NOL&#8221;) carryforwards that gave rise to significant portions of the deferred tax assets and deferred tax liabilities were approximately as follows at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and December 31, 2023 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carry forwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,870</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASC 842 Lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_59df80b9-4b23-4957-add5-f538f80c9bb3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_4dd0ce9c-9e6c-48e8-8f65-86135e742a26;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research &amp; development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,283</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,830</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,866</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrual to cash adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_08bd69a2-41d1-491f-a362-6162aa80c7fc;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_dc96f2f3-806d-4814-8f8e-b6e47d188ef7;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">466</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,167</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,014</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,776</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">391</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ASC 842 Right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">391</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities, net of valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_5f5fbe24-614b-499f-aced-c5af13aee5ae;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_fd5c8872-fbff-42c3-a6e0-bd84c28f075d;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reconciliations of the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.343%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal tax at statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State tax benefits, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_903b8dcc-7d05-4cc8-8ed2-00092d584312;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_9b1b95a1-5cfc-4117-a2c2-f442d0b99222;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917313472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following instruments (in thousands) were excluded from the calculation of diluted net loss per share because their effects would be antidilutive:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">806</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PSUs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,803</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,730</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,415</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917389984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Significant Expense Categories Provided to CODM</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company&#8217;s single reportable segment:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.953%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.903%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.903%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of revenues</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">508</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">488</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">R&amp;D costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,799</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">G&amp;A costs</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,869</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,002</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,731</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(5)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,973</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,413</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Contract Manufacturing and Clinical Trial revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Clinical Development, Research &amp; Discovery, CMC</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Executive, Finance, Legal, Business Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes compensation, benefits and equity-based compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes depreciation and amortization, (interest income) and other specific charges</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814363280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business, Basis of Presentation, and Liquidity - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business, Basis of Presentation, and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,973)<span></span>
</td>
<td class="num">$ (21,413)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(109,607)<span></span>
</td>
<td class="num">(84,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,232<span></span>
</td>
<td class="nump">$ 4,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501815388832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2024</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate202307Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 412,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Net unrealized gains and losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag', window );">Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options granted maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=lgvn_CustomerOneMember', window );">Customer One [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of contract manufacturing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 80: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgvn_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgvn_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820439984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Accounts and Grants Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Schedule of Accounts and Grants Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts and grants receivable</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=lgvn_AccountsReceivableFromCustomersMember', window );">Accounts receivable from customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Schedule of Accounts and Grants Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts and grants receivable</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=lgvn_NationalInstitutesOfHealthGrantMember', window );">National Institutes of Health &#8211; Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Schedule of Accounts and Grants Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts and grants receivable</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=lgvn_AccountsReceivableFromCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=lgvn_AccountsReceivableFromCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=lgvn_NationalInstitutesOfHealthGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=lgvn_NationalInstitutesOfHealthGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501815473136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Schedule of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 2,392<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgvn_ClinicalTrialRevenueMember', window );">Clinical trial revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Schedule of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgvn_ContractManufacturingLeaseRevenueMember', window );">Contract manufacturing lease revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Schedule of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">503<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgvn_ContractManufacturingRevenueMember', window );">Contract manufacturing revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Schedule of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">487<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgvn_NationalInstitutesOfHealthGrantMember', window );">National Institutes of Health &#8211; Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Schedule of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgvn_ClinicalTrialRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgvn_ClinicalTrialRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgvn_ContractManufacturingLeaseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgvn_ContractManufacturingLeaseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgvn_ContractManufacturingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgvn_ContractManufacturingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgvn_NationalInstitutesOfHealthGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgvn_NationalInstitutesOfHealthGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820340864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Accrued interest receivable related to marketable securities and money market funds</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized losses marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebtAmortizedCost', window );">Securities of amortized cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebtAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investments in debt securities classified as trading.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebtAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820381424">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,902<span></span>
</td>
<td class="nump">$ 4,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,902<span></span>
</td>
<td class="nump">3,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate bonds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate bonds [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate bonds [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate bonds [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,877<span></span>
</td>
<td class="nump">3,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,877<span></span>
</td>
<td class="nump">3,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AccruedIncomeReceivableMember', window );">Accrued income [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AccruedIncomeReceivableMember', window );">Accrued income [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AccruedIncomeReceivableMember', window );">Accrued income [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AccruedIncomeReceivableMember', window );">Accrued income [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Schedule of Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the balance sheets.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_AccruedIncomeReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_AccruedIncomeReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501819842928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Major Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Major Components of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">$ 7,623<span></span>
</td>
<td class="nump">$ 6,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Less accumulated depreciation and amortization</a></td>
<td class="nump">5,174<span></span>
</td>
<td class="nump">4,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 2,449<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Major Components of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">$ 4,402<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Major Components of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">$ 3,063<span></span>
</td>
<td class="nump">2,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Major Components of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Website [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Major Components of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total Property and Equipment</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814327392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820697312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Major Components of Intangible Assets [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to intangible assets</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Major Components of Intangible Assets [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Finite lived intangible assets, wrote-off</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag', window );">Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501815891376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Major Components of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Major Components of Intangible Assets [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 3,533<span></span>
</td>
<td class="nump">$ 3,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,132)<span></span>
</td>
<td class="num">(909)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total</a></td>
<td class="nump">$ 2,401<span></span>
</td>
<td class="nump">$ 2,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Major Components of Intangible Assets [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 2,043<span></span>
</td>
<td class="nump">$ 2,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,132)<span></span>
</td>
<td class="num">(909)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patent costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Major Components of Intangible Assets [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademark costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Major Components of Intangible Assets [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820605920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Future Amortization Expense for Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Schedule of Future Amortization Expense for Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501815874576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="nump">$ 882<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease costs</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501919505520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Payments Under the Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Minimum Payments Under the Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less interest (5% discount rate)</a></td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 1,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917405792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Payments Under the Operating Leases (Parenthetical) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Minimum Payments Under the Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Interest discount rate</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501727669408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2024</div></th>
<th class="th"><div>Jul. 19, 2024</div></th>
<th class="th"><div>Jul. 18, 2024</div></th>
<th class="th"><div>Jul. 17, 2024</div></th>
<th class="th"><div>Jul. 10, 2024</div></th>
<th class="th"><div>Jun. 17, 2024</div></th>
<th class="th"><div>Apr. 16, 2024</div></th>
<th class="th"><div>Aug. 16, 2023</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
<th class="th"><div>Apr. 08, 2024</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th"><div>Nov. 15, 2023</div></th>
<th class="th"><div>Dec. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,565,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.09<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 24,  2026<span></span>
</td>
<td class="text">Jul. 17,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PaymentPerWarrant', window );">Payment per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_SeriesBMember', window );">Series B warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Aggregate gross (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_SeriesAMember', window );">Series A warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesAAndSeriesBWarrantsMember', window );">Series A and Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_PreFundedWarrantMember', window );">Pre Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants or rights exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 10,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_ClassACommonStockWarrantsMember', window );">Class A common stock warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PaymentPerWarrant', window );">Payment per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesCWarrantsMember', window );">Series C warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesDWarrantsMember', window );">Series D Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesCWarrantsAndSeriesDWarrantsMember', window );">Series C Warrants and Series D warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JuneInducementWarrantsMember', window );">June Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan', window );">Deemed dividend to common stockholders (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JulyPrivatePlacementMember', window );">July Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JulyOfferingPlacementMember', window );">July Offering Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JulyOrdinaryCoursePlacementAgentMember', window );">July Ordinary Course Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueConsensusPricingModelMember', window );">Black-Scholes pricing model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_WarrantsToPurchase', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants or rights exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 12,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">3,395,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,802,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,563,764<span></span>
</td>
<td class="nump">4,967,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,020<span></span>
</td>
<td class="nump">501,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PercentageOfAggregateNumberOfShares', window );">Percentage of aggregate number of shares</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split</a></td>
<td class="nump">162,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PaymentPerWarrant', window );">Payment per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PercentageOfAggregateNumberOfShares', window );">Percentage of aggregate number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Series B warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Series A warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Placement agent warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PercentageOfAggregateNumberOfShares', window );">Percentage of aggregate number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 18,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Pre Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,572,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Class A common stock warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,799,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Series C warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,349,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 18,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Series D Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PercentageOfAggregateNumberOfShares', window );">Percentage of aggregate number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_ExerciseOfRemainingShares', window );">Exercise of remaining shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | June Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,395,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 18,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | June Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 18,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Placement Agent Warrants June 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 18,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | July Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | July Offering Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 20,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | First Tranche July Ordinary Course Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 17,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Second Tranche July Ordinary Course Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 24,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,212,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series D Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PercentageOfAggregateNumberOfShares', window );">Percentage of aggregate number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,435,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Stockholders shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="nump">3,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,970<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Class B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Stockholders shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,555)<span></span>
</td>
<td class="num">(3,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public offering [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public offering [Member] | Class A Common Stock [Member] | Underwriters Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_UnderwritersMember', window );">Underwriters [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_TwoThousandTwentyOnePIPEOfferingMember', window );">2021 private placement offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_TwoThousandTwentyOnePIPEOfferingMember', window );">2021 private placement offering [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_TwoThousandTwentyOnePIPEOfferingMember', window );">2021 private placement offering [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="nump">$ 114,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Aggregate gross (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="nump">$ 114,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_TwoThousandTwentyOnePIPEOfferingMember', window );">2021 private placement offering [Member] | Class A Common Stock [Member] | Underwriters Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  01,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_October2023RegisteredDirectOfferingMember', window );">October 2023 registered direct offering [Member] | Series B warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_October2023RegisteredDirectOfferingMember', window );">October 2023 registered direct offering [Member] | Series A warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_October2023RegisteredDirectOfferingMember', window );">October 2023 registered direct offering [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_October2023RegisteredDirectOfferingMember', window );">October 2023 registered direct offering [Member] | Class A Common Stock [Member] | Placement agent warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 11,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_December2023OfferingMember', window );">December 2023 registered direct offering [Member] | Underwriters Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_December2023OfferingMember', window );">December 2023 registered direct offering [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_December2023OfferingMember', window );">December 2023 registered direct offering [Member] | Class A Common Stock [Member] | Placement agent warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_December2023OfferingMember', window );">December 2023 registered direct offering [Member] | Class A Common Stock [Member] | Investor warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 22,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_December2023OfferingMember', window );">December 2023 registered direct offering [Member] | Class A Common Stock [Member] | Underwriters Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember', window );">New Warrant Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,319,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember', window );">New Warrant Shares [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_AprilTwoThousandTwentyFourPublicOfferingMember', window );">April 2024 Public Offering [Member] | Class A Common Stock [Member] | Placement agent warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  08,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_AprilTwoThousandTwentyFourPublicOfferingMember', window );">April 2024 Public Offering [Member] | Class A Common Stock [Member] | Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear', window );">Expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 10,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_JulyRegisteredDirectOfferingMember', window );">July Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering', window );">Public offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_JulyRegisteredDirectOfferingMember', window );">July Registered Direct Offering [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_ExerciseOfRemainingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_ExerciseOfRemainingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_PaymentPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_PaymentPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_PercentageOfAggregateNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_PercentageOfAggregateNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_WarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_WarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration, mandatory redemption, or due date, in YYYY-MM-DD format, of the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_SeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_SeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_SeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_SeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesAAndSeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesAAndSeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_ClassACommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_ClassACommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesCWarrantsAndSeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_SeriesCWarrantsAndSeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JuneInducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_JuneInducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JunePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_JunePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JulyPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_JulyPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JulyOfferingPlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_JulyOfferingPlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_JulyOrdinaryCoursePlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_JulyOrdinaryCoursePlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueConsensusPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueConsensusPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_PlacementAgentWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_PlacementAgentWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_UnderwritersWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_UnderwritersWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lgvn_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_TwoThousandTwentyOnePIPEOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lgvn_TwoThousandTwentyOnePIPEOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_October2023RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lgvn_October2023RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_December2023OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lgvn_December2023OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lgvn_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lgvn_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_AprilTwoThousandTwentyFourPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lgvn_AprilTwoThousandTwentyFourPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lgvn_JulyRegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lgvn_JulyRegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501724684720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 17, 2024</div></th>
<th class="th"><div>Jun. 17, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm', window );">Stock option expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Unrecognized equity based compensation</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 15.09<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
<td class="nump">$ 3.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=lgvn_StockOptionAwardFourYearVestingPeriodMember', window );">Stock Option Award Four Year Vesting Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Employee tax liabilities shares</a></td>
<td class="nump">142,306<span></span>
</td>
<td class="nump">5,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares (in Shares)</a></td>
<td class="nump">806,001<span></span>
</td>
<td class="nump">11,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option issued and outstanding (in Shares)</a></td>
<td class="nump">121,186<span></span>
</td>
<td class="nump">43,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Unrecognized equity based compensation</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Unrecognized equity-based compensation term</a></td>
<td class="text">2 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Stock Options, Options granted</a></td>
<td class="nump">88,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option issued and outstanding (in Shares)</a></td>
<td class="nump">121,186<span></span>
</td>
<td class="nump">43,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Unrecognized equity based compensation</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Unrecognized equity-based compensation term</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 15.09<span></span>
</td>
<td class="nump">$ 49.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options exercisable term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.79%<span></span>
</td>
<td class="nump">3.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options exercisable term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Equity Incentive Plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">RSUs vested</a></td>
<td class="nump">566,904<span></span>
</td>
<td class="nump">25,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of expiration of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgvn_StockOptionAwardFourYearVestingPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgvn_StockOptionAwardFourYearVestingPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501815626608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Schedule of RSU Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Schedule of RSU Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding (unvested) at December 31, 2023</a></td>
<td class="nump">11,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU granted</a></td>
<td class="nump">1,394,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested</a></td>
<td class="num">(566,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSU expired/forfeited</a></td>
<td class="num">(33,108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding (unvested) at December 31, 2024</a></td>
<td class="nump">806,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501922862480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Incentive Plan - Schedule of Issued and Outstanding Options (Details) - Stock Option [Member] - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Issued and Outstanding Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options vested (based on ratable vesting)</a></td>
<td class="nump">31,713<span></span>
</td>
<td class="nump">16,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Stock options unvested</a></td>
<td class="nump">89,473<span></span>
</td>
<td class="nump">27,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total stock options outstanding</a></td>
<td class="nump">121,186<span></span>
</td>
<td class="nump">43,786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917471856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plan - Schedule of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems', window );"><strong>Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Beginning</a></td>
<td class="nump">$ 4.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at ending</a></td>
<td class="nump">$ 15.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems', window );"><strong>Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options, Outstanding at Beginning | shares</a></td>
<td class="nump">43,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Beginning</a></td>
<td class="nump">$ 49.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Stock Options, Options granted | shares</a></td>
<td class="nump">88,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options granted</a></td>
<td class="nump">$ 2.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Stock Options, Options exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Stock Options, Options expired/forfeited | shares</a></td>
<td class="num">(11,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options expired/forfeited</a></td>
<td class="nump">$ 50.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options, Outstanding at ending | shares</a></td>
<td class="nump">121,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at ending</a></td>
<td class="nump">$ 15.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501724156480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 21, 2024</div></th>
<th class="th"><div>Oct. 24, 2023</div></th>
<th class="th"><div>Sep. 28, 2023</div></th>
<th class="th"><div>Nov. 16, 2022</div></th>
<th class="th"><div>Dec. 23, 2016</div></th>
<th class="th"><div>Dec. 22, 2016</div></th>
<th class="th"><div>Nov. 20, 2014</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenditures amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested', window );">Issued RSUs shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="nump">$ 638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,820,000<span></span>
</td>
<td class="nump">2,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392,000<span></span>
</td>
<td class="nump">709,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCashEquivalentsAtCarryingValue', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_TermsOfAgreement', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_MilestoneOfTriggeringPayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_MilestoneFeesPayable', window );">Milestone fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyExcessExpenseReimbursable', window );">Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalty fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_AnnualNetSalesPercentage', window );">Annual net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_NetSalesOfSubLicensees', window );">Net sales of sub licensees percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Initial fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedLicenseAgreements', window );">License agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_licenseAgreementTerm', window );">License agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_IncurredTerms', window );">Incurred term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP', window );">Employee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear', window );">Remaining costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lgvn_SupplyAgreementMember', window );">Supply Agreement [Member] | Secretome [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_AgreementTerm', window );">Agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_InitialStartUpPaymentReceived', window );">Initial start-up payment received</a></td>
<td class="nump">$ 242,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts', window );">Technology transfer, documentation preparation, training, and testing costs</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_ProjectManagementFees', window );">Project management fees</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_SuiteReservationFee', window );">Suite reservation fee</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PotentialAmountReceivableForEachProductLot', window );">Potential amount receivable for each product lot</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots', window );">Payments receivable for each additional product lot in excess of initial training run lots</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_MonthlyManufacturingSuiteReservationFee', window );">Monthly manufacturing suite reservation fee</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_HourlyFeeForProjectManagementServices', window );">Hourly fee for project management services</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_MarkupPercentageOnValueOfMaterialsCompensated', window );">Percentage markup on the value of materials compensated</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_OutsourcedTestingFeePerBatchReceivable', window );">Outsourced testing fee per batch receivable</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining', window );">Monthly payment receivable for in process samples and vialed harvests for training</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping', window );">Standard fee receivable for product packing, handling and shipping</a></td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService', window );">Increased fee for expedited or special hour service</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_AgreementTerminationDescription', window );">Agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Either party may terminate the agreement for cause and upon notice in the event of a material breach, within (i) 30 days of an uncured material breach that is not a payment default or (ii) 10 days for an uncured payment default. The Secretome Agreement further provides that either party may terminate the agreement at any time upon 90 days&#8217; notice to the other party.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lgvn_NondisclosureAgreementMember', window );">Nondisclosure Agreement [Member] | Secretome [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=lgvn_LongeveronMember', window );">Longeveron [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments to UM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lgvn_UMAgreementsMember', window );">UM Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments to UM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_MilestoneFeesPayable', window );">Milestone fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_LicenseMember', window );">UM License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments to UM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lgvn_firstPhase3ClinicalTrialMember', window );">first Phase 3 Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoanRestructuringTrialModificationsAmount', window );">Completion of trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lgvn_BiologicsLicenseMember', window );">Biologics license [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=lgvn_ChiefScienceOfficerMember', window );">Chief Science Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=lgvn_ChiefScienceOfficerMember', window );">Chief Science Officer [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Unregistered shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lgvn_SeriesCUnitsMember', window );">Series C Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Company value amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_AgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_AgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_AnnualNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual net sales percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_AnnualNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_HourlyFeeForProjectManagementServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hourly fee for project management services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_HourlyFeeForProjectManagementServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increased fee receivable for expedited or special hour service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_IncurredTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incurred terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_IncurredTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_InitialStartUpPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial start-up payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_InitialStartUpPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_MarkupPercentageOnValueOfMaterialsCompensated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Markup percentage on value of materials compensated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_MarkupPercentageOnValueOfMaterialsCompensated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_MilestoneFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone fees Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_MilestoneFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_MilestoneOfTriggeringPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone of triggering payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_MilestoneOfTriggeringPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_MonthlyManufacturingSuiteReservationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly manufacturing suite reservation fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_MonthlyManufacturingSuiteReservationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly payment receivable for in process samples and vialed harvests for training.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_NetSalesOfSubLicensees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales of sub licensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_NetSalesOfSubLicensees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_OutsourcedTestingFeePerBatchReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outsourced testing fee per batch receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_OutsourcedTestingFeePerBatchReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments receivable for each additional product lot in excess of initial training run lots.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_PotentialAmountReceivableForEachProductLot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential amount receivable for each product lot.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_PotentialAmountReceivableForEachProductLot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_ProjectManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Project management fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_ProjectManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of option right of use vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standard fee receivable for product packing, handling and shipping.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_SuiteReservationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Suite reservation fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_SuiteReservationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technology transfer, documentation preparation, training, and testing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_TermsOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_TermsOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_licenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>license agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_licenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends paid on stock held by an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyExcessExpenseReimbursable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of carryover of excess expense potentially reimbursable to adviser but not recorded as liability by investment company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyExcessExpenseReimbursable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of life settlement contracts accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 325<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481493/325-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 325<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481463/325-30-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanRestructuringTrialModificationsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financing receivable modified on trial basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 33<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-33<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanRestructuringTrialModificationsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost expensed and capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lgvn_SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lgvn_SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgvn_SecretomeTherapeuticsIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgvn_SecretomeTherapeuticsIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lgvn_NondisclosureAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lgvn_NondisclosureAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lgvn_LongeveronMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lgvn_LongeveronMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lgvn_UMAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lgvn_UMAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lgvn_firstPhase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lgvn_firstPhase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lgvn_BiologicsLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lgvn_BiologicsLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=lgvn_ChiefScienceOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=lgvn_ChiefScienceOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lgvn_SeriesCUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lgvn_SeriesCUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501724196384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits Plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefits Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company contributed amount</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501814882784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal taxes</a></td>
<td class="nump">$ 43.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State taxes</a></td>
<td class="nump">$ 40.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Ownership change more than percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgvn_OwnershipMember', window );">Ownership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Ownership change more than percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgvn_OwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgvn_OwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501815930544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Tax Effects of Temporary Differences and Net Operating Loss Carryforwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 10,870<span></span>
</td>
<td class="nump">$ 7,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_DeferredTaxAssetsLeaseLiability', window );">ASC 842 Lease liability</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity based compensation</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research &amp; development expenses</a></td>
<td class="nump">4,283<span></span>
</td>
<td class="nump">3,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrual to cash adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">18,248<span></span>
</td>
<td class="nump">14,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(18,014)<span></span>
</td>
<td class="num">(13,776)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_DeferredTaxLiabilitiesRightOfUseAsset', window );">ASC 842 Right-of-use asset</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(307)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax assets and liabilities, net of valuation allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820449232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax benefits, net of federal benefit</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(26.50%)<span></span>
</td>
<td class="num">(26.70%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501816108640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Schedule of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Schedule of Diluted Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7,730<span></span>
</td>
<td class="nump">8,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Schedule of Diluted Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">PSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Schedule of Diluted Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Schedule of Diluted Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Schedule of Diluted Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">6,803<span></span>
</td>
<td class="nump">7,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PhantomShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PhantomShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501917207056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The company&#8217;s measure of segment profit or loss is net loss. The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company&#8217;s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration', window );">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</a></td>
<td class="text">Operating Expenses<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment Reporting, Expense Information Used by CODM, Description</a></td>
<td class="text">Operating expenses are used to monitor budget versus actual results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45501820385952">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Significant Expense Categories Provided to CODM (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,392<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">508<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,137<span></span>
</td>
<td class="nump">9,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,269<span></span>
</td>
<td class="nump">12,184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,973)<span></span>
</td>
<td class="num">(21,413)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember', window );">Reportable Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">508<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,799<span></span>
</td>
<td class="nump">5,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">G&amp;A costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">5,646<span></span>
</td>
<td class="nump">6,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgvn_PersonnelCosts', window );">Personnel costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">9,002<span></span>
</td>
<td class="nump">7,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">410<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (15,973)<span></span>
</td>
<td class="num">$ (21,413)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Contract Manufacturing and Clinical Trial revenue</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Clinical Development, Research &amp; Discovery, CMC</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Executive, Finance, Legal, Business Operations</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes compensation, benefits and equity-based compensation</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes depreciation and amortization, (interest income) and other specific charges</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgvn_PersonnelCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgvn_PersonnelCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-!!Z(4T*^2]:5N<._!X*RX+3M Z&.TCCK/J+7VL0:P%#IR/ JP.\?P2X04>
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MD$U$Z*8H2GVSW:!Y1[78K-H&6VIM;,HV>.9,O\;VE2;0+C&K1@FFS7\W*'7
MLNH8;*FU82G'X)E3_%7Z4;?0:F8RSN:R>].;A@V*'3-%YJB=J>W#-7C*-7CF
ME+ZF-EU TX1^/\UQIDW8-LAT3H"8XW:&M0]KX"EKX&UE#60K1&/H\N>4Z6F9
M=<!''>(P)" C/9H4U-*SZ@]LJ;7I*7_@;>4/IBF&JG99%O!SH6^69IVN%RWF
ML)UA[<,6>,H6>%O9@JN4L+GHQ#Z! E\86ZA9L).:57=@2ZU-3;D#;RMW</6Z
M_HZJFCK2(C.K=7=J5CV!+;4V,^4)O*T\P4/YG,0ANDXHUKY4,:OL^G;=JMJD
M5AM(-;&:Y^7"]0)_.#P.SOHO&CJ^2OA]<X9>TQE%$=Q'<;#Z@.12A'OM=-CE
M!DGW=."BNV_H!-KSZ(5D^G9I%MEY <(^\G]?Y?_^5OF_GN+34I><7FZ0G)8Q
MF-:!IYWR,,?N#&\?+L!7+L#?R@4T\,;B&[CU)_!16G!FN<\Q3F,M-*MNP)9:
M&]K:^J&MW$ #K9GC>&#T)<Y"?</=\!+A5HO-[DJA?=@!7]D!?RL[T&![H 7'
M"?I/G'=."FU0]'W7UTZLF>-VYK8/9^ K9^";,WK9)D>,X&Y,9H%WOC/0K2,<
MF^-VQK0/"^ K"^";4_=;*M_E+6AFFNS>('+JG!XZPT#?\5OU +;4VK24!_#-
M*?M3S!/HLV;(]=X]OT=3$I8,ZID6F5EIG& 8;4<HI&D*&7'!:?CS .68H1><
ME 3][APYCHMRL+7% C-]0F+5*-A2:Z-51L$WI_9@#R(Y-_26/M-$2]0L</OI
MZYV6DE5K8$NM34E9 ]]L#58U#@Q5N,#9G'2^"MT@=#>:3D;_UO*R:@1LJ;47
MVBJS$&Q81U2ONNJBM"'\,V9AF:(DR76DS,$[K[C=AR$(E"$(S-G[BM1US%)T
M,]'",BL<#X=:2E8S?UMJ;4HJ\P_,J?J*DA@VQ52&%I-9XD_,^(RR"&S#DY:7
MU:3?EEJ;ETKZ W."ON)UG\=9%RZS0AV)X#^^(+JUNP7Z1M "OQ"$Q=5()$_$
M85C-S(E!Y1DG6*RVD3M/"C& WU+H/%\( ]F;+#Q"[T3,'[\-/<_Y6$_IR6_N
MQ_<(RX@)"8G(CYHM'7(3"GSP#^0%&4GDU'&A[@NB:$ZJE[J0NLM!?D&3B+!"
MB+LG'Q'YNQ3=N9 *<;% LX0N"P3U Q$<+H2"T.9+BMX(9@6**PQYM?B*B*TJ
MO][9@=1;OZF,<E*@=R%-Y!:F%Y*\B7U0A#&!BXHBK@&8-9!5858TCH 7HB6#
MDLD'<R W,D7B^8BC\A$4%1&=#)+5+.-HAF.6O!V( HG9YQ1.8.)4^#F'6_Q%
M(J?UY&&-I'Y(6SP<Q:(HD^JIQ.)/\V3D&>*0O2> 9,%"*O?*B >\C/E"ULDR
MDZ_ <@:6-\X3>"ISDL&=)/!$Q!N(7#RN^AI?,EF=94V7]SU*X:HAUJY<,K>C
MG?N-O6R06=LA8_:HNO08_?@L(6O7R9GU=IT,M:HVL:769JF<<%!92*L[MP*;
M)G=L56UB2ZW-4UGF8+M5=575G%;.;2I,6H'N2PY]72:<C):J33,\KM6.UR?9
M_>#$'YX.FTGVFM@^;'.@;'.PC=F];"$SMV:;SG9L56UB2ZW-4OGD8+B'UFS3
M X^MJDULJ;5Y*D<=;/6R[?]JS59?P-5JK=8<# +'&?RS,5NUU/VUW=CBU;;<
MU0ZID$A4JHW9S=%FY_Q([A?OJ].K;??@EN<QI%,)F4&H<W0"_32K=K)77SC-
MY=[N9\HY3>7'!<&0#HL3X/<9A32U_B(NT/S_!"[^!U!+ P04    "  +@%Q:
MJH>A=U,&  #X'@  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U986_;
M-A#]*X1;=!N0Q"(IR7+J&$B<#2NP;D&S;I]IF;:%2*)+4DZS7S]2<BRK/#%.
MZP]))/EX>8^^NW='31Z%?%!KSC7Z6N2ENAJLM=Y<#H<J7?."J0NQX:7Y9"ED
MP;2YE:NAVDC.%O6B(A^2((B'!<O*P712/[N3TXFH=)Z5_$XB514%DT\W/!>/
M5P,\>'[P*5NMM7TPG$XV;,7ON?Z\N9/F;KCWLL@*7JI,E$CRY=7@&E_.Z,@N
MJ"W^R?BC.KA&ELI<B =[\V%Q-0@L(I[S5%L7S/S9\AG/<^O)X/BR<SK8_T^[
M\/#ZV?MO-7E#9LX4GXG\WVRAUU>#9( 6?,FJ7'\2C[_S':'(^DM%KNK?Z'%G
M&PQ06BDMBMUB@Z#(RN8O^[K;B(,%..Q90'8+R+$+Z&X!K8DVR&I:MTRSZ42*
M1R2MM?%F+^J]J5<;-EEIO\9[+<VGF5FGIS<L9V7*T;WUH- Y^GQ_BWY^^\MD
MJ(UW:S-,=YYN&D^DQ],M3R\0Q6>(!"0$EL^.7TZ[RX>&TYX8V1,CM3_:XV]6
M2<E+C9A2AM@EQ*=Q$,(.;/Y<J@U+^=7 )(CB<LL'TW=O<!R\A]B=R%F'*]US
MI3[OTQE3:\3*!4KM!?]295N6&_(*8MVXBFI7-LFW4SPFU*1],!EN#QFYAN$X
M'!_:=<"&>["A%^Q')A^X9O.<UTCU$U(\K62F,P[B;;S%!S"^!>I:A)CTXHSV
M.",OSCO)-RQ;(/[5E$S%5;W!0J^Y-'EY&%L0Z,B!1(/$W6+ ;!3W(H_WR&,O
M\NLT%97Y]FO$*\GLI>0I-U%A=AV"&SLXDM!%ZUIAC'O1CO9H1UZT?PO-\B.V
M=.3^]W%, )BN892$22_.9(\S>2$>C'9*$ZYV5VWD;HR:Z3-4<@W!31P4).QF
M3X,6L(M(?Y:-]VC'7K0?2LW*56:SK-G27J!C &B 7:" '4E&O4!QT"I0X(7Z
ME]E6IK-RA7)N!+G!"^I/X(9I A0NP X3TA^I^$ LL1]JG?[],;I;WMFD $+H
MVN$Q[0?8BA[VZLPNF3P "1!N4024)L#2%-51?Q[A5JTP/4J:\XS-L[PN_* ^
M8Z_JO5:@3^6M2[I5/>R7O7U1WK"GOC*,724; R4#,(NIYXMI%0_[)<]@E!5O
M)0_$Z&H6KI/00>D:$ASUZS)NY0W[]>TY?C9"UJ. 6"+Q30UY#JTGD((K9#&A
M  /7+O)E::MXV"]YMWS)#86%4>4M+RLX%EP9"Z%=!M0NZ&\A<*MVV"]W75D^
M2%40+*1B8&EV#6F2],L=;O4.C[U%Y0]1KLXUE\7+9<6KG*\N*R?RUAUR6O$D
M?O%L:7]O-A! 5:&V"K##H:>O(JVJDF-4]840(X"TQA$ T[7K W@P2AZCJCD4
M82!40#J#!"CDD*%W2UN))?Z)<(?X!9S43<9X!+1^@&%$:7_O1UI5)'Y5G(FB
MR+1MI)MI)16EC5M>I@8S^OE/H3D:@X<1?L=PWB%P</]Q1UWRK=R2R%NR[K5(
M']8B7W"I?D*_UL,P?%#AE>U7GU2<R%N7=:O>Q*_>9J[>J9^R_,_0V^ B"+#I
MBR3:LKSBR%0OI-9,\C,4G9D@LS_- Q,DE5X+F?W'%V:@$<]/,Z5LWU)/Z)56
M9O19V.K'-+HU<V\Q-PZ?3Z9JHV^?4G#7O3Q>$V$_[JB[UVVC0?R-QO5BD5E1
M,+7 GF6<9R5*V28SM0$D#(S8%-?UR*D(KNG8M(']S1%I&P_B;SSJK$"JFJM4
M9AO='!?[#B^(VU,X<%V3<UOG>M&V;0?QS]FF9:Z**F?:A-^"+[,T T=7XD[/
M!L X#D; W@*V23CNGLATSPG;=H'ZVX5&%]1!X7GW)B%X]'YW%@<>&+K"3W"2
M ,@!RW@4]@_>M&T1J+]%</2L3N-7\@ Z"'CV!2S]LR]M6PGJ;R5FN1G.T36R
MPF<BNPYV$.Q)#Z=/Y:U+^N!XVC_P'RUT]*03_ZF\=5FWO0U]N;<Q7W$=I(VR
M@93=81X#LRADUA^.;0M"_1-_$XXWIN]JL8(H3]J!G,I;EW3;@=#X1.'X'<+M
M87TB;UW6;2] _;W D>$X<E\/ ='X@E4#<7CP6M*^$_[(Y"HKE1E*EV99<#$R
MZV7SFK6YT6)3OZF<"ZU%45^N.3-?DS4PGR^%F0=V-_;EY_YE]_1_4$L#!!0
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MP@3HXPO.U>O O,(7GVS^?U!+ P04    "  +@%Q:B?ZTA]H%  #%'0  &
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M $B4=X;EB^+[XMKMB2O%D^)QQRCL+G,#^'W#N3J]Y!W4-[>K?P!02P,$%
M  @ "X!<6G]AI$96 @  K04  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6RM5&UOTS 0_BM6F!!(K'EM!Z6)U'9,3&*H6AE\0'QPDVL3S2_!=MOQ[SD[
M:=:-MO"!+XGO?,]SSYWM&VVENM<E@"$/G F=>J4Q]=#W=5X"I[HG:Q"XLY2*
M4X.F6OFZ5D +!^+,CX)@X'-:"2\;.=],92.Y-JP2,%-$KSFGZM<$F-RF7NCM
M'+?5JC36X6>CFJY@#N:NGBFT_(ZEJ#@(74E!%"Q3;QP.IXF-=P%?*]CJO36Q
ME2RDO+?&=9%Z@14$#')C&2C^-C %QBP1ROC9<GI=2@O<7^_8KUSM6,N":IA*
M]JTJ3)EZ;SU2P)*NF;F5VX_0UM.W?+EDVGW)MHGM8W"^UD;R%HP*>"6:/WUH
M^[ '" =' %$+B)X#DB. N 7$KM!&F2OKDAJ:C93<$F6CD<TN7&\<&JNIA#W%
MN5&X6R'.9'-##>"I&$WDDDPEQ[M0VD/: /DDM2;GY&Y^25Z=O29GI!+D2RG7
MFHI"CWR#Z2V)G[>I)DVJZ$BJ,"(W4IA2DP^B@.(I@8^Z._'13OPD.LEX"7F/
MQ.$;$@51<D#0]-_A\0DY<=?+V/'%?^OEGZV\%KGD0+Z/%]HHO+H_#K6O84\.
ML]OG/-0US2'UD%B#VH"7O7P1#H+WATK_3V1/&I%TC4A.L6>?<?HPO#R'BFR0
M?8>T(V:3G8?]=Q?8_\V^_ -A49B$CV&-,'_OYG-0*S<0-,GE6ICF'G7>;N:,
MW5-[YI_@+&I&QR--,\ANJ%I50A,&2Z0,>A<H2C7#H3&,K-W[6DB#K]4M2YRG
MH&P [B^E-#O#)N@F=/8;4$L#!!0    (  N 7%IZ=Y0+O D  /M7   8
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULO9QK<]LV%H;_"D;M=-.9*"+ JU+;
M,XG$2V=VMQZ[Z7Z&2<CBAB)5DI+3_OH%*5H4 0@2DY/]DEC2P7- \!4 O3SD
MS4M1?J[6C-7HRR;+J]O)NJZW[V>S*EZS#:W>%5N6\T]61;FA-7]9/L^J;<EH
MTC;:9#-B&,YL0]-\<G?3OG=?WMT4NSI+<W9?HFJWV=#RKX\L*UYN)WCR^L9#
M^KRNFS=F=S=;^LP>6?UI>U_R5[,C)4DW+*_2(D<E6]U./N#WD>DV#=J(/U+V
M4IW\C9I#>2J*S\V+7Y/;B='TB&4LKAL$Y?_MV8)E64/B_?BS@TZ..9N&IW^_
MTH/VX/G!/-&*+8KL/VE2KV\GW@0E;$5W6?U0O$2L.R"[X<5%5K7_HI<NUIB@
M>%?5Q:9KS'NP2?/#__1+-Q G#;!YI@'I&A"A <%G&IA= _/:!E;7P!(;6&<:
MV%T#6VS@GFG@= T<L<&Y47*[!J[0P#K7):]KX+5G]W ZVG.YI#6]NRF+%U0V
MT9S6_-$*HFW-3V&:-]I]K$O^:<K;U7>/-:T9UV)=H6*%'NLB_KPNLH25U3^0
M_^<NK?]"4_3I<8G>_/@S^A&E.?I]7>PJFB?5S:SF'6@PL[A+]O&0C)Q)]GM1
MTTS1;*%OMB@V&R[SMG-HD=&J0A\4E.5HRD<%Q==3'G=/55RFV_:+]\!BEN[I
M4\84H$ /^I D:0.A&;JG:3+]-4<+NDW5 Q1>8,7Q;K/+^)E,T)*MTCBM%9#H
M>LAO]9J5B(\8GP_7S42U9^C-/XNJ^AF%?#X<PF=<<D?=D:/N2)O-.I/M(\UH
M'C-$:][C^!TR\5M$#$)4HCJ0[);4S,7[.V+8AGDSVY]J2(["PXCEQ0A?CIAB
MPQ@&!7*09[JF@ H5*(>XKM#K2!%FVNXQ:#"VYG%LS:O&]@W_MCZN:<GX:;MF
MG+749A%]7VUIS&XG7!45*_=L<O?3#]@Q?E%]I0\PY^3 '$Q<DPCG1 [#EC?'
MQEPX,Y!]"R!A(20L H(-9&,=96-I9;,H\CV?]YN)C2\%W0R)XL.T6;73)M\K
MO4[ PP].I*92EC;Q6&59DF1,V[8%7<E!4SG*A^Q7  D+(6$1$&R@*ONH*ENO
M*H5<WJ*TJG9\G6GT]/#XJ4)[5C7KS@49:3.-E9$M*838IN$).H),Z4/" DA8
M" F+@& #N3E'N3E?(;<URPYBJ^D7QG>Z^:GJ5$ISY.D#NY:PX]#V9.2@+2%A
M/B0LN&8L0LB,$1!L("#W*" 76D"7IBUMPK'3EBN?#9L085NYA$SI0\("2%@(
M"8N 8 /5>4?5>:-5=[I('MXH&R.F^:&^8F6:/[]%.:N;O5H3V.[XXZ*J+ZE1
MVY&Q:O3D[;OAV<(OIB5D2A\2%D#"0DA8! 0;J'%^5./\J]7(Q96D)8MKM,UX
M_M8Z4@M1);ZYI!?;-(4]UT+;N;'K*B3,AX0%UXQ%")DQ H(--(6-WFDT_@^J
MNC2]Z3LQ=G[K:(,?FRXQ3'&& \WJ@]("4%H(2HN@:$-)GIC?6"O)@\,];2Y^
M)(TNMRRO:./**I6%Y5^,AFAH+?09Q\Y>H#0?E!9<-1XA:,X(BC;42V]:8[UK
MO4SW:<+R!-&Z+M.G7=UX_Z@N4%*\Y*@L=ORC%:/UKF3-Q$4,@M$++4O*IS.E
MI+3I1D]6D+0E*,T'I04=[51Z[EQ<.A5!4RDJ@NK84%&]58_U7OVEC3]/NN*J
MXJ^T.I)M=/% %_J.C%8'),T'I057C$8(FC&"H@U%U!OW^()S/UI$%W=1H(X]
MEMUX>TXL<0\%F=,'I06@M!"4%D'1AN+K_7VL-_@?6'/5B'6JJ[996A]6PC1_
M1C3Y[ZZJF^W\1<6!FOM8=O==46YRB"-<'@+M4P!*"T%I$11MJ*'>M,=ZU_Y3
M7C*:I7_S&>J9<IV(VZMX3?-GUOQ*W-#R,_]5N*?9KMUBT3U-LS:LM<EHUD0U
MMFS[$U(I--G//KWBWND'U-L'I?F@M "4%H+2HHYFGSE50['U!C_6._S_YOK)
MBDHM#H6]3K"%Q6(3?8K1^@"UZT%I 2@MO')\(ZBL0XGT;CS6V_%GJI-,I61D
M#]QQ+2P*QKM8GG0YQ%?D4A0H*:+FV!.O$84JF&?-/4L\%]_#BL:]%XWU9O05
MU4SJ\P)IG2ZP[-9B@]C8$Z^\J0(MS[8=0SR7H&8R*"T$I450M&&A8>\[DPN^
M\_>K:])G'JLQ(IO-6*YL4D1-Y3 ?M&L!*"T$I450M*&\>@^9Z#UDR (G?:K1
M>I(-6MMQYH;XPQLTJP]*"T!I(2@M@J(-A7=20:TWHX%*G8C")C4MH?YVH>_+
MV TO*,T'I057C4<(FC."H@V5U)O09+P)_8TU3_J,HV<RV=&=8HN8AB-.9:"V
M-"@M *6%H+0(BC848&]@D_$&]F -O1^A/%#KFLC6M6<0\?(_:$X?E!: TD)0
M6@1%&\JNMZ[)U]2FR_/>_8455':2IUAT%/5=&;V @M:E@]*":X8C!$T90=&&
M.NKM:P)3=#YF%H,T4A=$4<-M$D]:/4%]:E!: $H+06D1%&THO][0)A=*UHOL
M]5;P8O5Z'>[T/M52=Y_J1R)[LI*GN-!W8?3T!6IX=S1;=P !:,H0E!9!T8;Z
MZ=UNHG>[1U7!$=DU)GPJ$>4"60N]!*7YH+3@JO$(07-&4+2A7GI'GGQ3>?AV
M]Y2E\86[%)324ECG?)%R1&W-I:^[Y&B!5GV#TH(S1RG638(FC:!HP_O1>PO>
M_*;2[ZL4<VG'I._"V!V3*;OLEF5Y[ERZ@1VT\AN4%H#20E!:!$4;*K)W[<WQ
MKOU!D>V6_5@GQ[ZP,D[YPGC]-&;*MCMV\%R\(MR%#9XC(6H+U)@'I07JHQ0O
MAX:@22,HVE TO>-NCG?<OT(T%V<RT*IP4U$K;9FV(SYB8PF:U@>E!:"T$)06
M0=&&HCQYV(O>O%\RMN'+:/)Z:\)//W@$XU]>U<C7UV1WN*/JL, JZY[T.49+
M#K34')3F@]("4[XPX3GB_:^A(FHJAT5071L*J3?A3;T)#U3(J\\R6DJR_^XX
M<U<TX$&3^J"T )06@M(B*-I0<KT!;^H->%TIIJFRD>VY^ 2MA3[%Z,D&U%@'
MI06@M/#*\8V@L@XETGOKIMY;/U.*:2DE(]<+$^QYXJ4819A8@+I4Q8B/) /U
MMY6=PI8GK25RW!0;<\=PQ?/V/4QILS>E3;TI?479IOH<@CXMQ51XVZ9EN)98
MH+M415J>91AB81UH!P-06@A*BZ!H!P7-3AY2VCP6]U^T?$[S"F5LQ?'&.Y=+
MNCP\:?;PHBZV[7-+GXJZ+C;MGVM&$U8V ?SS55'4KR^:1Z$>G_=[]S]02P,$
M%     @ "X!<6B;>F:_: @  ^P<  !@   !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6RM5=%.VS 4_96K#&U#8B1-FHRQ-E(I3-L#4D7']C#MP4UN&PO'#K;3
MPM_/=M*L0%M@VDMB._<>GW-BWSM8"7FC"D0-=R7C:N@56E>GOJ^R DNBCD6%
MW'R9"UD2;:9RX:M*(LE=4LG\, @2OR24>^G K4UD.A"U9I3C1(*JRY+(^S-D
M8C7T>MYZX8HN"FT7_'10D05.45]7$VEF?H>2TQ*YHH*#Q/G0&_5.QXF-=P$_
M**[4QABLDID0-W;R+1]Z@26$##-M$8AY+7&,C%D@0^.VQ?2Z+6WBYGB-_L5I
M-UIF1.%8L)\TU\70._$@QSFIF;X2JZ_8ZHDM7B:8<D]8M;&!!UFMM"C;9,.@
MI+QYD[O6AXV$7K(C(6P3PL<)_1T)49L0.:$-,R?KG&B2#J18@;31!LT.G#<N
MVZBAW/[%J9;F*S5Y.IUJHM'\%:U S&&J1793"):C5._@XK:F^A[>3X@T 05J
MFA&F#N$#7$_/X?W!(1P Y?"]$+4B/%<#7QM&%M?/VMW/FMW#';OW0K@4!EK!
M!<\Q?PC@&RF=GG"MYRS<BWB.V3%$O2,(@["_A=#XY>G1'CI19V_D\*+G[-WI
M[J_13&EI3O/O;?8UZ/WMZ/:&GZJ*9#CTS!56*)?HI6_?])+@\S;I_PGL@1']
MSHC^/O1TS(A2,(*Q*$MS>YT50)6J,0=3BT"Y!6DOG3V)<Y24+XZ HW/.!A*>
M(61"Z:WG;._NKS6J 8L=F"V#RS0*XX&_W*(_[O3'+]*?-?K5IGYSAW(J35V#
MBAF.[C;Z53UC--NPXGD/XB>TPR#I=[P;;4^#>F'X:;NXI!.7_+,X^W-71$IB
M2PS>H<RHPOPE<I*G3$_B^)&<O<1>>Z;]C3I:HERX]J(,PYKKI@1UJUT'&[G"
M_6C]S'2VIA']A6G:XB61"\H5,)P;R.#XH]$GFU;33+2H7+6>"6UJOQL6ICNC
MM 'F^UP(O9[8#;I^G_X!4$L#!!0    (  N 7%I'<%UL&P<  -(@   8
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MZ8VNM"C1SH1VHWAEVVK-E6Y2NRST& 5A O3]AG.UWY@$_6!._P!02P,$%
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MSR_[>Z*?:-&ZLWDMM#GIW; V5RM(&V">ET+HW<1NX"_K_ ]02P,$%     @
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MM\,L#0&:+O;OUJ"?AKAL_>\';$CPYSMC\!"$ M,/K?H)4$L#!!0    (  N
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M'@:G91F?I0A8!%36".^]+"GH&N"&DP08Y3)\K?]@/QEU7K4&C#M0V<8$3OK
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MJ >,\)#?[TC1BI:(6O;6?H2Y1\/"!-)&CN:$ILPC8_O(I31,R-9G@N22-AX
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MD'9+(7^NR)"L%7E!GR4@8>6H;21"$%'[B0 *>G=@7X*6E($-@.066+S9U'/
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M=;Q4[TWDN'1)N;.:5CGYV<5;IN_1LK5 N,.\T=QR-+/0$K0S"/,.9M7")(_
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M#&JG0/]+12703]P&P\MH\0502P,$%     @ "X!<6HJ'ZU"8 P  :0@  !D
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MJQ>S))Z^<T"<*D,H1"3/Y4$;\+&2%%"0&CX*FQ:<\VD(*[HT!RH$+-=HNV*
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MA,/XMY ?"U;L@Z)]L?&\(.,,QRYBOL'!TX2SA[3@[,@!C?;X,^HR\,S6,%M
M#_;"?TECY<U@$_://1\<[1 \PA?) \\*QH-P+P6Q71XE4G#C,E/5 E1Y9 7
M)/Y=U()(&X(\1P2_B>4I.4O2@AW+^S@*P3[@_YO@/@:5/I19E.QHP$<>9# 1
M$- ,PI$?[D'Q*B29(T:JM <S[8-D!Y>ZCN_[0GK[I$!.L5RHZSE6GIE=GME8
M>;HO-.7Y/<BR( $WOA/)#*^4W[%/>5X&20BWWX";!&!P^!$EAZ@Y@KEJVT1)
M5$00 &+^X:HM)RU?X!7>]/6G+Y_I+_?U2X<&*$'K[)1%!:B<@>[@D1MVJD0!
MCSF6&2B<PY5'_.A.G<5\.J@,^F\]"KG]-YZ%48ZNH+L8A,TV2P_B$SP _W=
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M'GJQ8@%^3%Y!3,912%(IZL6=ZG4FY&/&'Z*TS+535C86^I1C:/JK-.:$M'=
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MYP$427@!_+Y-TZ+Z@ ^H7\K_[K]02P,$%     @ "X!<6OB:P.W0"   _QD
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M[QUU+N5SIE;VIP?$ 97C[N?;I^VO&]?N4G][W/TT\@M5L#-H(M@21 /_=#*
MO</^W.#>&%G:*_Z%-$;F]F7&8(HK/ "?+Z4TS1LTT/[F<_4_4$L#!!0    (
M  N 7%JT[[1]:A@  )!#   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;+U<6W/;QI+^*U,ZV5-RA9)%2K(=WZIDR5XE:\4^5KS[L+4/0V!(3H0+,P!$
M,[_^?-T],QB E')YV*J40Q+ 3$]?O[Y KS>UNVM6QK3J6UE4S9N#5=NN7SY]
MVF0K4^KFN%Z;"E<6M2MUBZ]N^;19.Z-S?J@LGLY.3IX]+;6M#MZ^YM\^N[>O
MZZXM;&4^.]5T9:G=]ITIZLV;@^E!^.&+7:Y:^N'IV]=KO32WIOVZ_NSP[6E<
M);>EJ1I;5\J9Q9N#B^G+=V=T/]_PW]9LFN2SHI/,Z_J.OOR8OSDX(8),8;*6
M5M#XW[VY-$5!"X&,W_R:!W%+>C#]'%;_P&?'6>:Z,9=U\3\V;U=O#EX<J-PL
M=%>T7^K-M?'G.:?ULKIH^%^UD7O/L&/6-6U=^H?QO;25_%]_\WQ('GAQ\L #
M,__ C.F6C9C**]WJMZ]=O5&.[L9J](&/RD^#.%N14&Y;AZL6S[5O+^NRM"VX
MW#9*5[FZK*O65DM39=8TKY^VV()N?)KYY=[)<K,'EIO.U U66#7J?96;?+C
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M*4S#4;0:;BO/[Q#ZI\@:;1M((9-G4]-DREXD]#LSCP3G>:88P2*NWNBJ6R
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M* D\$*DPA7^@X*P%ESQV+O2\AG76;AN2O1Z@^K4\4=%,SKURS75+F9Z/2&,
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M:9)4N@NYPT-27IFX#J,?7>DEPDD9E:@*Z0,@7=\(/EV04RJV*6!F"TF:0*&
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M6;3J&KZN5;?;*G<$Q(.V7'^\OHVHRU94;+1+[0_XJ$K^^/-5?% :1W>V_5X
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M;"]W;W)K<VAE971S+W-H965T,C0N>&ULG55=;]HP%'WG5UQETK1)+?F 4L0
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M-<+1_+1_/CJZF/#^N.$W12N_<2TXDIFUG_GF?7G:'S(ATE0$1I#XNZ<I:<U
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MQM66]R.)="]UDPJT,3@9[Z-"^K@P;P+W&-:5W<1%=O!&!(GGJIPFR%.(CQ5
M3>SW(-V"<+K8&'OZBH,'\^$\QGE!^2IK5 #965-BOT#Q?<.%"\VCYQUQCH9
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M6"M3Z)?PX:6I]![H.U>7+?V2-M,2VCQ^9/<SA=_=*J!J.J%1C+_DQ&9JOS$
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M4@,:C;&N7!G+*5FD=14CK2>G)^I[A/L;P7U#66 V6:$LDS,Q[4\D Y#Z">V
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M!AZDF+%2V >UO,'&GXI@HH2IOK"L97NQ!TEIK"H:96)0<%FO[+F)PYK"(/A
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M@*?5Q>=5O+H^?F%RQ>G,4TQ(U1U,*%5D=26K)EH4]AJT%)HN57:XIELL2B-
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MGDU&'JCNU>@V1C;NIMY(0_>^6Y;TT**R"B3?2FD.&^N@?[J7_P%02P,$%
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MG5]H2:(>W?5"\=).OSE7>I9:,]>O'0@3H/<7G*O-PB1HW\_D'U!+ P04
M"  +@%Q:,57^-H0&  "\*@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6R]6FU/XS@0_BM6[W2ZDQ;:N*6\'%2"9E>+M"P(CKL/J_M@DDEKD<0]VP'V
M=#_^QDE(:C9U-UK#%TA2S^.9Q_9XGL3'CT+>JR6 )D]9FJN3P5+KU=%PJ*(E
M9$SMBA7D^$LB9,8TWLK%4*TDL+@TRM(A'8VFPXSQ?# [+I]=R=FQ*'3*<[B2
M1!59QN37,TC%X\D@&#P_N.:+I38/AK/C%5O #>C;U97$NV&#$O,,<L5%3B0D
M)X/3X"@<4V-0MOB3PZ-:NR8FE#LA[LW->7PR&!F/((5(&PB&_QY@#FEJD-"/
M?VK00=.G,5R_?D;_4 :/P=PQ!7.1_L5CO3P9' Q(# DK4GTM'C]"'=">P8M$
MJLJ_Y+%N.QJ0J%!:9+4Q>I#QO/K/GFHBU@R"R08#6AO0%P:3Z0:#<6TP?F%
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M<,PCCE]'Z'Z^#Y.,1&*K'^=>3/6[*#U^<' \47)?;L%?2Z5D7![NA+\1:5%
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M-X9.B;V6>K;KCO=X>BV>MF<?D'A0\AP\(K%<9S<T]-%EE#"ZA2ASR==KB);
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MG"N+W>V7-<Y?T"X OR^4LMN-NZ"?Z,4O4$L#!!0    (  N 7%H3LF""- ,
M .<)   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+U6;6_3,!#^*U9
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M,* +";R_MI;V06C6PU-3_ 502P,$%     @ "X!<6A.BIFQI2@  3\\& !D
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MEDLMEUDNM]S"<H7E2LM5EJLMUUBNM5QGN9YQ6V$U:$68OEPKPM2V(E!N;KG
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M?QV*F^3I5UIN4#_CS9*0Y_^BIW*LU4&S-1=)5 ;+&40L+O[WGTLAM@*(LR>
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M[KGWG./X9KR1ZDX7 (;<EUSHB5<84YWZOLX***D^DA4(W%E*55*#4[7R=:6
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M/3[G.KG7XRT7#S('4.BQH$Q.G%RI]87KRB2' LL>7P/3*QD7!59Z*E:N7 O
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M==W6[58]\:8,+<[*>&J8PC"G#A4M;Z#OF3%^-V$';<\[_0=02P,$%     @
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M01H#[)\)H5]?S #UE=OX7U!+ P04    "  +@%Q:!4C>#%L#   ,%@  #0
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M%](4"R^:G^X#@BQO7O<M:V..H>R+O7"RW'WLM_M0\?._4$L#!!0    (  N
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M&^IM!'H;ZFT$>AOJ;01ZVVRSA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U
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M/SSSUM3=(9\-?S*:O0%02P$"% ,4    "  +@%Q:!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  N
M7%IE%E.4[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    (  N 7%J97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ "X!<6C7N8,KW
M"0  6T   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    (  N 7%JJAZ%W4P8  /@>   8              "
M@3H2  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  +@%Q:
MX WCM3<#  "^#0  &               @('#&   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ "X!<6HG^M(?:!0  Q1T  !@
M     ("!,!P  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M  N 7%I_8:1&5@(  *T%   8              " @4 B  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    "  +@%Q:>G>4"[P)  #[5P  &
M            @(',)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ "X!<6B;>F:_: @  ^P<  !@              ("!OBX  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (  N 7%I'<%UL&P<  -(@
M   8              " @<XQ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    "  +@%Q:/!\+(D,-  "T6   &               @($?.0
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ "X!<6NZ&"Y5*
M @  I 4  !D              ("!F$8  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    "  +@%Q:,_EJ/FD"  "X!P  &0
M@($920  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (  N
M7%K'QH26$ (  -P$   9              " @;E+  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ "X!<6@V KO28"@  O!L  !D
M         ("! $X  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    "  +@%Q:I=PV,V@<  #'5@  &0              @('/6   >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (  N 7%J?)#K]K0,  ",)
M   9              " @6YU  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ "X!<6H8H&>D7 P  Y@8  !D              ("!4GD
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  +@%Q:__"G
MG+D#   E"0  &0              @(&@?   >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    (  N 7%J*A^M0F ,  &D(   9
M  " @9"   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M"X!<6@57D9TQ$P  H%\  !D              ("!7X0  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    "  +@%Q:^)K [= (  #_&0  &0
M            @(''EP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    (  N 7%JT[[1]:A@  )!#   9              " @<Z@  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ "X!<6B>R_54T!P
MP1   !D              ("!;[D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    "  +@%Q:DS !&OP"  "D!@  &0              @(':
MP   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (  N 7%IW
M)HNS% ,  -8&   9              " @0W$  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ "X!<6K>DZMPT!@  F0T  !D
M     ("!6,<  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  N 7%J2<9S:7 ,  *@(   9              "
M@13U  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ "X!<
M6AU52->I @  Q@4  !D              ("!I_@  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    "  +@%Q:V#5"%X #  ##"0  &0
M        @(&'^P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   (  N 7%H4IQK_OP0  ",+   9              " @3[_  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ "X!<6M-^?ZZX @  O04
M !D              ("!- 0! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    "  +@%Q:8_3@X,\#  #&!P  &0              @($C!P$
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (  N 7%I<G1/O
MQ0(  $L'   9              " @2D+ 0!X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ "X!<6C%5_C:$!@  O"H  !D
M ("!)0X! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  +
M@%Q:+ZBA@.,"  #R"@  &0              @('@% $ >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (  N 7%IXLCQXF@,  ,,0   9
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M970T,RYX;6Q02P$"% ,4    "  +@%Q:$[)@@C0#  #G"0  &0
M    @(&@*P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M  N 7%I8.P-4W ,  ( 3   9              " @0LO 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ "X!<6MSRP\J  @  _08  !D
M             ("!'C,! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    "  +@%Q:S9:5C#D#   '#@  &0              @('5-0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (  N 7%I>Y% .EP(
M +L&   9              " @44Y 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ "X!<6G6\DM,> @  =@0  !D              ("!
M$SP! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  +@%Q:
M$Z*F;&E*  !/SP8 &0              @(%H/@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    (  N 7%H<4*=J- @  *9&   9
M      " @0B) 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ "X!<6I3$!XJ^ @  _08  !D              ("!<Y$! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  +@%Q:*0>$M)("  # !@
M&0              @(%HE $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    (  N 7%K%  <U<P,  ),-   9              " @3&7 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ "X!<6I9))*DZ
M%   ]28! !D              ("!VYH! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    "  +@%Q:+^J+8EL"  "^!0  &0
M@(%,KP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (  N
M7%J(VW'"EP(  (<'   9              " @=ZQ 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ "X!<6B["T39M!   %Q$  !D
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M=#8R+GAM;%!+ 0(4 Q0    (  N 7%H%2-X,6P,   P6   -
M  "  <S) 0!X;"]S='EL97,N>&UL4$L! A0#%     @ "X!<6I>*NQS
M$P(   L              ( !4LT! %]R96QS+RYR96QS4$L! A0#%     @
M"X!<6J(5EX'S!   +"D   \              ( !.\X! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    (  N 7%IW2W&%!@(  /$D   :              "
M 5O3 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  N
M7%K_)Z=UXP$  &PD   3              "  9G5 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !& $8 (1,  *W7 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>274</ContextCount>
  <ElementCount>369</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>82</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Stockholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParentheticals</Role>
      <ShortName>Statements of Stockholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_NatureofBusinessBasisofPresentationandLiquidity</Role>
      <ShortName>Nature of Business, Basis of Presentation, and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlan1</Role>
      <ShortName>Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Employee Benefits Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_EmployeeBenefitsPlan</Role>
      <ShortName>Employee Benefits Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecurities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanTables</Role>
      <ShortName>Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlan1</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>Nature of Business, Basis of Presentation, and Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts and Grants Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Accounts and Grants Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Property and Equipment, Net - Schedule of Major Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Major Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Intangible Assets, Net - Schedule of Major Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Major Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense for Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Future Amortization Expense for Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Leases - Schedule of Future Minimum Payments Under the Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Payments Under the Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Leases - Schedule of Future Minimum Payments Under the Operating Leases (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesParentheticalDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Payments Under the Operating Leases (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Equity Incentive Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Equity Incentive Plan - Schedule of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails</Role>
      <ShortName>Equity Incentive Plan - Schedule of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Equity Incentive Plan - Schedule of Issued and Outstanding Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails</Role>
      <ShortName>Equity Incentive Plan - Schedule of Issued and Outstanding Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plan - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Employee Benefits Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEmployeeBenefitsPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefits Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences and Net Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Schedule of Tax Effects of Temporary Differences and Net Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Income Taxes - Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Loss Per Share - Schedule of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Loss Per Share - Schedule of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995937 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lgvn-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995947 - Disclosure - Segment Information - Schedule of Significant Expense Categories Provided to CODM (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails</Role>
      <ShortName>Segment Information - Schedule of Significant Expense Categories Provided to CODM (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="lgvn-20241231.htm">lgvn-20241231.htm</File>
    <File>lgvn-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img237815897_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="710">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lgvn-20241231.htm": {
   "nsprefix": "lgvn",
   "nsuri": "http://LongeveronInc.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "lgvn-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "lgvn-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 313,
   "keyCustom": 56,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 37,
   "memberCustom": 42,
   "hidden": {
    "total": 47,
    "http://fasb.org/us-gaap/2024": 44,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 274,
   "entityCount": 1,
   "segmentCount": 82,
   "elementCount": 725,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 710,
    "http://xbrl.sec.gov/dei/2024": 42,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets",
     "longName": "100010 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals",
     "longName": "100030 - Statement - Balance Sheets (Parentheticals)",
     "shortName": "Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations",
     "longName": "100040 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:GrossProfit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss",
     "longName": "100050 - Statement - Statements of Comprehensive Loss",
     "shortName": "Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity",
     "longName": "100060 - Statement - Statements of Stockholders' Equity",
     "shortName": "Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_713a5589-63ed-440c-848f-a0dc06ed8d24",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_713a5589-63ed-440c-848f-a0dc06ed8d24",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParentheticals",
     "longName": "100070 - Statement - Statements of Stockholders' Equity (Parentheticals)",
     "shortName": "Statements of Stockholders' Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_98c6f150-65f1-41d8-9201-4a23ff2331cc",
      "name": "lgvn:StockIssuedForStockRightsOfferingNetOfIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_98c6f150-65f1-41d8-9201-4a23ff2331cc",
      "name": "lgvn:StockIssuedForStockRightsOfferingNetOfIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
     "longName": "100080 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "100090 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_NatureofBusinessBasisofPresentationandLiquidity",
     "longName": "995457 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity",
     "shortName": "Nature of Business, Basis of Presentation, and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPolicies",
     "longName": "995467 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecurities",
     "longName": "995477 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNet",
     "longName": "995487 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNet",
     "longName": "995497 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_Leases",
     "longName": "995507 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_StockholdersEquity",
     "longName": "995517 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlan1",
     "longName": "995527 - Disclosure - Equity Incentive Plan",
     "shortName": "Equity Incentive Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_CommitmentsandContingencies",
     "longName": "995537 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995547 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_EmployeeBenefitsPlan",
     "longName": "995557 - Disclosure - Employee Benefits Plan",
     "shortName": "Employee Benefits Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShare",
     "longName": "995567 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995577 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995587 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPoliciesTables",
     "longName": "995597 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ReceivablesPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ReceivablesPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecuritiesTables",
     "longName": "995607 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNetTables",
     "longName": "995617 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNetTables",
     "longName": "995627 - Disclosure - Intangible Assets, Net (Tables)",
     "shortName": "Intangible Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LeasesTables",
     "longName": "995637 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanTables",
     "longName": "995647 - Disclosure - Equity Incentive Plan (Tables)",
     "shortName": "Equity Incentive Plan (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995657 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShareTables",
     "longName": "995667 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995677 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails",
     "longName": "995687 - Disclosure - Nature of Business, Basis of Presentation, and Liquidity - Additional Information (Details)",
     "shortName": "Nature of Business, Basis of Presentation, and Liquidity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995697 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails",
     "longName": "995707 - Disclosure - Summary of Significant Accounting Policies - Schedule of Accounts and Grants Receivable (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Accounts and Grants Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_611dbbc0-e2ce-41b4-85bf-90180810a5c5",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "us-gaap:ReceivablesPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails",
     "longName": "995717 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_75235aac-f968-4f7c-9c6b-79a7b4522881",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "longName": "995727 - Disclosure - Marketable Securities - Additional Information (Details)",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:AccruedInvestmentIncomeReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:AccruedInvestmentIncomeReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
     "longName": "995737 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)",
     "shortName": "Marketable Securities - Schedule of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails",
     "longName": "995747 - Disclosure - Property and Equipment, Net - Schedule of Major Components of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Major Components of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "995757 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
     "longName": "995767 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails",
     "longName": "995777 - Disclosure - Intangible Assets, Net - Schedule of Major Components of Intangible Assets (Details)",
     "shortName": "Intangible Assets, Net - Schedule of Major Components of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails",
     "longName": "995787 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense for Intangible Assets (Details)",
     "shortName": "Intangible Assets, Net - Schedule of Future Amortization Expense for Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995797 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:LeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails",
     "longName": "995807 - Disclosure - Leases - Schedule of Future Minimum Payments Under the Operating Leases (Details)",
     "shortName": "Leases - Schedule of Future Minimum Payments Under the Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesParentheticalDetails",
     "longName": "995817 - Disclosure - Leases - Schedule of Future Minimum Payments Under the Operating Leases (Parenthetical) (Details)",
     "shortName": "Leases - Schedule of Future Minimum Payments Under the Operating Leases (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995827 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_972466ee-785c-4232-9930-fe53db2cddaf",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_972466ee-785c-4232-9930-fe53db2cddaf",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
     "longName": "995837 - Disclosure - Equity Incentive Plan - Additional Information (Details)",
     "shortName": "Equity Incentive Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "lgvn:ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "lgvn:ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails",
     "longName": "995847 - Disclosure - Equity Incentive Plan - Schedule of RSU Activity (Details)",
     "shortName": "Equity Incentive Plan - Schedule of RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_caeb366f-d29c-4739-90bc-fff7fe6667f7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ccb7843f-3d8b-411f-883c-8583123a3129",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails",
     "longName": "995857 - Disclosure - Equity Incentive Plan - Schedule of Issued and Outstanding Options (Details)",
     "shortName": "Equity Incentive Plan - Schedule of Issued and Outstanding Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_966061df-c7de-4d04-b147-85979bffe716",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_966061df-c7de-4d04-b147-85979bffe716",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails",
     "longName": "995867 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Activity (Details)",
     "shortName": "Equity Incentive Plan - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_4bdbcc3c-77a0-4725-9531-5d9efae03259",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995877 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_309403c4-9ddf-4b25-a74d-ada45e629444",
      "name": "us-gaap:OtherExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_309403c4-9ddf-4b25-a74d-ada45e629444",
      "name": "us-gaap:OtherExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEmployeeBenefitsPlanAdditionalInformationDetails",
     "longName": "995887 - Disclosure - Employee Benefits Plan - Additional Information (Details)",
     "shortName": "Employee Benefits Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995897 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails",
     "longName": "995907 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences and Net Operating Loss Carryforwards (Details)",
     "shortName": "Income Taxes - Schedule of Tax Effects of Temporary Differences and Net Operating Loss Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0bbb3b66-2530-419f-a33c-8f144c3a0d78",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails",
     "longName": "995917 - Disclosure - Income Taxes - Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails",
     "longName": "995927 - Disclosure - Loss Per Share - Schedule of Diluted Net Loss per Share (Details)",
     "shortName": "Loss Per Share - Schedule of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "995937 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails",
     "longName": "995947 - Disclosure - Segment Information - Schedule of Significant Expense Categories Provided to CODM (Details)",
     "shortName": "Segment Information - Schedule of Significant Expense Categories Provided to CODM (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5447379-d637-4372-97dd-6cab7114b6af",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgvn-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r183",
      "r184",
      "r185",
      "r257",
      "r258",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r311",
      "r312",
      "r315",
      "r443",
      "r444",
      "r445",
      "r446",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r480",
      "r481",
      "r482",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r516",
      "r517",
      "r525",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r928"
     ]
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts and Grants Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r940"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r70"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r768"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "lgvn_AccountsReceivableFromCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "AccountsReceivableFromCustomersMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable From Customers Member",
        "terseLabel": "Accounts receivable from customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts and grants receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_AccruedIncomeReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeReceivableMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Receivable [Member]",
        "terseLabel": "Accrued income [Member]",
        "documentation": "Fees and other revenue recorded based on estimates or specific contractual terms as transactions occur or services are rendered, provided that persuasive evidence exists, the price to the customer is fixed or determinable and collectability is reasonably assured, which have not yet been received as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedInvestmentIncomeReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedInvestmentIncomeReceivable",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Investment Income Receivable",
        "terseLabel": "Accrued interest receivable related to marketable securities and money market funds",
        "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r569",
      "r913"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued Liabilities, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccruedLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Fair Value Disclosure",
        "terseLabel": "Aggregate value",
        "documentation": "Fair value portion of accrued expenses."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r1006",
      "r1007",
      "r1017"
     ]
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Gain",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9",
      "r14",
      "r484",
      "r487",
      "r538",
      "r601",
      "r602",
      "r915",
      "r916",
      "r917",
      "r925",
      "r926",
      "r927",
      "r929"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r768",
      "r1066"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r925",
      "r926",
      "r927",
      "r929",
      "r1005",
      "r1069"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Deemed dividend \u2013 warrant inducement offers",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Class A common stock, issued for PSUs vested",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r95"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "terseLabel": "Reverse stock split rounding adjustment",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r95"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Dividend attributable to down round feature of 2021 warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r33",
      "r95"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r820",
      "r830",
      "r863"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r866"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "lgvn_AgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "AgreementTerm",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement term.",
        "label": "Agreement Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_AgreementTerminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "AgreementTerminationDescription",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination description.",
        "label": "Agreement Termination Description",
        "terseLabel": "Agreement termination description"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r858",
      "r867",
      "r871",
      "r879"
     ]
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherCorporateBondsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Corporate Bonds [Member]",
        "terseLabel": "Corporate bonds [Member]",
        "documentation": "Investments in corporate fixed maturity debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Equity-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r418"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense related to intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r298",
      "r304",
      "r740"
     ]
    },
    "lgvn_AnnualNetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "AnnualNetSalesPercentage",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual net sales percentage.",
        "label": "Annual Net Sales Percentage",
        "terseLabel": "Annual net sales percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "lgvn_AprilTwoThousandTwentyFourPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "AprilTwoThousandTwentyFourPublicOfferingMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April Two Thousand Twenty Four Public Offering.",
        "label": "April Two Thousand Twenty Four Public Offering [Member]",
        "terseLabel": "April 2024 Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r117",
      "r149",
      "r175",
      "r211",
      "r220",
      "r245",
      "r249",
      "r268",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r473",
      "r477",
      "r518",
      "r561",
      "r658",
      "r730",
      "r731",
      "r768",
      "r787",
      "r963",
      "r964",
      "r1024"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r154",
      "r175",
      "r268",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r473",
      "r477",
      "r518",
      "r768",
      "r963",
      "r964",
      "r1024"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r1035",
      "r1036"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r43",
      "r314",
      "r1035",
      "r1036"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_BiologicsLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "BiologicsLicenseMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biologics License Member",
        "terseLabel": "Biologics license [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_NatureofBusinessBasisofPresentationandLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business, Basis of Presentation, and Liquidity",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r85",
      "r86"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r145",
      "r715"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Marketable securities",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r81",
      "r172"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r81"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r139",
      "r182",
      "r257",
      "r271",
      "r272",
      "r273",
      "r279",
      "r280",
      "r311",
      "r315",
      "r444",
      "r454",
      "r455",
      "r463",
      "r464",
      "r466",
      "r480",
      "r481",
      "r490",
      "r491",
      "r516",
      "r517",
      "r525",
      "r533",
      "r534",
      "r552",
      "r553",
      "r599",
      "r600"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r139",
      "r257",
      "r271",
      "r272",
      "r273",
      "r279",
      "r280",
      "r281",
      "r311",
      "r315",
      "r444",
      "r454",
      "r455",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r479",
      "r480",
      "r481",
      "r482",
      "r490",
      "r491",
      "r492",
      "r495",
      "r516",
      "r517",
      "r525",
      "r533",
      "r534",
      "r552",
      "r553",
      "r599",
      "r600",
      "r909"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r195",
      "r276"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "lgvn_ChiefScienceOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ChiefScienceOfficerMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Science Officer Member",
        "terseLabel": "Chief Science Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ClassACommonStockIssuedForRSUsVestedDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ClassACommonStockIssuedForRSUsVestedDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A common stock, issued for RSUs vested.",
        "label": "Class ACommon Stock Issued For RSUs Vested During Period",
        "terseLabel": "Class A common stock, issued for RSUs vested"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ClassACommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ClassACommonStockWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class ACommon Stock Warrants Member",
        "terseLabel": "Class A common stock warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r150",
      "r151",
      "r152",
      "r175",
      "r200",
      "r201",
      "r204",
      "r206",
      "r213",
      "r214",
      "r268",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r336",
      "r337",
      "r340",
      "r343",
      "r350",
      "r518",
      "r615",
      "r616",
      "r617",
      "r618",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r646",
      "r667",
      "r684",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r903",
      "r921",
      "r930"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r213",
      "r336",
      "r337",
      "r338",
      "r340",
      "r343",
      "r348",
      "r350",
      "r615",
      "r616",
      "r617",
      "r618",
      "r743",
      "r903",
      "r921"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Warrants or rights exercisable date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price per share (in Dollars per share)",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "netLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrant purchase shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of warrants outstanding",
        "verboseLabel": "Warrant shares",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ClinicalTrialRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ClinicalTrialRevenueMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Revenue Member",
        "terseLabel": "Clinical trial revenue",
        "verboseLabel": "Clinical trial revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "lgvn_CollectionOfStockSubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "CollectionOfStockSubscriptionReceivable",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of stock subscription receivable.",
        "label": "Collection Of Stock Subscription Receivable",
        "terseLabel": "Collection of stock subscription receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r110",
      "r563",
      "r645"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r318",
      "r319",
      "r707",
      "r958",
      "r960"
     ]
    },
    "lgvn_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A common stock [Member]",
        "terseLabel": "Class A Common Stock",
        "verboseLabel": "Class A",
        "netLabel": "Class A Common Stock [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Common Stock [Member]",
        "terseLabel": "Class B Common Stock",
        "verboseLabel": "Class B common stock",
        "netLabel": "Class B",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r925",
      "r926",
      "r929",
      "r1005",
      "r1065",
      "r1069"
     ]
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Aggregate shares",
        "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Price per share (in Dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r646"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r63",
      "r646",
      "r664",
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock value",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r565",
      "r768"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "lgvn_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants Member",
        "terseLabel": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_EmployeeBenefitsPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefits Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r159",
      "r161",
      "r166",
      "r555",
      "r575",
      "r576"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r46",
      "r47",
      "r256",
      "r706"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r46",
      "r47",
      "r256",
      "r612",
      "r706"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r46",
      "r47",
      "r256",
      "r706",
      "r908"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r123"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of contract manufacturing revenue",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r46",
      "r47",
      "r256"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r46",
      "r47",
      "r256",
      "r706"
     ]
    },
    "lgvn_ContractManufacturingLeaseRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ContractManufacturingLeaseRevenueMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Manufacturing Lease Revenue [Member]",
        "documentation": "Contract manufacturing lease revenue.",
        "terseLabel": "Contract manufacturing lease revenue [Member]",
        "verboseLabel": "Contract manufacturing lease revenue"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ContractManufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ContractManufacturingMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Manufacturing Member",
        "terseLabel": "Contract manufacturing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ContractManufacturingRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ContractManufacturingRevenueMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Manufacturing Revenue Member",
        "terseLabel": "Contract manufacturing revenue",
        "documentation": "Contract Manufacturing Revenue Member",
        "verboseLabel": "Contract manufacturing revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r365"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r365"
     ]
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Converted",
        "negatedLabel": "Conversion of Class B common stock for Class A common stock",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of Class B common stock for Class A common stock (in Shares)",
        "verboseLabel": "Stockholders shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenues",
        "totalLabel": "Cost of Revenue, Total",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r175",
      "r268",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r518",
      "r730",
      "r963"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r333",
      "r338",
      "r541",
      "r547",
      "r559",
      "r716",
      "r718"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal taxes",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r923",
      "r1000"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r923",
      "r1000"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r256"
     ]
    },
    "lgvn_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]",
        "documentation": "Customer One."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r890"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r890"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r892"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r892"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r894"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r892"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r885"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r886"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r886"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r884"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r884"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r884"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r887"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r889"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r889"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r890"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r804",
      "r893"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r891"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r888"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Expiration or Due Date",
        "terseLabel": "Expire date",
        "documentation": "Expiration, mandatory redemption, or due date, in YYYY-MM-DD format, of the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Initial fee paid",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "lgvn_December2023OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "December2023OfferingMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December2023 Offering Member",
        "terseLabel": "December 2023 registered direct offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_DeemedDividendWarrantInducementOffers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "DeemedDividendWarrantInducementOffers",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of deemed dividend warrant inducement offers.",
        "label": "Deemed Dividend Warrant Inducement Offers",
        "terseLabel": "Deemed dividend \u2013 warrant inducement offers",
        "negatedLabel": "Deemed dividend - warrant inducement offers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r109",
      "r436"
     ]
    },
    "lgvn_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs Policy Text Block",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueArrangementLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "terseLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Capitalized research &amp; development expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "lgvn_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASC 842 Lease liability",
        "label": "Deferred Tax Assets Lease Liability",
        "documentation": "Deferred tax assets lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "terseLabel": "Net operating loss carry forwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "terseLabel": "Tax credits",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Equity based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "terseLabel": "Accrual to cash adjustment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Deferred tax assets and liabilities, net of valuation allowance",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Depreciation And Amortization",
        "documentation": "Deferred tax liabilities depreciation and amortization.",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesAndNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Right of Use Asset",
        "documentation": "Deferred tax liabilities right of use asset.",
        "negatedLabel": "ASC 842 Right-of-use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEmployeeBenefitsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Company contributed amount",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r211",
      "r225",
      "r249",
      "r730",
      "r731"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r637",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r672",
      "r673",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r681",
      "r695",
      "r696",
      "r697",
      "r698",
      "r777",
      "r779",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44",
      "r45",
      "r106",
      "r635",
      "r637",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r672",
      "r673",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r681",
      "r695",
      "r696",
      "r697",
      "r698",
      "r718",
      "r777",
      "r779",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1018",
      "r1019"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlan1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plan",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r379",
      "r411",
      "r412",
      "r413",
      "r755"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816",
      "r859"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r197",
      "r200",
      "r204",
      "r205",
      "r206",
      "r210",
      "r461",
      "r470",
      "r499",
      "r500",
      "r556",
      "r577",
      "r721"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Diluted Net Loss per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r204"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r200",
      "r204",
      "r205",
      "r206",
      "r210",
      "r461",
      "r470",
      "r499",
      "r500",
      "r556",
      "r577",
      "r721"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r207",
      "r208",
      "r209"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r756"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r427",
      "r447",
      "r756"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r756",
      "r924",
      "r996"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r924",
      "r996",
      "r997"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Ownership change more than percentage",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax benefits, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r756",
      "r924",
      "r996"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock options [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDividendsPaidToESOP": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPDividendsPaidToESOP",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee paid",
        "label": "Employee Stock Ownership Plan (ESOP), Dividends Paid to ESOP",
        "documentation": "Dividends paid on stock held by an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "EquityBasedCompensationDetailsScheduleofIssuedandOutstandingOptionsTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation (Details) - Schedule of Issued and Outstanding Options [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_EquityBasedCompensationDetailsScheduleofRSUActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "EquityBasedCompensationDetailsScheduleofRSUActivityTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation (Details) - Schedule of RSU Activity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "EquityBasedCompensationDetailsScheduleofStockOptionActivityLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_EquityBasedCompensationDetailsScheduleofStockOptionActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "EquityBasedCompensationDetailsScheduleofStockOptionActivityTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation (Details) - Schedule of Stock Option Activity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_EquityBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "EquityBasedCompensationDetailsTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation (Details) [Table]",
        "terseLabel": "Equity Incentive Plan [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r136",
      "r163",
      "r164",
      "r165",
      "r179",
      "r180",
      "r181",
      "r184",
      "r190",
      "r192",
      "r194",
      "r212",
      "r275",
      "r282",
      "r312",
      "r352",
      "r442",
      "r443",
      "r457",
      "r458",
      "r459",
      "r462",
      "r469",
      "r470",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r498",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r538",
      "r574",
      "r601",
      "r602",
      "r603",
      "r623",
      "r684"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r453",
      "r904",
      "r905",
      "r906",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_EquitySecuritiesRestrictedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesRestrictedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, Restricted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r820",
      "r830",
      "r863"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r817",
      "r827",
      "r860"
     ]
    },
    "us-gaap_ExcessStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExcessStockSharesIssued",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Unregistered shares (in Shares)",
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "lgvn_ExerciseOfRemainingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ExerciseOfRemainingShares",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares exercised.",
        "label": "Exercise Of Remaining Shares",
        "terseLabel": "Exercise of remaining shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value of warrants (in Dollars)",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r514",
      "r761"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r514",
      "r761"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r512",
      "r513",
      "r515",
      "r542",
      "r543",
      "r544",
      "r741",
      "r742",
      "r751",
      "r752",
      "r753",
      "r759",
      "r762"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r367",
      "r372",
      "r502",
      "r513",
      "r542",
      "r751",
      "r752",
      "r753",
      "r759"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r367",
      "r372",
      "r502",
      "r503",
      "r513",
      "r543",
      "r741",
      "r742",
      "r751",
      "r752",
      "r753",
      "r759"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r502",
      "r503",
      "r504",
      "r505",
      "r513",
      "r544",
      "r741",
      "r742",
      "r751",
      "r752",
      "r753",
      "r759",
      "r762"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r512",
      "r513",
      "r515",
      "r542",
      "r543",
      "r544",
      "r741",
      "r742",
      "r751",
      "r752",
      "r753",
      "r759",
      "r762"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Lives",
        "verboseLabel": "Intangible assets estimated useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r286",
      "r303",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1072"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r711",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2024 (remaining three months)",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r711",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r711",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r711",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r711",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r551",
      "r554",
      "r711"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Amortization Expense for Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r303",
      "r554",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Major Components of Intangible Assets [Line items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r303",
      "r306",
      "r307",
      "r309",
      "r551",
      "r711",
      "r740"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r711"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Member]",
        "terseLabel": "Intangible Assets [Member]",
        "verboseLabel": "Finite-Lived Intangible Assets [Member]",
        "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r952"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedPatentsGross",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Abandoned patents",
        "label": "Finite-Lived Patents, Gross",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r952"
     ]
    },
    "lgvn_FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First tranche july ordinary course placement agent warrants.",
        "label": "First Tranche July Ordinary Course Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture Lab Equipment [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "G&amp;A costs",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r669"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944"
     ]
    },
    "lgvn_GrantRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "GrantRevenueMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Revenue Member",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r116",
      "r175",
      "r268",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r518",
      "r723",
      "r730",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936",
      "r963"
     ]
    },
    "lgvn_HourlyFeeForProjectManagementServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "HourlyFeeForProjectManagementServices",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hourly fee for project management services.",
        "label": "Hourly Fee for Project Management Services",
        "terseLabel": "Hourly fee for project management services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "Public offering [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r816"
     ]
    },
    "lgvn_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag",
        "documentation": "Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag",
        "documentation": "Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Finite lived intangible assets, wrote-off",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r920",
      "r957"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31",
      "r91",
      "r760"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r92"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r423",
      "r427",
      "r431",
      "r432",
      "r433",
      "r434",
      "r440",
      "r448",
      "r450",
      "r451",
      "r452",
      "r620",
      "r756"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Tax provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r131",
      "r193",
      "r194",
      "r211",
      "r228",
      "r249",
      "r426",
      "r427",
      "r449",
      "r578",
      "r756"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationsOfIncomeTaxBenefitFederalAndStateStatutoryTaxRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates [Abstract]",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r424",
      "r425",
      "r434",
      "r435",
      "r439",
      "r441",
      "r614"
     ]
    },
    "lgvn_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Accounts and grants receivable",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherDeferredLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherDeferredLiability",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Deferred Liability",
        "terseLabel": "Nonoperating lawsuit expense",
        "documentation": "Amount of increase (decrease) in deferred obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Operating lease asset and liability",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "lgvn_IncreasedFeeReceivableForExpeditedOrSpecialHourService": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "IncreasedFeeReceivableForExpeditedOrSpecialHourService",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increased fee receivable for expedited or special hour service.",
        "label": "Increased Fee Receivable for Expedited or Special Hour Service",
        "terseLabel": "Increased fee for expedited or special hour service"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_IncurredTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "IncurredTerms",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incurred terms.",
        "label": "Incurred Terms",
        "terseLabel": "Incurred term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedLicenseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedLicenseAgreements",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived License Agreements",
        "terseLabel": "License agreement amount",
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r954"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r858",
      "r867",
      "r871",
      "r879"
     ]
    },
    "lgvn_InitialStartUpPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "InitialStartUpPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial start-up payment received.",
        "label": "Initial Start-Up Payment Received",
        "terseLabel": "Initial start-up payment received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r883"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r883"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r883"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r308",
      "r310",
      "r710",
      "r711"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total",
        "verboseLabel": "Total",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r952",
      "r954"
     ]
    },
    "lgvn_InterestEarnedOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "InterestEarnedOnMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest earned on marketable securities",
        "label": "Interest Earned On Marketable Securities",
        "documentation": "Interest earned on marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r144",
      "r153",
      "r283",
      "r284",
      "r285",
      "r549",
      "r719"
     ]
    },
    "us-gaap_InvestmentCompanyExcessExpenseReimbursable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentCompanyExcessExpenseReimbursable",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company, Reimbursable Excess Expense",
        "terseLabel": "Reimbursement",
        "documentation": "Amount of carryover of excess expense potentially reimbursable to adviser but not recorded as liability by investment company."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "lgvn_InvestorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "InvestorWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investor warrants.",
        "label": "Investor warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_JulyOfferingPlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "JulyOfferingPlacementMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July Offering Placement Member",
        "label": "July Offering Placement Member",
        "terseLabel": "July Offering Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_JulyOrdinaryCoursePlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "JulyOrdinaryCoursePlacementAgentMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July Ordinary Course Placement Agent Member",
        "label": "July Ordinary Course Placement Agent Member",
        "terseLabel": "July Ordinary Course Placement Agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_JulyPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "JulyPrivatePlacementMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July Private Placement Member",
        "label": "July Private Placement Member",
        "terseLabel": "July Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_JulyRegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "JulyRegisteredDirectOfferingMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July registered direct offering.",
        "label": "July Registered Direct Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_JuneInducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "JuneInducementWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June Inducement Warrants.",
        "label": "June Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_JunePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "JunePlacementAgentWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June Placement Agent Warrants.",
        "label": "June Placement Agent Warrants [Member]",
        "terseLabel": "June Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_LawsuitExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "LawsuitExpenses",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lawsuit expense",
        "negatedLabel": "Lawsuit expense",
        "label": "Lawsuit Expenses",
        "documentation": "Lawsuit expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "terseLabel": "Lease costs",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r767"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r532"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Interest discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Payments Under the Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2024 (remaining three months)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less interest (5% discount rate)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52",
      "r53",
      "r54",
      "r56",
      "r57",
      "r58",
      "r61",
      "r175",
      "r268",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r474",
      "r477",
      "r478",
      "r518",
      "r644",
      "r722",
      "r787",
      "r963",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r111",
      "r567",
      "r768",
      "r922",
      "r942",
      "r1020"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r143",
      "r175",
      "r268",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r474",
      "r477",
      "r478",
      "r518",
      "r768",
      "r963",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r56",
      "r57",
      "r58",
      "r61",
      "r175",
      "r268",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r474",
      "r477",
      "r478",
      "r518",
      "r963",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License [Member]",
        "terseLabel": "License [Member]",
        "verboseLabel": "UM License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r422",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r952",
      "r954",
      "r955",
      "r956",
      "r995"
     ]
    },
    "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LifeSettlementContractsFairValueMethodCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Life Settlement Contracts, Fair Value",
        "totalLabel": "Life Settlement Contracts, Fair Value, Total",
        "terseLabel": "Settlement amount",
        "documentation": "Fair value amount of life settlement contracts accounted for under the fair value method."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270"
     ]
    },
    "us-gaap_LoanRestructuringTrialModificationsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoanRestructuringTrialModificationsAmount",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Restructuring, Trial Modifications, Amount",
        "terseLabel": "Completion of trial",
        "documentation": "Amount of financing receivable modified on trial basis."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_LongeveronMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "LongeveronMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Longeveron Member",
        "terseLabel": "Longeveron [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r746",
      "r770",
      "r774",
      "r966",
      "r1034",
      "r1037",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064"
     ]
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities",
        "terseLabel": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r912"
     ]
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable equity securities",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "lgvn_MarketableSecuritiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "MarketableSecuritiesDetailsTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "negatedLabel": "Interest earned on marketable securities",
        "terseLabel": "Unrealized losses marketable securities",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "lgvn_MarkupPercentageOnValueOfMaterialsCompensated": {
     "xbrltype": "percentItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "MarkupPercentageOnValueOfMaterialsCompensated",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Markup percentage on value of materials compensated.",
        "label": "Markup Percentage on Value of Materials Compensated",
        "terseLabel": "Percentage markup on the value of materials compensated"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_MasterServicesAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "MasterServicesAgreementsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Services Agreements [Member]",
        "documentation": "Master Services Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r375",
      "r419",
      "r505",
      "r548",
      "r597",
      "r598",
      "r611",
      "r636",
      "r637",
      "r691",
      "r692",
      "r693",
      "r694",
      "r699",
      "r708",
      "r709",
      "r738",
      "r743",
      "r754",
      "r762",
      "r763",
      "r764",
      "r765",
      "r771",
      "r965",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "lgvn_MilestoneFeesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "MilestoneFeesPayable",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone fees Payable.",
        "label": "Milestone Fees Payable",
        "terseLabel": "Milestone fees payable"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_MilestoneOfTriggeringPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "MilestoneOfTriggeringPayments",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone of triggering payments.",
        "label": "Milestone Of Triggering Payments",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r375",
      "r419",
      "r505",
      "r548",
      "r597",
      "r598",
      "r611",
      "r636",
      "r637",
      "r691",
      "r692",
      "r693",
      "r694",
      "r699",
      "r708",
      "r709",
      "r738",
      "r743",
      "r754",
      "r762",
      "r763",
      "r764",
      "r771",
      "r965",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "lgvn_MonthlyManufacturingSuiteReservationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "MonthlyManufacturingSuiteReservationFee",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly manufacturing suite reservation fee.",
        "label": "Monthly Manufacturing Suite Reservation Fee",
        "terseLabel": "Monthly manufacturing suite reservation fee"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly payment receivable for in process samples and vialed harvests for training.",
        "label": "Monthly Payment Receivable for In Process Samples and Vialed Harvests for Training",
        "terseLabel": "Monthly payment receivable for in process samples and vialed harvests for training"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r746",
      "r770",
      "r774",
      "r966",
      "r1034",
      "r1037",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "lgvn_NationalInstitutesOfHealthGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "NationalInstitutesOfHealthGrantMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "National Institutes Of Health Grant Member",
        "terseLabel": "National Institutes of Health \u2013 Grant [Member]",
        "verboseLabel": "NIH - grant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_NeilHareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "NeilHareMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neil Hare [Member]",
        "label": "NeilHare [Member]",
        "documentation": "NeilHare [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r84",
      "r113",
      "r141",
      "r158",
      "r160",
      "r165",
      "r175",
      "r183",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r193",
      "r194",
      "r202",
      "r268",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r461",
      "r470",
      "r500",
      "r518",
      "r573",
      "r666",
      "r682",
      "r683",
      "r785",
      "r963"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r186",
      "r187",
      "r188",
      "r189",
      "r197",
      "r198",
      "r203",
      "r206",
      "r470"
     ]
    },
    "lgvn_NetSalesOfSubLicensees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "NetSalesOfSubLicensees",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales of sub licensees.",
        "label": "Net Sales Of Sub Licensees",
        "terseLabel": "Net sales of sub licensees percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Standard Updates",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r858",
      "r867"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "lgvn_NonRule10b51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "NonRule10b51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule10b51 Arr Modified Flag",
        "terseLabel": "Non-Rule 10b51 ArrModified Flag"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash write-off of intangible assets",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "lgvn_NondisclosureAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "NondisclosureAgreementMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nondisclosure agreement.",
        "label": "Nondisclosure Agreement [Member]",
        "terseLabel": "Nondisclosure Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expenses), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_NoteWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoteWarrantMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Warrant [Member]",
        "terseLabel": "New Warrant Shares [Member]",
        "documentation": "A note that entitles the holder to buy stock of the company at a specified price, which is much higher than the stock price at the time of issue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r932"
     ]
    },
    "lgvn_October2023RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "October2023RegisteredDirectOfferingMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October2023 Registered Direct Offering Member",
        "terseLabel": "October 2023 registered direct offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r723",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Payments Under the Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderTheOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "verboseLabel": "Operating lease liability",
        "terseLabel": "Present value of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_OperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "OperatingSegmentMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segment",
        "label": "Operating Segment [Member]",
        "documentation": "Operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business, Basis of Presentation, and Liquidity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_OtherCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash payment",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remaining costs",
        "documentation": "Amount of commitment classified as other to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Net unrealized losses on available-for-sale securities",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r574"
     ]
    },
    "lgvn_OtherComprehensiveLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "OtherComprehensiveLossAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Loss Abstract",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses",
        "terseLabel": "Expenditures amount",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r1068"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income and (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities",
        "verboseLabel": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Long-term Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "lgvn_OtherRefundableTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "OtherRefundableTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Refundable Tax Credits",
        "documentation": "Other refundable tax credits.",
        "terseLabel": "Other refundable tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_OutsourcedTestingFeePerBatchReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "OutsourcedTestingFeePerBatchReceivable",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outsourced testing fee per batch receivable.",
        "label": "Outsourced Testing Fee per Batch Receivable",
        "terseLabel": "Outsourced testing fee per batch receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r822",
      "r832",
      "r865"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r835",
      "r868"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r835",
      "r868"
     ]
    },
    "lgvn_OwnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "OwnershipMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Member]",
        "documentation": "Ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PartnersCapitalAccountUnitsSoldInPublicOffering",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partners' Capital Account, Units, Sold in Public Offering",
        "terseLabel": "Public offering shares",
        "documentation": "The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r97"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "terseLabel": "Patent costs [Member]",
        "verboseLabel": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r945",
      "r946",
      "r947",
      "r948",
      "r950",
      "r952",
      "r955",
      "r956"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "lgvn_PaymentPerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "PaymentPerWarrant",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment per warrant.",
        "label": "Payment Per Warrant",
        "terseLabel": "Payment per warrant (in Dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Other Fees",
        "terseLabel": "Payments to UM",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "lgvn_PaymentsForTaxesOnRsusVestedAndPsusVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "PaymentsForTaxesOnRsusVestedAndPsusVested",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for taxes on RSUs vested and PSUs vested.",
        "label": "Payments For Taxes On RSUs Vested and PSUs Vested",
        "negatedLabel": "Payments for taxes on RSUs vested and PSUs vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Class A common stock issued in direct placements/public offering, issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "lgvn_PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments receivable for each additional product lot in excess of initial training run lots.",
        "label": "Payments Receivable for Each Additional Product Lot in Excess of Initial Training Run Lots",
        "terseLabel": "Payments receivable for each additional product lot in excess of initial training run lots"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Acquisition of intangible assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Acquisition of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "lgvn_PercentageOfAggregateNumberOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "PercentageOfAggregateNumberOfShares",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate number of shares.",
        "label": "Percentage Of Aggregate Number Of Shares",
        "terseLabel": "Percentage of aggregate number of shares"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_PersonnelCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "PersonnelCosts",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Costs",
        "documentation": "Personnel costs.",
        "terseLabel": "Personnel costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PhantomShareUnitsPSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PhantomShareUnitsPSUsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phantom Share Units (PSUs) [Member]",
        "terseLabel": "PSUs [Member]",
        "documentation": "Share-based payment arrangement awarded as phantom share or unit."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_PlacementAgentWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "PlacementAgentWarrants1Member",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent warrants one.",
        "label": "Placement Agent Warrants 1 [Member]",
        "terseLabel": "Placement Agent Warrants June 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants Member",
        "terseLabel": "Placement agent warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "lgvn_PotentialAmountReceivableForEachProductLot": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "PotentialAmountReceivableForEachProductLot",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential amount receivable for each product lot.",
        "label": "Potential Amount Receivable for Each Product Lot",
        "terseLabel": "Potential amount receivable for each product lot"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrant Member",
        "terseLabel": "Pre Funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r646"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r336"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r646",
      "r664",
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r564",
      "r768"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Net proceeds (in Dollars)",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock, net of issuance cost",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan",
        "terseLabel": "Deemed dividend to common stockholders (in Dollars)",
        "documentation": "Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Aggregate gross (in Dollars)",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from warrants exercised, net of issuance cost",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from License Fees Received",
        "terseLabel": "License fee",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from the sale of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ProceedsFromStockSubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ProceedsFromStockSubscriptionReceivable",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of proceeds from stock subscription receivable.",
        "label": "Proceeds From Stock Subscription Receivable",
        "terseLabel": "Proceeds from stock subscription receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Shares issuable",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r550",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r714",
      "r744",
      "r769",
      "r771",
      "r772",
      "r775",
      "r776",
      "r961",
      "r962",
      "r966",
      "r1034",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r550",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r714",
      "r744",
      "r769",
      "r771",
      "r772",
      "r775",
      "r776",
      "r961",
      "r962",
      "r966",
      "r1034",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "terseLabel": "Professional fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r785",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r158",
      "r160",
      "r170",
      "r175",
      "r183",
      "r190",
      "r193",
      "r194",
      "r268",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r461",
      "r470",
      "r472",
      "r475",
      "r476",
      "r500",
      "r518",
      "r557",
      "r572",
      "r622",
      "r666",
      "r682",
      "r683",
      "r757",
      "r758",
      "r786",
      "r917",
      "r963"
     ]
    },
    "lgvn_ProjectManagementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ProjectManagementFees",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Project management fees.",
        "label": "Project Management Fees",
        "terseLabel": "Project management fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r532"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r124",
      "r127",
      "r128"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total Property and Equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r146",
      "r571"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Major Components of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r532",
      "r558",
      "r571",
      "r768"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Other, Accumulated Depreciation",
        "terseLabel": "Less accumulated depreciation and amortization",
        "verboseLabel": "Less accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r124",
      "r127",
      "r570"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Major Components of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r532"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and Equipment, Useful Lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r366",
      "r375",
      "r405",
      "r406",
      "r407",
      "r419",
      "r505",
      "r545",
      "r546",
      "r548",
      "r597",
      "r598",
      "r611",
      "r636",
      "r637",
      "r691",
      "r692",
      "r693",
      "r694",
      "r699",
      "r708",
      "r709",
      "r738",
      "r743",
      "r754",
      "r762",
      "r763",
      "r764",
      "r765",
      "r771",
      "r779",
      "r959",
      "r965",
      "r1009",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r366",
      "r375",
      "r405",
      "r406",
      "r407",
      "r419",
      "r505",
      "r545",
      "r546",
      "r548",
      "r597",
      "r598",
      "r611",
      "r636",
      "r637",
      "r691",
      "r692",
      "r693",
      "r694",
      "r699",
      "r708",
      "r709",
      "r738",
      "r743",
      "r754",
      "r762",
      "r763",
      "r764",
      "r765",
      "r771",
      "r779",
      "r959",
      "r965",
      "r1009",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r70"
     ]
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesFromStockholderMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables from Stockholder [Member]",
        "terseLabel": "Subscription Receivable",
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts and Grants Receivable",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r939"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r817",
      "r827",
      "r860"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r373",
      "r539",
      "r540",
      "r562",
      "r568",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r663",
      "r665",
      "r690"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r1023"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r373",
      "r539",
      "r540",
      "r562",
      "r568",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r663",
      "r665",
      "r690",
      "r1023"
     ]
    },
    "us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReportableSegmentAggregationBeforeOtherOperatingSegmentMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Segment, Aggregation before Other Operating Segment [Member]",
        "terseLabel": "Reportable Segment [Member]",
        "documentation": "Aggregation of reportable segments before other operating segment. Excludes intersegment elimination and reconciling item."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r731"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r333",
      "r338",
      "r541",
      "r547",
      "r559",
      "r717",
      "r718"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "R&amp;D costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r711",
      "r730",
      "r1032"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r818",
      "r828",
      "r861"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r819",
      "r829",
      "r862"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r826",
      "r836",
      "r869"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs vested",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "RSUs [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureNatureOfBusinessBasisOfPresentationAndLiquidityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r95",
      "r566",
      "r605",
      "r610",
      "r619",
      "r647",
      "r768"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r179",
      "r180",
      "r181",
      "r184",
      "r190",
      "r192",
      "r194",
      "r275",
      "r282",
      "r312",
      "r442",
      "r443",
      "r457",
      "r458",
      "r459",
      "r462",
      "r469",
      "r470",
      "r483",
      "r485",
      "r486",
      "r488",
      "r498",
      "r525",
      "r527",
      "r601",
      "r603",
      "r623",
      "r1069"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRevenueDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Total revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r211",
      "r221",
      "r222",
      "r243",
      "r249",
      "r253",
      "r255",
      "r256",
      "r363",
      "r364",
      "r550"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Deferred Revenue",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r713"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r713",
      "r720"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Reverse Stock Split.",
        "label": "Reverse Stock Split Policy Text Block",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_RockSofferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "RockSofferMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rock soffer.",
        "label": "Rock Soffer [Member]",
        "terseLabel": "Rock Soffer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "terseLabel": "Annual royalty fee",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "lgvn_Rule10b51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "Rule10b51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule10b51 Arr Modified Flag",
        "terseLabel": "Rule 10b51 ArrModified Flag"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Company value amount",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued (in Shares)",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r907"
     ]
    },
    "lgvn_ScheduleOfAccountsAndGrantsReceivableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ScheduleOfAccountsAndGrantsReceivableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accounts And Grants Receivable Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAccountsAndGrantsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r70",
      "r260",
      "r940"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts and Grants Receivable",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Tax Effects of Temporary Differences and Net Operating Loss Carryforwards",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "lgvn_ScheduleOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ScheduleOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliations of Income Tax Benefit Federal and State Statutory Tax Rates",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r756",
      "r996"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r453",
      "r904",
      "r905",
      "r906",
      "r1001",
      "r1002",
      "r1003",
      "r1004"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r303",
      "r306",
      "r307",
      "r309",
      "r551",
      "r711",
      "r740"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Major Components of Intangible Assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r951"
     ]
    },
    "lgvn_ScheduleOfIssuedAndOutstandingOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ScheduleOfIssuedAndOutstandingOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Issued And Outstanding Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ScheduleOfMajorComponentsOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ScheduleOfMajorComponentsOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Major Components Of Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ScheduleOfMajorComponentsOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Major Components Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ScheduleOfMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ScheduleOfMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Marketable Securities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r532"
     ]
    },
    "lgvn_ScheduleOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ScheduleOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenue Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ScheduleOfRsuActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ScheduleOfRsuActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsu Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Significant Expense Categories Provided to CODM",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]",
        "terseLabel": "Schedule of Issued and Outstanding Options",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r102"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ScheduleOfStockOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_IntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Amortization Expense for Intangible Assets",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r953"
     ]
    },
    "lgvn_SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second tranche July ordinary course placement agent warrants.",
        "label": "Second Tranche July Ordinary Course Placement Agent Warrants [Member]",
        "terseLabel": "Second Tranche July Ordinary Course Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SecretomeTherapeuticsIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SecretomeTherapeuticsIncorporatedMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secretome Therapeutics, Incorporated.",
        "label": "Secretome Therapeutics, Incorporated [Member]",
        "terseLabel": "Secretome Therapeutics, Inc. [Member]",
        "verboseLabel": "Secretome [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r211",
      "r216",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r256",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r309",
      "r316",
      "r317",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r726",
      "r730",
      "r731",
      "r739",
      "r773",
      "r1034",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r729",
      "r737"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r726",
      "r734"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r211",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r232",
      "r234",
      "r235",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r256",
      "r724",
      "r727",
      "r728",
      "r730",
      "r732",
      "r735",
      "r736"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r235",
      "r249"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]",
        "documentation": "Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r235",
      "r249"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r234",
      "r235",
      "r249",
      "r730"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographic Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r252",
      "r255",
      "r725",
      "r726",
      "r733"
     ]
    },
    "lgvn_SeriesAAndSeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SeriesAAndSeriesBWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series AAnd Series BWarrants Member",
        "terseLabel": "Series A and Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A [Member]",
        "terseLabel": "Series A warrants [Member]",
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series B."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B [Member]",
        "terseLabel": "Series B warrants [Member]",
        "verboseLabel": "Series B [Member]",
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series A."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SeriesCUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SeriesCUnitsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CUnits Member",
        "terseLabel": "Series C Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SeriesCWarrantsAndSeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SeriesCWarrantsAndSeriesDWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Warrants and Series D warrants.",
        "label": "Series C Warrants and Series D warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SeriesCWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series CWarrants Member",
        "terseLabel": "Series C warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SeriesDWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series DWarrants Member",
        "terseLabel": "Series D Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSU expired/forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSU granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Outstanding (unvested) at December 31, 2023",
        "terseLabel": "Unvested shares (in Shares)",
        "periodEndLabel": "Outstanding (unvested) at December 31, 2024",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "RSUs vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation [Line Items]",
        "terseLabel": "Equity Incentive Plan [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of Stock Options, Options expired/forfeited",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Stock Options, Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Stock Options, Outstanding at ending",
        "periodStartLabel": "Number of Stock Options, Outstanding at Beginning",
        "terseLabel": "Stock option issued and outstanding (in Shares)",
        "totalLabel": "Total stock options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at Beginning",
        "terseLabel": "Exercise price (in Dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Stock options vested (based on ratable vesting)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Share percentage",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of expiration of stock options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Stock Option Expiration Term",
        "terseLabel": "Stock option expiration term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfRsuActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options expired/forfeited",
        "negatedLabel": "Weighted Average Exercise Price, Options expired/forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r383",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408",
      "r414",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Issued and Outstanding Options [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of option right of use vested.",
        "label": "Sharebased Compensation Arrangement By Share Based Payment Award Options RSUs Vested",
        "terseLabel": "Issued RSUs shares (in Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount",
        "terseLabel": "Award amount",
        "totalLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount, Total",
        "verboseLabel": "Unrecognized equity based compensation",
        "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock options exercisable term",
        "verboseLabel": "Payments term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Stock options unvested",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options granted maximum term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Unrecognized equity-based compensation term",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "terseLabel": "Share issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Employee tax liabilities shares",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r173"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfMajorComponentsOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Development [Member]",
        "terseLabel": "Software Website [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StandardFeeReceivableForProductPackingHandlingAndShipping": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StandardFeeReceivableForProductPackingHandlingAndShipping",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standard fee receivable for product packing, handling and shipping.",
        "label": "Standard Fee Receivable for Product Packing, Handling and Shipping",
        "terseLabel": "Standard fee receivable for product packing, handling and shipping"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSegmentInformationScheduleOfSignificantExpenseCategoriesProvidedToCodmDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r140",
      "r211",
      "r216",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r256",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r309",
      "r313",
      "r316",
      "r317",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r726",
      "r730",
      "r731",
      "r739",
      "r773",
      "r1034",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r150",
      "r151",
      "r152",
      "r175",
      "r200",
      "r201",
      "r204",
      "r206",
      "r213",
      "r214",
      "r268",
      "r324",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r336",
      "r337",
      "r340",
      "r343",
      "r350",
      "r518",
      "r615",
      "r616",
      "r617",
      "r618",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r646",
      "r667",
      "r684",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r903",
      "r921",
      "r930"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r63",
      "r67",
      "r68",
      "r136",
      "r163",
      "r164",
      "r165",
      "r179",
      "r180",
      "r181",
      "r184",
      "r190",
      "r192",
      "r194",
      "r212",
      "r275",
      "r282",
      "r312",
      "r352",
      "r442",
      "r443",
      "r457",
      "r458",
      "r459",
      "r462",
      "r469",
      "r470",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r498",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r538",
      "r574",
      "r601",
      "r602",
      "r603",
      "r623",
      "r684"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r212",
      "r527",
      "r550",
      "r613",
      "r634",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r780"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheetsParentheticals",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r212",
      "r259",
      "r527",
      "r550",
      "r613",
      "r634",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r780"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r821",
      "r831",
      "r864"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A common stock, held for taxes on RSUs vested.",
        "label": "Stock Issued During Period Class ACommon Stock Held For Taxes On RSUs Vested",
        "terseLabel": "Class A common stock, held for taxes on RSUs vested"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares Class A common stock, held for taxes on PSUs vested shares.",
        "label": "Stock Issued During Period Shares Class A Common Stock Held For Taxes On PSUs Vested",
        "terseLabel": "Class A common stock, held for taxes on PSUs vested (in Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Class A Common Stock Issued For Prefunded Warrants",
        "documentation": "Stock issued during period shares class A common stock issued for prefunded warrants.",
        "terseLabel": "Class A common stock issued for prefunded warrants (in Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Class A common stock issued in direct placements, net of issuance cost (in Shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Class A common stock issued in public offering, net of issuance cost (in Shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r63",
      "r95",
      "r615",
      "r684",
      "r701"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Class A common stock, held for taxes on PSUs vested (in Shares)",
        "verboseLabel": "Class A common stock issued for stock rights offering, net of issuance cost (in Shares)",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Reverse stock split rounding adjustment (in Shares)",
        "verboseLabel": "Reverse stock split",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options exercised",
        "terseLabel": "Class A common stock issue for warrants exercised, net of issuance cost (in Shares)",
        "verboseLabel": "Number of Stock Options, Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r63",
      "r95",
      "r389"
     ]
    },
    "lgvn_StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the amount of unrealized loss attributable to change in market value of available-for-sale securities.",
        "label": "Stock Issued During Period Unrealized Loss Attributable To Change In Market Value Of Available For Sale Securities",
        "terseLabel": "Unrealized gain attributable to change in market value of available for sale investments"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Class A Common Stock Issued For Prefunded Warrants",
        "documentation": "Stock issued during period value class A common stock issued for prefunded warrants.",
        "terseLabel": "Class A common stock issued for prefunded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock issued for  warrants exercised, net of issuance costs.",
        "label": "Stock Issued During Period Value For Warrants Exercised Net Of Issuance Costs",
        "terseLabel": "Class A common stock issued for warrants exercised, issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Class A common stock issued in direct placements, net of issuance cost",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Class A common stock issued in public offering, net of issuance cost",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r62",
      "r63",
      "r95",
      "r623",
      "r684",
      "r701",
      "r786"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Collection of stock subscription receivable",
        "verboseLabel": "Class A common stock issued for stock rights offering, net of issuance cost",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Class A common stock issue for warrants exercised, net of issuance cost",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r63",
      "r67",
      "r68",
      "r95"
     ]
    },
    "lgvn_StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A common stock, held for taxes on RSUs vested shares.",
        "label": "Stock Issued During Perios Shares Class ACommon Stock Held For Taxes On RSUs Vested",
        "terseLabel": "Class A common stock, held for taxes on RSUs vested (in Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockIssuedForStockRightsOfferingNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuedForStockRightsOfferingNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued For Stock Rights Offering Net Of Issuance Costs",
        "documentation": "Stock issued for stock rights offering net of issuance costs.",
        "terseLabel": "Class A Common Stock issued for stock rights offering, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockIssuesDuringPeriodSharesForPSUsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuesDuringPeriodSharesForPSUsVested",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued for PSUs vested.",
        "label": "Stock Issues During Period Shares For PSUs Vested",
        "terseLabel": "Class A common stock, issued for PSUs vested (in Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A common stock, issued for RSUs vested shares.",
        "label": "Stock Issues Suring Period Class ACommon Stock Issued For RSUs Vestedin Shares",
        "terseLabel": "Class A common stock, issued for RSUs vested (in Shares)"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockOptionAwardFourYearVestingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockOptionAwardFourYearVestingPeriodMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Award Four Year Vesting Period [Member]",
        "documentation": "Stock option award four year vesting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfIssuedAndOutstandingOptionsDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets",
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r67",
      "r68",
      "r88",
      "r648",
      "r664",
      "r685",
      "r686",
      "r768",
      "r787",
      "r922",
      "r942",
      "r1020",
      "r1069"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/lgvn_r_StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r174",
      "r335",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r352",
      "r489",
      "r687",
      "r688",
      "r705"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "negatedLabel": "Stock subscription receivable",
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r62",
      "r63",
      "r67",
      "r689"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SuiteReservationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SuiteReservationFee",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Suite reservation fee.",
        "label": "Suite Reservation Fee",
        "terseLabel": "Suite reservation fee"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_SupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "SupplyAgreementMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply agreement.",
        "label": "Supply Agreement [Member]",
        "terseLabel": "Supply Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "lgvn_TechnologyServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "TechnologyServicesAgreementMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Services Agreement Member",
        "terseLabel": "Technology Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_TechnologyTransferDocumentationPreparationTrainingAndTestingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "TechnologyTransferDocumentationPreparationTrainingAndTestingCosts",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology transfer, documentation preparation, training, and testing costs.",
        "label": "Technology Transfer, Documentation Preparation, Training, and Testing Costs",
        "terseLabel": "Technology transfer, documentation preparation, training, and testing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "terseLabel": "Class A common stock, held for taxes on PSUs vested",
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_TermsOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "TermsOfAgreement",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of agreement.",
        "label": "Terms Of Agreement",
        "terseLabel": "Agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1022"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureIntangibleAssetsNetScheduleOfMajorComponentsOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks [Member]",
        "terseLabel": "Trademark costs [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r740",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r952",
      "r954",
      "r955",
      "r956"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_TradingSecuritiesDebtAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingSecuritiesDebtAmortizedCost",
     "crdr": "debit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, Amortized Cost",
        "terseLabel": "Securities of amortized cost",
        "documentation": "Amortized cost of investments in debt securities classified as trading."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r912"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "lgvn_TwoThousandTwentyOneIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty One Incentive Plan",
        "terseLabel": "2021 Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_TwoThousandTwentyOnePIPEOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "TwoThousandTwentyOnePIPEOfferingMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty One PIPE Offering Member",
        "label": "Two Thousand Twenty One PIPEOffering Member",
        "terseLabel": "2021 private placement offering [Member]",
        "verboseLabel": "2021 PIPE Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "lgvn_UMAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "UMAgreementsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UMAgreements Member",
        "terseLabel": "UM Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Member",
        "terseLabel": "Underwriters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_UnderwritersWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "UnderwritersWarrantsMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Warrants Member",
        "terseLabel": "Underwriters Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Net unrealized gains and losses",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r121",
      "r122",
      "r125",
      "r126"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r762",
      "r1010"
     ]
    },
    "us-gaap_ValuationTechniqueConsensusPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueConsensusPricingModelMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Technique, Consensus Pricing Model [Member]",
        "terseLabel": "Black-Scholes pricing model [Member]",
        "documentation": "Valuation technique combining analyst price estimates."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r1008",
      "r1009",
      "r1010"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r762",
      "r1010"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994"
     ]
    },
    "lgvn_VestingOfRSUsAndPSUsIntoClassACommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "VestingOfRSUsAndPSUsIntoClassACommonStock",
     "crdr": "credit",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of vesting of RSU and PSUs into class A common stock.",
        "label": "Vesting Of RSUs And PSUs Into Class ACommon Stock",
        "terseLabel": "Vesting of RSUs and PSUs into Class A common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Exercise Price, Increase",
        "terseLabel": "Exercise price (in Dollars per share)",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureLossPerShareScheduleOfDilutedNetLossPerShareDetails",
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r781",
      "r782",
      "r783",
      "r784"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1008",
      "r1009",
      "r1010"
     ]
    },
    "lgvn_WarrantsToPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "WarrantsToPurchase",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase.",
        "label": "Warrants To Purchase",
        "terseLabel": "Warrants to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r206"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average common shares outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r206"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "lgvn_firstPhase3ClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "firstPhase3ClinicalTrialMember",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "first Phase3 Clinical Trial Member",
        "terseLabel": "first Phase 3 Clinical Trial [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgvn_licenseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://LongeveronInc.com/20241231",
     "localname": "licenseAgreementTerm",
     "presentation": [
      "http://LongeveronInc.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "license agreement term.",
        "label": "license Agreement Term",
        "terseLabel": "License agreement term"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-33"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "325",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481493/325-30-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "325",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481463/325-30-50-8"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0000950170-25-029968-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-029968-xbrl.zip
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MF 0D-@&.&-=S14P; /Z>:E>J$W@D2L]XX/\2(WH4\W@\\1Y$O,6N 6 X' Z
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MM!O0)C<SX"HSBJFW,L4F*UIGM=E<#KL,[;;P0/N"ZM-)!"[H+MP4,A%T"'G
M9EHRB4 D\UE",D7(8VOI&JE7(R7[N@$M<IJ'PJ+QD'PVD2)BZ!1NLI]!XI$T
M6AE?Z!/K4C!)1 *"PV>K&&2-5RDT>#3=*C/T4@I5IS0H*4($UI;L]_@TUFY
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MT0QQ=0,R7=8D@.4&\'@& #JBC0^Z&YA\B&HTTH9^HS'3SB D>6G>))Q5#1<
M+(Z:(N$1)5 #A*%VZ'$&",WO[084J?D2B%3M F= I.R^Q>(U D!"$1DL1G!N
M=1(, Y!RM%B0#?C06+M*8H<H[28(U.9U88PZ+A2+LU/H*#R;(#)U Q*2/3Z&
MAN0G$O%6-9**-8,2B;10/V E:L"0)5/0M%Z,QDVD!5_BQ#0!!V)@D@"3F>9!
MXCP2+<F-):F$'-"S@SG%#,8] B @(14JE(J<#*K;\_KUFT _'Y:N!#1RGQ:
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M%F%A)[OIN&1H,A7I3I&CDYEPEP6N)_K@ ;+$Y?'Y<II.++9RY%:WPZ:E83&
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MAXVS2;$&A9-GX#+1%"T 2>8DNP&A1V8$H"8!N-;9*CD):]<!)AZ$JU1"Y#[
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M&M(C&_ :C:NU0"!J/PUM?JLYN@&#:%B\A0M5JSDH/4X 0K^)YB&]3=-NV8
MF@?_JY)!E=^B*3X)XU!#0$T]I+?(AL7_AN9CJ &;50]1^I( "S<8'-XB%YY!
M=H/L0,12^UV\ , ?-06K^R :%O_F! 0+\&[9P/CM5ON=$C$FL)V*IJ2PN2Z2
MQYD$4@,WWR!UZ5A.,9.-P7&H9C4#"G$@]1X?RLW!.2%^#DI%\"'U"H(_^+4"
ME$Z-@.#07AH.+,>(#@1 UIL\*M[;"W C#F>E:F5F.<\K,\K$.+C.*,4[?'0<
M32@D!/T0 X6##,'IM+B-.#N$(R1)X5YWBD&6G(Q$,OPB*H'$) DL7"\-:O9Z
M110JU2-U\?ATIY!FX#IE.B<;D+G ,,GT H:>:*/!4=!V* 3M8MJ$.*V5C!4:
MA# W'JNP&1D4IM5EI5&U$+V<(I*#/BA+IM M+B+/ZA&1Q1J12*C!XTD6/$L$
MDHV>B&TR>^TX@]*+3+&A_'*.P.R1ZR5ZL=8J%+*9$% HGUID8# 5E"2UC&YA
M LE@V#8:]3@VH =K?8S>XQ5I)"8U6)LS@_S0)!%;<2EN.QJG=4G1!##R:L3)
MAA0D4:-B\EPZ2'(*7,#GF9E^N5M)P'#1>C[23=+0L1P3">)D@KZA4M,1@,@/
M\O-@G:*4JW%"%LB=B2P.VZ_&4:EVC$5-!["@5^*9%!16K\9)." 'Y<&<H"L)
M66H?V/#M[8+Q\!T;OTN[8%Y^9PF _[%=,#@P*<AW:?PN[8(2OF/C=VD7_,CU
M;T[ V]IU _Z?S.H?VW4#_KZQS^PS0B1J(\=GIK @)IO4[N.)28'-<+X *X!X
MK"*A2 3 1!053N'VRE2L9($M&:J".2!V-HK4LQ&D0;&L>J,>:4;"(%"$0L7P
MH6 Z# SD:# (%HP.?WOG-!CT++DFF<@G<45!;J/5V0&<(?&WC^?!+^-_.@_P
M#PYG_.6!@ZG=1W42Z&:'4V96J.BD:>"#>)U.F:#"(!50.!01!Y,K5'$J*!(9
M)X,CE'$(&1:)Q2*42KD\>"[@]]W_!$VR*%R!$TH]T$H06HG&H>!*.#0.A\*H
MXQ0R) *\@V/BD&J9"BJ7*11H&>PU]!O=_P2=;-=I=&:9\8TV+A>(CR+!H5@<
M'(E#$"@D @R&@R'Q6!0.2D+ 4% L$?L:^RW]_S0&3V56Z@+GLXA&F<,QK>>H
MS&N$/[S]L_(JN\ZM4E+L%M,[GMN8VGT"*D'WFT6[5<(B44B$'(J+PRIEB#@D
M#BJ/D\%DF#BX @U'J,'9D,E M?[4]VW0RC]/" ZK@,-0:'@<%H,"A\""<XU3
M*11Q:!D<A<4H94HD#/4:7?DV8_V&;OFWY^0O^[]M&/M?3,M;W_YA)?Q^7OX\
M:32=PVFQ^]YR+(>OLOW?.9;3?3HM0:8(R#C-(0-%"8C^QK._[J3[\U)]U^G[
M0_>_'L.C59G_?$P*AGU]3.J-5G\-XK"HG1Z97877@-/X#N>EWM;KK]$5(,/2
MJ)33@-<=7S]XMS#YOV/BWBW&_A]/W&_GV_[?G[C@T]\OQ->K^L\+=^H;1S,3
M^$Z9W>FR<NP6M<ZHFL:QZ\Q@Q/B;%G^!TW.HC^^2O_TDX.\Q_]#Z#4PKJ @X
ME-*E4-E[4#@DRCBC3FZ7V7WC8)AX*#AEOVLUX$TCO'%X.'@R&>@YFCQM &B1
MU^>BWS85__>O_PSRGT'^,\A_!OG/(/\9Y#^#_*\:9,!O?UD%ED6)$9Z(SZ;]
MTMEK<#?CZ*7\5^#OLWZYV&M>K_?>_>K]V_7^K]?K=]VOWWOSS3M>O_RK5TB_
M]Q</B7C_O9!>O4/>>S_DO5\.]/HI\.=C[_=][[U>OUX??M#OH_?[].T_H'=P
MR%Z]W__M]7N]W^_3[X,/^_<=,*17K[[O@V+T[=__HP\__/"]$6"[/GW?^^##
MD'ZA0\/&A_>'#3NS2H*/$ X7?S)BP$@N?,+)4WDKSZZ6(?C(J-,[/;N\.!LO
M$H7&8+\BR+=%NW>OL)-5.S:>FRL0J1=,S$@A*0_1=;[RA#G$>3?72&_M.1\;
M$OB+M][O#^[3!Y2ASP>]/NSU7@@X9JB@[WC8\>P3_)R3N>'#/AS^"9[+^T!6
M'"&$EPRU$1S]OMHBMV\-0Z(F;'.A'ZS8CR!&SE$\['_E6](O%WH-?!]4+^3]
MD%Z?]>IZT.L_UW^NWHT/GHT]S/'%C"J[399LS"A5G26'7S]WV/.U#Y:]C!Z9
MO2S;)XB=GQ8N/<U;F3^<D7[EQ-W-!;I1]T@L0VQ.5,>/M^OOZRI+$A[HPAJ3
M:WV3PR8O82\DAWZ+8\?^=S'O5>SF@7Y=\OC:= *0D<557S@J;#V;I>X<*#:=
MBS/W&=%(\'S&C;?75K!K=^2L;+(>1W ;<#>E"S:$SVX^OKHFXLZK80K[D@4C
MOCOY_ 1;]Z3A4)L-AQYT(2([*IWQW\Y"H6*2>>.-^ 6 1J/=E3JTCL0=7G,Q
MO+WN;B;O4E+&G!--M/!Z>LP!0:Y7@Z34Q.S?W#_MT]WQA7P?DK=7>\"Q!W6J
M]X.NT"'D# (^ZM"6-%%5TD/*PJ2&VVSI%X.7W$V>W97>9^>M)4]75]H4\C6U
MXA%IZ"D7O^K?'Y+3/#9;,-]#6N-IV'MB_+XQPU#BZJ1:?WG:R)/?M!:5L(YC
M!!GKN6.OMM:ENEW7/[3OJ\NG([)276+Y&N5&3U]ASLJ&&/W6/&9;D7_4SK67
M3UT:&E9"WK[REUZ3+D]9^ZIN?;RD:<\F)B:#NKX@G#F>7Z9>O,)87"FZ$PY\
M.R:V8.O:6RM;0\**T6?TFV[:2"U5$Q9\KYW1#[-R2>?/SL-9][/W46H:RTO[
M^7&OQ@M*IQ@ZW9G#*7E??,1JQ!9B%L0/-$R)@0 .3"'^%4MQPIR9=NQ0I7A)
MX>/*TZ,/G/QJP*IMN[9/K\I<<B"C!+WV8OC5N"FHV/E/#M>$VD_ ^^V"17F7
MT^\V%)9E[@XK1M&R.#M.;MOVC63O-$K6S*.2,LM$WXZ6L[V'I!Z^E)B,K;I[
MVK/*9??Z^<.[EMY'U\V\^2Q]';IUV/U-#4F.+/6]II&=.Y3Q?2+;6E*OGZ!%
MBYVL5=,'TTX]O[6G8K./L6II'>J1;PK!G)F_(BQKPO3A9H^JTO-?+<D62O:@
MB)DK+MS+H,>.V3^ N+)\966,X.EF5N>S0:R',$;D='KEVL9S$3<.#;>?#4L]
M=V9,R2;)]G51H"5S.VCR,:SIA>6W2@T_<^-J(F((\HHMSV(*/ O.7^7-Z#<Q
M_N*&JX7EJ8^2#^=/7;.]=-#I]&NL_1=G IW]2T<*G\=A)EW^IG/H[BWU1WZT
MI]TRH<^W#-V8C215;U2>32/ KLP05;&5SVD%0X=OVW7IIZ/DFENKUQ-(7$+J
M%&W=Q"I#EFW'@Z/K=&O.^]0= ^F,-5M#X8/'1K:<9C$F'L@R<'9<N0=>P\"%
MPCG.')$>=O2:I"EU,>M?\V*_213S*AH\TBEW1FTEU27"LO36$9L-]_<UC]AY
M*S,E:_6N,-8Y]]&S'TZTCI]\X_(-9]4)2$WXUZ/]FVY_3_T0GG></,F2WC7M
M5JHSZ51&2?RVG1<]TSW"?=,>/5._V#1U6\R' P_1$T8TLD2Q&T@[A(P-Y;=2
M$[L^[_9*;<61/7.KDC)=$S\+=Z$7Z&DK;4_56V:>>BK<VGPZX<).'/_8$QMC
M=MO^@"VAK!V"?>&(+T._#/_9.O[29Q];:Z_]TFO'7NL+;$UU^[ZO'KWXTLJ:
M=.)$P(YE6\8.W@-K/;7^U>93%U3E[6G4X_E17Q*/BR%(P2+]M1O)!&Z]KBL]
M:$+R=IYGZ47SW>P[NR>>;SMR;L?JE>GC6M<<GLA'TT\<%&3DE\>0GD8-VE#?
M8ST&CAG&NK3R:/F'(ZSC0V]<NOZ4?1I2DW>SCS_I[G[*S=C<TZ0[EME=7]PZ
MNHO$$LG+QC<@O'?@MQ1QUO'(35W,D[&9J2>6)+CO<S'#>8J1=6H7X^6EQX2[
M)<J,DHD[=A[W_E?+F7M7"ZX4[#QV<DMH\\BP[%Q$[H3UH^J$>_0E><F9RN/E
MNH;S%R^>0V$.-$S*C[T/DTU9%#GCB"8B?L&Q)?EX5.84<M:/95QG9&3;B(;8
M<]>3Y]W>&Y.>/OMFRS&F.2,K:6BX?8MWJ6O!IZN^']!"BXN+J&F*0A'JKI4(
M(T?4Q1B(GY9WE>\L3X=<Q[0,92 K'TC-7(;\WH>.<Y[<V4T3/:B5ZJ/]^^3*
M5R@GN09V9!_-0<5>(48]1U02W2=;AMTMD>?2=N:(0V:;FN_55-V^FYEWZT3B
M^FV/:_$K#D?Q=XW/(!Q'",,GK=U>/KMYO_QY1FG_G=L$\V>WXRYN&YN"=HS*
M[/?BH]1^SK6')XGS6"_6?7YWV)9,4C*Y_ =I7:/M3/W:M.,1MS+7I&0U# 0R
M;MIRRI_>B(^<R(R?YZ>%A-:53A^1O[2Y>,GIT:=>18WFK>WJ=,\_2[H?$D8*
M24^M.T?_?IKH)V6%\6NDNT00656QHG;>F01GNW@A/S??_<R]:,.GD>#LY@R<
M,2+6'2^*N&'Y8&Z_?&I%J[R^?*5HV>@]-_FE./J&WD\ B^5S,$B.6M\P_:XG
MI/D[N6'1I]C=RQT0>.WU@B-AU3A6UJW%#$+^PL09/P_>/*AKQR^]"B-;P24^
MF7(]3(V\^/2D,NW8+M*2RR>$N1J?8W5TRL@Q7^R,>F6?A4H%31F5FOOTS%K"
M,_>2UP&'.-[4?K?.$M.4-__:"51AQ:W8N>$?@=:,32I PU@"04G:\UN"UMRN
M0![D%!AB[SP\X-@5';]],F55Z,#U':?;A9[)]KJ*9.:G0R>,+:>3EE'#;L8^
MV; A?-;\CHYC-# 5;CIX?>0GFH^3K])Q&TX.G^ [<.T<1IM%R^N(_>J$3;BX
MN&;=ZII/ZHN*BEW'IQP@AWQVU/WX_K3:'P[.J-I7>=W*N-MT!]>R[Y+7=>7>
MRSFWOS]<%+9ES3=/?F;FS)_]L1TSEPV;NV!1Y):T,Y5%XC!)Q?!2'+.8>?[B
MA:A=),L.F*B^*..FJ2[5<VYI9^38PRW,IM@3DOD^TIIAA.B$Q(BU66NK((>%
M*Y:EC7PQZ/S%C=T)L*5D_O>UWII[=QL'7__2A\S6A-7<J6J '^9T#JB<&)?%
M.ZV*756?\ 1C2MRO?KZZ-#1N_8Y':9>J"MJ>Y==,J/Y@1=+ZE[NR]Q,.G;KE
MY$Z>D-M>,0!,?Q7'OB_+?31JU_:(H%\*-38Y[GPARWSU1E?HH%+9*OFVS+GA
M-V,.2U<\9/..+5SW];?"\U_\N.\Q17[K1/5^-6;2N2MU,*LBY3P])7U-7?O'
M[8:Q.4[&LP5D:9WQ9E':QAO1A?T$]47U):W.)',D.<19=M:">60'LO>E1!:<
M;6XMRZ-#*DC6*^2,(J_PRJGYTXJ*BD!S'CK.?+$NI/G:6<Y'W[70\,/&]^^S
M*J+!)]V#:!@Y!@%:4_<\ ;,YL:OU7NC%$LP9>6DF:,^IOO24'ZHB(R/CYT6'
MJB+7I''1'V3/72^-3AR6**H>KW= ]DO=W1EP=7;$"E*ZO*/YW@[SK5&9';=.
MX-<S'TU)7=$_BKA[/,U^&@Y:<^V.\OJVU[8\W71]](>.2ZMRYS>-\* RU0_[
M/<F1ERMCG4>.9\?EHO2MA-+GQ%*^F]\*"A21&PTRLQEE$XJ^7-@.^U8<VJ^)
M&I_5>%10C8.$XSY<-E#*V7!G]B.S-NW""V97GQ-+8E\-*\BU23S]6R1M-V;C
M ">ZP-C9_Q1]9(3X%-Q0/?Z3!U40\43XK$A6YJ+S%^__?"-@3M[XB$G+-#L;
MO$WLHXSBV7#SO,+MB^?$':&G18;Z'VIB2LQ])[%X$;EQSNXTN&Q%2=[C#R84
M'>HPA468(\>SS,71.=LVB?/6G9S&'I>YN@C6)+57CO:?7?3JYQ^<8-R\!&;"
M2R'-YT6S;YMI+33&E#W+[8LPY7G7^QUH:JCZ5UGB<%Q>]8"*8S]WL1MG'X^^
MM:8\A%:"_F?9<,;F.?'&KSQQ-G+K$MF%V(9%#+A@:SB.?6K!^%.G]S2NS1+M
MNQXT:&SYL .."IE[=^.JT+ZKS7ORD/<_:J8W35]RY.R@&.+3U"5G2M)FQDV[
MK.NA9I.I8)[UN&(^@[C0:_3>52N>J#-G'GLB;#P:'G%A#R[G6*Y%.KOM6$\^
MY*YB7P#ZW\UO+S3-0F@OJ-UI*;7$4%Z9<=[BN0LS,2@^+_-A1/ZI.&_ZE"E3
M^BYJC\A%\A8(P)#S)+PH?+AM_)#ZG7,VUEK+TP3526[C*,Z!V\W\D\3ML/IG
M^V8A3,=#MX7#TB84??-Y]2?ES,S^KDY2*'G=O*Q'\Y5RQ!<7RC[C.,;6%)UG
MW7>^! 5:$S%I48=I>]H0#*H6>^.YNF,[\AYIVX+YD:4#K_>[_<']<+-T8RF_
M/06IE]K<[F=!DA:=M:UI=<*U0ZMXCH=BOE:]/E/SJ<@0_E.R</KD#O[F2D5>
MXL?4L W=ZR4BI\]%<<+2"47)']4<%.Y>COQN?F.YQIMFITEGF,IV&QA?5W28
ME_ >O3!TO=^3#EGMA2$.Q<L]H[)X]PS0X]% OC";O+SXB(<4TZ^L:K#R"7L[
MR+9!0L3+#"&CO!T[._?$5\Z9773OZ**43,W60><+LUT(9=%D%2VS(CLWF<>Y
MD-[6G0L'A>5DPT9WW-6<=U]S'9@WO5;UP:$Z?W&:8-GB>=*! ^7<]_.DMMB\
MY/L[[E6WCEA4$ET)DQ0O?#BZ$VOPC(^SC4<:,OL=R!\#)L(1([+LUSC?WV'K
MSQ:DA(H*/[OA?CFGU<E^&$+BOK\3<C#:/4R8?CMGWH2H=>N'F7F,A_$Y$S/V
M<$,?EO/TY4/+==4:BW;;K%DYY/'JR1-MRD5K%E\C'[L0LHT6O66B=LM,06/\
MO'D%WV%+IX\N?U"$:0 S8MW+_/ZFXR'T.?(J$1#2_,UWCYY?F9[9MW2].$59
MME%<F,M8/Q<S/TZK>#KM*?HTH)I5]G).CWO&)*7^?YWI@Q\MVZ/LO+'UR/GB
M<=F+>9/G#RXNVIJR55TZ8Y)RWP<NK?E"^IS 0L\<=D+?#FS>T[I*V)IH@]>/
MI&Y?^85'"\=%5KBOP?I)H_4EI4//Y %[SDV>&2QDEE?74:>X%4W1S0K;^$_'
M&XH'YYR/&O"H?!_2.$9^!C8I\]8.W%WQ&G;"V6U-%R)30Q 0T*SS0;/"7=/J
M&@[,NZTZMHS>.T*<6ZE <,^?@M6LR_]ZWKHL?MM/S:"'%K5'9,P!#+L*^F-O
M-E[:E,?*N;'T%&->WFD>QIK_/;N0\>"./8?=UGS<>?5:?@P5+ELT-XK=T'A@
MQM'+QV1#:4^G;Q+O@#<>O[IJZAWGAACDY30P)P<<<X)S=>5L<SONG)%E4]P<
M'CI8I1;/VN:;DW<S9DMJ2":-S[E9^?7^T\5[G^U[/*]@'6-?7S K+CY8\$6-
M<=&%8;=6U(UD;%U\/][1IVD"L?K,@7U+DQ=4;E3NZU.Y=6W-R4-IS<?+]T;'
MD!;I4%IE')A\EUS'V;^IRZ=LRTOMRY$7*RO<U^DYZH,Q%5FYS$MC!@0*0_+#
M$,90DRHU#;O4?:WAS/R,$^WXW**:.D;5]:7B//IM1;M2<3IFTHI;[877TW*?
MM%<OKZ^OZ3^<E"I<W;*../#*[5>ZB<@?Y=<LV,*"#SI"Z*'UI9P$=NR67(S
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MU^P>XHO!7!HS=<^ SDS4_6A6P80&\B!Q^+4Q(_/K4 %;EIBK_P6RBGG_!JN
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M=&-/I+QH_>]#U[+++RX_,%Z[IB(K-UDJV'OS\RT]VQ:$O0]'=YQ?-KD M^3
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M\(L*\(L*\(L*\(L*\ M+_,(2O[#$+RSQ"TO\PA+_#V&)OUH#J=UQ67L9]:6
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M@Z9QQ\UE.8%R.H6\^C>1)RUK(1.R/<2RZ@[PK+W ^I*I+I$V$7AFG@5;FB"
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M-H1Q&E**^.,COR\&6, [HO&K58W<);+OV&\Z.*^8[%DI.U;L[2>,\42G!Y8
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M %TM*E5T/_MG1=@K '[:4&?V8T_<'K<=FOELC@B<!RPHD"_#R45H-+1#G4R
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MU]4!L$7[5I=4V:DT+>J]_MZB/J7AA/*EA\FQ+LZ^3ZFD2+,0VU=L?OTD"1^
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M;.1=L:^];"\T;DT+FIVK]GZ47+COT->8<)+6;M'$\7P&.CHJG##6G>@?/S5
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M4VLKV3)%Y.6><:+0/5&F)C<#KX?1;6?6G$Y;]EW*.^**(T?XWG_7$7Q4O7K
M++<@=F=(VF.@BBJE-P#)M&"ZB'_5]#-VS;8Z,T,0K-K=B. U]M+=KE:!9)2U
M0?%W)P6<G>X\@%VB-+(N9<ZTTDXK<E>,G7U6F[HGPIL>O]G*:TV!J,16!TES
MS%4VK>P @GJXA:IAD5+QC'H.VI+0^4:U%R>;)UQG6?==UO+&(<H[69!O&_H)
MX3BR9PZ'R^:<O)YS)#LN(%6)21-@^%N9ZW$O4K9LHA2X4?CC[OA*)^-BDJCW
M!"^6KNSJ'N6+2?_F?JA/T_2D5]9)_WM]Q60GW9@2*5 _K8QB4E0+^-L%.-V
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M_[A$Q<13Q=Z@Q7U]/-+=O6]TI;=^EZ). -[?HH7"=_3:V*SL!GW(%(I_@ZM
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M XJGA:QV!]#;-%JK=RU4MWZ]LLJ6'5MY*A&D\J#6MRB2#7J[3ZY./O(4C\K
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M*Y*Z-IX@2,,^'W.XK70S-J!LW2/([#XI*SV(E^<MS:#E>8*R93\6E9@:? 2
MG]-")[>>M"L9;QM1%=-Z1MG&]LU.\+TA219-%$I/#UKA@[\9]D;Z(A9(!1P7
MC5MPGK_T'O-UO*+1UV0LK ,9W8M5UYU<UA,V;."N9,X0@Y_ @\&('?59;'P!
M10S:(YD]AV;L2[7,AX\UE\F-DIP.$#Q=O=V#F/U!4<8/7L**W8*T:1&9P0?X
MF"*DI&2&4,'NZC?'SC(?B5-\WS4[,U<&/#=K1: I2%]H7)M9X<MVKVL.(<HS
MKN4=*XH.N\4.QJ8@A=2*MRV+)1]^2]=C81-*,$QVWY4E(R#82>T6Z"HB/C?%
M"^WC4.85I1L\Z&RZ('I!JRBM]> :;N:KA59G80]]+M/R\$>)EI==*1\%65?F
MJPN(,-EH\(\7\WO[OF;H8(;(?O-<'&"Z 9M:Y[V2D@+E?EU <8_FP\/Q)23>
M:8*KXCF"5YN)RK2W@3O>$%NDGCO  Z*2,']#0%)J;1!+Q)D@P[U'4KE>0U*Z
MC.9-V=O8'TI.E3I%1-)#;,MA;++J0/ZY^$$GK4H# Z">BCJMI4;)G>D7_Q0P
M2>'KVF&<L9R65$KPCVK \?02LFP521>@25WSD_> &BB]T'Y?6T# ]-7]A=&-
M_5?];X8S>%NDSRI7MB@T<GJ_EY71M$CY!H#%W]:Z<@TCA=N:EB/>_\]F&O\$
MW!USD@^)9GM&%R6C<*=[8F?AT(CI'89&%--5.H H.(O5I;]?.C+A4V@/89K!
M,YR>COUJ;F'V$"MCTB:X+7V,&ORRLW5EIAG+&73-BD4O<(CN&]A5P=.,?&PD
M<M\4&U9]S'%Y^6IVN@LYVY"FUV6;^@C505:^8$GS$JX;0Q7)'?NRI0:>W,['
MO;RYX@AR(.VR(-N]_%_LO65 F]VV[TN%&H46+UXL:*"X5W!2@GN0%B= \&"%
M"E:<X!"DN$.1! E2W-T)@:+%*=#BM+=]US[W[G7NO6OMO==ZSSY['_X?^)3P
M&W/.,<8S9YXYYY!ZM00Y(\!-%A)'YE)-SWER7..[YJCR* 3<EU'RC0>BGLQ+
M#O/S0\M!2[0V9 <-;NB5-.S2V" K;;@/[&@2FFG> 3%T#CTXX*-#G0K^NZBT
M@0VE??2V@^)S4RC(LM^%5[%:3NZV+#6/A0%/.CY12 Z[X1N\>T3SAK:O)4S2
M9K3CRC'W>/4I=Y;OS_9G>"_;N=LHB]0L[]EGF>DE$5<EI)>^C(5W#-7A9BD-
MI<$9RV3RS^"A/(OOAP7SH8&2*29PD8_.QI*-:8(&SW(27LWHFN421LBF2#G
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MOZ1F::!?:<=P&*&TL597U@JG3W%I]P3TQ Y54QH/6--C'LCR;&$<XEJ.BM-
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M]L%'<!]&AQ:(A6UC1EF,IYF6&W;.XLA4Z3?HJ94>6&YO:/9G6G8N2]Y[K9=
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M"%0&V=<%J,F.*Y5&RIK=EY!/?Y<\FKT(=3>^M_4=^)[R@..C#;]"H*4T=?A
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M;O>%>[8<$G[Q/:)4FATPJ5DY,GGUG4[5B(:NN7..Y?/"TJ2,;6[LI#N.TD'
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MC7JXL=QB^3HYN:ML@8"ZF8A*L.:NC?1HT"P=X(FL $-;P[/?V_#PXW;@7G#
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MEXQZ[:2!:%><BD ,J$ V/._DYG, LP\RT\K3O?7_^Y> 7XOXR/<4V,/HU<\
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MK%OD_T7>6T;%N67MHI40!4)"<$]P)[A#@GN"6X!@A16%N\6 X.X6I"!XH*"
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MS@SV(M2_):2BZ9)"-OLL52=A@4/TN>GS2>+E@YV/7)_$*Y(7,3)#O6B3[IK
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MCMSKDO2GLN$9A/PXFG8%1*[[D;5.!!0E4_6#W9__X5CND-.4/)..ZPANNU7
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MRZ.:XTQS8\1EZG%60,_E><W%K"MXFNN_XHG^<[AQVS#K<0"YBX3#-:!^QG?
MYQI0W=3D= U@NP90_0RS:X#?!8G5Z0=-2"[B@H6P;.7L[[S'1OKS[=F3[]>
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MYU][,^!V]'%P4(ZV8'S2.T*9=Z0W\D^]V%2OSC*8&\.NG0PH)#2G#8!+< 5
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M$NP\CN<>,>YKQ1P]J5=$0J>60C@\BS^M'IP@O#>G O6K'F/'T0C'K27,X+Q
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MF] 3] NN%[??)*\&4\ZNS/7KX?WD/:=?,WMS2/;OGLB!]$4/]%E/]J0<[/&
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M!/L];?C_2-KP3I@GF1:7,Y\ZOOW*[XS@L++G@!T,6$X*Q7J8Q*;&7"P) 9P
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MS603(0=O[S)%6A]A+'2+5%MM"Z+OD"H*LIN)I!-J1<9>K'4E=1?;^?<RY/^
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MH_S>?2KJI9#>S,N%';,L0D4R;QWQR:QU-&6:H\6@%2(ZNK5,Q7<WP\;5^@=
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MF?09*98EP]<7H^HET8\&;6YD#<[\>![^'[9+UPQ#7TUXJ%D.$?2"Y$5W!>/
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MU.EA<ZR[M:2<&H<:!54:'9B5;,EC::T# 6JX&=? ]V3/GS#3^-1F#=^.!X7
M@GW>S3IQ3AO@BQ?D)4<HC,IX6K&2J%VQV\PWZ4>#@T,J^&6&W13S"6R-=EE+
M8G3,P,OY BFE77-(C7=V"3+&$+<O'@I)[/>Q)@=*KOMWQCDY>"L2A86C#'E:
M$.-G'2AZ(_YJY)>Y[;*/"XGQ+XV=?>T-^>_>]54]QPM"=@Z7KN12?Q.24JA#
M'JGFS>ZGM.F?#!^P+$PVO!DO/S7X.G4(>UT,/"MP;,A\N=[0"99_5+D@VH1-
M@WN>W0!U[5D-^LYP[539?<MO/0L+1)SCL54]\!E,7+T+]0&O'CZ$\PRG_6__
MAP9SDC/D>*QF7B31<80L_>)JWZ#K#3BCG^+0;2A(<5@:\W+8@6NTK8N$?_P%
MXA>(7R!^@?@%XA>(7R!^@?@%XA>(7R!^@?@%XA>(7R!^@?@%XA>(7R!^@?@%
MXA>(7R!^@?@%XA>(7R!^@?@%XI\,1$F$O93^%7&# ZEG*$,H!\\85$U19V%M
MS-I0Z!RO*AC(^*R0O"78O%@Y-1@_*:R_AH'ENH92<D2(=#_["<^FU YRO]>7
MZ52]O*RT'2S& .TVW&SYO7D*BX(,M#2E[:_#U[.TOCGQ9QTAQWT7<C>\TU+/
M$B;'A#U.$UYO3/E;)NH?&F(0&$@X.5/#FC&Y,;_@69&,=9W$^J"+.XD+X@V/
M.'4472FY#2-V\'G6\V[N+H/.^9%0"-QXCR@IP"2$=(X^A&E0Y$L^IJ#<DZ8^
MZ12S+X\]QS-?7+0Z[8IM[II1Z?4_QVOQ#R8Z71-7*$YH_=HMLVP(- 575!_(
MKS^JEQP]7K1J[3^V @0F-@6%B4D%4N!;'5=7.RFOI1X&)_:CXLI7,UU>S<Y$
MQ/^[:P="&R/\KN$IY+&\D9#R%K:JZ?QHE;9LPFP;8P[-_=_>/%8S@7?6N[@U
M6VB[O3IXI(J+=5-S\W1K$TL;%G$\GG*C" Q4KR]![=N@B_M!S(5^?]Q(B*R)
M=E47;#=G,IO1"@;-Z!!+J46(-;>\I'++'QKFCQ$:6J%X9IT6TS$!$&H-CQ'$
M9<RT_B6Q[-\VPQR#[ICJL[VJXL2QZH1B%GB905/@D(?>S:2A\O[%# FQ6,W/
M^2S/M(*J#J:J > R7EV0C8"1?M,3O)L<I$_-A//1;UZ[\4]J]MYC VEL7IN$
M$JWT>NK%%[#%27U-'DF-*\52H2#_%4I'%7(&9:ZZ^/"DA3FG4GHKQ]0O-8?D
M&F\&O=7"\_KI=\9'<HXW^EB'>B:DWOX[I2,I.4.BTV5[.#].^8/?3C-%+85E
MKZ(LU?"\LR*9=>ZE]K0$54$J!"1B^B^+""_C(VG+J.US^=EN\/>U*_/PV0AO
M;!F;:'8],E!R#I#))XEUJ+;="E/!9:)KX7$G?Y0&H2TJO18T#UK?VV'L<^T"
M/&D)D*^EL.J3+Z1;-0$JY.E(#=@HN8ZDO;(=1\'A'0*'!4939_/E!WNFON=X
MLDR!\/)SO T/A^VM<[S90/\JJ?6DB"U>J2_Q_/W']"=F_TE#_\]@>NY3+!;B
M4FXM4V.(KS6<U)WW%P1<VNR4T$$Q,B$VLA.IH *2@A=;_E^,RRO%W&Z-9#T/
MX+)3.L<#V*V!8Y [%&MU50F-/?8GZC--S0ANA(^6XB0*L(YB<ZE DQ"?O6_#
M&!JNGYS"M<Q CN5H^;N'CH\WX-P1*;J ]=35XF2,,T1%18+3'MVV7)X-^WB0
M?VV@0).^__:TN0QK ?Y(7+[MRG$9 [%H>UJ@4MX&$7]LZT!L!).@\-?C;JD=
M]&O58_6N6B &S1_3BHIY%'!'<%#QA*LU\1R/W.W]K(?+F<T:BG/<Q_RE-:Z&
M**414285+D18IG\":0P^Q\,'3,84/0@TLU369#]J'?5&>QOL6N_.E"@##6*'
MGGT:5&)-HN$UL B:KSF=:7^?K4/&ILFJ^3XN6T)Z LYALZ:R=PRPF]^&CI^(
M9(^YQ_<DR'_C#DI6.U&!J$":NR4^C7L9@L#=X32#8T>A#WK[6D(PP8'.IO;G
M>#GCB44.*FIK:G/-2F6/^GR?_/DE+GU8RJ>L>%M=BG_]J681V'E:*3\Y1 _H
M.BC]_2[OJ\2,1[U2L%L^>RM>F0U2@R/>[7,'N:YG)R%&)0Z";3$FW(^^KR=I
M,PJYC8#;/ZYY![]MMK%$EO</BF/#7>94-OAK*:0N=SX6=<CO'Z9B-#$4'9KR
M'I^G2D++;ZEVGK']U$5(5_EM,U0/7+UQG+1Q'%9^N^LFII;"KD\FVK9@HC:V
M_WG!ME0^# .TR_'3[1G"3BIFN[D-?O=S+M-+,ZN=334;RV+Q$M?MYY/CF-F9
M:#O&8R4821V!E$)=[,[G>%=M]:8T_=R,28CDP,%A>T.W?Z9:S_VVL<=C+&GJ
MR8+$9<,[QBH%L$X%/M%6AO9LJG1@!?NPLPE3F)*>YKZ'W1@ (.<OR3G@7+AE
M_.2[+)] #POAKBUGP&C8Z4K<R&^IBE=<UXVTZ,Q/G2BZXT\@;\>D(QSRIO[
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M,_=_SG!GDEG5V3T_\8?Q;4*D)<PUR%O5#](O9Z]?@KTLR7%?F QHZUDP-EQ
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M627&XKV\DJRBD$[L.Z=]6.R2J,5>1INB=B\P<DY0&:@;=ZF?INNL>#$@O/G
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M$O%,37G%F'_I6G9BB8)8(;U:"R8W1A.#4%@9J^+T M+@_'1M^MMA-^,+1#2
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M96A@16BOQQJ'RN%+X&C7'2YP40L9-L]*^C0FSG+BN[48\KIW+R=C:^X]YE5
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M^:I\:P98Y"#'FI;UV5<*&RSE\6?\T7;0T;5'!9+_4Y?+B5+A$W-J[!<B.)J
M?N4Q1^9?QBIM<'V/*(MYS^/]MTVX].VQ'#2SK*DE"?_X/TASA?ZO-/<_Q>HF
M:)5S^VS#AL&@1UZHN!SA5_-2"0)EURQ6RH"55[!VY3TU)-NJ-K<SC,>Q!5.%
M#PZ99"T(PS]L0)>:=PIUD_CC8]#\&4;X?%)/4S._SL]CRM)CBD<[VRGYO"_
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MD =QRGN,MR9 V1J4^>OVP(0)U?F.6*ZYIQS(CQOK.:,UO7C.Z87+X HDQ=A
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MERM?>0+SLAW/'S9U!YRN96%[WM:7Z!KNU*.HQKS&S-U=IK3R:C-Z5E1I/86
M,7-KJ,U]0^(HA$+8V<^VWR^LQVD)K2+=UA=]/X^V,M:)[<X,7T4\;>F2TZF6
M0]>X-#V%:N^!/7C%O!SF&9?D8F5"472U0?:W@6NY_OP[P!$^^#;%,N,*7DQ=
MYGAZQARZ^VF]IY<=$2HXCL?5VSS T_5 1GS8MPPHG&\8Z,27&O@6V7'H]R&N
M/I$U^LUCPL!%\DZ?W_7).^T-CP&_Q%6@9BVG:-L?5GNRH3L;M"R-CS"\K;.T
M1&]JVSHBLE(M;2KCCW83Q$A1GZSX5G:U[:7D5#\QR^M*?7IN,A%[D^DZ"FM9
M&/5YSFI>1>!/ .&S-J.D81R\(OI]KZD8[UD.^P&D"V,\M6'(N^'R/J\$L2Q$
MHF4$D =^OIT#C)F)-KB14%?+-E7_HO5%9TT:Y&%8+9Y_'W]TB@S?RR!MFCJ4
M;WU)67K65E_:UW$L-K;<&*6YY==_+Q_<VR7IW&<[1PB[?E%67HU[@MJ +$_E
M./E=CYKRJ(XOG<:'',WG[YJP,];B)?,Y,G:J=@Y4T3FL)<F20%AT-]Z-8&<D
M("4EVT,S!UP\(;]N?W6T-Z J0*;*D<'FSE'KQ_2WCD^DW[IO22:Q3V.>=R^W
M3I!^K%D8R6U(]2P!9FRP&B;YA49W(XY8LRS!PFX?0UER7XEC[6\:1"J&\PS<
MYD,W[.!VH.]3$CQ<?;"?.[X2,/IEQ+4!^GFF1L6K7)>6["QSF?4;*M(Q=@W1
M:6PKA#2Y+[8GWS#SIJ;36+TR79>_ZTNRX[K35R/%):9HY93R\I/'VJM%=J2;
MM6OS? I_N]!.#T#'L#U^78YY)[QYWWKB97!L<)3D"V9,HFNK6Q$G+[KPIJ3F
M1:%^\G$BCW[V8&RO=+BR%3Q0PIMU1?_Y&F.7^GPEQ':,"P3VPA7L0D=8>.*Q
MF;9!-9\%55]\NH>H8T8E&E'_1BVV+"728-! "- @2]],OOT2IL!3S\:Q*[;S
M9JF:S<V\\,2NT!)D_J21GK*\AGF,\ VNBQUEG(=DWB+:S"T^(%P?)E,XD?\R
M=H=-LJYZ?/XVV1QWCYMDB@OBUI,H?XOGL^5';OQ.EO3:"09](=6AW,'(&]7:
MIE:PP%?91J^!Q. ZU?#1HJMR=R1/.'=_U6@5()Y(65YO\LII,NW<,NOH]R$=
M::'1W9KZY9F*AM7FR+/'<_X,UN W1=T<T:Y+]>8=S(_A6?9XO:&Q"-T.#YTT
MZ:8C:B,S$6^$@Y_SU,'6&\CD?7W:]YY3*D:P:IRW*6WI,J3$>W XJ-A\=I^H
M%>$1XSCQ8#STFN#&X@K16OPU5KTL:N-T.4+$F?79NV7&<<=Y18L3B0F.,'VO
M!GZ3+@<ERY-)W'C(UL=R>+F3>5=*RM4;YA!$_LV'M9W.R_BCSK9;$D'J"H2]
M7H)8MRNHF\Q9([(COLFXVN!^Z^FV,HP&:2SYB3 YWGRL#:[!_FA3&#J&\1/:
M;=E+PCW3JMOJT:#J,5V?VG>IE]"(;G4 ;&2O%?TN;$&NP_V''^%N9-TMTR82
MR6-T-J)?)+*^1@O.?VVT5K32S<B Q9K2\*PW0>R0$.$C_Q9W )OGFX:5+K 9
M5L0_;20-@I&;"N=I[F5^7%J HP5N1/UBO:729FSEUUU]<!:#@F;,J;5+O_5A
M9X>\:\.GE1@2VQ\%-;Y&O9\^&A6?Z,<20:3G$F,==2U61UJ@6$E-?)G4F34N
MT?1H=*VJ00B\7':39'I:4\C5L(S:G*1FI3WJ(W\]-R"BMG0Z:N.NA0I0OJ2S
MWHB"MY#E59SIX*NU 84V<(S2S=F1E!W.S@!Z3]PA.GJT)BP&I^!<F6QTWWM>
M=$@9?C^ 6QL8W"5XW<7D!HTKU?EYXTKVPDC<HX@8>@6Q"$@<(V\1/D%><F"7
M9V?G?0;'E$:36#F"&W\O#=L'\?=[94XOYN<Z7Y+Y.VY=O_KL]Q%LV-W37I6[
M<SD'"GI$RO(-T*&T8(/LM1 .IZTCA:-$;RVK4.&Q?L&N\L2S/Z65&P(Q)A1P
MW+TH>(F: PNUQWO+#:M*Y=NN4CCV91,4VP8Y_W@G9Y9.D7QV.W'C5&!T_JCT
M-(\2#K.5Y"H9T8_E !+;L8NIS^[*Z'1N42!$$+EF&DL>+M,'"I&"FM:[ 4?Q
M"*7>5!$]4+WRE7:A9ULM;VW>Y=]W1"T#9V;#2,XX4J6 A^1TAL5%D%4,K*ML
M9RFBN,KL065\I_.37OJU1HC>>+4VY%%.4(?8HQSOY2M::!X)7\J!49:=@48I
M]5-I#M>F._9=YX$M!@TRKBV:92:U,6QK@K^02T*FQ_?B\=-B5K>6-ZOX#>#F
M7M0Y.KTBEL#^%^R2+X.8!%Z.180<G=X D,>Y$C?6X0ZG(3KPEW]VG<AVE2?%
MB#6ES[YQXV?F6^NYM0X>\F+,>26JUZO5')<[V?4:26F4O2%F6?ST@$XPYM2B
MP<?%ZBCOX^;A.36&K<[1(7HDL\88XK30]P&2\5'J=GQ-[A63)KRW@]Y(4% N
M<A@""S*XZ1+#;DSU29(07#KQY9?Y_'>U/,X\+95M0F-Q[<;<W7XOI]F2WW]I
M&YL95J%V-S(B5#II#/(+>-S$JF)M6N;:+?9I:'6LN$<V4EOZRE*^U-KKV@=9
MK]R]:DKWLT])&S2W^X[,Q')#O'N3*:4LW>>EW-\OT#G%=[M'+-SE,[ENH^$^
MC?*MKR5_H2\'@:X(LMH@[[AQ>Q;>+?KS0WY04HS^:H/0?4)$M0"U$WR;>VSJ
M0*(:ZQ<,N'7XRV)R"N8J+=JM_"E?\3SIP8M:8O<%PQ4;226NNL,0L'2Y5FR.
M <F0TM9C=,/^9X2GD=>"<1YVI\LAM>$AP-WU85>;>8->F-A4)KWP'^C%@AGN
M&8R;<,F?T7S4%)7,2Y9*%;DQ<D OA<?YT@S4]N)W'P?JV[S-N7=D-^4ULPX
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M!)>"K,K5YO#D:PFK/2M(JFFV]E$,H 'W"+ROM=EL[!J\V'';F]V8*RDQM*I
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MZK\0&B>*"<5TNP-4@0MC,P.T*5+!]2LD31M(O;G/KSB@8K;*4 D=3UL/'NW
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ME=%G3%?C-5],M-,G>_64<LI2"P'K78-0&&OR-AMEYU0ILEXLSPJZ,F/,]ED
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M8#W/C$V,O:QU)*YKU<50O-MVU4T7E%8^QAZ)G@=[N.2.\\#5449[[E-L[29
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MJ,*YG<>ZWHY] \2<F7' -UL6Y&\@K^_8SX83]UA89_?4N@0AM2#!PU_R1K)
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MY. +%#$:+'JV"R@O"1AJ @M-,]:H*C_J"-@I?1I<B(EP(!K;GA"R&F#07,V
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M\*8MZEH!)I#)Q[LI^@G.C=L$B_ZZ_*ZS_I!+-UY]H-4,J%&_)<J+&)F9^)K
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M =F<D2U<RJGDI3A92&?_C\Q3G"0!7F&^[%DIZ1?$Y[?QQFU.G?CMM>1*(XA
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M8.'AT2$ZD-WA;IUS"3-I*:@@Y)6Y+O6[A:Q;EN&4V?:[R;:;5GJG..U 5[B
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MW>12/0/,E\R]BE.2WT24*. #.0BU[^3<J38U@W"SMBJY=P+,<T?,<K/D)<=
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MO(1:N51IFHG^4S4IY&Q^#8;.J&8*IY+&6^.W9T@K_UIHV\U"X!U@MN*3YC^
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MU(4H4[I"T&#W.'#8Q+]9+I/(\K8:>?G#X[._X> =X"N?%5;#%<L=(,"WX X
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MAA\,#0+C+Q<1CE-J*9!2&UXO! F2W*B_F[Z 5\(85-;Y2RV'Y?W%2O,(ULO
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MX'O8_3? >^QP?+2TC"7B[G\'R%]P]?_M3O^WF_.M\GLPV=\VHS+_H*1'MW>
MR[H[ #:J]('RC0+.T>)\V\5"TQV@V@?CT=@]_IR'V3F,@ U@<W3HM[I6>TM1
M%A7% Y_VFR;VO?L"DMS915':Y@HQ(Z/PPQF!61HD4SS7NJUFO[/FA* DR5+
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M8SWW,T1X/'4B*'-%<>C:)\(<'X]3TUBJ1M#>,@&2B66.L&JJ+\)X6O&(MA@
MP&+9.WFXX[',U:_W9$2_;:QX[$\+N5PJA/"I"K1/>:3XI)1L()%;M?1XK+ $
M9CSD#0!_!3P(B=X9O -$L7>*'Q+8W $Z9"P?I#@" /<0I'MU_<;]^,9H)ANM
MS?5@Q7S'YPX00>M^ 1ZZ YPAK+#*W[+U\.][DV\-!B%$4CW%FV@.@$6;\E@+
MD<WSGEBC"9E#3.&'U\I_* YI\[$ZD.=-Y[=2KIO%G/J"0R9P&Z^&#?I<YJ >
MP,_H76[_SU-7=X"#@_O4M;.5Z,'FQ0Z??WT6G<F%N_72E:+36RX< ()MU0'S
MP9ZD@_O!Y@6#)P/8'/-!G*QK*:.VS'*CI07>MOT5^^ 7H-2\(:'OT%NSKT,E
M6%(#)<F.I2_5C+Y_6-^R]T8<J__I$WQ#S1%P(CJT$KYB&<UNJ6TT[F]6/^K9
M6-["FHZW1-(3U.<&K*WA-PAETJXL*,,"XQ+L6C]^HU\7[ORSVK J'">(O;-9
MS.?5Q9\+B"[7DV"Y^!ZHU[2V1^ND ;4EJE]"@]<<-M0[LF%06G4@)7QFR<R\
MG^$T(T,N_5*]GOVKD.V?>U@_QFQ3V;'$\0<>5/]]=-3^IV=I#=06O?NZ\[;+
M*0:KYYM0\W'M'>#Y$F[V05A:6\[86Q&>>T@_IKJ'=.I[2$=&8#RB[\5ZWZ8O
M?.UV<>^,J?LM8*CUTT#-_ZUGE#/[QLD$>^)(9L=I^ [@U,P<84<^36^KR%)"
M-M];_7F>/ A[&K61I,==&"XKJ$A1RQ*H+I=ATX:D76"V*6ZS\EH\^G"L 7=/
M7A&&0,QYC/>(EU"&M97>+.[<M5&CS*-QNMK3Y;M[V;P:J32_DKLY(<.KSEM)
M\39R[+^;M"I(LN#8]7[E4Z)-[D$-.+@X9&1#&'4&=6ZS7U8Z/7#SXUV]PLUQ
M#51R\RL)1@>RJK!6.0/D!O0GK9H4?W3R%IYQ3QJ#7KX_)P(\BD@/#&XT+:@8
MB*+G\EO,CO!_(?R$K[V\G&>"ITQ+MU]J0+I5'LJE%J>D(\1.6BZ97RO+B:V?
M5/\5@QMO94_V"VOQGFW ,42P0W>'W'+8C)5,P\) X*0?YD2_KW.BV*./B+ 0
M>8.?3\GJEBPDA]=?ZD)V5E*F_RGVT]^\4F^HWM((B.3F<!% ;L0BDSR%7 LU
M+6K,$YB/^G/#8#L%&]JP,N/7Y^?3U?^AAGU[<ASRC\RT2Y.!T$Z3R6RI0=(U
M?):X+HVFKKM6;]8@$Y07$:M=*LW_1#,77,%[LJTVUA<:.04Q?O=O6J,>O>R9
MXOGB#;F<=C@0>Y^!V="'"-QQW=L'N9IAN3AW4U9W%ZW0@,;XKUL5/ &@J*,[
M0$/JPM7+6=Y9\@[=JSPK-*0A90*6Z*R5L4A:1YMV5"F14$88L]Y$DE#P4GD!
M8'3/\TE-C( VO7LTUMKFC[4]G0S1TY_TB;_0T2F?E%</&\+47CN1U6\Q_EFW
MD=  LFA,ZX_7J9Y3/2&=_^$X2E((V8%%1:Y*9<!M?]1)5Y8PS'[+]#0^S]H0
M!CC?Y_ML[F#2QB[O/;0VWX(,@<2F993S%W=9YQ[CB)6\REYDDOVVTPPAEM&W
M[TM9C2MS<M6-;);61*'BSL:ODYKUI^!?C5[AO,OBS-8VL1%[6\V/ *$CR)$(
MHTW&]L$\S*C9CQGLU .G%3MU_3*@ 6:J&MUWR0W:JMM,;M)O$TIMRW5PXA.I
M:2&/B \(^]-#CJ86(TMB5\TWG2I7^3)3DR66X1L):@$(';9(@9V'USV$:L3%
M.3K!638!/_4LY$"OG;OZ.PN4),?JL592#BZ"^AINN_L(%K1Y43%VN^"+S]QQ
M:OQ/@U!4>BK2DZ[;&FJ\I5U_?$ %MCGW5U[GOZ$I3S)FDMPF.IR2@=WG2TFV
M#[<W)J!CN[5Z F?]VT #8@9ZMC>BA$6+V\:C8V >IK\]I1X=__24"LXG9KH9
M)KO%G3Q<2DJQZ4KM/>[TILNDG9F,!^KCF^=KJ"9NC(<CY\E94T+3ZIS=AL4/
M=-[Y:\T^^L/ *D)V<4/ ?ZES#^X<L7]G4C4A+&]SDN\ PS41@UX4=P#SY?_E
M?.Q_!\,6TC?F>BHZ6-ZQ>3PZV#?HN#^6 *0=6&>RKFH5@I' F9[K:V[Q6DN,
MU5<P"H-.+G^7ZWX;0/.O+@C'4EY#9(<MG<4X-NQ;&FO%T+,I*$O(YKM:%/?#
MN:6P,!Z$F!HE:67J/&+ #-*T'6X?EAKJ;$#>>F&=YAX+,T<(!^Y?-T)G^6D4
M,STB8BU[%H@VJROPMXT-!8&>SDG,?75Z6EU8X7\$;>GC%Z7UV&0W(9%^"U?"
M^V1*"&],;@$H&!I91RB-E$G"SXZ8=@:+E2RF6=T6AV4/5)W*WEK5MCG=E&1?
M>3-E#MF)U]0<'7QOH\1\[5CW^SYVN&#;I38-.!2(YX$LW^ HWIKY%[A=0M?/
M816#FT.1%7/#^)FKJ[.6!FEB,WZWQHNV+BQXV;[<R (Z&BJ+]175!*Y *U2P
M/:$>QJL=ZM@A=<)96QZXF1,3X1@+<*:J.[ZQ\3;4[Q68AH,X0JX?> $RNX+3
M7X8[I+,(<;LAAD8)E304J'=SZ6O><#8A6LKF^*7+MI8R8OX+>^\9U>36K@OC
M0K&!2 L@1:5WI'=0>N\M5*67)/0F;2F]]PXB74KH$!("*+WWT)* ="D! 6D"
M<G2M]]W[V^/;YYQO['W>']\X7B/Y]XR,^YKSOJ^9YYGSN6[^VL#@["M*OP9@
MF<'D><^TNU@)KT#*-&M/64I\OJ=7NY6C4@*(YXN' Q[>#7MA5)Z7,&:X;7AE
M*5UQ$;BV-9FED]P3KUW9Q1'-PEF1D6;" ?550Z,M/OU50O870[W_2G]RX&AP
M0W5E"/-<LNM/G:_R)W +?7T0PYPKXF13AA'5KN3(<M+?EB>2F[5\ZOQARZ9;
M'I6U])?4_S'OZFV&J&<>\%+0*B-5K!V);A#O:P#6-TE9YC7Y]1F@H^ESZR]2
MRQQ^692K"X!0'G]YHTD^]UTP_^);[;L NO\I:#9+\!U9EX\<:+;UYBO,E^24
MM:9U7G0V-LE;+H_ W;OW5H2$Z"DYE# V;;OB-GO:4V5\=!$!H=5<0VRLW:2X
ML%B1-\G!+DWA2 P!UP2C=^Q\(T0>W>2 0M@R.":6/+UC0MY8PJZ*A_VSH#Y(
MI*&!7KB?*N5I-Z.K,5!V$,&'V[FYJBG?4^XG*PVKOH/B-*$)K;$J-M"*T5#K
M@4HXX-_%G1-E(%F1JCS&,1 -NW-3ZXMB/U.+5PI^;)CB7I$F<U-W%[;1X@W3
M<X(YI[?5--,EA1.'+"KR6]V>7Z@+A8=:) ,1N+9EZ( 5G'SMX >HS[M7OGF&
MH=' +@["UDTO&I9T^4A)UFDQR"M3^OF:AN*^*4=2OUYBSWL7'[)W;C.SSQ3-
M,!:FJ;J/:5Z!@CW6G'MV/)VV3CU,#B!,&;: _E+V-9:2!U$F]2"3 [AWO2/E
M$OV?DG9GJN:9ECM/]Z:\)$H/J.VM;3)!!,88_X:V"$TS09/1KLRE)TD[%V.L
MR*9D_\?,0=B&[F8&H&2>CK22KX@Q2H6?\6&LKT\@\;&]Y(//U9X\&Z8/FV?3
M(%?=T6 6 >EU'LZ7H[1'\*@:&PQUMN:PYT?DD?M"Q4><SCBR<>BCYL,]7N)E
M20G8$("7ZF4N,,%U43R,OT)A[JQW[,\ZG!V$5D=<W#>5N:537+IF$<60Y4.@
M6<GSVHW-FJ;QYCO\D;&97B YDNST#P4*#8&6 9K7"O '[HE#569#CJ+\RJFH
M$@/=R"<>TR4SR)M" :G0YYXI_Z]#05W>M-&!=JUI\L-ZI<%TY2F):T*$<HF+
M3WC4]<A[H*I6F4TS:66V#OC/OA(_L30WO>2J?7QZC=>3?^:%U;[GLZT=''ZR
M?HW7CIN]"OFL35_]?^5$_*Q2_ '*62FQ^\MR,8/6Y*5Z_F>Q4>.])1P>4\1[
M)*JIJ5 OO@]9A&!V= FG)3.>HJ6NUY&"I(2(S".%:/L1D1+)\Z[7VAA'P<1/
M+1H$SH^:>&^I(B9BTK,-FTKTJAO+[ IV/]Q^HU7=5E]9^(H.ZONG2>VV"OJD
MBBM\7H#L!&IDX.^6 M\R/7V@TJY#[TCVQE]$RJ/.P,LA&KP$MXDC+%A\6'(?
M\KU.QIB& J<X"%[>::<9D*!\ %A)RT17>[X#>ICX3N!F&59,5GO%*&:7'2%
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M&;WPW.Y\ 61:0WD:4.OPF(;A3XF\M>LZE G?CP 0+C2;MUKS#&> N /,9_/
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M$5G<L1BV'*L U9.O+%V3NG]&XW+?+B?]Z_$"+J=);7&X:)?O#5_>FZ1G#2H
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M5]5E]>4M1%38OE22B5!'4J"<3HQ@)MY$?_6T,?*.^O:7Y2K 83#1>'WZ#P&
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M=.E:=NXUVRX+K3M?=5^U5]>.)*:L%KQ;1 ^261;_X_1%0]8OKYIXV?<_I'0
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MM #*3T4A-H%@[G!P.3FY>^@4^J>XQ'$_$,R182'-!@3SL"P._'-"_P1SG_#
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MKD+G*G2NXG_)552&&TK>>^S'H<=%R((I"P&]NW,L,;0VC<4KFL3$ZGNPJG^
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MY/W:[UL5^31T[^%=IK.2F)HF%_*F?VKA1JEU8J=YA:UH/TM%9Z)WPD_<5X/
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MED^=QWAD5H,/)^ =<!VD-4GRR>5IU$W:7N@=&FMT[9)> Y7O78!=Z.T95T
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M($!4"'8A(/L'!LD)RH$(3UX<$N\FWTR[D$R3, 72KZ1,24T8$PAR1R>A<!S
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MI06K.!O;$#)-Q4MHLBK+-8X%^]<]O4Q+T:#.Y9">N/0R])/"1,,.J32:'-)
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MI8:\\8S0VT 2/0P26TLJO*ZBEE(:"5TIA+DT28FN81@&)1QJJTVW4O)X3(8
M?QV_P?ID2COP>IPGN+58X'+QR]YOZ;]F\WU:'"/2JWFJN)/F?]P<@]ZT%!H+
MR%8Y,XD[C68D!HB%3$D2!K_E&UYQ9I(1M9(#Z4#76 EC9<)8Q4D0JE4=;6ZB
M]=NHX'RAFB.E9=<3V=_TG(SK.?TU4G"#JPHA$P(TLI&JM>0Z>4=_"E6<ZS<2
ML;&VL.?7^-UWF%XC@#4\^C?M!X UF((.LO$2M'&FD,L@7>P.+7UF*OPP8?$V
M#X WRE>9703)4[>,BP:"L(2NR.$+SIL<5+=EX1>"4\]IIVYKTPZC4VRF(M1"
M/&)T4Y D!U9T*<YC*\%\)4>VE].)EG 12+\6G:BQFD;J4-1@R*F/2"0Q'H+-
MR0;A<^@O2Y]UXJOQDD^1GTSK^,VXKM+D:"G_]AC;RS+&::%+&FG,SZ5)G>N1
MUQ"]6:/38TPQPG@R>:UQ@W8F- <-FE3-UN:<ZB]S_,*[?A'\,RCF,Q3R)[3X
MS:$]CS:7C1L"DMYUS4"R)H(WY.R&6+/I=T#U9_MV#$KW5O>Z,M$I$Q,"^IC(
M.78"0N.RO&1,=;448;H]QNLPP?6(C*DURECF W$2+Z$5 54B$.30*FA-1K21
M@^%%_Q&,;F9 G$I'VR@;R'6R0<VEZ )^?Y@<8;5HM01;([:$Q!R;STJ\/@>[
M:,S19_ 8N0V\R1"%#Q!S=%(5EU+LMJ[IG(IJJY35SFKH\G\0EMG9G>,VWXTK
M$\MLYY;ZX265G+0'D9$GG%@%V8@&(M165&XYIRZ/7#\1.WF:]N?O<3WI>+E:
M(FF^OV&:++?_NIG>2SU B2J]-]E#]<&!X>+?6),#@H1)R9:\*]W6/'6:-/U\
MCCST#^O5= %>V\PB4XO-,CL>UY'!<+5@+%E":QA]U<(6[+>9W_J',O;CK-6J
M5<@*4/ L7I$\I)8B(&:G&WGQWG<7D?EZYMQ9(HU+6H#E;L,<G890J@$K,;CH
M8U2A_Q!FCY-IK\<>6FUUCCF!<":0U\9M[[!E**)(9[0,JM^<IMM45;8VG_'R
M8WEN*",;%YU57,?.31SC4 W'?F?V643$BOWU0_\,/G] "YRGLOPM35>-_E[-
MAS8AM_>LTQJ4C5L<6&Y(;I2.$'P+8$5NSB95=>T6D75T/+;.R:[6FM9(?L!)
M[A^(.4"(JH TJ-!5WW2__M*5-)+<F-/3@T[UFHO-%:10!.G4DB&'G*&%V%)V
M40377=W951Y4=D&B$HW,%G3DCF;2\!F7%"!KB,4(S;.8>R/15>9>K==S*V6^
MXE-0CG)^.+&Y*8ZU]:CYP!.*X[%':IAF3PP37""!CK%5T^T)S5<R)>V:E$BH
M5BC4@-Z23U^=A]@,5_0;D8T+374\PN S_M#6[GP\.344BYM#/5]ENO=7,A?K
M*\@2L &Y+V^"JAJY@5B(@5V*4$V.F-!E@]UEMW;H/:RS18V-+J;6-$3I+9@@
M&L1,[GF,%J5RJ535;>+&I[HHOUSM[D[V;G'[Y./LH$"M!X!$7WA6 QC+_KWP
M#J+E(A=4JC6&L6KCD?TO6[P:ZN+6THS%IBJ"+@6$EXV<*4>>M+.6%94DZ^M]
M3?WG!O1EU/Y]-25?H*[VH[PWK:S>9D$W# 9T(3XSUE6(9*KH[A+):VO)Y6Y=
MMRL)K5Q9D7X/H<]L<U+5@Q8!N>-C@)RL )6DS:Z*=A-Z>/:E':Z^:==Z,%-&
M5T1R=#LR$28U!2%B RD<"A0N"O_-3GRIG9CL'?IY[P\%;XZ9:+4R5,K)*:X9
M(K>&8WU:&9M+=K'%;@O -I"F<NYG]]\_:9U,4JSUHB60GD\_L0C(M090#J/7
M-@=1NPWMG6,:Y$'CI#YC-)=C@C5VWK EV(0&(;<2R</  "DD\K92=D:AMJ)V
M5^'4(TG6*I?%ND041N3663:1TY>U #1.&/2E*-M=UO#[%OND# ?\_@K+]G3\
MWZL3L??3GS^831=TE]7B.<%VCJG.*FXZ;8K@>CCBH7\:KA^[]%)PO324"@N8
MYGB(>E'<WR:";41=Z[4+_0X2NG91.QDK/MI#Y=.QXF.77HI^U<@8K"$#R6EO
MGD@7,$00 J-#+5+H-]/D*D:^7B?"ZT=YHV\AD=HHS66RHHF0M\D5:B'5[3.2
M1_&5'"BL$\M=6<*,.:=9.''II=1**TIXTB,-$X)13D*4I+0L^6I*9"&+Z-;<
M=YK/RK[[U26R;DB1-/2HHN3Y9HP".6<^:051AYRE1Q-=MXKD^A,OKB1[ZWJB
MODY@2%44\-9X[BCJ(7CB/&6BTKF6H%*_B1>]-.C?C,PZ*4J+/#>N#:31&G*5
M7">!V2%6H;"[?/**X_N_XNLT>32\SQ$M^NN,9.H-SF_I5% G9<VY"!Y=QW77
MV7#_GD;Z5@81I$BV]'N4=K.G@JY5Y- J51J0[,F#'IA615!HO1.D$2UV6_C7
MVW3>:[)GVCD1= :E*WE,2O%,PD!RJ++-P@2)HEL*=CX58XTEG$X70W?D3/%H
MP>CL(:9"T*,5RTT%2\W=4NGSA[ZTUOJUCM_=D%ZVDF?69Y"22WZS<Y!\<I!S
MK=++$*WM-HOOJ^KOZJPM,5D$EPLWMZ@!8L4"V9/EQ.:5C=T2JK^ U56F#O2
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M,-;!K-JKAPC>:&U*NG1^%8<MU+@54/<EH-88:]SFSUIV?O3L_,CS9VO%PW-
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MDTI*6L[EF(P3DBFD'6XX>Z,#S-T16"0Y\\:7"7Q"1BHT)0*87MC<9WQF=UH
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M5ZS'J_O"DX2407T;"\."D!9E*<*/:#"N2?QQ1W$!>;URV$DCX5'R'\:8*+&
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M0\1(]49=NV$RN>9BT]S*JIWC"1J]LPPPW31F'K &SWFEQFJB3'* ))K48 "
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M+TWBNK^S2W_\\&-[:FN(IKAWI..;^!)QFOZ+Q5#,TO;%1JZN]1SCE4A6/A:
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MK>2S1F]SR*T_,&$9. -@/=?SVG2D+G@V_1 S=LN.C5O;P*,,,==IH]"87TU
M\?(\-MJ(/8D>LM0TBI*!$)@/YKT.;FUC]T&>#=%W:VG$L\,] "[%6C<+6D[Z
M==_@J.*I,/4,\8B9R$,KAF,Z-YU>QF;P*.+<Q@>IV=N2%1D $BF7?.:=FG$\
M5MW"+B*=6:-_+H^,;QSF.5G,F!S_9'7.;]I9,B@_ND&@B?1#V,@/)KD<"EQI
MY].BAMZ,3/&[23N9 %B990U_QM*9'9QT(<7V ^YPATJH2G?ML.W&P(I9)\C"
M4!5VJ -)S8J<']HE./$0$%8XPN)&!VU;UM$Q5AP;A*$EER:OSX<0"D,N@A8@
MZUYR1=HW1QN]O!L1#/B+QN.WY6I^GO$.[/LW$>'WS8 [)@T&=NK TT;1/17T
MSFD:O-'#O()&17!K<<X<8^68C;@X942&%G<4",[%UG$$8](\#9=\&&=E[8&$
M=G2=<"SHSOJX'6,Q%SK,=<EE"]+IGC&>BC'!95Y-O$I-XOR<.^P,9UP^)N4"
MTO[>1GIX#JJ+*79XVE6'VVBHPN &C,DFDU_KE?/+V)8B7F!J S\TT7\S5J2>
M*L[&/T<W2>C8/BUXB$&T+X8I&V/V!*XLQ:JFR5# 2#_DVJ=JQKO,67;& ACA
MR0U\N##"=G2"DD&2_4KE#)4(1AHM*(M8C,T_3(C7X+ZY LE97,V]*9TW+F/"
MK'0.> C'DB&!YA5 *%K: EL]1^>@9$;)$C""%?I/'+O[5%]W#EG<MX_]!CO@
M(*D&L[R_.RU-29KY*?<R>[&_W=M&!^_UWK$6W/W P-V[+;C[81M(=P9W?_\,
MWU/-;P<G*O\4O"([@QQ0^G<(FS2CZSJHW(Z"GWO!6YT7GS*RZ?[LD-U:T)K_
MNQ>\RK)/4L'="7Z" ?Q;+SB?\)SX5SK]G9:5!F_C,AS':8$&C;]@M&EPIB81
MEV_3.^?!;W$Q)B.1OE1H\)HJ,J?S]-__;6MK]R6QV9_!27A,+G6J9UA,E6;!
MO\B,Q/5O=!)/=7 >ZSQ7G>!_QO'OL0Y^CA5R4N_B0M&EAXFB=S[)"BZQQPCE
MX /9>?02 SRI(DN.[GM._G::JC%M'%G$EQ6^_SDKQA7=@EY=P? =I&0@DY$V
MZ 6G27RE@I_S'EXS3S&7^I6J)CKI6;O6UJA)K7 ! 5'8FMZIZ28RUZUR%8A_
M58V\L9F##73O>K;D=_^N)M.7P1$;C+%ZP9;FS^3WI_(P6.'?B0;O.%UJ\97\
MIF;]@Q=;>_WN%ID=;431BRC.A<$?3+CF'F*&<]E@$AU^IJ50"1Q<KH^5>%WM
M:J%(.(^'E:F/'>5*&@6CF32&VK,B;\ZJ1C#/@VLO"TZ.ZFK]9LJ"U\+)%'8!
MD6R!QXX%&E>O7J.'JY..18@.L!R1%%=L6A281IBXJ/$VC912YL^ZU6XH1!TR
ME,P);]^RY=1) @Z#T@M,,I.?6+(!=NB&'V\LLVO(3Z_1@<6_\WY8,']=%:VY
M!Y5MF\4;J9&"6WB>DQH+J2';@,=UA+(W$XP6\N*YF14:)Y%$">J1IK(/]%R@
MNG1COK *?N>64_4&-2<)FX$?9K+&LH8-B[$>&5W:F(0,,C,)K+K]@WE]K.+K
M'D GEW!-R7C)3MG>QHP3DNF.J#X(0^* &@=FBM40*$G4=2N/&_)8DJM/6!(S
MD##6"8.%B=%-A@3X'/0+X>8!INNZ\)_4ZM<Y\\Y<#CW88&I5"V5%IB&$0)2Z
MG*'4''JU@,<.TAK#/%.2J1]A>#;N8\PVAXOTAX7F>JIB-'[07),//G(OH44@
M(T[*SS1+I?_@!X7K3$<B@!C$0SF91-40%K>UY*:F6_4@,1A+R+8S?[].S'[5
M'5W/3FSLM.,)*0/"5M%5%JIPUM :O>8M[1'X+6!,6Y@KGOYTL+V'AC!)=,U8
M*,ZEU<.A_&:O3XZPCPV*BGL&,[*712"C*DRW"43ETR[#Y?48XOL*(S&*TM8&
M-J O]1', U$<0LN;M"1*5IH=AK68(9T4B_(R Y_HCYG4U%EHRHV(T;B^Z\3@
M>*4[-K $0[HWDZ7K->$C<$#5DZR #N;< 127H7,.G?-;">"A?E4&.=1]YUR[
M=O^^S.GI)53_G;IY?=>0[Y?"%@\LPOVWM>T^.SH/_G<P"-%IZ P3MG*Q#X]@
MS2*G92?_O0Q^NGI[1+_]*5<C-Q5C#$(TOO++8/".;S:9966>34G9!  LPY L
MPH2HBLCS97""WYPXS&C]Q:L/N/TK(KYPC'D3DXS[]$<SA'^+6+T,#M\=TR\.
M[>BS))X,20Z$8SWA;T]P_6&6RW63.,SKCM_U&L_J%\Y59/S<PKSENI/](TOL
MK$.T%.\M*L4LJIFLP$O@VVZB9N0@2&#;S:OO;?[3IF[8"9D6^D5!I@RL%GK.
M_X,NU:6+GU_%12R)RA?VU^9']*O(T0#??+O?>[[S3S^P;98OD>T?5US6[_?V
MO_ZJW;W>SMZ7+OM?/Y;Y_!N9L/S.+AT-V2^11/M?2,P?'RP_U,67-IMHXO\N
M]]7("\2IW>O<)@/<#\T7/.1VV0W,%YO/Z29S 6BZ]T):J7Y4G6A:N*==!=]T
MC7,-OO]UJ_Z7MW:ZR+%MY!W*Z)L?;'N ]W> MMW#6Z_=0WN>#_8\:T@EYB Y
MZ+1GXR\[W!O$>O\OB_56?G\#<KF=)0]WM)A]D7];1OW6.__K^:#=].^]Z<?B
M]H7!.;F:GW0' PNJB>K<QI5MI>"C)8M7<<:COE3+D:T8? *;[L1@8Q3SR^!P
M#&11&)S,,@&')X'YZ5+.:*7?HZ"&5TFES[+P$Q+N;GQ RY2M)'P"F_Y!89Q&
MD:7_L3#L[I:2;GNSE70/Y;1YU-$YF?>3X!"HA5;@_;U6"#I5M_O^W6,^%KM;
MR[R7=6KUO$ZMOC-IV/-0N\_^NL!L3<.'0RJ0DA]RABRVOO%WW_TW.4/-?@Q:
MT_#O$),<$O1=X72D\G .+MI*O,=UZH=9KH&[.QSKR?*#;KGN/O??&U+2;OYW
M%WGOSH,-K_0E3OVA,<_((JRF59L.?KP$<#A+5:E:O_COY4([ JK=^N^]]8Q2
M[@I*N0N4<K=& +<9XB=,&&\U/2@K@E]^:9GR>^\]3[)KM_UOQLJT$O!ID\,O
M*HHG"JYQRXIMIN1I[/NM,R5'L1KJ4K>N\>.E!=1W3\DC:+FP#0D^H<T_)8V?
MJ;P<HWP6Y;;SA;9'MM"VE7V/E@A.=)$-Z9!;X=<& Y_.UK]M@J/?OGM[+NT,
MT [@B/Y]F&=CX&".6AS,(R>%,_U>5WF;#_X;4-%MP/7OB_P5'/EKY=JC/>ES
ME;Z*L^ P"]Z54<MH;<G'$]CT.>D&EU;%:7"<_E[E2_N2M++N49S[>:FYH:(R
MM1_>A+V6"5O)]P0V?3&CNRR_,>?V#DZ.;Q**]%_T.6O;WJT/+=Q[X^2WLVF&
MF"_&[+ZCA1J2L2" X-";6GM,%R7T2NA##NP _3(<MW-_'O;<G[UV[L_CZ63Y
M57-_6OG]\ [[@\Z#PSN.D[E5G[EOO6#3D>Y"IDA>9E?K-(^I8_JLN\&B>SQ7
M=+<C4RJ#:_S?]H&T>[_"?!_N]SXW&Y.;SV_M!MD0PR%M4W@[U3C@/N28@T(?
MS&A)G'S@Z0[!5*/[<(Z.]709NGQ/D8V5AL0JS#-,%$U,.S]>J3?2HQ<,)AEW
M\LZD^[A=\%905+D,&/47;E<K(P!DYCDD:(+)J7E&BAWSS&4=\DYI)FWKYV]D
M7HVG>KB';BT.=)8G\=?H0YYH,^28-V#QC>6A9O TO<_$7IIB6( ,$.#>^U<8
M\7D)V")1"5V7H4T[OUUOG:AKOL7P4Y[/L3ACRB3:OMK ?#IC#X2[B%$?DKSG
M"0AKQ843C/&9F]$#0;-L2(^;":%JP1/[L^J-#"4!A9'%6568H1)27\4C&W@^
M,UF^)<]=HE\.CGH!Z^T%77@[_=/9VWSN9*I1)F;> QG#NE8L*V?8=<S$%_S(
MTR<;I#ZR&%/\G'C&X.F<ME+QOS%T*,K5=?K,B69?$6 J]!OP;4->FQ5"6+-^
M6:(7>&+UW*B9G7DMBR?VFTKUV7K)]^ .$OX;RZ;U-[O_)F%\[QIM 4=U9Y+\
MDLZ_5XOCD>C*T[0>EM1_SE)TAZ5H\.9H4$]O.YME:1@GP4:N)]P: $.MWG7S
M3VDD@YU(Q&48*40F^4:4I5G^+!C2<S%I+L^N29OF//:^.=DGS_!?%F@;)^>'
MS]R@(=-WV\PA7% ,M( \BZ-NKD<YR4H>RL=U.9?SI8M6D <;YV==]=._WAX]
M@R&]X#\49/R34U".6:V@!SBD*/& SGONY7E"$$:%Y71CVIZNVQY:O%U[+S@N
MH0%+%9-AOGR24<?W)8)R-M5VW)(HT9 VE$<:6EU)7D9S)A<O#S]S<XYB=*/G
M(7\3B\V7*7NX?6'O7]B)@JM&+.48#Y4ELO>8!RM/=">)&XVU2LHQK2&B)P7C
M:H)UX,R+]5(S3Y:I?ZL'<^'X<HW(J9M;:8?K.D'L9C-:0A_.G 3(-2VU$,\V
MD" BW=4?D D.K8=?L646EW@^?59@/IV;F,7A;8_2A=<7I^2U\QG]$6[P['18
M5G1P'_(,$U1G3YFP"ZT_@:J(9LD+*>THUVD>ZQ*>0.V:=#CB(0:W##J,)RRO
M)TS.GKMB>WTD,_PDRTO%@U^9<GU2-Z-SAU5!SB"1,O$)EL.>P(3D/60^_X&'
M17JDT\C$AG UIU%9]FL6S.;.'-J1T:T)K5F%?U1Q7DM?;]8M#ZR3*:M+O^\%
MM#\\2$_&0^(5>+NPG!SQ*D3'R*DC-Z:L6&W*K$@[V=;LJ6Q8[?F0''".$0;J
M1C&T0ZZO8CI"NH:T[J031&B:H3_3145\%9<S.[G8_XQ78K8#_A)]5V+H(&)8
MU^*U7ZDX03+U+D+@+^26UHG*:VG*HIL-IS0C/UG7*ODW3+Q$SI$T<7#J#UVV
MHS=_>WMJ1V^ZP89!"CEL?I H)"IAA9'LM3,^1SS,-U\8]6Y5Q)C$]5!KHJ,H
MFX(,C*Z@I\GA5G9\M;%6;K (^@K_^Z[S,/WIH^^SU!<<[Q5NN[%.%LSQ^_?/
M9!IG?WL+S.OB'?UM"7@\=(/KL; L"5XVV!6TR3 6&H.^,*.^NMDU3_*%$DJ[
M3H:+*"Q\L6A&54M<GY.U,N47-E-WJ'"5LYQP-[K:>@E5(;D%\E.@Q$99$F?U
MR.)E]Q?@@#P HUCA^]2.W H? 8H1WACIEL^P2J)9,:K24&;W6@W$N^&_JK(+
MD+UN/'I""C&+V#0TJS@\VMKO_R?[571P8947F 0O#LPI-/Z2ES%.%\S,>"+Z
MO<,S[3']%E&Y8JK#>(2(6N)T'<LH\U!_*GR<LA-Z%4<5YWX0>1M<,AK*G,F;
MG#05U%P\F51I5F"><H@ O*A_<;Z0S;<7&%?44]-6)Y>YBF#9A+FVALE$S3!.
M]VO,D1X&N7CW@6T#]S .X:9Y)A.6IU,>$"_CJ*%YZ4^-7UQABG)EWCA+:8%)
M/&&%7UL'3U@WT]'!!))!]J,XX=G L=$HRZB2"*FHICA%]GRJG(<2<Y90K"<F
M-W+EHY@L*![)39L/!TE)6-S,Y)9)W2JM1HJ<@=RGQ(992U?X9F\QYLG,,M28
MY$2A;01 7@.<>?,+&$KT1)'^3"K),VP;/Z?GXXH0$D++.WI\SU8J&-AKL%=4
M(;_@=4PO'>FI9B')1BV8(QL:L]KL@#.S[8UKNA1J]IC _\Y:-OX1C"K:2KWD
M%"Q?.-%4%?+NAO\ZWE& X2.B%X3O<V%^,]9Z<O.[FIG7_,+(#LMWHRJ1V>_&
M>\B<N*-572*J5(K9W\4.T4Z/29[I]-(L&AZBXM,!!V<51-D(Y,+W$IO,-WO$
M*V%9PF/01#K!$K_&_R/:!EN4UOYK[[SG5C+6B;']/ >$WI1^RD>3E1R3PJL4
M)#\P1YA]#2&B>MR]V><X]S?4[F$O^$FFE,,QNB&KY,E;NJD\!;^C\ZJCF,B,
MT*W)D/:'E/,%]))FDYB)K.G*+WP\XMN3=Y(N&,4W!-%<:+".I73F-@ML8KU9
M*X[-?'.SR70MB1@F?4OLC74FZKJHXM*116682\FD7*'7$MN21JP*4PT*HV/O
ML&](@GEN3>Q?3)2XM- K])]",\2!O$^$&LV^XD.6-:R@')V:<PTR[]_.T;:$
M0)<W?BPL4%CJ9)^0Y:O%08@U82B5L[%D\R1QY&LR'D-L-PY!XT6=RM1I12%2
M;+'SFA%*3=U<>N! M%QC[\@,.^0(<PH*9O68Z\*J KC5UH1HNOWSTG'9E<M^
M"N7"Y%.YR*^(JP[1<,XKOM;-Q=:W:EH1=M%LY35OYEZL$04AWB,QQ%+8"-#F
M 3?T%=DUO+,S&PLP]JSH+6SPKVGM%OJB:Y6Z804C;W#-ZDMLZS301(&A: 5:
MS"C7.H(_G!FI1P+C#><+8J,N,X.@R?48808FHN)3PZ[&C6(_R#8U0;9.,$TX
M=4 \:EWF[^1M\9U?Q"71>/@U!;KT;L$;3H@4'+#9>GG&KWM6O^Z-\<1U,+!Z
M)A+1PJ,?-CQZOX5'/VQ/Y\[PZ,?BZET@[8P@-9N'-A;@%*RU6JJIL5L2?0F3
MU%S!=K;YJ=&X85:E9+%*)E=L&_IXQK:1>#DZ(H,S);U%ZN]W<O***)9PO(F.
M7VLV"_S@O#54.]X391&D!+<V@YE6>5''C>DO.&$EPO5LW3L#D_:BR_Y_L<H7
MY+75S[,VJ<L-\%.-R0&/A'Z:B@GC+TM%D*6P7VT:'!J:U+/X7>:WI'/AL%G'
M*E<F[TABN[ V-=OG'\PR2=US^ -)A^ 440\=;/SPZ_F'"Q<&Q[:1;:$FM3O)
MEI%O8+L;RA9ZCH!Y,7*H\Y+?"Z$E9Y879(8-?[<FG06#)6P<(1Y%=B5;GRH5
M1\4^[4C>R#IF2L($WB[@L1&L6)@BR_?Q"8=C&@19>@SK3J:V_!D$W8!M&*O.
MP.WH8>01QH:BD0Q!+*,.32+4"L<>)\*N.U&#IAV)X7EPI&998LL2^10441:-
M'V'*A@&9(MKC^,"&*^8Y.F%$2Y5;OI<$O4O?U1FY4,*!]).CO+HD.P_<X ##
M)E!B"/T"=S[S5C((F0;[!\\-$NBM*L-Q]S?U&4"/ 5%<Q*$F3D?B^U<QEQ"'
MQ8H'':=I=M6X]];FYH'9$>^D&OO&P>"I1-GH<$2,#?4L,X$9_9D[\)I?,L;
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M$0#' 7+ ?EKEK),$(&&\*3S%=U^?+@-#_V#[E^PCVQ.<)9J@PDT(DQUN?2F
M0=KI0G>'LR[^BQV.B:X'T15,?:2TLRHMM)0=-="1DRPR'Z=:1X4M#3.9-Q8
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M"[81)C3I/GYU&?-JHECXTKD$N6]JV^2."7!U.&*&ZR5:MK-KLY8>M*P(-FQ
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MESWVV3\&P'V+7*X_@K4Q7SK4D/PE_:A?=?2B0K7.SPI7QT"-:$AQ_**H@")
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M.1<@ZTV+EF,Y29/1['::Z6[[+>/L,!2<<AW5WM3+**,)[>E\YIUB&61YVRC
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M,HZS9X"'E3L1HR4V1>E;N$1G-='3JKWH$/%&PX8U1">,+@QQ6Y?%P@I'%F1
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MZ3K[L=[0?<JC[_[K/TX>/7SLD1P)SH,.PS([?8()_D=/:_1HECVX_^"+&]T
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M.%GU]O[U>U2O<:4V/8%/GO2*%H-.VU ,!OG75(^?>@@2%H#7<5.U&W423JL
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MRWC"N-0SX2*TKF$CG'B&YTCPR8W_Z<#1-!"G0I'!VA!/9LQ 838E9L:BB>=
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MS\DNY[,"$YTF& 1_.2U3*=0&K++ZDODI^5TQ\+321F8L\L.X9-,7;H<O G^
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MO[C#L;HW!80; EBNHC,HT?2!:D7[XH*Q-ICO,]HFC>]P'*<D0R<^11<V;NM
M0U3;/PU(BUC)3'BC&\]IJ"H"G<007[?G,+L< S-SYC['IF[<VE5<'J?W]6J<
MBY@N:RZR;M5RM5#12+I#38PN?^]BT0--)5$=?N8@+$@_((7_U2P,D>=.==K;
M_'UVUFN YQ_UO!5E+[+/E0R+9,$3 B;_( F(J O=]1M1E30@S:9PDUD.28.U
MP82,;X2@\E_M!XR[#G6\<2TX2GA1T\^LW< KX8)_H\R4>1DLV.@]"FT3'"]0
MSBSNF36R]1WA!N(2 U&1&08 *;^D]_:D''M5^ _N/[C/)67DB2Q90I[ZHGF.
MM,+F\2U^0<OQ@;E\<-^;'4?Z=*^VS_(E;9!\8:.A^<;$(6-\)$D8+K+GN)"1
M90QG:*1<$+?)JT/C.9E)L"\,/#(LS9+"/8XS8>J)C5.S1@,1&!]-8P-K"RM5
MQQZXS/V>C!-W,@NP;5LA>51 MP+@\O-SH'LX>\R&A&)B;3M%'?JLEMD*S1]\
M=L^V.)O<C=O(!M29\,G'5=%BOG@C/;C_\(0\2F[CG$H5(6B\PV+Y7]Z/8?W[
MD0*X]JX.UWFS#)<^>)(]P8:16)6#AY 8]9ZSF3-B$D"O*D'-:Z.WQ$YK76?I
M!<T&%(W&W*.HN6T*&0>R:F)Q&H]1^BY%!1O9:(AP^,6XY7('D;"1H,^D R0S
MF8[45PMU"9H0Q3A4-1\'0!)OIAI_TE5!^SE;Q=( (RH"51 7&UYQH8G6T(2V
M">9)I-4HD5MBB<4]7LV[=PXTW\& Y!?D4CXDF4Y:\FN1[&]!#.2Z+OL7V7$E
M+GM&"_(.5"ZTDF59ST@!D]M-OUW\2,:F6,>@+UK36+YSX&')L]=<74"K][;Q
MQ1NBW]4+'%XP&W.SA5DA\K?9M1=M^.S9$VY7,[)+?3XQ]ZCH%:VYNZR;=T+R
MH<(WZ8JZ$$">5_,1"S)##"Y#0IO>F-5IG*OB @<G3L@K.IHN.PG^0=>8H/&N
M%!M&(SS30G[[Y%03A7EI+&">2"2MTA$WJ8Q:O )32.[,NPAK9#4GKFIJ(<K!
MC9+1M4EQ2@"-82BP$)1/*.J20U]X9TUG3T^724I)HX7J$TV!L9^0G$ZVG]Z)
MS1SD@@^^=O7(:PXZD(YMJCM\R%]6V3]ZTD_?S-1*@M3F\(QKV<W-OL-_[,1%
M]N53(S'/7B*O BGQJJDW-9O\9U%>5X,<IQO C.B-G]+3Z\TNC=EPY*M>])Z)
MQ=!728HXTEY:4UGL]Q#=[C-+S M$!->51$/"3X]I5"/:"]"#P=M)]E%$RA,
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M?D/OL;O3IOFJ+DONJB1=GUJ9$E-EP=1M:.*LAS:C:/<JL'! #*<_BV@FI3N
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M3JC[\0TB?)$HT/13%!?CLR*/20961ZE$5RVW=>$1VY<CY0T#V1*@53%B"P
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M:^: <'H>(G*-I+$6LJLR+O2Z%![,@BL8Y'+&"VHW3G(]G'/AE%.F?)EJJ<5
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MAWL]Z$JEWMMUE@:718M&CZY<I9("\U/TY$>H;BQ1_!^?+('M9OD]3EI!4IJ
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MC!\(TR4KJH#-()!(6*V[82QG*/QJ8]J(L(F_NO,$J<.N9,]Y>T^*R.^1!7N
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MB6;QLC^+GR1EMDMV0 =9OO&)(WT,.M*LUY9W+T/;Z0V<1&4&IM'A=R@B9UT
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MC$E>;(E%MK0@Z=W!2!LDE#D[1750SBY#+SD4:PJ&NXE/,\X&'H)W7&,P&ZX
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M]!2J[-]B4\Z0_7L!V?_K#-F_WW6Z:<C^?#O.M^/O>CN:A@JSW8S@!8[2"$B
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MR#;T\%AW=K/WGO1D X]P,@[^;43*P.7C'!; T)K9NF?KOE/KMNY2 1B$NFT
ML(#'K%DS]BX0/!JAUHSE_U"P_%_.6/[['>[.6/[YDOA#+@D'M(NCRMJ\6DF]
MHH0FD&8M]"#USJR(<Q@Z6^N=AZ&.24 ][]SG5@9*X0F=2@Y*732UAJPM62M4
M:5VT4+!&"^7^8:JI9WT+*IOOFV:]>*:?>LFZB_$M/UI]_^QE]_%RL?K^IY?=
MX/.O(=F9?_HU/CV9&/9U\&6"\N0$[H/WE]H41)>4G:>HBVH?7S$C2:!"'15U
M:*\S8<*\G>?M_,=MYRZT5U2O!)U_=/1B:")2ALP5,,45A8)HL]WVM5-FB#OV
MAJ8!!5RG&F^UMPV#)AX>BR/_R7JT"QNLL7'->V7>*W>[5P1F"R-/(% R3"(C
M&/=*:IIJEY@$2 BJW/7\&];JK](+DPB=,D<(FP2FH);RUAM4NP&V6C5M*Y1R
MA8AY2IIXF6\EP']:AI$(2QU:#5@8VM@:65080LQT3U6&<<#U!L)G*7!S.3"K
MN!IXXZOXY7F?SOOT;@FOG$5C9VI])#/\+K'AH!NH=EXLPZ)H-RR9)1[H'L[>
MF21,0CIK!,<X1(%61]]N-T8$S6UHJ0WM=NUG %F:.,R!QAO7NUX:;,1<!\*N
M->MHZNX,-#L09IG+4(RIF3TD*<;COS<$Y1"TQ+<8S!"A(U;T75EC&D<S>Q@/
MEE_<1Y$_&VFB$#%=PIGE*[94B,HRK=U2X;9>?W$H+#AL7#/PF "%@3EF[-C#
MA1D=7-P!=O)PS^34^L3S82DLN+SX&Z9"G.%%LSMRIR7N=']T<8=W&SZ',N'N
M@?!,=H%Y6:"#:CA'CCT%KDYYY4HL3;CK=<JXR1E9U =/R?T<=,^[Y\^A3Z 9
MI5R? #2;<8 [:[9'N,J0<L*A4FCK=:!H3Q&+7_KO<NMV9!P%\'YCSY.N:VK$
M)&$I"XME7]DH G#VB7W]>J;2G+?0'W$!H5$34>Z>]=<L>^-B,/0XJ*$?NDE\
MES@23=;-I_"JV:!G@[YS@]8N+FU,Y#9EZ@!3OA)ET4!PW[1,J#%5,]=^IF'P
M_]5B-N39D/]83#=#/C@],&B<B\YY_+W9*&>C_(.,$LB(C@I 18).QV/U,D:,
MQ NP0Y<JGYTE9%JT[Y.)Y:N<3(1*/[/QSL;[QQBOI$XZJ8N&MY=*:$%/Y![R
M57-I?O $GYW/]+N*DJO[\&=_0S7G=\7'_G&3_.__\N3SQU^]>V+Z@X #/]^\
M8TZZ[([7"P:U &%9R%O/#]4+]'$0*5]*M8&ZT@<%A_=J5WY A:37U-J_N"@H
M41KJ!=C,XF3OJJ"D@I2X.1<^&/2-^Y6/[WA:_>,BQ!&U='@^^>*KCGC14,8D
M=@V394<UDVF[394<Z5U:3<H-<3Q.3SG\BY0'*RY#ORM7#[@^](VHO<=M43$U
MW"8ZTE5%Z0@NY:=*ZEG97!('8QP5S1H@J^MX!<9E9H(YAN<89Z/38:^;*Q)F
M=U..)3_]9LF$$$CN;^+XHU4\,A8U4X,C]C92*7E;D >U7)RN^XM0;775WG$B
MHV%B^+(<71\=(S>[GY]\\7L>\E]\FL*-/\.*?U3$PZZH^VUQ]JBXNBZ TET4
MVWW5E'3L[0KI<2+/L]Z59\UZOUQ<%PK#8'N ;ULO_KN/E_K3QT^?"$5(_+-M
M- K#*IRPGM!(F'J8CZF_%"9"VM[VQ2#EW1JT4&TT)]K7H5Y?-F6].\&SZ92Q
MRDY\N4T9[1+Y[$0N;N[(63SIXR0X A*Z3YKZO %M:G\6SSDP,/;<]:MI/3^H
MX8^=+'X,?P_;L_)>&.%GG_S)C+ *T08#V6!<N#.R0:) ?%=#) N,IDS,9-$(
M/Q$C!!/C,>,KB&RXXCH%T#*)E(;8UJ[+1 0Y95L/F&SK)\I]$_75;G\I5% (
M.0-?'''#='P[PP.0TQ_KQUEQ7C,Z]A/%Z+:IFU6%6$"6&511YX^ZL**B$R%&
MHH/&FE5"U0I8)=2G_OU?OOST\Z\>$<S,;(=J47W;,0)S%\"T'8HK2$#5_]AO
MP^*CKT^???MQ]D.4#+W<48Z(?)'U%5$\K1?GU5[21_'\>61D71\ANGO\U<^G
MWW^+__GDJ_S7XEG1[.C$6!3G31TC<1+*"M1N40/F>483F)[YT6<_O/[\8WK_
M]''KG>B8F_"JZ(BX\-=&>Y=87;5#<S>5O]/-BR6@<@7/][ F[OGSANX4BAM'
M7:K)6UP\LT0>N&X673/<*7/C[3UKO/WT\=QX>[]/[.G&VSEP'=#*3I#1=72)
M!&'[CHYGX8.<K ?A.)SUX0:7O] -1SUY[SEQBU>7805@5P5"36+2%3JSI'!^
M1GG%."%M$[V2MJCI4B <&,[1>$$QN?B"SXE0<Q?6.A" &5W"A"\FFL+I$6I*
M:M,3-?KBY06Y(Y^,1TI0[/BNK%F)L&;R][S?<]%0Z*V4K_R+Q#[$C6-(N@*"
M4]%5#)5H$G"^$@=W5T)O@?4PID7&-%GK<E[Q"FW[<I<4V^DS @>G+<!\F%X+
M6LG.&0@4_Y7+O"E_"]#Y-,8['O"D5J/-9?PZ77P^MV-/3CA%?:EEFP#FADAG
MJCL:$(9@/QMCN3,\:LB0MU27Y,R/*OKUJS?0Y 5QDS GC\<BC$\"W(,,U@;8
M5_>1B=&*?D&IFBC^,>ZK-C9,ZFA"_=;(6BR8C_G:_Y3QGM[B +MA]G_WD^P!
MW2(OO/1)65\UU97TQPBYZD7QCZ)=D^IM$DISY/VL3JNUEOJJ;!LCT+4VZGC"
M\&Y^T+<*(A8<B<2BG=0WZ*#Z+HZJ7!>B4M)FRB2J.HPFW"6!N'9"VKX):]"J
M5]1SY/1$L"O8FZ30IP%L>''=M&_HOTUT)IY1PL@,2.5((.126^.7H@A$)!6R
MN&(=#)),++GX.X[G&.<T'?=C)!.BX-;)^:1_$")U/"M=-O%PW-).)C63<M4V
MCYKV/#ZQV\H#38^Y6)=-P2V/5*]N>FKYZCL)))NZE@9\0X?:0<)7B4/"T:]@
M6>+MD+00EA*W8J:%]!G_^"+>/9?:-O8JH;-_8'7F4]6">DV"9XO71"CYRMYU
M\4PN2'Q,I_!GT?"D?Z5>Y\*X WX.(K=R*KS1HBMPWA?$"!A$5B,>[F!28X&A
M78&+!0<_W8:_]BQP2-,0MI=5LP]!KUW/90" [-3N-P9EW+M>VPL63OJ'+6M\
MT+E,5W^,GLLMT=J7:"7%+]/CIXR%YWG*,HQQ(>YF]:@H15(_ZB]%SB#P PNA
MV<[/HWPNUJRE4XC !=)G&#J)Z,0WI9TFLG6;&,3/M\@MI9F.D:S'Y?VQV<8/
M5(^^EOQNDXG '5(*2,S=N6B39L,/2:VSH\G*2>O\4X1864XZC;XQPWDX8F'F
MM^0CB?]6L*)$KH_B17N.",([ J#H\SENE%Q"Z7>3P/E ;M73>EILQF0]U!KI
M-)@TO<SB'B6R^Y&:4ZK\QS/B*D1;U#-NV]24/V6(2=:?$VUHM4^* +QNJHN7
MM^^K YM+0YDK*Q)2G%-5M2E4'_1GBL7/9?<FNO%%U:<;XZ=2NYH7K]!!=+Y?
M?/3SMS^]^ECSK@B36E0@&JU1W   %\^/?/,)?9@D\DGW(MVI+ X83^EXQRVV
M8:W81M(DH#;KBWT7[;T8T(E \Q&;PV_"2IX$;Y-.:_9MZ";YZ-O7IZ_^Y^-T
M;JMZ6, -$__G&<<_V["[:,"9*P.,)H1_EWM0NDUH.J/AQ9M&!!MW35.Q6Z C
M(G;RK&'JENJI:JJA.SC5+%&6NV.050GLMA%D[9Q>8?6F.,?_].^XS,5@! B-
MCW5Q)/&"E$_L<"4C@-\V\DI;^BP4@HC5090SHHT0K SW]V'$R\09'4\.%AJ2
MQNBC)S8,?*AHMD*'/OM<D/] P1/%&[??G+1:VJME3;PR:3\(('RI2U[(9&EM
MK7/7!8YNSHW@\ 6)%%\I1"NU%/S'?I3"T,-G>D^+5 Z!(\E*=!(I*GBCR1'Z
M#]<&*%/S;# @G4L,B;1!AE]!FT:7J10Y@7CJA>\NL)>O0YYMB-^GN)L9?N29
MRUPFTP!'ZAA*Y_OO@S_Z<"J/28-1'?RR]<'?D*[ .PQIZZA>Q6V/EYRM+$54
M.#.Y'A9M5%72-4\W%0+&,V?=MY"#JIFCJ<%.\+'FR>*TPZF[9#W<M0C^2*B;
M*5%.'1&RYV">0VE+S?"@7ML=V93%FNKA%G<D!<1ML0XJAC79!<NAE^I7&M!9
MQ*5U%(OFS*(Q>N,5'8GQERC)JV^-PB</[/HB!CG7''4OMGVWRR0\X4RN0?^V
M) <B[)?J--"92Z.EXXC8,.B8<VOL-Z0K1_M56^JAHJ?>8)T?\(9\)X?Q.-/
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MX7P%ZV"@C)^>%]ZBE!W<M& 6R4C+T#F#YI+;YC@Y*+T@_^!2JH2&)3FGY#?
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MIS-B]7X[1^]/9/B!>(?/E-&N2<X[,Q/@/^+AK\>XT=,^^^E58J<E)1JZ>C>
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M)XA,$T].OL'X<.L",9],[L!E(C.0P2Z%:'LI*-2J"A1>L0!T -93<$6T/R>
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M=K])E/&?,$_OH=OX@3APQRQ$6P][P=L:X,!A&R867S6JB5I2^FX,E7#(JJ"
M?@!J GA9/CA0F:O]TA"F;/AD\8J^.?5/^ &U7WLM]D&D#6_5M"S:NTX>X,4-
M"LEZ-X>+HMJ VW4P]CU<I&[H(#GI;D8G;LO.!LPO")B93(C]AG*,57M;*_:2
M"(!*GEOGZ4RHT0[MU1TH2#*&*\93"_1Y@,8654RM38*?G )C@ Y#?0YB-5:2
MY,<9>Y[Z]M*IH*PRB'>=B*<'DHL@]3:T!,/1UBK7KA1_NXJ1 GTM3E)_*?_N
ML.:^LEP3_2<MN'8G\ JY1*3U:D'8=KOM:_1?C;0^'0%\CG!GOG9.IH='-G=,
M #E]*G[8M_P=W%6CDZA'C[UC:PX'N?7$:%AV-B%,%3\ EB/_.%Y5W\HF*\R;
ML%6;D]H\AG(3TG;JE'0(Y#';H)ZLVGUPO*G"K'R:OOSA@AKORJ:>;X0'1'L^
M4O=H_AP.Q\1J.-@I-XRZR-.6VQ"X=\I0@%FB5&#+,?8L5G1P9>K@K8%=7<."
MU*7/@BEEE*.S;]-7&PK'Z,_)CH]LHO')*[M@.!/C#?5>A_/Q=6#:O!L.74@L
M!'G)0_MM:8,4?S;>OOTN=:/POS+;:-]9$^X8SH*.E *_N!.6:X<@?^^+[WGJ
M'U@Z]0I?B##Z%S_UBEN@ =!7KX.+O]-W24-[LT_MVS5(,'.'2ZIQFVA_5;ES
M))^:B1;.N>354!:'UI&T6=9%N^[2,YVF'(0QX 3%<3E'R*?HZ3/G?;E&;4T0
M2CB42?"E:U:<$3(?[>],P)'4BHK!&RF3OAI@RH</[$\6Z$ _)#&AHK'1&F1S
MF(C_."Z273S(*JB0UZ&=T;CW'8W[Z8S&O=_NP?NC<1^46YZ:H9E :=%?CAPJ
MB%=H((T2:W%M#FH73]J@E#1H>D@5A\.>LQ#AJF.5>A^@,H F2ZX'^VL3!25U
M?4#&L9;4X>[0L/7):\IDEV>]\!!LM(-NRJ^C$!Q-SWGM63(*X\-^.;Q9_ R
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M#A0UK7$WQ?/BU84<%.'DU>)_Z_>NRJZ4TB" "Y)E*/;1Z!^MB<B.ND[$%%*
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M+$%^<KF3\B)YID-$+!/7<^JH[R3= %#S(.4P&>K;(:GNE&FAM1@4G+IXLS8
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MXJD;Y4R.Z/O+^G1(?;MRQ-P=\K%UA_QY[@[YN(^G>T_>_X+N'=KX%CSV@+-
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MCH^NMS'U8+V_HRP;KSU>]60)]0Z[^QZ' N?1_9F$J9"'Y35PW#I^P]A21D
M7_R[F&"E)GC1/V&JB6-^KL2X1EOO<O&*!<ZD7>-<5P(/F[19J"H:#GLR+!NC
M#LA8M^X\I-@<[[2D2FJ[9\H\>T,<"Z-&#C5PC6[Q64I_4+Z8H+JB:H8Z+HOI
M30WH%N<T"1<8(81MV63H<6K*+N;3CH,>SJ\HR:&_/-#O/^@>>OBKO6Y>NXGI
MPNZ1<0L1TM&O3(HYWF(<X>4R=F\*BN:H4QVTY(?0?]_+D9P\J"8^ZOJ*FY58
MRW"ZZ_\>.XM7HM%Y\A1X4%Q>$9!VM2HJE#^BG-##B%*@A/ ^W  NHK<^XOIK
MN&6&6?Z =N)0N39N3<T'HCT+",3Q#J-TTKK-;QR6A>^.SKA9+;,^%R@8KM_;
M/0WD=+ H2=OR&!R:JY4A9<@@;(_?/<'=H&JF$UM;&-24;IS-7NC&'2?$F2=$
M^*G1_REM'ZC-5499XBY>M7"[6AWMA1G#\+%A&![/&(:/VR?/&(8[(YHMZOF)
M;F<O@^\&:0 1\L-U/BL(]A7%(\:]_O1O?_OA;Z]N[?0R&/P"&GN<3\8)<=T$
M'URT&HI9)<ZA0SEC!DQFK +6U-S4%-TH4[#XL=UOPQ(\:X>KNP__EE%W"!8/
M1<Z754'9BUKR-=A:?]7H[V^^X@FLA*+-$[3',6(A&.>5Q*;AM;9WL5$ZMT\9
M $3'8_I5RDQCD[#< MF%YC#6\3'4D]86-K!( $\QPDN2_UQ\(DP9%Z"/"Q_Z
MYH>7SU]Q6);%-CW85+_%37SJG<<CN^,6Y;9U(4NF-Z07R?P.N<.#;#OO64(2
MP=W$)D&(1'6WN^WQ!R]_^M^'BV'?I(2:1]N#"4+T6Q)#8G)   :>5Z=KN<\)
MM+0<>KD#HX2>#)=H1.HKI)0P5'X"U9J 7T[S9Y=/L,N?A=>!M.7C1QFH1]@T
M6V:<T-D3"NI%>+-DH"$21C!.%AG^IG0[&NL2JBI<O>@EA"4#!!)DLPQ?#BNX
M/C@>_#M9?Q?Q(Q;&NAYV#EF=:Z+Q@+NOIQWSBKH)\<:?\AM_X:CGXN+2FZ9+
M.+&-)EVVW '"\&QI11,J=T R&RG?>&#+- /=A&'YC\<Z=D1:GSJ67++4/R*V
M7 GQ/JXGGBV/;R<TRR"71[%]<NST*V']"U*4YCE#!V4W+'?0)?#-HL%)M)1O
MP,_)/^,&5&N/"+6NA#L$X6G6]O'N<O&_/(]&+V.%(R*;C5VJ86JH_?(KNH8R
MP"<FC$ ?ZM@!^29[K0_&?1\X ;P2FA+"NO9A&9AT>5.1MCT+,Z3-&[D^)7,@
M]1,G+7GCLE\H;H:'9CWB.CXX9Q4EHZ1SQ4((\CN.C_T. <%=0Y;;#_];'9KN
M<2J\>>(7'$E<?(GM84 &6=*Z!?^)\FI[P7<KX:&+&*=J%GUD,*6P,F\ND]=W
MYQAR4,@_P-Z[5:D>U2@K5V6[&G8=:)8ZRS? 3[GG2.,+915J23+"C<62/9+@
M/ K\Q4^=.D&#*<6A2/OW/4XN'36T:&CP;3CP%C^WE)WT%AVVQ[0?GH@(+A=/
M_&/\BCI D/:)5>$T@D=:;,)W:(E]'B7I 5,YF_:($D!*?+KMM*)75H<T5^.(
M9%FSXDP#ZRV-8O]^W/U[V=*'<"<L5- H3/ +:54CJ0UR"&NP(.7[P^+!3R^>
M_/P0:SMM4-W)NU=XA?7BR;.3KMB^8T=!!,J9@5$4#J/,+#GN.Z$R#FY*S=$>
MQ_+X8=Y9;*(Q7RK>:.JKX@HG*XUXJ(9Z1%_U\=C=;Z[1,;K5]#=-.H]W=5IJ
M*Z;_H!@: JKP:6A=_VGJ_*^_TI+'%\II;WNYH$\G'Y8@S%ZU <&W^VGM]Y1R
M]\'':'D8?E7%O\0^U,CNAPG)@HVO@\EE:*1H.U928.2'U<,;XN/>%!?]%N%S
MS5PE?&5@3)B$F1"-]3(,-GD%7?SJ5:'^LW!U,+NHX/IE; /TQE*Y/R[;=[$Z
M-C420M<=3RE%*7H'#1%855(U2H6&HM8H(J-<Z=L(,XOH?VBUO7[-X4_"Z<W\
MY'8?YSV>/.GD\7?L:(Z,>() /#D4O?];"DT]#=H*)Z4G:N6&TFPA.R,)Y#1T
MBF'8&=]$/WLTR[/#.G98OV7 )>M\J:*E#(8)>^ZJ%# 61RI)7(TU/!PQ?(Z1
M+W?=Z7RTU21YHGI?#MG'8D3%+EA]WQHEP:_9V##+R7W]=7" F[(7W.")J62^
M)E;/P=;:M()3F-S;"3L4B9$Y> [)53>M4!HIT#6F"1AO[$Z/H_P(7])QHW6D
M6B<&?MLU4ABT_A".X\04_";NX_[47@2SQPV:'I_.V%N1K"6DKVA4>-X8IU=1
M%5=E5TEN#1ER1U+F]\<M5'6<AH^-12(B5%_=WS+%-V^(CC9RY=G4NXONO@G+
M/MYFS"YGF3U'J^&?)!-=U/G*L5/0;A0D=L8-,9' [T2SP/35^'+Q#\NWA0?2
M0H\NUMDB;%UA"$0N',?4Y&@7QD(3KNI=D>C$.@MD_KN$5H]]=K8HRI[E9J)Q
MTH>7;9.O/?-)5S4W3'JA"-%\G>^=W"XLN8A+X["<V@^U;O9Z&Z >O_%G=,U4
M/4Q^&<U\\IM3]).1_\P:\*!>1YFM27QEE.6$^V>(<Z0HBM3[V[*X+IA0I^-V
M)H'#,U'+/0[#QL"U)T^? +W8YW7O=4FYPG%#4UWD5;]=Y9S49GX1[LV'<Z2/
M.0MGQLWRFE7\2*.OE0Q5JO_)0HSR,\Q33IB@, -#+SSCZ[!V[8' F+@N]1WO
M[!TV,J>RHWK-/P>Z PJL2:M2\!8?5 /T#&/ZR&%,G\XPIH_; [X]C.D/<@0$
M_UY5A07#DMQSA/!R+!@'"J%/5T?%PQB-N0<B3@L.>LVA@= 3T!F30@'N[P'\
M(X(VB_"N"PO"XEF&<(L8V\I:N"YI!F_R3D-;G^ ,/[_F<*IC/#^+PQE"^NJ*
MQ(![(3RUZSO2M<!<Y =;+$D)MMUBV--_/_[30Z,BX[+03F =0EBM+2^;DKHS
M4<U=/'[TZ2<A[ /]F[.2Y$R6('8$XL>!WJ'XA!@!D\'^K* P+X891/^\:D.D
M0#70:U9K5*9!T[B+?:+T1EUA)?>H=,Y19LK5AN_R. A++=5;(<]+WP)"?JTR
M[?JPG1,"J'R 25LU)<.*$7J<@!^DK>(C)TU*I+VEX=J_;=8D,:0D@*,X:6^Y
MKS"$)3*S2(6@HK_/2;7](&N+^PS-@?9I,\9/KD_;<N_$W>.'_#0J+4!LE;F_
M.YGJ>L_KC2SX3[J[%D]6N/4]?O3X<;9@*V!.Q"J_H:@9FCKMXF4P(\B9+KZF
M_T>EER?#%8%9/ODBDV_3CZ%E7\W/LP5BLZK*LLI](R$OJT??IZ_I!3HU+'<[
M'C%%C6@%+Q=/8,)D+*^+0_J[52XEF?2'?R9ZQ<7_]UR/DU<-8O-7U$E+^ 2:
M(\,FX,"0IR"FY:\0<V1/I1-Y!BX)SPJ"#5G%'5<3O-S?AAVP5BVS;Y#&EE)O
M+W*&:;P$^?G_:$-WF/"7LN5H<4@?)Z5^Q2M%^NQ]T81;$Z=*S7ORO!*3-'_<
MM%"EVC]!! I9%&79&/]>F.UOJ&V2/&DF_4GTG/,OD(UFC*?6Q'+S1;<CC$P]
M (9&#1J$50K;A.5CERURV,1SA#'0Q7E9PN>LR".6!*?LF1.(F^G#7SMND8L-
M')H+CT+*]I:B "#X+C[I@NGL.SOD1M@6X\J%!0/-1S-AT_Z2"%">+1X@LA;R
M4D+6<;T<?_WZZ*]?/E3@:5<(@2Z_[A293^UF>61,N_Q-N1MVU K4"J,^\^?#
MA'6,X6Q+SA]'_UMKXL,QX-K^*9*?UD-A:HCH,UU1\JC/WWBM0A#+ACW+QA!)
M9:5PYP:PTLX@DO+E=-*.DOQ@E'<[VF]Z+2?D+O1HBR6%&+3T^%IZ]+H:<KJ"
M7\?E>J9K01,BY[3 5T"TSWE^QARHT_V*M(Q!S!9.?A*Q#U9ZT6PN]LV*L&2V
M%VE8]L-+E$V".Z)SFT7(A"4G#/,_/_V<"P'!\6XI%T+-8UU87'T,I32J,M)"
MGS!,!C"&T?%)\"?U8?JYB\BNO2-*%4%XM=0RK;75\52M^8195O<Y?'X>H9R9
MF/OY6)I0@4TG.4(-K'W.U)V#[O"33&Q"K2L)?(BH>%VVIBMB-M<UX,78UX7>
M?@_$+>MR;)L!1JN!Z"JJ-.=V4"L/L-.-687(H=G1;AN)>"2=\=38*)8G276/
M7/6G?C;%)*QQ!+TB,Y?9E$R'\G>+X"W@/QG*3SB5=Q_/)Z:C104]T%5?KY@,
M^X-[GH[\[QZ@9UIY_/>#=%VVM[UQR$F@1/A/A!=1WOZZ" >V3@))"(DZ@#EO
MT@?( ;'V4P6:$\I#TX\6J8J#FT;$P&U3C:\]N.U(C!)O07'RX@;E0[6)TY*^
M[HIK\R7D%J&4.N!_M@4+"O"%N78AFQ#"H=(LDV_=Q=0/2P^IFFZ0'9ZL\RY,
M"<LL,? WE>CQ[PVR+0K>]4CF5A0J$ZG6JHBP\%P,U6NB%@@>L'N[&N,?Y8CX
MA\M8":Z*LUFQ<GOD=&5OZ.I$=[XLQH<&GPS9R-EC1[?E5=,R;0K?NU*6E/1,
M6#<W-:&T<0> L32JYN UFA2)JZW@1^1B8$^S V:!"INW;UB,'3F-"J4>NX%N
M?'XM-,1/GF[Y(J%2B>1LX2]-*SR&MK,-4X^M(1=:\3,RV3:FHP7I)FFTE@6\
MGA06Q_S'Q-MZ7/(;LV@5IVJ\]W??_.#BJ'%-'B<AT27$P K**2QEC<.2(N5)
MNE.-&>!-T3!CQZMI/$#@A]$U&[Y>]L5J6[.R=CQY8OT=-R%*1PO=H=M84_&@
M9JTM?XH[*G^503YV^&3&SLNL<;XW)#Y(BJ3R('$S&C\* 8+^>).P2$WP;)WC
M,F(JBDR<$51H8@ <B;\LEEH>8D_>!'O.D9X@/3>MS!Z1(4[Q13IGJC?2 5D7
MAF'U%.:(;TD92<U6XE.)"=J8(WO6OG%LN3/HZ5PY 3P^,3B4"[3SI.0&-< -
M]C2MXYTMGO[THVQ+>/$I]GS0=0AVRN&EXATI;N)C6?;CN-G?>=I\D!O:DG!W
M).T5+B!AP(6*-O$_);$4_U-RD)7@9@1,D8) :.!PCK DY;"=)E7*:U+1QE@T
M)<E/\Y>NX-GH:@>[GH[F3;BGRT7/)I/LBR5=.(E+0,L!>-!=" N(U(F;M32B
M2^Y%Z>))!!_>:NA5$8]"X6R,"PI'_KH0/-6ZQ)^V'"< )>I6K&!!G'O,[_>W
M9(JEYN6L?P^-;#*4':70POW#I$I)[GY'&>MXC4FRN*(G,-%9%1.C-XI=.GTH
M7"Y^G-YN():ZDJ/UW]CLF;XK2'DL>P">7V?X"^#)JE3:?+1=)_,8D_)\%-7.
M>)P9C_/;X7$^F_$X'[<K?FL\SA_D* +,67-0.&$LH"(V=$O")GZ?_:H/^Q2)
M80<,'RD9=_-S3$!A^7+HBU37=^I8FCJ/GE3"JI)\6W&^<E)!?E/2#\"(>@7$
MX[A&1"ZZ)$'!_[M<9UY3>"*IX4)*XJT_BBKM1Y)P+E',N]OY9D?9W0\Y*=@E
M4J2QH/Z3SRUR!<G__+E0>?(7M22':Z92Y_SU]-D6;'MW405[N"@X2P/[WA?M
M?XP<)FV4OWYV^?GC+_^4'F>C?3AY;L'-?H4==T&_V/V5FDS)T1[MS;@YPH]]
M^N<_?3B;];/+/W\>KLY??O'97QY_^N?/_OSX\S]]=1,<-9\.?WU=%/LPSLIF
M1TX23-*96?F/_TM7\L=??*6+Y(X4_N%/'CWZT^BI[V$6WO(:^JV8[*OP<J\7
M/^0W'U*0AV:($96W\(LR#2[RAJH8TX(8*'$PDQ>RV-CC;KD>\A%,?7/1%D0;
MP_D6%J;F2V*X0D!NQ42H .#0V;M<_ ,EM.@4,NYD) B1/@G$/2K.RP/F7R.W
M[>!]HN,B@ %2/A4,#ZHC,,-'7VD#6V$7YDZ@-/C )U^9IS;]C8-SB4YJ0;]W
M?#/B K_A(#9#*U?4O'=#4\HW>S,P#>\*@ZZ 6U3_&OF%=SN0.(7GPEZXV51?
M+QZC_M345S,0!@\A,UX9 "P*'CW6@IJ HE*7Y;9-N-4A=FPQ[US"O;7\>KKZ
M:FYD% '//G_V^>_:YS\)F^;B_RE7KT'K_0K<2\6'Y?__(;AU)68ZX;$GWT3)
MH.6T,/<F4LX:E[+2RFWQ+A?'3OQ.9[$H&9O@#J*W!_ZR9E9$52Z@1N<F.) V
MT[I<"/C1C*>%M]9S=B&>ID)G^-]ML1MJ\1]<-0PG([@.N:NY00<6M>8]*!]*
MYDO.,A:J"=X+W<X,T NOKF=.9A'\5+G1Z:W1H^79<AB4K(''=QW%7(W_'@YS
M\BQ,52:KD2Q#BLFZ\W#HSV% ,J)82R=T Z/0Z/MT1S\:)D\SYP6!.;CMR[P6
M]![N-7Z3M[A<_&_9Z,5 *D#G#3PM^YY"#V:3,O6$C$E3V4SK5^[-L,[O"(_4
M2(!1^KHA>ML9,7@4:V5:$:H1K6D@[^&,12TN#2-O+'U\PA)O=PCSP3T?W._[
MX$9=[2G7U9XX?;H/X;!>++ZFKN+C'(CO,;XJ:E $8+]'(3YV7:AGJ*LJJ.RW
MXJ11\ )-2]>F**!9#[L"B)VFOFH8*:Z%$O6?;M.*M)SX/48<%F^*U4"97(6"
MU6%TA(*Q=!FC(>'6' )_8JQ,6ZGH(U&<X6L'$&';B:)5!IA.; J)/Z"\2\G[
MA/]L*M'P_?;I$\7#CSXE/\V2+3T(;7M6!Y6N!K<61 _,8944S-#YS8 @ OTQ
M %_Z.BA\J8KU%>[>R++I".2>]LM0+OI\9Q<SHD2MBB4W9U#J:Z!(2.[=<7Q@
M&^YZ+KQQ7$)][GRAI.9$'-)\<QS_F>Z)$E:Q<EX8Z6NZ_E5 'G5%K8 1<,*L
MA3_7_2F72C6E:^F=AHI1AJRN@]81CLVB^M1$6TCX& T%L!I](BQ?_XH?U[]0
MM-&N&?\$J6C:S08.&\%$!)O2TEE&<1Z]N1ZFP-S:^,+/?/%HL2:Q.*74*86S
M*6<=00&BD?5$)@JG^<,#H5[%IBVOR*ZK0V3^\32MU>%R\=(B"?#@A&=>Q^!%
MLYH;:&+S[CK8@8N,JHUH%(3(_!*/[H#>HHFC=[XSST?O^SYZ7^$H^];J"T]0
M7_@A.+8/Z0R^7+S2?L,>R 6.J^$%! Q+WH$@$O2?AA--,IY4O0FWC==RV\C8
M-V8CGPY@PQCGLX"@-"4.E^0REL%%\<6Y6P47%@\WJX4<LSCKU6?'<H3A</+D
M3%S;(20,AP>XOE;-"A>!H>V3"LM(Q#-C74/D#'%?!]Z[+81L\?;D((XACFDF
M"TUC(:?H_M)[UQB@/E(LY(N+PE;"PQ-VJOG>,3N_=PRQ>O[R":/NM;]7@D=I
MVGWN 'D_1[ O'>;?A*<T.Y*Z)RX?Q3#)]ZAU&&CZOHLH\Q&G6,;.BAHG.@+@
M+BN-;:>9$SQ$CW:O-+W2%MM+GI"T1XB*<*WM>0(BS"*"T)H]=B4@6,A4U6'-
MRO7 S=7<D%LB-7",2YP#DGE/ON^ Y*65V5YJ7\>K@8IC1.3\H:4&?G8WIUL&
MKA#RS@,KCKN2)7F-RB2U7R&%E\7F=[YU""EK-W )T"%F].)$ER338#Z7N"7/
M\71;5NNVB+5+\XBJ+&MM_?!"IAQAQ4BF$.&F9R!N"/%,__3TQ:O%J.O]<0)]
MCDP1UL<3J[@J H*Y(1%>UJO5F:84L#3!'0%A4A1MKWW,VZ;;DTUV64J<.36@
MYJ8.WZ<&1VZ6HI0$3RY%=@71,&R+"L=(')++Q!Q5@+EFK U)R6_2?!5KZ^;8
M#^&$6!$(R!:Q00-4D5,>G_[[IEAV)8G_8$E<BY_I@^IRH*=\=N6S*W_/KISY
M&QRR_<.[5O[,:<?(ID&=2WK5)&87VKT39290,N2OF0CB.-4F5T>4+-6%IKE:
M]E=A=!=IS2P_B+=SKDPK.9>+O\.1?TO-HWR%(I4%UVFF9Q&-F/%#?]5$IEL&
MW/8UHTF#D8]P&OZ5IOA(&*3*N2&J\<OX(N][<F/ZB)\MAHZ/U]RQ*Q?'G"9?
M%BVI*1EK:"-TJW!%+KB629'IBB7%"[V8)NR?S)QA_:*C'FO)^QXX^1WS>'P1
M)_KO6.?.P]1537VPI-[HMILA75EV3<TE[>,$GTN<=OMP(#:M4X<60_MU\WOK
M%$J]G7**X<G,XXWNGE5X%OXW>DRON<([['TADJ(.9,C#.].E_76VN/V$F#L0
M/HH.A,_G#H2/&X$_W8$PAVJ_5:A&Q%&<E_SKMEROB_JW"=X^L*CM3J86SUN^
M:RYB8,.DYT;$ASB'$"HK<*L-S*WN@IY8&YQHU65-BBIL;^;/\S7(IITXU.G(
M)9O+/*KJWS['T4'O3G)1H-4GF%+&T,7TH#O9Z8Z+$G*,"6,RG6!Y4S=0=VIO
MPF6N$[+-@9+L2;5SHDCZ%$7Y%XI]BM5)@O%J-E$J]VGSK34 ,X#.-PO'BB9%
M3%ZG,KQ))6BPSA$7WJ5XR<BKW;YJ#H(MTQPF_2=L(*8>.RMWT[O<;!NN?;Q!
M>75] K9UEU%XTB=#!-+S@4ED^0#+*4#H::K/QU&R<83DH8D^RKS)R: E<Y/D
M+R(WFA"J=8L'0I@"J <P&,WF818Y862T9"T,)=S"&NF_R;0AZG#@.\6F&@IE
MXG5CM?P-TPEJ23T1MA6CS,+_RGDGUR*RRLFD-N'B]9,2W@^)AV.LH\ ?*LXC
M@T[R!&;/E%NID@^V(=-R8\*AF+:A56L;NA?0:V.F3T]REU+J>;A>RJ^7R*$B
M>R.CCCCY:4PB@#%XJS%:R7KTB0D06])?R5R)K.N(=)33/.(2;]JP+0DSFZ]Z
MOB3(*]_)M#HV:X: 6%^% \!&@AF]6:)&*J4(2"'YG@YET**B7V12G68:&.KP
M,1HYGR"=NZ:!3(":OHDEJ)"U46.A1&&+\X/3:#1^,F6F611"+'4=*M1@\KE"
MFA,,FQI/!+#SQ&:;..,F:+GD:$NSK<>],F[5$N(?4TAAVK6(WSI-J0H"K*1*
MJT!-*6 ++^F$2H]1S/6D"D8PT($):$L/%#4?%-E001J9N[,C/(W09'(AAZ62
M^'0(0\J>Z2ATOI=M\QJWQ,PE)]@8,%!YP:E6OY1Y1>KN^F;X0CE^PS#83@$S
MQ'B8B3*1,T2&A9&+O<Y9_FRTK&Y5RJX;R*Y&M>OLF'T#XF=37!O9$2_:AU5G
M.'$UOT=<4*^HM2%Q3TARCXB98HX-/'W!Q1VBKTT_JFHN=F8&@PO'=)ZH (%Y
M"3>>".L(CK&XSN&DDH\Q=VV(7(;J"I[SO'?@X)1?8H),$C$BBBAIG<#HK=^B
M6C+=,1Q/W*9U;=;$6$<(=")$LU/[5Z[ Q!LX2CD)-#4 &'$ZOHK>QSL35FO$
M5/JB=\J<8^G3Y*>-VM#+G1./%>/WA=>SI!.5(U# :GB^Z+L.U$J)#Y[-35_4
MUG(>MD"(@&7M!6[0;T&_)Z<M4S*:W0@ .,PO,_GV+#U%>&#BV@Q^C["*-!-K
M]NEA^VED1S]/$)WXLG!O<LQ\\W>*&7FBHBU^]^SE3QJN0 YLS5T\5P6%S_LM
M5Q45TQ2>(1Z35A@_2J<N<5$W]47XJT7P'#Q9**>M"W38,]-J%^6\)IX:%K$.
MD7[%/1T%#DA2]7(P"8XJDQ0Z=+_H\9T0(=OM(LQGN&A1+6S"#= <C*Z&3F[*
M@9L:X7%+KE4NDDV9?^O%]^&*L'C\)5'E?_)EIBV7/:;R*>DL-L'/Y4X,KO#_
M;*?U2[%HG-?AO9X^??E$UZQOFM>N=^3[X#+(87T">OY''$#2YVT6XZ383G%3
MYGY^)3_?2:V3:=RZ,WO,K4UX03.%;?@4[I".:[T3+EO;BVZDXGXZ=VU(RRS^
MMNI"C0CMQ@OAHL/6!()8LK EV*L5OEYVPL+)_M.4Z-U'0PBEF',W0K(5^S0H
MQ^(&9C)^II!3#57+"*C*&,=$<%]3--!]<DR OE;9.5T@=I^)(+^1/@F0T*+&
MC16]E?[MB)@*Y*!\'58.1N\>7 !Z&\$%OJO-"ZCB,: _.A*81O 2L+RPU!V2
M 1AX4O+S=P09D9%GY*GPA=S9Z<J];ICDQ(U>IZ(QLG#MW\B2H:-Q@+&=+LX^
MPS8R18<Z-2F@-:#QQA8U[JMO*-?%70K!J),$7M(\AX=*EF2BH?"(T@27V?V>
MLR+#*0J$1*(D-@_&+ Z\CNLF9&+V:;>?1<8\*0RNR^ZJ:=G,,N]PTXKAKVA*
M/)W>RH[I:7RJ(\.5^HK],V4/X!EYE>02E$(/^X*8G'.^6(=%"]N2!K NEN&R
MA6%/<@5.4/_=C=_/@NA@J^%PJ+23!,CA@6)?"0I3*R*5E8TTLOK.&IZ,5=(C
M1-N.T@"DZW'!IUJD)(\AMS<*1VD$3#.=5W5!]L9R)%R^!0%P$7M+5,PT"CQ3
M$'O[.#V3\Q(42;U]&$EUO^&UL2C$/03IL4 \<TW@"3G%-'EQ$N/'O"MYC9MM
ML$:GJ=:0:W$N5+<O>1O;PNX$'#M.H<6DW,7Q5M0MIJ24QUJRCK<R;E#;.]U1
MK?U,*GBF:3USI#Y!8J7@RQ)=.T'#&*<\K-(Z;!6 UX8H6B+LO1+=?O/4!<I3
M[9#2!%UJ;K5,&@*VI>D5(5(D+:>JR-<.=,>/MBV9&05P#05T)S1FR6C'R"T*
MZ]P=DI!M,_<YG 3A\EC<07?.#2G8Z ^QFH:]$3OOHJ50MH1T37":5=PP8;)B
M X3E\:(O4^>6[/!PK3^D3*\U*>2%_7!" .O>TJ124&X$ZD8FS;D&:%/@[.:F
MP]1&M'L5ER>^$>>W[(&DJ72-MD8<:;P=$*C3G>2\03O;=9?W\(,ALFJ1'A_E
MN"U8P__FJT78VRJ#W'V@F<F9KO3C! M],8.%/FZ7>-_I2I^(LHF*$S'RE9,J
M.+8/G'795'3!R$4XA16>H&K8<3I)TH%V&8WAAQP-R/C%4GIFIP]+.55Z8*,.
M5X#>LPC'BP7)>GU%U$!)G@E&;BKRTU$OAP+@+=S6RDDK"G:JL*W6!WL?[C2+
M[SY*3(YB9;E?W2U\LQ!F=*F/,<NDZAB@+<1&0+T*6H"E0(R?;J3\&65&1LQ7
M=-:9C.P*I4X>0DG)3+J%@=(UO'S)*8JA#N9%I<7\?NO0/2N[=MA+TJ4WVW2)
M;%U5@P!T5<-B7M# K N:;LH%4*#O8B=OGWP#9'-C/C BNC4)H!!4Q<=,6)1I
M-R/(%3(D0C-+2CL1>?T6(.N<.BJS*,06@HO>(/K8OEF4SO/41E2.W@X]9(WL
M"]@AO+<T/WVJJ5HS+7XF9=MD[%&V.3;E9F@K\*J0MA),EV%0A=01NF!F\6_1
M_*FIG3L,:">QZN@+;!E*YE--O+;:%S91LRM :%G6: +5U'MP3Q2!XD9?(#77
M7M&DAMB)&LG#)MXVU?H4*._IC__[_-G%)W]9D&A.L2M7J5]#KOJF:5\+3)V\
MY ZWHPO]@D3"W%QJ(_.^03$MW=!>%V55<95K63;F)'9-788ET$S-W@0I43=P
MKUMSXA^K1-<X$&Z$F62LE(Y<6][%(4&B4Q]"GB2U=?NEG"%Y[K-1W <I#RCY
MB6@IUX+A=U>'556$?R]DAI(N^+[-R=DW+>L@]BPGDW=<T*C=H!LJ>S7]T>@)
M?M;T0B@ ^RD6!=5W<UE*[AG3"WN6'GV=%!"E"B*JN=S^6TL)L&$0!34<JD2I
M%&I'Q=+<Y@&MR.$=2'"/VA480DJU4RG#R ,D-81_&NH>%$.C&4ZF]W+Q+,YO
M-$[TPVFALP@7>;Q>EC(8N?)@W82+.$3\C&OPU,@[7;E^)$U4UNYNY[XM[77>
M+J/@HWM?\&I/.9<C!,P$=45J1FHX<A4TI3+X+WD;P!EM4VK"TT4AT%%2(%+9
M)IXO>J7[>X0^!U:R#;].2EI)1T\X2'".-*L5@C.J-V\65U6S-+ 8-]ZT=>=2
M1[RQW;:?M ;DE 3H)99OJ].F/I4=#@_@^)D^LE()V51*2Y))_<DTBF3$7#9%
M=;F8F=I^# Q*8!7H?JTR[.B8UXRVU HFIET3B2X5YG:FZ%XB>F0WP2@6J>*S
M?D#T^*L<#< HK[;(2T+I-.R2ROY(<GR($1IF<AO7(^;4\OEM=%, ZCZ&7Q3U
M==DV4L[+=-\@1LHWA4A>'0,,;R(P'PRW7L1+0?T1,P HR IE^JY7ZKK?BHSS
MG-[PO4W*_D,K85&K7ED,WW+%Q]=*]@G(ND:R=SBF-8Y!#:,4?)(M   -D3>E
M!DBEK<A[@]Y17I'$(P&=RO^5MVL:JIH%/^V&Y-T[UKQR-U]/5ZC@*WL"LL-5
MOML)MX,\+RDU;^EPUA]Q<L'VZ:.?Q%6-KV*%^S$,,%6BC(&=5FVG4 ]:QO&S
MP!F/Z1F($I=%A>J=B(>T9?>:PZJPMI%>BG;?/P>*K(5:T#\8N0GZ,A^09[[-
M6PQE)P@,#^WQ?+L9=BXB0?6K2&U\G!6Q.=@_N 8>5659%71MPG%G!>!_"-V8
M'$1P,+Z&+$"@$<3?JIR&+9C@SKK'$9=1D@*X44**%[?-X)<E#,<!4M2= B6T
MG1Y'"R4%!L4&*A(+R%4TDP@<A%=+@GS8E^!3:8WC77UD<I-;W)D<<G-Q//1#
MC %E-D@KGYKTLA;YCY%BI5B8@'IL)N+3P2CI?:DS6W"COPEA#S56&/6 UXM&
MRYIC)1U.JFF*Q\1E;M)+_C8^[OY:?)*;3>SS"#N61*CG@5YO=<PJT^WQXR81
M;Q@I<"CJ&Y&ZR9+D[JC.SILVHIQ/HG*[$S\*GWL+6#=+@S_!3"J.9([5;PG=
MU'$MQU@F>,>(O!2NN(/X!G:^OM'M.%N<<-/?W_CX1[==4FU[)HP&(?&V0<)]
M5X+]VF8;7"9V8$SI<1^*WBY;AY)BGVN.?4X(OIH$J]^WB)-<*LT2E.;69_&V
MF3CJW6P/\C-)JI6EOX0=_=B(K70A+8$67W 6!^< *QX6>!2W,>-?XBF2][VF
MTO4QK\.<].5JIN&>+?YWLGA7*B<JK*'L1RR1S&R%?.Q7P:AG0YT-]9T:ZKG(
M@P(8]+UMK#=T6(=_H3AR2[42 D1RF;S=@2B KL6<:W6!^BK\F1KB6FH/7&FO
M5KUF;@(EQS@@PSC4D00#A;WK*:%ZSNRLMF5A?T:-8(\BYAUXQF?DXD>!7/SS
MC%S\N.]%;XU<_*,D@WXZNA3Z>_8)")9U,+D\"!KP*0;.1LU,VR&,R.>QGUOC
MTE CN$AN]NS'->ZPJ@E?',-<V-T1Q=&)BR1R6@"D2$I!?T/*L/H^(G$,6B?.
M.1%*H5E;+5D<_<U(>L*GW.E<T2QN?&M3YN,N/D68N=)QUS>KUTP.,B>'[IRW
M. WCC)47:ZX %B@<@)1S3K&UU@@[ADGE=;F#)8,EX/XFBYX*+'$R':I[?X"G
MH+F"14]X"9M1@O!M()O%XF3(T.O.[;G<%[N X2^(9B]9#;_8L8,=;$92\Y5*
M7HNNTX/?>X+)"!<=>ZHP$%RUS;#W5 M->Q7&_"]-_:(%/C+&<?6^[X5A@QI[
M"5B9GQSIDN72.NU=(]&USC$Y>0HAE:3)*?&E[$UK@=0R)(?^&A_>;]&ZR2P6
M74+#LBLPA3\SH PT&X*XB5^WFJM.0M))JO@BQKM.VH%RU(]>/_:O<;=0EN3J
MSVUBD[ +,0^]-3&.Z!X.HQ'H!038N, 60IC9?=[F/F,C[=%,CX#O@ %^*W#?
MIPW68/'2^OV5#010+3"">&X)"%LM29VJE<U'_[#BIPAO"\-5^,Y%A(2MD)()
M(EM[%(N$90.C\FAI!20'&T"U$9L>Y="6= )=^R[V[PZ?FJX^/1TU$4L9*)AV
MI8YN)X1V RKZN_((^X7B,&M*Z<@\^$OGF/UE0M497IB)"(!FV-W? T?@6G*)
M#^L*3Y9B4!2O*EA!(6T+[B!<6HF/4(@$8S'((LYQK<^009-^+2PC>%@2:31O
MH^%673LM,0;+W'V3T<XYO7&:=G+?'+%GM -3+]YE-ZG$0/C=",^)A.Z3 JY)
M]P# .Q<L7PKG#$V1UG"C8(!D,C]4C_ _K\IK(6$5G.F_%%$->()J0>7UH5<%
M<_"%98NBQ#MQ1H/E1^D0YO]BD1>P/XW;+<(P2L3?OF@=B4KMSPH.]ZW6<C<
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MWVTE(X\EL-XAEE]PFK[#:Z-,$;E.1S_+U<XP) H7HT9N]!?\9+ISE-=%Z@^
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MCGY9K((IGWOEH:X4CS,Y903!5^YD3"SA=\3\@Y&$^;K'"@U/6-: '8-!F,X
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M0GJ3^RV?< ]*62F.BL?30]5J"E2;5EC*257!IB&\/PW#"_9![W$]M+JDHK]
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MVN5(JNT1MK%;@'37YB*L-(MK=$.GQ&@;HVR])['XV\JBD$]&2F44&,6><>Q
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M7%>L&:=-)^,B5<"!U$PN#_![^ZS-S_6NVTY9K$79S>?P$]5L46*+Z*(2#K@
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M48B X(@(2\C3XJ<)D,ASLCE 4UK,<,  ?\++:$&\[#[F]0MQGDB>!&A-X0M
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M&)?>%<HCM2,(OG&D-#YF9QB@9- /[P_YG7A%$L,T))H+',:5B MX,CG%+U+
M]8P)\,Z[]&9P RC%89;#+CFG/:64TSR%@8)^%Q>H1Y)WNSI>?)D:+N\ZWL)
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M'^ (GCD#Y/:NDE1=79!T@]^\*'J9P'U/I5![>@VU<).40N#^&G B:!)"2I2
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M4XT]X.33):9H.X?P!K!FDP+]/_$%Z@P8HD!&<!>E8-R*/-"88.&+0#MJ%7U
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MN-$ 8B6A]=E81K9X:O%T"]C0XFGILQG9QDK69V.1U2*K1=;']=GTGSOJ9IN
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M,$8@=')ZCIP/#C?T+YTP@_>G,.& >]+B*YI'X-Z9X/ ((-6Z],9/TP@_P3R
MS12]<:+5NV 8W6YG78J7Z[9,=*".I%.-CI)*E2FOG+&<:*<<(5 _ ]+ADWCT
M TT$[OR[M' 1354OGR35K;<MK_?=\>U6B'TBB'M\8(B\7& _ ,8SO7-I?4QB
M+E/W3IQ=QXD;T+'7[0UZXV<DPODE[&AF?IA#"'-U+@C*YP3E2!=O#G]_#V=
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M%JZ=%ZE_Z4DD0 R;*_2L%5V]#/W+E0@Y3Q-?B"#CFI5<DY+Q>:V:KH;\N2U
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MXTQP,EF68 ^?TN^TK 2MGLN2R%#4;)#@-U"$=C)]HB(997P!IE G=)Y<9%3
M+**5<2D0):BOKUP<WH9<7T/=[#;5J_6<W/LF@N1:5DJE,G^7(IJN.K\HCRSZ
M]2.+X7YWO_?:/(ZZU<,N U99UO1V6-:@MQ$7IZR85T^;7V+)I4O6T,I7,V"#
MFE9C< (/"OFAXC(/2LI]T)Z_G1(K]+G*D&^Y\V:S=MPQXSUD62\S>D0[C,?F
MSC3/4E''ZD@=J^IL-C4,*G0KC;O56B ?,F<A,*&7LG99C<;K#H;NH'=[%-7*
ML+M!N]/O]I=)?ZON75V!NZA356BL*3F5[G3KJ2I4PH'VA'ZRKLMIU9A-!L<O
MNI9L8U&&QSIQ[_;&X[N<N/?<P7#@]L>W!K/>Y<0=C\E(?IJ)#35P]&2-E=O.
MQF\&N)HK1$)%FI5/K)4;:7Z@3'VH(<SR$!N'=RM\&*/\ PAU3<V+W8:@K'I(
M)IO82;5FKX@O/"[C[GSB@')BCO+)9OI$%TNWE1Z?=6>TKK']X(EY^#%N>5S_
M&$=E3"]JG%ZC"@A[]RI,BJP,F1:K3<Z&F(K;E3S>N]U>+9)B]X#L!&-JY[EN
MW_1H>1"W%9K1NWN)_YJK,>GL BQ"V@ B>M]R[L!7_?@R:Z L+L6U^%85;%)%
M[)8>P64Y*T4Y5V=%R(G+<<OZ[,;^Q*3XAE> I4-)1N3[4![W&'>AU"F,Y9*^
M>5+6FHIT55=V971TPRAJ*?0<TKSO=@X.;E78N/0W9>\O=1IH*/DD'TMS,,IM
M/6H^3IE5LXH;&TCP.-RXI2RWDJ7,)7H@0X$L&]Q6 DGUG\!7EV71PLSI=EK_
MUUU%LX:P8EUO<C>J?*^%_;^28^F06I;\J$+>3V5HO)!&6!_0_M0]L!Q50[NI
ML+4PV)[:T#0U@JGV"K](KF 0N'^E$Q6[%< =, ;M@L1++Y1O7Z;1J-=0&V*S
M@<A2XZ957:Y<U3!*Y2/A2"Z%%[0=YDINI$,J+D:07\1 6 )C4 U%7,B:9X&@
MAA5H$+!]H#HLS 1@0AQF,Y<> ==A0(KV,454UQQ'K/N_PZ.C8@:<5<ST3/%6
ML-HN+DCVX!#)]RD"@2HO%P\&F$\":MZ4>M>Q4_HM/;#Q VH\I0XX8.F5,IPM
MP*";J;<3'*8BG$U005<YC=H5H!J>M9U3GKPB"1?M]>'7#"OL,0FX$9&J-%SV
M^4B-SFETMH):.CLA-MFI8"/5MBU2;60CU;9;Z-P[4NV%"%T4E[(E&XL?ZG]\
M0RLT%$58(I@54F]&F Z7%C%)2$9D%$UF26+OR@LCG=?)G;A0AI 'HR:X.^UN
MI7F:^44UN5/&.)<U>KGC?#'#7G=_BZP4$9G2$K;=I_RH>^ZVF=X&T^O/]+__
MJSOLO*U-5RY7!2)QF(R!5=F'D\'+6R#1DD)>PF_J=CKMSL_J>NHB.<_$FTR
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M?<0^QDXHB>(911DEE0;$1D\;:ZH@<=%CF#6(I36@1*))J12$[D<O.F=M'!>
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M F\9@IB(1KCG<3;B7!6_K3VRP:WL_(F$)K>'^[V!F?)SR7&:^>-FT>Y87>E
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M"AK=!4:H8"1CZ9*^"1=:_<)HH+-&>CJ9BRM15;8' [A^!9K?AUB^)5ER/1M
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M*Y#!]76#8\_'61*I]#RK2]C4D&;9C^ Q;TL"#RXI>IZ5,UI!'*EH5F7G<!O
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MF*71N"HOD,U92)H%UFB'H U2,ZS<"BR[_N7L7?2+FN([3\M*OP&=)$$V.*Z
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MD<C[+,^S,7JI$G:E@O&K,#-##(X8_QYK. I.C\ ;00/X]WRJK4Y%,N9,4BR
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M$[X CO>4OWN"N!J]F6-<]57%24"7KV0E\*]<V*KU+SUZW>K)&Y0E\P0DV6H
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M7+$\7YI*) XY'=JZ*\Y,&GGP&%=\?5YBD]CZ&6RA1%6 F;B5OO^/U/%0LH%
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M<(#.]D(_VHYWMK<[]4*R/=C5"CA2U\*.1Q\>LKL3'QT<F!M'XO:7AKJU6\[
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MZ?TURK[P_-,UMGZE1S3]7#(?+,:[ZB%L^X<=%K$$#\OA-.E:%>IJ,H*^,PB
MD[=XK6; N@44)9N.V1F7SSGC%#T+:&"5%Z!3.C,+]$'V0B"(^&(S^M=-+7#N
M ]]GX)1&RP, /K:Q([L4N(,F97]VBO/!8-SPME>71$[IU':>=:.5FT0[F-^
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M9"HW_?'CZ!.<0]U6H55^2$=Y^.DHH57^9J'J(Q:1CQ3K;K]I:IAC%) PL+Z
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M%"ZG)?3AHC2KD[:N,_@=OL9+*IWK<UP@/*6=SAKXJ8ZF*M4,5X:W:MP=M3;
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MGD8*Q'Y\)93HL*]$AW<>%K[&0VIIHH/%OL&*X1&V;7(>3GZA2@^BI^.B(5.
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MF$TR#EX!CDY\/KW ;^_%$VHM+U##2I, ]0<(T]YPFHU0W7HN@L$K,/D5ZUX
M'3D:4Z_ZX4\D!TXQ'25\LB*/<Y? ];1S8+M>P%YK+@P!RY/^BZLYBA8B,UZ
M^X1SY=B\X$D<OIK_ BBM/]:+K_(M^1"F>\'].SZ5KYZ]S-ED:80)U[# %_?6
M=[?+N%G<R%#EP^XMX(EI7Z'V1ZEC$4$V$K<A /""P7L _P( >[QS]P(H9/(K
M/!C<NG=<VP2NK+%O!>4_XFHC7O GSKP'VD< \\ I6/,LJB)'4]90^PQ'7PK/
M\6#GA9L(%1X ZP0&DGH,]14 P6-8!!>_.)_JK6H@[D $M(&G,#DW*(6''X(M
M!5OZF76I+BTP-UB18('!]@GW(^TZ&P">LSO8.L&$4>S0-Z%]E^E>!Y1!YJ*
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M6H38F:C=U*S5!6)U.5B+B=BMO;@G;ZH8VYWG^_!*U4GP!AM[QKI5YLU-)&Y
MU)8T#5TVQ+2>K*<+7&%=W""M-:M$1H 1,DW_UM<<M2XS\P9:&+_;C>\NV$<P
M\>\Z.Q?H./(F<J;TUJY_6]ERT>^!4,QNU-B5IA0@;(%2*2[["I:_13R0W)VU
M5GBCNN0 ![P'K)P@D&-]#ZHMC6HP+X_.TP+34U45>HZ$RPM,SZI$WPDVXJ
M^]AGF+,)8"!VXTR_G36]A<]N0Q_SD;&AIT!]&D9:^/4'[!?;J6-#,-UP.W\$
M@DW:=7N0KB4"RD_A)K%NK3OT7-6:.[)4]VVX\ ?L\'PQN!'6_9ZB^+!Q"#
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M9)SB-V:O %IKY/?0?)B?)'SO*]_9/3T3PG[LAA>"!&#'3]+1PNN&'F:7 <#
MC*TT1#;R)CCYN4ZS7H"[@3RL&@(?>&C9W871#Y@B$E_1@A<,= 4,N9%^[^WW
MALJE#%TO'6LJRF@4*0TR XL4R7 82ML4=<U=R,Z<U,HL>"*MW/I1@RSL*5),
M2C<6Z U#"RPEZHQTI)CF).QS0>'8;:5PG'D] Z8(AGU3I$8#&'<G:#*G*1K-
MKF4WZ^SK]1\I7^*V(T_ZN.5^HKVY]9K#8+2^6B:9:P>U\JFYDQDU!3UVN53)
M**F1>0_B.Y%G@Z *_0@V#.I-F$RCQBY71+Z15?"*^>GBY')KG_N8G84L+/+4
M,M!PJ%VP*-=/#P.[L&. N35F<X/GP@=V]H&5B0K@D3^ULMV94E@Z_N>'Z-%#
ML\#WM/V$S=X4V"P09O%9>(WRP*M <O&M^O;%4:XUJ(679@-!+E#+IAJNI-H6
M/U>$0Q%/Z06K(D1<=DD[0DCMMX^_?GS#/H EA&3/.?\I!LH19G$(&\90-,5H
M?Z2<4WH-,X,<DSRPKY#$_5WZW:+YK!<?TU/@-2#H'SY<60I*AT- A-2'@2$X
M1" 4R2P_8-8C/M&^N*LW3L?^_Y@K?#_QN?H*9@Q6D7!' 5#F!H$#;9U).$G\
M?//6QT0[('04WIW#H#U,\1EC^JL[FHY5/HT8JX=*G=:@/(FJ%?P@VSAR%H53
M[FN3"Q^7N9:R[8YVT00BAOV)+W+/<4J2 >YE!XD;G\D7.!G8TBH'XT!EZX">
M5\9=J!U4B<0_$+)A)N<9P;6;Z4YE.6:$UHZ1V=SOTE5"0^[>#((LS2EW)]KU
MY]DX[PU\X=7?YK9TGM3;>K0M$2^U.R'=CJ4AT]Q!I?QV6H-A4#-ME,=@[?-/
M$,[A9:E9I;*- *+5Z%$SJ[RM/MP$A-<4<^JI_:2#N$5GV+LWEVEA2<RG2E>!
MRUA[GR),LU)9RNF"X-/@5Q=5#8\\J79@F=\S'9T"X<P3B?M5?!:0"M,NP$!\
MET0X8VNFY+.,C%2S#O4%2H.D(U*<7%@[)&E?X,O3)"\U1J6?QF$4Z[\D*C/E
M.F7AK9A102T/^I6%2L;.Y5#M)%'#%YPVFFQZ3[[:<D#VCG4[,CT)KQ#)+U%"
MSA&4Q)<\?I_NR:_2K+V///H!QL-<_F=Y*+D'\_QR$@%<=#-?T+P+2'F*D>G9
M1.$=YH<)Q<4@0<D$N;+=Z%G=CE/(N5Z6';7L5 -H";1,M7KZ O-\ERB!R#MY
M(F8FD3O"P()^V9SI;UNMCF-U>\U'3T]\&^6F/,K6LG<IJ54J( YOA,).-:XK
M_:!UQP1#<"S'=JQ.N[W6L."3OO+:+Q)X@IU/V1W S2].K=%2T1.=EJX]"AK;
MYH>G]P9P>;.GKK\_T0=NUN-9G*_>^F1IJV#E"]V:51GI*G%&J0C<%FE.LNN*
ME7JU?-MN:;-BQ+UHS/7&X6KDB2&[=CUD+_99)QU:["/<\14S]:\5&=",F.7/
MXD.4OUEO2SZJIP-%!MGS\9%O\TS&]*$ZT%1(Y\D=>844/;-\="=LX%[#EM$;
M8H0(-XVY^RV3N'L[SD9+98*O$K%\:YEO(1?96_$"&E(%9KCO;UJ\2V4P%.1
MV8L*#.QFUVKTBJ*O>'/IV&)MMZ>=CK6\J[0T$'=D_=RUL3AI>$>G4:^UZRH1
M0B:879^*M_:ZJR<.6!JDF7]%;5'*C.)]RF K>P:;31ELY<;@PV6P&4J U=K&
M:>U!VRS \39*I]&UG%YWOTI'S[W6>(+2T>;::FV^-_+J%V]#V;K5;NR8L+_
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M@7"V8S=Z];ICU^UNQVZ_'-KU'T[=J8N?SKG]W<^[>M=&\7AS3^CN')]??*Z
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MPIE=KS6?$I68E6 @]]W!46NS'JDG0QA"K66HU3(0M0!6(B'A,W4Z;7/H:ID
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M-;,M-B+;OT0@(NX#'/F"2U&$257J0"-.XR&;$N,R3T')UH.[[<L L,]?#-4
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MQB/!L';- %$1;;+\]MF(LH$L6SXRU0Z++]=7OQ*^$+X\ 5^^\9]A$(ZG8-C
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MY@W;6_T_F,YC^O@ ^,,\2Q\AMA':=%$&<#%;G\P?QFE].G.?'C2O[L#JOBS
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MD6L'#V+DVE$9=ZPP1:Y%KAT\B)%K1V7<L<*T'Q6)UR7;\V&^_G#\=#82!ZV
M--9+82P#Y9@ 810#*Z@ RUT.SC+E@[M< 4DR2]SQ",X$6SXC+)AHFQ],,4NY
M,CE>/I;V>5H]FX?%26J*':]?KUB7D2F_?:=PD=&)H/S0M8L#TK8O@75]#/T\
M%/9 D1N5<8]=Y#"A& 'ICA7$R+6C,NY888H)Q9TD%,I0;B530+S/(+R08)(F
M8 PES@6:M,BWV5*%"44?M:W3A */;MGCSJD/&T/ZQ2S^P#C]XF9N'E+E5M6O
M*:03GY85IY.*$<9Q>]50HQ!VGS6<$A?KYD@>C$/NR);]B$3N/#+0S$AM=0"B
MI %!J 7CBN@'PZUB2K'LP^7((,1LN$H42%8,1"8)7#8:HG7&)&$$D>IR9/#Z
MG5NF^L5Z5:_<O+'^%]%!W;YZ,2QX]OSI=\(!.B%,3JCI641P"7)]BPG&Z\"H
M-2,S[TW#US\.![-'*CHL\<BX+7D!M[HDE(:"8U% =#1$P6)(VG8B.DV3CW<E
MJ$[+^LE_UM/5IXZ:<E#4'-0<U)SQF7>\4#U2J?'4"&%D@*RU!9&T!-\D.4S+
M0%)B+B>^(S4D,RYYA$@9!:%]!A>" 2^28MQE2Y*\B_RFW/=$*H):@PZ,6C,^
M\V)^,U;1H43X;&F$$&(1G9+1@).*@PY:N!P="7JG@^&-1 ?SFSXX,FH.:LY
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M!Y+O0,R+Y#O6"2\K.&?&:<@R"A N)C">E!!?B.!\EC(QMG.,KH\^!!Y :T=
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M+-<@@A0G(E49R37+E6$1C>F&M^\^L;AG$5M1QKS8\M7A3M9L[JO##6O";2L
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M@V4R]D"YQU=V?JE,^PYUOO^V.A]H@#MCUX=BZ0<7.A[%TAQT(W@!<&Q[R0N
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M[>'K)UJVO<*!+?'6GDYQ[93Z?>GUAJ/7&WQGPT.I$+ZSX9;.A@GH$(72),0
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MJ @6>]7P:*JA;V-I3QO+KZ-05T:\GZ54"J+Z019MJ.%\$MTKA[.1@A/A C=
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MW0VRE_N5S#]Z(O+Q1VO>.U?Y)+7P65;JL7MI#XW*M(Q:FXD#3DM.5 L#WIL
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ME&2PWH/F2J,V8 R<<A8D%8HXR;Q3C4Z&4VF0-Z-Y*#4Q?W6+7<UQN9REC>H
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M.>@&.=@NF\BP^&J+DD=?>6P!5V2.*L4M*H8&U"?C95&&%3U#&KQ/$\1+XYH
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MR!%N=7%EHD2G1S!F46VA>6".2^NB3;')T6(("4ZB'TZM0T.B++I,$36?5NC
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MJ"S++#T40,.C!^43)1X==A=MVTI6.'KG<J@[X@D]P6Y=S[P@@H<R5M85U47
MY!! VA2UYMKHT& M.)F@M<-,RY8'QW=9\6[;K%N=]/"M0IDF!&O9 [<>_8_
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MY!@,\;QX'%A9Q]I8^!?XF#YPG-5];T(VB#05I\>3J.HHONZ5C]S$()7EFK"
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M2.8SE]P1)BD8;]P8 3VA')2RA2<I9']^?,E&6-@SW#H&6PC'0T8+[G3$.06
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M-0$L^'4"S=MJUN8NNWF#TR9D]Y\>3O39 :[O5:&"]EQM9JA =]IBJQA&O3!
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M.^I8>^IHFK]>G5Z#U AW! >X'.' =[%I1PMQ=.MWO,+V8"R$YI&!BL^$:>3
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M0=";BU_W7/(Z.0>XGZV=R>H7-E>/8I5?.(&EREP*92]&9Z:"T=EOO,[V=*B
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M/N\7OO-C %1]KK#//F,.KM\PQ3\4GBR9%@@V0=(V3HALY82I'=*&WI9 _1)
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MT'LB'I?\!<=,@-R:@Y P237F8.OZL[3^,YM/!VL_KS='*(AJGXR&2K-PU$:
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MT'"DTSB)]@&>?<G.VE.:(2.KK_QGAN(FO,1ZN$;7DAWX3O\(C^N-)Z$9,N@
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M+9=I'#>"@HGMR&-[*M9#BXIS0.2O1U$O*3BA^39T7YC4(I]5C6[*M55F8>S
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M''?MTCYJ5T4.]>Q$$B1(\2C8R*!/H+5),6.$%UP^8NWNSSX\,6F^:S)(]A*
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M(FSH;A^6,?V$X6!IDGZ6.<-@U#UD%QXL@P,C(?X"_$J[609' :^ZN*.V8J+
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MSZWKTP_]L"Q54F7Q@2!-LGH-3, H<'GNRG?0WM\70D%@)UQA/+L!VWV%(XN
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M9L%=LH0Z>JQ=;\W-W M*/DRV#?FTT!ZYY0H=BT/5V! @'C"U7HHSPR+&5RA
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M9?3CTUI>YV%(Q 5+S@C\M7IMGVN1$>R3'GS38Q\] CY4I6QQ5QAMA<G=)4%
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M;DZ<Y%=@<)Y7D$?GRO3C,5G/R?D2?SQ%2NS1OL)I@>6;>.P37@UT]:R*/WJ
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M(1\H_&Y3&_#&I:PP>&DHFL>H.C9E5>N7=?*^%@4=152.W ^C;,CI*X<5<$=
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MD.;F:9JACA?-QV&U"K8I6J,X"]\0>%4';L^B+$,Y*@66F7I[3D!2<VF6%;K
M/?R_IE=0!$_E6.50F)8B.BUME$01LA<,"ZX.2E/@HB*X]HNQ/5&SF2E6FM0)
M*H@&F <2_SD.N&Q1A*@<WF:@Z32TBD=36G7)K1C*D43^?F&F<PG^\[)D+O$?
M'#O/80Z7U"V^%-_"8.='  K^B&@Z$Z21/R?T1ATDFY*OD,OI(6'P G.ED9T'
M_]BQ0*KG1&$F%Q!TQRB-*7R20&,HBSZ<>2+(\-G,A3/GY$P[9K!0)>=A/K!@
MIC11K M\@[,3+$"&?<M0<($%E6!SA0HKVC 5S2L^=\8K2%1 RN"3D*ESN;CZ
M>N8)GYU?%^""!199B)@H2!3C:D 5"89*I,*W#I-P!72,0.@K]0C,Y_X4!&X2
M835"/.89#1R;"T%Z* 62H$P:/$XBP.92"Y*51J2@E?4D@L7H&+-:J2L[\^A,
M*D)7<6/9PYZUP3P5(*V.0_"6S58XME8*(&O6M[M)TH>QBD30@JG  %Z/<]6L
M=O<P?X6(L<GF9Z84T[):+0AF6KCA],Y:\&%L<ON*:7/6<%1"NMVCH8!^#R*.
M6S$NK6L_7U$'A7]I=/CB Z&CFHQ0DC,3.O'(U-1J&X-1IXP]GYFD!H)[26.2
M916X]-XH; T,^S.KL.P3DIPG6%^^ZTGWF?><S% X<4KR:UEG HPX4+N$L;VY
MEEE3 VB*BC\'1$Y=_1%I6E:J&/T1'!;>WR9_SV78,7<#L=]%"5T.(C,'$/PD
M%%9R<*V35H-0H6K!8G4%D%DH&,NGUP!4*=6/IF</L$[)UP^<=G&AV9C>.V>$
MSQC!A7.FA,WGWYR:>.$Q[;?Z,[VH3^%K'*[")>@B53\@U, 9:JHI!Q=<GAX?
MWONO.8TODQ!:#5/=;"!^&M953_A\SONZ?T PTU_LV1_'-,@U/ 2B8^",P'?Q
MRFL62S]-RA65I4W<$]S"=NGGZ#4AM<&P[@X(UP3:&APGDWO/&N&_6.H=5FE(
M$M=\YOFK'.(IHRAY)ZY!L+PPX"F0V6>K030FO=(H9RO^D%90N19,.6IF RL4
M"U!X3N!7PH-$'ZL)0?U,,?WH5*EIBT=3X+,"OSZKOJ!TRJ?*^LK]0^R^"<O&
MY+;.%\)G2%OTJ? -?\#?FUQ5,HT_GR7L_E")%47+245$8JNGN;2-;3X"."H=
M678YS :0.A6%E6(%-#OZEH O0F@J*6LQ!V$\8>\Y><!-UIC @4ZS(@,0'Z(M
M&W):Q]AP$K@&SJ?^G'A\*,=G7D%DE7!^JNDO]\%OE_L7^#J%"P=\T*]^[--7
M[7D=IO@Y2_/]=?R*?Q?<1'Y?NTCE,P2'U"L_Y)$O>>13'ON6]U_PM?D16"]0
MO%P#X,Z@*,(FYJQ7##QY/&$9M/ZT\:/H8I>%,7ZAAD6IDZ$\/M;<P6XC%MO4
MZJVS6"1;CAV!BP3(NYN$9(EE&3 @@#=EM8<2'G% &N,?G]<I\O/!QAO]X2SF
M0Q2Z8D9GGC G6CR-3\MC\YK%ZE. UM_&P8ZFL8]?9* <>\;Z F,1Q%991<A,
MM5I+#XY?<PR-(&%J?5X68/C+6.1FV O]/3[<3RA]"Y>]_7QB0'8UTH=G$?%
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MN#; -3)3+:'=1G"":"/#KUL&W]*+'R?<@T,%#(WK7-G8"5+**UFNX=.<)!0
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M:<;R=Z:UFQ/D]0X9%9O#VR05*,8;W0EFR?'#5.*]NK43Q*@1=!W"QNV]@62
M3G#ZX-X!**!QMVOKUYQ@)K?]%.YJPSJ)LO9.$#0==A%-++*#%5O]MA.,QCL@
M)<D5B/[W-B:3YAM$6]C#M*\3A-ZC=Z%^9)K$^$=JYV>0(@8P)%W'<,2'P\"K
M+_&/B_0Y>5<@Q3>:.;%N0DEKLKLD<;;J""?CSDZ0RM#Z-)%+U19.3)J6QCEO
MJYUS[A"?"X#ZBUT6QGC+,Y2 =D1[60<G2+HF6=/%IH: -3SE:M :S:\I\Z2D
M&ZS'.-9ON?-=$.9)R@WM]=NM]F<GUHM'F+.L#V74L4E[]^*QAN;\&Z8=#_^(
M$WMA.GF397W9$G<;GW<@>D('6$8R&,Z%Q)>?411@(D@=C47\D.V4B >C#.LJ
M>S(C.G2 $*,,Z\1AO4)8@%R&2L A\>].3%@PX]:PD 00)'S$Z1\-BE@8#^/>
MN_2\#E/J("P*C4#IJ  "QE<A%0\*# NC1ZCSB$[LB=)ELUA53?I$52)21>/.
MUT?I#!S2O;UB7GV6GH3GA)2YZ8J8TG5L)_8/#0:'LM$:.-W6QO:?N\;3PZ,]
ME24\M>WM$T0<T=D5ROTP4I0&:S:Q/VUV'6"I@#&T,>M&"R?. 8MP)N8!4CQS
MV0T07-_1_KI\^]J*E]ULXL3*U(44P'>\C8/P+0QVF-5A'@'?^>V[2+^DR6XK
MW,&0Q]P;9'*TCUFWK%##\,/N)0J7-U'B*P+_A09NK+XF3?L>O9._* Q]!AV=
M(+$1 7Z/S#*8<3LG"-"Q>BC^N'H0)T@7G*WL(=#9_-6MG2"&6H'*T/PR"*C=
MD:'K9?WNXXC0@"Y4O_;$O]E_IA^Q7O[IQY>_?CI/TZ])@!7/)G*CMJ%U7K.-
ML/_T^84\EW5^U__NQ,Y71 'EEUA"W>.[B-Q"'<*'JAV=(%&6QZ".P%:W=H(8
M#B[-$F2%>U6MO+;U<=EN\01 [^AUC[?:E^0-I3$LSITL[7;00$ZL;>&A90ZR
M=1(%F)QVC[I11^OW8UF=(,.:(A5R;O#O&D7.E V=6"5MZ*QL=;0=G""IM_=,
M6CY<&:$^P6<.FWV8$,!YP3?48B5D,),S_-7_'FYVFU'Y:/ ]^X)@0]FK)J8T
MY,&6]D[L$#$ %Z#F\ QW>,J+^!'>*M#Y\%J%V;<X>8&$9S!HWL;;75Z-6;G8
MD^[$@*N!N)OH6TXP4ED57'GIZ'LX050M267 #4E]S$ EC^Y.X%?"6>^<,C/C
M;.S?/:1\F$_ ='8K_%]BCE'Y4=1M[1.R"M,L?UCCA?GI$O\M!-,\1! I:-$W
MMT\.=[4*$15%P E8I=5!+<8]G;@)&(@R<P\MTD?PQ5= K8L_9NROF315I-=
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M^=LXV"V9W((9+C4'FG5T[/Y0H)D:=AJ9]?B902E^?B#]&P6+V$ (,>_GT$5
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M#,GYD2GQ)/_TFKS]>;D/:%8*_J%,1L'_^*U!RT7BI\%B=84UX"4>/%M G07
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MOUK$XZK91.KV]D["&F[HVU@$. _Q/;3%1[7XU1-$COIID'W;!GZ.SH-DFZ-
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M'72K!PXO%F'\>+-X]'X:ZM+[R?0"=8P$JE,]AFZ,^KY2I2X3&'7X ^]84%4
MBHTY3FN8]W,O)) VR>-C7X^!SU42AHXRP3*45K'B.O":FUL(@M4-R;Q!8O90
MF!2QY#%)Y$(F>'.JFQ1*Q^J[$WO%M6=#Y?T-$248>2N,.SY-6SN!MX S?7V*
MA8_Q5YWX=!MEF,O:<DS" _*>QMCA#KVE]85?=<?W&"9IG-'(U(^C']-56L=W
M&2+^W3OG1)^88CU/D)="Q\B:E_'!CY.41#6[>R1;&+FZ<<9H(!01LD!?$;:R
M2@V"I-A1\:AQ.FJW1]PH]+2MUCG#F5LN)TY#O(%NG:.?.L'*I:]FOH7X;'N-
M KR7VHY_WMH-' 7"#>8ZW1<WCXF"1U+:S^QQF^0JB^A,+)N D RU24&V^B ;
MA': \7!-^B2I^4I-^/AGZ2D/U9\,M>J-UF]R+B*1A](#GR9 G&<T2^<F\1.<
M)D#\]RY+QTCXPJHEE_HO:J; !E!645;(OPR?]DL8K0!5Z1E22."PW])4>7ME
M[UR6OKVDKV.:+*1R^BT5L &OHEJ0\?%=*E(LL?0DREK+?2-T$<J2PF/Z)EB=
MV)D+.>)D[WW%NI+P(=1%,-DPNX7['.LB\N0-5J=NIH0'@D0?>_:)S<"EHC7X
M_!OS(N]"P%,]%3OO^RY"3HV0Z:JO$!>=N?-<:=9_YS@%7  WHXHF+WU(.056
M !56Z:M8ADN]I7&4./VX=/MPF(CONJZ6*:+.$/$#WMTN.H_P2"G/<\E/@17
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M4RH5E(1Z:S=[)RPNI;]&-.(+F["9:(?-]GUC$-/I$L5'L%O;;>!R0\);CIJ
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M,8IVQLY51+9#4O,*2YD?[@K/)D:DCLAL(:4:[W7^!T _ EJ5_%'Q1:OQ&>^
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ML&-"=B.^'##4SHH9CPE3&T3.!KT+><O)'W8^<&_T+<T0?>XQ83WARL>#.*[
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MW1SN9<QN+F7J:$S!IA;W,49*9S9"KF&W-39UDBV9'IT;Y.Y#_W\S4?I33F-
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M:U<-2L.P#*"4MI4HF\,4,/PGZ!VEDD/"<E24=Y$X^\0R4%"S[SAY+J: X*\
M&4&>+6,92"@Q SLGQQ0 _,T65I#G]E@&/&K\(4L6,LE%&\20'7FJD85 ,<!\
MZ64TF00"B'?2DLPH"\%A "OTLHM, @&DRT5>RI>%$#Y&#/!SS4P""KB;(Z5$
M-@N!0HD_Q/ER)D$"TGV!+"_/0@!09H7YKQ9_@N@F/R.+T$(P.N,B^J=)V06B
M_U><TV@A,"C*$'[ZI$EP@.C(')R!:2'(*',(-[/3)$! =''.EAMJ(8BJLY9"
M[JA),('H/=62<FHA:"EQT#EIJR:)3X;H9U7);+40,!1=+&>DSYH$*(C^V,$)
MMB9!!I)[<D NKDFP@.2<8R?QFH1L2.XGE91@:B#\]Z<.!OA[?S1^9OS:@@A]
MI(B$')2S:V'P%&&M%.L.48BMVA_=Z/"I3"+X*74^HC ZG#Y13.[\A(":Q2B/
M5,;-L<SSWXD0#%>>Y^<3?PRW47R@>D<1R_R#=4E:>^NI*_]J/;#N].-T27I3
M8D63MQ*1*W0SETL/\Q6)M1+6.>XTFJ&L98OO^9DR5;L:@_<%84O!=['-T'B4
METMGJO7E?WB(XHWS\9N?[LDS!7Q@\?;$Z.&,\Y>@9'.KB?&)#M@(YHM[_XKY
M :^O -QF"]/3%$+;;F//5"=B@B1.&]/%_ZJGBO_Q^PLY!)ERL?OKK-/Z@K6C
M0W;@3JS].]S$\@E/MZ#_L\%36X6>DL28Y%-0CC-J?+Z\?F.NMUH?TT7/&'E:
MV!7-F@T-9YUNI^-C3[K?<'[YQ#B6VK\9+"5 K]BPDEB[<E_\Y _!02KL H"0
MVRA,8\=-B<00\K.PRU((,:^:29/$]>K%\-H;(Z$^@?C3;K>YGNCC/F6>75]0
M0!YX$R?SJ?'J2K#RHA[0R! NJ+C/<D@YF\EXU4_J_&24P\ES5G+S69A)>>R&
MH-K)@.YF:X+EDQ3J7?UVALMY/#N^U_,'X3^PI9A(Y T=:E[#T_D0&YZMW^$>
M4[RCH[P-*#7/A%YT;?9.6,2S?(UH&"7R\EALW3[UP=\W"_&;G,0W3F!0(UM#
M)S"HBFTNU<W,"<BS*%XI;!,ST2W:1_!+0P36T3&,2M43?,"^?=U\3M&XL,X+
M#>0R2_=65OFD?;N7_D^A,N2/%VLZ=>]/X;?LX\%"W'RF836/8:YP?8ZC1/O-
MK.!+]L%6OX],DNQ0BNPC(I[.ZG4#UL9U@ZC\7?LVL8BT24Y:^0>7P9?$4?D0
M(_08DC0I23H77S*_:Q^D_9CQ:;1L[G?LV\K-YB2D5?O6[7\ &$BYT;S*TGT4
M^_]"'LW;U-!=B0<P:3TVH!<C#:V_8 =%Y?_G00C//[LE;/L%EA$__Y8@H.,B
MCTTI.4[#A(>.8F?3M\1#T^>(+I('CF6,=.KA^8Q"S&O!*O16W@'OZR2-Z8V;
M>%65NEI;>5=?Q&O]@%XELM3RPDGLRS5A?0MF%*CE,.CE'DZ0S8 X4]!P*I5C
M8X68MMX&=!C/$HI%Q1J'D6Q'+4;%&K[]B-=658=V^*8E] JK]0X@V)*%Y@M)
M3F@K(9@17FHID7/$K C.AF[0IN4H7F(=8V:$9;E)6OO'7AJ'A&JVG^R+ @DM
MP4-T(.@$Q)(#XUJ55PT"9L#FH*PIHXX<2X 3;2HCR"UI]RG$C[9U$F%PHR5X
MB#A*)R"6,(I<66.^KJOS@ P))+4<"97W#KV4:.T 5,@(J%5F&_"@WF"YUSE+
MJ$_B'!P7"6PIE#(70CM0&#*1D^RACNEH>4W@"??+/%':D/&?5(:+K5C+:]%.
MR)9S1[9#7HE)&;1C$5I>ZG2".VO-;P,@ SPIH[4N>"PO#PKL/%9Z70$9\DD9
M3^BAL+R@)K 36/PZ!3+6DW)@.XS!\@*5P&2?Z%6/Y=4?@2&M_A#(\JJ*P(2J
MPFLAV^L56L#I[*=%ME<'! 8\_P&2[:7X@,D4QK,EVXO9S8FP@3=/MA>8 R]I
M#)3'L=YCH?HFRO;*9M.@!ZAF^9Q%P*8!4^T9UV)J)+RZ>^1E 2E%FF0K%_\9
MMS!=(Z&.P+YU$E(8BOP_,OEW)R#7A'3Q>JO(S:.K-,BLM0]*U*/MR^NW$O61
M!1$$8]GWA/B:MTL;Q+ S>%YS<E\3SNK9D6V/[>P"H?/Y!0+\*Y5WQ@#N?'Z!
M #]$\1;Y)C'NS\#:; /C=$?%S (BO0UR>+&"-34>MX6$ 4*ZIKB^9-5QCRZW
MLF8.8+N^;H,;!V^#'.RJNI"CH2V'NJOT0H[KM1QJAOJ[0/=JGEP((]^X*BH
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M5<LLDLO&%#)4*I6@6-98'?C-4:670?1@P0HF_>&<=6]Y#*+)*EL&/(-9B6_
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MKHR%3J3R01)GI(P$5S^ 3B=?OCZ&J1/NB$\B;X/%:A7;\CF*O.\^"5FL8PM
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M3S&PZG+)C+6G1PG2(:>!!%]2W):BHE-<7W C*E(F@S56GD96B,#QX\/:H?[
M-LS%M3,[(Y$3VJK [M@,M:L*,EHPL*O@#$0%RAQHZ@UQ)FDS:]KA>S;/K9('
M&X;U:TH,H$183:F@"[)CJR 'UO#?N=U\SYI&[0BOVPZG']NC6/\$=M%'L&'P
M%P!_4H%+"V_FO,:)8*+JLIW"BY>KHN'5QZ]%9+%O-5Z':8-)!!]6):Y$ZO"K
M+^(1G6+'X6CO_NZU4%F"9(.Y3TYM>'WYRF6 +D'BIZLM6QX<6Y:;L&50J&W"
MREC>H/R5NB_,.!2V;)-K+LQ:>WSQG1(%H,G%!/1H3MF?4B:OR=H(<HOL[D?&
M&4P/K018HZ.$*K^1QCD_VO->>U.RXV\2R:*<*&20<TSU)3^=J 4ENJA4[N+S
M&\IO!_:,*W*47N$SB6P-G8;N0.NU-WD[+D]G=.L8YR7MAA9T$6[(D#3J9"B<
MN BAD].UI?C!4?QT$XJ?CL?PZK'QH.CQ0F1R3)@TQCJ L:T@'@C%G^4NI155
MFTR:3-CUQ2-9DS)MD;P5-Y3GSUE\Y/?740[B1+K$+9N^'XGZ+=H/#NUGFZ#]
M;#R&+U.)%83 0E>Q'TF@.U-FX[H<"-J_QK529B.L]332_LQ:$7D!N.^84Y-H
M(+$":\<R. !N2A'@<T %$"(%!I)TY'-%<P-V09F.<.'?%2R:Q*.3B864F=%_
M ZHQ5L7OY:2=VFOD;-86LBQ'O;2\K<2J5TLJ)7)/-D:02<[9)EINB&N?*M'R
MX4=4^9JR0\JSU.C51-P8BMYY&=1%(CF\M0O<BH?!B8=-$RVQG)@]4B$Z@K@(
M'%33@>#C;Z[T.:S8!7$1>*C:I;^A762*1H2KT\9"@DY2D(GEFT04]@M3ZP7C
M/ G>/>)2 :MAT;O3M&I07#0U:%8-B@7GI,#R1KH%[X&5I.U$YK9?!LTR2M<8
M<3D%U2 T;%V9]@^\$:L=]GL\_I^^C<>'3"HI8(<I0*/7P.HI'5C7"*;E-NM]
M_\A46USMTI%A78&3I1T+E22_J[:^+AM07<.,C-M*UY94)2-P1*4-N>#4$8IG
M4 [NSO'!KE\)5:?Z_)(4R!$0N,)JB[2AHE\Z2,Q-J\@F9E^;7?\<M(F)E(5U
M7G&V;UGX2C3CH:2CCN_%@P? F_H1W!P6Z8"=;</4':K8 2(U6;KY:G0O0V%G
MAI3.F+P&&1#;I[)R<56JS/HKLK*9U";OV_AQV^5&UZV\0A,BX]B4IWEGWN&+
M,4.;U-!1BPQ'Z^G0=S PWA87771^[H!&Z?6^E]8VIV!X4G[S'&3R:DJLSNO$
MGY1FV3\0*?_"]!3!M78"4$K[0(AKPF&]H.VT&5LK?"Y #B<[5%$PY1"1!&MR
MEPH75\X_^G-98N4VZ@T]%[- -,%ER[%;+.J#R8)17(9Y-L ),W\X1F3T (#/
M7B6O2I]?)&!AN13]VT U)LQ")-5CB3&-("$1&S.8,C\ IZ0*UC MV-:.!%7;
MU@'%PM:G2%*EB<JL]L,9VS8Y"7@9/)-*'(VUX(-TA@OY3%1N6[%SO)LLX/SG
MOH5<C:N0-\!9\("#"AO:C*1F.R3[$.!S@:4H9?4.]]1@>Q[;!";(%>%"QI%/
MC^[AV0":!7H0*&<UZI<VLJH2)QNX *<!'YR\S1L=)?/R&M]I=#;8<U&22F7X
M.:6*M6$3^O<T)WDBF$T9#FHDUQ(K:'<.C_X K,R9&ETA;Q9+.-G%J2URA<-3
M4]^\)L[@SQQJYJYUC@GAF0!NJP'(^:MG;\YZ A&D;\>2ABY%+\Q"-0N\OU8,
M%]O2"%&#-TS9CZ@U[1P^<3OWB7@=O0=5]9%7VG%S*=$->SVC3?(RS+;X]A2;
MM(F9'-E$9O>4"6@_B]8#@)BQIAK1  $%4OQ*Y)+:$A&$[-/86R4*$SYA7;B*
MU-].Z4/0T,!ZN)A0,5>%\\5S:2,;#C%=QK4U60+8W$*>?\TIR8='FS<^]5V0
MAR AC_X4"<JM/M#'C[XY;2F3#Q\]_3,HD\?[3P\.'W[_Y,G1]P?'1]\_>OQH
M4/FJ1=Q<@A1-UUS".)B&4JK[@488U%M/M+U+;1WTO5KF>I726.U:W20[CWM$
MF4C.0=!S_XUS-O@B9:]MP@U'(R4ET&H77460%)YF$0CU/BTF=,%QPUH%REBF
M0([E5G6UE8,=..$2$4DCG6C/RLVN=-UI"=%=H\L.7AT*(?=U:$&!,DJZ.[:5
MP3V9.K7(-<*J+A";(V"*8!N"VS$^RE680;+'&E'\&/L.P +K&&-L</E>A!5Z
M]PY*QS^D==R>>2&@AN0$8Y>EK%(JFW.=_LC37I?INZ1<UK:W** 6 IQ+X^"A
M>V2\F9O>@\B1<[_;R C>Q=F(AC.0HPPY2+MW9SL+E$PSREJGGF2^5=!$ J7)
M(C%]6[UKK>5+B_(P*%:,>1?=*]'5%OO5$E:-_*(I"9UV&N,Z\>/0N]=I6FDC
M&L"9A<JW_KK!^>LV31J/_'6(JWU.NX'H5)&_CNCJ_4Z[EOI$(@A5IQ&W)J4H
MCG$/<>H?=C0>!?V,\;HKL#:+&BD]ZG[,HH4<)CX9 U4HG59JPDH4BBOC8=F9
M@.8R*5$+"N[T+BIM^Q9W[Q3N3J=@F?98ZVJ$G3NM+Y5K2[N#H]U-,XO-.6,,
M'8X]R.IPR8=E-13:?2U<UVX2V\XMZ9 5[1E7G!&4Y?51$1*ZO,'D*IVO?!P*
M2,$W+4=CP9L69$?,X/D5Z.?7 INHFP:.;%K [X#]B@L#R"E-_1Y-  S5@%1R
MEI9K2-=.V+)\YMY6!!HS:TB:7SATA*U:;@JRAV[FG:-#VY^Z)R[=%.33#EJW
MDK->Q9EVKMH$#\W:F61[H-[D)YL07K%:MU155(T=6*M&S32M#,G#CBWV6_%\
M^QI"8D10$Z&O9-UP1DC4MV;7MXJTEF#6TUV^HR?R(^#]2$C^IVY89S]Y@53I
M%Q,L$$7-FG5]Z$0V.@QK!P9+0/B^<^G\?8DVE!R98]\/M@M\=1 %I[$GNF#+
MS?.=7MG(??=M\?L:6?X0V! W[G0--S$"9LL,2A[O8!P,D;7K^\E.)"=;FR='
M1BWU/(6O\IP8(_GA$1@UF^.89&'"1V2]%LPYT;E$"WA\ .B ;=@_8+7S9J>J
MTG44A3,KM"U[E@'CAJ][8FVDB?F8'<?P*%)&22B81N2<*MP_EWP&Y):0&7<2
MI02H.!88A<AP8P7PQ*"1'+L*0M?-K39\N].]VG6LWWV?[NYT#GUSZ&_5L*&I
M89N6>\#9C^VX!]3%HC*/>B@*V/N'4IRL0<?>R7]=5/M:1_]]I!9'+_J8 ;7T
MJA,%LD"E?V#99.4.48V+9<N($DB,,9NKA>*6U=QVV_C\N)[9)U4VA6A 7%2P
M0%#V.0QBFF4W%:OQ93'%\@Q*F5 %N6=97:NP4"+#G CLO=!I<>X:3DRT I%2
MK4;VJX6@3F' ]BM*6R5CXKK"',DB<+=9CUZT]$ 5BUYC>J>[MZFX--+&>@@L
M1GOH74>Q"AP@HVCW-! &XRFF.S=_0 ,B5=0+W920^RV<LIJY!O8HD976K/J.
MJ&=?6KO<@=(V0ZNK%4-H"5H+_C5K5,[.E,^$DQN230$K2?ACAO[:(5&0L3$]
M6F$ZIDBFH,!30K/-R@85VB'V;P51U%O 'ZD=>M>F9KZ2."R'OP1-"+5Q:IZ/
MV <4A<6UFD]M4:+1##; 4M6H$KK6+ 9][-WTY>]-I30B!J%)4V.I5'<UNZ<F
M$K,&U6952?51,Q )5&D%KT37U[3)$\!!M/@;;+=O[2Q5X'O+1K=ME/=1F\78
M[NOMJ\BSMY2<B254WG"[_TI.&VURSR+MW8Z) /T-1!GE#6(U\:E//1<\D6!:
MB28; >5.Y'_^DYNY4(Z\88?4O0749L>Z@B-)3?,6YWD(F,T,.SO4MP0!K.N*
MC\"]VHQ(P:2P]K,-MZF:G(!@JIK[F6C/R_ [/J_XL7.1.5[*\^E.\2D['F!X
M5(;Q$!H3"K.1@&6HP;/\\WVO"^>O<2TGM0E.VDWS;XC$-$X+@2T68A8$3@ )
MFMIZ?I>V!22EXE%J=3R9@L,N07G"6@FS'^37;-6M^ZIN!;D70Q(93NG"<7+:
M)$^D+J-A#>L+AC:UYE&2G1_0#)>"ZW4/,GH:CZ[CV3A5S[P<([8HP1#(!;8H
M9JQ.N3*<.?$;S7185K5V^<".;64@BHK&-FA9LR+WDJ@<*F@M$62&C#I]?TB/
M"]I 2S>/#@6HZVG<S0CP+<%L =0N</X;U\^B,*#DY!JJOB+7B+;^:J[;Z>OW
M8VJ=VHR&/9KQ*\S!6Z\3H$EA/!N]TRE[LI%N%S^+)X*RD(6' ' J0&<>1 -8
MT.3^OCC@9GH)3#3)?=/DFX+IV"N7/:RG ]<D;8KVD-C!R(5,?1"1O'0DX&@>
M*L4147/II)1UYHKZ@:Z,>D/::=*2JMNTXWN6=GQ\7]..;W-*7XFN%G('"B>Q
MUF"FU(:*QNT4 5WFLBL?0OVC*,VX5I#)G,:Z;"; EU$\HE\GLP/,1KY&QG9]
M,LPO7#2[HHSW*4/_!P6XJ+S%QJMVSEH6JGVP;IDL';-S&J2JS'BJ;:4X+;(G
M53>L G;A,U1[4LXL37U1.#]R1\NZ-GEN1GJ#X#8>L. ZZWP"_:0RD4R1FN)A
M9QAIC+[4'8,/;?1GNW$*#=C 9#VEC8EWW':'N$X[*/CAH]TP)-J&I'%-@)#A
M >4]KH_U\?9S7-AK4A)<[-B4(9VWS]*E"JW584U/L;7'Y(,\['O1-<5^+.+Z
MM;0-O6V8Y]ZU-W*Y &-APCQRC)$\_-NUM1@(<[YP>0O"\1);I_7^S->197T^
MH(L1>JE[$NJ (I!VW61/5"M'R.Y+]+BG9+B$DW0-+[8<R";J8'FC\QO1!3S[
M$[^C%+?5R*FEE-=-\TRG/#YL4E(**U96^J&Z@6M[ABGA!1EW909R9M=4KIOV
MQ]U&J=AQB?SAL;H\LIV;#30Z%I=)GN!^A#*G!"..=D<]&_R U[!+FFD*2-<'
M:8:F#ZV+>' P IV&G8D!\) I-D7$O:=4'\(^+OPRV^U9"<T] Q,0SIK,79?2
M'I0+,/",6\R)\6WH>G \;;X)3YM3]F\TU89BV<C8<,:OTCQ ?2 \[4413^!Q
M]=5VK5R?:M-'6KRJ8\"ZT/<'*?OC2@DZ?8)6GL%@M(G=R4ZIP<H47(2I'@!S
M0RL[PCQLY $<%EZI@YC->MX@)LA]?4L;LOHQK@.,B/Y^5Y37P"9F,HQ NN;/
M]E5^G)>HN#B?LEYP>RZU#9LCW!?GS*#B>P1IBPTJ,D^B*<A^[+1CV&&JFQVP
MS8Z=,NY;Z NA&.&I[6S4&9P<0\X[ZAOZNG(]O%6$K0<M[F+C1$3JC *3W9;
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MOGA//[73^X?O)F6V^O&_?OAN7B_R'_\_4$L#!!0    (  R 7%J:%'F_Q3<
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MV%0%<;@.:*,9@<:YT&PM*;Q/< 6Q;*DLQV=6B4/CJ2B#'9 )#K\JR[!:A<?
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M?69J2K0"I#2&]TCN4>@HPI4TJ0!5PR);%5,E\[N4>GQ!APXCZF&3T5>;\;T
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M$KR7/B"*@2E%A6]6 ;JES'')"E-!#W@3[1X8U)23<](NV*22MX1Q5_ITN%;
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MA"1+I9[)A0O;S?D1_ZCFXHOSH_!SG#\ 4$L#!!0    (  R 7%IBWU,2$ 4
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MNJ0)A*4";Z%H6:E;5![$DJ?1AFT/F>-H5Z"$C9^0 EPX%BPU>9@QXR5(!Q?
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MW>W2[]CWX"<O^AWW!OUO4$L#!!0    (  R 7%JS\>7H.04  )D7   /
M;&=V;BUE>#,R7S(N:'1M[5AM4]M&$/Z>7[&%(4-F+-NR@8#D,.,:,V6:P1GL
M=-*/)VEE73F=E+LSMO/KNW>6##A 4PHMF89A,-;NW;X]^Z9>9G)Q_ IZ&;*$
M/J%GN!%X//SD=3O-3J^U^DH,K8JC%Q7)$K19"GRW5;(DX7(:'):+,&=JRF7
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MG\!D!!^;X^:@">/AP)'\[G[[[WONT=A^X6[KCZ%_,OHP&9XXGU4NJWW5:1_
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M_R=02P$"% ,4    "  ,@%Q:(D19.8#\ P#KR08 $@              @ $
M    :6UG,C,W.#$U.#DW7S N:G!G4$L! A0#%     @ #(!<6B[AW&/!XP0
M?#@X !$              ( !L/P# &QG=FXM,C R-#$R,S$N:'1M4$L! A0#
M%     @ #(!<6J[8W<YL:P$ D>D4 !$              ( !H. ( &QG=FXM
M,C R-#$R,S$N>'-D4$L! A0#%     @ #(!<6HH<Q_L',P  M&4! !
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M   /              "  <K0"@!L9W9N+65X,S)?,BYH=&U02P4&      H
,"@!J @  ,-8*

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>lgvn-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:lgvn="http://LongeveronInc.com/20241231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lgvn-20241231.xsd" xlink:type="simple"/>
    <context id="C_800ca5b3-19a9-469b-ad8c-765f4cf802f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8043ee3e-2733-4b91-a33a-2a0763fad881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lgvn:SeriesCUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-23</startDate>
            <endDate>2016-12-23</endDate>
        </period>
    </context>
    <context id="C_830ceff8-2513-4d56-879f-3cc26a4081b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_831b093d-c619-43f4-90d9-56df47a2666a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2016-12-23</instant>
        </period>
    </context>
    <context id="C_8517f575-39c7-4d46-8576-6a86abfaa79e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-17</instant>
        </period>
    </context>
    <context id="C_852485d6-ba04-474c-a47e-395518e87aea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8561f2ca-4d1a-475a-bc19-fcface1b15dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="C_8828b9f4-08cf-4cd9-86ab-83a206aaab8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_885350a8-cf29-4eb2-a100-dd267e1f76ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-15</instant>
        </period>
    </context>
    <context id="C_88f70043-2bab-4fbd-a7ff-7ca163bafeae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ContractManufacturingLeaseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_89410ccd-0c4e-45f8-bf14-c2ca134fe7ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_8a695d29-400b-42bb-81da-34af6591dda8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="C_8b8d20b6-58a6-4f02-b93e-8d56eedb8243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8bd66a75-3699-4e56-8cd2-f92fabc91f0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueConsensusPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-16</instant>
        </period>
    </context>
    <context id="C_8e3349a5-e8ad-4d9f-932c-91af4f1b95ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ClinicalTrialRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8fb325dd-2a4c-427e-b457-7d9e26d11251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_906ca24e-44d3-40ab-b91a-b4250b408e3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_924ecf1f-101e-4065-841a-2f62764b7c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-17</startDate>
            <endDate>2024-07-17</endDate>
        </period>
    </context>
    <context id="C_9474be27-a471-40f6-84ce-28e85ee32e08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_966061df-c7de-4d04-b147-85979bffe716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_972466ee-785c-4232-9930-fe53db2cddaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="C_97d5f78e-ff73-4686-9599-d8a719ba798c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_98c6f150-65f1-41d8-9201-4a23ff2331cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9a653252-42fd-451f-b16d-80dfc3b20336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9aa77719-3220-42ff-b34d-4e36497e3a08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9ad503fc-d399-4534-b7b8-40dad723f514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9dcd6c86-0172-4023-b693-3ddef2e87823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9fa8323f-6ecb-4760-888b-b865f49ee572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ContractManufacturingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a153ce10-2e61-4bc3-acd9-4005eae448d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a24d65d6-9396-4617-9b12-342686401195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a3cf52d5-51ea-46c9-a0ff-4a136cfdc855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a40fe316-3a4c-45cf-a412-d4ebc66d9819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a5052b3f-7b15-4f4e-a480-ac371b45c8fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lgvn:ChiefScienceOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a54ada20-1a44-4de3-803f-884629580212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a5b385af-6f58-47c5-83db-6be10bedcad9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-17</instant>
        </period>
    </context>
    <context id="C_a75f8163-8123-4c7b-8abf-018d61948b64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7d1800f-a37a-45fd-8dea-2364d19b5d11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JuneInducementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_aa3f1212-2350-4425-9290-9e78374aa7c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-17</instant>
        </period>
    </context>
    <context id="C_aab874c5-5eb9-44be-987c-9dfe72f5a008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgvn:BiologicsLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-20</startDate>
            <endDate>2014-11-20</endDate>
        </period>
    </context>
    <context id="C_ac111904-200e-4f5d-bf20-50cfa1be5544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ac1c02ac-9c7a-4aa5-b23c-caf1a6d79afb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ac41fb9d-662d-4175-a25e-3ade70bb7db8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-29</instant>
        </period>
    </context>
    <context id="C_ad3fe0e4-e995-40c1-bc38-77db69fa7a3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:AprilTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_af1e0bf2-f9b3-4719-89f9-f37749bdfb82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="C_b14e7beb-bb0f-4f7a-971e-b4f66076e0c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-10</instant>
        </period>
    </context>
    <context id="C_b186b4ae-25c4-45b0-8e3c-637d9c03a871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b2d83ae4-7a58-420c-b89e-bc88b246fd41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b35ec15a-1d7a-48da-bb29-ded77d1dd6e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b5a79c7f-92c4-4fca-aa5a-8390eb7d7186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b5cc0db4-91de-465c-bb48-5b53ca7e01b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="C_b9192f71-3161-4b98-9cf0-b50270b7d523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b94a44e3-eb07-42c8-b01e-5d44090f5b4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b988428e-be70-43a6-a20f-4a0d1af53866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bdad186e-621a-48f4-845c-d93f9eac4f04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_bdba25ca-ce76-451a-a79b-72c6a6a68dbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_be58ec30-718f-49dc-9b0b-5da7ce7d3da6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c0238eb0-efac-4481-a961-ca7376905c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c0f2353d-d121-47bf-acc8-b4e623af90e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c17b9bfa-207b-4863-b527-d6ad7945f5f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c2617445-260c-4016-83d7-e383b81dadab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c2653ae9-c06d-4781-a567-ba19aae19693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2024-07-17</startDate>
            <endDate>2024-07-17</endDate>
        </period>
    </context>
    <context id="C_c28d2aec-e976-4127-9697-03bb7896c0e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:ClassACommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="C_c3264d47-ea98-488c-addc-6cdd4c066842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c3874ec0-4371-433c-8e08-3d6bcf9a60d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-24</startDate>
            <endDate>2024-07-24</endDate>
        </period>
    </context>
    <context id="C_c4442eac-31f6-4b65-9025-3e8e2289cc06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">lgvn:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c6ce0b7e-d437-4704-9765-d88f29ce0adb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c6d1288e-2e0f-44c3-bc7e-30f39c656ecc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c7147bf9-99b9-448b-938b-630f1b775c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="C_c7555a19-6815-4308-a228-e63b0c8a4703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_c8996def-ed25-41c0-9cde-57e67fd24599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c920b7f7-14c0-4ed4-8bef-d33b2189d204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c92a5e48-5a59-41b6-85ff-8ee27a7ded47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c984fb4f-1fdc-4b32-b577-b0d95a9c9e4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="C_caeb366f-d29c-4739-90bc-fff7fe6667f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cbb6d537-8377-408a-a06e-a422b97464ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ccb7843f-3d8b-411f-883c-8583123a3129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cdc2df3b-5c8c-44c7-a3c8-e65d385a5523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cdf836e1-0f62-4f0e-af87-d9a88e484056">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cdfee0ba-2fda-4acb-bf1e-85d83d8ae89f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ce0f0327-6771-414c-b1ab-e8b2040413f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgvn:SecretomeTherapeuticsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lgvn:SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-21</startDate>
            <endDate>2024-02-21</endDate>
        </period>
    </context>
    <context id="C_cec0b67c-0b8b-4bc4-9170-1fbad94ea8f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ClinicalTrialRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cee66114-9a5c-4865-9e37-ed6c8eea4537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-15</instant>
        </period>
    </context>
    <context id="C_d018a83c-69ba-4776-9f87-503309a9913d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:JulyRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-18</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="C_d059abac-e58b-43e2-a95a-5a8879af8f3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_d061083c-5970-4784-a095-643917174816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d1bc4f98-b538-4530-9021-04474129f4f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d1dbc3f6-3e73-4cc4-a7c7-bc22662d8467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d3638195-ab5a-4291-9ae5-867e2b6cf88c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d496e54d-c6ce-4319-8f1d-e8da390d52f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="C_d5f7e310-6aa6-4ef9-ba0b-23c17f14bd5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrants1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d68599d9-47e2-4ece-8323-0052aa98f47b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="C_d75ceeb2-ec46-49ab-a15a-5b9237a9730c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JuneInducementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d8c195d2-126b-4a62-8221-e81b21de8e4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:AprilTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d928293f-8f03-4263-a9cb-8b1b15166f54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dacd79be-b988-4527-b1bf-f17043f4b8a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lgvn:UMAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dde951fe-7b4d-4fe4-8fe2-29b317fefcff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dfe8bcec-cbcf-444b-8845-a535ef3f03eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e11b48f3-b181-48a1-9aba-5a7956f22930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e1adbcb7-b9b2-43f3-afc8-b17cbfef377a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JuneInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e32174f8-44a9-4669-8a00-c469ea7d76ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e434dc91-ef31-47bc-8cef-615fb2777b8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e4cfce79-c2b0-4ca4-8408-3fc1d9f375ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="C_e577d4b1-7eb8-446b-9a4f-8502fde888f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgvn:SecretomeTherapeuticsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lgvn:SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e584071b-f7ae-411b-be56-e2130dbedae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e5e6b360-d445-4c3e-bc79-675f33b37486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e6f0b313-1ad4-4509-b95a-760e3a3d6430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="C_e6f33f88-f256-4289-b5e6-07ec6c716dee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e7b06b06-de62-4546-8211-520778c26862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ebecf041-4bf7-4e13-a8bb-d1dc47e42040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eeb0c913-518a-4d04-9452-efbaf66ce005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f23ba838-5cb1-45db-a43c-3c3ea606ba58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgvn:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f3787016-d57b-41d8-93d0-083f687dccac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f492dbe2-0361-48ff-be3f-265ad6408614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f5447379-d637-4372-97dd-6cab7114b6af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f5c01cc3-f4ac-4cac-b32c-b2eec7d32119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f620f41f-099b-4180-8d31-3b93f07907a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2024-07-17</instant>
        </period>
    </context>
    <context id="C_f62d3e71-2071-4235-baa6-e8487a08b092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f6a93e10-9d65-4c37-b7bd-599ff82c8e50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-09-28</endDate>
        </period>
    </context>
    <context id="C_f8a92122-f474-4b31-b2b6-a0fe54800397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fb198e78-e33b-404a-872e-c2d863686fc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fc09c49d-eaa5-4b33-8d36-7cb35209c791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_fcc6b1eb-c243-4fbc-8e56-d5caa3a5c35e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ff6c86a5-5367-4252-82ff-f27f2520421d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_003e9629-0270-4293-930d-9e35e517c34f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lgvn:ChiefScienceOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_01ea16bf-996c-4f70-aec4-bfd677595c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_060bd5b3-20e9-452b-9a05-b0270d3c7018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_07d8a382-8bbb-46f9-8af5-da2391d2ed5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ContractManufacturingLeaseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0922a283-969e-4183-84f1-754212457538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_09e3c48c-8324-4e5f-b8ba-e37b4bea78af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="C_0a31e712-6c10-4d5f-a17e-78ce49207e63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0bffd59a-5e1d-4d4e-8b68-f305bbb2e10c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2022-11-16</startDate>
            <endDate>2022-11-16</endDate>
        </period>
    </context>
    <context id="C_0c05e440-f556-4213-b61b-eda6feaf9090">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0d1788e0-51e1-4f67-b903-b27ef0e08ec1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">lgvn:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0d186ce3-11b3-4bf0-afd5-6b860eabc151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0e8a73c4-ea0e-438b-b7f5-e4427532c51a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0f2e3a3d-a8c9-4849-8d99-8d26291368fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0f3486fa-b30f-4c7f-a57a-ecbf7bf415e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:InvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0fa78e15-5237-44e1-ac71-f1d25f041ced">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="C_10494440-1436-4801-9d95-e37fad25c83b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_10a053c8-c2a2-4e48-84b4-b5ed263c95d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_110002f2-7209-44ec-b8bb-e70434de6600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2023-09-28</instant>
        </period>
    </context>
    <context id="C_1265d1c0-07a0-47c5-a6e0-1db933689ef8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_12e07091-6e3f-4a59-802d-ada554263431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_130be5b2-21d0-478a-b3b4-fa7cffb2136b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_134d5e58-28b4-43ed-938b-934bfff4116f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1400ed16-357f-49fb-8ddc-3ef9e892f328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1603a247-a9e5-422a-846b-6d3ba3b022c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2014-11-20</instant>
        </period>
    </context>
    <context id="C_17a45533-4b30-4885-b609-d19b1db34a37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="C_192155e6-0c54-4184-b414-7318e5281259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1a1782e7-88b3-418e-978c-52f25f9bd58c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1a4b8c2d-4195-4bab-8513-5d2b8c496ede">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lgvn:UMAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1dcfeb4c-c36e-4113-9bd0-cb07f984983e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyOfferingPlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="C_1ef16fb7-28d8-4b6f-b55c-d02b22740228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_202c13b7-a778-4220-862c-5376ad67002b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_20a3ae2b-fe8d-415d-9a71-83546b838508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2165fc3d-60ff-463a-ac2e-ab3e6e0ab4ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2196011d-eb59-453d-922a-463609b50727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2209f280-17a3-4fd1-94a9-c9d5d6bd6b30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:TwoThousandTwentyOnePIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_231d6559-39de-40e2-92ca-0ce4ccbeea1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_236ea03d-46b1-4bac-973b-e724dd4cb6ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_25de8810-47ca-4f3b-b23d-79bd1ccf287e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_268ad250-3034-4601-a1f3-6fe024bad788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:ClassACommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="C_27694a1f-8536-4e3a-90cb-ee31e0d92d39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="C_28896f23-6bbf-4287-b699-1d223de107ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgvn:firstPhase3ClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-20</startDate>
            <endDate>2014-11-20</endDate>
        </period>
    </context>
    <context id="C_29c20658-0d07-4fb3-b57a-a2b98683e7ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2a71fae8-4d00-48eb-bf4d-2a741ccb4f26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2016-12-23</startDate>
            <endDate>2016-12-23</endDate>
        </period>
    </context>
    <context id="C_2af1430d-300c-4a83-ab6c-f2efb9b2b469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2c7472b4-63fb-4213-8963-db0f9caec040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2d460a19-5b01-4993-8a57-12e7d78c57f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-29</instant>
        </period>
    </context>
    <context id="C_2e7abbe2-22f9-4dec-88c2-e983a64471e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgvn:SecretomeTherapeuticsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lgvn:NondisclosureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-24</startDate>
            <endDate>2023-10-24</endDate>
        </period>
    </context>
    <context id="C_2e7d7aea-3be2-4828-ad68-c7631d50cb13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-10</instant>
        </period>
    </context>
    <context id="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2e89703c-f1d8-47e0-91e2-c47b8050d0e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">lgvn:AccountsReceivableFromCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2e8cf413-7785-4109-aeb3-90e76b3f91b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_309403c4-9ddf-4b25-a74d-ada45e629444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2014-11-20</startDate>
            <endDate>2014-11-20</endDate>
        </period>
    </context>
    <context id="C_30abdd0a-27e1-4d75-a863-e2cce39841ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgvn:StockOptionAwardFourYearVestingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_313e3c1d-a177-40fe-a408-6990d730e5ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_31c839fd-7132-4e3c-bef4-2e938e7520cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_31d229d0-f489-478a-b8c4-7a980e71248a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="C_31e78a64-3bdd-47be-ac65-3b87c7c4e859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:UnderwritersWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_329d5c2e-7887-4b19-bf7f-646f3efde941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsAndSeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="C_32a5c33d-d25b-44e7-987a-deec4533967d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_33ea8560-6aa0-4787-a29e-7ac5e23721b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3643e2ad-d20e-482f-b92d-71aace47a7e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_375c44e5-dc70-4557-aa86-d4d7438ddb81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesAAndSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_377db0af-954f-408b-bd6c-7c6b6d74118a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_39a27885-81f0-4ba6-9f1c-ee208299badf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3cb893e8-ebe9-452e-b2d1-71116392d51a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-18</instant>
        </period>
    </context>
    <context id="C_3cf0423a-d017-4bc5-a03a-6a1be7ecd8b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-15</instant>
        </period>
    </context>
    <context id="C_3d0dcccf-31cc-483e-b3d8-b27e06e3534a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3f3103ec-1fd2-48ed-9be1-19cba6a04ef5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-10</instant>
        </period>
    </context>
    <context id="C_40dda296-3d9d-40bb-bc61-02fd395bf0f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4106fb7d-8b1c-41f8-b586-7658602c66b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4207ea7a-dee3-4ce6-b471-3464cadf1696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:GrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_427d1b69-1c7f-4694-805f-39f18674b82e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_43a9f4de-dc23-43f2-a1af-93cc67efc849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-17</instant>
        </period>
    </context>
    <context id="C_43ed4fe3-0d84-459e-a147-85ba5807b813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lgvn:ChiefScienceOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_44c40476-bff5-429e-a017-f12f5df662e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_44e4401f-ab33-46f4-a549-74a0489db4c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_496249ae-e79a-4060-8ff9-4a44d6dcc042">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4ba85633-032f-48ff-b8fd-3307bf64c707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4bdbcc3c-77a0-4725-9531-5d9efae03259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4c3eb97b-7e9e-414b-9078-9b9612c6aa90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4cacba37-0be4-4152-b40f-08dfc2bfbbaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4d1774b7-d786-4c83-9da6-6f4a21fa76cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="C_4dc5b1b6-411b-4ddf-9cb1-ffe97d305ce8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4dd328b2-e009-40a7-afa9-eeb63f4c4773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_528b6a30-52ca-427d-8cd4-51e869799289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5353b9ba-0648-487a-aefb-c0c16431821a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:October2023RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_54696521-4d07-49be-ac31-5b7b09eede1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:ContractManufacturingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_54e1f014-5bac-4239-87f8-50bf65a2d3d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-20</instant>
        </period>
    </context>
    <context id="C_554ff09e-61fb-4eb8-892c-14e2e6d7f3cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_573f4892-a8c0-49cb-b8bb-f89fab69086c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_57c941b5-3999-414f-ab10-1d89c4034885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_57e34a04-c6a3-42fb-8d4f-86889f99fd47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_58d502e3-e75a-4d67-9f49-bf40b468f239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:AprilTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_58e4471a-d2f1-4ec9-b6a9-d4b9eae6b4e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="C_5969aff3-9175-480f-9b07-995e126acd22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgvn:SecretomeTherapeuticsIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lgvn:SupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-21</instant>
        </period>
    </context>
    <context id="C_597c2a74-45ac-4076-9561-0e22ff41b523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2022-11-16</instant>
        </period>
    </context>
    <context id="C_5ad083cc-071f-4968-8655-4ec150277da0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JuneInducementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5b020284-3c22-456d-94b9-311e885fa6b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5b5ba2d7-308e-4e38-ba50-2a15b6d0f5ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="C_5be6c0a6-1868-4af2-89ef-106e0e069070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyOfferingPlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5bfdd076-ba62-43f9-b999-3245bcb69f9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5c5570fa-1707-4ec0-bdd8-26e9735b80d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-15</instant>
        </period>
    </context>
    <context id="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5cc56a11-ee4f-45a8-8b30-e4604e7cc25f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueConsensusPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-16</startDate>
            <endDate>2023-08-16</endDate>
        </period>
    </context>
    <context id="C_5cfe12ec-4f6d-46c2-b279-5fb305736864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-10</startDate>
            <endDate>2024-07-10</endDate>
        </period>
    </context>
    <context id="C_5d419854-2648-4779-8e89-00e96e30a8d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5e7f8a23-cf6b-4aa9-b4bd-dc4e77beffe6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="C_5fc20789-feae-4261-9107-524520b01c0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:JulyRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5fe7e291-90ef-457d-8a32-938bb17e4966">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_60e8ad0c-7547-4527-8724-24923bdc82a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_610cf94d-af47-4533-bd1a-06eb6eed02ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lgvn:LongeveronMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_611dbbc0-e2ce-41b4-85bf-90180810a5c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">lgvn:AccountsReceivableFromCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_61e522cf-6101-40bb-b529-2e57609235e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6366083b-23db-422d-a18f-92b5b0481e03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_63c4202f-ab95-43b7-9ac7-8fc5f186cdb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_651c763b-11ca-4b66-a7a6-bbdd17189552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_655c9a5e-6bc6-4cd8-9dec-b75e3ef72592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyOfferingPlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_65a27186-d86b-45fd-9ea9-84445417ac27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_66ab6a93-936f-44ff-be1a-6cfc54371b2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrants1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_681d8182-c08b-4f2c-b850-c94acff077c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:AprilTwoThousandTwentyFourPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_682a89cb-47a9-46e1-bdd9-3cd1abe13dd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_68de77cc-d120-4576-8f01-a84116620f4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-26</startDate>
            <endDate>2024-03-26</endDate>
        </period>
    </context>
    <context id="C_68efe625-4084-44ea-8dd6-7181da4c1023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:InvestorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_69d91da2-7bca-4bff-9cb8-c9cfd3c244e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6f844770-8d63-4c0a-b0d4-165e7185f787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_701daa93-ad26-4a44-8b06-338415e1f2ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:AccruedIncomeReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_70201005-5bfe-4448-ba31-f3aebe56ae09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_711f128e-33db-462a-b513-6bbea4533ff0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2024-07-10</startDate>
            <endDate>2024-07-10</endDate>
        </period>
    </context>
    <context id="C_713a5589-63ed-440c-848f-a0dc06ed8d24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_724dcd9a-d231-46d1-a3ea-7d375a83a614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="C_72fb5ee4-e997-41b0-a33d-75e6db840ad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_747cbc79-ca1c-46c7-be44-ba004328f6dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgvn:OwnershipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7483a01b-1311-4461-aef8-66d710fd0bf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_75235aac-f968-4f7c-9c6b-79a7b4522881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgvn:NationalInstitutesOfHealthGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7534eddc-bba5-4cf0-ba3e-08178e69ed62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgvn:December2023OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-29</instant>
        </period>
    </context>
    <context id="C_762471a3-e00f-4635-974d-de11609e581f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7697e068-658d-48a3-9b3b-a722fcb2fa76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2024-07-19</startDate>
            <endDate>2024-07-19</endDate>
        </period>
    </context>
    <context id="C_7707aae5-ac5b-4ae5-9938-ac6e3ea965d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="C_77836947-2834-438d-856e-a46d1692ea17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:JulyOrdinaryCoursePlacementAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="C_77ca1123-0343-4fd4-a5b4-64151b7b9e0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7b2a701b-185b-46d8-a802-15cd82f62888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lgvn:SeriesDWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7bec887e-3248-45a0-9092-39870e2cd880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7dc4f84c-8059-4df0-9eab-ce1957519154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7ebcdbcd-409e-4f2d-81dd-ac2a0d38a037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001721484</identifier>
        </entity>
        <period>
            <startDate>2016-12-16</startDate>
            <endDate>2016-12-22</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>lgvn:Segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_001b3cb7-6a6b-4caa-a178-5fa7e199c284">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_b052d2d8-c02c-4026-ad5f-9ad664505600">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_8308b784-deb7-43c5-aa8f-a3d7c8be59c7">0001721484</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      id="F_67f6638a-5395-4219-9e87-130051a737fc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      id="F_b32d22a7-f5c5-47a3-8a4b-a4ef13404364"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      id="F_e2b63699-fc70-43ef-83b0-3ec8d8d5c95b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      id="F_9969c8c5-df41-4078-a8e1-6b3423b5476c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_68de77cc-d120-4576-8f01-a84116620f4c"
      decimals="2"
      id="F_4a0b75b5-4668-44fe-9ab3-6ac34d6f5dc3"
      unitRef="U_pure">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0fa78e15-5237-44e1-ac71-f1d25f041ced"
      decimals="2"
      id="F_2e46777d-d9ea-4884-a9bb-dd1d15ee5f6a"
      unitRef="U_pure">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_382d7ea9-fe54-4942-9ed3-f6ed091b8df0">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_07d8a382-8bbb-46f9-8af5-da2391d2ed5e"
      id="F_27ce6dd3-639b-41e2-9150-1333292d9101"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_54696521-4d07-49be-ac31-5b7b09eede1d"
      id="F_ab57fa60-fbf9-444e-8dc1-8543b8bc25bd"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4cacba37-0be4-4152-b40f-08dfc2bfbbaf"
      id="F_491c5dcc-2520-4145-b055-747c1b012785"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_5bfdd076-ba62-43f9-b999-3245bcb69f9e"
      id="F_5860e748-b626-4760-9959-04c8458de42e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_5d419854-2648-4779-8e89-00e96e30a8d8"
      id="F_b5db85cc-838d-40fc-a08f-983e2963015b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_eeb0c913-518a-4d04-9452-efbaf66ce005"
      id="F_edf3cd8e-fee7-4f2b-bae4-3cb7da56e51c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_d3638195-ab5a-4291-9ae5-867e2b6cf88c"
      id="F_26429428-9ef1-47d7-90cc-f345882c97e5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_c6ce0b7e-d437-4704-9765-d88f29ce0adb"
      id="F_261c32f6-80e4-43ac-b52b-25b87d6e73cb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_29c20658-0d07-4fb3-b57a-a2b98683e7ca"
      id="F_8adfe637-2df8-4137-b76b-d02b023f34c0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_4106fb7d-8b1c-41f8-b586-7658602c66b4"
      id="F_7a05c076-4b13-4782-980f-f1db531e3014"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_1400ed16-357f-49fb-8ddc-3ef9e892f328"
      id="F_1ae67987-286c-4292-ad79-4c71735dd6d9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_a54ada20-1a44-4de3-803f-884629580212"
      id="F_b98a551e-dc71-4388-aafc-fbc75338dd46"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_c0238eb0-efac-4481-a961-ca7376905c7b"
      id="F_382c332e-e576-4e25-b8f8-144ea2ba7f4f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_e434dc91-ef31-47bc-8cef-615fb2777b8b"
      id="F_40e58eda-d3eb-4484-86f2-e1fe5a77793e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_cbb6d537-8377-408a-a06e-a422b97464ac"
      id="F_588625ea-79fb-4a9a-8abb-1ccf786357c5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="C_762471a3-e00f-4635-974d-de11609e581f"
      id="F_1809098a-d0f5-4df3-8175-e912d38dfd37"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_cdfee0ba-2fda-4acb-bf1e-85d83d8ae89f"
      id="F_93e3078f-8d95-4815-8772-dedb12df7e8d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_3d0dcccf-31cc-483e-b3d8-b27e06e3534a"
      id="F_76c75a36-7343-4618-abb0-0a79d6e55a20"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_b35ec15a-1d7a-48da-bb29-ded77d1dd6e0"
      id="F_cfc4d707-5861-482b-84d7-64104ba53727"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_c92a5e48-5a59-41b6-85ff-8ee27a7ded47"
      id="F_b8f1c0ca-aab8-4e72-a961-0a1daf3f73fb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"
      id="F_80fc046b-9fe3-4c96-90ec-96afcbbbd494">P4Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_800ca5b3-19a9-469b-ad8c-765f4cf802f8"
      id="F_428f7fa2-6f69-4ce1-97cd-53b8e1f3b7a5">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_8fb325dd-2a4c-427e-b457-7d9e26d11251"
      id="F_d317f701-e4a6-46de-af03-196205d6c7fb">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_8828b9f4-08cf-4cd9-86ab-83a206aaab8c"
      id="F_a211f642-62a5-42ee-bc71-d3f13e686a7e">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"
      id="F_d44a448c-95da-42af-9268-94b3f97749eb"
      unitRef="U_shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"
      id="F_e72c3d8a-06d5-4f57-820b-ef886d45e808"
      unitRef="U_UnitedStatesOfAmericaDollarsShare"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      id="F_59df80b9-4b23-4957-add5-f538f80c9bb3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      id="F_4dd0ce9c-9e6c-48e8-8f65-86135e742a26"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      id="F_08bd69a2-41d1-491f-a362-6162aa80c7fc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      id="F_dc96f2f3-806d-4814-8f8e-b6e47d188ef7"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      id="F_5f5fbe24-614b-499f-aced-c5af13aee5ae"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      id="F_fd5c8872-fbff-42c3-a6e0-bd84c28f075d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_903b8dcc-7d05-4cc8-8ed2-00092d584312"
      unitRef="U_pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      id="F_9b1b95a1-5cfc-4117-a2c2-f442d0b99222"
      unitRef="U_pure"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_eb2962d5-c458-43df-b1ef-4f45299e5db3">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="INF"
      id="F_13fc1c78-4d1d-440f-aa75-9a7f20b97683"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_577d3f24-3615-4da2-a77f-a18b9428fc43">http://fasb.org/us-gaap/2024#OperatingExpenses</us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_6726c95e-3d29-4ee2-a6cd-abbe6c2db935">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_31355f70-39eb-4f93-8627-9708c10f5f49">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_fa698a0b-1a62-4315-9811-2eb7a9974344">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_5c0526a9-aa45-406e-85a3-b231fa4fbf0b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_63658d3e-df75-487f-aa51-9e164a90882e">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_e8cd5bd3-74ee-404e-b5d1-8d798a917f35">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_07911fd8-c977-4381-9ce0-6a70a2b13e02">001-40060</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_320e716a-0c71-4309-a2db-7d84942b4e9a">LONGEVERON INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_cf51ad73-fefe-48a5-9495-7c6b330695e7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_cdd3de36-857f-4380-b93d-7181974c50e5">47-2174146</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_2cbc8cf6-ef3f-4bbf-9913-653fea465fcd">1951 NW 7th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_ac92825c-fc92-41f9-83d5-c56847410c8a">Suite 520</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_5c86d870-2242-479e-a817-4c141a53ec2b">Miami</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_eedbd206-3972-486c-85ff-7853cfde6c82">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_8ae6076c-f924-4018-b64b-51f977885c5a">33136</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_6d1b1d2c-dc55-4486-8502-cb6d4daae2c4">(305)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_2a562a78-10dc-4a65-989c-ac6f35ef9909">909-0840</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_5e676ed1-810f-4d99-9a05-3f44f5b08b02">Class A common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_c8b82cc2-62c7-4aa8-8959-5046dc3ff12c">LGVN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_3606efd9-6935-4162-8611-2132e38b569f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_f0aee12c-1117-4bd4-92af-1a5e849d3ccf">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_c68e67a2-0efe-48f0-99ea-59c3fc68ef9c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_dd97f40b-9457-4929-9155-147744696255">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_508c812e-3634-4c19-86a5-0bbe658fb963">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_85cc83cc-9402-4701-850d-586e20279f63">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_86445a9d-c671-4de9-8adf-21046fc54f56">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_c41d5b93-dd14-44ca-ace1-7deaf502b33c">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_88ff95bd-3ada-4eac-810d-2a9c8c9acc0b">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_3db81d20-3260-4045-b844-c6f96dcf8f67">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_728179c3-49f0-458b-8d30-cf7b9b7cbeba">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_95d25ec1-babc-4d28-9599-9913463f349b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_bdad186e-621a-48f4-845c-d93f9eac4f04"
      decimals="0"
      id="F_1f5678a1-d296-4195-b39c-85ce3665064a"
      unitRef="U_USD">12438864</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_43a9f4de-dc23-43f2-a1af-93cc67efc849"
      decimals="INF"
      id="F_a1dec795-959a-4112-a14a-e915fa3e1d53"
      unitRef="U_shares">13473898</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_8517f575-39c7-4d46-8576-6a86abfaa79e"
      decimals="INF"
      id="F_967515b9-bc41-4c34-997c-c61602e82ac0"
      unitRef="U_shares">1454005</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_78cc14b1-e2b0-4279-895e-7410b7f23a7d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;None&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_4bdd1749-d690-4c4b-bd88-f5f9a989f985">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) recognizes the critical importance of maintaining the trust and confidence of our customers, clients, business partners and employees. The Board is actively involved in oversight of the Company&#x2019;s risk management program, and cybersecurity represents an important component of the Company&#x2019;s overall approach to enterprise risk management (&#x201c;ERM&#x201d;). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s cybersecurity policies, standards, processes, and practices are fully &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into the Company&#x2019;s ERM program and are based on recognized frameworks established by the National Institute of Standards and Technology, the International Organization for Standardization and other applicable industry standards.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In general, the Company seeks to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that the Company collects and stores by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As one of the critical elements of the Company&#x2019;s overall ERM approach, the Company&#x2019;s cybersecurity program is focused on the following key areas:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As discussed in more detail under the heading &#x201c;Governance,&#x201d; The Board&#x2019;s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the &#x201c;Audit Committee&#x201d;), which regularly interacts with the Company&#x2019;s General Counsel ("GC"), Chief Technology Officer ("CTO"), other members of management and relevant management committees, including Company&#x2019;s Senior Leadership Team (&#x201c;SLT&#x201d;), regarding cybersecurity oversight and risk management.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaborative Approach: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, through its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;information technology partner&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, has implemented a comprehensive, cross-functional approach to identifying, preventing, and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Technical Safeguards: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, through its information technology partner, deploys technical safeguards that are designed to protect the Company&#x2019;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti- malware functionality and access controls, which are evaluated and improved through vulnerability assessments, penetration testing, and cybersecurity threat intelligence.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Incident Response and Recovery Planning: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, with its information technology partner, maintains comprehensive incident response and recovery plans that fully address the Company&#x2019;s response to a cybersecurity incident.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Education and Awareness: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, through its information technology partner, provides regular, mandatory training for personnel regarding cybersecurity threats to equip the Company&#x2019;s personnel with effective tools to address cybersecurity threats, and to communicate the Company&#x2019;s evolving information security policies, standards, processes, and practices.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company engages in the periodic assessment and testing of the Company&#x2019;s policies, standards, processes, systems, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability and penetration testing and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. The Company with our information technology partner regularly engages assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the CTO and GC who shares data with the SLT and Audit Committee, and the Company adjusts its cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CTO, in coordination with the SLT, oversees the Company&#x2019;s ERM process, including the management of risks arising from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The CTO and the SLT, through its information technology partner receives regular reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, the threat environment, technological trends and information security considerations.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On an annual basis, the Audit Committee and the Board discuss the Company&#x2019;s approach to cybersecurity risk management with the members of the SLT, which includes the Company&#x2019;s CTO, GC, and Chief Financial Officer (&#x201c;CFO&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CTO, in coordination with the SLT, works collaboratively across the Company to implement a program designed to protect the Company&#x2019;s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company&#x2019;s incident response and recovery plans. To facilitate the success of the Company&#x2019;s cybersecurity risk management program, multidisciplinary teams are prepared to address cybersecurity threats and to respond to cybersecurity incidents. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Through ongoing communications with the Company&#x2019;s information technology partner, these teams monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to the Company&#x2019;s SLT and Audit Committee, when appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s information technology partner has worked in information technology and information security for over 30 years with over 300 employees with six locations in the United States. A virtual Chief Information Officer (&#x201c;vCIO&#x201d;) from the partner works directly with the Company to align business and technical strategies, decisions, and implementations. The CTO has nearly 20 years of experience in the pharmaceutical and biotech industry managing programs and projects across a variety of implementation methodologies and risk factors and holds undergraduate degrees and certifications in his respective field. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Chief Executive Officer, CFO and General Counsel each hold undergraduate and graduate degrees in their respective fields, and each have over 25 years of experience managing risks at similar companies, including risks arising from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity threats, including the results of any previous cybersecurity incidents, have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not materially&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; affected or are reasonably likely to affect the Company, including its business strategy, results of operations or financial condition.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_f07aadfb-a845-49af-8aad-b26f8ded3db4">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s cybersecurity policies, standards, processes, and practices are fully &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into the Company&#x2019;s ERM program and are based on recognized frameworks established by the National Institute of Standards and Technology, the International Organization for Standardization and other applicable industry standards.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_796695d1-913a-498e-a0eb-cafc369d7e3c">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_205fc986-1dae-47cd-9331-b3c39cc3b99e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As one of the critical elements of the Company&#x2019;s overall ERM approach, the Company&#x2019;s cybersecurity program is focused on the following key areas:&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As discussed in more detail under the heading &#x201c;Governance,&#x201d; The Board&#x2019;s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the &#x201c;Audit Committee&#x201d;), which regularly interacts with the Company&#x2019;s General Counsel ("GC"), Chief Technology Officer ("CTO"), other members of management and relevant management committees, including Company&#x2019;s Senior Leadership Team (&#x201c;SLT&#x201d;), regarding cybersecurity oversight and risk management.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collaborative Approach: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, through its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;information technology partner&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, has implemented a comprehensive, cross-functional approach to identifying, preventing, and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Technical Safeguards: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, through its information technology partner, deploys technical safeguards that are designed to protect the Company&#x2019;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti- malware functionality and access controls, which are evaluated and improved through vulnerability assessments, penetration testing, and cybersecurity threat intelligence.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Incident Response and Recovery Planning: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, with its information technology partner, maintains comprehensive incident response and recovery plans that fully address the Company&#x2019;s response to a cybersecurity incident.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Education and Awareness: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, through its information technology partner, provides regular, mandatory training for personnel regarding cybersecurity threats to equip the Company&#x2019;s personnel with effective tools to address cybersecurity threats, and to communicate the Company&#x2019;s evolving information security policies, standards, processes, and practices.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company engages in the periodic assessment and testing of the Company&#x2019;s policies, standards, processes, systems, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability and penetration testing and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. The Company with our information technology partner regularly engages assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the CTO and GC who shares data with the SLT and Audit Committee, and the Company adjusts its cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CTO, in coordination with the SLT, oversees the Company&#x2019;s ERM process, including the management of risks arising from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The CTO and the SLT, through its information technology partner receives regular reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, the threat environment, technological trends and information security considerations.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On an annual basis, the Audit Committee and the Board discuss the Company&#x2019;s approach to cybersecurity risk management with the members of the SLT, which includes the Company&#x2019;s CTO, GC, and Chief Financial Officer (&#x201c;CFO&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CTO, in coordination with the SLT, works collaboratively across the Company to implement a program designed to protect the Company&#x2019;s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company&#x2019;s incident response and recovery plans. To facilitate the success of the Company&#x2019;s cybersecurity risk management program, multidisciplinary teams are prepared to address cybersecurity threats and to respond to cybersecurity incidents. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Through ongoing communications with the Company&#x2019;s information technology partner, these teams monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to the Company&#x2019;s SLT and Audit Committee, when appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s information technology partner has worked in information technology and information security for over 30 years with over 300 employees with six locations in the United States. A virtual Chief Information Officer (&#x201c;vCIO&#x201d;) from the partner works directly with the Company to align business and technical strategies, decisions, and implementations. The CTO has nearly 20 years of experience in the pharmaceutical and biotech industry managing programs and projects across a variety of implementation methodologies and risk factors and holds undergraduate degrees and certifications in his respective field. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Chief Executive Officer, CFO and General Counsel each hold undergraduate and graduate degrees in their respective fields, and each have over 25 years of experience managing risks at similar companies, including risks arising from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity threats, including the results of any previous cybersecurity incidents, have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;not materially&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; affected or are reasonably likely to affect the Company, including its business strategy, results of operations or financial condition.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_8f294675-2f03-49d1-92bc-181b14bf6e28">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As discussed in more detail under the heading &#x201c;Governance,&#x201d; The Board&#x2019;s oversight of cybersecurity risk management is supported by the Audit Committee of the Board (the &#x201c;Audit Committee&#x201d;), which regularly interacts with the Company&#x2019;s General Counsel ("GC"), Chief Technology Officer ("CTO"), other members of management and relevant management committees, including Company&#x2019;s Senior Leadership Team (&#x201c;SLT&#x201d;), regarding cybersecurity oversight and risk management.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_6a0588e6-2dcd-48be-84bc-d63f67ef2782">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_bd82d109-c713-45ba-b710-6cc325e4332c">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_8dbf9909-162c-4cd2-85ed-32ce1ac9bc38">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company engages in the periodic assessment and testing of the Company&#x2019;s policies, standards, processes, systems, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability and penetration testing and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. The Company with our information technology partner regularly engages assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits and reviews are reported to the CTO and GC who shares data with the SLT and Audit Committee, and the Company adjusts its cybersecurity policies, standards, processes and practices as necessary based on the information provided by these assessments, audits and reviews.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_8bf9b296-64a8-4b58-b569-0a52b80af3d6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CTO, in coordination with the SLT, oversees the Company&#x2019;s ERM process, including the management of risks arising from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The CTO and the SLT, through its information technology partner receives regular reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, the threat environment, technological trends and information security considerations.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On an annual basis, the Audit Committee and the Board discuss the Company&#x2019;s approach to cybersecurity risk management with the members of the SLT, which includes the Company&#x2019;s CTO, GC, and Chief Financial Officer (&#x201c;CFO&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CTO, in coordination with the SLT, works collaboratively across the Company to implement a program designed to protect the Company&#x2019;s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company&#x2019;s incident response and recovery plans. To facilitate the success of the Company&#x2019;s cybersecurity risk management program, multidisciplinary teams are prepared to address cybersecurity threats and to respond to cybersecurity incidents. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Through ongoing communications with the Company&#x2019;s information technology partner, these teams monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents in real time and report such threats and incidents to the Company&#x2019;s SLT and Audit Committee, when appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s information technology partner has worked in information technology and information security for over 30 years with over 300 employees with six locations in the United States. A virtual Chief Information Officer (&#x201c;vCIO&#x201d;) from the partner works directly with the Company to align business and technical strategies, decisions, and implementations. The CTO has nearly 20 years of experience in the pharmaceutical and biotech industry managing programs and projects across a variety of implementation methodologies and risk factors and holds undergraduate degrees and certifications in his respective field. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Chief Executive Officer, CFO and General Counsel each hold undergraduate and graduate degrees in their respective fields, and each have over 25 years of experience managing risks at similar companies, including risks arising from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_ae4a9a2e-9be3-4d6f-8071-f1d8583c3680">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CTO, in coordination with the SLT, oversees the Company&#x2019;s ERM process, including the management of risks arising from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The CTO and the SLT, through its information technology partner receives regular reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, the threat environment, technological trends and information security considerations.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_e5cfd4b5-d765-4f90-a4ef-33412775af90">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_1e8a5ddb-e375-4fc1-8ad1-2902ac9f0702">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On an annual basis, the Audit Committee and the Board discuss the Company&#x2019;s approach to cybersecurity risk management with the members of the SLT, which includes the Company&#x2019;s CTO, GC, and Chief Financial Officer (&#x201c;CFO&#x201d;).&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_57a946ff-e8e5-4567-a940-973c619eec69">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_83f420be-fa44-401c-821b-ac5dadf397df">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Chief Executive Officer, CFO and General Counsel each hold undergraduate and graduate degrees in their respective fields, and each have over 25 years of experience managing risks at similar companies, including risks arising from cybersecurity threats.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_3866ff6f-cb48-4e1f-8c24-c1788c03700f">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3"
      id="F_1707753c-d0d0-4d12-9876-5fca4835b86a">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3"
      id="F_94ff215e-780e-40ff-a266-d4dafb868a31">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3"
      id="F_62f2e9b1-4d99-4237-bb66-56f2985693c6">false</ecd:NonRule10b51ArrAdoptedFlag>
    <lgvn:Rule10b51ArrModifiedFlag
      contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3"
      id="F_71db1c6f-e3a2-43ee-8989-301fee8856a2">false</lgvn:Rule10b51ArrModifiedFlag>
    <lgvn:NonRule10b51ArrModifiedFlag
      contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3"
      id="F_6eeaad0f-fa55-46bc-b8ef-68f98431f708">false</lgvn:NonRule10b51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3"
      id="F_66854962-0436-4ffe-b23b-fcf98f828595">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_6a7c9b3b-ea84-4b51-9155-ff5f2555f2f3"
      id="F_7c79ab1d-af1c-457d-b84b-324644630442">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_726d5505-b0c2-45a8-89d5-c1ec3d7d45a9">688</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_34262a91-124c-41ca-9deb-92ff971fdf71">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying balance sheets of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Longeveron Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Company&#x201d;) as of December 31, 2024 and 2023, the related statements of operations, stockholders&#x2019; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, based on our audits, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years in the period ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_163d50a3-17a4-45cc-b1a6-35c286e8fa1f">Marcum llp</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_9a82ba98-be63-458c-bf05-9f9aeb159867">Hartford, CT</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_a6607846-f235-487a-b511-5e1f2a4ed7d0"
      unitRef="U_USD">19232000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_e25fd67d-4f2f-43dc-b27b-8fd71173142e"
      unitRef="U_USD">4949000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_88312f1e-32d0-465e-aafa-0adcebc2e4a0"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_d3fbbc65-cf90-4865-af80-808be0b2f86b"
      unitRef="U_USD">412000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_d7863e46-bc66-495a-b22f-93b3a4602ba5"
      unitRef="U_USD">308000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_f830f5ff-00c5-4570-834b-bfaef84b05e0"
      unitRef="U_USD">376000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_658c1df8-52b4-42ad-9121-a32daa3a08c9"
      unitRef="U_USD">84000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_9d1ad11d-f033-419f-a063-dc0c49c6bf35"
      unitRef="U_USD">111000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_97d08508-babe-4d0f-a092-b9e2246d1d82"
      unitRef="U_USD">19624000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_ecc95d94-97b3-49e6-806a-84ad238df6e7"
      unitRef="U_USD">5848000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_89b856ca-21fc-4532-9762-9c41e25c6d3c"
      unitRef="U_USD">2449000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_ab6fbcd2-0d5f-4e73-95b4-323a4b1102bb"
      unitRef="U_USD">2529000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_77b6b173-b8e0-4d89-82a0-01bf7438f95c"
      unitRef="U_USD">2401000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_5098eb6b-ce93-4f9b-ba5c-3082f3b4b186"
      unitRef="U_USD">2287000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_891acd17-cfe0-4542-84b7-2901b6b5ad83"
      unitRef="U_USD">882000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_1fc71622-8b00-4c61-ba60-fca9f723824c"
      unitRef="U_USD">1221000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_546bc32e-d7b5-48df-8bfd-f82274b1498d"
      unitRef="U_USD">202000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_246d2ac3-2bb1-4c07-ac5c-4c98edd48a15"
      unitRef="U_USD">193000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_240f3147-33d3-428f-96f1-2607b3dd3aa8"
      unitRef="U_USD">25558000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_cd44e6ef-4bc7-4b9d-9f84-3bca36cb7279"
      unitRef="U_USD">12078000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_9cc720e6-6d3f-4484-8985-3784924aa328"
      unitRef="U_USD">99000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_7acb88f4-3196-40f2-8ac7-a47a1faf3cf1"
      unitRef="U_USD">638000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_35e42e7f-40d8-4aa6-9243-fe1e39139bd4"
      unitRef="U_USD">1820000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_ae904991-7238-4ae4-b2b8-1317c99cf727"
      unitRef="U_USD">2152000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_283c66d3-a0f0-4724-adb5-1f8ee375f9fd"
      unitRef="U_USD">623000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_5fecbb5b-29b8-450b-b730-91f0fed1aec8"
      unitRef="U_USD">593000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_d8940340-345b-405e-8b20-db7c8375cbc5"
      unitRef="U_USD">40000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_4a1ed031-d79b-427f-8f1c-7d4bd0d8db7f"
      unitRef="U_USD">506000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_da9972d5-54d1-43ae-99ed-536a69ea8526"
      unitRef="U_USD">2582000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_5069f836-6baf-48b9-939b-1a28898d2c99"
      unitRef="U_USD">3889000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_c1089af2-cc6f-4da2-8cae-d6a7892522c6"
      unitRef="U_USD">824000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_02e4657a-5b2b-43a1-b8c4-3635077f0cd6"
      unitRef="U_USD">1448000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_281a130a-e6ef-4114-bd5a-a0954f3eff78"
      unitRef="U_USD">265000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_390d071f-96ea-437f-b1a2-6629d7b51ce9"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_df9f8636-8179-4abd-ad31-1f6eb1ad4787"
      unitRef="U_USD">1089000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_1a8aaa90-885b-48f0-9010-499d41594f0b"
      unitRef="U_USD">1448000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_4d70dd09-d2dd-4d89-82ee-6a18741d817b"
      unitRef="U_USD">3671000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_7aeea995-b90c-4e03-96bf-716ebdf2ab9b"
      unitRef="U_USD">5337000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="INF"
      id="F_69a78db0-2e87-40fb-b27f-a7a1e4f217c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="INF"
      id="F_875d8b66-936c-4e99-b6f4-8f8a46edfef8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="INF"
      id="F_2017412e-2cae-4128-b568-8874d4df3d7c"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="INF"
      id="F_efebd779-23ad-41c7-aa79-7336ece16a4b"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="INF"
      id="F_1580effe-f615-40c2-a445-5b2cf80e30bc"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="INF"
      id="F_007b951d-7848-4163-987d-939904db7986"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="INF"
      id="F_878bdf52-4c40-4b34-a1c0-66f28d7fe3b8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="INF"
      id="F_e6cfed86-93eb-4702-9061-7c567f9f230d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"
      decimals="INF"
      id="F_4474f21d-c981-4ebf-a3a8-806eee0544ba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c"
      decimals="INF"
      id="F_f51f35a3-60e2-4d55-92da-85a8cb04431e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"
      decimals="INF"
      id="F_0e5fced3-214f-4a13-8cf3-904d5170235f"
      unitRef="U_shares">84295000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c"
      decimals="INF"
      id="F_1495ce8a-8292-4715-a440-4c7db7fef72b"
      unitRef="U_shares">84295000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"
      decimals="INF"
      id="F_3d1c37b0-69b6-4440-a57b-1f9932a82808"
      unitRef="U_shares">13407441</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"
      decimals="INF"
      id="F_30029745-3860-41a3-a996-835fdb1d52f4"
      unitRef="U_shares">13407441</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c"
      decimals="INF"
      id="F_e60aaf13-5295-4b47-a6bb-e1a232441b64"
      unitRef="U_shares">1025183</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c"
      decimals="INF"
      id="F_f1c04eda-5bcd-4b8e-a9ab-7cea033f8f45"
      unitRef="U_shares">1025183</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"
      decimals="-3"
      id="F_d1a5e853-6c53-4207-a1ef-6b355fd5d8f0"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_32fbc3ff-66d0-4712-af04-ca0004c25e5c"
      decimals="-3"
      id="F_e917f54b-758b-48b9-8995-8ad22cde51ac"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1"
      decimals="INF"
      id="F_cb0f5b0c-356c-46b5-b380-63f63b485772"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c2617445-260c-4016-83d7-e383b81dadab"
      decimals="INF"
      id="F_341d1c4f-56df-4c2f-9f8c-b9a50451d757"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1"
      decimals="INF"
      id="F_db0e0e0f-1134-4c43-aee9-106829222185"
      unitRef="U_shares">15705000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c2617445-260c-4016-83d7-e383b81dadab"
      decimals="INF"
      id="F_67625e4c-80f4-42b8-94b0-e1aefc3033f3"
      unitRef="U_shares">15705000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1"
      decimals="INF"
      id="F_22da5135-8a0c-4786-8c52-128a634c4121"
      unitRef="U_shares">1484005</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1"
      decimals="INF"
      id="F_1c562dc8-a0fe-4e83-902d-b188181509db"
      unitRef="U_shares">1484005</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c2617445-260c-4016-83d7-e383b81dadab"
      decimals="INF"
      id="F_db74eaff-c19d-4b88-a04c-0d1f78b2d1aa"
      unitRef="U_shares">1485560</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c2617445-260c-4016-83d7-e383b81dadab"
      decimals="INF"
      id="F_aa346b7b-6184-4503-8ed5-f1d3382a8fc1"
      unitRef="U_shares">1485560</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_9fc29763-7eeb-4993-adbc-a5cf3bc84db1"
      decimals="-3"
      id="F_848d2344-3dfc-4ccf-9e0c-36c8ea13d667"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_c2617445-260c-4016-83d7-e383b81dadab"
      decimals="-3"
      id="F_ed43934f-f0fd-4d29-940e-3ace48fad624"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_82767416-1dbb-4eba-b67a-e3b9e6292b15"
      unitRef="U_USD">131480000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_1a290993-4767-4bf0-81e1-ad217611ccc2"
      unitRef="U_USD">91823000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_1f634019-695b-41c5-be67-bafe517e35e7"
      unitRef="U_USD">0</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_1919c4e4-4838-4b7c-bbc5-320c447c9b4e"
      unitRef="U_USD">100000</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_d88b0264-d95e-4bff-812d-9d7fcce4c779"
      unitRef="U_USD">-109607000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_0a6463d8-3905-4d81-8b78-59ab7abc550c"
      unitRef="U_USD">-84984000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_14e78ea1-9763-419e-9c02-225b6bd3989f"
      unitRef="U_USD">21887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_a6100881-4b7b-41be-97f8-25ffa8d7409c"
      unitRef="U_USD">6741000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_45287ee1-ef61-40a0-a347-e57a50eff13d"
      unitRef="U_USD">25558000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_f480c157-89be-427e-8d14-c2673a3a4f1a"
      unitRef="U_USD">12078000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8e3349a5-e8ad-4d9f-932c-91af4f1b95ad"
      decimals="-3"
      id="F_309e1c26-5b8f-454e-8c2d-787b70bcd077"
      unitRef="U_USD">1402000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cec0b67c-0b8b-4bc4-9170-1fbad94ea8f8"
      decimals="-3"
      id="F_c68e6185-9f72-4033-9f8d-9f474879e5d9"
      unitRef="U_USD">668000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_88f70043-2bab-4fbd-a7ff-7ca163bafeae"
      decimals="-3"
      id="F_22e2a2cc-d058-48c8-bf74-0599866ecce7"
      unitRef="U_USD">503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9fa8323f-6ecb-4760-888b-b865f49ee572"
      decimals="-3"
      id="F_bfcd95e0-04d4-44ed-9686-06bb001e569c"
      unitRef="U_USD">487000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4207ea7a-dee3-4ce6-b471-3464cadf1696"
      decimals="-3"
      id="F_44e2dabe-400d-40c6-9be5-8a041618d6f2"
      unitRef="U_USD">41000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_92e1c7b0-13b5-414c-94a0-005e8d86e28f"
      unitRef="U_USD">2392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_9d4b45c2-f8b5-45f4-99b5-8863056de160"
      unitRef="U_USD">709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_2216930b-cf5a-47db-ac2f-b4519029b1fa"
      unitRef="U_USD">508000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_12fa6fa4-3591-4187-94b6-806dda491abd"
      unitRef="U_USD">488000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_f9460d78-a6ae-447b-86da-801f540fa7f7"
      unitRef="U_USD">1884000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_bbb8fbdf-ef5f-4487-bf04-bab2ef30fa3a"
      unitRef="U_USD">221000</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_38c781e5-2cd7-4a76-b316-cc7cd676fff4"
      unitRef="U_USD">10269000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_0861dc1d-0273-40e7-92cb-cf07fdc8174b"
      unitRef="U_USD">12184000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_53f06491-f813-4396-92c1-2b587340d8a7"
      unitRef="U_USD">8137000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_4a7974cf-8ff6-4659-b904-a456e75719af"
      unitRef="U_USD">9066000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_46266856-edd1-44bb-b002-38a2c7761b52"
      unitRef="U_USD">18406000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_c0d227cf-a917-442a-9192-76898d4c18a0"
      unitRef="U_USD">21250000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_f8def8fc-6e52-4e38-b45f-8577aff49150"
      unitRef="U_USD">-16522000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_f357a17b-b36f-4211-aeb2-5b9adcd107b5"
      unitRef="U_USD">-21029000</us-gaap:OperatingIncomeLoss>
    <lgvn:LawsuitExpenses
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_f52754c6-e1a6-4515-9e7a-a64dcd099bde"
      unitRef="U_USD">30000</lgvn:LawsuitExpenses>
    <lgvn:OtherRefundableTaxCredits
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_8feab7bd-4169-4b5f-8626-c982e6bbc540"
      unitRef="U_USD">23000</lgvn:OtherRefundableTaxCredits>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_b1b5e320-70f6-4083-8b2d-f2235066e2af"
      unitRef="U_USD">549000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_48128241-7c19-4309-a98c-499789872d06"
      unitRef="U_USD">-377000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_a888f587-baef-460c-8f94-b7e07b797fbe"
      unitRef="U_USD">549000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_0ca14343-e686-4c2d-9740-7ed00e452958"
      unitRef="U_USD">-384000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_737e3984-9258-4cde-8762-00ae6df800b6"
      unitRef="U_USD">-15973000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_03270bb4-5a16-469f-9e57-9aa147fd0021"
      unitRef="U_USD">-21413000</us-gaap:NetIncomeLoss>
    <lgvn:DeemedDividendWarrantInducementOffers
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_d225f212-cbc7-4ed6-88d7-0ecadac3496d"
      unitRef="U_USD">8650000</lgvn:DeemedDividendWarrantInducementOffers>
    <lgvn:DeemedDividendWarrantInducementOffers
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_153d87e0-c4a9-482b-af08-51b35acc6dd6"
      unitRef="U_USD">798000</lgvn:DeemedDividendWarrantInducementOffers>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_7e751694-bb0a-46be-acfc-5ce4468f2aec"
      unitRef="U_USD">-24623000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_91dab373-1a7d-4d6b-97ea-3e6112287434"
      unitRef="U_USD">-22211000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="2"
      id="F_36cd6462-3caa-4c69-ae78-428e7eca9203"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="2"
      id="F_23fe0f46-b53e-44e5-ae9e-2403f601110c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="2"
      id="F_060690f0-ccf5-4772-a1f3-ba759cf5ac9d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-10.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="2"
      id="F_196d475d-d887-49d6-8c98-0ff6f7e3172a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-10.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_0cae9456-3881-4a7b-a1cc-422c0312fce5"
      unitRef="U_shares">9411164000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_c57db8aa-47c9-4f56-b86a-120956fd284f"
      unitRef="U_shares">9411164000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_a6209eda-27ce-430a-a19f-eb3c2d4f5011"
      unitRef="U_shares">2173490000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_ca3f70bc-d8f7-4674-abdc-235e9c5b2acf"
      unitRef="U_shares">2173490000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_7483a01b-1311-4461-aef8-66d710fd0bf5"
      decimals="INF"
      id="F_58e9d9bc-0ca1-4816-9892-cbd4034b91e6"
      unitRef="U_shares">612732</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7483a01b-1311-4461-aef8-66d710fd0bf5"
      decimals="-3"
      id="F_66bbb643-07a8-4fd6-bb74-c8b314bff659"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_f492dbe2-0361-48ff-be3f-265ad6408614"
      decimals="INF"
      id="F_5d911f9a-dfb4-470a-95d9-e12a8a2853e7"
      unitRef="U_shares">1489109</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f492dbe2-0361-48ff-be3f-265ad6408614"
      decimals="-3"
      id="F_aecc3f46-0c67-4e43-af6e-e8b2a38459d3"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_496249ae-e79a-4060-8ff9-4a44d6dcc042"
      decimals="-3"
      id="F_4a56060e-801b-472b-9df8-f73bf92e44b1"
      unitRef="U_USD">-100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e5e6b360-d445-4c3e-bc79-675f33b37486"
      decimals="-3"
      id="F_b7ebc143-917a-4034-a2ab-198a1fcdd13f"
      unitRef="U_USD">83731000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c17b9bfa-207b-4863-b527-d6ad7945f5f4"
      decimals="-3"
      id="F_e7b3e280-213f-43eb-bf2f-9338f6329e64"
      unitRef="U_USD">-62773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e11b48f3-b181-48a1-9aba-5a7956f22930"
      decimals="-3"
      id="F_182221f7-44b1-471f-9557-70b3c46542a6"
      unitRef="U_USD">-357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_713a5589-63ed-440c-848f-a0dc06ed8d24"
      decimals="-3"
      id="F_f84f7ad1-b331-42d1-8b7d-5eb3bb3d73bc"
      unitRef="U_USD">20503000</us-gaap:StockholdersEquity>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154"
      decimals="INF"
      id="F_1b414aee-1975-46c0-b1de-19e9e77009b3"
      unitRef="U_shares">3555</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_40dda296-3d9d-40bb-bc61-02fd395bf0f7"
      decimals="INF"
      id="F_72f4c6a2-17c4-4a1e-b6d7-12f24bd2b423"
      unitRef="U_shares">-3555</us-gaap:ConversionOfStockSharesConverted1>
    <lgvn:StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares
      contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154"
      decimals="INF"
      id="F_78210ef0-0a39-4143-8725-2ad920e04c7c"
      unitRef="U_shares">25308</lgvn:StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares>
    <lgvn:StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested
      contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154"
      decimals="INF"
      id="F_6830e358-d4d2-4f23-850a-c6a494303fb1"
      unitRef="U_shares">-5223</lgvn:StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested>
    <lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested
      contextRef="C_12e07091-6e3f-4a59-802d-ada554263431"
      decimals="-3"
      id="F_41dc673e-da1d-42f4-a109-758376657a10"
      unitRef="U_USD">-174000</lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested>
    <lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_bc507792-2af6-4646-8639-9b9453c453f4"
      unitRef="U_USD">-174000</lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested>
    <lgvn:StockIssuedForStockRightsOfferingNetOfIssuanceCosts
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_8ab4ff6e-eada-4e35-91e9-047b245c2b24"
      unitRef="U_USD">325000</lgvn:StockIssuedForStockRightsOfferingNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154"
      decimals="INF"
      id="F_6f9b0571-90dc-40e0-b095-ad702ccb3468"
      unitRef="U_shares">10850</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_c287005f-1fa5-441f-bbbc-3c1b8f3498e9"
      unitRef="U_USD">1229000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154"
      decimals="INF"
      id="F_d10992ab-ab03-43e2-938e-5bab71a8e2ef"
      unitRef="U_shares">372030</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_12e07091-6e3f-4a59-802d-ada554263431"
      decimals="-3"
      id="F_76b1ba13-1819-40ba-b13b-22252afeab11"
      unitRef="U_USD">5338000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_abd7ad60-544f-445c-aa4f-d2d73e155b25"
      unitRef="U_USD">5338000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_12e07091-6e3f-4a59-802d-ada554263431"
      decimals="-3"
      id="F_2527aef7-606c-49d5-a67b-ce6adf68603b"
      unitRef="U_USD">2032000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_75cff404-81a1-4b5b-a827-9094a0206de8"
      unitRef="U_USD">2032000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_12e07091-6e3f-4a59-802d-ada554263431"
      decimals="-3"
      id="F_8051b982-54fc-4284-af91-0e562cc86fd4"
      unitRef="U_USD">798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_0f2e3a3d-a8c9-4849-8d99-8d26291368fd"
      decimals="-3"
      id="F_9f38a893-e41a-4724-b1f7-29261853071c"
      unitRef="U_USD">-798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lgvn:StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants
      contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154"
      decimals="INF"
      id="F_7aea2a3a-3bbd-4f5a-8916-178a2b3bfe06"
      unitRef="U_shares">5924</lgvn:StockIssuedDuringPeriodSharesClassACommonStockIssuedForPrefundedWarrants>
    <lgvn:StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants
      contextRef="C_12e07091-6e3f-4a59-802d-ada554263431"
      decimals="-3"
      id="F_cfda8a09-1af9-456b-93b6-2b18dffccb47"
      unitRef="U_USD">98000</lgvn:StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants>
    <lgvn:StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_3b28ba54-3f83-4d4c-a2fe-27ce0f9055b3"
      unitRef="U_USD">98000</lgvn:StockIssuedDuringPeriodValueClassACommonStockIssuedForPrefundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154"
      decimals="INF"
      id="F_92c21624-b9a1-45d8-a8d3-c2c043c70c8d"
      unitRef="U_shares">7</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_40dda296-3d9d-40bb-bc61-02fd395bf0f7"
      decimals="INF"
      id="F_1d4f680b-d143-4aee-a69e-a0df940b459c"
      unitRef="U_shares">6</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <lgvn:StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities
      contextRef="C_4c3eb97b-7e9e-414b-9078-9b9612c6aa90"
      decimals="-3"
      id="F_c97138bd-8d86-416f-81a6-7bea183c0071"
      unitRef="U_USD">357000</lgvn:StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities>
    <lgvn:StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_d528d387-7bd1-4f5b-963a-17ccc5827b07"
      unitRef="U_USD">357000</lgvn:StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="C_0f2e3a3d-a8c9-4849-8d99-8d26291368fd"
      decimals="-3"
      id="F_89b54892-6a24-4862-9414-93afca926bca"
      unitRef="U_USD">-21413000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_68139526-0bbf-4b45-8e70-8810aac1e74f"
      unitRef="U_USD">-21413000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_cdf836e1-0f62-4f0e-af87-d9a88e484056"
      decimals="INF"
      id="F_7285797c-0658-4019-8a50-c83962662fbc"
      unitRef="U_shares">1025183</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_cdf836e1-0f62-4f0e-af87-d9a88e484056"
      decimals="-3"
      id="F_2e3d239d-b397-4a81-a2d4-da1cd42dce79"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_c0f2353d-d121-47bf-acc8-b4e623af90e5"
      decimals="INF"
      id="F_b184485c-f779-4e75-b019-275c0ee2afe3"
      unitRef="U_shares">1485560</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c0f2353d-d121-47bf-acc8-b4e623af90e5"
      decimals="-3"
      id="F_104bf91d-ccd9-442d-a563-7c74afda0c77"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_77ca1123-0343-4fd4-a5b4-64151b7b9e0f"
      decimals="-3"
      id="F_03c9499b-3a37-42ff-9fa6-6ca270b7bcc8"
      unitRef="U_USD">-100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fb198e78-e33b-404a-872e-c2d863686fc7"
      decimals="-3"
      id="F_6c78eb76-2caa-4577-bf8e-7efafbeb1109"
      unitRef="U_USD">91823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20a3ae2b-fe8d-415d-9a71-83546b838508"
      decimals="-3"
      id="F_4b3c8a89-e567-4090-afe0-1b769b535c03"
      unitRef="U_USD">-84984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_943328a7-f5d4-4ade-8b0b-f44cabf55e22"
      unitRef="U_USD">6741000</us-gaap:StockholdersEquity>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="INF"
      id="F_76106a15-aba9-427d-85bd-53a53dc3fa14"
      unitRef="U_shares">1555</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_69d91da2-7bca-4bff-9cb8-c9cfd3c244e7"
      decimals="INF"
      id="F_14ff789c-3cc5-4da5-a012-81c0674ef651"
      unitRef="U_shares">-1555</us-gaap:ConversionOfStockSharesConverted1>
    <lgvn:StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="INF"
      id="F_d8d2ed62-734e-4b94-91c9-bc538fd41e29"
      unitRef="U_shares">566904</lgvn:StockIssuesSuringPeriodClassACommonStockIssuedForRSUsVestedinShares>
    <lgvn:StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="INF"
      id="F_780ff3c2-868c-4124-a8f0-a21c07e6bf42"
      unitRef="U_shares">-142306</lgvn:StockIssuedDuringPeriosSharesClassACommonStockHeldForTaxesOnRSUsVested>
    <lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested
      contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289"
      decimals="-3"
      id="F_89b58709-3c76-488a-9ced-96b8ba770846"
      unitRef="U_USD">-349000</lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested>
    <lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_19910e5c-eadb-4400-a067-6350c89c610a"
      unitRef="U_USD">-349000</lgvn:StockIssuedDuringPeriodClassACommonStockHeldForTaxesOnRSUsVested>
    <lgvn:StockIssuesDuringPeriodSharesForPSUsVested
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="INF"
      id="F_0a709003-66b2-470a-9e33-4a2119862e39"
      unitRef="U_shares">8020</lgvn:StockIssuesDuringPeriodSharesForPSUsVested>
    <lgvn:StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="INF"
      id="F_8c5dabf9-ef55-4adc-810f-1911f7d80b84"
      unitRef="U_shares">-3286</lgvn:StockIssuedDuringPeriodSharesClassACommonStockHeldForTaxesOnPsusVested>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289"
      decimals="-3"
      id="F_d6dd2bc3-eb33-4000-b6ce-44b89bec2f60"
      unitRef="U_USD">-17000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_dcb30fd6-0974-4a80-aec0-21f1497bc17a"
      unitRef="U_USD">-17000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <lgvn:CollectionOfStockSubscriptionReceivable
      contextRef="C_313e3c1d-a177-40fe-a408-6990d730e5ec"
      decimals="-3"
      id="F_c76c6fb4-b88d-4e5b-9a72-dcb3b8389c02"
      unitRef="U_USD">100000</lgvn:CollectionOfStockSubscriptionReceivable>
    <lgvn:CollectionOfStockSubscriptionReceivable
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_e8523a07-a017-4e8f-a986-47c1d88aa813"
      unitRef="U_USD">100000</lgvn:CollectionOfStockSubscriptionReceivable>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289"
      decimals="-3"
      id="F_57693813-938f-4486-bb4d-45e4e5b6c592"
      unitRef="U_USD">2328000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_cf079426-5522-4244-b8cc-24c4e0f1439f"
      unitRef="U_USD">2328000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_0f1873e7-5b6b-445a-ab3e-c0534a8a15c1"
      unitRef="U_USD">2064000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="INF"
      id="F_6eb4893b-1706-4934-ae49-d52dc4d890e1"
      unitRef="U_shares">4448792</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="-3"
      id="F_3b68cff7-220d-40b9-ad0a-38bc0477106f"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289"
      decimals="-3"
      id="F_601499d6-c91b-4dad-a389-ceacb050f727"
      unitRef="U_USD">12862000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_55dda0be-81fb-49c8-8544-419fc3dcaccc"
      unitRef="U_USD">12866000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <lgvn:StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_4de4b047-faf2-4dca-999e-72215b8d88ff"
      unitRef="U_USD">1855000</lgvn:StockIssuedDuringPeriodValueForWarrantsExercisedNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="INF"
      id="F_53695e26-5f5a-48ee-8e3c-c46ced15dba5"
      unitRef="U_shares">7435609</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="-3"
      id="F_da6add3d-9838-479d-bb33-d5e6859b1968"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289"
      decimals="-3"
      id="F_1ba47ea3-ebad-4778-b2b9-b6342e7e90ae"
      unitRef="U_USD">16183000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_27f57723-2e63-4b69-9ec3-3ef34a89abfa"
      unitRef="U_USD">16191000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="C_528b6a30-52ca-427d-8cd4-51e869799289"
      decimals="-3"
      id="F_5dd0eacf-4d80-4c56-8fe2-1bc1a7b488c3"
      unitRef="U_USD">8650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="C_32a5c33d-d25b-44e7-987a-deec4533967d"
      decimals="-3"
      id="F_8f22bec2-a794-4bfc-b70c-192a403ba4d9"
      unitRef="U_USD">-8650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="INF"
      id="F_dd873592-49a4-4c9d-ba23-54c5b05e249d"
      unitRef="U_shares">66970</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="C_32a5c33d-d25b-44e7-987a-deec4533967d"
      decimals="-3"
      id="F_032327b5-62c4-40f0-870f-4791bed77fd6"
      unitRef="U_USD">-15973000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_465170ab-2481-465b-9aab-4e91d18b3ed9"
      unitRef="U_USD">-15973000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_ff6c86a5-5367-4252-82ff-f27f2520421d"
      decimals="INF"
      id="F_61048633-c987-47f7-9ef8-e6ac53d30fbf"
      unitRef="U_shares">13407441</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ff6c86a5-5367-4252-82ff-f27f2520421d"
      decimals="-3"
      id="F_3a0c316e-e65a-41de-a25b-8b5e2280090a"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_c920b7f7-14c0-4ed4-8bef-d33b2189d204"
      decimals="INF"
      id="F_361b09f8-4924-4527-b2c3-5bc9b32d5b3d"
      unitRef="U_shares">1484005</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c920b7f7-14c0-4ed4-8bef-d33b2189d204"
      decimals="-3"
      id="F_42f1a87a-9d1f-442b-9e3c-a43538b7b7cb"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ac111904-200e-4f5d-bf20-50cfa1be5544"
      decimals="-3"
      id="F_e59a6ffb-158f-4ea4-966f-f0dbdc6184c1"
      unitRef="U_USD">131480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_60e8ad0c-7547-4527-8724-24923bdc82a9"
      decimals="-3"
      id="F_224e6fb4-82ce-41b7-8338-902c25123bf1"
      unitRef="U_USD">-109607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_91e17de1-6a08-4922-ba7d-59244c3e45bc"
      unitRef="U_USD">21887000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_4153208a-f06e-48ce-a12d-e623e3a05585"
      unitRef="U_USD">-15973000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_68c694ef-ffa6-4abd-926c-f37543028263"
      unitRef="U_USD">-21413000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_4cc4425a-9029-4638-9721-001e74f2b41e"
      unitRef="U_USD">958000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_f1366841-ae08-4a4f-b51c-dcc7d3f1c11c"
      unitRef="U_USD">946000</us-gaap:DepreciationAndAmortization>
    <lgvn:InterestEarnedOnMarketableSecurities
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_7122d535-bfcc-4521-bedd-7c126e3e3fd0"
      unitRef="U_USD">-60000</lgvn:InterestEarnedOnMarketableSecurities>
    <lgvn:InterestEarnedOnMarketableSecurities
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_eb0d186e-34a3-46f1-8540-cfc496fa84c0"
      unitRef="U_USD">-220000</lgvn:InterestEarnedOnMarketableSecurities>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_9e2f735b-66ad-45b9-8a9f-da86904cc709"
      unitRef="U_USD">2328000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_8a0431f5-696a-4fa8-93ca-97e84adbac3f"
      unitRef="U_USD">2032000</us-gaap:ShareBasedCompensation>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_78ec13ba-f6c8-4b96-93ed-536cf1af768a"
      unitRef="U_USD">290000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_c7c7b292-87bd-4d10-ad08-71b751c84ebd"
      unitRef="U_USD">-27000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_a9f3b648-4e4f-44fa-86ce-fa3e5739a9a0"
      unitRef="U_USD">-107000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_224dc1d2-3c4c-4e6a-8881-56a0ee2273b9"
      unitRef="U_USD">-68000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_096ffcc8-0cb6-4803-b2ec-afaebbbaff41"
      unitRef="U_USD">-28000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_7725bb2b-016a-4fa8-909c-b6df6981e746"
      unitRef="U_USD">9000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_2a0c7a25-55d5-4d02-8358-fd5043c35af7"
      unitRef="U_USD">-51000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_aa18ce51-9f37-4572-8064-71a8ea26ad85"
      unitRef="U_USD">-540000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_ef182f93-faa8-4e5a-8bee-b71fc00c96c2"
      unitRef="U_USD">-1113000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_16efc132-5a7e-48bd-be77-24323f50cd4e"
      unitRef="U_USD">-466000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_8ecb92cc-22a6-48c9-af7d-fd890f42411e"
      unitRef="U_USD">-1398000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_b8c1aed0-389d-498d-a503-2104003594d1"
      unitRef="U_USD">-332000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_1ab805c6-f9d7-4f70-8011-3c649c0907c8"
      unitRef="U_USD">1502000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_c6539c94-8be1-42a1-a654-5e522f294240"
      unitRef="U_USD">254000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_a0936de8-050d-487c-bc34-201da50c02df"
      unitRef="U_USD">254000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_03f593a5-7787-454e-831d-42ef69023a85"
      unitRef="U_USD">265000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_dfb70f36-826d-41cc-8d40-ac3c3dfe8892"
      unitRef="U_USD">-13868000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_e0a3f346-b166-4210-af06-8efbf76634a2"
      unitRef="U_USD">-19002000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_5882deb0-17b7-492b-b56e-9c62f4df7691"
      unitRef="U_USD">352000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_145f2672-701c-4cf3-bc7c-51051061d783"
      unitRef="U_USD">8880000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_bab2b89d-a52f-4e67-afe6-73cb464dc1d3"
      unitRef="U_USD">655000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_b09529f1-0033-4e05-8f0a-2de315c3c789"
      unitRef="U_USD">301000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_7b726d80-37c5-4db0-8179-0c76aa0fa834"
      unitRef="U_USD">337000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_ccabd64b-2aa1-4354-8c6c-05b2e68faf3d"
      unitRef="U_USD">393000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_a7ab3321-3831-44e2-a418-12484f0c413a"
      unitRef="U_USD">-640000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_26cf6ac3-7c66-4c4a-9e1c-e66655c063f6"
      unitRef="U_USD">8186000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_66c3ddff-c766-41a8-89a3-ee2abdd52317"
      unitRef="U_USD">12866000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_1626dd7f-8c2d-4658-8fb0-b2b43758b949"
      unitRef="U_USD">5338000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_c866400c-c57b-4f92-b670-8287be29485a"
      unitRef="U_USD">16191000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_905ca164-8d38-4c80-bddb-bbf8526354f0"
      unitRef="U_USD">98000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <lgvn:ProceedsFromStockSubscriptionReceivable
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_329ca66a-923d-41c6-908e-62de9ab70dd5"
      unitRef="U_USD">100000</lgvn:ProceedsFromStockSubscriptionReceivable>
    <lgvn:PaymentsForTaxesOnRsusVestedAndPsusVested
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_0b26c05d-c0c9-44f6-b36a-83f1de4014cd"
      unitRef="U_USD">366000</lgvn:PaymentsForTaxesOnRsusVestedAndPsusVested>
    <lgvn:PaymentsForTaxesOnRsusVestedAndPsusVested
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_23999183-b48e-4cda-b6d7-8e48df413235"
      unitRef="U_USD">174000</lgvn:PaymentsForTaxesOnRsusVestedAndPsusVested>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_170acd26-9515-4fc7-9cd3-4a9fd00a78ca"
      unitRef="U_USD">28791000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_acbb95c0-0ca3-450b-bdf6-3a040ad95aba"
      unitRef="U_USD">5262000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_43390714-f609-4424-ae60-a07a6437682b"
      unitRef="U_USD">14283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_f6362bf6-2cd2-42c0-ac5b-8a8dbc5fa7fe"
      unitRef="U_USD">-5554000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_5d145596-c5ea-43f8-a2fc-6cfb5af431fa"
      unitRef="U_USD">4949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_713a5589-63ed-440c-848f-a0dc06ed8d24"
      decimals="-3"
      id="F_ba4e0c8e-0bf2-41a2-8732-99bc8dc9502e"
      unitRef="U_USD">10503000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_62811304-1a55-403f-95c3-c1340d5da7b5"
      unitRef="U_USD">19232000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_5bb07738-cfbe-4230-b3ce-d5f27ee8ba9e"
      unitRef="U_USD">4949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <lgvn:VestingOfRSUsAndPSUsIntoClassACommonStock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_61ac7825-a25e-4b85-8700-546272c7969a"
      unitRef="U_USD">-1109000</lgvn:VestingOfRSUsAndPSUsIntoClassACommonStock>
    <lgvn:VestingOfRSUsAndPSUsIntoClassACommonStock
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_ce76cfd2-d003-464e-a53e-97512a90ac9c"
      unitRef="U_USD">-777000</lgvn:VestingOfRSUsAndPSUsIntoClassACommonStock>
    <lgvn:DeemedDividendWarrantInducementOffers
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_d5bc39e3-d9a2-485c-93e9-6dbf00c4ca16"
      unitRef="U_USD">8650000</lgvn:DeemedDividendWarrantInducementOffers>
    <lgvn:DeemedDividendWarrantInducementOffers
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_9ad91bf8-5428-4a56-9e20-3024ae0c4c24"
      unitRef="U_USD">798000</lgvn:DeemedDividendWarrantInducementOffers>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_96055a76-8545-41a4-b337-665be0a2928a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Nature of Business, Basis of Presentation, and Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nature of Business:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Longeveron LLC was formed as a Delaware limited liability company on October 9, 2014 and authorized to transact business in Florida on December 15, 2014. On February 12, 2021, Longeveron LLC converted its corporate form (the &#x201c;Corporate Conversion&#x201d;) from a Delaware limited liability company (Longeveron, LLC) to a Delaware corporation, Longeveron Inc. (the &#x201c;Company,&#x201d; &#x201c;Registrant,&#x201d; &#x201c;Longeveron,&#x201d;, &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;). The Company is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on licenses, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting capabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s product candidates are currently in development. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid technological change and substantial competition from, among others, existing pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, partners and consultants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Going Concern and Liquidity:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since inception, the Company has primarily been engaged in organizational activities, including raising capital, and research and development activities. The Company does not yet have a product that has been approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;), and has only generated revenues from grants, the Bahamas Registry Trials and contract manufacturing. The Company has not yet achieved profitable operations or generated positive cash flows from operations. The Company intends to continue its efforts to raise additional equity financing, develop its intellectual property, and secure regulatory approvals to commercialize its products. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. Further, the Company&#x2019;s future operations are dependent on the success of the Company&#x2019;s efforts to raise additional capital, its research and commercialization efforts, regulatory approval, and, ultimately, the market acceptance of the Company&#x2019;s products. These financial statements do not include adjustments that might result from the outcome of these uncertainties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has incurred recurring losses from operations since its inception, including a net loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively. In addition, as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company expects to continue to generate operating losses for the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company currently believes that its cash and cash equivalents as of December 31, 2024 will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025 based on its current operating budget and cash flow forecast. However, as a result of its successful Type C meeting with the U.S. FDA in August 2024 with respect to the HLHS regulatory pathway, the Company has started to ramp up Biologics License Application (BLA) enabling activities as the Company currently anticipates a potential filing with the FDA in 2026 if the current ELPIS II trial is successful. The Company's operating expenses and capital expenditure requirements are expected to accelerate in calendar 2025 as a result of these activities, including CMC (Chemistry, Manufacturing, and Controls) and manufacturing readiness, and there will be a need to increase the Company's current proposed spend and further increase its capital investments. The Company intends to seek additional financing/capital raises/non-dilutive funding options to support these activities, and current cash projections may be impacted by these ramped up activities and any&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;financing transactions entered into. There can be no assurance the Company will be able to attain future financing at terms favorable to the Company or at all.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has prepared a cash flow forecast which indicates that it does not have sufficient cash to meet its minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore needs to raise additional funds to continue as a going concern. As a result, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-5"
      id="F_3d88bde6-303d-445a-9f4a-dc2a78cf4194"
      unitRef="U_USD">-16000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-5"
      id="F_d3da3446-e424-4d94-843c-638782c0f71e"
      unitRef="U_USD">-21400000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-5"
      id="F_92602bb7-9aa8-49ba-bb25-3106c93ec20f"
      unitRef="U_USD">-109600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-5"
      id="F_25c3c901-410c-4cd0-938b-f58f6c0f72ec"
      unitRef="U_USD">19200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_1b138a75-e94e-4bac-a023-4a215483f330">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial statements of the Company were prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain reclassifications have been made to prior period amounts to conform to the current period presentation. These reclassifications had no impact on previously reported net loss for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reverse Stock Split:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 26, 2024, the Company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_4a0b75b5-4668-44fe-9ab3-6ac34d6f5dc3;"&gt;&lt;span style="-sec-ix-hidden:F_2e46777d-d9ea-4884-a9bb-dd1d15ee5f6a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-for-10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (1:10) basis (the &#x201c;Reverse Stock Split&#x201d;). The Reverse Stock Split became effective at 11:59 p.m. Eastern Time on March 26, 2024 via a certificate of amendment to the Company&#x2019;s Certificate of Incorporation filed with the Secretary of State of the State of Delaware. At the effective time of the Reverse Stock Split, every 10 shares of the Company&#x2019;s Class A common stock and Class B common stock, whether issued and outstanding or held by the Company as treasury stock, were automatically combined and converted (without any further act) into one fully paid and nonassessable share of Class A common stock or Class B common stock, respectively, subject to rounding up of fractional shares to the nearest whole number of shares resulting from the Reverse Stock Split without any change in the par value per share. All share, per share, option, warrant, equity award, and other derivative security numbers and exercise prices appearing in this Annual Report on Form 10-K and the accompanying condensed financial statements have been adjusted to give effect to the Reverse Stock Split for all prior periods presented. However, the Company&#x2019;s annual, other periodic, and current reports, and all other information and documents incorporated by reference into this Annual Report on Form 10-K that were filed prior to March 19, 2024, do not give effect to the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The presentation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounting Standard Updates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2023-07, "Improvements to Reportable Segment Disclosures". The amendments in this ASU are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and by extending the disclosure requirements to entities with a single reportable segment. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_382d7ea9-fe54-4942-9ed3-f6ed091b8df0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is effective for the Company for the annual period of its fiscal year ending December 31, 2024. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; this standard as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the adoption did not have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on its financial statements. See Note 13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, for disclosures related to the adoption of ASU 2023-07.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &#x201c;Improvements to Income Tax Disclosures&#x201d;. The amendments in this ASU change disclosure requirements for various items, including effective tax rate reconciliations and cash taxes paid. This ASU is effective for public companies for the financial reporting periods beginning on January 1, 2025, with early adoption permitted. The Company has not adopted ASU 2023-09 for its financial reporting period ending December 31, 2024, and does not anticipate the adoption of this ASU will have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#x201d;. The amendments in this ASU require additional disclosure about the nature of expenses included in the expense captions presented on the face of the income statement, including research and development and other operating expenses. This ASU is effective for public companies for the financial reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively, with the option for retrospective application, and early adoption is permitted. ASU 2024-03 will be effective for the Company for the annual period of its fiscal year ending December 31, 2027. The Company is currently evaluating the impact of adopting this ASU on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers cash to consist of cash and cash equivalents and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; marketable securities at December 31, 2024. Marketable securities at December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as available-for-sale securities and are thus marked to market and stated at fair value in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 820 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and / or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized gains and losses were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts and Grants Receivable:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of December 31, 2024 and 2023 are deemed to be collectible and no amount has been recognized for credit losses. In addition, for the clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the clinical trial revenue are recorded to deferred revenue. Advance contract manufacturing payments are recorded to deferred revenue.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts and grants receivable by source, as of (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.939999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.939999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts receivables from customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;National Institutes of Health &#x2013; Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of proceeds generated as a result of the offering.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, including improvements that extend useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the Statement of Operations as the assets are primarily related to the Company&#x2019;s clinical programs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets include payments on license agreements with the Company&#x2019;s co-founder and Chief Scientific Officer (&#x201c;CSO&#x201d;) and the University of Miami (&#x201c;UM&#x201d;) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;20 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the statements of operations as the assets are primarily related to the Company&#x2019;s clinical programs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;impairment loss&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is reflected on the statements of operations. Upon evaluation, management determined that there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million impairment of long-lived assets during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Revenue:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The unearned portion of advanced grant funds, contract manufacturing revenues, and prepayments for Clinical trial revenue, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the balance sheets. For the years ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of funds that were previously classified as deferred revenue. Due to the MSCRF &#x2013; TEDCO &#x2013; grant ARDS program being discontinued, the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million recorded as deferred revenue was reversed when the funds were returned to MSCRF &#x2013; TEDCO.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company recognizes revenue when performance obligations related to respective revenue streams are met. For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant received the treatment. For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and / or statement of work has been satisfied. Additionally, the Company's contract manufacturing agreements include a lease component, under which customers pay a fixed monthly fee per&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;suite &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to reserve and maintain a dedicated manufacturing suite with one production line. Customers may also secure additional suites based on capacity needs, which are billed at a fixed fee per suite per month. furthermore, customers pay the Company a fixed fee per month for storage of in-process samples, vialed harvests for training, and in-process samples for product lots. As these arrangements grant customers the right to control the use of an identified space, the Company classifies the suite reservation fees and storage fees as lease revenue in accordance with ASC 842 Leases. Payment terms may vary depending on specific contract terms. In 2024, the Company derived &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of its contract manufacturing revenue from a single customer, resulting in a significant concentration of revenue risk. Should this customer terminate their business relationship, the Company's contract manufacturing revenue could be materially adversely impacted.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue by source (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.272%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trial revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract manufacturing lease revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_27ce6dd3-639b-41e2-9150-1333292d9101;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_ab57fa60-fbf9-444e-8dc1-8543b8bc25bd;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;National Institute of Health - grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_491c5dcc-2520-4145-b055-747c1b012785;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records cost of revenues based on expenses directly related to revenue. For Grants, the Company records allocated expenses for Research and development costs to a grant as a cost of revenues. For the Clinical trial revenue directly related expenses for that program are expensed as incurred. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These expenses are similar to those described under &#x201c;Research and development expense&#x201d; below. For the contract manufacturing, the Company records costs incurred under the contract as cost of revenues.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are charged to expense when incurred in accordance with ASC 730 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities, and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company&#x2019;s tax&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;provision &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the uncertainty of realizing a benefit in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authority. It is the Company&#x2019;s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity-Based Compensation:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for equity-based awards based on estimated fair values on the date of grant. The fair value of the options is estimated at the date of the grant using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Neither the Company&#x2019;s stock options nor its restricted stock units (&#x201c;RSUs&#x201d;) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company&#x2019;s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the option was granted. The expected life is the period of time that the options granted are expected to remain outstanding. Options granted have a maximum term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company had insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_617a6498-cf8d-4532-9e59-92d3c3c98c6e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial statements of the Company were prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain reclassifications have been made to prior period amounts to conform to the current period presentation. These reclassifications had no impact on previously reported net loss for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <lgvn:ReverseStockSplitPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_6b68c1e5-f448-4dce-9356-282dc32b7f38">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reverse Stock Split:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 26, 2024, the Company effected a reverse stock split of the outstanding shares of its Class A common stock and Class B common stock on a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_4a0b75b5-4668-44fe-9ab3-6ac34d6f5dc3;"&gt;&lt;span style="-sec-ix-hidden:F_2e46777d-d9ea-4884-a9bb-dd1d15ee5f6a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-for-10&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (1:10) basis (the &#x201c;Reverse Stock Split&#x201d;). The Reverse Stock Split became effective at 11:59 p.m. Eastern Time on March 26, 2024 via a certificate of amendment to the Company&#x2019;s Certificate of Incorporation filed with the Secretary of State of the State of Delaware. At the effective time of the Reverse Stock Split, every 10 shares of the Company&#x2019;s Class A common stock and Class B common stock, whether issued and outstanding or held by the Company as treasury stock, were automatically combined and converted (without any further act) into one fully paid and nonassessable share of Class A common stock or Class B common stock, respectively, subject to rounding up of fractional shares to the nearest whole number of shares resulting from the Reverse Stock Split without any change in the par value per share. All share, per share, option, warrant, equity award, and other derivative security numbers and exercise prices appearing in this Annual Report on Form 10-K and the accompanying condensed financial statements have been adjusted to give effect to the Reverse Stock Split for all prior periods presented. However, the Company&#x2019;s annual, other periodic, and current reports, and all other information and documents incorporated by reference into this Annual Report on Form 10-K that were filed prior to March 19, 2024, do not give effect to the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;</lgvn:ReverseStockSplitPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_7797fa89-9de5-4aa0-8eee-d0a95dc2bb5e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The presentation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_1f42eaf7-5ae4-44fa-b892-8aaa427abedf">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounting Standard Updates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2023-07, "Improvements to Reportable Segment Disclosures". The amendments in this ASU are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and by extending the disclosure requirements to entities with a single reportable segment. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_382d7ea9-fe54-4942-9ed3-f6ed091b8df0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is effective for the Company for the annual period of its fiscal year ending December 31, 2024. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; this standard as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the adoption did not have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on its financial statements. See Note 13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, for disclosures related to the adoption of ASU 2023-07.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &#x201c;Improvements to Income Tax Disclosures&#x201d;. The amendments in this ASU change disclosure requirements for various items, including effective tax rate reconciliations and cash taxes paid. This ASU is effective for public companies for the financial reporting periods beginning on January 1, 2025, with early adoption permitted. The Company has not adopted ASU 2023-09 for its financial reporting period ending December 31, 2024, and does not anticipate the adoption of this ASU will have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#x201d;. The amendments in this ASU require additional disclosure about the nature of expenses included in the expense captions presented on the face of the income statement, including research and development and other operating expenses. This ASU is effective for public companies for the financial reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The requirements will be applied prospectively, with the option for retrospective application, and early adoption is permitted. ASU 2024-03 will be effective for the Company for the annual period of its fiscal year ending December 31, 2027. The Company is currently evaluating the impact of adopting this ASU on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      id="F_29b93aca-9b94-4dae-a6b4-ad93d142ff46">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      id="F_fe662b55-0e55-42fb-af86-f9c2cdef65fa">2024-12-31</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      id="F_d4eed576-8e32-47fd-bff1-94398eff0aae">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_d1fc26af-90cf-4544-81a7-bbc7eaae25c2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers cash to consist of cash and cash equivalents and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_a694c30a-99dd-42f1-b212-902923e83419">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; marketable securities at December 31, 2024. Marketable securities at December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as available-for-sale securities and are thus marked to market and stated at fair value in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 820 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and / or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized gains and losses were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="0"
      id="F_b349f8ed-096d-421c-8a47-6d2332827bb5"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-6"
      id="F_c2d830fe-ac68-4f3c-99ec-380d7c22e323"
      unitRef="U_USD">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-5"
      id="F_fe49037e-d7a2-457d-8d75-597ee897419b"
      unitRef="U_USD">300000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_2239d4e7-109e-464d-82f3-3016ebb84e98">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts and Grants Receivable:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts and grants receivable include amounts due from customers, granting institutions and others. The amounts as of December 31, 2024 and 2023 are deemed to be collectible and no amount has been recognized for credit losses. In addition, for the clinical trial revenue, most participants pay in advance of treatment. Advanced grant funds and prepayments for the clinical trial revenue are recorded to deferred revenue. Advance contract manufacturing payments are recorded to deferred revenue.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts and grants receivable by source, as of (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.939999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.939999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts receivables from customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;National Institutes of Health &#x2013; Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_c724d3f1-c058-426b-8145-34cf21f0cc43">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts and grants receivable by source, as of (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:58%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.939999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.06%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.939999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts receivables from customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;National Institutes of Health &#x2013; Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_611dbbc0-e2ce-41b4-85bf-90180810a5c5"
      decimals="-3"
      id="F_f00af57b-1a95-468d-8ce7-fbefaaefa7af"
      unitRef="U_USD">25000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_2e89703c-f1d8-47e0-91e2-c47b8050d0e4"
      decimals="-3"
      id="F_5744f5b2-1f0f-4ed5-ac08-b9940c970074"
      unitRef="U_USD">15000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0d1788e0-51e1-4f67-b903-b27ef0e08ec1"
      decimals="-3"
      id="F_d4a5da50-0228-45d5-b351-20e09353ef52"
      unitRef="U_USD">59000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_c4442eac-31f6-4b65-9025-3e8e2289cc06"
      decimals="-3"
      id="F_9caa1132-7e69-4661-91aa-47b2b3f9aff9"
      unitRef="U_USD">96000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_5dd739c9-dc07-4d1a-9485-78517528c049"
      unitRef="U_USD">84000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_69969306-83ab-47db-bc90-7940e0bfd1ea"
      unitRef="U_USD">111000</us-gaap:AccountsReceivableNetCurrent>
    <lgvn:DeferredOfferingCostsPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_e57c8f17-c722-4e4f-ab39-08dc41886ae0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recorded certain legal, professional and other third-party fees that were directly associated with in-process equity financings as deferred offering costs until the applicable equity financing was consummated. After consummation of an equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of proceeds generated as a result of the offering.&lt;/span&gt;&lt;/p&gt;</lgvn:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_4d8d5c62-4f0e-4013-ae91-45b636a2f8cd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, including improvements that extend useful lives of related assets, are recorded at cost, while maintenance and repairs are charged to operations as incurred. Depreciation is calculated using the straight-line method based on the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the original term of the lease. Depreciation expense is recorded in the research and development line of the Statement of Operations as the assets are primarily related to the Company&#x2019;s clinical programs.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_eb19efb5-4412-4bd4-81f0-acdd48630003">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible Assets:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets include payments on license agreements with the Company&#x2019;s co-founder and Chief Scientific Officer (&#x201c;CSO&#x201d;) and the University of Miami (&#x201c;UM&#x201d;) (see Note 9) and legal costs incurred related to patents and trademarks. License agreements have been recorded at the value of cash consideration, common stock and membership units transferred to the respective parties when acquired.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Payments for license agreements are amortized using the straight-line method over the estimated term of the agreements, which range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;20 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Patents are amortized over their estimated useful life, once issued. The Company considers trademarks to have an indefinite useful life and evaluates them for impairment on an annual basis. Amortization expense is recorded in the research and development line of the statements of operations as the assets are primarily related to the Company&#x2019;s clinical programs.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_7bec887e-3248-45a0-9092-39870e2cd880"
      id="F_5e652d62-f345-4be8-814d-f1828929c813">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_44c40476-bff5-429e-a017-f12f5df662e4"
      id="F_5625679f-2669-4307-8a3e-f5a68125916f">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_09cb9f4a-4fe4-4dd3-b206-a64ceb5fa105">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates long-lived assets for impairment, including property and equipment and intangible assets, when events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Upon the occurrence of a triggering event, the asset is reviewed to assess whether the estimated undiscounted cash flows expected from the use of the asset plus the residual value from the ultimate disposal exceeds the carrying value of the asset. If the carrying value exceeds the estimated recoverable amounts, the asset is written down to the estimated fair value. Any resulting &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;impairment loss&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is reflected on the statements of operations. Upon evaluation, management determined that there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million impairment of long-lived assets during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <lgvn:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_b4893190-16cf-47a1-ae54-7bbbd2ab64db">false</lgvn:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <lgvn:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      id="F_0a1dd616-9e9e-46b4-bc9f-222cf64613f0">false</lgvn:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-6"
      id="F_f7e9ddd0-b263-4808-b325-c5a3945fe51e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-5"
      id="F_f988cf93-ded0-453d-ba42-e97f13448a05"
      unitRef="U_USD">300000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_c531d2a7-b443-4d32-888e-b3a1953ecb97">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred Revenue:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The unearned portion of advanced grant funds, contract manufacturing revenues, and prepayments for Clinical trial revenue, which will be recognized as revenue when the Company meets the respective performance obligations, has been presented as deferred revenue in the balance sheets. For the years ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of funds that were previously classified as deferred revenue. Due to the MSCRF &#x2013; TEDCO &#x2013; grant ARDS program being discontinued, the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million recorded as deferred revenue was reversed when the funds were returned to MSCRF &#x2013; TEDCO.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-6"
      id="F_050d625c-b283-4d73-b8c5-134240d83d37"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-6"
      id="F_91e69c74-bcc6-4d69-8096-6e89804b1844"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_70201005-5bfe-4448-ba31-f3aebe56ae09"
      decimals="-5"
      id="F_e683d840-c157-454f-8821-ce4939906ee1"
      unitRef="U_USD">400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_023316e7-dc86-491f-b034-7d86c74ba422">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company recognizes revenue when performance obligations related to respective revenue streams are met. For grant revenue, the Company considers the performance obligation met when the grant related expenses are incurred or supplies and materials are received. The Company is paid in tranches pursuant to terms of the related grant agreements, and then applies payments based on regular expense reimbursement submissions to grantors. There are no remaining performance obligations or variable consideration once grant expense reporting to the grantor is complete. For clinical trial revenue, the Company considers the performance obligation met when the participant has received the treatment. The Company usually receives prepayment for these services or receives payment at the time the treatment is provided, and there are no remaining performance obligations or variable consideration once the participant received the treatment. For contract manufacturing revenue, the Company considers the performance obligation met when the contractual obligation and / or statement of work has been satisfied. Additionally, the Company's contract manufacturing agreements include a lease component, under which customers pay a fixed monthly fee per&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;suite &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to reserve and maintain a dedicated manufacturing suite with one production line. Customers may also secure additional suites based on capacity needs, which are billed at a fixed fee per suite per month. furthermore, customers pay the Company a fixed fee per month for storage of in-process samples, vialed harvests for training, and in-process samples for product lots. As these arrangements grant customers the right to control the use of an identified space, the Company classifies the suite reservation fees and storage fees as lease revenue in accordance with ASC 842 Leases. Payment terms may vary depending on specific contract terms. In 2024, the Company derived &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of its contract manufacturing revenue from a single customer, resulting in a significant concentration of revenue risk. Should this customer terminate their business relationship, the Company's contract manufacturing revenue could be materially adversely impacted.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue by source (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.272%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trial revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract manufacturing lease revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_27ce6dd3-639b-41e2-9150-1333292d9101;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_ab57fa60-fbf9-444e-8dc1-8543b8bc25bd;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;National Institute of Health - grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_491c5dcc-2520-4145-b055-747c1b012785;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records cost of revenues based on expenses directly related to revenue. For Grants, the Company records allocated expenses for Research and development costs to a grant as a cost of revenues. For the Clinical trial revenue directly related expenses for that program are expensed as incurred. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These expenses are similar to those described under &#x201c;Research and development expense&#x201d; below. For the contract manufacturing, the Company records costs incurred under the contract as cost of revenues.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_f23ba838-5cb1-45db-a43c-3c3ea606ba58"
      decimals="INF"
      id="F_9e6492e6-0e30-4548-8e3f-604ad049d397"
      unitRef="U_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_a46a2ba7-7859-4e55-9ec3-385e2f6c5a69">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue by source (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.272%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trial revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract manufacturing lease revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_27ce6dd3-639b-41e2-9150-1333292d9101;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_ab57fa60-fbf9-444e-8dc1-8543b8bc25bd;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;National Institute of Health - grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_491c5dcc-2520-4145-b055-747c1b012785;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8e3349a5-e8ad-4d9f-932c-91af4f1b95ad"
      decimals="-3"
      id="F_6745d6bc-ecec-46ad-8576-570c68c05c86"
      unitRef="U_USD">1402000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cec0b67c-0b8b-4bc4-9170-1fbad94ea8f8"
      decimals="-3"
      id="F_f386bdca-4cd8-45af-ae37-36c0496e3e68"
      unitRef="U_USD">668000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_88f70043-2bab-4fbd-a7ff-7ca163bafeae"
      decimals="-3"
      id="F_6787d530-3c38-44ad-b2bc-53398f3b443a"
      unitRef="U_USD">503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9fa8323f-6ecb-4760-888b-b865f49ee572"
      decimals="-3"
      id="F_cd66614b-fcaa-4ffc-b07a-e3b9684d3ce8"
      unitRef="U_USD">487000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_75235aac-f968-4f7c-9c6b-79a7b4522881"
      decimals="-3"
      id="F_1e7804c6-78b7-480a-b20b-66564ddcd3e1"
      unitRef="U_USD">41000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-3"
      id="F_46b9470d-6f01-4530-827a-79f69db4a912"
      unitRef="U_USD">2392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-3"
      id="F_39104671-9b17-48ff-9dec-6b58a15ac522"
      unitRef="U_USD">709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_0733008f-71c5-42dd-a0ec-f14540a43214">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expense:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs are charged to expense when incurred in accordance with ASC 730 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. ASC 730 addresses the proper accounting and reporting for research and development costs. It identifies: 1) those activities that should be identified as research and development; 2) the elements of costs that should be identified with research and development activities, and the accounting for these costs; and 3) the financial statement disclosures related to them. Research and development costs include costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, property and equipment depreciation and allocation of various corporate costs. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by the third parties, patient enrollment in clinical trials, administrative costs incurred by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expense in future periods as the related services are rendered.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_af103952-8991-4c6f-886b-9be10582c93c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities, and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_42ac54c8-1246-4f43-95db-1ff5328102a8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company&#x2019;s tax provision consists of taxes currently payable or receivable, plus any change during the period in deferred tax assets and liabilities. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In addition, a valuation allowance is established to reduce any deferred tax asset for which it is determined that it is more likely than not that some portion of the deferred tax asset will not be realized. The Company&#x2019;s tax&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;provision &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 due to net operating losses. The Company has not recorded any tax benefit for the net operating losses incurred due to the uncertainty of realizing a benefit in the future.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes the tax benefits from uncertain tax positions that the Company has taken or expects to take on a tax return. In the unlikely event an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by a taxing authority. Reserves for uncertain tax positions would then be recorded if the Company determined it is probable that either a position would not be sustained upon examination or a payment would have to be made to a taxing authority and the amount was reasonably estimable. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authority. It is the Company&#x2019;s policy to expense any interest and penalties associated with its tax obligations when they are probable and estimable.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="0"
      id="F_1bf9533d-28d3-446d-a8e1-d5c98ba1ad67"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="0"
      id="F_fe0d1b1e-b667-41cb-b202-51e90288440e"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_fc51c616-5121-4939-b81f-d47b101d15b9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity-Based Compensation:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for equity-based compensation expense by the measurement and recognition of compensation expense for equity-based awards based on estimated fair values on the date of grant. The fair value of the options is estimated at the date of the grant using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Black-Scholes option-pricing model requires the input of highly subjective assumptions, the most significant of which are the expected share price volatility, the expected life of the option award, the risk-free rate of return, and dividends during the expected term. Because the option-pricing model is sensitive to changes in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Neither the Company&#x2019;s stock options nor its restricted stock units (&#x201c;RSUs&#x201d;) trade on an active market. Volatility is a measure of the amount by which a financial variable, such as a stock price, has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Given the Company&#x2019;s limited historical data, the Company utilizes the average historical volatility of similar publicly traded companies that are in the same industry. The risk-free interest rate is the average U.S. treasury rate (having a term that most closely approximates the expected life of the option) for the period in which the option was granted. The expected life is the period of time that the options granted are expected to remain outstanding. Options granted have a maximum term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company had insufficient historical data to utilize in determining its expected life assumptions and, therefore, uses the simplified method for determining expected life.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_d1874156-cf40-4056-98dd-2d917c60f862">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_0d8d5a45-c280-41e7-86f3-ae721da3f0a9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is summary of marketable securities that the Company measures at fair value (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.628%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_5860e748-b626-4760-9959-04c8458de42e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b5db85cc-838d-40fc-a08f-983e2963015b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="-sec-ix-hidden:F_edf3cd8e-fee7-4f2b-bae4-3cb7da56e51c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_26429428-9ef1-47d7-90cc-f345882c97e5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="-sec-ix-hidden:F_261c32f6-80e4-43ac-b52b-25b87d6e73cb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="-sec-ix-hidden:F_8adfe637-2df8-4137-b76b-d02b023f34c0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_7a05c076-4b13-4782-980f-f1db531e3014;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_1ae67987-286c-4292-ad79-4c71735dd6d9;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b98a551e-dc71-4388-aafc-fbc75338dd46;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_382c332e-e576-4e25-b8f8-144ea2ba7f4f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_40e58eda-d3eb-4484-86f2-e1fe5a77793e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_588625ea-79fb-4a9a-8abb-1ccf786357c5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_1809098a-d0f5-4df3-8175-e912d38dfd37;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company reported accrued interest receivable related to marketable securities and money market funds of less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. These amounts are recorded in other assets on the Balance Sheets and are not included in the carrying value of the marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unrealized losses attributable to changes in marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the amortized cost of these securities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_b0705566-ab6d-4bfa-9ce4-c1ea915fd435">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is summary of marketable securities that the Company measures at fair value (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.628%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.842%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_5860e748-b626-4760-9959-04c8458de42e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b5db85cc-838d-40fc-a08f-983e2963015b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="-sec-ix-hidden:F_edf3cd8e-fee7-4f2b-bae4-3cb7da56e51c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_26429428-9ef1-47d7-90cc-f345882c97e5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="-sec-ix-hidden:F_261c32f6-80e4-43ac-b52b-25b87d6e73cb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="-sec-ix-hidden:F_8adfe637-2df8-4137-b76b-d02b023f34c0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_7a05c076-4b13-4782-980f-f1db531e3014;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_1ae67987-286c-4292-ad79-4c71735dd6d9;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b98a551e-dc71-4388-aafc-fbc75338dd46;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_382c332e-e576-4e25-b8f8-144ea2ba7f4f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_40e58eda-d3eb-4484-86f2-e1fe5a77793e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_588625ea-79fb-4a9a-8abb-1ccf786357c5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_1809098a-d0f5-4df3-8175-e912d38dfd37;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecurities
      contextRef="C_130be5b2-21d0-478a-b3b4-fa7cffb2136b"
      decimals="-3"
      id="F_3e89db0d-7516-4cec-996c-1c90638f3e28"
      unitRef="U_USD">6877000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_4dc5b1b6-411b-4ddf-9cb1-ffe97d305ce8"
      decimals="-3"
      id="F_e7605902-0fdc-48bc-ac79-49562b553579"
      unitRef="U_USD">6877000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_57c941b5-3999-414f-ab10-1d89c4034885"
      decimals="-3"
      id="F_badff5da-4d0e-4ef0-94f6-a1fbe41c6fd7"
      unitRef="U_USD">25000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_a40fe316-3a4c-45cf-a412-d4ebc66d9819"
      decimals="-3"
      id="F_dffe4c30-2f57-4b19-97af-ed274527fdf3"
      unitRef="U_USD">25000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_0d186ce3-11b3-4bf0-afd5-6b860eabc151"
      decimals="-3"
      id="F_d188004a-984b-4db3-83be-e84df965edfd"
      unitRef="U_USD">6902000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_1ff5a749-c2ba-4edc-bdb2-0c4ac6845d10"
      unitRef="U_USD">6902000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_c3264d47-ea98-488c-addc-6cdd4c066842"
      decimals="-3"
      id="F_b268ce2c-1e85-44ea-8d20-00ce353ce432"
      unitRef="U_USD">412000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_4dd328b2-e009-40a7-afa9-eeb63f4c4773"
      decimals="-3"
      id="F_9716215b-948d-4dac-b33b-2e14adb69f26"
      unitRef="U_USD">412000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_a75f8163-8123-4c7b-8abf-018d61948b64"
      decimals="-3"
      id="F_5e12fe2a-e38a-40fb-b7a3-505eb340170c"
      unitRef="U_USD">3948000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_f5c01cc3-f4ac-4cac-b32c-b2eec7d32119"
      decimals="-3"
      id="F_65783fe8-1f0d-4364-afe5-73df559ef586"
      unitRef="U_USD">3948000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_b5a79c7f-92c4-4fca-aa5a-8390eb7d7186"
      decimals="-3"
      id="F_cba38198-3e99-45ca-9665-f3cc596bcdad"
      unitRef="U_USD">16000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_701daa93-ad26-4a44-8b06-338415e1f2ed"
      decimals="-3"
      id="F_0c19e343-50ae-436e-bf54-ba2254e42790"
      unitRef="U_USD">16000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_651c763b-11ca-4b66-a7a6-bbdd17189552"
      decimals="-3"
      id="F_159e39de-0198-4362-9da8-e4b74615439c"
      unitRef="U_USD">3964000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_3643e2ad-d20e-482f-b92d-71aace47a7e2"
      decimals="-3"
      id="F_e9532fd7-2b43-40fe-b9d1-c47706148997"
      unitRef="U_USD">412000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_56a25cbe-75b5-4eb1-93d7-479666065b80"
      unitRef="U_USD">4376000</us-gaap:MarketableSecurities>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-5"
      id="F_1068f3d0-9090-4ee7-b8e6-fe6dc5f18df9"
      unitRef="U_USD">100000</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-5"
      id="F_6760546c-a785-4096-9765-f3b410e694ad"
      unitRef="U_USD">100000</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="INF"
      id="F_b26cba1e-9958-461e-982b-b4dd5a0b84c1"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="INF"
      id="F_dcad8ceb-cafa-4683-9fac-d417c33ed3be"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:TradingSecuritiesDebtAmortizedCost
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-6"
      id="F_6d4f0609-2290-46ae-9849-08052f14d8ff"
      unitRef="U_USD">0</us-gaap:TradingSecuritiesDebtAmortizedCost>
    <us-gaap:TradingSecuritiesDebtAmortizedCost
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-5"
      id="F_ce1ae922-dd9f-4851-a7eb-b639b466ae7f"
      unitRef="U_USD">400000</us-gaap:TradingSecuritiesDebtAmortizedCost>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_917fbe6a-8e56-4432-aa82-fb1f28d4b201">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Major components of property and equipment are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Lives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture/Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software/Website&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization expense amounted to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_ff483b7e-0491-4eb0-9a3a-b01e146063b5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Major components of property and equipment are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Lives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture/Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software/Website&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_33ea8560-6aa0-4787-a29e-7ac5e23721b4"
      id="F_021155dd-eadd-451f-b373-8caa0b212b77">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_33ea8560-6aa0-4787-a29e-7ac5e23721b4"
      decimals="-3"
      id="F_08d6636c-4626-42a3-bef4-a77a49a56b9a"
      unitRef="U_USD">4402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6366083b-23db-422d-a18f-92b5b0481e03"
      decimals="-3"
      id="F_0692f37c-82e5-450d-81dc-40e1e5288365"
      unitRef="U_USD">4328000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_852485d6-ba04-474c-a47e-395518e87aea"
      id="F_b87bcfe2-0485-4ea5-9f88-cb55547d9b8c">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_852485d6-ba04-474c-a47e-395518e87aea"
      decimals="-3"
      id="F_966cd728-c815-455d-ad25-c47b0c182857"
      unitRef="U_USD">3063000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2c7472b4-63fb-4213-8963-db0f9caec040"
      decimals="-3"
      id="F_646fb59b-934a-4d4e-b4f9-5534bb3c77a8"
      unitRef="U_USD">2483000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_be58ec30-718f-49dc-9b0b-5da7ce7d3da6"
      id="F_ea37e1df-2769-402e-9e75-d59dbe34eb6c">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_be58ec30-718f-49dc-9b0b-5da7ce7d3da6"
      decimals="-3"
      id="F_8bcd407d-fcd7-4a64-b716-b7dacad30718"
      unitRef="U_USD">120000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9a653252-42fd-451f-b16d-80dfc3b20336"
      decimals="-3"
      id="F_6ef1c3fb-4fb4-408e-9749-28748d17720c"
      unitRef="U_USD">120000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_25de8810-47ca-4f3b-b23d-79bd1ccf287e"
      id="F_8b413717-df3f-4066-ad57-d64c03c3c7f6">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_25de8810-47ca-4f3b-b23d-79bd1ccf287e"
      decimals="-3"
      id="F_f35d5978-b195-4c00-88ad-b79810d458fd"
      unitRef="U_USD">38000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_192155e6-0c54-4184-b414-7318e5281259"
      decimals="-3"
      id="F_fe8ed69c-1fb1-4a03-a591-01c0c1959838"
      unitRef="U_USD">38000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_cbc0d91c-dbd6-448e-b866-78f51ebc5278"
      unitRef="U_USD">7623000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_2942373e-31b3-45d7-92ef-64b22c5029bf"
      unitRef="U_USD">6969000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_06f531c0-b279-42d9-bf4f-db76812e40f0"
      unitRef="U_USD">5174000</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_384de38f-eca7-48d7-86c1-b001658c40a0"
      unitRef="U_USD">4440000</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_638a04d5-a6ae-49eb-8d7a-46aaea9c4499"
      unitRef="U_USD">2449000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_9951e74f-1643-49fd-af12-723c2af9f735"
      unitRef="U_USD">2529000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-5"
      id="F_a6a35599-d9b1-4fc3-b63c-bba9b70adb36"
      unitRef="U_USD">700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-5"
      id="F_4b6cc794-04c9-4ec8-b899-a1f5d0d69bc8"
      unitRef="U_USD">700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_f56c4925-f3fb-4fb9-a8ad-6392f198886e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Intangible Assets, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Major components of intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.033%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.217%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.198%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.117%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.198%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Lives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_93e3078f-8d95-4815-8772-dedb12df7e8d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trademark costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_76c75a36-7343-4618-abb0-0a79d6e55a20;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Major components of intangible assets as of December 31, 2023, are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.65%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Lives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_cfc4d707-5861-482b-84d7-64104ba53727;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trademark costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b8f1c0ca-aab8-4e72-a961-0a1daf3f73fb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amortization expense related to intangible assets amounted to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023. During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company wrote-off $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, of abandoned patents that it was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;no longe&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;r pursuing in several jurisdictions.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future amortization expense for intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 is approximately as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:25.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_d72de460-4a0b-4c62-ac98-6652f0171c1c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Major components of intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.033%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.217%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.198%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.117%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.198%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Lives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_93e3078f-8d95-4815-8772-dedb12df7e8d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trademark costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_76c75a36-7343-4618-abb0-0a79d6e55a20;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Major components of intangible assets as of December 31, 2023, are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.65%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.902000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Lives&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Patent costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_cfc4d707-5861-482b-84d7-64104ba53727;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trademark costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_b8f1c0ca-aab8-4e72-a961-0a1daf3f73fb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_d061083c-5970-4784-a095-643917174816"
      id="F_4304ac38-1f54-4b90-badb-ff677ad3b4e2">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_d061083c-5970-4784-a095-643917174816"
      decimals="-3"
      id="F_a556f5f1-dff6-45ae-a88d-a5cb081d9a39"
      unitRef="U_USD">2043000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_d061083c-5970-4784-a095-643917174816"
      decimals="-3"
      id="F_3e0224ac-ab49-4953-93c6-07d32f4deb54"
      unitRef="U_USD">1132000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_d061083c-5970-4784-a095-643917174816"
      decimals="-3"
      id="F_be87b54a-706c-4012-987c-fc3c4dad9371"
      unitRef="U_USD">911000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_cdfee0ba-2fda-4acb-bf1e-85d83d8ae89f"
      decimals="-3"
      id="F_0dda6a77-8f11-46a7-9ec2-36b5e52a00a7"
      unitRef="U_USD">1273000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_cdfee0ba-2fda-4acb-bf1e-85d83d8ae89f"
      decimals="-3"
      id="F_6534939a-4c9b-4150-974f-dbf2f4c544d3"
      unitRef="U_USD">1273000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_3d0dcccf-31cc-483e-b3d8-b27e06e3534a"
      decimals="-3"
      id="F_3937b6da-8783-4f51-b90e-7090c8a5e13b"
      unitRef="U_USD">217000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_3d0dcccf-31cc-483e-b3d8-b27e06e3534a"
      decimals="-3"
      id="F_ac9c0a31-9669-4a1f-bc7e-e2728aa37844"
      unitRef="U_USD">217000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_58be5789-6730-4295-953c-35ff185a7a41"
      unitRef="U_USD">3533000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_54236db3-a517-4eca-a409-64c2dd8dd8b3"
      unitRef="U_USD">1132000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_9e9280a7-efc5-4dd2-a50b-67a7621f644d"
      unitRef="U_USD">2401000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_e32174f8-44a9-4669-8a00-c469ea7d76ef"
      id="F_92199f0a-3130-4748-bb8c-51b6987842d7">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_e32174f8-44a9-4669-8a00-c469ea7d76ef"
      decimals="-3"
      id="F_28f76a24-2e1b-46ef-8365-f54602ac007e"
      unitRef="U_USD">2043000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_e32174f8-44a9-4669-8a00-c469ea7d76ef"
      decimals="-3"
      id="F_477a654d-817d-4e0b-85f7-342ab32e57c1"
      unitRef="U_USD">909000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_e32174f8-44a9-4669-8a00-c469ea7d76ef"
      decimals="-3"
      id="F_584664ca-dce8-415c-8b73-2fdbe3749101"
      unitRef="U_USD">1134000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_b35ec15a-1d7a-48da-bb29-ded77d1dd6e0"
      decimals="-3"
      id="F_25512b3b-af9f-43ac-bde1-754ec15e982c"
      unitRef="U_USD">959000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_b35ec15a-1d7a-48da-bb29-ded77d1dd6e0"
      decimals="-3"
      id="F_5077571e-e4d2-47ab-8f06-d3120fb786b4"
      unitRef="U_USD">959000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_c92a5e48-5a59-41b6-85ff-8ee27a7ded47"
      decimals="-3"
      id="F_3ffe80d8-f773-40a8-9b23-4f88d5f4ce22"
      unitRef="U_USD">194000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_c92a5e48-5a59-41b6-85ff-8ee27a7ded47"
      decimals="-3"
      id="F_dba1fe3d-c229-4598-9413-a4e41fc0b37d"
      unitRef="U_USD">194000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_c1ba7562-fc3e-48dd-942b-6f8c9b308b67"
      unitRef="U_USD">3196000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_4db9349b-1c1a-4c3c-a8de-05500a760f9a"
      unitRef="U_USD">909000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_67426e55-937a-4bd5-b14c-b341aaa09562"
      unitRef="U_USD">2287000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-5"
      id="F_664990c3-9a0b-417a-ad7a-f565a1e0e22a"
      unitRef="U_USD">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-5"
      id="F_7723a499-bdc8-4164-a746-3e9a2f3798a6"
      unitRef="U_USD">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_427d1b69-1c7f-4694-805f-39f18674b82e"
      decimals="-6"
      id="F_377b97cf-e9bd-49c5-86b2-211997c68d96"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_72fb5ee4-e997-41b0-a33d-75e6db840ad0"
      decimals="-5"
      id="F_e9504264-8fe6-4faa-b13a-a36df33344df"
      unitRef="U_USD">300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <lgvn:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="C_427d1b69-1c7f-4694-805f-39f18674b82e"
      id="F_0194928b-be57-45cc-bbc4-d45852f0bd0e">true</lgvn:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <lgvn:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="C_72fb5ee4-e997-41b0-a33d-75e6db840ad0"
      id="F_3babea3c-3bd8-4f91-86fb-59e0b397ca86">true</lgvn:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_9bca829b-76b2-4f69-80d7-71ec10a03683">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future amortization expense for intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 is approximately as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:25.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_843cca95-c0a9-497e-8788-d2316a031d4c"
      unitRef="U_USD">224000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_7fb50818-ce2a-40a3-bec5-8b0120e1ceee"
      unitRef="U_USD">102000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_afc4de5b-894e-498a-9f50-9b8a46fbf1e8"
      unitRef="U_USD">61000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_2ee1b43e-a876-424e-8974-9ae3214d90dc"
      unitRef="U_USD">61000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_256208d9-a1c7-4ebb-a5ec-0bdc157ac157"
      unitRef="U_USD">61000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_3e6f2680-f137-4cf9-9291-5c154cfcebd6"
      unitRef="U_USD">402000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_4b71a32d-dc95-4603-b673-e71ef33b6e1a"
      unitRef="U_USD">911000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_0b282529-1ad3-445e-aaf2-cbcaff802f83">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records a right-of-use operating lease asset and a lease liability related to its operating leases (there are no finance leases). The Company&#x2019;s corporate office lease expires in March 2027. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the operating lease asset and operating lease liability were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the operating lease asset and operating lease liability were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum payments under the operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less interest (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% discount rate)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company incurred approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, of total lease costs that are included in the general and administrative expenses in the statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e584071b-f7ae-411b-be56-e2130dbedae5"
      decimals="-5"
      id="F_acddd209-1ad1-4942-8207-ff1fc65db4ab"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e584071b-f7ae-411b-be56-e2130dbedae5"
      decimals="-5"
      id="F_66ba4011-3149-494a-8e3d-ca0f0ac9b06d"
      unitRef="U_USD">1400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_39a27885-81f0-4ba6-9f1c-ee208299badf"
      decimals="-5"
      id="F_94afdca4-061a-4b79-8dbf-cfdd06c2b613"
      unitRef="U_USD">1200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_39a27885-81f0-4ba6-9f1c-ee208299badf"
      decimals="-5"
      id="F_939164de-f414-4c2b-92b2-6b04ff3c6391"
      unitRef="U_USD">2000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_50600459-2912-432a-abd2-c13cd8be6448">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum payments under the operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less interest (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;% discount rate)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_ae6f81f5-19fa-493c-aae5-ac9e0a9da60c"
      unitRef="U_USD">682000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_3d2c42d3-9515-495f-b3a0-f585748827b1"
      unitRef="U_USD">682000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_d5a184ed-8b79-48c4-becc-a06d14d4e2bb"
      unitRef="U_USD">169000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_39e38a3f-eb26-4e5e-ad19-fd5cc9fe2208"
      unitRef="U_USD">1533000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="2"
      id="F_0ee5c9bb-7367-4122-a6a9-51460a52ba63"
      unitRef="U_pure">0.05</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_911a21c9-b6f3-4221-adb9-9f2a19c3d1db"
      unitRef="U_USD">86000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_ee4e5f67-93c2-4e67-bb32-5b27d47f9def"
      unitRef="U_USD">1447000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCost
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-5"
      id="F_97fb450e-5f27-4f62-9f38-f3ec32609140"
      unitRef="U_USD">800000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="-5"
      id="F_7ebc5636-894a-4d04-9290-057a65a0a96d"
      unitRef="U_USD">900000</us-gaap:LeaseCost>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_54014ccb-3f79-47aa-a573-ca0e80661778">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Class A and Class B Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Holders of Class A common stock generally have rights identical to holders of Class B common stock, except that holders of Class A common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vote per share and holders of Class B common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (5) votes per share. The holders of Class B common stock may convert each share of Class B common stock into one share of Class A common stock at any time at the holder&#x2019;s option. Class B common stock is not publicly tradable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, stockholders exchanged &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,555&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class B common stock for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,555&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock. During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, stockholders exchanged &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,555&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class B common stock for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,555&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Summary of Warrant Issuances&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;), the underwriter received warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,640&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock. The warrants are exercisable at any time and from time to time, in whole or in part, during the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_80fc046b-9fe3-4c96-90ec-96afcbbbd494;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four and a half-year period&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; commencing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;August 12, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and the fair value of warrants was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. During 2021, the underwriters assigned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,576&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the warrants to its employees.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of the Company&#x2019;s 2021 private placement offering, the Company issued warrants to investors to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,935&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, equal to the number of shares of Class A common stock purchased by such investor in the offering, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share , which were immediately exercisable, were set to expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of issuance, and had certain downward pricing adjustment mechanisms, subject to a floor, as set forth in greater detail therein (the &#x201c;Purchaser Warrants&#x201d;). In addition, the Company granted the underwriters warrants, under similar terms, to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,679&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. On August 16, 2023, the Company announced its Stock Rights Offering, which triggered the downward pricing mechanism on the Purchaser Warrants, at which time these warrants were adjusted downward to an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the period remaining through expiration. This resulted in a deemed dividend to common stockholders of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the change in the fair value of the warrants using a Black-Scholes pricing model.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 15, 2021, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-261667) registering the resale of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,535&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, including (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,935&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issued to purchasers in the Company&#x2019;s 2021 private placement offering; (ii) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;116,935&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon exercise of the Purchaser Warrants; and (iii)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,679&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon exercise of the underwriters warrants issued as part of the 2021 private placement offering. The Form S-1 was declared effective by the SEC on December 22, 2021.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of an October 2023 registered direct offering, the Company issued Series A warrants and Series B warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;242,425&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;242,425&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, shares of Class A common stock. Each series of warrants had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, with the Series A warrants having a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_428f7fa2-6f69-4ce1-97cd-53b8e1f3b7a5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five and one-half (5.5) years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of issuance, and the Series B warrants having a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d317f701-e4a6-46de-af03-196205d6c7fb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;eighteen (18) months&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of issuance. Both the Series A and Series B warrants became exercisable as of December 26, 2023, following stockholder approval. In addition, the Company granted the placement agent warrants, under similar terms, to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,971&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.625&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 15, 2023, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-275578) registering the resale of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;501,821&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, including (i) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;242,425&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of issuable upon exercise of the Series A Warrants; (ii) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;242,425&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon exercise of the Series B Warrants; and (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,971&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon exercise of warrants granted to the placement agent as part of the October 2023 registered direct offering. The Form S-1 was declared effective by the SEC on November 21, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2024, the Series A Warrants and Series B Warrants were amended to reduce the exercise price to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The Series A Warrants and Series B Warrants were subsequently exercised in full in April 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of a December 2023 registered direct offering, the Company issued warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,531&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock. These warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, became immediately issuable upon issuance, and expire on June 22, 2029. In addition, the Company granted the placement agent warrants, under similar terms, to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,489&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.813&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 29, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-276745) registering the resale of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,020&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, including (i) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,531&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon the exercise of warrants issued in a concurrent private placement in connection with the December 2023 registered direct offering and (ii) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,489&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon the exercise of warrants granted to the placement agent in connection with the December 2023 registered direct offering. The Form S-1 was subsequently amended by the Company on April 16, 2024 and declared effective by the SEC on April 17, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 8, 2024, the Company commenced a public offering of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;639,872&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s Class A common stock, along with pre-funded warrants to purchase up to an aggregate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,572,894&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock (the &#x201c;Pre-Funded Warrants&#x201d;). The shares and Pre-Funded Warrants were sold together with warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,212,766&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Common Stock (the &#x201c;Common Warrants&#x201d;). The combined public offering price was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and related Common Warrant and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.349&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per Pre-Funded Warrant and related Common Warrant. Subject to certain limitations, the Pre-Funded Warrants were immediately exercisable and could be exercised at a nominal consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share of Class A common stock at any time until all of the Pre-Funded Warrants were exercised in full. The Common Warrants were immediately exercisable and expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 10, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As compensation to the placement agent the Company also issued to designees of the placement agent warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,894&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, which had substantially the same terms as the Common Warrants, and with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the commencement of sales in the offering.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the offering, the Company also entered into an agreement with a holder of existing warrants to amend the holder&#x2019;s existing Series A warrants and Series B warrants to reduce the exercise price to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and (ii) amend the expiration date of the Series A Warrants to five and one-half (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) years following the closing of the public offering and the Series B warrants to eighteen (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) months following the closing of the public offering, in each case for a payment to the Company of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per amended warrant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 16, 2024, the Company entered into inducement letter agreements with certain holders of its existing Series A warrants and Series B warrants, and Common Warrants issued on April 10, 2024, whereby the holders agreed to exercise the warrants for cash at the exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share in consideration for payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per new warrant and for the Company&#x2019;s agreement to issue new unregistered Class A common stock warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,799,488&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, and which were immediately exercisable upon issuance. The warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,399,744&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock (the &#x201c;Series C Warrants&#x201d;) have a term of five (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) years from the issuance date, and the warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,399,744&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock (the &#x201c;Series D Warrants&#x201d;) have a term of twenty-four (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;months from the issuance date, with all of the Series C Warrants and Series D Warrants being immediately exercisable. All&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Series D Warrants were exercised in June 2024, pursuant to ordinary course exercise as well as a subsequent inducement transaction.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, the Company issued to the placement agent or its designees as compensation, warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,982&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the inducement transaction, which had the same terms as the Series C Warrants, except that the placement agent warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Furthermore, upon exercise, if any, of the Series D Warrants for cash, the Company agreed to issue the placement agent or its designees, within five (5) business days of the Company&#x2019;s receipt of the exercise price, warrants to purchase the number of shares of Class A common stock equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate number of shares underlying such Series D Warrants that have been exercised, with such warrants to be in the same form and terms as the prior placement agent warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 18, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-278995) registering the resale of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,967,470&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,399,744&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon the exercise of the Series C Warrants issued in the April 2024 warrant inducement transaction; (ii) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,399,744&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon the exercise of the Series D Warrants issued in the April 2024 warrant inducement transaction; and (iii) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,982&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon exercise of the warrants issued to the placement agent or its designees in the April 2024 warrant inducement transaction. The Form S-1 was subsequently amended by the Company and declared effective by the SEC on May 21, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 17, 2024, the Company entered into additional inducement letter agreements with the holders of its existing Series D Warrants to exercise the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,697,891&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock underlying Series D Warrants that remained outstanding for cash at the exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share in consideration for the Company&#x2019;s agreement to issue new unregistered Class A common stock warrants (the "June Inducement Warrants"), for payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per new warrant, to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,395,782&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and which were immediately exercisable upon issuance and have a term of twenty-four (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) months from the issuance date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also issued to the placement agent or its designees as compensation, (i) warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,852&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate number of shares of Class A common stock issued upon exercise of the warrants pursuant to the June inducement transaction and (ii) warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Common Stock, equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate number of shares of Common Stock issued upon exercise of certain Series D warrants prior to the inducement transaction, which had substantially the same terms as the June Inducement Warrants, except that the warrants exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,852&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and the warrants exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively (collectively, the "June placement agent warrants").&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon exercise, if any, of the June Inducement Warrants for cash, the Company agreed to issue within five (5) business days to the placement agent or its designees, warrants to purchase the number of shares of Class A common stock equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate number of shares of Class A common stock underlying such June Inducement Warrants that have been exercised, with such warrants to be in the same form and terms as the June placement agent warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The issuance under the inducement offers represented $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders. The June Inducement Warrants expire on June 18, 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On June 28, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-280577) registering the resale of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,563,764&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock issuable upon exercise of certain warrants, including (i) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,395,782&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon the exercise of the June Inducement Warrants and (ii) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,982&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issuable upon the exercise of the June placement agent warrants. The Form S-1 was subsequently declared effective by the SEC on July 9, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 10, 2024, a holder exercised Series C warrants for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock for cash (the &#x201c;July Series C warrant exercise&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 10, 2024, certain holders of warrants issued in June of 2024 exercised warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock for cash (the &#x201c;July 10 warrant exercise&#x201d;). In addition, on July 17, 2024, the Company issued to the placement agent warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate number of shares of Class A common stock issued in the July 10 warrant exercise (the &#x201c;first tranche July ordinary course placement agent warrants&#x201d;). The first tranche July ordinary course placement agent warrants have substantially the same terms as the June placement agent warrants, except that the first tranche July ordinary course placement agent warrants (i) have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and (ii) expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 17, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 17, 2024, a holder of the June Inducement Warrants exercised the same to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,319,186&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock for cash (the &#x201c;July 17 warrant exercise&#x201d; and together with the July 10 warrant exercise&lt;/span&gt;&lt;span style="color:#008080;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and the July Series C warrant exercise,&lt;/span&gt;&lt;span style="color:#008080;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;collectively, the &#x201c;July warrant exercises&#x201d;). Accordingly, on July 24, 2024, the Company issued to the placement agent warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,344&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate number of shares of Class A common stock issued in the July 17 warrant exercise (the &#x201c;second tranche July ordinary course placement agent warrants&#x201d;, and together with the first tranche July ordinary course placement agent warrants, the &#x201c;July ordinary course placement agent warrants&#x201d;, and collectively with the July offering placement agent warrants, the &#x201c;July placement agent warrants&#x201d;). The second tranche July ordinary course placement agent warrants have substantially the same terms as the first tranche July ordinary course placement agent warrants, except that the second tranche July ordinary course placement agent warrants expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 24, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The gross proceeds to the Company from the July warrant exercises, inclusive of the payment consideration for such Series C warrants and June Inducement Warrants, were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, inclusive of the payment consideration for such warrants, before deducting placement agent fees payable by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 18, 2024, the Company entered into a securities purchase agreement with institutional and accredited investors relating to the registered direct offering and sale of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,236,026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our Class A common stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share of Class A common stock and associated warrant (the &#x201c;July registered direct offering&#x201d;). The securities issued in the July registered direct offering were offered pursuant to a prospectus supplement, dated July 18, 2024, and accompanying prospectus, in connection with a takedown from our shelf registration statement on Form S-3 (File No. 333-264142), which was declared effective by the SEC on April 14, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In a concurrent private placement (the &#x201c;July private placement&#x201d; and together with the July registered direct offering, the &#x201c;July offering&#x201d;), the Company also sold unregistered Class A common stock warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,236,026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our Class A common stock (the &#x201c;July private placement warrants&#x201d;). The unregistered July private placement warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, became exercisable on July 19, 2024, and expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 20, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In addition, the Company granted the placement agent warrants, under similar terms, to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,522&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0313&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;July offering placement agent warrants&#x201d;). The gross proceeds to the Company from the July offering were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting placement agent fees and other offering expenses payable by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 6, 2024, the Company filed a registration statement with the SEC on Form S-1 (File No. 333-281299) registering the resale of an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,565,392&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock issuable upon exercise of certain warrants, of which (i) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,236,026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares are issuable upon the exercise of the July private placement warrants issued to the purchasers upon the closing of the July private placement; (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,522&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares are issuable upon exercise of the July offering placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of the current engagement Letter with Wainwright; and (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172,844&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares are issuable upon exercise of the July ordinary course placement agent warrants issued to Wainwright, or its designees, pursuant to the terms of a then-applicable engagement letter with Wainwright, in connection with previously exercised June Inducement Warrants. The Form S-1 was declared effective by the SEC on August 12, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2024, the Company entered into additional inducement letter agreements with certain holders of its existing Purchaser Warrants issued as part of the Company&#x2019;s 2021 private placement offering to amend and reduce the exercise price of the Purchaser Warrants to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share in consideration for the holders&#x2019; cash exercise of all Purchaser Warrants held by such holder on or before September 27, 2024. In connection with the September 2024 inducement transaction, Purchaser Warrants were exercised for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,077&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, resulting in gross proceeds to the Company of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,077&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2024, the Company entered into additional inducement letter agreements with the remaining holders of its existing Purchaser Warrants issued as part of the Company&#x2019;s 2021 private placement offering to amend and reduce the exercise price of the Purchaser Warrants to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share in consideration for the holders&#x2019; cash exercise of all Purchaser Warrants held by such holder. In connection with the October 2024 inducement transaction, Purchaser Warrants were exercised for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,858&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock, resulting in gross proceeds to the Company of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,858&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Purchaser Warrants have been exercised in full.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Summary of Warrants Outstanding&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, warrants exercisable for an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,802,668&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s Class A common stock remain outstanding. This includes:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IPO underwriter warrants exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,536&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;February 12, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Underwriter warrants issued in connection with the 2021 private placement offering exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,679&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 1, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Placement agent warrants issued in connection with the October 2023 registered direct offering exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,971&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.625&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 11, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investor warrants issued in connection with the December 2023 registered direct offering exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,531&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 22, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Placement agent warrants issued in connection with the December 2023 registered direct offering exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,489&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.813&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 20, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Warrants issued in connection with the April 2024 public offering exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;297,872&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 10, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Placement agent warrants issued in connection with the April 2024 public offering exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,894&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 8, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Series C Warrants issued in connection with the April 2024 inducement transaction exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,349,744&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 18, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Placement agent warrants issued in connection with the April 2024 inducement transaction exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,982&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 18, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June placement agent warrants issued in the ordinary course prior to the June 2024 inducement transaction exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 18, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June Inducement Warrants exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;926,596&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 18, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Placement agent warrants issued in connection with the June 2024 inducement transaction exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,852&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 18, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;First tranche July ordinary course placement agent warrants exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 17, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Second tranche July ordinary course placement agent warrants exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,344&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 24, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July private placement warrants exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,236,026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 20, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July offering placement agent warrants exercisable for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,522&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0313&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, which expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;July 20, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701"
      id="F_e8b1ead3-4f81-4b75-b86b-e82d53c530c2">one</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockVotingRights
      contextRef="C_d1dbc3f6-3e73-4cc4-a7c7-bc22662d8467"
      id="F_1c1856ba-0e39-4919-930e-37e0b3b2f43d">five</us-gaap:CommonStockVotingRights>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_69d91da2-7bca-4bff-9cb8-c9cfd3c244e7"
      decimals="INF"
      id="F_dd416ecc-d416-4f02-bf80-dccb66a60fec"
      unitRef="U_shares">-1555</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_97d5f78e-ff73-4686-9599-d8a719ba798c"
      decimals="INF"
      id="F_e862b149-e2c7-4b67-8db1-7386f495f84d"
      unitRef="U_shares">1555</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_40dda296-3d9d-40bb-bc61-02fd395bf0f7"
      decimals="0"
      id="F_b2a54ba6-1176-404b-90a9-1191dd32e9e7"
      unitRef="U_shares">-3555</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_7dc4f84c-8059-4df0-9eab-ce1957519154"
      decimals="0"
      id="F_a1cf8ab4-7071-4c36-98c4-b4cb9606215e"
      unitRef="U_shares">3555</us-gaap:ConversionOfStockSharesConverted1>
    <lgvn:WarrantsToPurchase
      contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701"
      decimals="INF"
      id="F_19a65127-8cfb-4de0-bde7-6af84493ef51"
      unitRef="U_shares">10640</lgvn:WarrantsToPurchase>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701"
      id="F_8e1b5ec8-5ab9-4144-b026-da05d9a26d8c">2021-08-12</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b9192f71-3161-4b98-9cf0-b50270b7d523"
      decimals="2"
      id="F_1ec07b62-5a2a-43fc-ab58-474c2b4c13bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">120</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_bdba25ca-ce76-451a-a79b-72c6a6a68dbe"
      decimals="-5"
      id="F_6068a0bc-1987-4298-b3e9-73714fc05e1f"
      unitRef="U_USD">500000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_4ba85633-032f-48ff-b8fd-3307bf64c707"
      decimals="INF"
      id="F_bb3ae21f-2555-404e-aa0f-72667ae2cfd0"
      unitRef="U_shares">9576</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2196011d-eb59-453d-922a-463609b50727"
      decimals="INF"
      id="F_3c68eef6-5cb8-4123-89e3-7c2332feee8b"
      unitRef="U_shares">116935</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f3787016-d57b-41d8-93d0-083f687dccac"
      decimals="2"
      id="F_c376e98c-eff0-47bd-94cd-7e4a6f3f74c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">175</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_e7b06b06-de62-4546-8211-520778c26862"
      id="F_b0ee1c09-5b05-4b30-b9f4-4f2b19f9059a">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_f3787016-d57b-41d8-93d0-083f687dccac"
      decimals="INF"
      id="F_e860cdd7-6311-4169-901c-1125bb11efa5"
      unitRef="U_shares">4679</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f3787016-d57b-41d8-93d0-083f687dccac"
      decimals="2"
      id="F_3c1507aa-b130-40c8-a4ff-1ff67f366786"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">175</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_8bd66a75-3699-4e56-8cd2-f92fabc91f0a"
      decimals="2"
      id="F_8fc19caa-0780-4ebc-bbf2-f752a08ec5c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">52.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_5cc56a11-ee4f-45a8-8b30-e4604e7cc25f"
      decimals="-5"
      id="F_dcd4ebc1-0049-45a4-a199-3f0a14edd939"
      unitRef="U_USD">800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_8a695d29-400b-42bb-81da-34af6591dda8"
      decimals="INF"
      id="F_a1ade4af-c12c-453d-b293-a6c62ef13ae5"
      unitRef="U_shares">238535</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_af1e0bf2-f9b3-4719-89f9-f37749bdfb82"
      decimals="INF"
      id="F_b44dc0ef-fe0f-4902-9e0a-9d5f4d931db9"
      unitRef="U_shares">116935</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_27694a1f-8536-4e3a-90cb-ee31e0d92d39"
      decimals="INF"
      id="F_64b80d7d-d256-480b-ace6-78aa6bcc67e8"
      unitRef="U_shares">116935</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_09e3c48c-8324-4e5f-b8ba-e37b4bea78af"
      decimals="INF"
      id="F_9a5ac33d-1e7f-48da-a3f6-0cc90fe0e454"
      unitRef="U_shares">4679</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_800ca5b3-19a9-469b-ad8c-765f4cf802f8"
      decimals="INF"
      id="F_10397a1f-d5e6-4229-b879-2a359ad9edec"
      unitRef="U_shares">242425</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_8fb325dd-2a4c-427e-b457-7d9e26d11251"
      decimals="INF"
      id="F_87597c0b-5336-4e34-84a4-df8b4669a971"
      unitRef="U_shares">242425</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_800ca5b3-19a9-469b-ad8c-765f4cf802f8"
      decimals="2"
      id="F_1315b97b-6502-4e2a-a77e-f61a6b28b92d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ac1c02ac-9c7a-4aa5-b23c-caf1a6d79afb"
      decimals="INF"
      id="F_0e9a4a8f-5154-47f8-ba33-26a449b4f532"
      unitRef="U_shares">16971</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1ef16fb7-28d8-4b6f-b55c-d02b22740228"
      decimals="3"
      id="F_2b79f47b-5e92-4ca8-9c3e-091c235e470a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_3cf0423a-d017-4bc5-a03a-6a1be7ecd8b6"
      decimals="INF"
      id="F_72fffb8a-6437-47d6-b303-46c6f73dab12"
      unitRef="U_shares">501821</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_885350a8-cf29-4eb2-a100-dd267e1f76ed"
      decimals="INF"
      id="F_88dd080d-44cc-4d09-ab01-0a9b71c778a2"
      unitRef="U_shares">242425</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_5c5570fa-1707-4ec0-bdd8-26e9735b80d7"
      decimals="INF"
      id="F_24d8028f-d2f7-49e4-8c1a-8f36d0489377"
      unitRef="U_shares">242425</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_cee66114-9a5c-4865-9e37-ed6c8eea4537"
      decimals="INF"
      id="F_2a65290a-78f6-4de2-9352-2bb9d7044c1c"
      unitRef="U_shares">16971</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_375c44e5-dc70-4557-aa86-d4d7438ddb81"
      decimals="2"
      id="F_5debf6bb-56d9-4861-b9af-e4272c291ceb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_9dcd6c86-0172-4023-b693-3ddef2e87823"
      decimals="INF"
      id="F_d6b27dcc-56a6-4c26-8184-53cdf99419ed"
      unitRef="U_shares">135531</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9dcd6c86-0172-4023-b693-3ddef2e87823"
      decimals="2"
      id="F_cc49d6db-59bb-483b-ac52-46863578112f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_31c839fd-7132-4e3c-bef4-2e938e7520cc"
      decimals="INF"
      id="F_8f748efb-572f-45b2-907c-edc0b24f5613"
      unitRef="U_shares">9489</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_31c839fd-7132-4e3c-bef4-2e938e7520cc"
      decimals="3"
      id="F_687b7131-da4b-45f0-b94f-cd3b8765f76e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.813</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_2d460a19-5b01-4993-8a57-12e7d78c57f5"
      decimals="INF"
      id="F_83dd8c61-9bcc-437d-9594-81d31c4ee91d"
      unitRef="U_shares">145020</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_7534eddc-bba5-4cf0-ba3e-08178e69ed62"
      decimals="INF"
      id="F_d24a701f-d71b-4835-aee2-00ddb3a79798"
      unitRef="U_shares">135531</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ac41fb9d-662d-4175-a25e-3ade70bb7db8"
      decimals="INF"
      id="F_a30e8ffd-5638-47f3-b2c5-74d4a2d2be60"
      unitRef="U_shares">9489</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_17a45533-4b30-4885-b609-d19b1db34a37"
      decimals="INF"
      id="F_27ecb787-316e-45a8-b4c3-c705758725cd"
      unitRef="U_shares">639872</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_4d1774b7-d786-4c83-9da6-6f4a21fa76cb"
      decimals="INF"
      id="F_46d94874-8736-4a67-a339-3945fd0a9e33"
      unitRef="U_shares">1572894</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d68599d9-47e2-4ece-8323-0052aa98f47b"
      decimals="INF"
      id="F_07828cb9-e41a-422f-83b8-7fb6156cc3f0"
      unitRef="U_shares">2212766</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c984fb4f-1fdc-4b32-b577-b0d95a9c9e4a"
      decimals="2"
      id="F_704025c3-5f7a-455e-af07-f1775493a821"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e4cfce79-c2b0-4ca4-8408-3fc1d9f375ff"
      decimals="INF"
      id="F_cd05d98e-cc76-49a5-9e74-e73952649e2b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.349</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4d1774b7-d786-4c83-9da6-6f4a21fa76cb"
      decimals="3"
      id="F_d2309a1c-2d24-4d46-84c3-4853d7e52c7f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_44e4401f-ab33-46f4-a549-74a0489db4c1"
      id="F_757f9551-59f4-488d-9dfa-b2298e979316">2029-04-10</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"
      decimals="INF"
      id="F_8a5e0887-7cf9-4e88-b0df-4174443d7538"
      unitRef="U_shares">154894</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9aa77719-3220-42ff-b34d-4e36497e3a08"
      decimals="4"
      id="F_799b49e8-f5ca-47d9-a3c2-614e234015d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.9375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_c984fb4f-1fdc-4b32-b577-b0d95a9c9e4a"
      id="F_9607042c-a860-46f8-9dbf-eb6551c7666b">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_375c44e5-dc70-4557-aa86-d4d7438ddb81"
      decimals="2"
      id="F_75f9dc4d-24de-47d5-9141-b66996f31a8c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_1a1782e7-88b3-418e-978c-52f25f9bd58c"
      id="F_6354c5c3-fe3a-4216-b521-e2bcf98c2b11">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_906ca24e-44d3-40ab-b91a-b4250b408e3c"
      id="F_e536e70b-d1fa-4562-8952-b4950a63f736">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <lgvn:PaymentPerWarrant
      contextRef="C_cdc2df3b-5c8c-44c7-a3c8-e65d385a5523"
      decimals="3"
      id="F_64b037bd-8b51-4f13-97d5-e2fd77a2c5b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.125</lgvn:PaymentPerWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6f844770-8d63-4c0a-b0d4-165e7185f787"
      decimals="2"
      id="F_3f344092-5491-4d1a-a3fe-0a3629de17ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lgvn:PaymentPerWarrant
      contextRef="C_5e7f8a23-cf6b-4aa9-b4bd-dc4e77beffe6"
      decimals="3"
      id="F_0ae0a784-237f-40a8-b442-b0bf305bceb4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.125</lgvn:PaymentPerWarrant>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_268ad250-3034-4601-a1f3-6fe024bad788"
      decimals="INF"
      id="F_35bb9ca5-e21f-4d54-a682-3311491afcec"
      unitRef="U_shares">4799488</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_268ad250-3034-4601-a1f3-6fe024bad788"
      decimals="2"
      id="F_3ff09274-e591-41d2-8cec-3d5bf475a1d7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_724dcd9a-d231-46d1-a3ea-7d375a83a614"
      decimals="INF"
      id="F_5c851637-0cc9-4243-9ac9-3b8a3a301517"
      unitRef="U_shares">2399744</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_7707aae5-ac5b-4ae5-9938-ac6e3ea965d6"
      id="F_f2eee12d-010c-4a71-9bf6-266df4241803">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_e6f0b313-1ad4-4509-b95a-760e3a3d6430"
      decimals="INF"
      id="F_e0bdf1d9-4413-4df1-aaf3-25ee9cc72cc7"
      unitRef="U_shares">2399744</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_329d5c2e-7887-4b19-bf7f-646f3efde941"
      id="F_de9927bd-0eca-4830-8259-2dd006fb2bfc">P24M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_682a89cb-47a9-46e1-bdd9-3cd1abe13dd7"
      decimals="INF"
      id="F_75c81eab-409f-4373-a30b-28018495ed82"
      unitRef="U_shares">167982</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <lgvn:PercentageOfAggregateNumberOfShares
      contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701"
      decimals="3"
      id="F_0bcca1c7-d808-4936-a04d-932a85ad5786"
      unitRef="U_pure">0.07</lgvn:PercentageOfAggregateNumberOfShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_134d5e58-28b4-43ed-938b-934bfff4116f"
      decimals="2"
      id="F_044a9476-38c7-462b-9837-9a81ea21577c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lgvn:PercentageOfAggregateNumberOfShares
      contextRef="C_f8a92122-f474-4b31-b2b6-a0fe54800397"
      decimals="3"
      id="F_18bab890-8c46-4c46-9ccb-55a57d8c490d"
      unitRef="U_pure">0.07</lgvn:PercentageOfAggregateNumberOfShares>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_58e4471a-d2f1-4ec9-b6a9-d4b9eae6b4e6"
      decimals="INF"
      id="F_95e4e659-63e3-4c03-bcc6-a6e840e6e193"
      unitRef="U_shares">4967470</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b5cc0db4-91de-465c-bb48-5b53ca7e01b1"
      decimals="INF"
      id="F_6d54b840-2a83-4de3-baec-4687ad1d1fa2"
      unitRef="U_shares">2399744</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_5b5ba2d7-308e-4e38-ba50-2a15b6d0f5ec"
      decimals="INF"
      id="F_39866d1e-c056-4de6-8a06-96dabf34edc0"
      unitRef="U_shares">2399744</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_31d229d0-f489-478a-b8c4-7a980e71248a"
      decimals="INF"
      id="F_97b80500-1375-4303-b189-adaa37c771f1"
      unitRef="U_shares">167982</us-gaap:ClassOfWarrantOrRightOutstanding>
    <lgvn:ExerciseOfRemainingShares
      contextRef="C_8561f2ca-4d1a-475a-bc19-fcface1b15dc"
      decimals="INF"
      id="F_f65165b5-377b-4281-83bc-21dd39e8884e"
      unitRef="U_shares">1697891</lgvn:ExerciseOfRemainingShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_aa3f1212-2350-4425-9290-9e78374aa7c6"
      decimals="2"
      id="F_2b6fad1a-05f3-401d-8a05-726f1865f2b9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lgvn:PaymentPerWarrant
      contextRef="C_c28d2aec-e976-4127-9697-03bb7896c0e0"
      decimals="3"
      id="F_745a8a72-ec17-4e1a-bbc5-d7270c8d7013"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.125</lgvn:PaymentPerWarrant>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_a5b385af-6f58-47c5-83db-6be10bedcad9"
      decimals="INF"
      id="F_3f845ca0-757f-458e-b447-17aa4f0a4172"
      unitRef="U_shares">3395782</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a5b385af-6f58-47c5-83db-6be10bedcad9"
      decimals="2"
      id="F_b2b4043c-12ea-4e10-8fcc-59ed773787c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_a5b385af-6f58-47c5-83db-6be10bedcad9"
      id="F_f1e7c6fb-39bb-4c36-9bd8-b74fb7e334f4">P24M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_b9192f71-3161-4b98-9cf0-b50270b7d523"
      decimals="INF"
      id="F_cd0f4f7b-9266-4059-b090-25adde8a3087"
      unitRef="U_shares">118852</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <lgvn:PercentageOfAggregateNumberOfShares
      contextRef="C_231d6559-39de-40e2-92ca-0ce4ccbeea1d"
      decimals="3"
      id="F_02641f47-fe09-42f0-ba07-1d7329799863"
      unitRef="U_pure">0.07</lgvn:PercentageOfAggregateNumberOfShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_fcc6b1eb-c243-4fbc-8e56-d5caa3a5c35e"
      decimals="INF"
      id="F_c2ecfcc6-288d-42bf-b623-7748dd53c851"
      unitRef="U_shares">49130</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <lgvn:PercentageOfAggregateNumberOfShares
      contextRef="C_7b2a701b-185b-46d8-a802-15cd82f62888"
      decimals="3"
      id="F_26fb2e61-8023-474b-8d5c-348636f40d0e"
      unitRef="U_pure">0.07</lgvn:PercentageOfAggregateNumberOfShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_236ea03d-46b1-4bac-973b-e724dd4cb6ce"
      decimals="INF"
      id="F_d38345a4-ce25-4acd-adba-5ac174f564fa"
      unitRef="U_shares">118852</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_236ea03d-46b1-4bac-973b-e724dd4cb6ce"
      decimals="2"
      id="F_18df0778-f1de-4f07-ba51-613d376fd03b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0922a283-969e-4183-84f1-754212457538"
      decimals="INF"
      id="F_bc6f30d3-1974-4d27-b538-472b014d0153"
      unitRef="U_shares">49130</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0922a283-969e-4183-84f1-754212457538"
      decimals="4"
      id="F_73609b70-116a-4563-89cc-0b3ce253c0f5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.9375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lgvn:PercentageOfAggregateNumberOfShares
      contextRef="C_dfe8bcec-cbcf-444b-8845-a535ef3f03eb"
      decimals="3"
      id="F_55915a6c-ba9c-47f5-bf52-b66034a35a6d"
      unitRef="U_pure">0.07</lgvn:PercentageOfAggregateNumberOfShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan
      contextRef="C_e1adbcb7-b9b2-43f3-afc8-b17cbfef377a"
      decimals="-5"
      id="F_0f194a6e-2438-45bd-9c74-742be2d324c6"
      unitRef="U_USD">8500000</us-gaap:ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_1265d1c0-07a0-47c5-a6e0-1db933689ef8"
      decimals="INF"
      id="F_e9fc5e3d-feca-4179-928a-758f3f0840c3"
      unitRef="U_shares">3563764</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_a7d1800f-a37a-45fd-8dea-2364d19b5d11"
      decimals="INF"
      id="F_02a8c3b5-38c8-4fd5-b66f-8e5cda67727e"
      unitRef="U_shares">3395782</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_89410ccd-0c4e-45f8-bf14-c2ca134fe7ba"
      decimals="INF"
      id="F_04bdbbb7-a7fb-49d9-b933-2a350e2a763a"
      unitRef="U_shares">167982</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2e7d7aea-3be2-4828-ad68-c7631d50cb13"
      decimals="INF"
      id="F_06b78efe-c9a9-4225-b1b2-3f84993bdfe6"
      unitRef="U_shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_3f3103ec-1fd2-48ed-9be1-19cba6a04ef5"
      decimals="INF"
      id="F_09ffab92-1c82-4934-8f39-bf81442288a7"
      unitRef="U_shares">150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_5cfe12ec-4f6d-46c2-b279-5fb305736864"
      decimals="INF"
      id="F_9dea5441-fdf0-462b-b683-5c63d77600ed"
      unitRef="U_shares">10500</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <lgvn:PercentageOfAggregateNumberOfShares
      contextRef="C_924ecf1f-101e-4065-841a-2f62764b7c61"
      decimals="3"
      id="F_a8542c07-7564-44c0-ab95-03a48801e9c1"
      unitRef="U_pure">0.07</lgvn:PercentageOfAggregateNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f620f41f-099b-4180-8d31-3b93f07907a0"
      decimals="3"
      id="F_4481c710-33b0-441c-8307-0164f5354459"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_711f128e-33db-462a-b513-6bbea4533ff0"
      id="F_5293f134-2648-4284-83c8-798a10715d14">2026-07-17</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_b14e7beb-bb0f-4f7a-971e-b4f66076e0c5"
      decimals="INF"
      id="F_a6f686de-a4bf-4fcf-a59e-559c26f9e36f"
      unitRef="U_shares">2319186</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="C_c3874ec0-4371-433c-8e08-3d6bcf9a60d5"
      decimals="INF"
      id="F_be1ea30b-ecec-4b76-a8c0-f9352d8dd601"
      unitRef="U_shares">162344</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <lgvn:PercentageOfAggregateNumberOfShares
      contextRef="C_c3874ec0-4371-433c-8e08-3d6bcf9a60d5"
      decimals="3"
      id="F_a13e6e04-1363-4e35-b3d8-cef31eb2db8a"
      unitRef="U_pure">0.07</lgvn:PercentageOfAggregateNumberOfShares>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_c2653ae9-c06d-4781-a567-ba19aae19693"
      id="F_15e6aef2-88c1-402d-9d43-c217c2100713">2026-07-24</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="C_ebecf041-4bf7-4e13-a8bb-d1dc47e42040"
      decimals="-5"
      id="F_b5dd8b05-075f-4b6c-9897-c733885c3cd4"
      unitRef="U_USD">6300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering
      contextRef="C_d018a83c-69ba-4776-9f87-503309a9913d"
      decimals="INF"
      id="F_26fd0578-18d2-453e-81e9-a5670ccc15f0"
      unitRef="U_shares">2236026</us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="C_3cb893e8-ebe9-452e-b2d1-71116392d51a"
      decimals="3"
      id="F_df6aa026-ef5d-4115-aa14-61a823d9eef9"
      unitRef="U_shares">4.025</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_5fc20789-feae-4261-9107-524520b01c0f"
      decimals="INF"
      id="F_f6d02988-1759-45a1-802b-f5c5a5e68a26"
      unitRef="U_shares">2236026</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="C_7697e068-658d-48a3-9b3b-a722fcb2fa76"
      decimals="2"
      id="F_2e01b485-5d66-4556-9935-6dce1c41590e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.9</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_7697e068-658d-48a3-9b3b-a722fcb2fa76"
      id="F_52f40f1a-9853-4944-a532-42b4087f656f">2026-07-20</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:SharesIssued
      contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"
      decimals="INF"
      id="F_e4142430-d8c6-4a2f-a711-ddd5e1457683"
      unitRef="U_shares">156522</us-gaap:SharesIssued>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="C_687bfee2-7b52-4e98-b96d-4a9d0d83f701"
      decimals="4"
      id="F_212c56d1-7e05-4a58-b77e-3da690bad326"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.0313</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_e6f33f88-f256-4289-b5e6-07ec6c716dee"
      decimals="-5"
      id="F_59c81e23-663d-4608-81ac-c70dfd6d44b3"
      unitRef="U_USD">9000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_972466ee-785c-4232-9930-fe53db2cddaf"
      decimals="INF"
      id="F_64e97fe2-2273-41df-8222-59760f24799b"
      unitRef="U_shares">2565392</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_d496e54d-c6ce-4319-8f1d-e8da390d52f5"
      decimals="INF"
      id="F_45ba9605-098a-4310-9272-b9639af89538"
      unitRef="U_shares">2236026</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_1dcfeb4c-c36e-4113-9bd0-cb07f984983e"
      decimals="INF"
      id="F_d6c390dc-a187-4f17-b44e-8bd3ab537002"
      unitRef="U_shares">156522</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_77836947-2834-438d-856e-a46d1692ea17"
      decimals="INF"
      id="F_dc2beef1-87a0-47f8-a91d-e8dcb0397d96"
      unitRef="U_shares">172844</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_fc09c49d-eaa5-4b33-8d36-7cb35209c791"
      decimals="2"
      id="F_17c36cd0-dcef-4771-901d-d14b300a4b93"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="C_d059abac-e58b-43e2-a95a-5a8879af8f3d"
      decimals="0"
      id="F_483c2b3a-2005-4cca-bf10-de884e448c9e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">114077</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_d059abac-e58b-43e2-a95a-5a8879af8f3d"
      decimals="0"
      id="F_acd71bc8-945e-47a7-b907-4d7b26df190e"
      unitRef="U_USD">114077</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c7555a19-6815-4308-a228-e63b0c8a4703"
      decimals="2"
      id="F_69638465-4e5d-49cb-8cff-c4c7af875d85"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="C_dde951fe-7b4d-4fe4-8fe2-29b317fefcff"
      decimals="0"
      id="F_7a1b0658-f0ea-4cdd-b2e9-72dda511e288"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2858</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_dde951fe-7b4d-4fe4-8fe2-29b317fefcff"
      decimals="0"
      id="F_4d16685d-672a-4d08-85e9-fd5ca95844dd"
      unitRef="U_USD">2858</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_5c85ae4e-bfc9-49e8-a8a4-4ab642e350d4"
      decimals="INF"
      id="F_4079f040-49f6-4c56-b434-15e6e91d49f3"
      unitRef="U_shares">6802668</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_31e78a64-3bdd-47be-ac65-3b87c7c4e859"
      decimals="INF"
      id="F_a3d5f6ef-d537-4c57-8336-b87d93e58d75"
      unitRef="U_shares">5536</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_31e78a64-3bdd-47be-ac65-3b87c7c4e859"
      decimals="2"
      id="F_074fecb7-a2fa-418a-9718-97024ab248ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">120</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_0e8a73c4-ea0e-438b-b7f5-e4427532c51a"
      id="F_7cb45826-1b63-4be6-8db3-6eb57827b762">2026-02-12</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_8b8d20b6-58a6-4f02-b93e-8d56eedb8243"
      decimals="INF"
      id="F_62609572-4b2b-45d2-af9e-bc5061456ca8"
      unitRef="U_shares">4679</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_8b8d20b6-58a6-4f02-b93e-8d56eedb8243"
      decimals="2"
      id="F_92f69a3b-0959-4152-85ef-109d81498923"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">175</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_2209f280-17a3-4fd1-94a9-c9d5d6bd6b30"
      id="F_2a992299-22df-462b-b449-0ea1854a1c6c">2026-12-01</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_1ef16fb7-28d8-4b6f-b55c-d02b22740228"
      decimals="INF"
      id="F_20a9c4d9-e5dd-41eb-a47c-cb5d70eba56c"
      unitRef="U_shares">16971</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1ef16fb7-28d8-4b6f-b55c-d02b22740228"
      decimals="3"
      id="F_c38c6ffe-8e6d-4462-bf6a-bbcc94a39b0a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_5353b9ba-0648-487a-aefb-c0c16431821a"
      id="F_6c30588c-54a9-4305-a964-47d430a04b89">2028-10-11</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_68efe625-4084-44ea-8dd6-7181da4c1023"
      decimals="INF"
      id="F_475c3739-56c7-41ed-87e7-9bf9a0a138c7"
      unitRef="U_shares">135531</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_68efe625-4084-44ea-8dd6-7181da4c1023"
      decimals="2"
      id="F_e0af66a1-24ce-4d5a-991f-6692a4d2c841"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_0f3486fa-b30f-4c7f-a57a-ecbf7bf415e1"
      id="F_0f68509f-1360-48a0-b124-fca57a04e3cd">2029-06-22</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_b186b4ae-25c4-45b0-8e3c-637d9c03a871"
      decimals="INF"
      id="F_78dd9522-0dd1-4fc6-b9a1-b2f02ca6c202"
      unitRef="U_shares">9489</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_b186b4ae-25c4-45b0-8e3c-637d9c03a871"
      decimals="3"
      id="F_5563108f-923c-42cd-85c4-3b6ce0304634"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.813</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_65a27186-d86b-45fd-9ea9-84445417ac27"
      id="F_809bd342-ecc1-4ebb-b967-241d7987a53b">2028-12-20</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d8c195d2-126b-4a62-8221-e81b21de8e4a"
      decimals="INF"
      id="F_b35f230a-21df-49df-be6c-858e5de7bf26"
      unitRef="U_shares">297872</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d8c195d2-126b-4a62-8221-e81b21de8e4a"
      decimals="2"
      id="F_56a026e9-cb95-43fd-894f-83e3d64766a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_58d502e3-e75a-4d67-9f49-bf40b468f239"
      id="F_f510ab66-f971-4459-ae23-ac7e9a619dae">2029-04-10</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_681d8182-c08b-4f2c-b850-c94acff077c7"
      decimals="INF"
      id="F_a2dbbfbb-6cbe-49a4-a65c-a2ff3dddd6a3"
      unitRef="U_shares">154894</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_681d8182-c08b-4f2c-b850-c94acff077c7"
      decimals="4"
      id="F_16e7c070-7cfe-4907-8a32-3ce9c12f9545"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.9375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_ad3fe0e4-e995-40c1-bc38-77db69fa7a3f"
      id="F_b29fcf10-57d1-4f31-aa69-390312496f0c">2029-04-08</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_060bd5b3-20e9-452b-9a05-b0270d3c7018"
      decimals="INF"
      id="F_7fb951fa-a75c-472a-8dba-b7adf6776402"
      unitRef="U_shares">2349744</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_060bd5b3-20e9-452b-9a05-b0270d3c7018"
      decimals="2"
      id="F_0325964e-46c0-4e53-b5e5-c6281a44456f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_10494440-1436-4801-9d95-e37fad25c83b"
      id="F_c9775129-f225-4591-a1d6-162f4dff65b6">2029-04-18</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_682a89cb-47a9-46e1-bdd9-3cd1abe13dd7"
      decimals="INF"
      id="F_6d4dc197-55f4-4162-a380-dbba91696c33"
      unitRef="U_shares">167982</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_682a89cb-47a9-46e1-bdd9-3cd1abe13dd7"
      decimals="2"
      id="F_8d466ccb-c23e-4d06-beb9-036cdd36259f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_231d6559-39de-40e2-92ca-0ce4ccbeea1d"
      id="F_6deeaab0-4809-4a27-8769-ab7918a5ef44">2029-04-18</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d928293f-8f03-4263-a9cb-8b1b15166f54"
      decimals="INF"
      id="F_ecd44336-ace2-4648-a9cf-b2872084aacd"
      unitRef="U_shares">49130</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d928293f-8f03-4263-a9cb-8b1b15166f54"
      decimals="4"
      id="F_7c9d26e3-59ce-4988-814b-ab90d1fdd167"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.9375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_9474be27-a471-40f6-84ce-28e85ee32e08"
      id="F_53db0637-f701-4587-99cb-7512bfa33590">2026-06-18</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5ad083cc-071f-4968-8655-4ec150277da0"
      decimals="INF"
      id="F_ec052bb5-b397-4637-b637-3f1d1ddc9042"
      unitRef="U_shares">926596</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5ad083cc-071f-4968-8655-4ec150277da0"
      decimals="2"
      id="F_924866bf-2f1f-405d-bef0-4cc9113ec002"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_d75ceeb2-ec46-49ab-a15a-5b9237a9730c"
      id="F_f5ef0b4a-a8c4-466c-b7e7-ec6d23abb38c">2026-06-18</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d5f7e310-6aa6-4ef9-ba0b-23c17f14bd5d"
      decimals="INF"
      id="F_7d42db17-4e5d-425a-9b29-c8364c0189b7"
      unitRef="U_shares">118852</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d5f7e310-6aa6-4ef9-ba0b-23c17f14bd5d"
      decimals="2"
      id="F_a6a71f6a-8f66-4621-b599-566e308e661f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_66ab6a93-936f-44ff-be1a-6cfc54371b2d"
      id="F_b0336827-b2a2-496a-bae3-8db3b9908086">2026-06-18</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_a3cf52d5-51ea-46c9-a0ff-4a136cfdc855"
      decimals="INF"
      id="F_7421afd7-dcd3-4ca0-873c-e8c02f27ccc0"
      unitRef="U_shares">10500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a3cf52d5-51ea-46c9-a0ff-4a136cfdc855"
      decimals="3"
      id="F_46379618-4ebe-42e1-973e-5a41d646a4d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_2e8cf413-7785-4109-aeb3-90e76b3f91b0"
      id="F_7c60c456-206d-405d-a5ce-ac18c0297495">2026-07-17</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_63c4202f-ab95-43b7-9ac7-8fc5f186cdb3"
      decimals="INF"
      id="F_e511751d-7f16-4f61-9780-301acd046be8"
      unitRef="U_shares">162344</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_63c4202f-ab95-43b7-9ac7-8fc5f186cdb3"
      decimals="3"
      id="F_4375697b-4ec8-436a-9659-b290859a37c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_c8996def-ed25-41c0-9cde-57e67fd24599"
      id="F_4beace2e-24bb-4c5a-86e3-7ec80304842f">2026-07-24</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_b988428e-be70-43a6-a20f-4a0d1af53866"
      decimals="INF"
      id="F_4e5616d1-51d7-4757-b6b9-b5ea4d40b0d5"
      unitRef="U_shares">2236026</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_b988428e-be70-43a6-a20f-4a0d1af53866"
      decimals="2"
      id="F_b3714922-256f-4754-832e-aa51a1130ce0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_0c05e440-f556-4213-b61b-eda6feaf9090"
      id="F_d62e4abc-6ecd-46be-8d52-fd2039131359">2026-07-20</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_5be6c0a6-1868-4af2-89ef-106e0e069070"
      decimals="INF"
      id="F_443d05a3-09c0-4923-b871-167e53559055"
      unitRef="U_shares">156522</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5be6c0a6-1868-4af2-89ef-106e0e069070"
      decimals="4"
      id="F_12706212-7962-4ca2-9795-bd6a5293d9db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.0313</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear
      contextRef="C_655c9a5e-6bc6-4cd8-9dec-b75e3ef72592"
      id="F_797502a9-3818-428b-9e89-52d142b681a1">2026-07-20</us-gaap:DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_c1ae2429-1400-4a5e-b6be-eb558f2d4347">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of the Company&#x2019;s IPO, the Company adopted and approved the 2021 Incentive Award Plan, which has been subsequently amended and restated twice (as accordingly amended and restated, the &#x201c;2021 Incentive Plan&#x201d;). Under the 2021 Incentive Plan, the Company may grant cash and equity incentive awards to employees and eligible service providers in order to attract, motivate and retain the talent for which the Company competes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs are taxable upon vesting based on the market value on the date of vesting. The Company is required to make mandatory tax withholding for the payment and satisfaction of income tax, social security tax, payroll tax, or payment on account of other tax related to withholding obligations that arise by reason of vesting of an RSU. The taxable income is calculated by multiplying the number of vested RSUs for each individual by the closing share price as of the vesting date and a tax liability is calculated based on each individual&#x2019;s tax bracket. During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;566,904&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs vested for Class A common stock shares. Of that amount, the Company withheld &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,306&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Class &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A common stock shares to satisfy employee tax liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,308&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs vested for Class A common stock shares. Of that amount, the Company withheld &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,223&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Class A common stock shares to satisfy employee tax liabilities. The shares withheld are available for reissuance pursuant to the Company&#x2019;s Second Amended and Restated 2021 Incentive Award Plan. Each RSU grant made during 2024 and 2023 is expensed ratably over its respective vesting period, with prorated adjustments made as needed to align with grant dates and the applicable service periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;806,001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,239&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively RSUs outstanding (unvested).&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSU activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:25.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding (unvested) at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,394,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;566,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSU expired/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding (unvested) at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;806,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock options may be granted under the 2021 Incentive Plan. The exercise price of options is equal to the fair market value of the Company&#x2019;s Class A common stock as of the grant date. Options historically granted have generally become exercisable over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a211f642-62a5-42ee-bc71-d3f13e686a7e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and expire &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2024, the Company granted options that vest quarterly over three years. Non-employee awards, including options granted to directors and certain third-party service providers, are granted similar to the Company&#x2019;s employee awards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2023, the Company granted options to executives and non-employee directors under various vesting schedules, including a four-year vesting period with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% vesting per year and a one-year cliff vesting for the CEO.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the options issued are estimated using the Black-Scholes option-pricing model. For 2024, the following assumptions were used: a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%; an expected life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years; volatility ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%; and risk-free interest rate based on the grant date ranging from of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.52&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For 2023, the following assumptions were used: a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%; an expected life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years; volatility ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%; and risk-free interest rate based on the grant date ranging from of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. Each option grant made during 2024 and 2023, will be expensed ratably over the option vesting periods, with prorated adjustments made as needed to align with grant dates and applicable service periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company has recorded issued and outstanding options to purchase a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,186&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock pursuant to the 2021 Incentive Plan, at a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.09&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Also, as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company has recorded issued and outstanding options to purchase a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,786&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Class A common stock pursuant to the 2021 Incentive Plan, at a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.96&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options vested (based on ratable vesting)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock options outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options vested (based on ratable vesting)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock options outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Option activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_d44a448c-95da-42af-9268-94b3f97749eb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_e72c3d8a-06d5-4f57-820b-ef886d45e808;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options expired/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the equity-based compensation expense amounted to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, which is included in the research and development and general and administrative expenses in the statements of operations for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the remaining unrecognized RSUs compensation of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will be recognized over approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.08&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. The remaining unrecognized stock options compensation of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will be recognized over approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_a153ce10-2e61-4bc3-acd9-4005eae448d3"
      decimals="0"
      id="F_5d7c979f-f01d-4bb1-abb7-3d98410a3d77"
      unitRef="U_shares">566904</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129"
      decimals="0"
      id="F_93e93216-a1de-41e1-8966-595a4105acc5"
      unitRef="U_shares">142306</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_10a053c8-c2a2-4e48-84b4-b5ed263c95d5"
      decimals="0"
      id="F_2bed3b16-f6f1-4d75-89a8-669ddb400199"
      unitRef="U_shares">25308</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_d1bc4f98-b538-4530-9021-04474129f4f8"
      decimals="0"
      id="F_34977355-7949-48c8-a9a8-c035f0247085"
      unitRef="U_shares">5223</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_377db0af-954f-408b-bd6c-7c6b6d74118a"
      decimals="INF"
      id="F_ed73e522-69a5-49b7-8da6-035339def906"
      unitRef="U_shares">806001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_caeb366f-d29c-4739-90bc-fff7fe6667f7"
      decimals="INF"
      id="F_6d0c912a-75b6-4f42-b876-21e52ce7292e"
      unitRef="U_shares">11239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_3dad03ac-bb7f-4eab-b3fe-bdb8b53754ab">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSU activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:25.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding (unvested) at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,394,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;566,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSU expired/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding (unvested) at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;806,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_caeb366f-d29c-4739-90bc-fff7fe6667f7"
      decimals="INF"
      id="F_961e83d7-0be8-40fa-a246-81b04503ed6b"
      unitRef="U_shares">11239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129"
      decimals="INF"
      id="F_c4441bd2-f80b-4fb7-9dcb-a3f0f1316d5c"
      unitRef="U_shares">1394774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129"
      decimals="INF"
      id="F_07d174a6-201b-4f66-ae9d-a6cdaef12a44"
      unitRef="U_shares">566904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129"
      decimals="INF"
      id="F_c3fec33e-d626-409f-88a9-17108463ffe4"
      unitRef="U_shares">33108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_377db0af-954f-408b-bd6c-7c6b6d74118a"
      decimals="INF"
      id="F_bdd15238-63cd-4b17-bffa-8eabf612bb21"
      unitRef="U_shares">806001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_573f4892-a8c0-49cb-b8bb-f89fab69086c"
      id="F_6d55492e-b216-43e2-a5d8-ef911eb8ef91">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <lgvn:ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_d2d86f6c-b9cd-4349-8e31-4719cc762f02">P10Y</lgvn:ShareBasedCompensationArrangementByShareBasedPaymentStockOptionExpirationTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_30abdd0a-27e1-4d75-a863-e2cce39841ab"
      decimals="2"
      id="F_7d70dbe9-cab3-409c-9b0b-30bef3b11b11"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="2"
      id="F_b8c49644-71e2-41aa-9089-53bcafc1e992"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_dda33eec-5d55-46ee-8cf8-8be9a6b83964">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_8828b9f4-08cf-4cd9-86ab-83a206aaab8c"
      decimals="2"
      id="F_a003e88e-c6aa-4a7a-9eee-8ec0ab73d43b"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_573f4892-a8c0-49cb-b8bb-f89fab69086c"
      decimals="2"
      id="F_16faf480-fc06-4471-9143-1c526ae0b1f5"
      unitRef="U_pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_57e34a04-c6a3-42fb-8d4f-86889f99fd47"
      decimals="4"
      id="F_89754cfd-4568-44a0-bab6-33d1d7a6ad49"
      unitRef="U_pure">0.0379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_01ea16bf-996c-4f70-aec4-bfd677595c42"
      decimals="4"
      id="F_3baa48a5-bda5-4982-a434-2ea4e33433f9"
      unitRef="U_pure">0.0452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="2"
      id="F_7657311c-7730-46a0-afe0-72ac5868b487"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      id="F_69194715-30bd-4077-a20a-cbd1d1a6f53d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_c6d1288e-2e0f-44c3-bc7e-30f39c656ecc"
      decimals="2"
      id="F_38bff53c-4baf-4a8c-a825-b7ed35511a4d"
      unitRef="U_pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_830ceff8-2513-4d56-879f-3cc26a4081b4"
      decimals="2"
      id="F_1bffcfe9-31c3-4d2e-b323-438004c3a102"
      unitRef="U_pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_2165fc3d-60ff-463a-ac2e-ab3e6e0ab4ed"
      decimals="4"
      id="F_95e7a563-7896-4286-a465-748d8b2dddb2"
      unitRef="U_pure">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5fe7e291-90ef-457d-8a32-938bb17e4966"
      decimals="4"
      id="F_889b6030-e22b-4f6f-b168-25be811d0c43"
      unitRef="U_pure">0.0401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_377db0af-954f-408b-bd6c-7c6b6d74118a"
      decimals="0"
      id="F_6bceb2ae-2fa3-428f-a65e-52be5579f9c4"
      unitRef="U_shares">121186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="2"
      id="F_fc2a6023-70e4-481d-9f3e-0214f7f4e596"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_caeb366f-d29c-4739-90bc-fff7fe6667f7"
      decimals="0"
      id="F_faee2cfe-7960-4d65-bc11-d2df1a04ffcb"
      unitRef="U_shares">43786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="2"
      id="F_12761a46-9fc3-40d5-9059-1754e7422327"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_ede4e436-f783-41e8-8190-184264382267">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options vested (based on ratable vesting)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock options outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options vested (based on ratable vesting)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock options outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_966061df-c7de-4d04-b147-85979bffe716"
      decimals="INF"
      id="F_c2a4b780-d0b0-41bf-9288-4987d4a2267a"
      unitRef="U_shares">31713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_966061df-c7de-4d04-b147-85979bffe716"
      decimals="INF"
      id="F_75faa229-dcf3-47a9-a93a-83a4061246fd"
      unitRef="U_shares">89473</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_966061df-c7de-4d04-b147-85979bffe716"
      decimals="INF"
      id="F_6b3f3517-7510-4fda-9f3e-f283c589c3f3"
      unitRef="U_shares">121186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514"
      decimals="INF"
      id="F_dde9c5bf-5aaf-4727-922c-29e0e8cb5f4d"
      unitRef="U_shares">16091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514"
      decimals="INF"
      id="F_f40251bd-1519-47b3-aa66-dfe20a3f7c0e"
      unitRef="U_shares">27695</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514"
      decimals="INF"
      id="F_e75203d0-73aa-478a-a284-129ab73643fb"
      unitRef="U_shares">43786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_25f70b64-40dc-4c1c-af2b-708b27cc31b6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Option activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted &lt;br/&gt;Average&lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_d44a448c-95da-42af-9268-94b3f97749eb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_e72c3d8a-06d5-4f57-820b-ef886d45e808;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options expired/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514"
      decimals="INF"
      id="F_e2a6a528-c043-4c22-96a3-7b1aa687c630"
      unitRef="U_shares">43786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_9ad503fc-d399-4534-b7b8-40dad723f514"
      decimals="2"
      id="F_2c705f35-665a-418d-af09-7cc99f8512ac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">49.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"
      decimals="INF"
      id="F_ea81121f-9dd0-44c4-b7c9-bd43177c2bbd"
      unitRef="U_shares">88625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"
      decimals="2"
      id="F_3afd0344-e82a-485f-99c7-7581077852dc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"
      decimals="INF"
      id="F_d2dee0ff-810d-4f59-9bb7-22bc498c5e7e"
      unitRef="U_shares">11225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"
      decimals="2"
      id="F_8c8550a8-a053-4162-9e20-359942a38f63"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">50.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_966061df-c7de-4d04-b147-85979bffe716"
      decimals="INF"
      id="F_536ec01e-ab2c-4bf8-bd48-9b1623af190d"
      unitRef="U_shares">121186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_966061df-c7de-4d04-b147-85979bffe716"
      decimals="2"
      id="F_778d5fb9-79bc-4fd3-a15a-cd22953a4b21"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"
      decimals="-5"
      id="F_0a5807e6-640e-4391-84a8-3cbeca978aba"
      unitRef="U_USD">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_61e522cf-6101-40bb-b529-2e57609235e3"
      decimals="-5"
      id="F_887d0c9a-b48b-403b-9126-84b5b7f38f95"
      unitRef="U_USD">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129"
      decimals="-5"
      id="F_7e198f00-7fdd-4db0-96b9-8fc9b49197f4"
      unitRef="U_USD">1600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_ccb7843f-3d8b-411f-883c-8583123a3129"
      id="F_7de8ce8b-985f-48b8-94e5-94a1dbb4600f">P2Y29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"
      decimals="-5"
      id="F_4a458bc6-3dc8-4653-99d9-875891a4e74f"
      unitRef="U_USD">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_2e880b8b-7f99-451b-ac83-0cbf9ef4cb64"
      id="F_e358a5e2-00be-4186-a92e-a6ba63ef23db">P1Y11M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_38aafd4a-cdbe-42e9-9041-8877cd905eb2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Master Services and Clinical Studies Agreements:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Company terminated its active master services agreements with third parties that were previously engaged to conduct its clinical trials and manage clinical research programs and clinical development services. This termination was due to the Company&#x2019;s decision in April 2024 to discontinue trial activities in Japan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Consulting Services Agreement:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 20, 2014, the Company entered into a ten-year consulting services agreement with Dr. Joshua Hare, its Chief Science Officer (CSO). Under the agreement, the Company has agreed to pay the CSO $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;265,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; annually. The compensation payments are for scientific knowledge, medical research, technical knowledge, skills, and abilities to be provided by the CSO to further develop the intellectual property rights assigned by the CSO to the Company. This agreement requires the CSO to also assign to the Company the exclusive right, title, and interest in any work product developed from his efforts during the term of this agreement. On November 16, 2022, the Company accounted for but had not issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,140&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; RSUs convertible to unregistered shares of Class A common stock, with an aggregate value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as payment for accrued expenses under a consulting agreement with the CSO. These shares were issued on May 24, 2023. The initial term of the agreement ended on November 22, 2024, however, the Company continues to operate under the same terms until a new agreement is executed. In addition, t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;he Company entered into a deferred compensation agreement with the CSO to defer payment of the consulting fees earned for services rendered during 2024. The 2024 consulting fees will be paid in the form of a lump sum distribution in February 2027.  As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, the Company had accrued balances due to the CSO of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, included in other long-term liabilities and accrued expenses, respectively, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, included in accrued expense and accounts payable in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Manufacturing Services Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 21, 2024, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Supply Agreement with a third-party biotechnology company developing multiple, novel secretomes (&#x201c;Secretome&#x201d;), to address a spectrum of diseases driven by pathological processes , to manufacture, test, release, and supply Secretome with cardiac stem cells (the &#x201c;Product&#x201d;) to be used in Phase 1 and Phase 2 clinical trials (the &#x201c;Secretome Agreement&#x201d;).  The Company received an initial start-up payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;242,400&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; upon signing of the  Secretome Agreement, which was comprised of (a) technology transfer, documentation preparation, training, and testing costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, (b) a ten-hour prepayment of project management fees of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,400&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and (c) a first month suite reservation fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company will bill Secretome on a variable fee basis for quality control, in process, release, and stability testing service items. For each Product lot, Secretome will pay the Company $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per lot as well as a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;each additional&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Product &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lot in excess of two initial &#x201c;training run&#x201d; lots. Secretome will also pay a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; monthly manufacturing suite reservation fee to the Company as well as a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per hour hourly fee for project management services.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Secretome  has also agreed to compensate the Company for the value of all materials involved in manufacturing and quality control testing the Product, plus a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; percent markup on these materials. For any outsourced testing, Secretome will be billed directly by the laboratory conducting the testing, plus a fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per batch payable to the Company. Furthermore, Secretome will pay the Company $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; monthly for storage of in process samples, vialed harvests for training, and in process samples for Product lots. The Company will receive certain variable payments related to product packing, handling and shipping, with a standard fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with an increased fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for expedited or special hour service.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following the initial &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term, the Secretome Agreement may be renewed for additional successive two-year terms upon the mutual written agreement of the parties. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Either party may terminate the agreement for cause and upon notice in the event of a material breach, within (i) 30 days of an uncured material breach that is not a payment default or (ii) 10 days for an uncured payment default. The Secretome Agreement further provides that either party may terminate the agreement at any time upon 90 days&#x2019; notice to the other party.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition, either party may terminate the agreement immediately in the event the other party seeks the protection of any bankruptcy court, becomes insolvent, makes an assignment for the benefit of creditors, or any debarment activity occurs with respect to that party. A force majeure provision also permits termination of the Secretome Agreement upon written notice to the other party as a result of a delay or interference of performance continuing for more than 60 days.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, the Company has earned revenues of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million under the Secretome Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is also a party to a Mutual Nondisclosure Agreement with Secretome, signed and effective as of October 24, 2023 (the &#x201c;Nondisclosure Agreement&#x201d;), by which both parties have agreed to maintain the strict confidentiality of, restrict access to, and not to disclose  any intellectual property, trade secrets, business dealings, customers, operations, products, research, clinical data, or other competitively sensitive or proprietary confidential information shared between them, subject to certain customary carve-outs for disclosures pursuant to applicable law or filings with regulatory or governmental agencies including the SEC. The Nondisclosure Agreement has a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the later of (i) the effective date of the Nondisclosure Agreement, (ii) the date of the last disclosure of information under the Secretome Agreement, any &#x201c;Quality Agreement&#x201d; which may be entered into between the parties, or any scope of work; or (iii)  the expiration of any patents issued arising out of or resulting from the confidential information. The Nondisclosure Agreement will not terminate with respect to trade secrets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Exclusive Licensing Agreements:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;UM Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 20, 2014, the Company entered into an Exclusive License Agreement with UM (the &#x201c;UM License&#x201d;) for the use of certain Aging-related Frailty Mesenchymal Stem Cell (&#x201c;MSC&#x201d;) technology rights developed by our CSO at UM. The UM License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how specifically related to the development of the culture-expanded mesenchymal stem cells for Aging-related Frailty used at the Human-induced pluripotent stem cell-derived mesenchymal stem cells (IMSCs&#x201d;), all standard operating procedures used to create the IMSCs, and all data supporting isolation, culture, expansion, processing, cryopreservation and management of the IMSCs. The Company is required to pay UM (i) a license issue fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, (ii) a running royalty in an amount equal to three percent of annual net sales on products or services developed from the technology, payable on a country-by-country basis beginning on the date of first commercial sale through termination of the UM License Agreement, and which may be reduced to the extent we are required to pay royalties to a third party for the same product or process, (iii) escalating annual cash payments of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;fifty thousand&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; dollars, subject to offset. The agreement extends for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years from the last date a product or process is commercialized from the technology and was amended in 2017 to modify certain milestone completion dates as detailed below. In 2021 the license fee was increased by an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, to defray patent costs. In addition, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110,387&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unregistered shares of Class A common stock to UM.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The milestone payment amendments shifted the triggering payments to three payments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to be paid within six months of: (a) the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (b) the receipt by the Company of approval for the first new drug application (&#x201c;NDA&#x201d;), biologics application (&#x201c;BLA&#x201d;), or other marketing or licensing application for the product; and (c) the first sale following product approval. &#x201c;Approval&#x201d; refers to Product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successor agency. The amendments also provided for the Company&#x2019;s license of additional technology, to the extent not previously included in the UM License, and granted the Company an exclusive option to obtain an exclusive license for (a) the Hypoplastic Left Heart Syndrome (&#x201c;HLHS&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;investigational &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;new drug application (&#x201c;IND&#x201d;) with ckit+ cells; and (b) UMP-438 titled &#x201c;Method of Determining Responsiveness to Cell Therapy in Dilated Cardiomyopathy.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has the right to terminate the UM License upon 60 days&#x2019; prior written notice, and either party has the right to terminate upon a breach of the UM License. To date, the Company has made payments totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to UM, and as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, in the accompanying balance sheets, the Company had accrued $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in milestone fees payable to UM for both years, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for both years, respectively, for patent related reimbursements based on the estimated progress to date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company also entered into an additional Exclusive License Agreement with UM, signed and effective as of July 18, 2024, for technology rights developed by our CSO at UM. This License is a worldwide, exclusive license, with right to sublicense, with respect to any and all know-how, SOPs, data and other all other rights related to UMP-144, entitled &#x201c;A method to derive GHRHR+ cardiomyogenic cells from pluripotent stem cells (PSCs) for therapeutic and pharmacologic applications&#x201d; and having inventors Joshua Hare and Konstantinos Chatzistergos. UM retained a non-exclusive, royalty-free, perpetual, irrevocable, worldwide right to practice, make, and use the Patent Rights or Technology for any non-profit purposes, including educational, and research purposes. Pursuant to the terms of the license agreement, Longeveron must pay to UM: (a) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; within 30 days of the Effective Date; and (b) reimbursement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,307&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; within 90 days of the Effective Date for previously incurred patent expenses; and (c) an annual $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; fee which is both creditable against other royalty payments for the applicable license year and is waived so long as Company is current on annual fee payments in accordance with the Exclusive License Agreement entered into November 20, 2014 between Company and UM. In addition to certain those certain other royalty payments that would be due should the Company&#x2019;s sublicense of the technology result in revenue, Longeveron also agreed to the following additional milestones and payments: (c) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; upon completion of the first Phase 3 Clinical Trial; and (d) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; upon issuance of a biologics license application or new drug application based on the licensed technology. The Company has the right to terminate the new UM License for convenience upon 90 days&#x2019; prior written notice, and both parties have additional termination rights for material breach of the agreement. To date, the Company has made payments totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to UM, and as of December 31, 2024, the Company had not yet accrued any milestone fees payable to UM.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;CD271&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On December 22, 2016, the Company entered into an exclusive license agreement with an affiliated entity of Dr. Joshua Hare, JMH MD Holdings, LLC (&#x201c;JMHMD&#x201d;), for the use of CD271 cellular therapy technology. The Company recorded the value of the cash consideration and membership units issued to obtain this license agreement as an intangible asset. The Company is required to pay as royalty &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the annual net sales of the licensed product(s) used, leased, or sold by or for licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to JMHMD, and issued to it &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Series C Units, valued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of value provided to JMHMD for the license agreement, along with professional fees of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. Further, expenses related to the furtherance of the CD271+ technology is being capitalized and amortized as incurred over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; license fees due for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 pertaining to this agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other Royalty&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the grant award agreement with the Alzheimer&#x2019;s Association, the Company may be required to make revenue sharing or distribution of revenue payments for products or inventions generated or resulting from this clinical trial program. The potential payments, although not currently defined, could result in a maximum payment of five times (5x) the award amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contingencies &#x2013; Legal&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. For the year ended December 31, 2024, the Company is not aware of any legal proceedings or material developments requiring disclosure.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 13, 2021, the Company and certain of its directors and officers were named as defendants in a securities lawsuit filed in the U.S. District Court for the Southern District of Florida and brought on behalf of a purported class. The suit alleges there were materially false and misleading statements made (or omissions of required information) in the Company&#x2019;s initial&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;public &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;offering materials and in other disclosures during the period from our initial public offering on February 12, 2021, through August 12, 2021, in violation of the federal securities laws. The action sought damages on behalf of a proposed class of purchasers of the Company&#x2019;s common stock during said period. On July 12, 2022, all parties preliminarily agreed to settle the action for approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which settlement was preliminarily approved by the Court on or about May 12, 2023, and which settlement amount was paid on May 24, 2023. Legal expenses incurred in ordinary business activities are reported within general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On or about May 18, 2023, a former employee of the Company filed a charge with the Equal Employment Opportunities Commission (&#x201c;EEOC&#x201d;) and the Florida Commission on Human Relations alleging discrimination based on disability, and on or about August 15, 2023, the former employee filed a complaint in Miami-Dade Circuit Court alleging unpaid wages were outstanding.  Both matters were addressed and fully resolved and settled in a mediation between the Company and the former employee held on September 28, 2023, by which it was agreed that the former employee would be paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; towards this resolution was paid by the Company and all remaining costs were covered by the Company&#x2019;s insurance carrier) and that the EEOC and FCHR charges were withdrawn and the action in the Miami-Dade Circuit Court was dismissed with prejudice.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherExpenses
      contextRef="C_309403c4-9ddf-4b25-a74d-ada45e629444"
      decimals="0"
      id="F_192508a6-a1d5-4349-90d5-07f693a44c82"
      unitRef="U_USD">265000</us-gaap:OtherExpenses>
    <lgvn:SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested
      contextRef="C_0bffd59a-5e1d-4d4e-8b68-f305bbb2e10c"
      decimals="0"
      id="F_a5ee9b7e-385c-4d82-b67d-7798a80dd33c"
      unitRef="U_shares">48140</lgvn:SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="C_597c2a74-45ac-4076-9561-0e22ff41b523"
      decimals="0"
      id="F_9be8dbe3-9257-42ae-80f8-9d5457204e3a"
      unitRef="U_USD">207000</us-gaap:AccruedLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_003e9629-0270-4293-930d-9e35e517c34f"
      decimals="-5"
      id="F_d006307a-e19a-4566-aed8-c8e1ebf9d4d9"
      unitRef="U_USD">300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_a5052b3f-7b15-4f4e-a480-ac371b45c8fb"
      decimals="-5"
      id="F_43a1bdac-2629-45ac-aafb-ecbabff699c1"
      unitRef="U_USD">100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_43ed4fe3-0d84-459e-a147-85ba5807b813"
      decimals="-5"
      id="F_7bbe3ac0-899d-43e1-8fef-263769440292"
      unitRef="U_USD">100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a5052b3f-7b15-4f4e-a480-ac371b45c8fb"
      decimals="-5"
      id="F_d948a703-8584-4306-a2e8-c689a4f525b8"
      unitRef="U_USD">100000</us-gaap:AccountsPayableCurrent>
    <lgvn:AgreementTerm
      contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9"
      id="F_6427e7ac-5349-4837-9f0a-5ecf2e6c9287">P5Y</lgvn:AgreementTerm>
    <lgvn:InitialStartUpPaymentReceived
      contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9"
      decimals="0"
      id="F_123dfaef-e1d1-4fd7-a1b5-9a6b464b81bb"
      unitRef="U_USD">242400</lgvn:InitialStartUpPaymentReceived>
    <lgvn:TechnologyTransferDocumentationPreparationTrainingAndTestingCosts
      contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9"
      decimals="0"
      id="F_19bc04c1-dc31-4397-9474-34399235c52b"
      unitRef="U_USD">210000</lgvn:TechnologyTransferDocumentationPreparationTrainingAndTestingCosts>
    <lgvn:ProjectManagementFees
      contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9"
      decimals="0"
      id="F_98629cd3-2150-4134-a2ff-40c3a6b2f375"
      unitRef="U_USD">2400</lgvn:ProjectManagementFees>
    <lgvn:SuiteReservationFee
      contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9"
      decimals="0"
      id="F_48b7df1a-5c0c-4514-b297-5bbd6b019dc2"
      unitRef="U_USD">30000</lgvn:SuiteReservationFee>
    <lgvn:PotentialAmountReceivableForEachProductLot
      contextRef="C_5969aff3-9175-480f-9b07-995e126acd22"
      decimals="0"
      id="F_f68ec7e4-927b-4f25-b0a9-4620f5d69aac"
      unitRef="U_USD">55000</lgvn:PotentialAmountReceivableForEachProductLot>
    <lgvn:PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots
      contextRef="C_5969aff3-9175-480f-9b07-995e126acd22"
      decimals="0"
      id="F_1aea0047-3b22-475f-b672-6420747bec32"
      unitRef="U_USD">30000</lgvn:PaymentsReceivableForEachAdditionalProductLotInExcessOfInitialTrainingRunLots>
    <lgvn:MonthlyManufacturingSuiteReservationFee
      contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9"
      decimals="0"
      id="F_a0e5a90a-7e74-4e51-869e-101dcdfc4b8c"
      unitRef="U_USD">30000</lgvn:MonthlyManufacturingSuiteReservationFee>
    <lgvn:HourlyFeeForProjectManagementServices
      contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9"
      decimals="0"
      id="F_b2bfd67c-8265-4d45-8ebd-75dd85182100"
      unitRef="U_USD">240</lgvn:HourlyFeeForProjectManagementServices>
    <lgvn:MarkupPercentageOnValueOfMaterialsCompensated
      contextRef="C_5969aff3-9175-480f-9b07-995e126acd22"
      decimals="2"
      id="F_b11e38d8-51e9-4dac-9be3-b0cbac6ec7a9"
      unitRef="U_pure">0.20</lgvn:MarkupPercentageOnValueOfMaterialsCompensated>
    <lgvn:OutsourcedTestingFeePerBatchReceivable
      contextRef="C_5969aff3-9175-480f-9b07-995e126acd22"
      decimals="0"
      id="F_8671da9b-3d6f-4e8f-a3df-bb74229ea686"
      unitRef="U_USD">500</lgvn:OutsourcedTestingFeePerBatchReceivable>
    <lgvn:MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining
      contextRef="C_5969aff3-9175-480f-9b07-995e126acd22"
      decimals="0"
      id="F_ed4fdc2a-1f72-4b9c-ae11-48985853505c"
      unitRef="U_USD">2000</lgvn:MonthlyPaymentReceivableForInProcessSamplesAndVialedHarvestsForTraining>
    <lgvn:StandardFeeReceivableForProductPackingHandlingAndShipping
      contextRef="C_5969aff3-9175-480f-9b07-995e126acd22"
      decimals="0"
      id="F_65b3fb28-a914-4535-a82d-a3d6a708d824"
      unitRef="U_USD">750</lgvn:StandardFeeReceivableForProductPackingHandlingAndShipping>
    <lgvn:IncreasedFeeReceivableForExpeditedOrSpecialHourService
      contextRef="C_5969aff3-9175-480f-9b07-995e126acd22"
      decimals="0"
      id="F_6285d22f-c2e7-4fb0-9772-9833c9caaacd"
      unitRef="U_USD">1500</lgvn:IncreasedFeeReceivableForExpeditedOrSpecialHourService>
    <lgvn:AgreementTerm
      contextRef="C_ce0f0327-6771-414c-b1ab-e8b2040413f9"
      id="F_9c723184-bf24-4a36-9f09-23a4e5e5abb5">P5Y</lgvn:AgreementTerm>
    <lgvn:AgreementTerminationDescription
      contextRef="C_e577d4b1-7eb8-446b-9a4f-8502fde888f2"
      id="F_ec429d7a-01bf-44e9-a365-0c069f782c22">Either party may terminate the agreement for cause and upon notice in the event of a material breach, within (i) 30 days of an uncured material breach that is not a payment default or (ii) 10 days for an uncured payment default. The Secretome Agreement further provides that either party may terminate the agreement at any time upon 90 days&#x2019; notice to the other party.</lgvn:AgreementTerminationDescription>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e577d4b1-7eb8-446b-9a4f-8502fde888f2"
      decimals="-5"
      id="F_57e8b20a-b1ff-4bf5-a203-71b95aed125f"
      unitRef="U_USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <lgvn:AgreementTerm
      contextRef="C_2e7abbe2-22f9-4dec-88c2-e983a64471e1"
      id="F_c0504fd9-a896-4ee7-9ca5-59c762622d5d">P10Y</lgvn:AgreementTerm>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_309403c4-9ddf-4b25-a74d-ada45e629444"
      decimals="0"
      id="F_58440c37-b4e0-4903-80f1-6eba79df36d4"
      unitRef="U_USD">5000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:OtherCashEquivalentsAtCarryingValue
      contextRef="C_1603a247-a9e5-422a-846b-6d3ba3b022c6"
      decimals="0"
      id="F_223355e5-ad3f-4af6-8c79-2854de5442a0"
      unitRef="U_USD">50000</us-gaap:OtherCashEquivalentsAtCarryingValue>
    <lgvn:TermsOfAgreement
      contextRef="C_309403c4-9ddf-4b25-a74d-ada45e629444"
      id="F_34a7ae85-c062-4b00-afa2-f1962d08ec77">P20Y</lgvn:TermsOfAgreement>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_b2d83ae4-7a58-420c-b89e-bc88b246fd41"
      decimals="0"
      id="F_d2708f1a-ce33-42ac-ae6e-cb0c0be62b8a"
      unitRef="U_USD">100000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ExcessStockSharesIssued
      contextRef="C_54e1f014-5bac-4239-87f8-50bf65a2d3d8"
      decimals="0"
      id="F_d54a0304-ba74-456f-a33e-124de993aba3"
      unitRef="U_shares">110387</us-gaap:ExcessStockSharesIssued>
    <lgvn:MilestoneOfTriggeringPayments
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="0"
      id="F_06ab4de4-3356-45f8-9939-5fb9f86359c8"
      unitRef="U_USD">500000</lgvn:MilestoneOfTriggeringPayments>
    <us-gaap:PaymentsForFees
      contextRef="C_202c13b7-a778-4220-862c-5376ad67002b"
      decimals="0"
      id="F_d1b1683b-84cc-4fb3-9bda-6b633762ea97"
      unitRef="U_USD">200000</us-gaap:PaymentsForFees>
    <lgvn:MilestoneFeesPayable
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="0"
      id="F_df1375fc-6f97-43ff-a55e-7fcd9e43cdb7"
      unitRef="U_USD">50000</lgvn:MilestoneFeesPayable>
    <lgvn:MilestoneFeesPayable
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="0"
      id="F_2573ce61-3feb-4196-87e9-234f25b21112"
      unitRef="U_USD">50000</lgvn:MilestoneFeesPayable>
    <lgvn:MilestoneFeesPayable
      contextRef="C_1a4b8c2d-4195-4bab-8513-5d2b8c496ede"
      decimals="0"
      id="F_1fe290e5-b528-400c-b445-7c9535c76642"
      unitRef="U_USD">15000</lgvn:MilestoneFeesPayable>
    <lgvn:MilestoneFeesPayable
      contextRef="C_dacd79be-b988-4527-b1bf-f17043f4b8a0"
      decimals="0"
      id="F_83b78866-ac43-4347-9c3b-d48b12275381"
      unitRef="U_USD">15000</lgvn:MilestoneFeesPayable>
    <us-gaap:PaymentsForFees
      contextRef="C_610cf94d-af47-4533-bd1a-06eb6eed02ed"
      decimals="0"
      id="F_f37d97cd-70bc-420a-a2ed-966c31d436dc"
      unitRef="U_USD">5000</us-gaap:PaymentsForFees>
    <us-gaap:InvestmentCompanyExcessExpenseReimbursable
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="0"
      id="F_fde93c60-ff92-4508-b3a5-dc52e4148466"
      unitRef="U_USD">21307</us-gaap:InvestmentCompanyExcessExpenseReimbursable>
    <us-gaap:RoyaltyExpense
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="0"
      id="F_38bfb497-36d3-4253-ada2-cd0ce71a73bc"
      unitRef="U_USD">10000</us-gaap:RoyaltyExpense>
    <us-gaap:LoanRestructuringTrialModificationsAmount
      contextRef="C_28896f23-6bbf-4287-b699-1d223de107ca"
      decimals="0"
      id="F_b42c5b1b-9afc-4f2e-be63-bc085e92ad46"
      unitRef="U_USD">150000</us-gaap:LoanRestructuringTrialModificationsAmount>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_aab874c5-5eb9-44be-987c-9dfe72f5a008"
      decimals="0"
      id="F_a6433e54-f34a-48f0-9e77-a32c8473c439"
      unitRef="U_USD">250000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:PaymentsForFees
      contextRef="C_1a4b8c2d-4195-4bab-8513-5d2b8c496ede"
      decimals="0"
      id="F_9fda143c-d5bb-4531-beb4-f93e961f761f"
      unitRef="U_USD">5000</us-gaap:PaymentsForFees>
    <lgvn:AnnualNetSalesPercentage
      contextRef="C_7ebcdbcd-409e-4f2d-81dd-ac2a0d38a037"
      decimals="2"
      id="F_d654d0e1-4c72-4be2-907d-856045b64a7e"
      unitRef="U_pure">0.01</lgvn:AnnualNetSalesPercentage>
    <lgvn:NetSalesOfSubLicensees
      contextRef="C_7ebcdbcd-409e-4f2d-81dd-ac2a0d38a037"
      decimals="2"
      id="F_226d6a59-08f7-4180-8460-3edaa7ffa97f"
      unitRef="U_pure">0.10</lgvn:NetSalesOfSubLicensees>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="C_831b093d-c619-43f4-90d9-56df47a2666a"
      decimals="0"
      id="F_9c841df1-e5b5-41b3-b682-0590d10c250c"
      unitRef="U_USD">250000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_8043ee3e-2733-4b91-a33a-2a0763fad881"
      decimals="0"
      id="F_a86e6c8b-bafc-4734-b237-8cc06473a37f"
      unitRef="U_shares">10000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_8043ee3e-2733-4b91-a33a-2a0763fad881"
      decimals="0"
      id="F_9fa6ef4b-3df2-4acc-8db5-4969772966b3"
      unitRef="U_USD">250000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:IndefiniteLivedLicenseAgreements
      contextRef="C_831b093d-c619-43f4-90d9-56df47a2666a"
      decimals="-5"
      id="F_191ee3de-bfbe-4bcb-aaa6-d4a0b89e41f2"
      unitRef="U_USD">500000</us-gaap:IndefiniteLivedLicenseAgreements>
    <us-gaap:ProfessionalFees
      contextRef="C_2a71fae8-4d00-48eb-bf4d-2a741ccb4f26"
      decimals="0"
      id="F_fe7d1ff8-1686-446f-9e36-c9303b9a2d17"
      unitRef="U_USD">27000</us-gaap:ProfessionalFees>
    <lgvn:licenseAgreementTerm
      contextRef="C_2a71fae8-4d00-48eb-bf4d-2a741ccb4f26"
      id="F_91bbe14c-e4f6-4c26-a1f8-83620559dbd3">P20Y</lgvn:licenseAgreementTerm>
    <lgvn:IncurredTerms
      contextRef="C_2a71fae8-4d00-48eb-bf4d-2a741ccb4f26"
      id="F_dce0a4cf-222a-42ac-bcde-d9abd63803ef">P20Y</lgvn:IncurredTerms>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="0"
      id="F_b9c1e959-21f6-4da8-8641-3447fed90b41"
      unitRef="U_USD">0</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="0"
      id="F_ba8ef68b-cc47-4dd4-b714-df6e740ac452"
      unitRef="U_USD">0</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-5"
      id="F_87824492-d2b6-4c7c-b5e0-09571f1ff2d6"
      unitRef="U_USD">3000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="C_c7147bf9-99b9-448b-938b-630f1b775c57"
      decimals="-5"
      id="F_352abf6d-8914-4718-bf2f-f96af4c7f442"
      unitRef="U_USD">1400000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:EmployeeStockOwnershipPlanESOPDividendsPaidToESOP
      contextRef="C_f6a93e10-9d65-4c37-b7bd-599ff82c8e50"
      decimals="0"
      id="F_24c30cac-f689-43cd-ab00-50570e25ed3b"
      unitRef="U_USD">75000</us-gaap:EmployeeStockOwnershipPlanESOPDividendsPaidToESOP>
    <us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="C_110002f2-7209-44ec-b8bb-e70434de6600"
      decimals="0"
      id="F_5e721a00-ccfc-4bce-bf20-ac096e0b0d20"
      unitRef="U_USD">35000</us-gaap:OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_cac39752-528d-4799-b638-f9f99be5b89c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Employee Benefits Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company sponsors a defined contribution employee benefit plan (the &#x201c;Plan&#x201d;) under the provisions of Section 401(k) of the Internal Revenue Code. The Plan covers substantially all full-time employees of the Company who are eligible upon date of hire. Contributions to the Plan by the Company are at the discretion of the Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company contributed approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;131,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to the Plan during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="0"
      id="F_a1cbac84-e0cb-478e-b996-f6f82fb1953f"
      unitRef="U_USD">154000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="0"
      id="F_c61e2c70-f016-416c-91d9-5c84a06b3674"
      unitRef="U_USD">131000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_fd7f3412-1c11-4f74-9efe-245886f62583">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The tax effects of temporary differences and net operating loss (&#x201c;NOL&#x201d;) carryforwards that gave rise to significant portions of the deferred tax assets and deferred tax liabilities were approximately as follows at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ASC 842 Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_59df80b9-4b23-4957-add5-f538f80c9bb3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_4dd0ce9c-9e6c-48e8-8f65-86135e742a26;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research &amp;amp; development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrual to cash adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_08bd69a2-41d1-491f-a362-6162aa80c7fc;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_dc96f2f3-806d-4814-8f8e-b6e47d188ef7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ASC 842 Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_5f5fbe24-614b-499f-aced-c5af13aee5ae;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_fd5c8872-fbff-42c3-a6e0-bd84c28f075d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had NOL carryforwards for federal purposes of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, all of which have no expiration. The Company also had state NOL carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, all of which have no expiration. However, these NOLs are subject to various limitations under Internal Revenue Code (&#x201c;IRC&#x201d;) Section 382. IRC Section 382 limits the use of NOLs to the extent there has been an ownership change of more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; percentage points in shares owned by any &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;owner. In addition, the NOL carry forwards are subject to examination by the taxing authority and could be&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adjusted &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;or disallowed due to such exams. Although the Company has not undergone an IRC Section 382 analysis, it is likely that the utilization of the NOLs may be substantially limited.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reconciliations of the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax benefits, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_903b8dcc-7d05-4cc8-8ed2-00092d584312;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_9b1b95a1-5cfc-4117-a2c2-f442d0b99222;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2024, there were no uncertain positions. The Company&#x2019;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from 2021, the earliest year with a net operating loss carryover, because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the years ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_62b6a939-a779-4def-b6e8-3b461f34f036">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The tax effects of temporary differences and net operating loss (&#x201c;NOL&#x201d;) carryforwards that gave rise to significant portions of the deferred tax assets and deferred tax liabilities were approximately as follows at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ASC 842 Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_59df80b9-4b23-4957-add5-f538f80c9bb3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_4dd0ce9c-9e6c-48e8-8f65-86135e742a26;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research &amp;amp; development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrual to cash adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_08bd69a2-41d1-491f-a362-6162aa80c7fc;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_dc96f2f3-806d-4814-8f8e-b6e47d188ef7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ASC 842 Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_5f5fbe24-614b-499f-aced-c5af13aee5ae;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_fd5c8872-fbff-42c3-a6e0-bd84c28f075d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_65e2cfab-04a0-4242-a4ce-2b0f794a0940"
      unitRef="U_USD">10870000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_a9bf682b-ae58-45ab-9794-e02353616bc0"
      unitRef="U_USD">7790000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <lgvn:DeferredTaxAssetsLeaseLiability
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_5b288242-abfd-479d-8750-27ea5053acca"
      unitRef="U_USD">361000</lgvn:DeferredTaxAssetsLeaseLiability>
    <lgvn:DeferredTaxAssetsLeaseLiability
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_7aca44d5-8ea3-465b-8ee3-371f14f9b7df"
      unitRef="U_USD">514000</lgvn:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_21bdd6c9-2c8f-4a6f-b3e0-e97ebb1dc0b8"
      unitRef="U_USD">244000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_62c119fe-1616-4e2d-9003-214a15d91582"
      unitRef="U_USD">201000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_25c48e9e-16ab-46c8-9e85-ac6a7e06131c"
      unitRef="U_USD">158000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_95f21ad2-63ba-4af6-bfa8-d8ac1a01c861"
      unitRef="U_USD">106000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_272cc942-688a-45a2-bc25-b7229f41dabf"
      unitRef="U_USD">4283000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_9c889e4e-69f2-47ce-ae4c-3fd15eebb780"
      unitRef="U_USD">3830000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_3eeeea6a-8af0-4d81-a4ab-583d153db130"
      unitRef="U_USD">1866000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_35708475-e23f-48b5-836b-b347d1434a5b"
      unitRef="U_USD">1258000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_d21908d4-b8c2-455b-832c-060438e2bfa4"
      unitRef="U_USD">466000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_acd4b58a-42e8-40c7-98ce-6233d8039074"
      unitRef="U_USD">468000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_102787ef-ab3b-451d-acb1-3c336de4015f"
      unitRef="U_USD">18248000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_ff0c422f-da98-4403-b730-91195ada0736"
      unitRef="U_USD">14167000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_e729121b-811f-4ac7-9dfa-3388fa66c10b"
      unitRef="U_USD">18014000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_354df90c-9004-4a71-89c1-6570f35e91d9"
      unitRef="U_USD">13776000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_3bd98d9a-23de-499d-9674-345dc3213a69"
      unitRef="U_USD">234000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_a9cb8399-27d9-4dfd-bd35-39c1358b3b05"
      unitRef="U_USD">391000</us-gaap:DeferredTaxAssetsNet>
    <lgvn:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_f12e39b1-ce2a-4777-9cfc-68c7acdb14d2"
      unitRef="U_USD">220000</lgvn:DeferredTaxLiabilitiesRightOfUseAsset>
    <lgvn:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_469c56c1-2a7b-402f-897e-f07cacff2ea1"
      unitRef="U_USD">307000</lgvn:DeferredTaxLiabilitiesRightOfUseAsset>
    <lgvn:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_1cddac2d-8c2c-45d1-8f22-334d8b35e058"
      unitRef="U_USD">14000</lgvn:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <lgvn:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_e8c0fedc-98e2-4652-9672-3d475724c76f"
      unitRef="U_USD">84000</lgvn:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0bbb3b66-2530-419f-a33c-8f144c3a0d78"
      decimals="-3"
      id="F_4d59f022-7ae9-4170-b671-1d5a61be739b"
      unitRef="U_USD">234000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_4bdbcc3c-77a0-4725-9531-5d9efae03259"
      decimals="-3"
      id="F_978fc027-832b-4396-bd53-46d4231d8573"
      unitRef="U_USD">391000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-5"
      id="F_bdc854b8-c0b3-44ac-8b8c-ea7f8e98f2f9"
      unitRef="U_USD">43400000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="-5"
      id="F_d6fcd523-e3e0-4460-bb7e-6910223f26d9"
      unitRef="U_USD">40400000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="2"
      id="F_229dc1bf-4c98-4f62-9851-5e2ba9527c27"
      unitRef="U_pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_747cbc79-ca1c-46c7-be44-ba004328f6dd"
      decimals="2"
      id="F_5902b89a-694b-44c1-8c9a-5627537e28a7"
      unitRef="U_pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_bff388b7-0157-4871-be20-46063579cbcb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reconciliations of the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State tax benefits, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_903b8dcc-7d05-4cc8-8ed2-00092d584312;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_9b1b95a1-5cfc-4117-a2c2-f442d0b99222;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="3"
      id="F_d9976c18-ce29-4b44-8366-7043301e3d65"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="3"
      id="F_6907fc8f-9a2b-4a4a-bbb6-8b852919b8d5"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="3"
      id="F_e6577065-ce27-401f-b44d-7c766cd127c7"
      unitRef="U_pure">0.039</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="3"
      id="F_9c5c1a2c-c5d5-494f-81fe-e16be3657c8f"
      unitRef="U_pure">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="3"
      id="F_8bdb0dd3-d420-442f-9cd2-ec51fccc633d"
      unitRef="U_pure">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="3"
      id="F_bd57664e-a719-445b-becd-45353612f015"
      unitRef="U_pure">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="3"
      id="F_29da5302-a5e4-4926-ab33-fbdfcdb939e4"
      unitRef="U_pure">-0.265</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="3"
      id="F_3649e7e9-c113-4f94-9550-24f7b68ecf42"
      unitRef="U_pure">-0.267</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_e8bf2382-08eb-4f37-8699-2fce28f412f1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share have been computed using the weighted-average number of shares of common stock outstanding during the period. We have outstanding equity-based awards that are not used in the calculation of diluted net loss per share because to do so would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following instruments (in thousands) were excluded from the calculation of diluted net loss per share because their effects would be antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;PSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_be074b5a-6a8b-46ba-94f0-23b38220894f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following instruments (in thousands) were excluded from the calculation of diluted net loss per share because their effects would be antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;PSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0a31e712-6c10-4d5f-a17e-78ce49207e63"
      decimals="0"
      id="F_0fec4d67-369b-4346-89f1-5b5977ef4a17"
      unitRef="U_shares">806</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5b020284-3c22-456d-94b9-311e885fa6b5"
      decimals="0"
      id="F_03be1e83-76b8-4c30-b5a1-707e0d0a4964"
      unitRef="U_shares">112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f62d3e71-2071-4235-baa6-e8487a08b092"
      decimals="0"
      id="F_6ca18ef5-2515-4560-bfc1-67fa6c6c4da6"
      unitRef="U_shares">125</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b94a44e3-eb07-42c8-b01e-5d44090f5b4d"
      decimals="0"
      id="F_fdfd19f1-175b-4ecd-a7a3-65ebbb78ffcd"
      unitRef="U_shares">121</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2af1430d-300c-4a83-ab6c-f2efb9b2b469"
      decimals="0"
      id="F_669c50ef-d492-4796-ba56-81d59ddbcdc6"
      unitRef="U_shares">438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_554ff09e-61fb-4eb8-892c-14e2e6d7f3cb"
      decimals="0"
      id="F_ae183cf3-d693-497b-882c-d3054e41dea7"
      unitRef="U_shares">6803</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a24d65d6-9396-4617-9b12-342686401195"
      decimals="0"
      id="F_882483f6-daca-4d0a-9302-717fbf8aa351"
      unitRef="U_shares">7740</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      decimals="0"
      id="F_d991f407-dcb8-4597-9ca3-48fcda707214"
      unitRef="U_shares">7730</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_98c6f150-65f1-41d8-9201-4a23ff2331cc"
      decimals="0"
      id="F_769aa368-7775-4a19-b3e5-e8bcfd93e825"
      unitRef="U_shares">8415</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_5e6d8fc8-7de4-4d03-823a-e4471a5371e5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which discrete financial information is available and regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) to allocate resources and assess performance. The Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_eb2962d5-c458-43df-b1ef-4f45299e5db3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CODM is its Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and the Company manages its operations as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_13fc1c78-4d1d-440f-aa75-9a7f20b97683;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment focused on developing regenerative medicines to address unmet medical needs. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The company&#x2019;s measure of segment profit or loss is net loss. The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company&#x2019;s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_577d3f24-3615-4da2-a77f-a18b9428fc43;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; are used to monitor budget versus actual results.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  All material long-lived assets of the Company are located in the United States and Company&#x2019;s revenues are derived from the United States, the Bahamas and Israel. The total assets of the one reporting segment are disclosed on the balance sheets as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company&#x2019;s single reportable segment:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.953%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;G&amp;amp;A costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes Contract Manufacturing and Clinical Trial revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes Clinical Development, Research &amp;amp; Discovery, CMC&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes Executive, Finance, Legal, Business Operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes compensation, benefits and equity-based compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes depreciation and amortization, (interest income) and other specific charges&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_1d2ff9e2-e9ec-4891-b0f9-7d869d1e9486">The company&#x2019;s measure of segment profit or loss is net loss. The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a consolidated basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with the Company&#x2019;s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources, and setting incentive targets.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_adcd7300-1e3e-48b8-bdd8-e3653d2fbef3">Operating expenses are used to monitor budget versus actual results.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_6fe738ec-2891-4c8f-9c84-8c2ff309ca8f"
      id="F_a19976de-89c0-4c8d-bfbf-51e247c35fcd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company&#x2019;s single reportable segment:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.953%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.903%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;R&amp;amp;D costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;G&amp;amp;A costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes Contract Manufacturing and Clinical Trial revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes Clinical Development, Research &amp;amp; Discovery, CMC&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes Executive, Finance, Legal, Business Operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes compensation, benefits and equity-based compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(5) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes depreciation and amortization, (interest income) and other specific charges&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af"
      decimals="-3"
      id="F_4fe7344d-dc91-49e0-aee7-d442e2d389dd"
      unitRef="U_USD">2392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75"
      decimals="-3"
      id="F_e0775914-fe76-4600-af8b-6b08dc8dac74"
      unitRef="U_USD">709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af"
      decimals="-3"
      id="F_a60c8288-0084-40e9-a69c-c78344db5801"
      unitRef="U_USD">508000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75"
      decimals="-3"
      id="F_0e208ffd-4204-46ec-85de-1aba2131ae16"
      unitRef="U_USD">488000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af"
      decimals="-3"
      id="F_68c40c4e-72da-4111-a80c-2a6b9a5d361f"
      unitRef="U_USD">2799000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75"
      decimals="-3"
      id="F_1506c981-952d-431b-9ae9-0eee92cf20a8"
      unitRef="U_USD">5704000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af"
      decimals="-3"
      id="F_7b0064f9-c27c-44e2-9b5c-e6fbce2f3e7f"
      unitRef="U_USD">5646000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75"
      decimals="-3"
      id="F_79c07512-b711-4832-aae8-da319894fc9a"
      unitRef="U_USD">6869000</us-gaap:GeneralAndAdministrativeExpense>
    <lgvn:PersonnelCosts
      contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af"
      decimals="-3"
      id="F_b1e54a54-2fef-4b3f-9eb7-bbe5f27d191f"
      unitRef="U_USD">9002000</lgvn:PersonnelCosts>
    <lgvn:PersonnelCosts
      contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75"
      decimals="-3"
      id="F_28d74d80-ba84-4ec2-b668-ae0a233df880"
      unitRef="U_USD">7731000</lgvn:PersonnelCosts>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af"
      decimals="-3"
      id="F_be21a908-5147-465a-b102-ef2722d341f4"
      unitRef="U_USD">410000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75"
      decimals="-3"
      id="F_d5e1e494-ef20-49f0-8135-b7dfd7673fce"
      unitRef="U_USD">1330000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="C_f5447379-d637-4372-97dd-6cab7114b6af"
      decimals="-3"
      id="F_de7d4c32-1111-461e-8d50-dea872572a6f"
      unitRef="U_USD">-15973000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_ded7a62d-ee5b-4736-a185-f7c17a25ec75"
      decimals="-3"
      id="F_551f98a6-33d2-4b92-8f6a-18a71655fd77"
      unitRef="U_USD">-21413000</us-gaap:NetIncomeLoss>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_e7605902-0fdc-48bc-ac79-49562b553579"
          xlink:label="F_e7605902-0fdc-48bc-ac79-49562b553579"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3e89db0d-7516-4cec-996c-1c90638f3e28"
          xlink:label="F_3e89db0d-7516-4cec-996c-1c90638f3e28"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5e12fe2a-e38a-40fb-b7a3-505eb340170c"
          xlink:label="F_5e12fe2a-e38a-40fb-b7a3-505eb340170c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_65783fe8-1f0d-4364-afe5-73df559ef586"
          xlink:label="F_65783fe8-1f0d-4364-afe5-73df559ef586"
          xlink:type="locator"/>
        <link:footnote id="FNT_f8479f6d-5b6c-4d05-a3d1-b92c863314eb" xlink:label="FNT_f8479f6d-5b6c-4d05-a3d1-b92c863314eb" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the balance sheets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e7605902-0fdc-48bc-ac79-49562b553579"
          xlink:to="FNT_f8479f6d-5b6c-4d05-a3d1-b92c863314eb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3e89db0d-7516-4cec-996c-1c90638f3e28"
          xlink:to="FNT_f8479f6d-5b6c-4d05-a3d1-b92c863314eb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5e12fe2a-e38a-40fb-b7a3-505eb340170c"
          xlink:to="FNT_f8479f6d-5b6c-4d05-a3d1-b92c863314eb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_65783fe8-1f0d-4364-afe5-73df559ef586"
          xlink:to="FNT_f8479f6d-5b6c-4d05-a3d1-b92c863314eb"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_4fe7344d-dc91-49e0-aee7-d442e2d389dd"
          xlink:label="F_4fe7344d-dc91-49e0-aee7-d442e2d389dd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e0775914-fe76-4600-af8b-6b08dc8dac74"
          xlink:label="F_e0775914-fe76-4600-af8b-6b08dc8dac74"
          xlink:type="locator"/>
        <link:footnote id="FNT_affce6d7-8e57-4056-a01d-c9ca371ee566" xlink:label="FNT_affce6d7-8e57-4056-a01d-c9ca371ee566" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Contract Manufacturing and Clinical Trial revenue</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4fe7344d-dc91-49e0-aee7-d442e2d389dd"
          xlink:to="FNT_affce6d7-8e57-4056-a01d-c9ca371ee566"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e0775914-fe76-4600-af8b-6b08dc8dac74"
          xlink:to="FNT_affce6d7-8e57-4056-a01d-c9ca371ee566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_1506c981-952d-431b-9ae9-0eee92cf20a8"
          xlink:label="F_1506c981-952d-431b-9ae9-0eee92cf20a8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_68c40c4e-72da-4111-a80c-2a6b9a5d361f"
          xlink:label="F_68c40c4e-72da-4111-a80c-2a6b9a5d361f"
          xlink:type="locator"/>
        <link:footnote id="FNT_f578064d-d204-42b8-aee5-f8e88fc6a93c" xlink:label="FNT_f578064d-d204-42b8-aee5-f8e88fc6a93c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Clinical Development, Research &amp; Discovery, CMC</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1506c981-952d-431b-9ae9-0eee92cf20a8"
          xlink:to="FNT_f578064d-d204-42b8-aee5-f8e88fc6a93c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_68c40c4e-72da-4111-a80c-2a6b9a5d361f"
          xlink:to="FNT_f578064d-d204-42b8-aee5-f8e88fc6a93c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_7b0064f9-c27c-44e2-9b5c-e6fbce2f3e7f"
          xlink:label="F_7b0064f9-c27c-44e2-9b5c-e6fbce2f3e7f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_79c07512-b711-4832-aae8-da319894fc9a"
          xlink:label="F_79c07512-b711-4832-aae8-da319894fc9a"
          xlink:type="locator"/>
        <link:footnote id="FNT_a97c71f4-761d-4b7e-8797-b7ae4e3b378b" xlink:label="FNT_a97c71f4-761d-4b7e-8797-b7ae4e3b378b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes Executive, Finance, Legal, Business Operations</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7b0064f9-c27c-44e2-9b5c-e6fbce2f3e7f"
          xlink:to="FNT_a97c71f4-761d-4b7e-8797-b7ae4e3b378b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_79c07512-b711-4832-aae8-da319894fc9a"
          xlink:to="FNT_a97c71f4-761d-4b7e-8797-b7ae4e3b378b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_b1e54a54-2fef-4b3f-9eb7-bbe5f27d191f"
          xlink:label="F_b1e54a54-2fef-4b3f-9eb7-bbe5f27d191f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_28d74d80-ba84-4ec2-b668-ae0a233df880"
          xlink:label="F_28d74d80-ba84-4ec2-b668-ae0a233df880"
          xlink:type="locator"/>
        <link:footnote id="FNT_cc02af35-7765-4878-8a7d-93447031342c" xlink:label="FNT_cc02af35-7765-4878-8a7d-93447031342c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes compensation, benefits and equity-based compensation</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b1e54a54-2fef-4b3f-9eb7-bbe5f27d191f"
          xlink:to="FNT_cc02af35-7765-4878-8a7d-93447031342c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_28d74d80-ba84-4ec2-b668-ae0a233df880"
          xlink:to="FNT_cc02af35-7765-4878-8a7d-93447031342c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_d5e1e494-ef20-49f0-8135-b7dfd7673fce"
          xlink:label="F_d5e1e494-ef20-49f0-8135-b7dfd7673fce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_be21a908-5147-465a-b102-ef2722d341f4"
          xlink:label="F_be21a908-5147-465a-b102-ef2722d341f4"
          xlink:type="locator"/>
        <link:footnote id="FNT_e02994b6-ff61-46f2-aac1-3e0c30130e6b" xlink:label="FNT_e02994b6-ff61-46f2-aac1-3e0c30130e6b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes depreciation and amortization, (interest income) and other specific charges</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d5e1e494-ef20-49f0-8135-b7dfd7673fce"
          xlink:to="FNT_e02994b6-ff61-46f2-aac1-3e0c30130e6b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_be21a908-5147-465a-b102-ef2722d341f4"
          xlink:to="FNT_e02994b6-ff61-46f2-aac1-3e0c30130e6b"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
